,Article,Date,Symbol,Time,Title,Url
0,"  Jan 14 Aetna Inc said on Tuesday that based on sign-ups for private Medicare, its first-quarter membership for these health plans for seniors would be ""meaningfully better"" than previously projected.The company, the nation's third-largest insurer, said it now expects full year 2014 operating revenue of at least $54 billion compared with its previous projection of about $53 billion. Aetna, which made the remarks ahead of Chief Executive Officer Mark Bertolini's presentation at the J.P. Morgan healthcare conference on Wednesday morning, reaffirmed the company's 2014 operating earnings per share projection of at least $6.25 per share. Aetna and competitors UnitedHealth Group Inc and Humana Inc have been forecasting that cuts to reimbursement for private Medicare, called Medicare Advantage, would make the program challenging for them this year. Aetna shares rose to $71.48 in after-hours trading after closing at $71.04 on the New York Stock Exchange.",2014-01-14,AET,"Tue Jan 14, 2014 | 4:55pm EST",Aetna says private Medicare sign-ups better than expected,http://www.reuters.com//article/aetna-forecast-idUSL2N0KO23Q20140114?type=companyNews
1,"  Aetna Inc said on Tuesday that based on sign-ups for private Medicare, its first-quarter membership for these health plans for seniors would be ""meaningfully better"" than previously projected.The company, the nation's third-largest insurer, said it now expects full year 2014 operating revenue of at least $54 billion compared with its previous projection of about $53 billion.Aetna, which made the remarks ahead of Chief Executive Officer Mark Bertolini's presentation at the J.P. Morgan healthcare conference on Wednesday morning, reaffirmed the company's 2014 operating earnings per share projection of at least $6.25 per share. Aetna and competitors UnitedHealth Group Inc and Humana Inc have been forecasting that cuts to reimbursement for private Medicare, called Medicare Advantage, would make the program challenging for them this year. Aetna shares rose to $71.48 in after-hours trading after closing at $71.04 on the New York Stock Exchange. (Reporting by Caroline Humer; Editing by Bernard Orr)",2014-01-15,AET,"Wed Jan 15, 2014 | 1:03pm EST",Aetna says private Medicare sign-ups better than expected,http://www.reuters.com//article/us-aetna-forecast-idUSBREA0E19W20140115?type=companyNews
2,"   By Caroline Humer  Aetna Inc (AET.N), the third-largest U.S. health insurer, said on Thursday it expects to lose money on the Obamacare exchanges even as demand for these insurance plans has picked up over the past few weeks.President Barack Obama's healthcare reform law, often called Obamacare, created online insurance exchanges where individuals can buy health coverage with income-based government subsidies. The exchanges opened on October 1 to sell plans for coverage effective January 1, but technology issues delayed enrollment for the first few months.Chief Executive Officer Mark Bertolini said the demographics of the new members were ""a little skewed"" toward an older, higher-cost population. He said the financial risks of the business were manageable but that Aetna's 2014 profit outlook was based on losses from the new plans.""We expect the business to lose money in the first year,"" Bertolini told investors during a conference call. He said Aetna had signed up 135,000 paid members through the end of January.The company also reported higher fourth-quarter earnings and revenue.Aetna, which is operating on the exchanges in 17 states, is considering where it will offer Obamacare plans in 2015, and at what price, as it gathers information on the health of the new members.The company has been looking at these members' pharmacy records as well as the health records of previous Aetna customers to understand what its costs from Obamacare will be.The website problems and the extension of some old health plans into 2014 have shrunk the pool of applicants for the exchange plans and diverted younger and healthier people.HealthCare.gov, which sells insurance in 36 states, began working better in December, and about 3 million people had signed up through that site and in the 14 states running their own websites as of late January, the government has said.About 6 million people are expected to sign up for 2014 on the exchanges, the Congressional Budget Office said earlier this week, cutting its outlook by about 1 million. Another factor in 2015 pricing is the size of the network of doctors and hospitals. These networks have come under scrutiny as individuals have begun to realize their new plans may exclude their desired hospital or doctor.The Centers for Medicare and Medicaid Services, which oversee the exchanges, this week outlined new expectations for 2015 network disclosures and standards that may be tougher for insurers to meet.Aetna Chief Financial Officer Shawn Guertin said in an interview that he did not believe the administration was asking for larger networks in 2015 than the insurers use in 2014.""I don't think we can conclude that yet from this letter,"" Guertin said. ""This is not a new issue ... It's a longstanding issue of balancing access with affordability.""White House spokesman Jay Carney told reporters on Thursday that the Affordable Care Act includes measures to make sure consumers have a choice in providers, but added that Health and Human Services (HHS) was working on additional measures.""For 2015, HHS plans to have even more aggressive efforts in place to ensure that consumers have good networks of doctors, community providers and specialists,"" Carney said. Smaller networks are less expensive for insurers because they are able to keep tighter control on costs.For 2014 coverage, Aetna said it had received about 200,000 enrollment applications in all, but only about 70 percent have paid. Competitor Humana Inc (HUM.N) reported a similar enrollment number on Wednesday, WellPoint Inc WLP.N said last month that it had received 400,000 enrollment applications.UnitedHealth Group Inc (UNH.N), the largest U.S. insurer, is only selling on a few exchanges and has not reported enrollment.Cigna Corp (CI.N) reports its quarterly earnings on Friday.MEDICARE GROWTH  The individual business represents about 3 percent of Aetna's total medical membership, which reached 22.2 million at the end of 2013.About 18 million of the customers are in Aetna's corporate health plan business, and the company has a growing private Medicare business. About 150 million people in the United States have employer-based healthcare.Aetna said it expected to add 110,000 new private Medicare customers in the first quarter. Government-paid healthcare programs, like Medicare for older people, are growing fast as baby boomers age into the program.Both earnings and revenue were helped by the more than $5 billion acquisition of Coventry Healthcare in 2013.Aetna reported net income of $369 million, or $1 per share, up from $190 million, or 56 cents per share, a year earlier.Excluding acquisition-related costs, a charge for increasing liability for life insurance claims, and other items, earnings were $1.34 per share, compared with analysts' expectations of $1.36, according to Thomson Reuters I/B/E/S.Shares of Aetna were down 0.3 percent at $67.96 in afternoon trading.Revenue rose 33 percent to $13.18 billion, above analysts' average estimate of $13.14 billion.In Aetna's largest commercial business, which includes corporate as well as individual plans, the ratio of healthcare spending to premium revenue fell from a year earlier, to 81.7 percent from 83.4 percent.(Additional reporting by Roberta Rampton; editing by Lisa Von Ahn, Bernadette Baum and David Gregorio)",2014-02-06,AET,"Thu Feb 6, 2014 | 3:41pm EST","Aetna to lose money on Obamacare exchanges, CEO says",http://www.reuters.com//article/us-aetna-results-idUSBREA151QJ20140206?type=companyNews
3,"  By Caroline HumerFeb 6 Aetna Inc, the third-largest U.S. health insurer, said on Thursday it expects to lose money on the Obamacare exchanges even as demand for these insurance plans has picked up over the past few weeks.President Barack Obama's healthcare reform law, often called Obamacare, created online insurance exchanges where individuals can buy health coverage with income-based government subsidies. The exchanges opened on Oct. 1 to sell plans for coverage effective Jan. 1, but technology issues delayed enrollment for the first few months.Chief Executive Officer Mark Bertolini said the demographics of the new members were ""a little skewed"" toward an older, higher-cost population. He said the financial risks of the business were manageable but that Aetna's 2014 profit outlook was based on losses from the new plans.""We expect the business to lose money in the first year,""  Bertolini told investors during a conference call. He said Aetna had signed up 135,000 paid members through the end of January.The company also reported higher fourth-quarter earnings and revenue.Aetna, which is operating on the exchanges in 17 states, is considering where it will offer Obamacare plans in 2015, and at what price, as it gathers information on the health of the new members.The company has been looking at these members' pharmacy records as well as the health records of previous Aetna customers to understand what its costs from Obamacare will be.The website problems and the extension of some old health plans into 2014 have shrunk the pool of applicants for the exchange plans and diverted younger and healthier people.HealthCare.gov, which sells insurance in 36 states, began working better in December, and about 3 million people had signed up through that site and in the 14 states running their own websites as of late January, the government has said.About 6 million people are expected to sign up for 2014 on the exchanges, the Congressional Budget Office said earlier this week, cutting its outlook by about 1 million. Another factor in 2015 pricing is the size of the network of doctors and hospitals. These networks have come under scrutiny as individuals have begun to realize their new plans may exclude their desired hospital or doctor.The Centers for Medicare and Medicaid Services, which oversee the exchanges, this week outlined new expectations for 2015 network disclosures and standards that may be tougher for insurers to meet.Aetna Chief Financial Officer Shawn Guertin said in an interview that he did not believe the administration was asking for larger networks in 2015 than the insurers use in 2014.""I don't think we can conclude that yet from this letter,"" Guertin said. ""This is not a new issue ... It's a longstanding issue of balancing access with affordability.""White House spokesman Jay Carney told reporters on Thursday that the Affordable Care Act includes measures to make sure consumers have a choice in providers, but added that Health and Human Services (HHS) was working on additional measures. ""For 2015, HHS plans to have even more aggressive efforts in place to ensure that consumers have good networks of doctors, community providers and specialists,"" Carney said.Smaller networks are less expensive for insurers because they are able to keep tighter control on costs.For 2014 coverage, Aetna said it had received about 200,000 enrollment applications in all, but only about 70 percent have paid. Competitor Humana Inc reported a similar enrollment number on Wednesday, WellPoint Inc said last month that it had received 400,000 enrollment applications.UnitedHealth Group Inc, the largest U.S. insurer, is only selling on a few exchanges and has not reported enrollment.Cigna Corp reports its quarterly earnings on Friday. MEDICARE GROWTH The individual business represents about 3 percent of Aetna's total medical membership, which reached 22.2 million at the end of 2013.About 18 million of the customers are in Aetna's corporate health plan business, and the company has a growing private Medicare business. About 150 million people in the United States have employer-based healthcare.Aetna said it expected to add 110,000 new private Medicare customers in the first quarter. Government-paid healthcare programs, like Medicare for older people, are growing fast as baby boomers age into the program.Both earnings and revenue were helped by the more than $5 billion acquisition of Coventry Healthcare in 2013.Aetna reported net income of $369 million, or $1 per share, up from $190 million, or 56 cents per share, a year earlier.Excluding acquisition-related costs, a charge for increasing liability for life insurance claims, and other items, earnings were $1.34 per share, compared with analysts' expectations of $1.36, according to Thomson Reuters I/B/E/S.Shares of Aetna were down 0.3 percent at $67.96 in afternoon trading.Revenue rose 33 percent to $13.18 billion, above analysts' average estimate of $13.14 billion.In Aetna's largest commercial business, which includes corporate as well as individual plans, the ratio of healthcare spending to premium revenue fell from a year earlier, to 81.7 percent from 83.4 percent.",2014-02-06,AET,"Thu Feb 6, 2014 | 3:40pm EST","UPDATE 4-Aetna to lose money on Obamacare exchanges, CEO says",http://www.reuters.com//article/aetna-results-idUSL2N0LB0FI20140206?type=companyNews
4,"  Feb 6 Aetna Inc :  * CEO says 80 to 90 percent of customers enrolled through Obamacare exchangebefore January 1 have paid  * Has received about 200,000 enrollment applications, about 70 percent of them paid - CEO  * CEO says depth of provider network impacts pricing for Obamacare products  * CEO says provider network debate is largely ""political posturing"" around  Affordable Care Act",2014-02-06,AET,"Thu Feb 6, 2014 | 9:36am EST","BRIEF-Aetna CEO says has received 200,000 Obamacare applications",http://www.reuters.com//article/aetna-results-idUSWEN00CHO20140206?type=companyNews
5,"  Feb 6 Aetna Inc :  * CEO Bertolini says enrolled 135,000 paid members through public exchangesthrough January 31  * CEO says believes enrollment in obamacare exchanges will increase during  period  * CEO says Obamacare related pressures on business start to abate in 2016 ",2014-02-06,AET,"Thu Feb 6, 2014 | 8:47am EST","BRIEF-Aetna has enrolled 135,000 paid members through Obamacare exchanges",http://www.reuters.com//article/aetna-brief-idUSWEN00CHL20140206?type=companyNews
6,"  Aetna Inc (AET.N), the third-largest U.S. health insurer, on Thursday said fourth-quarter profit rose due to the acquisition of Coventry Healthcare, and it forecast an increase in medical customers in its private Medicare business in 2014.Aetna, which had 22.2 million medical customers at the end of 2013, said it expected to add 110,000 new private Medicare customers in the first quarter. Government-paid healthcare programs, like Medicare for older people, are among the fastest-growing businesses for insurers.Aetna reported net income of $369 million, or $1 per share, up from $190 million, or 56 cents per share, a year earlier. Excluding special items, earnings were $1.34 per share, compared with analysts' expectations of $1.36, according to Thomson Reuters I/B/E/S. The company reported revenue of $13.18 billion, above the analysts' average estimate of $13.14 billion. In Aetna's largest commercial business, which includes corporate as well as individual plans, the ratio of healthcare spending to premium revenue fell from a year earlier, to 81.7 percent from 83.4 percent.(Reporting by Caroline Humer; Editing by Lisa Von Ahn)",2014-02-06,AET,"Thu Feb 6, 2014 | 6:38am EST",Aetna profit rises; company forecasts more Medicare customers in 2014,http://www.reuters.com//article/us-aetna-results-idUSBREA150PP20140206?type=companyNews
7,"  Feb 6 Aetna Inc, the third-largest U.S. health insurer, on Thursday said fourth quarter profit rose due to the acquisition of Coventry Healthcare and forecast an increase in medical customers in its private Medicare business in 2014.Aetna, which had 22.2 million medical customers at the end of 2013, said it expected to add 110,000 new private Medicare customers in the first quarter. Government-paid healthcare programs, like Medicare for older people, is one of the fastest-growing businesses for insurers.  Aetna reported net income of $369 million, or $1 per share, up from $190 million, or 56 cents per share, a year earlier. ",2014-02-06,AET,"Thu Feb 6, 2014 | 6:17am EST",Aetna profit rises; company forecasts more Medicare customers in 2014,http://www.reuters.com//article/aetna-results-idUSL2N0LB0F620140206?type=companyNews
8,"  Tenet Healthcare Corp (THC.N) on Monday said it signed a two-year agreement with insurer Aetna Inc (AET.N) to provide healthcare services to Aetna members at Tenet's hospitals and outpatient centers.The agreement, which went into effect on January 1, expands the relationship between the companies to include all of Tenet's facilities and also implements accountable care organization (ACO) arrangements in Texas and Arizona. The ACO healthcare delivery model, encouraged under the Affordable Care Act, aims to improve the quality of healthcare while slowing spending growth. ACO participants agree to cost and quality targets, such as lowering hospital readmission rates and reducing patients' blood pressure and cholesterol levels, and then share savings tied to meeting those goals. Dallas-based Tenet, the third-largest U.S. for-profit hospital chain with 77 hospitals and 186 outpatient centers, has been one of the first among its peers in the for-profit sector to experiment with the ACO approach. (Reporting by Susan Kelly in Chicago; Editing by Diane Craft)",2014-02-24,AET,"Mon Feb 24, 2014 | 4:06pm EST","Tenet, Aetna sign contract to expand healthcare services",http://www.reuters.com//article/us-tenet-aetna-idUSBREA1N1S620140224?type=companyNews
9,"  Feb 24 Tenet Healthcare Corp on Monday said it signed a two-year agreement with insurer Aetna Inc  to provide healthcare services to Aetna members at Tenet's hospitals and outpatient centers.The agreement, which went into effect on Jan. 1, expands the relationship between the companies to include all of Tenet's facilities and also implements accountable care organization (ACO) arrangements in Texas and Arizona. The ACO healthcare delivery model, encouraged under the Affordable Care Act, aims to improve the quality of healthcare while slowing spending growth. ACO participants agree to cost and quality targets, such as lowering hospital readmission rates and reducing patients' blood pressure and cholesterol levels, and then share savings tied to meeting those goals.  Dallas-based Tenet, the third-largest U.S. for-profit hospital chain with 77 hospitals and 186 outpatient centers, has been one of the first among its peers in the for-profit sector to experiment with the ACO approach.",2014-02-24,AET,"Mon Feb 24, 2014 | 3:56pm EST","Tenet, Aetna sign contract to expand healthcare services",http://www.reuters.com//article/tenet-aetna-idUSL1N0LT1UM20140224?type=companyNews
10,"   By Julie Steenhuysen | CHICAGO  CHICAGO Increased attention given to patients in primary care practices organized into so-called medical homes may not improve quality of care or reduce health costs as reformers of the U.S. healthcare system had hoped, researchers said on Tuesday.Thousands of primary care doctors in the United States are revamping their practices based on this new medical home model.Under this scheme, doctors and other providers receive bonuses from insurance companies for spending extra time with patients by extending office hours and providing follow-up care in hopes of keeping them healthier and out of the hospital.In medical home practices, primary care doctors adopt a team-based care approach using patient registries, electronic health records and other tools to help identify high-risk patients and deliver more personalized care.The thinking is that this extra attention will result in improved quality and reduced spending.But new evidence from a large, three-year pilot study among 32 physician practices in Pennsylvania found modest improvements in quality of care and no reductions in hospitalizations, emergency department visits or total costs of care.""The medical home has gained popularity as a new model of primary care, with the expectation that the approach will produce better and lower-cost health care,"" said Dr Mark Friedberg, the study's lead author and a scientist at RAND, a nonprofit research organization. ""Our findings suggest that achieving all of these goals is a challenge.""The findings were published in the Journal of the American Medical Association (JAMA) on Tuesday. This adds to evidence from a study of five Rhode Island physician practices published in September in JAMA Internal Medicine that found no statistically significant improvements in quality or emergency department visits, although there were signs that ER use was declining.Dr Thomas Schwenk of the University of Nevada School of Medicine in Reno said the findings from the Pennsylvania trial suggest that the medical home movement may not work for every patient in every practice.""It's gotten to be almost a fad in which it is applied indiscriminately,"" said Schwenk, who wrote an editorial accompanying the study in JAMA. Schwenk calls the medical home model a ""powerful technology"" for treating expensive, high-risk patients, but when it has been applied in broad practice settings, it ""by and large has been shown not to be that effective.""Friedberg said the findings suggest it may be a little harder to achieve the goals of the medical home model than previously thought. ""I would not say our findings say the medical home model is doomed."" But, he added, ""It's not a sure thing.""Friedberg's team evaluated practices taking part in the Southeastern Pennsylvania Chronic Care Initiative, one of the first medical home pilots in the state. In this region, 32 primary care practices and six health plans took part in the pilot between 2008 and 2011.Practices in the pilot program were required to transform their practices into medical homes and become accredited by the National Committee for Quality Assurance or NCQA. Such practices enlist the help of everyone from nurses to front desk staff to help avoid costly and preventable complications by focusing on preventing and managing chronic disease.To motivate doctors in the Pennsylvania study, each practice was eligible to receive a $20,000 bonus support payment in the first year and annual bonus payments, which ranged from $28,000 to $95,000, depending on the size and structure of the practice. Using data on approximately 120,000 patients, researchers compared quality, use of medical services and costs of care between the pilot practices and 29 other practices.But over the three-year period, researchers found rates of quality significantly improved on only one out of 11 quality measures that included asthma care, cancer screening and overall diabetes control.They also did not find any reductions in the number of hospital visits, emergency department use or ambulatory care services, or in the total costs of medical care.The study did not examine why the pilot failed to make a major impact. Yet, the authors said the fact that many of the practices volunteered for the study suggest they may have already been more quality-conscious than other practices even before the pilot began.A POPULAR HYPOTHESIS  The findings contradict the hypothesis that better preventive and primary care will help patients avoid more costly medical problems down the line.Insurance companies pay a premium to primary care practices that organize themselves into a team of professionals, including nurse practitioners and 0physician assistants.More than 10 percent of U.S. primary care practices or about 7,000 practices, are recognized as patient-centered medical homes by the NCQA, the nation's largest group that certifies such practices.The movement got its start with an American Academy of Family Physicians report called the 2004 Future of Family Medicine. It has since been championed in President Barack Obama's healthcare law through provisions that allow states to boost reimbursements to primary care practices designated as medical homes for Medicaid patients.Health insurer Aetna Inc helped pay for the Pennsylvania study along with the nonpartisan Commonwealth Fund. The company said it was still convinced of the value of the medical home model, noting it has come a long way since the start of the pilot.Elizabeth Curran, Aetna's head of National Network Strategy and Program Development, said Aetna has nearly 1 million commercial members being treated in patient centered medical homes under an estimated 5,000 primary care physicians.She said Aetna patients treated in a medical home have a range of 3 to 13 percent fewer visits to the emergency department per 1,000 patients than patients treated in typical practices. Medical costs per patient are from $2 to $24 cheaper per month in medical homes versus typical practices.Dr Elbert Huang, a health care policy expert at the University of Chicago Medicine who was not involved in the study, said three years may not be enough to show a significant impact in improving chronic diseases such as diabetes or asthma.""The practices clearly changed the way they do business,"" he said.(Reporting by Julie Steenhuysen; Editing by Michele Gershberg and Diane Craft)",2014-02-25,AET,"Tue Feb 25, 2014 | 6:45pm EST","Popular U.S. health reform plan may not cut costs, boost quality: study",http://www.reuters.com//article/us-usa-healthcare-medicalhomes-idUSBREA1O21G20140225?type=companyNews
11,"   By Julie Steenhuysen | CHICAGO  CHICAGO Feb 25 Increased attention given to patients in primary care practices organized into so-called medical homes may not improve quality of care or reduce health costs as reformers of the U.S. healthcare system had hoped, researchers said on Tuesday.Thousands of primary care doctors in the United States are revamping their practices based on this new medical home model.Under this scheme, doctors and other providers receive bonuses from insurance companies for spending extra time with patients by extending office hours and providing follow-up care in hopes of keeping them healthier and out of the hospital.In medical home practices, primary care doctors adopt a team-based care approach using patient registries, electronic health records and other tools to help identify high-risk patients and deliver more personalized care.The thinking is that this extra attention will result in improved quality and reduced spending.But new evidence from a large, three-year pilot study among 32 physician practices in Pennsylvania found modest improvements in quality of care and no reductions in hospitalizations, emergency department visits or total costs of care.""The medical home has gained popularity as a new model of primary care, with the expectation that the approach will produce better and lower-cost health care,"" said Dr Mark Friedberg, the study's lead author and a scientist at RAND, a nonprofit research organization. ""Our findings suggest that achieving all of these goals is a challenge.""The findings were published in the Journal of the American Medical Association (JAMA) on Tuesday. This adds to evidence from a study of five Rhode Island physician practices published in September in JAMA Internal Medicine that found no statistically significant improvements in quality or emergency department visits, although there were signs that ER use was declining.Dr Thomas Schwenk of the University of Nevada School of Medicine in Reno said the findings from the Pennsylvania trial suggest that the medical home movement may not work for every patient in every practice.""It's gotten to be almost a fad in which it is applied indiscriminately,"" said Schwenk, who wrote an editorial accompanying the study in JAMA. Schwenk calls the medical home model a ""powerful technology"" for treating expensive, high-risk patients, but when it has been applied in broad practice settings, it ""by and large has been shown not to be that effective.""Friedberg said the findings suggest it may be a little  harder to achieve the goals of the medical home model than previously thought. ""I would not say our findings say the medical home model is doomed."" But, he added, ""It's not a sure thing.""Friedberg's team evaluated practices taking part in the Southeastern Pennsylvania Chronic Care Initiative, one of the first medical home pilots in the state. In this region, 32 primary care practices and six health plans took part in the pilot between 2008 and 2011.Practices in the pilot program were required to transform their practices into medical homes and become accredited by the National Committee for Quality Assurance or NCQA. Such practices enlist the help of everyone from nurses to front desk staff to help avoid costly and preventable complications by focusing on preventing and managing chronic disease.To motivate doctors in the Pennsylvania study, each practice was eligible to receive a $20,000 bonus support payment in the first year and annual bonus payments, which ranged from $28,000 to $95,000, depending on the size and structure of the practice. Using data on approximately 120,000 patients, researchers compared quality, use of medical services and costs of care between the pilot practices and 29 other practices.But over the three-year period, researchers found rates of quality significantly improved on only one out of 11 quality measures that included asthma care, cancer screening and overall diabetes control.They also did not find any reductions in the number of hospital visits, emergency department use or ambulatory care services, or in the total costs of medical care.The study did not examine why the pilot failed to make a major impact. Yet, the authors said the fact that many of the practices volunteered for the study suggest they may have already been more quality-conscious than other practices even before the pilot began. A POPULAR HYPOTHESIS The findings contradict the hypothesis that better preventive and primary care will help patients avoid more costly medical problems down the line.Insurance companies pay a premium to primary care practices that organize themselves into a team of professionals, including nurse practitioners and 0physician assistants.More than 10 percent of U.S. primary care practices or about 7,000 practices, are recognized as patient-centered medical homes by the NCQA, the nation's largest group that certifies such practices.The movement got its start with an American Academy of Family Physicians report called the 2004 Future of Family Medicine. It has since been championed in President Barack Obama's healthcare law through provisions that allow states to boost reimbursements to primary care practices designated as medical homes for Medicaid patients.Health insurer Aetna Inc helped pay for the Pennsylvania study along with the nonpartisan Commonwealth Fund. The company said it was still convinced of the value of the medical home model, noting it has come a long way since the start of the pilot.Elizabeth Curran, Aetna's head of National Network Strategy and Program Development, said Aetna has nearly 1 million commercial members being treated in patient centered medical homes under an estimated 5,000 primary care physicians.She said Aetna patients treated in a medical home have a range of 3 to 13 percent fewer visits to the emergency department per 1,000 patients than patients treated in typical practices. Medical costs per patient are from $2 to $24 cheaper per month in medical homes versus typical practices.Dr Elbert Huang, a health care policy expert at the University of Chicago Medicine who was not involved in the study, said three years may not be enough to show a significant impact in improving chronic diseases such as diabetes or asthma.""The practices clearly changed the way they do business,"" he said.   (Reporting by Julie Steenhuysen; Editing by Michele Gershberg and Diane Craft)",2014-02-25,AET,"Tue Feb 25, 2014 | 6:42pm EST","Popular U.S. health reform plan may not cut costs, boost quality- study",http://www.reuters.com//article/usa-healthcare-medicalhomes-idUSL1N0LU1YD20140225?type=companyNews
12,"  (The following statement was released by the rating agency) CHICAGO, March 04 (Fitch) Fitch Ratings has assigned an expected rating of 'A-'  to Aetna Inc.'s (AET) proposed issuance of $750 million of senior unsecured  notes. AET's Long-term Issuer Default Rating is unaffected by this rating  action. Fitch affirmed the ratings of AET and its insurance operating subsidiaries with  a Negative Outlook on Nov. 27, 2013. KEY RATING DRIVERS Fitch expects proceeds from the issuance to be used to fund the recently  announced redemption of AET's $750 million of 6.00% senior notes due June 2016. Aetna's financial leverage has risen significantly over the past year as a  result of its acquisition of Coventry Health Care, Inc. (CVH) in May 2013. At  Dec. 31, 2013, the company's financial leverage was approximately 38%, and  debt-to-EBITDA was 2.1x for the 12 months ended Dec. 31, 2013. This is up from  33% and 1.3x, respectively, at June 30, 2012. The company's elevated financial  leverage and execution risk related to the CVH transaction are the primary  drivers of the Negative Outlook on Aetna's ratings. Fitch expects financial  leverage and run-rate debt-to-EBITDA to move below 35% and 1.8x, respectively,  by the end of the second quarter of 2015. Aetna's ratings reflect the organization's major market position and significant  size and scale, strong profitability and interest coverage, and generally solid  balance sheet characteristics. The company's ratings also reflect the risks  derived from government involvement in health insurance and managed care  companies' ongoing business activities. Fitch's long-held concern is that  government efforts to advance public policy goals could adversely affect health  insurance and managed care companies' ability to manage their business and  hinder their ability to generate cash flow supporting debt obligations. RATING SENSITIVITIES The key rating triggers that could result in a revision of the Outlook to Stable  include substantial progress toward a return of financial leverage metrics to  levels within guidelines for the company's ratings, specifically a  debt-to-EBITDA ratio of 1.8x or below and financial leverage ratio of 35% or  lower. The key rating triggers that could lead Fitch to downgrade the ratings include  run-rate: --Debt-to-EBITDA ratios that exceed 1.8x; --Debt-to-capital ratios that exceed 35%;  --EBITDA-to-revenue margins less than 7%; --EBITDA-based interest coverage ratios less than 10x or maximum allowable  dividend interest expense coverage below 5x; --Organization-wide run-rate Fitch-adjusted NAIC risk-based capital (RBC) ratios  below 275%. Fitch expects to assign the following rating: Aetna Inc. --$750 million senior unsecured notes 'A-'. Contact: Primary Analyst Bradley S. Ellis, CFA Director +1-312-368-2089 Fitch Ratings, Inc. 70 W. Madison Street Chicago, IL 60602 Secondary Analyst Mark E. Rouck, CPA, CFA Senior Director +1-312-368-2085 Committee Chairperson James B. Auden, CFA Managing Director +1-312-368-3146 Media Relations: Brian Bertsch, New York, Tel: +1 212-908-0549, Email:  brian.bertsch@fitchratings.com. Additional information is available at 'www.fitchratings.com'.  Applicable Criteria and Related Research:  --'Insurance Rating Methodology' (Nov. 13, 2013); --'Health Insurance and Managed Care (U.S.) Sector Credit Factors' (Dec. 18,  2013); --'2013 Outlook Report: U.S. Health Insurance and Managed Care' (Dec. 10, 2013). Applicable Criteria and Related Research:  2013 Outlook Report: U.S. Health Insurance and Managed Care here Health Insurance and Managed Care (U.S.)  here Insurance Rating Methodology  here Additional Disclosure  Solicitation Status  here ALL FITCH CREDIT RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND DISCLAIMERS.  PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING THIS LINK:  here. IN ADDITION, RATING  DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE AVAILABLE ON THE AGENCY'S  PUBLIC WEBSITE 'WWW.FITCHRATINGS.COM'. PUBLISHED RATINGS, CRITERIA AND  METHODOLOGIES ARE AVAILABLE FROM THIS SITE AT ALL TIMES. FITCH'S CODE OF  CONDUCT, CONFIDENTIALITY, CONFLICTS OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE  AND OTHER RELEVANT POLICIES AND PROCEDURES ARE ALSO AVAILABLE FROM THE 'CODE OF  CONDUCT' SECTION OF THIS SITE. FITCH MAY HAVE PROVIDED ANOTHER PERMISSIBLE  SERVICE TO THE RATED ENTITY OR ITS RELATED THIRD PARTIES. DETAILS OF THIS  SERVICE FOR RATINGS FOR WHICH THE LEAD ANALYST IS BASED IN AN EU-REGISTERED  ENTITY CAN BE FOUND ON THE ENTITY SUMMARY PAGE FOR THIS ISSUER ON THE FITCH  WEBSITE.   ",2014-03-04,AET,"Tue Mar 4, 2014 | 12:07pm EST",Fitch Expects to Rate Aetna Inc.'s Sr Unsecured Notes 'A-',http://www.reuters.com//article/fitch-expects-to-rate-aetna-incs-sr-unse-idUSFit69193520140304?type=companyNews
13,"  Aetna Inc, the third largest U.S. health insurer, said on Friday it would not proceed with a proposed $120 million settlement with healthcare providers and plan members over out-of-network reimbursements.Aetna, which had agreed to settle in December 2012, said enough claimants had opted out to trigger a provision enabling it to cancel the deal.""Various legal and factual developments since the date of the settlement agreement led the company to believe terminating the settlement agreement was in its best interests,"" Aetna said in a filing with the U.S. Securities and Exchange Commission.Aetna had set aside reserves for the settlement and said it would add the remainder of those reserves to earnings, excluding amounts due to the settlement administrator. It took a $78 million after-tax charge for the settlement in the fourth quarter of 2012. Aetna said it will resume its defense in court.Patients and doctors accused the Hartford, Connecticut based insurer of using databases provided by Ingenix, part of UnitedHealth Group Inc since renamed OptumInsight, to systematically underpay claims involving services and supplies from out-of-network providers. In 2008, then-New York attorney general, Andrew Cuomo, who is now the state's governor, opened a separate probe into insurer reimbursements that ended in settlements with many national insurers.On January 13, 2009, UnitedHealth and Aetna agreed to stop using the Ingenix database and to help fund a new independent database Fair Health to calculate rates. Days later, UnitedHealth agreed to pay $350 million to settle lawsuits over its out-of-network reimbursements. Aetna did not disclose how many claimants had opted out of the settlement it was now vacating but said they had exceeded a threshold that allowed Aetna to end the agreement.The threshold was $20 million in value represented by the difference between charges providers billed for out-of-network services and the insurer's allowed amount that it agreed to pay on those services, the company said. The Aetna settlement would have paid claims on reimbursement practices starting March 1, 2001 for health plan members and June 3, 2003 for providers. The agreement did not contain an admission of wrongdoing.The case is In re: Aetna UCR Litigation, U.S. District Court, District of New Jersey, Nos. MDL-2020 and 07-03541.(Reporting by Caroline Humer; Editing by Lisa Von Ahn and Sofina Mirza-Reid)",2014-03-14,AET,"Fri Mar 14, 2014 | 1:47pm EDT",Aetna rejects $120 million out-of-network settlement,http://www.reuters.com//article/us-aetna-lawsuit-idUSBREA2D1HJ20140314?type=companyNews
14,"  March 14 Aetna Inc, the third largest U.S. health insurer, said on Friday it would not proceed with a proposed $120 million settlement with healthcare providers and plan members over out-of-network reimbursements.Aetna, which had agreed to settle in December 2012, said enough claimants had opted out to trigger a provision enabling it to cancel the deal.""Various legal and factual developments since the date of the settlement agreement led the company to believe terminating the settlement agreement was in its best interests,"" Aetna said in a filing with the U.S. Securities and Exchange Commission.Aetna had set aside reserves for the settlement and said it would add the remainder of those reserves to earnings, excluding amounts due to the settlement administrator. It took a $78 million after-tax charge for the settlement in the fourth quarter of 2012. Aetna said it will resume its defense in court. Patients and doctors accused the Hartford, Connecticut based insurer of using databases provided by Ingenix, part of UnitedHealth Group Inc since renamed OptumInsight, to systematically underpay claims involving services and supplies from out-of-network providers.In 2008, then-New York attorney general, Andrew Cuomo, who is now the state's governor, opened a separate probe into insurer reimbursements that ended in settlements with many national insurers. On Jan. 13, 2009, UnitedHealth and Aetna agreed to stop using the Ingenix database and to help fund a new independent database Fair Health to calculate rates. Days later, UnitedHealth agreed to pay $350 million to settle lawsuits over its out-of-network reimbursements.Aetna did not disclose how many claimants had opted out of the settlement it was now vacating but said they had exceeded a threshold that allowed Aetna to end the agreement. The threshold was $20 million in value represented by the difference between charges providers billed for out-of-network services and the insurer's allowed amount that it agreed to pay on those services, the company said.The Aetna settlement would have paid claims on reimbursement practices starting March 1, 2001 for health plan members and June 3, 2003 for providers. The agreement did not contain an admission of wrongdoing.The case is In re: Aetna UCR Litigation, U.S. District Court, District of New Jersey, Nos. MDL-2020 and 07-03541.",2014-03-14,AET,"Fri Mar 14, 2014 | 1:45pm EDT",UPDATE 1-Aetna rejects $120 million out-of-network settlement,http://www.reuters.com//article/aetna-lawsuit-idUSL2N0MB10E20140314?type=companyNews
15,"  March 14 Health insurer Aetna Inc said on Friday it would not go forward with a proposed $120 million settlement with healthcare providers and plan members regarding out-of-network reimbursement after claimants opted out of the suit and triggered a provision enabling it to cancel the deal.Aetna, which had agreed to settle in December 2012, said in a filing with the U.S. Securities and Exchange Commission that it would not move forward with the final settlement.The company did not disclose how many claimants had opted out of the settlement but said that providers and plan members who chose to opt out of the settlement exceeded a threshold that allowed Aetna to end the settlement. The threshold was $20 million in value represented by the difference between charges providers billed for out-of-network services and the insurer's allowed amount that it agreed to pay on those services, the company said. Aetna, which had set aside reserves for the settlement, said they would be added back into its results as earnings and accounted for as a special item. Aetna spokeswoman Cynthia Michener said the company would resume its defense in court.",2014-03-14,AET,"Fri Mar 14, 2014 | 10:32am EDT",Aetna rejects $120 million out-of-network settlement,http://www.reuters.com//article/aetna-lawsuit-idUSL2N0MB0PM20140314?type=companyNews
16,"  (New throughout, updates share price)By Caroline HumerApril 24 Aetna Inc said on Thursday its first few months under Obamacare turned out better than some investors had feared as it added new members not only on the exchanges but in its traditional large corporate business.Aetna's shares surged nearly 6 percent as the company allayed Wall Street concerns that health costs were higher than what it and competitors had planned for. It also said it beat first-quarter profit expectations as bad weather helped keep down doctor visits and medical costs.This year, Aetna introduced health plans in 17 of the new insurance exchanges created by President Barack Obama's healthcare law nationwide, making it the largest player by number of states, ahead of even WellPoint Inc.A rocky start to the exchanges, with technical failures and an advertising counteroffensive by Republican opponents of the Affordable Care Act, had raised fears of weak enrollment skewed toward older and sicker consumers.Aetna, which had warned it could lose money on the insurance exchanges, said enrollment exceeded expectations at about 230,000 sign-ups. It also said the health of its new members so far appeared to match how it priced those plans. It is considering remaining in 17 markets for 2015.The No. 3 U.S. health insurer also said membership in its corporate-sponsored plans surged by more than 400,000 people, helping quarterly profit beat Wall Street expectations and countering concerns that employers would be quick to send workers to the Obamacare exchanges.""With one quarter down, it appears that our pricing for this year on all of our commercial business was appropriate and it appears adequate enough for us to recover the new taxes and fees that are going to be imposed on us,"" Aetna Chief Financial Officer Shawn Guertin said during an interview. Aetna said the total number of Obamacare enrollees for 2014 could even swell to 450,000 as more last-minute sign-ups are processed, and as some people qualify for coverage due to changes in status. The Obama administration has reported 8 million new sign-ups in the program nationwide so far.Aetna shares rose 5.9 percent to $72.96 and WellPoint Inc., which reports next week, gained nearly 2 percent to $96.54. Larger rival UnitedHealth Group rose 1.7 percent.""Part of the reason (Aetna) stock is reacting so well is their comments on pricing,"" explained Sarah James, an analyst for Wedbush Securities.Last week, UnitedHealth said more healthy consumers and small businesses renewed their policies rather than buying Obamacare plans, making the latter less profitable. Aetna said the renewals had occurred as expected and that its pricing was on target. Chief Executive Officer Mark Bertolini said Aetna expects to submit proposed premium rates ranging from the low single-digit to double-digit percentages or more in its Obamacare markets for 2015. Those price increases are expected to play into the political fight over Obamacare as Republican lawmakers play up its faults ahead of congressional elections in November.HEPATITIS C DRUG CONCERNS Aetna raised its forecast for 2014 profit, saying it expected to end the year with an additional 800,000 to 1 million customers, with a total of more than 23 million people and $56 billion to $57 billion in operating revenues. It expects earnings of $6.35 to $6.55 per share, up from a previous forecast of at least $6.25 per share.Aetna said that another area of cost concern, an $84,000 new hepatitis C drug by Gilead Sciences Inc, had not materialized in its first quarter but would still be tracked closely this year.UnitedHealth said last week that spending on the new treatment, which has spurred a global outcry over the rising cost of novel drugs, had exceeded its expectations several times over. Aetna said it spent $30 million paying for the Sovaldi drug from Gilead in the first quarter, matching its expectations.In all, the health insurer's quarterly operating profit grew to $1.98 per share as severe winter weather slowed medical services use, which kept claims and costs down. A moderate flu season also helped, it said.Analysts on average had expected earnings of $1.55 per share, according to Thomson Reuters I/B/E/S. That figure excludes items such as acquisition costs for the purchase of Coventry last year, whose inclusion also helped profit.Revenue rose to $14 billion from $9.54 billion in the year earlier quarter. Aetna said it had raised health plan premiums to offset new taxes and fees set by Obama's Affordable Care Act. They include a fee used to help fund the exchanges, which began providing coverage on Jan. 1.Aetna said it had 22.72 million medical customers at the end of March, up from 22.19 million at the end of December and 18.3 million at the end of March 2013.   (Reporting by Caroline Humer; Editing by Michele Gershberg, Sofina Mirza-Reid and David Gregorio)",2014-04-24,AET,"Thu Apr 24, 2014 | 4:42pm EDT",UPDATE 4-Aetna says early months of Obamacare better than feared,http://www.reuters.com//article/aetna-results-idUSL2N0NG0ED20140424?type=companyNews
17,"  April 24 Aetna Inc. spent about $30 million during the first quarter on Sovaldi, the pricey new hepatitis C treatment from Gilead Sciences Inc., Chief Financial Officer Shawn Guertin said on Thursday during a conference call with investors.Guertin said the costs were in line with the company's expectations. Most of it was in its commercial business and in Medicare Part D, the government program in which private insurers manage drug benefits.  Medicaid-related Sovaldi costs accounted for the smallest portion of that $30 million, he said, as some states continue to develop policies on the drug and because some states where it operates do not use private insurance to pay for any pharmaceutical benefits.   (Reporting by Caroline Humer; Editing by Chizu Nomiyama) ",2014-04-24,AET,"Thu Apr 24, 2014 | 9:30am EDT","Aetna CFO says spent $30 mln on Sovaldi in Q1, as expected",http://www.reuters.com//article/aetna-results-hepatitisc-idUSL2N0NG0U620140424?type=companyNews
18,"   By Caroline Humer  Aetna Inc (AET.N) on Thursday reported a better-than-expected first quarter, helped by a surge in profits from its commercial business and by adding new customers.New customers were sourced partly from employers and partly from insurance exchanges created under President Barack Obama's signature healthcare law.It raised its forecast for 2014 profit, saying it expected to end the year with an additional 800,000 to 1 million customers, with a total of more than 23 million people and $56 billion to $57 billion in operating revenues.""Improvements appear to span the entire company, with limited health reform impact,"" Stifel analyst Thomas Carroll said in a research note.The third largest U.S. health insurer's quarterly operating profit grew to $1.98 per share as the percentage it spent on claims declined in its commercial business. Severe winter weather slowed medical services use, which kept claims and costs down, and a moderate flu season helped, it said. Aetna also said it had raised health plan premiums as it sought to recover Affordable Care Act-related taxes and fees in its revenues. Those taxes include an overall insurance fee that is used to help fund the exchanges, which began providing coverage on January 1.Revenue rose to $14 billion from $9.54 billion in the year earlier quarter.Aetna has one of the largest total memberships on these exchanges, behind WellPoint Inc. WLP.N, and offers plans in 17 states. Its better-than-expected quarter and raised outlook for 2014 growth comes one week after UnitedHealth Inc , which has only a small role on the exchanges, issued a conservative view for the year that brought sector shares down. Analysts on average had expected earnings of $1.55 per share, according to Thomson Reuters I/B/E/S. That figure excludes items such as acquisition costs for the purchase of Coventry last year, which also helped profit.The company reported net income of $665.5 million, or $1.82 per share, up from $490.1 million, or $1.48 per share, a year earlier. Aetna said it had 22.72 million medical customers at the end of March, up from 22.19 million at the end of December and 18.3 million at the end of March 2013.The company's commercial business grew by 405,000 during the first quarter, which includes new customers on the exchanges and also from its employer-based business.For 2014, it expects earnings of $6.35 to $6.55 per share, up from a previous forecast of at least $6.25 per share.The company cautioned it had signed up more new exchange members than expected and was not certain of their medical costs. Previously the company has said it expects to lose money on this new business as some of the previously uninsured may bear higher health costs.(Reporting by Caroline Humer; Editing by Lisa Von Ahn and Sofina Mirza-Reid)",2014-04-24,AET,"Thu Apr 24, 2014 | 9:04am EDT",Aetna quarterly profit beats forecasts as new members surge,http://www.reuters.com//article/us-aetna-results-idUSBREA3N0Q320140424?type=companyNews
19,"  The Chief Executive Officer of health insurer Aetna Inc (AET.N) said on Thursday that the company has a ""bias"" towards remaining in 2015 in the markets in the 17 states where it now offers health plans to individual on the public exchanges.Insurers must submit 2015 health plans to regulators in the next two months and are currently working out the premium rates and structures of those plans. Aetna CEO Mark Bertolini said the company added 230,000 paid members through the exchanges in the first quarter and anticipates ending 2014 with more than 450,000 members who have enrolled through the exchanges. While enrollment on the exchanges has officially closed, people are still able to enroll for new plans throughout this year if they meet certain requirements, such as life changes like job loss. (Reporting by Caroline Humer)",2014-04-24,AET,"Thu Apr 24, 2014 | 9:04am EDT",Aetna CEO says has 'bias' to maintain exchange markets in 2015,http://www.reuters.com//article/us-aetna-results-ceo-idUSBREA3N16K20140424?type=companyNews
20,"  April 24 The Chief Executive Officer of health insurer Aetna Inc said on Thursday that the company has a ""bias"" towards remaining in 2015 in the markets in the 17 states where it now offers health plans to individual on the public exchanges.Insurers must submit 2015 health plans to regulators in the next two months and are currently working out the premium rates and structures of those plans. Aetna CEO Mark Bertolini said the company added 230,000 paid members through the exchanges in the first quarter and anticipates ending 2014 with more than 450,000 members who have enrolled through the exchanges.  While enrollment on the exchanges has officially closed, people are still able to enroll for new plans throughout this year if they meet certain requirements, such as life changes like job loss.   (Reporting by Caroline Humer)",2014-04-24,AET,"Thu Apr 24, 2014 | 9:02am EDT",Aetna CEO says has 'bias' to maintain exchange markets in 2015,http://www.reuters.com//article/aetna-results-ceo-idUSL2N0NG0QF20140424?type=companyNews
21,"  (Refocuses on exchanges)By Caroline HumerApril 30 WellPoint Inc on Wednesday said that its Obamacare exchange business was sustainable so far, echoing comments from another major insurer last week that these new customers have cost as much as expected, not more.The report lifted shares in WellPoint, the second-largest U.S. health insurer, by about 5 percent and gave its next largest competitor Aetna Inc a 1.5 percent increase as it eased some investor concerns about the profitability of this business.""They are saying that there were no issues in the exchange experience so far. They are growing gang busters if you will. Even if there were any issues that manifested themselves going forward, they have very strong reserves and good overall results,"" Leerink Partners analyst Ana Gupte said.The exchanges, created under President Barack Obama's healthcare reform law, have sold new health plans to more than 8 million people. Insurers, and critics, have worried about the health of these new customers and whether the business will be a drain on insurers and U.S. taxpayers.WellPoint is selling individual policies on the new exchanges in the 14 states where it operates Blue Cross Blue Shield plans. It has the most total customers on the exchanges, about 150,000 more than Aetna, which is in 17 states.WellPoint said it added 400,000 new customers during the quarter and expects a total of 600,000 this year after it accounts for all enrollees, including those who signed up after a Feb. 15 cut-off for March 1 coverage. The business is ""in the green"", with profit margins of 3 to 5 percent, its top finance executive said.The age and general characteristics of the customers as well as the type of insurance coverage they have purchased were in line with the premium prices it set, WellPoint said, similar to the experience Aetna Inc described last week.WellPoint Chief Financial Officer Wayne DeVeydt cautioned he wants to see the remaining enrollments in the second quarter before declaring a win.""I want to make sure that converts before we officially say that we've got it all right, but it's very encouraging right now,"" DeVeydt said. The results underscored the company's improved outlook for 2014, which it raised by about 20 cents per share to at least $8.40 per share, excluding items.WellPoint's comments were more positive than Aetna's, which said that pricing had been in line with customer demographics but that ultimately it continued to see the business as a ""headwind"" for 2014 results.Like Aetna, WellPoint also said it is keeping an eye on the costs of the pricey new hepatitis C treatments, which cost $50 million in the first quarter alone. It has built in $100 million in additional hepatitis C drug costs for 2014, the company said.Gilead Sciences' new treatment Sovaldi broke sales launch records during the first quarter with its $84,000 price tag. An estimated 3.2 million Americans have this virus that can cause liver wasting disease and for the first time, this drug promises many of them a cure. NET PROFIT FALLS Net profit fell during the quarter, largely because of investment spending related to healthcare reform and higher administrative costs of adding new commercial customers.WellPoint, which runs Anthem and Empire Blue Cross Blue Shield plans, reported net income of $701 million, or $2.40 per share, down from $885 million, or $2.89 per share, a year earlier.Excluding net gains on investments, WellPoint's profit was $2.30 per share. Analysts on average had expected $2.12, according to Thomson Reuters I/B/E/S.The company said it had spent less on medical claims than expected, partly due to bad weather. Taxes were also lower than expected, while overall costs remained constrained.The company added 1.2 million members in its commercial business, which includes large national employers, local employers and the individual markets.   (Reporting by Caroline Humer; Editing by Lisa Von Ahn, Chizu Nomiyama and Sofina Mirza-Reid)",2014-04-30,AET,"Wed Apr 30, 2014 | 12:45pm EDT","UPDATE 3-WellPoint's Obamacare business making a profit, so far",http://www.reuters.com//article/wellpoint-results-idUSL2N0NM0E820140430?type=companyNews
22,"   By Ben Hirschler | LONDON  LONDON As Pfizer's (PFE.N) pursuit of AstraZeneca (AZN.L) provokes uproar, another big U.S. healthcare group is taking a much quieter path into the heart of UK bioscience from an inconspicuous office off London's Oxford Street.Johnson & Johnson's (JNJ.N) life science ""innovation centre"", which opened a year ago, represents a different approach to drug development based on building networks and scouting for small deals, rather than mega-merger consolidation.Its team of two dozen scientists-cum-dealmakers, operating in the shadow of the Debenhams department store, struck 16 agreements last year for promising new treatments from universities and biotech companies in Britain and across Europe.Rival drugmakers are also putting an increased emphasis on doing external deals for early-stage science, but J&J has gone further than most in decentralizing the decision-making process. It has set up similar talent-spotting innovation offices in Shanghai, Boston and Menlo Park, California, in the past 12 months.""Other companies have two or three scouts in certain countries, but they need to call head office to get a decision, which means going to one committee and then another,"" said Patrick Verheyen, who heads up J&J's innovation operation in London.His team, by contrast, have autonomy to strike deals and see projects right through until the ""proof of concept"" stage of clinical testing.For many in the pharmaceutical industry, this outward-looking approach represents the future, because tapping into external science is vital if large corporations are to keep up with fast-moving developments in basic science and biotechnology. And that leaves some analysts wondering whether Pfizer's $106 billion attempt to buy AstraZeneca - a move rejected by the British firm - is actually focused on better drug discovery or really all about tax and cost savings, as many critics charge.""Pharma companies need to spend fewer biodollars internally and externalize more, yet Pfizer seem to be arguing they can succeed by pooling more intellectual capital in-house,"" said Navid Malik, head of life sciences research at Cenkos Securities.ONE PLUS ONE EQUALS LESS THAN TWO AstraZeneca, for its part, says the notion that smashing together two Big Pharma research departments leads to improved productivity has been debunked by past large-scale mergers in the sector. ""When you bring two huge organizations together, our industry tells us that it is hugely disruptive in terms of site closures, role closures,"" Mene Pangalos, the British group's head of early drug development, told a parliamentary panel on Wednesday. ""Overall, one plus one doesn't equal two - one plus one equals one point something.""Still, the situation is not black and white.Pfizer itself also does early-stage research deals - it struck a tie-up with UK universities in rare diseases just last week - and J&J has not shied away from some big acquisitions, with its medical devices unit buying Swiss-based Synthes for $20 billion in 2012. But J&J's business development work in pharmaceuticals is primarily focused these days on acquiring individual experimental medicines, whether at an early or late stage of testing. As a result, about half of J&J's drug pipeline now comes from outside the company, against an industry average of around a third.Interestingly, AstraZeneca also has a large proportion of experimental drugs that were invented externally, following a deal-making splurge by the company in the past few years, which was designed to plug a gap left by patent expiries and a run of in-house pipeline failures.With his small team in London - plus satellite partnering offices in Cambridge, Oxford, Manchester and Cardiff - Verheyen knows his operation is just one cog in the larger J&J research and development machine, which has interests spanning drugs, medical devices and consumer health products.But after years working on mergers and acquisitions within the U.S. group's pharmaceuticals division, he sees a clear rebalancing of the R&D model across J&J and the wider industry.""There is a shift to external research, absolutely. Most of the innovation is happening outside the walls of our organization,"" he said.""We as taxpayers fund a lot of academic research, so if we can help to make something from that academic research and help bring products closer to market then that is good for everybody.""(Reporting by Ben Hirschler; Editing by Will Waterman)",2014-05-14,AET,"Wed May 14, 2014 | 7:42am EDT",J&J taps British science quietly where Pfizer storms in,http://www.reuters.com//article/us-astrazeneca-pfizer-jj-idUSBREA4D09T20140514?type=companyNews
23,"  * J&J's London office aims to talent-spot new drugs* External deals an increasing focus across industry* Scepticism over smashing together big R&D operationsBy Ben HirschlerLONDON, May 14 As Pfizer's pursuit of AstraZeneca provokes uproar, another big U.S. healthcare group is taking a much quieter path into the heart of UK bioscience from an inconspicuous office off London's Oxford Street.Johnson & Johnson's life science ""innovation centre"", which opened a year ago, represents a different approach to drug development based on building networks and scouting for small deals, rather than mega-merger consolidation.Its team of two dozen scientists-cum-dealmakers, operating in the shadow of the Debenhams department store, struck 16 agreements last year for promising new treatments from universities and biotech companies in Britain and across Europe.Rival drugmakers are also putting an increased emphasis on doing external deals for early-stage science, but J&J has gone further than most in decentralising the decision-making process. It has set up similar talent-spotting innovation offices in Shanghai, Boston and Menlo Park, California, in the past 12 months.""Other companies have two or three scouts in certain countries, but they need to call head office to get a decision, which means going to one committee and then another,"" said Patrick Verheyen, who heads up J&J's innovation operation in London. His team, by contrast, have autonomy to strike deals and see projects right through until the ""proof of concept"" stage of clinical testing.For many in the pharmaceutical industry, this outward-looking approach represents the future, because tapping into external science is vital if large corporations are to keep up with fast-moving developments in basic science and biotechnology.And that leaves some analysts wondering whether Pfizer's $106 billion attempt to buy AstraZeneca - a move rejected by the British firm - is actually focused on better drug discovery or really all about tax and cost savings, as many critics charge.""Pharma companies need to spend fewer biodollars internally and externalise more, yet Pfizer seem to be arguing they can succeed by pooling more intellectual capital in-house,"" said Navid Malik, head of life sciences research at Cenkos Securities. ONE PLUS ONE EQUALS LESS THAN TWO AstraZeneca, for its part, says the notion that smashing together two Big Pharma research departments leads to improved productivity has been debunked by past large-scale mergers in the sector.""When you bring two huge organisations together, our industry tells us that it is hugely disruptive in terms of site closures, role closures,"" Mene Pangalos, the British group's head of early drug development, told a parliamentary panel on Wednesday. ""Overall, one plus one doesn't equal two - one plus one equals one point something."" Still, the situation is not black and white.Pfizer itself also does early-stage research deals - it struck a tie-up with UK universities in rare diseases just last week - and J&J has not shied away from some big acquisitions, with its medical devices unit buying Swiss-based Synthes for $20 billion in 2012.But J&J's business development work in pharmaceuticals is primarily focused these days on acquiring individual experimental medicines, whether at an early or late stage of testing. As a result, about half of J&J's drug pipeline now comes from outside the company, against an industry average of around a third.Interestingly, AstraZeneca also has a large proportion of experimental drugs that were invented externally, following a deal-making splurge by the company in the past few years, which was designed to plug a gap left by patent expiries and a run of in-house pipeline failures.With his small team in London - plus satellite partnering offices in Cambridge, Oxford, Manchester and Cardiff - Verheyen knows his operation is just one cog in the larger J&J research and development machine, which has interests spanning drugs, medical devices and consumer health products.But after years working on mergers and acquisitions within the U.S. group's pharmaceuticals division, he sees a clear rebalancing of the R&D model across J&J and the wider industry.""There is a shift to external research, absolutely. Most of the innovation is happening outside the walls of our organisation,"" he said.""We as taxpayers fund a lot of academic research, so if we can help to make something from that academic research and help bring products closer to market then that is good for everybody.""   (Reporting by Ben Hirschler; Editing by Will Waterman)",2014-05-14,AET,"Wed May 14, 2014 | 7:41am EDT",J&J taps British science quietly where Pfizer storms in,http://www.reuters.com//article/astrazeneca-pfizer-jj-idUSL6N0NY44920140514?type=companyNews
24,"  Ventas Inc, one of the largest U.S. healthcare real estate investment trusts, said it would buy American Realty Capital Healthcare Trust Inc in a cash and stock deal valued at about $2.6 billion.Ventas also said it would buy 29 independent living seniors housing communities in Canada from Holiday Retirement Corp for about C$980 million (about $902 million) in cash.Ventas said the deal with ARC Healthcare would add 143 properties, comprising medical office buildings and senior housing communities, to its portfolio.Ventas had about 1,029 medical office buildings and senior housing communities as of Dec. 31, 2013. Ventas said ARC Healthcare shareholders will have the option to receive either 0.1688 Ventas shares or $11.33 in cash for each ARC Healthcare share. The cash offer represents a premium of about 14 percent to ARC Healthcare's Friday closing. Ventas said the deals would add at least 10 cents per share to its 2015 funds from operations (FFO), a measure of cash flow for real estate management companies.  (Reporting by Ankit Ajmera in Bangalore; Editing by Saumyadeb Chakrabarty)",2014-06-02,AET,"Mon Jun 2, 2014 | 8:22am EDT",Ventas to buy ARC Healthcare in $2.6 billion deal,http://www.reuters.com//article/us-american-realty-capital-healthcare-tr-idUSKBN0ED0ZX20140602?type=companyNews
25,"  (Adds details, background)June 2 Ventas Inc, one of the largest U.S. healthcare real estate investment trusts, said it would buy American Realty Capital Healthcare Trust Inc in a cash and stock deal valued at about $2.6 billion.Ventas also said it would buy 29 independent living seniors housing communities in Canada from Holiday Retirement Corp for about C$980 million (about $902 million) in cash. Ventas said the deal with ARC Healthcare would add 143 properties, comprising medical office buildings and senior housing communities, to its portfolio. Ventas had about 1,029 medical office buildings and senior housing communities as of Dec. 31, 2013. Ventas said ARC Healthcare shareholders will have the option to receive either 0.1688 Ventas shares or $11.33 in cash for each ARC Healthcare share. The cash offer represents a premium of about 14 percent to ARC Healthcare's Friday closing.Ventas said the deals would add at least 10 cents per share to its 2015 funds from operations (FFO), a measure of cash flow for real estate management companies.  ($1 = 1.0859 Canadian Dollars)   (Reporting by Ankit Ajmera in Bangalore; Editing by Saumyadeb Chakrabarty)",2014-06-02,AET,"Mon Jun 2, 2014 | 8:19am EDT",UPDATE 1-Ventas to buy ARC Healthcare in $2.6 bln deal,http://www.reuters.com//article/american-realty-capital-healthcare-trust-idUSL3N0OJ2BR20140602?type=companyNews
26,"   By Lucia Mutikani | WASHINGTON  WASHINGTON The U.S. economy likely contracted at a much sharper pace in the first quarter than previously estimated with data on Wednesday showing weaker healthcare spending. The Commerce Department's quarterly services survey, or QSS, showed healthcare outlays were not as strong as the government had assumed when it published its second gross domestic product estimate for the first quarter last month.The government reported that the economy contracted at a 1.0 percent annual rate in the January-March period. But with healthcare spending data now in hand, economists say growth probably declined at a rate of at least 1.7 percent. A widening of the nation's trade deficit in March had already led economists to anticipate a downward revision to GDP when the government publishes its third estimate later this month. Ryan Sweet, a senior economist at Moody's Analytics in West Chester, Pennsylvania said the latest numbers on services spending ""made the first quarter look even worse.""""Healthcare spending did not add nearly as much to growth as we initially thought in the first quarter,"" he said. It is not unusual for the government to make big revisions to GDP numbers as it does not have complete data when it makes its first and second estimates, and the QSS has led to big revisions at times over the last several years.Even if the economy turns out to have been much weaker than previously thought, there is little cause for concern as many of the factors that held it down in the first quarter were temporary and data ranging from employment to factory and services sector activity indicate it has since rebounded.The government previously estimated that healthcare spending contributed one percentage point to growth, but economists said the QSS suggested healthcare spending added only about 0.7 percentage point. Since the fourth quarter, demand for healthcare services has helped to push up consumer spending, which accounts for more than two-thirds of U.S. economic activity. Part of the rise in spending reflects the implementation of President Barack Obama's signature healthcare law.Daniel Silver, an economist at JPMorgan in New York, said there was some uncertainty about how the government would incorporate the QSS data into its healthcare consumption estimate in the GDP data. ""But it looks like there could be a significant downward revision to healthcare consumption, which would make the healthcare data more in line with most of the other components of GDP which looked weak in the first quarter,"" said Silver. Should first-quarter GDP be revised sharply lower, economists could trim their growth estimates for 2014, which had been dubbed as a break-out year.""Because we had such a horrible start to the year, you're going to see GDP estimates for all of 2014 ratcheted down a little bit,"" said Sweet. ""But the good news is the data has improved and the second quarter is going to look better."" (Reporting by Lucia Mutikani; Editing by Andrea Ricci)",2014-06-11,AET,"Wed Jun 11, 2014 | 3:48pm EDT",U.S. healthcare data points to much weaker first-quarter GDP,http://www.reuters.com//article/us-usa-economy-gdp-idUSKBN0EM26H20140611?type=companyNews
27,"  (Adds context on exchanges)June 11 Health insurer Aetna Inc is submitting premium rates to regulators for Obamacare insurance plans for 2015 that generally increase less than 20 percent from 2014, its Chief Executive Officer Mark Bertolini said on Wednesday.Bertolini's comments, made during a Goldman Sachs healthcare conference outside Los Angeles, come as insurers prepare next year's health plans for the insurance exchanges created under the Affordable Care Act, known as Obamacare.About 8 million people have signed up for these plans, which are provided by commercial subscribers and come with income-based government subsidies. While Aetna and other insurers say they have lost money providing these plans this year, insurers are expanding into new markets for 2015 to capture a growing customer base.Bertolini said about half the rate of increases the insurer has submitted for 2015 were due to changes in Obamacare. Over the past year, President Barack Obama's administration has made such changes to the law as allowing some plans that had been due to phase out this year to remain in place. That has changed some of the assumptions that determine premium rates.Bertolini had predicted rate increases along these lines in April when he announced the company's first quarter earnings report. In addition, the company expects about 450,000 exchange customers at year end, in line with his previous outlook, Bertolini said during the presentation to investors.Aetna is one of the largest players on the exchanges, along with WellPoint Inc.Bertolini said the 2014 outlook takes into account that Aetna customers were disenrolling from exchange plans on a regular basis. While he didn't know why they were leaving, he suspected it was due to out-of-pocket costs before members reach their deductibles.   (Reporting by Caroline Humer; Editing by Chris Reese and Bernadette Baum)",2014-06-11,AET,"Wed Jun 11, 2014 | 2:42pm EDT",UPDATE 1-Aetna CEO says 2015 Obamacare rates to rise less than 20 pct,http://www.reuters.com//article/aetna-insurance-idUSL2N0OS1GT20140611?type=companyNews
28,"   By Lucia Mutikani | WASHINGTON, June 11  WASHINGTON, June 11 The U.S. economy likely contracted at a much sharper pace in the first quarter than previously estimated with data on Wednesday showing weaker healthcare spending.The Commerce Department's quarterly services survey, or QSS, showed healthcare outlays were not as strong as the government had assumed when it published its second gross domestic product estimate for the first quarter last month.The government reported that the economy contracted at a 1.0 percent annual rate in the January-March period. But with healthcare spending data now in hand, economists say growth probably declined at a rate of at least 1.7 percent.A widening of the nation's trade deficit in March had already led economists to anticipate a downward revision to GDP when the government publishes its third estimate later this month.Ryan Sweet, a senior economist at Moody's Analytics in West Chester, Pennsylvania said the latest numbers on services spending ""made the first quarter look even worse."" ""Healthcare spending did not add nearly as much to growth as we initially thought in the first quarter,"" he said.It is not unusual for the government to make big revisions to GDP numbers as it does not have complete data when it makes its first and second estimates, and the QSS has led to big revisions at times over the last several years.Even if the economy turns out to have been much weaker than previously thought, there is little cause for concern as many of the factors that held it down in the first quarter were temporary and data ranging from employment to factory and services sector activity indicate it has since rebounded. The government previously estimated that healthcare spending contributed one percentage point to growth, but economists said the QSS suggested healthcare spending added only about 0.7 percentage point.Since the fourth quarter, demand for healthcare services has helped to push up consumer spending, which accounts for more than two-thirds of U.S. economic activity. Part of the rise in spending reflects the implementation of President Barack Obama's signature healthcare law.Daniel Silver, an economist at JPMorgan in New York, said there was some uncertainty about how the government would incorporate the QSS data into its healthcare consumption estimate in the GDP data.""But it looks like there could be a significant downward revision to healthcare consumption, which would make the healthcare data more in line with most of the other components of GDP which looked weak in the first quarter,"" said Silver.Should first-quarter GDP be revised sharply lower, economists could trim their growth estimates for 2014, which had been dubbed as a break-out year.""Because we had such a horrible start to the year, you're going to see GDP estimates for all of 2014 ratcheted down a little bit,"" said Sweet. ""But the good news is the data has improved and the second quarter is going to look better.""   (Reporting by Lucia Mutikani; Editing by Andrea Ricci)",2014-06-11,AET,"Wed Jun 11, 2014 | 2:29pm EDT",U.S. healthcare data points to much weaker first-quarter GDP,http://www.reuters.com//article/usa-economy-gdp-idUSL2N0OS1EU20140611?type=companyNews
29,"  June 11 Health insurer Aetna Inc is submitting premium rates to regulators for 2015 Obamacare insurance plans that generally increase less than 20 percent from 2014, Chief Executive Officer Mark Bertolini said on Wednesday.Speaking during a Goldman Sachs healthcare conference outside Los Angeles, Bertolini said that about half of the rate increases that the insurer has submitted are related to changes since the creation of the Affordable Care Act, often called Obamacare. In the past year, President Barack Obama's administration has made changes to the law, such as allowing some plans that had been due to phase out this year to remain in place. That has changed some of the information used to set premium rates. The comments were similar to expectations that Bertolini had laid out in April when announcing the company's first quarter earnings report. Bertolini said that customers are disenrolling from exchange plans on a regular basis but that the company still expects to have 450,000 exchange customers at year end. He said that while he did not know the reason for these customers leaving, he suspected that it was due to the out-of-pocket costs before members reach their deductibles.   (Reporting by Caroline Humer; Editing by Chris Reese)",2014-06-11,AET,"Wed Jun 11, 2014 | 1:30pm EDT",Aetna CEO says 2015 Obamacare rates increase less than 20 pct,http://www.reuters.com//article/aetna-insurance-idUSL2N0OS1CF20140611?type=companyNews
30,"   By Lucia Mutikani | WASHINGTON  WASHINGTON The U.S. economy likely contracted at a much sharper pace in the first quarter than previously estimated with data on Wednesday showing weaker healthcare spending. The Commerce Department's quarterly services survey, or QSS, showed healthcare outlays were not as strong as the government had assumed when it published its second gross domestic product estimate for the first quarter last month.The government reported that the economy contracted at a 1.0 percent annual rate in the January-March period. But with healthcare spending data now in hand, economists say growth probably declined at a rate of at least 1.7 percent. A widening of the nation's trade deficit in March had already led economists to anticipate a downward revision to GDP when the government publishes its third estimate later this month. Ryan Sweet, a senior economist at Moody's Analytics in West Chester, Pennsylvania said the latest numbers on services spending ""made the first quarter look even worse.""""Healthcare spending did not add nearly as much to growth as we initially thought in the first quarter,"" he said. It is not unusual for the government to make big revisions to GDP numbers as it does not have complete data when it makes its first and second estimates, and the QSS has led to big revisions at times over the last several years.Even if the economy turns out to have been much weaker than previously thought, there is little cause for concern as many of the factors that held it down in the first quarter were temporary and data ranging from employment to factory and services sector activity indicate it has since rebounded.The government previously estimated that healthcare spending contributed one percentage point to growth, but economists said the QSS suggested healthcare spending added only about 0.7 percentage point. Since the fourth quarter, demand for healthcare services has helped to push up consumer spending, which accounts for more than two-thirds of U.S. economic activity. Part of the rise in spending reflects the implementation of President Barack Obama's signature healthcare law.Daniel Silver, an economist at JPMorgan in New York, said there was some uncertainty about how the government would incorporate the QSS data into its healthcare consumption estimate in the GDP data. ""But it looks like there could be a significant downward revision to healthcare consumption, which would make the healthcare data more in line with most of the other components of GDP which looked weak in the first quarter,"" said Silver. Should first-quarter GDP be revised sharply lower, economists could trim their growth estimates for 2014, which had been dubbed as a break-out year.""Because we had such a horrible start to the year, you're going to see GDP estimates for all of 2014 ratcheted down a little bit,"" said Sweet. ""But the good news is the data has improved and the second quarter is going to look better."" (Reporting by Lucia Mutikani; Editing by Andrea Ricci)",2014-06-12,AET,"Wed Jun 11, 2014 | 9:25pm EDT",U.S. healthcare data points to much weaker first-quarter GDP,http://www.reuters.com//article/us-usa-economy-gdp-idUSKBN0EM26H20140612?type=companyNews
31,"  (Adds CEO quote on rate increase range)June 11 Health insurer Aetna Inc is submitting premium rates to regulators for Obamacare insurance plans for 2015 that generally increase less than 20 percent from 2014, its Chief Executive Officer Mark Bertolini said on Wednesday.""We have rates that are in the zero category. On average, it's in the low double digits, as a rate increase across the population,"" Bertolini said.Bertolini's comments, made during a Goldman Sachs healthcare conference outside Los Angeles, come as insurers prepare next year's health plans for the insurance exchanges created under the Affordable Care Act, known as Obamacare.About 8 million people have signed up for these plans, which are provided by commercial subscribers and come with income-based government subsidies. While Aetna and other insurers say they have lost money providing these plans this year, insurers are expanding into new markets for 2015 to capture a growing customer base.Bertolini said about half the rate of increases the insurer has submitted for 2015 were due to changes in Obamacare. Over the past year, President Barack Obama's administration has made such changes to the law as allowing some plans that had been due to phase out this year to remain in place. That has changed some of the assumptions that determine premium rates.Bertolini had predicted rate increases along these lines in April when he announced the company's first quarter earnings report. In addition, the company expects about 450,000 exchange customers at year end, in line with his previous outlook, Bertolini said during the presentation to investors.Aetna is one of the largest players on the exchanges, along with WellPoint Inc.Bertolini said the 2014 outlook takes into account that Aetna customers were disenrolling from exchange plans on a regular basis. While he didn't know why they were leaving, he suspected it was due to out-of-pocket costs before members reach their deductibles.   (Reporting by Caroline Humer in New York; Editing by Chris Reese, Bernadette Baum and Bernard Orr)",2014-06-12,AET,"Wed Jun 11, 2014 | 8:29pm EDT",UPDATE 2-Aetna CEO says 2015 Obamacare rates to rise less than 20 pct,http://www.reuters.com//article/aetna-insurance-idUSL2N0OS1GT20140612?type=companyNews
32,"   By Andrew  M. Seaman | NEW YORK  NEW YORK (Reuters Health) - Young adults were more likely to report better physical and mental health after the U.S. passed sweeping changes to its healthcare system in 2010, according to a new study.Young people also spent less money after they were allowed to be covered under their parents health insurance plans until they turned 26 years old under the Affordable Care Act - better known as Obamacare, the researchers report.I think our study suggests it improved health and reduced exposure to healthcare costs, Dr. Kao-Ping Chua said. I think the larger question of cost versus benefit requires further study, but there do appear to have been significant benefits.Chua is the studys lead author and a pediatrician at Boston Childrens Hospital.He and his colleague Dr. Benjamin Sommers write in JAMA, the journal of the American Medical Association, that the effect expanding insurance access to young Americans had on healthcare spending, use and overall health was unknown. The reality is that when policies come out it takes about one to two years for national surveys to collect data on the post policy years, Chua said. So right now is when data from 2011 and 2012 are coming out.They analyzed data collected between 2002 and 2011 in annual surveys conducted by the U.S. Agency for Healthcare Research and Quality and compared results for 26,453 people between the ages of 19 and 25 years old to those for 34,052 people between the ages of 26 and 34.Before the healthcare law was implemented, about 63 percent of the younger group and about 73 percent of the older group were covered by health insurance. Insurance coverage increased to about 69 percent after the laws implementation in the younger group, but didnt change significantly for the older group. About 27 percent of the younger group reported excellent physical health before the policy change and that increased to about 31 percent after the laws implementation. There was also an increase in the percentage reporting excellent mental health.For the older age group, however, the percentage reporting excellent physical or mental health dropped slightly between the two time periods.The researchers also found that yearly out-of-pocket healthcare costs declined by about 18 percent for the younger group compared to the older group. I think our study suggests there was an improvement in self-reported physical and mental health as well as a decrease in out-of-pocket medical expenditures, Chua said.He added that they did not see an increase in how much healthcare people were using from before the policy was implemented, but more time may be needed to see a trend like that.Utilization may not have picked up in year one of the provision but as people get used to the idea of having insurance they may start using it more, he said.Also, because they only had data on a brief amount of time after the policy was implemented, Chua said additional research will be needed to confirm these findings.I think that will be an active area in future research, he said.",2014-06-17,AET,"Tue Jun 17, 2014 | 4:28pm EDT",U.S. healthcare law tied to benefits for young adults,http://www.reuters.com//article/us-obamacare-young-adults-idUSKBN0ES2QM20140617?type=companyNews
33,"   By Olivia Oran and Mike Stone | NEW YORK  NEW YORK U.S. drugmaker AbbVie Inc (ABBV.N) has recently approached London-listed Shire PLC (SHP.L) about a potential takeover, according to people familiar with the matter, marking the latest attempt by U.S. healthcare companies looking to acquire overseas rivals partly to lower their tax rates. AbbVie, which makes rheumatoid arthritis drug Humira, has a market capitalization of around $86 billion, while Shire has a market capitalization of roughly $38 billion.The companies have held talks in recent weeks following AbbVie's takeover approach, but there is no guarantee the discussions will lead to a transaction, the people said, asking not to be named because the matter is not public. Both parties have exchanged letters about a potential deal, the people said. It is also possible that other suitors will emerge for Shire, the people added.AbbVie said it does not comment on speculation and Shire could not be immediately reached for comment. Founded in 1986 in Britain, Shire conducts most of its business in the United States and has been domiciled in Ireland for tax purposes since 2008. With its tax base in Ireland, where effective corporate tax rates are among the lowest in the world, Shire, with a mid-sized market value, has been seen as a prime takeover target for U.S. drugmakers. Shire is weighing AbbVie's approach against the merits of remaining independent, as its chief executive Fleming Ornskov has only completed his first year on the job and has an alternative strategy of growing through acquisitions, one of the people said.Shire specializes in medicines for attention deficit hyperactivity disorder (ADHD), which account for around 40 percent of its sales. The firm also sells pricey drugs to treat rare genetic disorders and is building up a portfolio of treatments in ophthalmology and other specialty disease areas.AbbVie, based in North Chicago, Illinois, was founded last year as a spin-off from Abbott Laboratories (ABT.N). The company has been criticized for its overreliance on its top drug, Humira, which comprised over half of its revenue in the most recent quarter.  To lessen its reliance on Humira, the company is attempting to develop treatments for hepatitis C, cancer and other diseases.Shire had also been approached by Allergan Inc (AGN.N) in the months before the Botox maker itself became a takeover target for Valeant, Reuters previously reported.That approach did not lead to serious discussions between the two parties and there are currently no talks with Allergan, Reuters reported earlier this week.  U.S. pharmaceutical companies are in a race to keep up with rivals and are looking at lowering their tax rates in order to do so, in what is called as an inversion. Recent inversion deals have included medical device company Medtronic Inc's (MDT.N) $42.9 billion deal for Covidien this week, as well as Pfizer Inc's (PFE.N) abortive $118 billion bid for AstraZeneca PLC (AZN.L).Some U.S. lawmakers are concerned that the deals erode government revenue by giving corporations another tax-avoiding loophole. Two bills in the U.S. Congress and a White House proposal would make inversions harder to do, but neither has gained much traction. (Reporting by Olivia Oran and Mike Stone in New York, additional reporting by Soyoung Kim; Editing by Chris Reese and Diane Craft)",2014-06-19,AET,"Thu Jun 19, 2014 | 6:52pm EDT",Exclusive: AbbVie approaches Shire about possible takeover - sources,http://www.reuters.com//article/us-shire-abbvie-exclusive-idUSKBN0EU2Q020140619?type=companyNews
34,"  (Adds Canary Wharf, Dia, Coloplast, Telefonica, Baltic Exchange, Publicis, Clessidra, Letrika, Vivendi, Revel Casino, updates Alstom)June 20 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Friday:** British drugmaker Shire Plc has rejected a 27 billion-pound ($46 billion) takeover offer from AbbVie Inc , the latest attempt by a U.S. healthcare firm to tap into lower tax rates abroad via an acquisition.** France chose General Electric to form an alliance with Alstom on Friday - rejecting an offer from Siemens and Mitsubishi Heavy Industries - but said the deal still needed some work and added it would buy a 20 percent stake in the hotly-contested company.Mitsubishi Heavy Industries said on Friday it acknowledged and regretted the French government's decision to reject its joint offer with Siemens for a tie-up with Alstom.** Midstream energy company Targa Resources Corp  said on Thursday it is no longer in discussions with Energy Transfer Equity LP, the pipeline company controlled by billionaire Kelcy Warren, regarding a deal.Targa responded to a Bloomberg report on Thursday that said Energy Transfer is near a deal to buy Houston-based Targa Resources and its energy logistics operating unit Targa Resources Partners LP.** Sprint Corp has lined up eight banks to finance its proposed acquisition of T-Mobile US Inc, edging closer to a deal that would merge the third- and fourth-biggest U.S. mobile operators, according to people familiar with the matter.Five global banks - JPMorgan Chase & Co, Goldman Sachs Group, Deutsche Bank AG, Bank of America Merrill Lynch and Citigroup Inc - have agreed to finance Sprint.** Activist investor Carl Icahn has asked struggling retailer Family Dollar Stores Inc to put itself up for sale immediately, threatening a proxy war to replace its board otherwise.Icahn, who became Family Dollar's largest shareholder earlier this month, also sought three places on the board immediately and to be part of the committee for finding a buyer.** Eurasia Mining Plc, which operates gold and platinum group metals projects in Russia, said it would buy out partner Anglo American Platinum Ltd's stake in their platinum mining joint venture. The miner said its unit Eurasia Investments Ltd would buy the 50 percent stake it does not already own in Urals Alluvial Platinum from Rustenburg Platinum Mines.** Shares in TSB Banking Group PLC rose sharply following its debut on the London Stock Exchange after Lloyds Banking Group sold more of the offshoot business than originally planned, raising the prospect of a further sale this year. Lloyds said on Friday it had sold a 35 percent stake in TSB, Britain's 7th-largest lender, at 260 pence a share. That valued the business at 1.3 billion pounds ($2.22 billion), less than the figure on Lloyds' books.** Canary Wharf Group has sold a 1 million square foot (93,000 sq metre) building in London's financial district to a Chinese-Qatari consortium for 795 million pounds ($1.4 billion), the group's owner said on Friday.** Spain's Dia, the world's third-largest discount supermarkets group, said on Friday it had reached a preliminary deal to sell its loss-making Dia France unit to Carrefour . The deal values Dia France, which operates more than 800 stores, at 600 million euros ($814 million) including debt, the two companies said in separate statements.** Oando Plc said it had won government approval to complete a $1.65 billion acquisition of ConocoPhillips'  Nigerian assets.** Mediaset Espana Comunicacion SA's option to make an offer on a 56 percent stake in pay-tv company Canal+, a stake that Prisa plans to sell to Telefonica, has been extended to July 4, the companies said in a statement on Friday. Telefonica has already offered up to 355 million euros ($483.34 million) for the 22 percent stake that Mediaset already owns. ** Carlyle Group has sold its entire 7.13 percent stake in Moncler SpA for 215 million euros ($293 million), the asset manager said on Friday, six months after the Italian luxury down jacket maker listed on the Milan bourse.Carlyle, which held its Moncler holding through CEP III Participations, sold the shares at 12.04 euros each, a 0.5 percent discount compared with the stock's closing price on Thursday.** Swiss bank Vontobel Holding AG said on Friday it will buy back 12.5 percent of its shares currently held by Swiss retail bank Raiffeisen. The move comes after Raiffeisen said earlier it would end its back-office partnership with Vontobel, which runs to the middle of 2017.** Any alliance between Barrick Gold Corp and China's sole state-owned gold mining company is likely to involve a smaller, non-core Barrick mine or project and not any of the Canadian miner's main assets, a China National Gold Group official said on Thursday.** Italian defense conglomerate Finmeccanica SpA  said on Thursday it has opened the data room of its loss-making train unit AnsaldoBreda to potential bidders, without naming them, and also announced a revamp of its corporate structure. ** British grocer J Sainsbury Plc has teamed up with Denmark's Dansk Supermarked to bring the Netto brand back to the UK and take on fast-growing German discount chains Aldi Inc and Lidl UK GmbH at their own game.Denmark's largest retailer and Sainsbury's said they would spend an initial 25 million pounds ($43 million) setting up a joint venture that will open 15 Netto stores in the UK by the end of 2015.** Danish healthcare products maker Coloplast  could be negatively affected in the key German market by private equity firm Nordic Capital's acquisition of GHD GesundHeits, brokerage Nordea wrote in a note to clients on Friday.** Telefonica has sold bonds it held which are convertible into Telecom Italia shares, a source at the Spanish group said on Friday, raising questions among market players about its commitment to the Italian phone company.** London's centuries-old Baltic Exchange and clearing house LCH.Clearnet are in talks about a tie-up aimed at breathing new life into the loss-making Baltex dry bulk freight derivatives platform, the two groups said on Friday.** Publicis boss Maurice Levy plans to shift the French advertising group more quickly and deeply into digital services following last month's collapse of his plan to merge with Omnicom to create the world's largest ad agency.** Italian private equity firm Clessidra could take a stake of around a third in Harmont & Blaine to help the Naples-based firm expand ahead of a planned bourse listing, the head of the high-end casual wear maker said on Friday.** Six Slovenian state-owned firms and banks sold 54 percent of car parts maker Letrika to Austrian rival Mahle Holding Austria GmbH, state-owned company SDH, which coordinated the sale, said on Friday.** France's Vivendi said on Friday it had signed a definitive agreement to sell its telecom unit SFR to cable company Numericable after ""constructive"" talks with labour unions.** Atlantic City's bankrupt Revel Casino Hotel has received court approval to borrow $23.9 million that it said would keep the 1,400-room resort operating for the coming month as it scrambles to find a buyer.    (Compiled by Lehar Maan and Ankit Ajmera in Bangalore)",2014-06-20,AET,"Fri Jun 20, 2014 | 4:20pm EDT",Deals of the day- Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL4N0P131K20140620?type=companyNews
35,"   By Kate Holton and Chris Vellacott | LONDON  LONDON British drugmaker Shire (SHP.L) has rejected a 27 billion-pound  ($46 billion) takeover offer from AbbVie (ABBV.N), the latest attempt by a U.S. healthcare firm to tap into lower tax rates abroad via an acquisition.Shire, which has no single controlling shareholder, has been seen as a prime takeover target for U.S. drugmakers due to its attractive rare diseases business and its Irish tax base. Saying its annual product sales are set to more than double by 2020 to $10 billion, Shire rejected the 46.26 pounds per share offer as failing to reflect its true value, despite the offer being at a 30 percent premium to its share price over the last month.But analysts and one large shareholder said the firm may struggle to resist a bid of over 50 pounds per share.""You can easily see other people coming for Shire now because its in a good space,"" one of Shire's 40 biggest shareholders told Reuters.""Their pipeline is fantastic, its growing at 20 percent so for them (Abbvie) to offer 46 quid for that sort of growth profile we think is not enough. If they came back with 50-plus people would find it difficult (to say no) and that would be very sad.""Founded in 1986 in Britain, Shire conducts most of its business in the United States and has been domiciled in Ireland for tax purposes since 2008. AbbVie's takeover offer proposed creating a new U.S.-listed holding company with a tax domicile in Britain, where the government has also introduced tax breaks designed to encourage research and development. The approach marks the latest in a long line of mergers proposed by U.S. firms seeking to lower their tax rates, and comes less than a month after the collapse of Pfizer's (PFE.N) $118 billion bid for AstraZeneca (AZN.L) which was also motivated in part by tax considerations.    Ireland's corporation tax rate currently sits at 12.5 percent, one of the lowest in the world, while Britain has been cutting its rate from 28 percent in 2010 to 21 percent this year and 20 percent from 2015, well below the U.S. headline rate of 35 percent plus local taxes.Tax advisers say the British system also enables international companies to lower their tax rates in other ways.  Shire said the offer from AbbVie not only undervalued the company's prospects but ""the board also had concerns regarding the execution risks associated with the proposed (tax) inversion structure, as AbbVie would redomicile in the UK for tax purposes."" HIGHER PRICE NEEDED AbbVie was first to release a statement confirming that its offer had been rejected, after Reuters revealed the talks late on Thursday. Confirmation of the offer could kick off a bidding war for Shire, with sector bankers expecting the group to also prove appealing to U.S. pharmaceutical and biotech firms such as Bristol-Myers Squibb (BMY.N), Amgen (AMGN.O), Gilead (GILD.O) and Biogen (BIIB.O). Shire's share price was up 15 percent at over 43 pounds by 1150 GMT, valuing the firm at over 25 billion pounds ($43 billion). Shire said the rejected offer comprised 0.7988 AbbVie shares and 20.44 pounds in cash for every Shire share.AbbVie, which has a market capitalisation of around $86 billion, said it made an initial cash and share proposal in early May with an indicative value of 39.50 pounds per share. It did not describe the latest offer as final, meaning it could come back with an even higher price and has been given a deadline under UK takeover rules to either make a firm intention to make an offer, or walk away, by 1600 GMT on July 18. However, analysts at Barclays said that the cost synergies and tax inversion benefits of the existing offer could be limited.""With no obvious therapeutic overlaps between AbbVie and Shire, the prospect for cost savings appears limited to us,"" they said. ""We would view Shire as very much a bolt-on acquisition for AbbVie, albeit one with a $47 billion price tag.""We also believe the cash component of AbbVies current proposal is on the cusp of what it can come up with,"" the analysts said, adding, however, that a deal would help AbbVie to become less reliant on its rheumatoid arthritis drug Humira.Shire, which specialises in medicines for attention deficit hyperactivity disorder (ADHD) and drugs to treat rare genetic disorders, was previously approached by Botox-maker Allergan (AGN.N) months before the U.S. group itself became a takeover target for Valeant (VRX.TO). Shire is being advised by Citi, Evercore and Morgan Stanley whilst Abbvie is being advising by JPMorgan. (Editing by Jane Merriman and Greg Mahlich)",2014-06-20,AET,"Fri Jun 20, 2014 | 3:34pm EDT",Shire rejects AbbVie's $46 billion takeover bid,http://www.reuters.com//article/us-abbvie-shire-idUSKBN0EV0GW20140620?type=companyNews
36,"   By Kate Holton and Chris Vellacott | LONDON  LONDON British drugmaker Shire (SHP.L) has rejected a 27 billion-pound ($46 billion) takeover offer from AbbVie (ABBV.N), the latest attempt by a U.S. healthcare firm to tap into lower tax rates abroad via an acquisition.Shire, which has no single controlling shareholder, has been seen as a prime takeover target for U.S. drugmakers due to its attractive rare diseases business and its Irish tax base. Saying its annual product sales are set to more than double by 2020 to $10 billion, Shire rejected the 46.26 pounds per share offer as failing to reflect its true value, despite the offer being at a 30 percent premium to its share price over the last month.But analysts and one large shareholder said the firm may struggle to resist a bid of over 50 pounds per share.""You can easily see other people coming for Shire now because its in a good space,"" one of Shire's 40 biggest shareholders told Reuters.""Their pipeline is fantastic, its growing at 20 percent so for them (Abbvie) to offer 46 quid for that sort of growth profile we think is not enough. If they came back with 50-plus people would find it difficult (to say no) and that would be very sad.""Founded in 1986 in Britain, Shire conducts most of its business in the United States and has been domiciled in Ireland for tax purposes since 2008. AbbVie's takeover offer proposed creating a new U.S.-listed holding company with a tax domicile in Britain, where the government has also introduced tax breaks designed to encourage research and development. The approach marks the latest in a long line of mergers proposed by U.S. firms seeking to lower their tax rates, and comes less than a month after the collapse of Pfizer's (PFE.N) $118 billion bid for AstraZeneca (AZN.L) which was also motivated in part by tax considerations.    Ireland's corporation tax rate currently sits at 12.5 percent, one of the lowest in the world, while Britain has been cutting its rate from 28 percent in 2010 to 21 percent this year and 20 percent from 2015, well below the U.S. headline rate of 35 percent plus local taxes.Tax advisers say the British system also enables international companies to lower their tax rates in other ways.  Shire said the offer from AbbVie not only undervalued the company's prospects but ""the board also had concerns regarding the execution risks associated with the proposed (tax) inversion structure, as AbbVie would redomicile in the UK for tax purposes."" HIGHER PRICE NEEDED AbbVie was first to release a statement confirming that its offer had been rejected, after Reuters revealed the talks late on Thursday. Confirmation of the offer could kick off a bidding war for Shire, with sector bankers expecting the group to also prove appealing to U.S. pharmaceutical and biotech firms such as Bristol-Myers Squibb (BMY.N), Amgen (AMGN.O), Gilead (GILD.O) and Biogen (BIIB.O). Shire's share price was up 15 percent at over 43 pounds by 1150 GMT, valuing the firm at over 25 billion pounds ($43 billion). Shire said the rejected offer comprised 0.7988 AbbVie shares and 20.44 pounds in cash for every Shire share.AbbVie, which has a market capitalisation of around $86 billion, said it made an initial cash and share proposal in early May with an indicative value of 39.50 pounds per share. It did not describe the latest offer as final, meaning it could come back with an even higher price and has been given a deadline under UK takeover rules to either make a firm intention to make an offer, or walk away, by 1600 GMT on July 18. However, analysts at Barclays said that the cost synergies and tax inversion benefits of the existing offer could be limited.""With no obvious therapeutic overlaps between AbbVie and Shire, the prospect for cost savings appears limited to us,"" they said. ""We would view Shire as very much a bolt-on acquisition for AbbVie, albeit one with a $47 billion price tag.""We also believe the cash component of AbbVies current proposal is on the cusp of what it can come up with,"" the analysts said, adding, however, that a deal would help AbbVie to become less reliant on its rheumatoid arthritis drug Humira.Shire, which specialises in medicines for attention deficit hyperactivity disorder (ADHD) and drugs to treat rare genetic disorders, was previously approached by Botox-maker Allergan (AGN.N) months before the U.S. group itself became a takeover target for Valeant (VRX.TO). Shire is being advised by Citi, Evercore and Morgan Stanley whilst Abbvie is being advising by JPMorgan. (Editing by Jane Merriman and Greg Mahlich)",2014-06-20,AET,"Fri Jun 20, 2014 | 8:27am EDT",Shire rejects AbbVie's $46 billion takeover bid,http://www.reuters.com//article/uk-abbvie-shire-idUSKBN0EV16O20140620?type=companyNews
37,"  * Shire rejects AbbVie offer valued at 46.26 pounds a share* Investor, analysts say a deal might be done at over 50 pounds* Shire says to double product sales by 2020* Share price up 15 percent   (Adds further background, reaction)By Kate Holton and Chris VellacottLONDON, June 20 British drugmaker Shire  has rejected a 27 billion-pound  ($46 billion) takeover offer from AbbVie, the latest attempt by a U.S. healthcare firm to tap into lower tax rates abroad via an acquisition.Shire, which has no single controlling shareholder, has been seen as a prime takeover target for U.S. drugmakers due to its attractive rare diseases business and its Irish tax base.Saying its annual product sales are set to more than double by 2020 to $10 billion, Shire rejected the 46.26 pounds per share offer as failing to reflect its true value, despite the offer being at a 30 percent premium to its share price over the last month.But analysts and one large shareholder said the firm may struggle to resist a bid of over 50 pounds per share.""You can easily see other people coming for Shire now because it's in a good space,"" one of Shire's 40 biggest shareholders told Reuters. ""Their pipeline is fantastic, it's growing at 20 percent so for them (Abbvie) to offer 46 quid for that sort of growth profile we think is not enough. If they came back with 50-plus people would find it difficult (to say no) and that would be very sad.""Founded in 1986 in Britain, Shire conducts most of its business in the United States and has been domiciled in Ireland for tax purposes since 2008.AbbVie's takeover offer proposed creating a new U.S.-listed holding company with a tax domicile in Britain, where the government has also introduced tax breaks designed to encourage research and development.The approach marks the latest in a long line of mergers proposed by U.S. firms seeking to lower their tax rates, and comes less than a month after the collapse of Pfizer's  $118 billion bid for AstraZeneca which was also motivated in part by tax considerations.Ireland's corporation tax rate currently sits at 12.5 percent, one of the lowest in the world, while Britain has been cutting its rate from 28 percent in 2010 to 21 percent this year and 20 percent from 2015, well below the U.S. headline rate of 35 percent plus local taxes. Tax advisers say the British system also enables international companies to lower their tax rates in other ways.Shire said the offer from AbbVie not only undervalued the company's prospects but ""the board also had concerns regarding the execution risks associated with the proposed (tax) inversion structure, as AbbVie would redomicile in the UK for tax purposes.""HIGHER PRICE NEEDED AbbVie was first to release a statement confirming that its offer had been rejected, after Reuters revealed the talks late on Thursday. Confirmation of the offer could kick off a bidding war for Shire, with sector bankers expecting the group to also prove appealing to U.S. pharmaceutical and biotech firms such as Bristol-Myers Squibb, Amgen, Gilead  and Biogen.Shire's share price was up 15 percent at over 43 pounds by 1150 GMT, valuing the firm at over 25 billion pounds ($43 billion). Shire said the rejected offer comprised 0.7988 AbbVie shares and 20.44 pounds in cash for every Shire share.AbbVie, which has a market capitalisation of around $86 billion, said it made an initial cash and share proposal in early May with an indicative value of 39.50 pounds per share.It did not describe the latest offer as final, meaning it could come back with an even higher price and has been given a deadline under UK takeover rules to either make a firm intention to make an offer, or walk away, by 1600 GMT on July 18.However, analysts at Barclays said that the cost synergies and tax inversion benefits of the existing offer could be limited.""With no obvious therapeutic overlaps between AbbVie and Shire, the prospect for cost savings appears limited to us,"" they said. ""We would view Shire as very much a bolt-on acquisition for AbbVie, albeit one with a $47 billion price tag.""We also believe the cash component of AbbVie's current proposal is on the cusp of what it can come up with,"" the analysts said, adding, however, that a deal would help AbbVie to become less reliant on its rheumatoid arthritis drug Humira.Shire, which specialises in medicines for attention deficit hyperactivity disorder (ADHD) and drugs to treat rare genetic disorders, was previously approached by Botox-maker Allergan  months before the U.S. group itself became a takeover target for Valeant.Shire is being advised by Citi, Evercore and Morgan Stanley whilst Abbvie is being advising by JPMorgan.    ($1=0.5864 British pounds)     (Editing by Jane Merriman and Greg Mahlich)",2014-06-20,AET,"Fri Jun 20, 2014 | 8:22am EDT",UPDATE 3-Shire rejects AbbVie's $46 billion takeover bid,http://www.reuters.com//article/abbvie-shire-idUSL6N0P113Q20140620?type=companyNews
38,"   By Greg Roumeliotis and Olivia Oran  Aetna Inc, the third largest U.S. health insurer, is exploring a sale of some of Coventry Health Care Inc's assets worth as much as $1.5 billion, according to people familiar with the matter, a year after it acquired its rival for $5.6 billion.Aetna is working with Bank of America Merrill Lynch on a sale process for Coventry's workers' compensation business that is expected to attract interest from other companies in the sector as well as private equity firms.Aetna and Bank of America Merrill Lynch declined to comment. The sale process reaffirms that Aetna's acquisition of Coventry was always about boosting its share of the fast-growing, U.S. government-backed Medicare and Medicaid programs.Aetna has its own workers' compensation business called Workers' Comp Access. The Hartford, Connecticut-based company completed the acquisition of Coventry in May 2013.  The business for sale offers cost and care management services to underwriters and administrators of workers' compensation insurance, as well as employers.  The health insurance claims services sector has seen robust deal activity in the past year, including Maurice ""Hank"" Greenberg's Starr Investment Holdings LLC-led $4.4 billion takeover of MultiPlan Inc and Apax Partners LLP's more than $3 billion acquisition of One Call Care Management Inc and Align Networks Inc. (Reporting by Greg Roumeliotis and Olivia Oran in New York; Editing by Bernard Orr)",2014-06-24,AET,"Tue Jun 24, 2014 | 5:20pm EDT",Exclusive: Aetna mulls sale of Coventry Health Care assets - sources,http://www.reuters.com//article/us-aetna-coventry-idUSKBN0EZ2QD20140624?type=companyNews
39,"   By Megan Davies | MOSCOW  MOSCOW U.S. healthcare firm Abbott Laboratories (ABT.N) is to buy Russian drugmaker Veropharm VRPH.MM for up to $495 million, giving it a manufacturing presence in a country where it has been operating for nearly 40 years, Abbott said on Tuesday.The deal bucks a drought in Russian M&A activity this year due to the country's faltering economy and the Ukraine crisis. U.S. companies have been particularly stymied from investing here with Washington advising top executives to steer clear of a major Russian investment forum in May. Abbott's purchase is the largest acquisition by a U.S. company in Russia since Philip Morris International Inc (PM.N) and Japan Tobacco Inc (2914.T) in December announced plans to buy stakes in cigarette distributor Megapolis for $750 million each, according to Thomson Reuters data. Shares in Veropharm, one of Russia's biggest drugmakers with a market capitalization of $300 million, shot up 34 percent to a three-year high by early afternoon trading in Moscow.""Russia's middle class is growing and when the middle class grows the sector that grows is healthcare,"" said one trader. ""There is an aging population and it is a country that really needs good pharma. If you want to get a part of that market you've got to be a local producer and this is a way for Abbott to be locally producing.""  It is the latest foray by Abbott into emerging markets, following a $2.9 billion deal earlier in the year to buy Chile's CFR Pharmaceuticals SA CFR.SN. Abbott, which sells healthcare devices and branded generics in 150 countries, last year split into two businesses and spun off its blockbuster rheumatoid arthritis drug in a new company, AbbVie Inc (ABBV.N). It has said it plans to focus the branded generics business on about 14 or 15 fast-growing emerging markets.Under the deal, Abbott will buy Garden Hills, a holding company which owns a controlling interest in Veropharm, for a range of $395 million to $495 million, depending on Garden Hills' ownership of Veropharm at the time of closure, Abbott said.  Garden Hills currently owns more than 80 percent of Veropharm but is expected to own more than 95 percent when the deal closes, Abbott said. Abbott will assume net debt of $136 million and plans to fund the transaction with cash on the balance sheet, it said. It expects the deal, to close in the fourth quarter, to add $150 million in sales in 2015. The Illinois-based company, which has been operating in Russia since 1978, said the deal would allow it to establish a manufacturing presence in the country. Veropharm has three pharmaceutical manufacturing sites in Pokrov, Belgorod and Voronezh. Abbott employs 1,400 staff in Russia in research and development, logistics, sales and marketing, according to its website. (Editing by Jason Bush and Susan Fenton)",2014-06-24,AET,"Tue Jun 24, 2014 | 6:45am EDT",U.S. firm Abbott to buy Russian drugmaker for up to $495 million,http://www.reuters.com//article/us-russia-veropharm-idUSKBN0EZ11J20140624?type=companyNews
40,"  * Rare deal in Russian M&A drought* Latest foray by Abbott into emerging markets* Gives Abbott manufacturing presence in Russia   (Adds background about Abbott, quote)By Megan DaviesMOSCOW, June 24 U.S. healthcare firm Abbott Laboratories is to buy Russian drugmaker Veropharm  for up to $495 million, giving it a manufacturing presence in a country where it has been operating for nearly 40 years, Abbott said on Tuesday.The deal bucks a drought in Russian M&A activity this year due to the country's faltering economy and the Ukraine crisis. U.S. companies have been particularly stymied from investing here with Washington advising top executives to steer clear of a major Russian investment forum in May. Abbott's purchase is the largest acquisition by a U.S. company in Russia since Philip Morris International Inc  and Japan Tobacco Inc in December announced plans to buy stakes in cigarette distributor Megapolis for $750 million each, according to Thomson Reuters data.Shares in Veropharm, one of Russia's biggest drugmakers with a market capitalisation of $300 million, shot up 34 percent to a three-year high by early afternoon trading in Moscow.""Russia's middle class is growing and when the middle class grows the sector that grows is healthcare,"" said one trader. ""There is an ageing population and it is a country that really needs good pharma. If you want to get a part of that market you've got to be a local producer and this is a way for Abbott to be locally producing."" It is the latest foray by Abbott into emerging markets, following a $2.9 billion deal earlier in the year to buy Chile's CFR Pharmaceuticals SA.Abbott, which sells healthcare devices and branded generics in 150 countries, last year split into two businesses and spun off its blockbuster rheumatoid arthritis drug in a new company, AbbVie Inc. It has said it plans to focus the branded generics business on about 14 or 15 fast-growing emerging markets.Under the deal, Abbott will buy Garden Hills, a holding company which owns a controlling interest in Veropharm, for a range of $395 million to $495 million, depending on Garden Hills' ownership of Veropharm at the time of closure, Abbott said. Garden Hills currently owns more than 80 percent of Veropharm but is expected to own more than 95 percent when the deal closes, Abbott said.Abbott will assume net debt of $136 million and plans to fund the transaction with cash on the balance sheet, it said.It expects the deal, to close in the fourth quarter, to add $150 million in sales in 2015.The Illinois-based company, which has been operating in Russia since 1978, said the deal would allow it to establish a manufacturing presence in the country. Veropharm has three pharmaceutical manufacturing sites in Pokrov, Belgorod and Voronezh.Abbott employs 1,400 staff in Russia in research and development, logistics, sales and marketing, according to its website.    (Editing by Jason Bush and Susan Fenton)",2014-06-24,AET,"Tue Jun 24, 2014 | 6:41am EDT",UPDATE 2-U.S. firm Abbott to buy Russian drugmaker for up to $495 mln,http://www.reuters.com//article/russia-veropharm-idUSL2N0P506920140624?type=companyNews
41,"  (Adds item on Reliance Communications)June 25 The following corporate finance-related stories were reported by media:* Aetna Inc, the third largest U.S. health insurer, is exploring a sale of some of Coventry Health Care Inc's assets worth as much as $1.5 billion, according to people familiar with the matter, a year after it acquired its rival for $5.6 billion.* One of Britain's largest hospital chains, Spire Healthcare, is about to list on the London Stock Exchange in a float estimated to be about 1 billion pounds ($1.70 billion), two sources familiar with the matter told Reuters. * Belgian nappy maker Ontex has set the price for its Brussels listing at 18 euros a share, giving the firm an equity value of 1.23 billion euros ($1.7 billion), two sources familiar with the matter said on Tuesday. * Deutsche Telekom and its Slovak Telekom unit are likely to be fined by EU antitrust regulators for squeezing out competitors by charging unfair wholesale prices in Slovakia, two people with knowledge of the matter said on Tuesday.* India's Reliance Communications Ltd on Wednesday raised $804 million by selling shares, people involved in the process said, in what is the single biggest equity issue since the pro-business Narendra Modi government took office. * Electronics retailer Best Buy Co is looking at a sale of or partnership for its Chinese business to better focus on its U.S. business, the Wall Street Journal reported citing people familiar with the matter.For the deals of the day click onFor the Morning News Call-EMEA newsletter click on     (Compiled by Esha Vaish in Bangalore)",2014-06-25,AET,"Wed Jun 25, 2014 | 1:58am EDT",UPDATE 1-Market Chatter-Corporate finance press digest,http://www.reuters.com//article/market-chatter-idUSL4N0P619R20140625?type=companyNews
42,"  June 25 The following corporate finance-related stories were reported by media:* Aetna Inc, the third largest U.S. health insurer, is exploring a sale of some of Coventry Health Care Inc's assets worth as much as $1.5 billion, according to people familiar with the matter, a year after it acquired its rival for $5.6 billion.* One of Britain's largest hospital chains, Spire Healthcare, is about to list on the London Stock Exchange in a float estimated to be about 1 billion pounds ($1.70 billion), two sources familiar with the matter told Reuters. * Belgian nappy maker Ontex has set the price for its Brussels listing at 18 euros a share, giving the firm an equity value of 1.23 billion euros ($1.7 billion), two sources familiar with the matter said on Tuesday. * Deutsche Telekom and its Slovak Telekom unit are likely to be fined by EU antitrust regulators for squeezing out competitors by charging unfair wholesale prices in Slovakia, two people with knowledge of the matter said on Tuesday. * Electronics retailer Best Buy Co is looking at a sale of or partnership for its Chinese business to better focus on its U.S. business, the Wall Street Journal reported citing people familiar with the matter.For the deals of the day click onFor the Morning News Call-EMEA newsletter click on     (Compiled by Esha Vaish in Bangalore)",2014-06-25,AET,"Wed Jun 25, 2014 | 12:26am EDT",Market Chatter- Corporate finance press digest,http://www.reuters.com//article/market-chatter-idUSL4N0P610P20140625?type=companyNews
43,"  LYNCHBURG Va. U.S. healthcare costs are a growing issue for businesses across the country, with the Federal Reserve keeping close tabs on the issue, a top Fed official said on Thursday.Speaking in a question and answer session after a speech to business leaders in Lynchburg, Virginia, Richmond Federal Reserve Bank President Jeffrey Lacker said that healthcare costs are a growing concern.""A lot of small businesses have been spending an inordinate amount of time trying to figure (out) a strategy for provisions that took effect at the beginning of this year,"" Lacker said. Lacker also said he supported maintaining interest rates at current levels, though he added that it would be a mistake to let inflation get out of control before raising rates.   (Reporting by Michael Flaherty; Editing by Paul Simao)",2014-06-26,AET,"Thu Jun 26, 2014 | 10:15am EDT",Fed carefully eyeing U.S. healthcare costs: Lacker,http://www.reuters.com//article/us-usa-fed-lacker-healthcare-idUSKBN0F11JH20140626?type=companyNews
44,"  LYNCHBURG, Va., June 26 U.S. healthcare costs are a growing issue for businesses across the country, with the Federal Reserve keeping close tabs on the issue, a top Fed official said on Thursday.Speaking in a question and answer session after a speech to business leaders in Lynchburg, Virginia, Richmond Federal Reserve Bank President Jeffrey Lacker said that healthcare costs are a growing concern. ""A lot of small businesses have been spending an inordinate amount of time trying to figure (out) a strategy for provisions that took effect at the beginning of this year,"" Lacker said.  Lacker also said he supported maintaining interest rates at current levels, though he added that it would be a mistake to let inflation get out of control before raising rates.   (Reporting by Michael Flaherty; Editing by Paul Simao)",2014-06-26,AET,"Thu Jun 26, 2014 | 9:46am EDT",Fed carefully eyeing U.S. healthcare costs - Lacker,http://www.reuters.com//article/usa-fed-lacker-healthcare-idUSW1N0N902A20140626?type=companyNews
45,"   By Caroline Valetkevitch | NEW YORK  NEW YORK U.S. healthcare companies are winning higher profit forecasts, bucking a wider trend on Wall Street, as pricey new biotech drugs hit the market and insurance enrollment rises under the Affordable Care Act.Analysts' profit expectations for the group have risen sharply since the start of the year, while estimates for most of the other nine Standard & Poor's 500 macro sectors have fallen, according to Thomson Reuters data.The jump in forecasts has come in the past two months, thanks largely to rising estimates for biotechnology companies such as Gilead (GILD.O), and for insurers, including Aetna (AET.N).It provides some early evidence that President Barack Obama's signature healthcare overhaul could be a long-term source of profit growth for managed care providers.""Now you're actually seeing real numbers grow and that population start to take off,"" said Betsy Pecor, portfolio manager at Eagle Asset Management, based in St. Petersburg, Florida. Companies ""are actually seeing that growth.""About 8 million people have signed up for the plans, which are provided by commercial subscribers and come with income-based government subsidies, above the 2 million who had enrolled by January.Aetna and other insurers have said they lost money on the plans this year, but insurers are heading into new markets for 2015 to add customers.Many healthcare companies are better able to manage Obamacare now than they were last year, Pecor said.EXCEEDS FORECASTS Profit estimates for healthcare companies for 2014 have jumped from up 8.3 percent at the start of January to up 12.2 percent now, one of just a few sectors with a 2014 earnings outlook that exceeds profit-growth forecasts at the start of the year, Thomson Reuters data showed.Earnings growth estimates for the whole S&P 500 this year have gone down slightly in that period, from 10.8 percent in January to 9.1 percent now. The upward revision is also the most of any sector except utilities, where estimates reflect a blow-out first quarter courtesy of home heating needs during the cold winter in North America. By contrast, the revisions to the health sector earnings reflect rising expectations for the second quarter and beyond.The question for investors is whether the improving outlook is already reflected in stock prices. The healthcare sector .SPXHC jumped 39 percent in 2013, more than any other sector except consumer discretionaries .SPLRCD. Healthcare is up 10.2 percent so far for 2014, outpacing the 6 percent rise for the wider S&P 500, but its advance has shown signs of slowing in the last month or so.""You have more people using healthcare at these higher rates, and that's going to get you earnings, but my question is for how long,"" said Kim Forrest, senior equity research analyst, Fort Pitt Capital Group in Pittsburgh.  ""It's really unclear at this point how much money this is and how long it can be sustained."" To be sure, valuations for the healthcare sector are relatively high. The price-to-earnings multiple for the sector is at 16.9, down from 17.3 at the start of the year. That compares with the S&P 500's earnings multiple of 16.0, which is up from about 15.1 at the start of 2014, Thomson Reuters data showed.There may still be pockets of value, especially in the health industry groups that have seen the greatest growth in earnings forecasts: biotech and insurance. Biotech's P/E ratio is 16.8 compared with 24.5 at the start of the year, while the average P/E ratio for the five managed care companies in the S&P 500 is 13.6, up from 12.4 at the beginning of 2014. Phil Orlando, chief equity market strategist at Federated Investors in New York, said his firm rotated money out of the high-growth biotech names and into less volatile names in the healthcare sector in March, but he still likes biotech.""There will come a point in the cycle, maybe later this year, that we put some money back into these biotechnology names.""PRICING POWER Biotechnology companies, which were top victims in the sell-off of so-called momentum stocks earlier this year, are the biggest contributors to the gain.Biotechs are benefiting from pricing power, as more of their blockbuster drugs come on the market, analysts said. The U.S. Food and Drug Administration approved 27 drugs last year and 39 in 2012, the most of any year except 1996. ""They're all in the midst of launching or have launched new products that are head and shoulders above the existing products out there, and they're getting the pricing and the demand,"" said David Heupel, senior healthcare analyst at Thrivent Investment Management, in Minneapolis.In the past 90 days, 25 analysts raised their profit expectations for the full year on Gilead, the maker of the market-leading hepatitis C treatment, Sovaldi, with a mean change of 65 percent higher. None revised expectations lower, Thomson Reuters StarMine data showed.Sovaldi's $84,000 price tag for a 12-week treatment is so high, however, that it has come under fire from insurers, who are pushing Gilead's rivals to offer lower prices when their hepatitis C medicines go on the market.For Alexion Pharmaceuticals (ALXN.O), 18 analysts raised their profit estimates in the past 90 days, with a mean change of 9.8 percent higher, while none revised them lower.Among insurers, 12 analysts raised their profit expectations over the past 90 days for Aetna's earnings, with a mean change of 2.2 percent higher, and just one revised them lower. For Cigna (CI.N), 15 analysts increased their profit estimates in the period, with a mean of 1.8 percent higher, compared with one revising them down, according to the StarMine data.The number of analysts who raised their earnings expectations for the healthcare sector as a whole in the past 90 days is 416 compared with 391 who lowered them over the same period, with a mean change of 3.1 percent higher.(Paragraph 20 of this story has been corrected to fix the number of FDA drug approvals last year to 27 from 39, which was the figure for 2012.) (Reporting by Caroline Valetkevitch, editing by John Pickering)",2014-06-26,AET,"Thu Jun 26, 2014 | 9:04am EDT","U.S. healthcare profit outlook brightens on Obamacare, drug prices",http://www.reuters.com//article/us-usa-healthcare-results-outlook-idUSKBN0F113R20140626?type=companyNews
46,"   By Caroline Valetkevitch | NEW YORK  NEW YORK U.S. healthcare companies are winning higher profit forecasts, bucking a wider trend on Wall Street, as pricey new biotech drugs hit the market and insurance enrollment rises under the Affordable Care Act.Analysts' profit expectations for the group have risen sharply since the start of the year, while estimates for most of the other nine Standard & Poor's 500 macro sectors have fallen, according to Thomson Reuters data.The jump in forecasts has come in the past two months, thanks largely to rising estimates for biotechnology companies such as Gilead, and for insurers, including Aetna.It provides some early evidence that President Barack Obama's signature healthcare overhaul could be a long-term source of profit growth for managed care providers.""Now you're actually seeing real numbers grow and that population start to take off,"" said Betsy Pecor, portfolio manager at Eagle Asset Management, based in St. Petersburg, Florida. Companies ""are actually seeing that growth.""About 8 million people have signed up for the plans, which are provided by commercial subscribers and come with income-based government subsidies, above the 2 million who had enrolled by January.Aetna and other insurers have said they lost money on the plans this year, but insurers are heading into new markets for 2015 to add customers.Many healthcare companies are better able to manage Obamacare now than they were last year, Pecor said.EXCEEDS FORECASTS Profit estimates for healthcare companies for 2014 have jumped from up 8.3 percent at the start of January to up 12.2 percent now, one of just a few sectors with a 2014 earnings outlook that exceeds profit-growth forecasts at the start of the year, Thomson Reuters data showed. Earnings growth estimates for the whole S&P 500 this year have gone down slightly in that period, from 10.8 percent in January to 9.1 percent now.The upward revision is also the most of any sector except utilities, where estimates reflect a blow-out first quarter courtesy of home heating needs during the cold winter in North America. By contrast, the revisions to the health sector earnings reflect rising expectations for the second quarter and beyond.The question for investors is whether the improving outlook is already reflected in stock prices. The healthcare sector jumped 39 percent in 2013, more than any other sector except consumer discretionaries. Healthcare is up 10.2 percent so far for 2014, outpacing the 6 percent rise for the wider S&P 500, but its advance has shown signs of slowing in the last month or so.""You have more people using healthcare at these higher rates, and that's going to get you earnings, but my question is for how long,"" said Kim Forrest, senior equity research analyst, Fort Pitt Capital Group in Pittsburgh.  ""It's really unclear at this point how much money this is and how long it can be sustained."" To be sure, valuations for the healthcare sector are relatively high. The price-to-earnings multiple for the sector is at 16.9, down from 17.3 at the start of the year. That compares with the S&P 500's earnings multiple of 16.0, which is up from about 15.1 at the start of 2014, Thomson Reuters data showed. There may still be pockets of value, especially in the health industry groups that have seen the greatest growth in earnings forecasts: biotech and insurance. Biotech's P/E ratio is 16.8 compared with 24.5 at the start of the year, while the average P/E ratio for the five managed care companies in the S&P 500 is 13.6, up from 12.4 at the beginning of 2014.Phil Orlando, chief equity market strategist at Federated Investors in New York, said his firm rotated money out of the high-growth biotech names and into less volatile names in the healthcare sector in March, but he still likes biotech.""There will come a point in the cycle, maybe later this year, that we put some money back into these biotechnology names.""PRICING POWER  Biotechnology companies, which were top victims in the sell-off of so-called momentum stocks earlier this year, are the biggest contributors to the gain.Biotechs are benefiting from pricing power, as more of their blockbuster drugs come on the market, analysts said. The U.S. Food and Drug Administration approved 39 drugs last year, the most of any year except 1996.""They're all in the midst of launching or have launched new products that are head and shoulders above the existing products out there, and they're getting the pricing and the demand,"" said David Heupel, senior healthcare analyst at Thrivent Investment Management, in Minneapolis.In the past 90 days, 25 analysts raised their profit expectations for the full year on Gilead, the maker of the market-leading hepatitis C treatment, Sovaldi, with a mean change of 65 percent higher. None revised expectations lower, Thomson Reuters StarMine data showed.Sovaldi's $84,000 price tag for a 12-week treatment is so high, however, that it has come under fire from insurers, who are pushing Gilead's rivals to offer lower prices when their hepatitis C medicines go on the market.For Alexion Pharmaceuticals, 18 analysts raised their profit estimates in the past 90 days, with a mean change of 9.8 percent higher, while none revised them lower.Among insurers, 12 analysts raised their profit expectations over the past 90 days for Aetna's earnings, with a mean change of 2.2 percent higher, and just one revised them lower. For Cigna, 15 analysts increased their profit estimates in the period, with a mean of 1.8 percent higher, compared with one revising them down, according to the StarMine data.The number of analysts who raised their earnings expectations for the healthcare sector as a whole in the past 90 days is 416 compared with 391 who lowered them over the same period, with a mean change of 3.1 percent higher. (Reporting by Caroline Valetkevitch, editing by John Pickering)",2014-06-26,AET,"Thu Jun 26, 2014 | 1:04am EDT","U.S. healthcare profit outlook brightens on Obamacare, drug prices",http://www.reuters.com//article/us-usa-healthcare-results-outlook-analys-idUSKBN0F10BX20140626?type=companyNews
47,"  WELLINGTON, July 11 New Zealand dairy co-operative Fonterra and U.S. healthcare company Abbott are planning to build up to five dairy farms in China to secure domestic supply to meet rising demand for milk in the world's second-largest economy.In a statement issued on Friday, the world's largest dairy exporter and Abbott, a major infant formula seller in China, said they had signed a $300 million agreement to build up the  farms in one of the world's fastest growing dairy markets, which would produce up to 160 million litres of milk each year.The planned hub, whose location is yet to be decided, would be Fonterra's third, following similar dairying centres in China's Shanxi and Hebei provinces. If the plan is approved by Chinese authorities, the companies said the first farm would begin producing in early 2017.""Farming hubs are a key part of our strategy to be a more integrated dairy business in Greater China, contribute to the growth and development of the local Chinese dairy industry and help meet local consumers' needs for safe, nutritious dairy products,"" Fonterra Chief Executive Officer Theo Spierings said in a statement. The deal would build on the existing relationship between the two companies, as Fonterra counts Abbott as a wholesale client of its milk powder products, which include Similac infant formula brand.Abbott is expanding its production capabilities in China, opening an infant formula plant near Shanghai in June. ""This strategic partnership gives us flexibility for the future on however we use milk,"" an Abbott spokesman said.Abbott recalled some of its milk formula brands in China and Vietnam in August after a contamination scare involving  products containing Fonterra-produced ingredients, which proved to be false. Abbott in April said the recall crimped sales of milk formula products by $75 million in the first quarter.Global milk formula makers are pushing to capitalise on increasing dairy demand from China, where growing middle classes are developing a voracious appetite for cheese, milk formula and other products.(Reporting by Naomi Tajitsu; Editing by Cynthia Osterman)",2014-07-10,AET,"Thu Jul 10, 2014 | 6:30pm EDT","Fonterra, Abbott to build dairy farms in China",http://www.reuters.com//article/abbott-fonterra-china-idUSL4N0PL5JI20140710?type=companyNews
48,"   By Sharon Begley | NEW YORK  NEW YORK In one of the largest tests of a novel way to deliver and pay for healthcare, insurer CareFirst BlueCross BlueShield announced on Thursday that 1.1 million people receiving care through its ""patient-centered medical homes"" last year were hospitalized less often and stayed for fewer days compared to patients in traditional fee-for-service care.Medical homes, a centerpiece of President Barack Obama's healthcare reform, have been heralded as one of the best hopes for reducing the cost of U.S. healthcare, the highest in the world, and improving its quality, which lags that of many other wealthy countries.Medical homes are basically groups of primary-care providers who pledge to coordinate care, adhere to guidelines meant to improve patients' health, and avoid unnecessary tests, among other steps.According to CareFirst, its medical home program, in its fourth year, also delivered high-quality care, measured by yardsticks such as whether doctors gave recommended cancer screenings and immunizations. The organization said it saved $130 million or 3.5 percent compared to projected spending under standard fee-for-service.The savings reached a level ""I wouldn't have thought possible,"" said CareFirst President Chet Burrell. The non-profit covers 3.4 million people in Maryland, Washington, D.C., and northern Virginia. Providers who hit the mark receive higher reimbursements from CareFirst: 12 percent above the standard rate just for participating in the medical home program and up to 36 percent more for quality outcomes. A physician could therefore receive $148 for a procedure usually reimbursed at $100.The insurer can afford that because better primary care, which accounts for just 6 percent of all medical spending, can reduce hospitalizations and visits to expensive specialists.A key element of the medical homes model is data, including information about which specialists are especially pricey, and electronic medical records alerting doctors about check-ups, medications and other care for patients with chronic conditions such as asthma and diabetes. The $130 million in savings was driven largely by 6.4 percent fewer hospital admissions, 11 percent fewer hospital days and 11 percent fewer visits to outpatient facilities.The last reflects the fact that medical homes have evening and weekend hours, so patients don't need to visit clinics and emergency rooms for non-urgent care after-hours. Medical homes have not been uniformly assessed as successful, however. A study of 32 of them, published in the Journal of the American Medical Association this year, found they did not reduce hospitalizations or costs and missed 10 of 11 quality goals.Other studies have been more encouraging, said Marci Nielsen, chief executive of the Patient-Centered Primary Care Collaborative. A year ago, BlueCross Blue Shield of Michigan reported its medical-home program saved $155 million and cut both emergency-room visits and hospital stays.The varying results underline the need to identify which aspects of medical homes such as being open on weekends and evenings or aggressively managing the care of the sickest patients - are key, she said. (Reporting by Sharon Begley; Editing by Cynthia Osterman)",2014-07-10,AET,"Thu Jul 10, 2014 | 12:07am EDT","New form of U.S. healthcare saves money, improves quality, one insurer finds",http://www.reuters.com//article/us-healthcare-medicalhome-idUSKBN0FF0AI20140710?type=companyNews
49,"   By Sharon Begley | NEW YORK, July 10  NEW YORK, July 10 In one of the largest tests of a novel way to deliver and pay for healthcare, insurer CareFirst BlueCross BlueShield announced on Thursday that 1.1 million people receiving care through its ""patient-centered medical homes"" last year were hospitalized less often and stayed for fewer days compared to patients in traditional fee-for-service care.Medical homes, a centerpiece of President Barack Obama's healthcare reform, have been heralded as one of the best hopes for reducing the cost of U.S. healthcare, the highest in the world, and improving its quality, which lags that of many other wealthy countries.Medical homes are basically groups of primary-care providers who pledge to coordinate care, adhere to guidelines meant to improve patients' health, and avoid unnecessary tests, among other steps.According to CareFirst, its medical home program, in its fourth year, also delivered high-quality care, measured by yardsticks such as whether doctors gave recommended cancer screenings and immunizations. The organization said it saved $130 million or 3.5 percent compared to projected spending under standard fee-for-service. The savings reached a level ""I wouldn't have thought possible,"" said CareFirst President Chet Burrell. The non-profit covers 3.4 million people in Maryland, Washington, D.C., and northern Virginia.Providers who hit the mark receive higher reimbursements from CareFirst: 12 percent above the standard rate just for participating in the medical home program and up to 36 percent more for quality outcomes. A physician could therefore receive $148 for a procedure usually reimbursed at $100.The insurer can afford that because better primary care, which accounts for just 6 percent of all medical spending, can reduce hospitalizations and visits to expensive specialists. A key element of the medical homes model is data, including information about which specialists are especially pricey, and electronic medical records alerting doctors about check-ups, medications and other care for patients with chronic conditions such as asthma and diabetes.The $130 million in savings was driven largely by 6.4 percent fewer hospital admissions, 11 percent fewer hospital days and 11 percent fewer visits to outpatient facilities. The last reflects the fact that medical homes have evening and weekend hours, so patients don't need to visit clinics and emergency rooms for non-urgent care after-hours.Medical homes have not been uniformly assessed as successful, however. A study of 32 of them, published in the Journal of the American Medical Association this year, found they did not reduce hospitalizations or costs and missed 10 of 11 quality goals.Other studies have been more encouraging, said Marci Nielsen, chief executive of the Patient-Centered Primary Care Collaborative. A year ago, BlueCross Blue Shield of Michigan reported its medical-home program saved $155 million and cut both emergency-room visits and hospital stays.The varying results underline the need to identify which aspects of medical homes such as being open on weekends and evenings or aggressively managing the care of the sickest patients - are key, she said.   (Reporting by Sharon Begley; Editing by Cynthia Osterman)",2014-07-10,AET,"Thu Jul 10, 2014 | 12:01am EDT","New form of U.S. healthcare saves money, improves quality, one insurer finds",http://www.reuters.com//article/healthcare-medicalhome-idUSL2N0PD0TG20140710?type=companyNews
50,"   By Lionel Laurent | LONDON  LONDON European stocks and the euro fell on Tuesday after shares in Portugal's biggest listed bank hit a record low, while a plunge in German economic sentiment pushed up borrowing costs for some peripheral euro zone countries.Global stock markets have recently been supported by dovish policy measures from major central banks and signs that economies are recovering, though worries persist over the pace of growth in Europe and the health of the region's banks.U.S. Federal Reserve Chair Janet Yellen is due to testify to  Congress on monetary policy later on Tuesday.A surprise jump in British inflation in June sent sterling higher and gilts lower. The 1.9 percent reading was the highest since January, picking up from May's 1.5 percent, a 4-1/2-year low. The pan-European FTSEurofirst 300 share index slipped 0.1 percent, with benchmark indexes in Frankfurt, Paris and London trading 0.1 to 0.5 percent lower after German economic morale sank to its lowest level since Jan. 2013. The weaker-than-expected ZEW survey also pushed the euro to a one-month low versus the dollar. The banking sector was a sharp underperformer, with Portugal's Banco Espirito Santo BES.LS slumping 17.5 percent to a fresh record low. Traders blamed concerns over the bank's Angolan loan portfolio and the sale of a stake at a low price by the bank's founding family on Monday. The MSCI All-Country World index traded flat, near record highs hit earlier this month.""The key takeaway is that the banking sector globally continues to struggle despite time having been bought, and policy being tremendously supportive,"" said Jeremy Batstone-Carr, head of private client research at Charles Stanley. ""The sector feels like a minefield."" Bond yields for Portugal and Greece were up 4 basis points and 3 basis points respectively, though Spanish and Italian yields were slightly lower.German bund futures gained 0.2 percent and the U.S. dollar index rose against a basket of currencies including the euro and yen after ECB chief Mario Draghi said a stronger euro was a risk to the sustainability of the recovery. Draghi said on Monday the European Central Bank's Governing Council was unanimous on the use of unconventional measures if inflation stayed too low. ""With the ECB signaling that it will continue to maintain an easing bias, with the possibility of quantitative easing in coming months, peripheral (bond) spreads probably have scope to come further in,"" said Nick Stamenkovic, bond strategist at RIA Capital Markets. The Bank of Japan maintained its stimulus program and stuck to a forecast that inflation will approach its 2 percent target next year, unfazed by recent data casting doubt on its scenario of an investment-led economic recovery. ""The BOJ have essentially backed off the idea of quantitative easing for now but are sending some cautious signals on growth,"" said Simon Derrick, head of currency strategy at BNY Mellon. ""Everything is stable and we are heading slowly and jerkily back towards higher inflation.""CITI STRENGTH U.S. and Asian stocks gained ground, with the Dow Jones Industrial average .DJI hitting an intraday record on Monday, helped by Citigroup's (C.N) better-than-expected earnings and more deals in the healthcare sector. In Asia, Japan's Nikkei average rose 0.7 percent while South Korea's Kospi .HS11 gained 1.0 percent. MSCI's broadest index of Asia-Pacific shares outside Japan gained 0.2 percent.The MSCI Emerging Market index, MSCI's benchmark emerging equity index, inched up to a 16-month high.Asian stock markets showed little reaction to stronger-than-expected new loan and money supply data for China. Chinese banks gave 1.08 trillion yuan ($173.90 billion) of new loans in June, beating expectations of 915 billion. The data, coming ahead of GDP and other numbers from China due on Wednesday, underscored the perception that the Chinese economy is stabilizing after a shaky start to the year but still needs more policy support to meet Beijing's growth target.In the Middle East, Israel approved an Egyptian-proposed deal that would halt the week-old Gaza shelling war on Tuesday but the Palestinian territory's dominant Hamas Islamists said they had not been consulted by Cairo. U.S. crude oil slipped to $100.45 and Brent crude futures edged down to $106.04. (Reporting by Lionel Laurent; Additional reporting by Atul Prakash, Emelia Sithole-Matarise and Anirban Nag; Editing by Catherine Evans)",2014-07-15,AET,"Tue Jul 15, 2014 | 7:14am EDT","BES slide, tumbling German sentiment hit markets",http://www.reuters.com//article/us-markets-global-idUSKBN0FK01B20140715?type=companyNews
51,"  TOKYO, July 15 Japan's Nikkei share average climbed to a 1-1/2-week high on Tuesday after Citigroup's strong earnings and a merger and acquisition deal in the U.S. healthcare industry lifted sentiment.     The Bank of Japan's policy meeting outcome got a muted reaction from the market. Investors are focused on BOJ Governor Haruhiko Kuroda's speech after the market close.     The Nikkei ended 0.6 percent higher to 15,395.16, the highest closing level since July 4.     The broader Topix gained 0.7 percent to 1,273.68 and the JPX-Nikkei Index 400 advanced 0.7 percent to 11,588.42.     The BOJ maintained its stimulus programme and stuck to its forecast that inflation will approach its 2 percent target next year, but slightly cut its economic growth projection for the current fiscal year.    (Reporting by Ayai Tomisawa; Editing by Richard Borsuk)   ",2014-07-15,AET,"Tue Jul 15, 2014 | 2:17am EDT",Nikkei rises to 1-1/2-week high on U.S. optimism; BOJ gets muted reaction,http://www.reuters.com//article/markets-japan-stocks-idUSL4N0PQ1ST20140715?type=companyNews
52,"  * Japan, South Korea lead gains; ex-Japan Asian MSCI up 0.2 pct* Focus on Yellen's testimony, investors count on slow exit from low rates* Gold licks wounds after biggest daily fall since DecemberBy Hideyuki SanoTOKYO, July 15 Asian shares rose on Tuesday after Citigroup's earnings and a fresh round of merger and acquisition activity in the U.S. healthcare sector lifted global stock prices.Yet, with elevated prices on Wall Street and elsewhere relying substantially on support from low interest rates, many investors were now focusing on Federal Reserve Chair Janet Yellen's testimony to a U.S. Senate committee.""Markets expect her to stick to the stance that she will guide policy by watching the pace of recovery in the job market and the economy,"" said Hirokazu Kabeya, senior strategist at Daiwa Securities.European shares are expected to tick down after hefty gains on Monday, with French shares seen dipping as much as 0.2 percent and Britain's FTSE and Germany's DAX  by 0.1 percent. In Asia, Japan's Nikkei average rose 0.7 percent while South Korea's Kospi gained 1.0 percent. MSCI's broadest index of Asia-Pacific shares outside Japan  gained 0.2 percent.Asian stock markets showed little reaction to stronger-than-expected new loan and money supply data for China. Chinese banks gave 1.08 trillion yuan ($173.90 billion) of new loans in June, beating expectations of 915 billion.The data, coming ahead of GDP and other numbers from China due on Wednesday, underscored the perception that the Chinese economy is stabilising after a shaky start to the year but still needs more policy support to meet Beijing's growth target.U.S. stocks ended higher on Monday, with the Dow Jones industrial average hitting an intraday record, helped by  Citigroup's better-than-expected earnings and more deals in the healthcare sector. Investors put aside concerns about euro zone banks for now, as Portugal's biggest bank reassured investors of its stability despite recent difficulties.Portuguese 10-year bond yields fell to 3.83 percent, retreating further from a six-week high above 4 percent hit last week after disclosures of financial problems at a web of family-held holding companies behind Banco Espirito Santo .Gold licked its wounds after the biggest fall in 7-1/2 months on Monday as the fading fears over Portugal's banking sector and a gain in U.S. equities prompted investors to take profits after bullion's rally to 3-1/2 month highs last week. It traded at $1,306.80 per ounce, having fallen as low as $1,302.90 on Monday.As risk appetite returned, the 10-year U.S. Treasury yield rose back to 2.541 percent from a five-week low of 2.494 percent last week. U.S. bond yields have been kept low as the Fed has signalled it plans to keep interest rates around zero even after it finishes tapering its stimulus programme.Yellen's testimony gives bond traders a chance to look for clues on when and how the Fed plans to raise interest rates, after the minutes of the Fed's last meeting showed policymakers discussed exit strategies from its ultra-loose policy.A shift in the U.S. rate outlook could have a big impact on asset prices.""While Yellen dismissed the recent rise in inflation as 'noise', our economists believe that inflationary pressures are building in a sustainable fashion and investors may be forced to start pricing in a more aggressive pace of hikes later this year,"" Sreekala Kochugovindan, an analyst at Barclays, wrote in a report.Major currencies hardly budged ahead of Yellen's comments. The euro stood at $1.3620 and the yen changed hands at 101.55 to the dollar, both stuck in their recent ranges.The yen showed no reaction to the BOJ's widely expected decision to keep its policy on hold and broadly maintain its economic forecasts, with the focus now on Governor Haruhiko Kuroda's upcoming news conference.Elsewhere, U.S. crude oil futures hit a nine-week low of $100.22 per barrel on Monday on signs of improving supply from key producers but renewed violence in Libya prompted a rebound to around $101.   (Editing by Eric Meijer and Alan Raybould)",2014-07-15,AET,"Tue Jul 15, 2014 | 1:38am EDT","GLOBAL MARKETS-Asian shares gain, count on Fed's support",http://www.reuters.com//article/markets-global-idUSL4N0PQ02N20140715?type=companyNews
53,"  * Main Medicare fund seen lasting into 2030* Disability insurance fund could run dry in 2016   (Adds comments by trustees, officials and background)By Jason Lange and David MorganWASHINGTON, July 28 Tamer spending at U.S. hospitals and expected savings from President Barack Obama's healthcare overhaul are shoring up the funding outlook for the Medicare program for the elderly, trustees of the program said on Monday.Medicare's trust fund for hospital bills will run out of money in 2030, four years later than previously estimated, the trustees said in a report. The trustees, however, reiterated a warning that the Social Security program would run out of money to fully pay disability benefits by 2016 and could not meet all of its obligations on pensions after 2033.The report gives mixed messages about the urgency of reforming America's biggest social welfare programs, which together make up about 40 percent of federal spending. While the arrival date for Medicare's crunch has been pushed into the future, an aging population is already stressing the finances of programs that provide income for the disabled.""The long-term picture this year looks very similar to last year's report. The short-term picture has grown more urgent,"" Charles Blahous, the lone Republican on the board of trustees, said at a news conference.U.S. Treasury Secretary Jack Lew, who is one of the trustees, said the disability program could be temporarily patched up by Congress redirecting revenues from another Social Security fund. That would buy time to work out a long-term solution, he said. A partisan divide in Washington has made major reforms of Medicare and Social Security appear nigh impossible in recent years. Republicans want to rein in government spending, while Lew said Obama will not support any proposal that hits current beneficiaries or that slashes benefits for future retirees.The trustees said the Medicare hospital fund would last longer than previously thought because ""expenditures in 2013 were significantly lower than the previous estimate."" They said it wasn't clear how much of the slowdown was because of a weak economy and how much was due to Obama's healthcare overhaul, which is expanding insurance coverage. Nevertheless, the trustees said they expected ""substantial"" savings from Obamacare. The trustees said congressional action was still needed to address long-term solvency in Medicare and Social Security.""The sooner the policymakers address these challenges, the less disruptive the unavoidable adjustments will be,"" said trustee Robert Reischauer, a former director of the Congressional Budget Office.The report's conclusions largely mirrored those made earlier this month by the nonpartisan CBO, which also pushed back to 2030 its projection of when Medicare's main trust fund would be exhausted.Depletion of the Medicare and Social Security trust funds does not mean that all benefits would stop. At the current rate of payroll tax collections, for example, Medicare would be able to pay about 85 percent of costs in 2030.Social Security would be able to pay about 80 percent of disability benefits starting in ""late 2016,"" the Treasury Department said in a statement.    (Reporting by Jason Lange and David Morgan; Editing by Andrea Ricci and Cynthia Osterman)",2014-07-28,AET,"Mon Jul 28, 2014 | 3:28pm EDT",UPDATE 2-Slower U.S. healthcare cost rise extending life of Medicare fund- trustees,http://www.reuters.com//article/usa-fiscal-health-idUSL2N0Q319L20140728?type=companyNews
54,"  (Rewrites throughout with commentary on medical costs, industry share moves)By Caroline HumerJuly 29 Aetna Inc, the third-largest U.S. health insurer, reported a rise in medical costs on Tuesday, raising investor concerns that a long run of low growth in such costs might be ending and pushing shares in the industry lower.U.S. insurer profits have benefited from several years of relatively low use of medical services by their members due to an economic downturn and higher out-of-pocket costs for patients.Aetna said its medical spending rose in the second quarter due to an expensive new treatment for hepatitis C made by Gilead Sciences and the higher costs of covering patients who bought insurance under President Barack Obama's healthcare law for the first time.The insurer said that it spent 83.1 percent of the premiums it took in on medical claims, a measure called medical benefit ratio, higher than some Wall Street estimates. It said that ratio increased from 82.5 percent a year earlier. Aetna shares fell 3.4 percent to $81.94 in early afternoon trading on the New York Stock Exchange. Among rivals, UnitedHealth Group slipped 1.7 percent, WellPoint Inc  dropped 2.9 percent and Humana Inc slid 3 percent.Aetna executives said the quarter did not represent a new trend and that they expect 2014 medical spending to be at the low end of company forecasts. But investors were skeptical, and cited evidence of higher medical costs when UnitedHealth reported its quarterly profits last week.""Investors are concerned that cost trend is creeping up,"" Jefferies & Co analyst David Windley said. Industry analysts also pointed to the financial performance of U.S. hospitals as another sign that medical use is up. After years of low utilization, hospitals such as HCA Holdings Inc  have reported quarterly profits that blew past Wall Street expectations.Aetna's chief financial officer said its data did not show any reason for concern.""When we look at our core business and we look at medical cost trends in the second quarter, everything looks very well behaved,"" CFO Shawn Guertin said in an interview. ""The (cost ratios) are actually down year over year."" Cost increases are tied to the new Obamacare exchange business and the new hepatitis C treatment Sovaldi, he said. The drug was approved in December and costs $84,000 for a 12-week treatment that cures most patients who take it.Aetna second-quarter profit was boosted by Medicare and Medicaid provider Coventry Health Care. Excluding costs related to that purchase in 2014, earnings were $1.69 per share, above the $1.60 per share that analysts had anticipated.The insurer raised its 2014 earnings forecast due to greater profits created by the deal, predicting a range of $6.45 to $6.60 per share from $6.35 to $6.55.Aetna's second-quarter net income rose to $549 million, or $1.52 per share, from $536 million, or $1.49 per share, a year earlier.Revenue rose to $14.5 billion from $11.5 billion.   (Reporting by Caroline Humer; Editing by Michele Gershberg and Jonathan Oatis)",2014-07-29,AET,"Tue Jul 29, 2014 | 1:35pm EDT","UPDATE 3-Aetna says medical costs rose, insurer shares drop",http://www.reuters.com//article/aetna-results-idUSL2N0Q40F520140729?type=companyNews
55,"  Aetna Chief Executive Officer Mark Bertolini said on Tuesday that the company would begin selling Obamacare exchange plans in Georgia in 2015, adding the southern state to the 17 states where it sold these plans in 2014.Bertolini said it was still too soon to tell if the new customers it gained through the exchanges in the first half of this year are more expensive than it expected, but based on what Aetna has seen, it still expects the business to be only a ""modest headwind"" to 2014 profits. He made the comments during a call with investors.   (Reporting by Caroline Humer; Editing by Lisa Von Ahn)",2014-07-29,AET,"Tue Jul 29, 2014 | 9:01am EDT",Aetna to sell Obamacare exchange plans in Georgia,http://www.reuters.com//article/us-aetna-results-ceo-idUSKBN0FY18N20140729?type=companyNews
56,"  July 29 Aetna Chief Executive Officer Mark Bertolini said on Tuesday that the company would begin selling Obamacare exchange plans in Georgia in 2015, adding the southern state to the 17 states where it sold these plans in 2014.Bertolini said it was still too soon to tell if the new customers it gained through the exchanges in the first half of this year are more expensive than it expected, but based on what Aetna has seen, it still expects the business to be only a ""modest headwind"" to 2014 profits.  He made the comments during a call with investors.   (Reporting by Caroline Humer; Editing by Lisa Von Ahn) ",2014-07-29,AET,"Tue Jul 29, 2014 | 8:58am EDT",Aetna to sell Obamacare exchange plans in Georgia,http://www.reuters.com//article/aetna-results-ceo-idUSL2N0Q40Q520140729?type=companyNews
57,"  WASHINGTON A top U.S. healthcare official involved in the botched rollout of the website HealthCare.gov may have deleted some emails that were later sought by Republican congressional investigators, administration officials said on Thursday.The emails were from a public email account maintained by Marilyn Tavenner, who heads the Centers for Medicare and Medicaid Services (CMS), the Department of Health and Human Services (HHS) agency chiefly responsible for implementing President Barack Obama's healthcare reform law.""While we have not identified any specific emails that we will be unable to retrieve, it is possible that some emails may not be available,"" a CMS records official said in an Aug. 6 letter informing the National Archives of the situation.The letter made no reference to any evidence that Tavenner intentionally hid or destroyed the emails. An administration official, who spoke on condition of anonymity, attributed the potential loss to ""sloppy record keeping"".Republicans who have made the Affordable Care Act, including last October's  problem-riddled launch of HealthCare.gov, top issues in the November congressional elections. Some House Republicans have raised questions about congressional testimony from Tavenner and other administration officials who predicted before the rollout that HealthCare.gov would launch successfully.  An initial analysis gives us confidence that the vast majority of Administrator Tavenners email records are retrievable,"" said CMS spokesman Aaron Albright.He said CMS has identified more than 71,000 emails that include Tavenner's name as recipient or author.""There are no significant chronological gaps and we are working to compile the most complete email record for her as possible, Albright said. U.S. Representative Darrell Issa, Republican chairman of the House Oversight and Government Reform Committee, which subpoenaed Tavenners' emails late last year, accused the administration of losing or destroying the emails of more than a score of witnesses in its investigations.""Yet again, we discover that this administration will not be forthright with the American people unless cornered, Issa said in a statement. CMS said the missing emails were from a public account that received an extremely high volume of messages from outside groups. Tavenner sought to preserve some emails by forwarding them to her internal staff for retention and retrieval. But officials said the practice was irregular and that emails she did not forward to the internal HHS system may not be retrievable. Last November, CMS said Tavenner began to maintain her own copies. (Reporting by David Morgan; Editing by David Gregorio)",2014-08-07,AET,"Thu Aug 7, 2014 | 7:00pm EDT",U.S. says some healthcare emails sought by Congress are missing,http://www.reuters.com//article/us-usa-healthcare-tavenner-idUSKBN0G72KY20140807?type=companyNews
58,"  WASHINGTON Aug 7 A top U.S. healthcare official involved in the botched rollout of the website HealthCare.gov may have deleted some emails that were later sought by Republican congressional investigators, administration officials said on Thursday.The emails were from a public email account maintained by Marilyn Tavenner, who heads the Centers for Medicare and Medicaid Services (CMS), the Department of Health and Human Services (HHS) agency chiefly responsible for implementing President Barack Obama's healthcare reform law.""While we have not identified any specific emails that we will be unable to retrieve, it is possible that some emails may not be available,"" a CMS records official said in an Aug. 6 letter informing the National Archives of the situation.The letter made no reference to any evidence that Tavenner intentionally hid or destroyed the emails. An administration official, who spoke on condition of anonymity, attributed the potential loss to ""sloppy record keeping"".Republicans who have made the Affordable Care Act, including last October's  problem-riddled launch of HealthCare.gov, top issues in the November congressional elections. Some House Republicans have raised questions about congressional testimony from Tavenner and other administration officials who predicted before the rollout that HealthCare.gov would launch successfully. ""An initial analysis gives us confidence that the vast majority of Administrator Tavenner's email records are retrievable,"" said CMS spokesman Aaron Albright.He said CMS has identified more than 71,000 emails that include Tavenner's name as recipient or author. ""There are no significant chronological gaps and we are working to compile the most complete email record for her as possible,"" Albright said.U.S. Representative Darrell Issa, Republican chairman of the House Oversight and Government Reform Committee, which subpoenaed Tavenners' emails late last year, accused the administration of losing or destroying the emails of more than a score of witnesses in its investigations. ""Yet again, we discover that this administration will not be forthright with the American people unless cornered,"" Issa said in a statement.CMS said the missing emails were from a public account that received an extremely high volume of messages from outside groups. Tavenner sought to preserve some emails by forwarding them to her internal staff for retention and retrieval. But officials said the practice was irregular and that emails she did not forward to the internal HHS system may not be retrievable.Last November, CMS said Tavenner began to maintain her own copies.   (Reporting by David Morgan; Editing by David Gregorio)",2014-08-07,AET,"Thu Aug 7, 2014 | 6:57pm EDT",U.S. says some healthcare emails sought by Congress are missing,http://www.reuters.com//article/usa-healthcare-tavenner-idUSL2N0QD2X920140807?type=companyNews
59,"  * Russia sanctions, geopolitical concerns weigh on Wall St* Aetna, other health insurers fall after Goldman note* Jobless claims fall unexpectedly in latest week* Indexes off: Dow 0.5 pct, S&P 0.6 pct, Nasdaq 0.5 pct   (Updates to close, changes prices and comment)By Akane OtaniNEW YORK, Aug 7 U.S. stocks ended lower on Thursday, continuing a recent streak of weakness as Russia's surprisingly harsh retaliatory measures in response to Western sanctions raised concerns about global growth. In addition to Moscow's ban on imports of many Western foods, following sanctions imposed for Russia's support of rebels in eastern Ukraine, investors worried that the conflict between Russian and Ukraine is escalating, with the downing of a Ukrainian fighter jet. .The declines briefly dragged the Dow below its 200-day moving average in afternoon trading. The S&P 500 is now nearly 4 percent below the record closing high it set last monthWhile the full extent of the sanctions are still unknown, escalating tensions in Russia could continue to spur selling in stocks, analysts said. ""Before this point, U.S. investors have always thought of geopolitical concerns as being largely no more than a 24-hour event. Now, the growing concern is that the outlook for global growth is pointing down,"" said Andrew Wilkinson, chief market analyst at Interactive Brokers Group in Greenwich, Connecticut.""To that extent, investors seem more prone to selling, and asking questions later rather than buying the dip as they had become accustomed to doing in the past.""All but one of the S&P 500's industry sectors ended down on the day, backtracking from brief gains in the morning. Consumer staples shares, the bright spot of trading on Wednesday, slipped 0.8 percent on Thursday, while utilities  shares posted the sole sector gains. Health insurer stocks were poor performers, dipping after Goldman Sachs downgraded Aetna to ""neutral"" and cut earnings estimates on a number of its peers. Aetna  shares slid 4.0 percent to $75.22, UnitedHealth Group  shares lost 2.7 percent to $79.26 and Cigna shares fell 3.0 percent to $88.75.The Dow Jones industrial average fell 75.07 points, or 0.46 percent, to 16,368.27, the S&P 500 ended down 10.67 points, or 0.56 percent, to 1,909.57, and the Nasdaq Composite lost 20.09 points, or 0.46 percent, to 4,334.97.Twenty-First Century Fox surged 5.1 percent to $33.97 after the company's quarterly profit beat Wall Street's expectations.Jobless claims reports lent optimism to the market in the morning as the four-week claims average fell to its lowest level since February 2006, suggesting labor market conditions are continuing to improve.About 5.5 billion shares traded on all U.S. platforms, according to BATS exchange data, compared with the five-day average of 6.9 billion.   (Editing by Leslie Adler)",2014-08-07,AET,"Thu Aug 7, 2014 | 4:43pm EDT",US STOCKS-Wall Street ends down on heightened Russia concerns,http://www.reuters.com//article/markets-usa-stocks-idUSL2N0QD23M20140807?type=companyNews
60,"  (Removes extraneous words in second paragraph.)* Aetna, other health insurers fall after Goldman note* Jobless claims fall unexpectedly in latest week* Dow down 0.3 pct, S&P down 0.3 pct, Nasdaq down 0.1 pctBy Akane OtaniNEW YORK, Aug 7 U.S. stocks dipped in choppy trading Thursday, with all three indexes erasing morning gains spurred by upbeat labor data, amid uncertainty following Russia's retaliatory measures over Western sanctions.Investors were wary over any possible impact from Moscow's ban on imports of many Western foods Thursday, which followed Western sanctions for Russia's support of rebels in eastern Ukraine. The equity market has fluctuated for much of the past two weeks, and investors see few reasons to commit more capital, analysts said.""We've been all over the place,"" said Kim Forrest, senior equity research analyst at Fort Pitt Capital Group in Pittsburgh.""There's just not enough market participants to absorb either the demand for stocks when people are buying or demand for buyers when they're selling."" Consumer staples shares, the bright spot of trading on Wednesday, slipped 0.6 percent on Thursday. All but one of the benchmark index's 10 sectors were lower, backtracking from brief gains in the morning that were fueled by earnings reports and employment data.Still, while sanctions could hurt European economies which have closer trading ties to Russia, some analysts believed the measures were unlikely to make a significant dent on U.S. equities.""Russia isn't that large a trading partner for the U.S., except for things like poultry, so I think specific stocks could get hit by the overall market, probably not,"" Forrest said. The Dow Jones industrial average was down 51.98 points, or 0.32 percent, to 16,391.36, the S&P 500 was down 6.41 points, or 0.33 percent, to 1,913.83 and the Nasdaq Composite fell 6.05 points, or 0.14 percent, to 4,349.00.iDreamSky Technology shares jumped as high as 27 percent to $19.05 in the mobile game company's trading debut, blowing past its IPO price of $15 per share. The company's value hit $811.3 million at its peak.Health insurer stocks took a hit after Goldman Sachs downgraded Aetna to neutral and cut earnings estimates on a number of its peers. Aetna shares slid 3.2 percent to $75.85, UnitedHealth Group shares lost 2.2 percent to $79.69 and Cigna shares fell 2.3 percent to $89.37.Twenty-First Century Fox posted the biggest gains in the S&P 500. Shares surged 5.1 percent to $33.96 after the company's quarterly profit beat Wall Street's expectations.Jobless claims reports lent optimism to the market in the morning as the four-week claims average fell to its lowest level since February 2006, suggesting labor market conditions are continuing to improve.    (Editing by Bernadette Baum)",2014-08-07,AET,"Thu Aug 7, 2014 | 2:47pm EDT",REFILE-US STOCKS-Wall Street dips as investors eye Russia tensions,http://www.reuters.com//article/markets-usa-stocks-idUSL2N0QD1SI20140807?type=companyNews
61,"  * Aetna, other health insurers fall after Goldman note* S&P 500 tests support as it dips below 100-day average* Jobless claims fall unexpectedly in latest week* Indexes off: Dow 0.3 pct, S&P 0.4 pct, Nasdaq 0.3 pct   (Recasts, updates prices, changes comment, adds Aetna, Harman)By Rodrigo CamposNEW YORK, Aug 7 U.S. stocks fell in choppy trading on Thursday as a sanctions confrontation between Russia and the West kept traders eager to cash any gains.The S&P 500 had risen as much as 0.45 percent on the back of some strong earnings and a surprise tick lower in applications for unemployment insurance, before selling off to trade below its 100-day moving average for a second consecutive session. It has closed below that level just four times this year, the last one in mid April. Markets kept an eye on eastern Europe as Moscow imposed a ban on imports of many Western foods, retaliating against sanctions imposed for its support of rebels in eastern Ukraine and the annexation of Crimea. Russia will ban various imports from the United States, the European Union, Australia, Canada and Norway in a measure that isolates its consumers from world trade to a degree unseen since Soviet days.""The Russian situation has gone from bad to worse,"" said Brian Jacobsen, chief portfolio strategist at Wells Fargo Funds Management in Menomonee Falls, Wisconsin, adding that ""imposing an import restriction on agricultural products will likely lead to rapid inflation.""However, he said the recent volatility and pullback are not foreshadowing a market correction. ""Earnings are robust, revenues are rising, and interest rates are likely to go up gradually,"" Jacobsen said. ""These are not the conditions that create market corrections.""The sanctions by Moscow are seen as possibly hurting European economies more than the United States due to closer ties between Russia and Europe. Such a scenario could favor U.S. equities and other assets as foreign cash looking for yield may head towards the world's largest economy. The full extent of the impact, however, is yet to be known.""Geopolitical risks are heightened, are higher than they were a few months ago. And some of them, like the situation in Ukraine and Russia, will have a greater impact on the euro area than they ... have on other parts of the world,"" European Central Bank President Mario Draghi said after the ECB left interest rates unchanged at record lows. The Dow Jones industrial average fell 68.62 points or 0.42 percent, to 16,374.72, the S&P 500 lost 8.33 points or 0.43 percent, to 1,911.91 and the Nasdaq Composite  dropped 11.15 points or 0.26 percent, to 4,343.90.Health insurer stocks fell after Goldman Sachs downgraded Aetna to neutral and cut earnings estimates on a number of its larger peers. Aetna shares fell 3 percent to $75.97. The S&P managed healthcare index fell 2.7 percent.Shares of Harman International Industries fell 4.1 percent to $106.71 after the maker of JBL and Harman Kardon audio systems forecast full-year profit below market estimates as it spends more to boost production in lower-cost countries.On the flip side, Twenty-First Century Fox was the largest gainer on the S&P 500 after quarterly profit beat Wall Street's expectations. Executives stressed they would not make a new approach for Time Warner Inc after withdrawing an $80-billion bid. Fox shares rose 5.5 percent to $34.09.The number of Americans filing new claims for unemployment benefits unexpectedly fell last week and the four-week claims average, considered a better measure of labor market trends, fell to its lowest since February 2006.    (Editing by Bernadette Baum and Nick Zieminski)",2014-08-07,AET,"Thu Aug 7, 2014 | 1:08pm EDT",US STOCKS-Wall St falls in choppy trading on Russia concern,http://www.reuters.com//article/markets-usa-stocks-idUSL2N0QD1KJ20140807?type=companyNews
62,"   By Greg Roumeliotis and Soyoung Kim | NEW YORK  NEW YORK Private equity firm Apax Partners LLP is exploring a sale of U.S. healthcare information technology company TriZetto Corp, hoping to fetch as much as $3 billion including debt, according to people familiar with the matter. London-based Apax has hired investment bank JPMorgan Chase & Co (JPM.N) to run an auction for TriZetto, a software vendor to the U.S. health insurance industry, the people said this week. TriZetto will target other companies in its sector as potential buyers, such as information technology consulting company Cognizant Technology Solutions Corp (CTSH.O), although private equity firms are also expected to weigh offers, some of the people added.TriZetto had 12-month earnings before interest, tax, depreciation and amortization of more than $190 million as of June 30, one of the sources added.The sources asked not to be named because the matter is not public. Apax and TriZetto declined to comment while JPMorgan and Cognizant representatives did not immediately respond to requests for comment. TriZetto provides information technology solutions, including care management and the administration of benefits, to the healthcare industry. The company says it reaches 245,000 healthcare providers, representing more than half of the insured population in the United States.Apax took the Englewood, Colorado-based company private in 2008 for $1.4 billion. Uncertainty over the impact of healthcare exchanges on payors weighed on TriZetto in the run-up to U.S. President Barack Obama's healthcare reforms, though it has since improved both cash flow and margins. Moody's Investors Service Inc upgraded TriZetto's credit rating in June, citing operational improvements, cost management and strong perpetual license revenue. The company had 12-month revenue of $682 million to the end of March, Moody's added.TriZetto is the latest in a string of companies serving the U.S. health insurance industry to hit the auction block, hoping for a high valuation at a time when payors and providers of healthcare seek new technology solutions to cut costs.In March, private equity firms Silver Lake Partners LP and BC Partners Ltd sold health insurance claims processor MultiPlan Inc for $4.4 billion to a consortium led by Maurice ""Hank"" Greenberg's buyout firm Starr Investment Holdings LLC.  Greenberg is the former chairman and CEO of American International Group Inc (AIG.N). Blackstone Group LP (BX.N), the world's largest private equity firm, bought healthcare information technology company Emdeon Inc for $3 billion in 2011. (Additional reporting by Olivia Oran in New York; editing by Matthew Lewis)",2014-08-19,AET,"Tue Aug 19, 2014 | 11:13am EDT",Apax seeks $3 billion sale of healthcare IT firm TriZetto : sources,http://www.reuters.com//article/us-trizetto-sale-idUSKBN0GJ1JK20140819?type=companyNews
63,"   By Greg Roumeliotis and Soyoung Kim | NEW YORK  NEW YORK Aug 19 Private equity firm Apax Partners LLP is exploring a sale of U.S. healthcare information technology company TriZetto Corp, hoping to fetch as much as $3 billion including debt, according to people familiar with the matter.London-based Apax has hired investment bank JPMorgan Chase & Co to run an auction for TriZetto, a software vendor to the U.S. health insurance industry, the people said this week.TriZetto will target other companies in its sector as potential buyers, such as information technology consulting company Cognizant Technology Solutions Corp, although private equity firms are also expected to weigh offers, some of the people added.TriZetto had 12-month earnings before interest, tax, depreciation and amortization of more than $190 million as of June 30, one of the sources added. The sources asked not to be named because the matter is not public. Apax and TriZetto declined to comment while JPMorgan and Cognizant representatives did not immediately respond to requests for comment.TriZetto provides information technology solutions, including care management and the administration of benefits, to the healthcare industry. The company says it reaches 245,000 healthcare providers, representing more than half of the insured population in the United States. Apax took the Englewood, Colorado-based company private in 2008 for $1.4 billion. Uncertainty over the impact of healthcare exchanges on payors weighed on TriZetto in the run-up to U.S. President Barack Obama's healthcare reforms, though it has since improved both cash flow and margins.Moody's Investors Service Inc upgraded TriZetto's credit rating in June, citing operational improvements, cost management and strong perpetual license revenue. The company had 12-month revenue of $682 million to the end of March, Moody's added. TriZetto is the latest in a string of companies serving the U.S. health insurance industry to hit the auction block, hoping for a high valuation at a time when payors and providers of healthcare seek new technology solutions to cut costs.In March, private equity firms Silver Lake Partners LP and BC Partners Ltd sold health insurance claims processor MultiPlan Inc for $4.4 billion to a consortium led by Maurice ""Hank"" Greenberg's buyout firm Starr Investment Holdings LLC.  Greenberg is the former chairman and CEO of American International Group Inc.Blackstone Group LP, the world's largest private equity firm, bought healthcare information technology company Emdeon Inc for $3 billion in 2011.   (Additional reporting by Olivia Oran in New York; editing by Matthew Lewis)",2014-08-19,AET,"Tue Aug 19, 2014 | 11:07am EDT",Apax seeks $3 bln sale of healthcare IT firm TriZetto -sources,http://www.reuters.com//article/trizetto-sale-idUSL5N0QO3WK20140819?type=companyNews
64,"   By David Lawder | WASHINGTON  WASHINGTON U.S. healthcare spending is expected to grow more slowly in the coming decade as a sluggish economic recovery and higher cost sharing in private insurance plans limit demand for services, a government report released on Wednesday said.The Centers for Medicare and Medicaid said it expects average annual healthcare spending to grow by 5.7 percent from 2013 to 2023, compared to 5.8 percent in last year's projections, which covered the years 2012 to 2022.The projected growth rate is well below the 7.2 percent annual average between 1990 and 2008, CMS said.The projections coincide with Congressional Budget Office estimates released last week that show another $11 billion reduction in projected spending for Medicare, the federal healthcare program for the elderly, for the 2015-24 period. This reduction from projections made in February contributes directly to lower federal deficits. The CMS study projects both public and private healthcare outlays and showed the overall total will make up a smaller portion of the economy than previously thought in coming years. In 2023, it estimated that healthcare spending will equal 19.3 percent of Gross Domestic Product, compared with last year's projection of 19.9 percent for 2022. It made up 17.2 percent of GDP in 2012.The spending growth rate for 2013 will be 3.6 percent, nearly at the historic low since CMS started tracking health care spending in 1960.For 2014, the spending growth will accelerate to 5.6 percent as more people gain healthcare coverage under President Barack Obama's health insurance reform law, largely through its expansion of Medicaid, and because of an increase in economic growth. But this will still be below last year's estimate of 6.1 percent growth for 2014. ""The major factor is the relationship between health spending and economic growth,"" said Andrea Sisko, an economist in the CMS actuarial division.Loss of jobs and associated healthcare benefits tend to discourage healthcare utilization, she said, adding that employment has been slow to recover. Another deterrent has been the increase in healthcare plans that require beneficiaries to bear a greater proportion of costs for doctor visits, procedures and prescription drugs. Medicare reimbursement rates also have been curtailed by the ""sequester"" budget cuts and by the Affordable Care Act, and prescription drug costs have eased because patents on a number of major medications have expired in recent years, making cheaper generic versions available.But as the economy improves and more Baby Boomers retire and draw benefits, spending growth is still expected to pick up, averaging 6.0 percent from 2015-23, CMS said. (Reporting by David Lawder; Editing by Bernard Orr)",2014-09-03,AET,"Wed Sep 3, 2014 | 5:02pm EDT",U.S. healthcare spending growth to slow further: government report,http://www.reuters.com//article/us-usa-healthcare-spending-idUSKBN0GY2I620140903?type=companyNews
65,"   By David Lawder | WASHINGTON, Sept 3  WASHINGTON, Sept 3 U.S. healthcare spending is expected to grow more slowly in the coming decade as a sluggish economic recovery and higher cost sharing in private insurance plans limit demand for services, a government report released on Wednesday said.The Centers for Medicare and Medicaid said it expects average annual healthcare spending to grow by 5.7 percent from 2013 to 2023, compared to 5.8 percent in last year's projections, which covered the years 2012 to 2022.The projected growth rate is well below the 7.2 percent annual average between 1990 and 2008, CMS said.The projections coincide with Congressional Budget Office estimates released last week that show another $11 billion reduction in projected spending for Medicare, the federal healthcare program for the elderly, for the 2015-24 period. This reduction from projections made in February contributes directly to lower federal deficits. The CMS study projects both public and private healthcare outlays and showed the overall total will make up a smaller portion of the economy than previously thought in coming years. In 2023, it estimated that healthcare spending will equal 19.3 percent of Gross Domestic Product, compared with last year's projection of 19.9 percent for 2022. It made up 17.2 percent of GDP in 2012.The spending growth rate for 2013 will be 3.6 percent, nearly at the historic low since CMS started tracking health care spending in 1960. For 2014, the spending growth will accelerate to 5.6 percent as more people gain healthcare coverage under President Barack Obama's health insurance reform law, largely through its expansion of Medicaid, and because of an increase in economic growth. But this will still be below last year's estimate of 6.1 percent growth for 2014.""The major factor is the relationship between health spending and economic growth,"" said Andrea Sisko, an economist in the CMS actuarial division. Loss of jobs and associated healthcare benefits tend to discourage healthcare utilization, she said, adding that employment has been slow to recover. Another deterrent has been the increase in healthcare plans that require beneficiaries to bear a greater proportion of costs for doctor visits, procedures and prescription drugs.Medicare reimbursement rates also have been curtailed by the ""sequester"" budget cuts and by the Affordable Care Act, and prescription drug costs have eased because patents on a number of major medications have expired in recent years, making cheaper generic versions available.But as the economy improves and more Baby Boomers retire and draw benefits, spending growth is still expected to pick up, averaging 6.0 percent from 2015-23, CMS said.   (Reporting by David Lawder; Editing by Bernard Orr)",2014-09-03,AET,"Wed Sep 3, 2014 | 4:59pm EDT",U.S. healthcare spending growth to slow further - gov't report,http://www.reuters.com//article/usa-healthcare-spending-idUSL1N0R42IC20140903?type=companyNews
66,"   By Caroline Copley | ZURICH  ZURICH U.S. healthcare group Danaher Corp (DHR.N) is to buy Nobel Biocare Holding AG NOBN.S for an agreed $2.2 billion to become the world's biggest player in a dental implants market benefiting from growing demand for cosmetic dentistry.Danaher said on Monday it would pay 17.10 Swiss francs per Nobel Biocare share in cash, about 23 percent above Nobel Biocare's closing price on July 28, the day before the Swiss firm said it was in talks with potential buyers. However, Nobel Biocare shares fell as much as 6 percent after analysts had predicted the company could fetch over 20 francs per share.""From my side, it doesnt fill me with that much enthusiasm. But I dont expect there will be a second bid,"" Sebastien Buch, a portfolio manager at Union Investment which owns roughly 3 percent of Nobel Biocares shares, told Reuters. Danaher is a leading provider of dental equipment, but only a small player in the fragmented dental implants market after its acquisition of low-cost manufacturer Implant Direct.The purchase of Nobel Biocare, the world's No.2 dental implants maker, will bring Danaher a premium range of implants and boost its dental business to sales of around $3 billion.Vontobel analysts forecast the global dental implants market is set to double to $6 billion by 2025, helped by recovering Western economies and rising incomes in developing countries.Danaher President and Chief Executive Thomas P. Joyce told a conference call that Nobel Biocare's recent investment in high-growth markets such as China, eastern Europe and Latin America - which now make up about 20 percent of sales - had made it an attractive opportunity.Fellow dental implant players such as Henry Schein (HSIC.O) and Dentsply (XRAY.O) had been cited as possible bidders for Nobel Biocare, while the company had reportedly also attracted interest from buyout group EQT Partners. Analysts at Berenberg said it was ""by no means a certainty"" that Nobel Biocare's shareholders would agree to tender their shares at Danaher's price, adding it was possible that other potential suitors could enter the fray with a higher offer.The deal, recommended by Nobel Biocare's board, requires the acceptance of 67 percent of Nobel Biocare's shareholders.But other analysts said the price was fair and counter bids looked unlikely. Swiss rival Straumann (STMN.S) ruled out interest in Nobel Biocare last month, while Zimmer ZMH.N is busy with its purchase of Biomet Inc for more than $13 billion. ""Nobel has run an extensive sales process and we believe that Nobel is less attractive for private equity in light of its weak cash flow and no synergy opportunities,"" said Bank of America Merrill Lynch analyst Ed Ridley-Day.Joyce said Danaher expected the deal to help it deliver a 10 percent return on invested capital (ROIC) by 2019. It expects the deal to add five cents to earnings per share by 2015 and ten cents by 2016. MEDTECH M&A The Nobel Biocare deal follows on from a wave of mergers among medical supplies makers this year, including Medtronic Inc's (MDT.N) $42.9 billion deal to buy Dublin-based Covidien Plc COV.N in June. Like other makers of premium implants, Nobel Biocare has struggled since the financial crisis as cash-strapped consumers, particularly in southern Europe, cut back on pricey dental work which is not generally reimbursed by insurers.Nobel Biocare's stock is down 80 percent since its all-time high in 2007. The company grappled with years of sliding sales and dwindling market share as it faced competition from a growing number of so-called ""value"" players. But signs have grown that a long-awaited turnaround is taking root and the company has notched up five consecutive quarters of revenue growth at constant exchange rates.Although the premium market is growing at a slower pace than the value segment, Danaher said it still expects dentists to prefer premium implants for complex cases. It expects the premium segment to keep growing in the 3-5 percent range.Nobel Biocare had sales of 567 million euros ($735 million) and net profit of 42.6 million euros in 2013. It has $556 million of bonds and loans.Danaher said Nobel Biocare would continue to operate as a standalone company and maintain its own brand and identity. The deal is expected to be completed in late 2014 or early 2015. Nobel Biocare was advised by Goldman Sachs, while Credit Suisse acted as financial adviser and offer manager to Danaher.At 1315 GMT (9.15 a.m. EDT), Nobel Biocare shares were down 5.5 percent at 17.1 Swiss francs.  (Additional reporting by Supriya Kurane in Bangalore; Editing by Louise Heavens and Mark Potter)",2014-09-15,AET,"Mon Sep 15, 2014 | 9:38am EDT",Danaher to buy Nobel Biocare for $2.2 billion,http://www.reuters.com//article/us-nobel-biocare-m-a-danaher-idUSKBN0HA0B420140915?type=companyNews
67,"  * Deal to make Danaher world No.1 maker of dental implants* 17.10 Sfr per share cash offer represents a 23 pct premium* Dental implants market seen doubling by 2025 - analyst* Nobel Biocare shares drop, analysts had seen higher bid   (Adds Danaher CEO comments, updates shares)By Caroline CopleyZURICH, Sept 15 U.S. healthcare group Danaher Corp is to buy Nobel Biocare Holding AG for an agreed $2.2 billion to become the world's biggest player in a dental implants market benefiting from growing demand for cosmetic dentistry.Danaher said on Monday it would pay 17.10 Swiss francs per Nobel Biocare share in cash, about 23 percent above Nobel Biocare's closing price on July 28, the day before the Swiss firm said it was in talks with potential buyers.However, Nobel Biocare shares fell as much as 6 percent after analysts had predicted the company could fetch over 20 francs per share.""From my side, it doesn't fill me with that much enthusiasm. But I don't expect there will be a second bid,"" Sebastien Buch, a portfolio manager at Union Investment which owns roughly 3 percent of Nobel Biocare's shares, told Reuters.Danaher is a leading provider of dental equipment, but only a small player in the fragmented dental implants market after its acquisition of low-cost manufacturer Implant Direct.The purchase of Nobel Biocare, the world's No.2 dental implants maker, will bring Danaher a premium range of implants and boost its dental business to sales of around $3 billion. Vontobel analysts forecast the global dental implants market is set to double to $6 billion by 2025, helped by recovering Western economies and rising incomes in developing countries.Danaher President and Chief Executive Thomas P. Joyce told a conference call that Nobel Biocare's recent investment in high-growth markets such as China, eastern Europe and Latin America - which now make up about 20 percent of sales - had made it an attractive opportunity.Fellow dental implant players such as Henry Schein  and Dentsply had been cited as possible bidders for Nobel Biocare, while the company had reportedly also attracted interest from buyout group EQT Partners.Analysts at Berenberg said it was ""by no means a certainty"" that Nobel Biocare's shareholders would agree to tender their shares at Danaher's price, adding it was possible that other potential suitors could enter the fray with a higher offer.The deal, recommended by Nobel Biocare's board, requires the acceptance of 67 percent of Nobel Biocare's shareholders.But other analysts said the price was fair and counter bids looked unlikely. Swiss rival Straumann ruled out interest in Nobel Biocare last month, while Zimmer is busy with its purchase of Biomet Inc for more than $13 billion. ""Nobel has run an extensive sales process and we believe that Nobel is less attractive for private equity in light of its weak cash flow and no synergy opportunities,"" said Bank of America Merrill Lynch analyst Ed Ridley-Day.Joyce said Danaher expected the deal to help it deliver a 10 percent return on invested capital (ROIC) by 2019. It expects the deal to add five cents to earnings per share by 2015 and ten cents by 2016.MEDTECH M&A The Nobel Biocare deal follows on from a wave of mergers among medical supplies makers this year, including Medtronic Inc's $42.9 billion deal to buy Dublin-based Covidien Plc in June. Like other makers of premium implants, Nobel Biocare has struggled since the financial crisis as cash-strapped consumers, particularly in southern Europe, cut back on pricey dental work which is not generally reimbursed by insurers.Nobel Biocare's stock is down 80 percent since its all-time high in 2007. The company grappled with years of sliding sales and dwindling market share as it faced competition from a growing number of so-called ""value"" players.But signs have grown that a long-awaited turnaround is taking root and the company has notched up five consecutive quarters of revenue growth at constant exchange rates.Although the premium market is growing at a slower pace than the value segment, Danaher said it still expects dentists to prefer premium implants for complex cases. It expects the premium segment to keep growing in the 3-5 percent range.Nobel Biocare had sales of 567 million euros ($735 million) and net profit of 42.6 million euros in 2013. It has $556 million of bonds and loans.Danaher said Nobel Biocare would continue to operate as a standalone company and maintain its own brand and identity.The deal is expected to be completed in late 2014 or early 2015. Nobel Biocare was advised by Goldman Sachs, while Credit Suisse acted as financial adviser and offer manager to Danaher.At 1315 GMT, Nobel Biocare shares were down 5.5 percent at 17.1 Swiss francs.($1 = 0.9342 Swiss francs)(1 US dollar = 0.7718 euro)   (Additional reporting by Supriya Kurane in Bangalore; Editing by Louise Heavens and Mark Potter)",2014-09-15,AET,"Mon Sep 15, 2014 | 9:21am EDT",UPDATE 4-Danaher to buy Nobel Biocare for $2.2 bln,http://www.reuters.com//article/nobel-biocare-ma-danaher-idUSL3N0RG1U420140915?type=companyNews
68,"  HealthCare.gov, President Barack Obama's health insurance exchange, has security and privacy protection vulnerabilities, a U.S. government watchdog reported on Tuesday, nearly a year after the website's troubled rollout.The General Accounting Office (GAO) said that despite steps taken by the Centers for Medicare & Medicaid Services (CMS) for security and privacy protection, weaknesses remain in the processes used for managing information security and privacy.The GAO also identified issues regarding the technical implementation of IT security controls.""Until these weaknesses are addressed, increased and unnecessary risks remain of unauthorized access, disclosure, or modification of the information collected and maintained by Healthcare.gov..."", the GAO said.  The report follows a security breach on the website in August. An unknown computer hacker infiltrated the HealthCare.gov website, apparently uploading malicious files.The president and his administration launched HealthCare.gov knowing that the personal information of Americans who bought insurance through the website was not safe.Their personal information was not safe then, and it is not safe now,"" Senator Lamar Alexander said in a statement. The report says most of the issues could be attributed to disagreements about security roles and responsibilities with the various contractors, states and federal agencies that are part of the HealthCare.gov system.  ""Someone should be held accountable for this kind of gross mismanagement, and security must be fixed immediately before a major hacking attack does massive damage, Alexander said. (Reporting By Krishna Chaithanya; Editing by Ken Wills)",2014-09-17,AET,"Tue Sep 16, 2014 | 10:24pm EDT",GAO report warns of security risks in U.S. healthcare website,http://www.reuters.com//article/us-healthcare-gov-security-idUSKBN0HC04920140917?type=companyNews
69,"  Sept 16 HealthCare.gov, President Barack Obama's health insurance exchange, has security and privacy protection vulnerabilities, a U.S. government watchdog reported on Tuesday, nearly a year after the website's troubled rollout.The General Accounting Office (GAO) said that despite steps taken by the Centers for Medicare & Medicaid Services (CMS) for security and privacy protection, weaknesses remain in the processes used for managing information security and privacy.The GAO also identified issues regarding the technical implementation of IT security controls. ""Until these weaknesses are addressed, increased and unnecessary risks remain of unauthorized access, disclosure, or modification of the information collected and maintained by Healthcare.gov..."", the GAO said.The report follows a security breach on the website in August. An unknown computer hacker infiltrated the HealthCare.gov website, apparently uploading malicious files. ""The president and his administration launched HealthCare.gov knowing that the personal information of Americans who bought insurance through the website was not safe. Their personal information was not safe then, and it is not safe now,"" Senator Lamar Alexander said in a statement. The report says most of the issues could be attributed to disagreements about security roles and responsibilities with the various contractors, states and federal agencies that are part of the HealthCare.gov system.""Someone should be held accountable for this kind of gross mismanagement, and security must be fixed immediately before a major hacking attack does massive damage,"" Alexander said.   (Reporting By Krishna Chaithanya; Editing by Ken Wills)",2014-09-17,AET,"Tue Sep 16, 2014 | 10:23pm EDT",GAO report warns of security risks in U.S. healthcare website,http://www.reuters.com//article/healthcaregov-security-idUSL1N0RI03320140917?type=companyNews
70,"  (The following statement was released by the rating agency) CHICAGO, September 22 (Fitch) Fitch Ratings has published a new report detailing  key credit metrics of nine-publicly-traded U.S. health insurance and managed  care companies that are either rated or followed by Fitch: Aetna, Inc., Centene  Corp., Cigna Corp., Health Net Inc., Humana, Inc., Molina Health Care Inc.  UnitedHealth Group, Incorporated, WellCare Health Plans, Inc. and WellPoint,  Inc.  The report is meant to be used as a desktop guide, providing financial data and  rankings, key credit strengths and concerns, and current ratings levels and  rating sensitivities. Fitch views the key credit metrics of these nine publicly traded health insurers  as improving in the first half of 2014 compared to the prior year period. Strong  revenue growth driven by the Affordable Care Act's (ACA) exchanges and Medicaid  expansion, continuing popularity of Medicare Advantage products and  acquisition-related growth generated increases in EBITDA that more than offset  declining margins. Interest coverage ratios improved, and leverage ratios  declined modestly. The first section of the report includes company rankings based on revenue  growth, EBITDA margin and returns on capital as well as capitalization measures  such as debt-to-EBITDA and financial leverage. The second section of the report  provides a more detailed discussion of the nine individual companies including  credit strengths and concerns, ratings and rating triggers (where applicable),  and detailed information about each company's capital structure. The report 'U.S. Health Insurance: Credit Metrics Update' is available on the  Fitch web site at 'www.fitchratings.com'.  Contact:  Mark Rouck, CPA, CFA  Senior Director +1-312-368-2085 Fitch Ratings, Inc. 70 W. Madison Street Chicago, IL 60602  Doug Pawlowski, CFA  Senior Director +1-312-368-2054  Media Relations: Brian Bertsch, New York, Tel: +1 212-908-0549, Email:  brian.bertsch@fitchratings.com. Additional information is available at 'www.fitchratings.com'. Applicable Criteria and Related Research: U.S. Health Insurance: Credit Metrics  Update here ALL FITCH CREDIT RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND DISCLAIMERS.  PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING THIS LINK:  here. IN ADDITION, RATING  DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE AVAILABLE ON THE AGENCY'S  PUBLIC WEBSITE 'WWW.FITCHRATINGS.COM'. PUBLISHED RATINGS, CRITERIA AND  METHODOLOGIES ARE AVAILABLE FROM THIS SITE AT ALL TIMES. FITCH'S CODE OF  CONDUCT, CONFIDENTIALITY, CONFLICTS OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE  AND OTHER RELEVANT POLICIES AND PROCEDURES ARE ALSO AVAILABLE FROM THE 'CODE OF  CONDUCT' SECTION OF THIS SITE. FITCH MAY HAVE PROVIDED ANOTHER PERMISSIBLE  SERVICE TO THE RATED ENTITY OR ITS RELATED THIRD PARTIES. DETAILS OF THIS  SERVICE FOR RATINGS FOR WHICH THE LEAD ANALYST IS BASED IN AN EU-REGISTERED  ENTITY CAN BE FOUND ON THE ENTITY SUMMARY PAGE FOR THIS ISSUER ON THE FITCH  WEBSITE.   ",2014-09-22,AET,"Mon Sep 22, 2014 | 2:30pm EDT",Fitch Releases U.S. Health Insurance Credit Metrics Update,http://www.reuters.com//article/fitch-releases-us-health-insurance-credi-idUSFit75128020140922?type=companyNews
71,"   By Supantha Mukherjee and Anya George Tharakan  U.S. healthcare technology group Danaher Corp is combining its communications unit with NetScout Systems Inc, scaling up the business at a time when companies are spending aggressively on cybersecurity.Danaher shareholders will get NetScout shares worth $2.6 billion, giving them majority stake in the company, while NetScout will have operational control.Danaher's communications business sells cybersecurity products and tools to manage networks, while NetScout makes products that monitor software applications on networks.Danaher's technology will help jump start NetScout's cyber security efforts, NetScout CEO Anil Singhal said, noting that the deal comes after five years of talks with Danaher.Cybersecurity has become a hot area in the face of increasingly sophisticated attacks and companies are spending more on internet security to prevent breaches.""(Danaher's communications) business needed a broader set of growth drivers as well as scale, and NetScout made for an excellent partner,"" ISI Group analyst Ross Muken wrote in an email. The combination is structured as a Reverse Morris Trust transaction, which allows a company to sell a unit in a tax-efficient manner by merging it with a smaller company.Danaher will create a wholly owned subsidiary to hold its communications business and will distribute ownership of the business to its shareholders.Under the deal, NetScout will issue 62.5 million new shares to Danaher's shareholders, giving them a stake of 59.5 percent in the combined company. The rest will be owned by NetScout shareholders. ""Danaher's shareholders don't have much beyond voting capability. They control enough of the shares so they could replace board members but I don't see that happening,"" D.A. Davidson & Co analyst Mark Kelleher said.Danaher's communications business reported 2013 revenue of about $836 million.NetScout had a market value of $1.72 billion as of Friday and reported revenue of $396 million for the year ended March 31. The combined entity would have more than 3,000 employees, of which about 2,000 would come from Danaher.The transaction will add to earnings in the first full year of operation after closing in 2015.NetScout would continue to be led by CEO Anil Singhal, who owns more that 5 percent of the company.NetScout shares were up 3 percent at $43.16 in early trading on Monday, while Danaher shares were up nearly 1 percent at $72.43. (Editing by Saumyadeb Chakrabarty)",2014-10-13,AET,"Mon Oct 13, 2014 | 11:23am EDT",Danaher to combine communications unit with NetScout,http://www.reuters.com//article/us-danaher-m-a-netscout-syst-idUSKCN0I20TK20141013?type=companyNews
72,"  * Danaher shareholders to own 59.5 pct of combined company* Combination structured as Reverse Morris Trust transaction* Transaction expected to close in 2015* NetScout shares up 3 pct; Danaher 1 pct   (Adds details from conference call, analyst comment, share movement)By Supantha Mukherjee and Anya George TharakanOct 13 U.S. healthcare technology group Danaher Corp is combining its communications unit with NetScout Systems Inc, scaling up the business at a time when companies are spending aggressively on cybersecurity.Danaher shareholders will get NetScout shares worth $2.6 billion, giving them majority stake in the company, while NetScout will have operational control.Danaher's communications business sells cybersecurity products and tools to manage networks, while NetScout makes products that monitor software applications on networks. Danaher's technology will help jump start NetScout's cyber security efforts, NetScout CEO Anil Singhal said, noting that the deal comes after five years of talks with Danaher.Cybersecurity has become a hot area in the face of increasingly sophisticated attacks and companies are spending more on internet security to prevent breaches.""(Danaher's communications) business needed a broader set of growth drivers as well as scale, and NetScout made for an excellent partner,"" ISI Group analyst Ross Muken wrote in an email. The combination is structured as a Reverse Morris Trust transaction, which allows a company to sell a unit in a tax-efficient manner by merging it with a smaller company.Danaher will create a wholly owned subsidiary to hold its communications business and will distribute ownership of the business to its shareholders.Under the deal, NetScout will issue 62.5 million new shares to Danaher's shareholders, giving them a stake of 59.5 percent in the combined company. The rest will be owned by NetScout shareholders.""Danaher's shareholders don't have much beyond voting capability. They control enough of the shares so they could replace board members but I don't see that happening,"" D.A. Davidson & Co analyst Mark Kelleher said. Danaher's communications business reported 2013 revenue of about $836 million.NetScout had a market value of $1.72 billion as of Friday and reported revenue of $396 million for the year ended March 31.The combined entity would have more than 3,000 employees, of which about 2,000 would come from Danaher.The transaction will add to earnings in the first full year of operation after closing in 2015.NetScout would continue to be led by CEO Anil Singhal, who owns more that 5 percent of the company.NetScout shares were up 3 percent at $43.16 in early trading on Monday, while Danaher shares were up nearly 1 percent at $72.43.   (Editing by Saumyadeb Chakrabarty)",2014-10-13,AET,"Mon Oct 13, 2014 | 11:20am EDT",UPDATE 2-Danaher to combine communications unit with NetScout,http://www.reuters.com//article/danaher-ma-netscout-syst-idUSL3N0S83J220141013?type=companyNews
73,"   By Gene Emery | NEW YORK  NEW YORK (Reuters Health) - For decades, it's been the conventional wisdom that U.S. healthcare costs are high because doctors order expensive tests to protect themselves from malpractice lawsuits, but new evidence says that assumption is wrong.The study from the RAND Corporation found that in three states where the laws were rewritten to make it virtually impossible to sue a doctor for mistakes, the cost of care did not go down in hospital emergency departments.""If your goal is cost savings, if you believe there is a lot of pure waste going on, then malpractice reform is a blind alley,"" Dr. Daniel Waxman, chief author of the study, told Reuters Health by phone.The idea that defensive medicine is responsible for higher health costs ""has come up over and over and over again,"" said Waxman, of Rand HEALTH in Santa Monica, California. ""It distracts people from looking for other avenues"" that might bring costs down more effectively.A 2010 study even pegged the cost of needless care motivated by fear of malpractice lawsuits at $210 billion a year.The new study in the New England Journal of Medicine looked at costs before and after Georgia, Texas and South Carolina changed their laws to only allow emergency department doctors to be sued for gross negligence, in which the doctor knows that a treatment will likely cause serious injury, yet does it anyway. ""People say the letter of that law is an almost-impossible threshold to meet,"" although such decisions are ultimately left up to the courts, said Waxman, who is an emergency department physician.The team's analysis of more than 3.8 million Medicare records from 1,166 hospitals also included neighboring states where the standard of malpractice remained ordinary negligence, which is a failure to exercise reasonable care.""If you ask physicians, 'Do you practice defensively?' They overwhelmingly say, 'Yes we do.' They say they order more CT scans and MRIs. They admit people to the hospital. That certainly is a long-standing belief among physicians and lay people at this point,"" said Dr. Waxman. But when the team examined emergency room bills and the likelihood that the patients would be admitted to the hospital or receive a CT or MRI scan, Waxman and his colleagues found no difference in nearly every measure before and after the three states changed their laws.Only in Georgia did they see any shift - a 3.6 percent drop in the average emergency room charge compared to neighboring states after the Peach State revised its law in 2005.""Although there was a small reduction in charges in one of the three states (Georgia), our results in aggregate suggest that these strongly protective laws caused little (if any) change in practice intensity among physicians caring for Medicare patients in emergency departments,"" the researchers conclude in the report. The new laws may not have changed how doctors practice, but in Texas the 2003 reforms cut the number of malpractice lawsuits by 60 percent and the total of malpractice payments by 70 percent. ""This certainly runs counter to most people's expectation,"" Waxman said. ""Basically, there are a whole bunch of things going on. No doctor wants to be sued. But doctors also don't want to make mistakes. They don't want to cause harm. They don't want to say no to patients. So everything favors doing more. There are reasons to be faulted for not doing more, and very little pushback if you don't.""""It's easy to blame something that's out of your control,"" he said, ""and the legal system is a convenient scapegoat.""SOURCE: bit.ly/Zrpqde New England Journal of Medicine, online October 15, 2014.",2014-10-15,AET,"Wed Oct 15, 2014 | 5:31pm EDT",Malpractice laws that favor doctors fail to cut health costs: study,http://www.reuters.com//article/us-healthcare-costs-malpractice-law-idUSKCN0I42OR20141015?type=companyNews
74,"  (Repeats with no change to text)By Julie SteenhuysenCHICAGO Oct 16 The infection of two U.S. healthcare workers who cared for a dying Ebola patient in Dallas is challenging assumptions about how to protect Western medical workers who perform advanced, life-saving procedures that may increase their risk of exposure.The U.S. Centers for Disease Control and Prevention says the infection of the two Dallas nurses likely occurred in the first few days of patient Thomas Duncan's admission to Texas Health Presbyterian Hospital in late September, and is investigating whether they correctly used personal protective gear such as gloves and gowns recommended by the agency.Workers at the hospital also performed invasive procedures on Duncan such as inserting a breathing tube and filtering his blood through a dialysis machine, procedures that are unprecedented in the care of an Ebola patient in the last throes of the disease. But those same procedures make it more likely that a healthcare worker will come into contact with bodily fluids at their most infectious.""The thing we don't know is, was it truly a breakdown in personal protective equipment or was it because we were instrumenting the patient by intubation or dialysis?"" said Dr Peter Hotez, a tropical disease expert at Baylor College of Medicine in Houston.In West Africa, where the worst Ebola outbreak on record has killed more than 4,000 people, the use of advanced lifesaving measures is rarely an option. But in the United States, they are routine.""We tend to go to the mat"" in an effort to save patients, Hotez said. ""Should we rethink whether we should be doing these life-saving measures? That is a question that medicine needs to address."" In most places in Africa, Ebola patients are only able to get supportive care, said CDC spokeswoman Abbigail Tumpey.""Now that we're treating patients with Ebola in the U.S., we are using modern Western medicine that has not ever been used in field studies in Africa,"" she said. Treatment approaches such as dialysis and intubation ""certainly have not been happening.""Tumpey said the CDC is now looking at the risks associated with these procedures.""Because we don't have experience with treating patients with Ebola in U.S. hospitals where we have all of this technology and resources, it's possible that some of these procedures may put healthcare workers more at risk."" Dr. Jesse Goodman of Georgetown University Medical Center said that despite the fact Ebola has been around for decades, it is ""entirely new to Western healthcare,"" and it is important to not be overly reliant on what has worked in prior outbreaks, especially when the healthcare systems are so dissimilar.GREATER BENEFIT OR HARM? To many, the questions Ebola is raising are reminiscent of the early days of caring for patients infected with the human immunodeficiency virus, or HIV, the virus that causes AIDS. Many of the safety protocols developed for blood-borne pathogens were developed through caring for AIDS patients. But Ebola is different in some very important ways. It rapidly turns off the body's innate ability to fight viruses, multiplying unchecked as the disease progresses until patients' bodies are filled with billions of virus particles.""Towards the last days of infection, that patient is basically a bag of virus,"" Hotez said.When a patient with Ebola is reaching the stage in the disease where there is need for intubation or dialysis, the risk becomes greater to the healthcare worker than the benefit to the patient because they are ""crashing"" and near death.""If it's that late a stage in the disease, the chances are that even if those are performed, the patient is already going to die,"" said Sean Kaufman, president of Behavioral-Based Improvement Solutions in Atlanta, who helps train hospital staff on safety measures.Dr. Marc Napp, deputy chief medical officer and senior vice president for medical affairs at Mount Sinai Health System in New York, said that as a general rule ""any patient that comes in, no matter what the condition, if they require certain medical therapy based upon clinical judgment and they want that therapy, we are obligated to provide it.""Napp said in the case of Ebola, there has not been any discussion about withholding life-saving treatments such as intubation for fear of harming staff members. But he said healthcare workers take risks all of the time.""I'm a general surgeon. I've stuck myself with a needle. I've cut my finger on a broken bone from a person with hepatitis. We're exposed to this regularly,"" he said. ""What's different here is there is the panic factor. It's a highly lethal infection.""      (Reporting by Julie Steenhuysen; Editing by Michele Gershberg and Ken Wills)",2014-10-16,AET,"Thu Oct 16, 2014 | 7:00am EDT","RPT-Extreme measures: U.S. hospitals take on Ebola, but at what risk?",http://www.reuters.com//article/health-ebola-usa-protocol-idUSL2N0SB0C420141016?type=companyNews
75,"   By Julie Steenhuysen | CHICAGO  CHICAGO The infection of two U.S. healthcare workers who cared for a dying Ebola patient in Dallas is challenging assumptions about how to protect Western medical workers who perform advanced, life-saving procedures that may increase their risk of exposure.The U.S. Centers for Disease Control and Prevention says the infection of the two Dallas nurses likely occurred in the first few days of patient Thomas Duncan's admission to Texas Health Presbyterian Hospital in late September, and is investigating whether they correctly used personal protective gear such as gloves and gowns recommended by the agency. Workers at the hospital also performed invasive procedures on Duncan such as inserting a breathing tube and filtering his blood through a dialysis machine, procedures that are unprecedented in the care of an Ebola patient in the last throes of the disease. But those same procedures make it more likely that a healthcare worker will come into contact with bodily fluids at their most infectious. ""The thing we don't know is, was it truly a breakdown in personal protective equipment or was it because we were instrumenting the patient by intubation or dialysis?"" said Dr Peter Hotez, a tropical disease expert at Baylor College of Medicine in Houston. In West Africa, where the worst Ebola outbreak on record has killed more than 4,000 people, the use of advanced lifesaving measures is rarely an option. But in the United States, they are routine. ""We tend to go to the mat"" in an effort to save patients, Hotez said. ""Should we rethink whether we should be doing these life-saving measures? That is a question that medicine needs to address."" In most places in Africa, Ebola patients are only able to get supportive care, said CDC spokeswoman Abbigail Tumpey. ""Now that we're treating patients with Ebola in the U.S., we are using modern Western medicine that has not ever been used in field studies in Africa,"" she said. Treatment approaches such as dialysis and intubation ""certainly have not been happening.""  Tumpey said the CDC is now looking at the risks associated with these procedures. ""Because we don't have experience with treating patients with Ebola in U.S. hospitals where we have all of this technology and resources, it's possible that some of these procedures may put healthcare workers more at risk.""Dr. Jesse Goodman of Georgetown University Medical Center said that despite the fact Ebola has been around for decades, it is ""entirely new to Western healthcare,"" and it is important to not be overly reliant on what has worked in prior outbreaks, especially when the healthcare systems are so dissimilar.   GREATER BENEFIT OR HARM?  To many, the questions Ebola is raising are reminiscent of the early days of caring for patients infected with the human immunodeficiency virus, or HIV, the virus that causes AIDS. Many of the safety protocols developed for blood-borne pathogens were developed through caring for AIDS patients. But Ebola is different in some very important ways. It rapidly turns off the body's innate ability to fight viruses, multiplying unchecked as the disease progresses until patients' bodies are filled with billions of virus particles. ""Towards the last days of infection, that patient is basically a bag of virus,"" Hotez said. When a patient with Ebola is reaching the stage in the disease where there is need for intubation or dialysis, the risk becomes greater to the healthcare worker than the benefit to the patient because they are ""crashing"" and near death. ""If it's that late a stage in the disease, the chances are that even if those are performed, the patient is already going to die,"" said Sean Kaufman, president of Behavioral-Based Improvement Solutions in Atlanta, who helps train hospital staff on safety measures. Dr. Marc Napp, deputy chief medical officer and senior vice president for medical affairs at Mount Sinai Health System in New York, said that as a general rule ""any patient that comes in, no matter what the condition, if they require certain medical therapy based upon clinical judgment and they want that therapy, we are obligated to provide it."" Napp said in the case of Ebola, there has not been any discussion about withholding life-saving treatments such as intubation for fear of harming staff members. But he said healthcare workers take risks all of the time. ""I'm a general surgeon. I've stuck myself with a needle. I've cut my finger on a broken bone from a person with hepatitis. We're exposed to this regularly,"" he said. ""What's different here is there is the panic factor. It's a highly lethal infection.    (Reporting by Julie Steenhuysen; Editing by Michele Gershberg and Ken Wills)",2014-10-16,AET,"Thu Oct 16, 2014 | 1:21am EDT","Extreme measures: U.S. hospitals take on Ebola, but at what risk?",http://www.reuters.com//article/us-health-ebola-usa-protocol-idUSKCN0I50DB20141016?type=companyNews
76,"   By Julie Steenhuysen | CHICAGO  CHICAGO Oct 16 The infection of two U.S. healthcare workers who cared for a dying Ebola patient in Dallas is challenging assumptions about how to protect Western medical workers who perform advanced, life-saving procedures that may increase their risk of exposure.The U.S. Centers for Disease Control and Prevention says the infection of the two Dallas nurses likely occurred in the first few days of patient Thomas Duncan's admission to Texas Health Presbyterian Hospital in late September, and is investigating whether they correctly used personal protective gear such as gloves and gowns recommended by the agency.Workers at the hospital also performed invasive procedures on Duncan such as inserting a breathing tube and filtering his blood through a dialysis machine, procedures that are unprecedented in the care of an Ebola patient in the last throes of the disease. But those same procedures make it more likely that a healthcare worker will come into contact with bodily fluids at their most infectious.""The thing we don't know is, was it truly a breakdown in personal protective equipment or was it because we were instrumenting the patient by intubation or dialysis?"" said Dr Peter Hotez, a tropical disease expert at Baylor College of Medicine in Houston.In West Africa, where the worst Ebola outbreak on record has killed more than 4,000 people, the use of advanced lifesaving measures is rarely an option. But in the United States, they are routine.""We tend to go to the mat"" in an effort to save patients, Hotez said. ""Should we rethink whether we should be doing these life-saving measures? That is a question that medicine needs to address.""In most places in Africa, Ebola patients are only able to get supportive care, said CDC spokeswoman Abbigail Tumpey. ""Now that we're treating patients with Ebola in the U.S., we are using modern Western medicine that has not ever been used in field studies in Africa,"" she said. Treatment approaches such as dialysis and intubation ""certainly have not been happening.""Tumpey said the CDC is now looking at the risks associated with these procedures.""Because we don't have experience with treating patients with Ebola in U.S. hospitals where we have all of this technology and resources, it's possible that some of these procedures may put healthcare workers more at risk."" Dr. Jesse Goodman of Georgetown University Medical Center said that despite the fact Ebola has been around for decades, it is ""entirely new to Western healthcare,"" and it is important to not be overly reliant on what has worked in prior outbreaks, especially when the healthcare systems are so dissimilar.GREATER BENEFIT OR HARM? To many, the questions Ebola is raising are reminiscent of the early days of caring for patients infected with the human immunodeficiency virus, or HIV, the virus that causes AIDS. Many of the safety protocols developed for blood-borne pathogens were developed through caring for AIDS patients.But Ebola is different in some very important ways. It rapidly turns off the body's innate ability to fight viruses, multiplying unchecked as the disease progresses until patients' bodies are filled with billions of virus particles. ""Towards the last days of infection, that patient is basically a bag of virus,"" Hotez said.When a patient with Ebola is reaching the stage in the disease where there is need for intubation or dialysis, the risk becomes greater to the healthcare worker than the benefit to the patient because they are ""crashing"" and near death.""If it's that late a stage in the disease, the chances are that even if those are performed, the patient is already going to die,"" said Sean Kaufman, president of Behavioral-Based Improvement Solutions in Atlanta, who helps train hospital staff on safety measures.Dr. Marc Napp, deputy chief medical officer and senior vice president for medical affairs at Mount Sinai Health System in New York, said that as a general rule ""any patient that comes in, no matter what the condition, if they require certain medical therapy based upon clinical judgment and they want that therapy, we are obligated to provide it.""Napp said in the case of Ebola, there has not been any discussion about withholding life-saving treatments such as intubation for fear of harming staff members. But he said healthcare workers take risks all of the time.""I'm a general surgeon. I've stuck myself with a needle. I've cut my finger on a broken bone from a person with hepatitis. We're exposed to this regularly,"" he said. ""What's different here is there is the panic factor. It's a highly lethal infection.""      (Reporting by Julie Steenhuysen; Editing by Michele Gershberg and Ken Wills)",2014-10-16,AET,"Thu Oct 16, 2014 | 1:00am EDT","Extreme measures: U.S. hospitals take on Ebola, but at what risk?",http://www.reuters.com//article/health-ebola-usa-protocol-idUSL2N0SB00P20141016?type=companyNews
77,"  LONDON U.S. insurance firm Epic said on Thursday it had launched Ebola cover for U.S. healthcare and emergency workers.The cover also applies to other blood-borne pathogens such as HIV, Hepatitis B and Hepatitis C, Epic said in a statement.The insured person has to have contracted the disease while in the United States and in the case of Ebola, it has to be reported within 24-48 hours, Epic said.The cost is $269 a year for individuals, it added.    (Reporting by Carolyn Cohn; editing by Alex Smith)",2014-10-23,AET,"Thu Oct 23, 2014 | 2:44pm EDT","Insurer Epic launches Ebola cover for U.S. health, emergency workers",http://www.reuters.com//article/us-health-ebola-insurance-idUSKCN0IC20520141023?type=companyNews
78,"   By Carolyn Cohn | LONDON  LONDON U.S. insurer Epic said on Thursday it had launched Ebola indemnity cover for U.S. healthcare and emergency workers.At least 4,877 people have died in the world's worst recorded outbreak of Ebola, mainly in West Africa. Three cases have been diagnosed inside the United States and the spread of the disease has prompted some insurers to exclude Ebola from their policies. Epic President Richard Kosinski said the group's Ebola cover had been added to an existing policy which also applies to other blood-borne pathogens such as HIV, Hepatitis B and Hepatitis C. The price of an individual policy has been increased by $10 to $269 a year to include Ebola, he added. Centinela Hospital Medical Center in Inglewood, California, is the first hospital to sign up to the cover, Epic said in a statement. ""We would expect all the other hospitals to sign up,"" Kosinski said. ""There have been numerous enquiries from hospitals, nurses, paramedics and others."" The insured person has to have contracted the disease while in the United States, and in the case of Ebola, the disease has to be reported within 24 to 48 hours of diagnosis, Epic said.The policy would pay out a $200,000 lump sum for HIV, Hepatitis B and C or workplace violence and an extra $20,000 per month - for up to 10 months - for Ebola, from diagnosis until return to work. The Ebola crisis is forcing the American healthcare system to consider withholding some medical interventions because they are too dangerous to doctors and nurses and unlikely to help a patient.  (Reporting by Carolyn Cohn; Editing by Alex Smith and David Holmes)",2014-10-23,AET,"Thu Oct 23, 2014 | 2:44pm EDT",Insurer Epic offers Ebola cover for U.S. health and emergency workers,http://www.reuters.com//article/us-health-ebola-insurance-epic-idUSKCN0IC23Y20141023?type=companyNews
79,"  (Adds details, comment from company president, background)By Carolyn CohnLONDON Oct 23 U.S. insurer Epic said on Thursday it had launched Ebola indemnity cover for U.S. healthcare and emergency workers.At least 4,877 people have died in the world's worst recorded outbreak of Ebola, mainly in West Africa. Three cases have been diagnosed inside the United States and the spread of the disease has prompted some insurers to exclude Ebola from their policies. Epic President Richard Kosinski said the group's Ebola cover had been added to an existing policy which also applies to other blood-borne pathogens such as HIV, Hepatitis B and Hepatitis C.The price of an individual policy has been increased by $10 to $269 a year to include Ebola, he added. Centinela Hospital Medical Center in Inglewood, California, is the first hospital to sign up to the cover, Epic said in a statement.""We would expect all the other hospitals to sign up,"" Kosinski said. ""There have been numerous enquiries from hospitals, nurses, paramedics and others."" The insured person has to have contracted the disease while in the United States, and in the case of Ebola, the disease has to be reported within 24 to 48 hours of diagnosis, Epic said.The policy would pay out a $200,000 lump sum for HIV, Hepatitis B and C or workplace violence and an extra $20,000 per month - for up to 10 months - for Ebola, from diagnosis until return to work.The Ebola crisis is forcing the American healthcare system to consider withholding some medical interventions because they are too dangerous to doctors and nurses and unlikely to help a patient.    (Reporting by Carolyn Cohn; Editing by Alex Smith and David Holmes)",2014-10-23,AET,"Thu Oct 23, 2014 | 1:18pm EDT",UPDATE 1-Insurer Epic offers Ebola cover for U.S. health and emergency workers,http://www.reuters.com//article/health-ebola-insurance-epic-idUSL6N0SI5PP20141023?type=companyNews
80,"  LONDON Oct 23 U.S. insurance firm Epic said on Thursday it had launched Ebola cover for U.S. healthcare and emergency workers.The cover also applies to other blood-borne pathogens such as HIV, Hepatitis B and Hepatitis C, Epic said in a statement.The insured person has to have contracted the disease while in the United States and in the case of Ebola, it has to be reported within 24-48 hours, Epic said. The cost is $269 a year for individuals, it added.  (Reporting by Carolyn Cohn; editing by Alex Smith)",2014-10-23,AET,"Thu Oct 23, 2014 | 12:17pm EDT","Insurer Epic launches Ebola cover for US health, emergency workers",http://www.reuters.com//article/health-ebola-insurance-idUSL6N0SI5JY20141023?type=companyNews
81,"  (The following statement was released by the rating agency) CHICAGO, October 27 (Fitch) Fitch Ratings has affirmed the 'A' Issuer Default  Rating (IDR) of Aetna Inc. (Aetna) and the 'AA-' Insurer Financial Strength  (IFS) ratings of various Aetna insurance operating subsidiaries. The Rating  Outlook has been revised to Stable from Negative. A complete list of ratings is  included at the end of this release.  KEY RATING DRIVERS Fitch's revision of Aetna's Outlook reflects the company's favorable fulfillment  of conditions established when a Negative Outlook was placed on the ratings upon  Aetna's completion of its acquisition of Coventry Health Care, Inc. (CVH) in May  2013. Specifically, the company has made substantial progress over the past year  in returning to debt-to-EBITDA and financial leverage metrics within Fitch's  guidelines for the company's current ratings. Debt-to-EBITDA has declined from  2.2x in first half 2013 to 1.6x in first half 2014 relative to a rating  sensitivity of 1.8x, and financial leverage has declined from 40% at June 30,  2013 to 37% at June 30, 2014, and is expected to be approximately 36% at  year-end 2014 relative to a rating sensitivity of 35%. Fitch expects Aetna to  report financial leverage of 35% during 2015. Aetna's ratings reflect the organization's major market position and significant  size and scale, strong profitability and interest coverage, and generally solid  balance sheet characteristics. The ratings also reflect what Fitch considers to be modest deterioration in  Aetna's capitalization metrics and ongoing sector-wide operational uncertainty  tied to the Affordable Care Act. Fitch considers Aetna to be a leading health insurance and managed care  organization due to the company's large membership, significant revenue and  earnings base, and strong competitive position. The breadth of Aetna's provider  network and its contracting capabilities are key competitive strengths.  Aetna generates consistently strong EBITDA-based profit margins and returns on  capital. From 2009 through 2013, the company's EBITDA margin and net  income-based return on equity averaged approximately 9% and 18%, respectively,  both of which are modestly above median guidelines for Aetna's rating  categories. This strong profitability, coupled with reasonable debt levels, has  resulted in solid EBITDA-based interest coverage ratios averaging approximately  12.5x over the past five years, despite a temporary increase in financial  leverage to fund its acquisition of CVH. Fitch views Aetna's statutory capitalization metrics as having deteriorated  moderately over the last 12-24 months. The company's organization-wide Fitch  adjusted NAIC risk-based capital (RBC) ratio, which excludes the impact of  excess of loss health reinsurance derived capital, declined to 255% at year-end  2013 from 262% at year-end 2012. Fitch expects the company to maintain an  adjusted RBC ratio above 260% of the company action level. Fitch's ratings on Aetna continue to reflect the risks derived from government  involvement in health insurance and managed care companies' ongoing business  activities. Fitch's long-held concern is that government efforts to advance  public policy goals could adversely affect health insurance and managed care  companies' ability to manage their business and hinder their ability to generate  cash flow supporting debt obligations.  RATING SENSITIVITIES The key rating triggers that could lead Fitch to upgrade the ratings include  run-rate: --EBITDA / revenue margin exceeding 10%; --EBITDA-based interest coverage ratios exceeding 14x; --Sustained run-rate debt-to-EBITDA ratios of less than 1.0x; --A sustained commitment to maintain a debt-to-capital ratio of less than 25%; --Organization-wide run-rate Fitch adjusted NAIC Risk-Based Capital (RBC) ratios  approximating 300%. The key rating triggers that could lead Fitch to downgrade the ratings include  run-rate: --Debt-to-EBITDA ratios that exceed 1.8x; --Debt-to-capital ratios that exceed 35%;  --EBITDA-to-revenue margins less than 7%; --EBITDA-based interest coverage ratios less than 10x or maximum allowable  dividend interest expense coverage below 5x; --Organization-wide run-rate Fitch adjusted NAIC risk-based capital (RBC) ratios  below 275%. Fitch has affirmed the following ratings: --$228 million of 6.125% senior unsecured notes due Jan. 15, 2015 at 'A-'; --$250 million of 1.75% senior unsecured notes due May 15, 2017 at 'A-'; --$500 million of 1.5% senior unsecured notes due Nov. 15, 2017 at 'A-'; --$383 million of 5.95% senior unsecured notes due March 15, 2017 at 'A-'; --$496 million of 6.5% senior unsecured notes due Sept. 15, 2018 at 'A-'; --$375 million of 2.2% senior unsecured notes due March 15, 2019 at 'A-'; --$750 million of 3.95% senior unsecured notes due Sept. 1, 2020 at 'A-'; --$500 million of 4.125% senior unsecured notes due June 1, 2021 at 'A-'; --$600 million of 5.450% senior unsecured notes due June 15, 2021 at 'A-';  --$1 billion of 2.75% senior unsecured notes due Nov. 15, 2022 at 'A-'; --$771 million of 6.625% senior unsecured notes due June 15, 2036 at 'A-'; --$534 million of 6.75% senior unsecured notes due Dec. 15, 2037 at 'A-'; --$500 million of 4.5% senior unsecured notes due May 15, 2042 at 'A-'; --$500 million of 4.125% senior unsecured notes due Nov. 15, 2042 at 'A-'; --$375 million of 4.75% senior unsecured notes due March 15, 2044 at 'A-'; --Short-term IDR at 'F1'; --$2 billion commercial paper program at 'F1'. Fitch has affirmed the following ratings and revised the Rating Outlook to  Stable from Negative:  Aetna Inc.  --Long-term IDR at 'A'. Aetna Life Insurance Company  Aetna Health Inc. (a Pennsylvania Corporation)  Aetna Health Inc. (a Florida Corporation)  Aetna Health Inc. (a New Jersey Corporation)  Aetna Health Inc. (a Texas Corporation)  Aetna Health Inc. (a New York Corporation) Aetna Health of California Inc. --IFS at 'AA-'. Contact: Primary Analyst Bradley S. Ellis, CFA Director +1-312-368-2089 Fitch Ratings, Inc. 70 W. Madison St. Chicago, IL 60602 Secondary Analyst Mark E. Rouck, CPA, CFA Senior Director +1-312-368-2085 Committee Chairperson James B. Auden, CFA Managing Director +1-312-368-3146 Media Relations: Brian Bertsch, New York, Tel: +1 212-908-0549, Email:  brian.bertsch@fitchratings.com. Additional information is available at 'www.fitchratings.com'.  Applicable Criteria and Related Research:  --'Insurance Rating Methodology' (Sept. 4, 2014); --'Health Insurance and Managed Care (U.S.) Sector Credit Factors' (Aug. 28,  2014); --'2013 Outlook Report: U.S. Health Insurance and Managed Care' (Dec. 10, 2013). Applicable Criteria and Related Research:  Insurance Rating Methodology here Health Insurance and Managed Care (U.S.) (Sector Credit Factors) here 2014 Outlook: U.S. Health Insurance and Managed Care (ACA to Increase Volumes  but Reduce Margins) here Additional Disclosure  Solicitation Status  here ALL FITCH CREDIT RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND DISCLAIMERS.  PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING THIS LINK:  here. IN ADDITION, RATING  DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE AVAILABLE ON THE AGENCY'S  PUBLIC WEBSITE 'WWW.FITCHRATINGS.COM'. PUBLISHED RATINGS, CRITERIA AND  METHODOLOGIES ARE AVAILABLE FROM THIS SITE AT ALL TIMES. FITCH'S CODE OF  CONDUCT, CONFIDENTIALITY, CONFLICTS OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE  AND OTHER RELEVANT POLICIES AND PROCEDURES ARE ALSO AVAILABLE FROM THE 'CODE OF  CONDUCT' SECTION OF THIS SITE. FITCH MAY HAVE PROVIDED ANOTHER PERMISSIBLE  SERVICE TO THE RATED ENTITY OR ITS RELATED THIRD PARTIES. DETAILS OF THIS  SERVICE FOR RATINGS FOR WHICH THE LEAD ANALYST IS BASED IN AN EU-REGISTERED  ENTITY CAN BE FOUND ON THE ENTITY SUMMARY PAGE FOR THIS ISSUER ON THE FITCH  WEBSITE.   ",2014-10-27,AET,"Mon Oct 27, 2014 | 1:54pm EDT",Fitch Affirms Aetna's IDR at 'A'; Outlook Revised to Stable,http://www.reuters.com//article/fitch-affirms-aetnas-idr-at-a-outlook-re-idUSFit80780120141027?type=companyNews
82,"   By Caroline Humer  Aetna Inc (AET.N), the third-largest U.S. health insurer, said on Tuesday it expects 2014 medical costs to increase at the high end of its forecasts, underpinning investor concerns that years of stabilized medical use could be ending.Shares in Aetna fell 2.2 percent and others insurers including UnitedHealth Group Inc (UNH.N) and WellPoint Inc WLP.N also fell.Aetna said that in the third quarter, it experienced an unexpected rise in its medical cost ratio due to more spending on claims at companies with 50 to 300 employees, the price of new hepatitis C treatments, and the performance of the individual business. The company said it expects spending to pick up during the fourth quarter, a typical seasonal trend that occurs as people reach their insurance deductibles.Its 2014 medical spending trend forecast is now for an increase at the high end of the 6 to 7 percent range. For 2015, it said it is pricing premiums based on an expectation that spending will accelerate by another 50 to 100 basis points. Investors have been watching medical cost trends closely for any reversal of the low use of medical services in recent years.  Some hospitals have reported an uptick in use driven by a rebound in the economy. Others have said medical services use is up because of implementation of the national healthcare reform law. So far, Aetna said unexpected increases have been largely in areas like pharmaceutical cost and hospital outpatient use.""I wouldn't say we have gotten to the point where we are drawing a conclusion that there is a widespread move upwards in medical cost trends,"" Aetna Chief Financial Officer Shawn Guertin said. Aetna said third-quarter profit rose as the benefits of its Coventry government healthcare acquisition offset these higher medical costs.Aetna said the percentage of premiums collected that it spent on covering medical services increased 0.5 percentage points to 81 percent in its commercial business, which includes new individual health plans. For commercial and government businesses combined, the ratio fell to 82.3 percent from 83.1 percent.In 2014, Aetna began selling health insurance to individuals on the new healthcare exchanges created under the Affordable Care Act. Aetna said it has almost 600,000 new insurance exchange customers and that they have higher costs per patient than expected. But it said it began making a slight profit on the business during the third quarter as high volume helped defray fixed costs. Aetna reported net income of $594.5 million, or $1.67 per share, up from $518.6 million, or $1.38 per share, a year earlier. Revenue rose 13 percent to $14.7 billion, slightly above analysts' expectations.Aetna said operating earnings were $1.79 per share excluding transaction costs, beating analysts' expectations of $1.58.Aetna raised its 2014 earnings forecast to $6.60 to $6.70 per share from $6.45 to $6.60. (Reporting by Caroline Humer Editing by W Simon, Lisa Von Ahn and David Gregorio)",2014-10-28,AET,"Tue Oct 28, 2014 | 11:16am EDT",Aetna sees higher medical cost spending than expected,http://www.reuters.com//article/us-aetna-results-idUSKBN0IH10120141028?type=companyNews
83,"  (Recasts to focus on medical costs)By Caroline HumerOct 28 Aetna Inc, the third-largest U.S. health insurer, said on Tuesday it expects 2014 medical costs to increase at the high end of its forecasts, underpinning investor concerns that years of stabilized medical use could be ending.Shares in Aetna fell 2.2 percent and others insurers including UnitedHealth Group Inc and WellPoint Inc  also fell.Aetna said that in the third quarter, it experienced an unexpected rise in its medical cost ratio due to more spending on claims at companies with 50 to 300 employees, the price of new hepatitis C treatments, and the performance of the individual business.The company said it expects spending to pick up during the fourth quarter, a typical seasonal trend that occurs as people reach their insurance deductibles.Its 2014 medical spending trend forecast is now for an increase at the high end of the 6 to 7 percent range. For 2015, it said it is pricing premiums based on an expectation that spending will accelerate by another 50 to 100 basis points. Investors have been watching medical cost trends closely for any reversal of the low use of medical services in recent years.Some hospitals have reported an uptick in use driven by a rebound in the economy. Others have said medical services use is up because of implementation of the national healthcare reform law.So far, Aetna said unexpected increases have been largely in areas like pharmaceutical cost and hospital outpatient use. ""I wouldn't say we have gotten to the point where we are drawing a conclusion that there is a widespread move upwards in medical cost trends,"" Aetna Chief Financial Officer Shawn Guertin said.Aetna said third-quarter profit rose as the benefits of its Coventry government healthcare acquisition offset these higher medical costs.Aetna said the percentage of premiums collected that it spent on covering medical services increased 0.5 percentage points to 81 percent in its commercial business, which includes new individual health plans. For commercial and government businesses combined, the ratio fell to 82.3 percent from 83.1 percent. In 2014, Aetna began selling health insurance to individuals on the new healthcare exchanges created under the Affordable Care Act.Aetna said it has almost 600,000 new insurance exchange customers and that they have higher costs per patient than expected. But it said it began making a slight profit on the business during the third quarter as high volume helped defray fixed costs.Aetna reported net income of $594.5 million, or $1.67 per share, up from $518.6 million, or $1.38 per share, a year earlier. Revenue rose 13 percent to $14.7 billion, slightly above analysts' expectations.Aetna said operating earnings were $1.79 per share excluding transaction costs, beating analysts' expectations of $1.58.Aetna raised its 2014 earnings forecast to $6.60 to $6.70 per share from $6.45 to $6.60.   (Reporting by Caroline Humer Editing by W Simon, Lisa Von Ahn and David Gregorio)",2014-10-28,AET,"Tue Oct 28, 2014 | 11:13am EDT",UPDATE 3-Aetna sees higher medical cost spending than expected,http://www.reuters.com//article/aetna-results-idUSL1N0SN0FN20141028?type=companyNews
84,"  Aetna Inc (AET.N) Chief Executive Officer Mark Bertolini said during a conference call with investors that he expects the company to grow operating earnings as it does every year but did not provide specific figures for 2015 earnings.Chief Financial Officer Shawn Guertin said that higher-than-expected medical costs in the smaller middle-market business  were due in part to care management initiatives not producing the lower medical costs for which it had priced.    (Reporting by Caroline Humer, Editing by Franklin Paul)",2014-10-28,AET,"Tue Oct 28, 2014 | 8:38am EDT",Aetna CEO says company will grow earnings in 2015,http://www.reuters.com//article/us-aetna-results-ceo-idUSKBN0IH16020141028?type=companyNews
85,"  Oct 28 Aetna Inc Chief Executive Officer Mark Bertolini said during a conference call with investors that he expects the company to grow operating earnings as it does every year but did not provide specific figures for 2015 earnings. Chief Financial Officer Shawn Guertin said that higher-than-expected medical costs in the smaller middle-market business  were due in part to care management initiatives not producing the lower medical costs for which it had priced.   (Reporting by Caroline Humer, Editing by Franklin Paul)  ",2014-10-28,AET,"Tue Oct 28, 2014 | 8:36am EDT",Aetna CEO says company will grow earnings in 2015,http://www.reuters.com//article/aetna-results-ceo-idUSL1N0SN0OC20141028?type=companyNews
86,"  Oct 28 Aetna Inc, the third largest U.S. health insurer, said on Tuesday that third-quarter profit rose, helped by strength in its government healthcare plan management business which it beefed up last year with the purchase of Coventry Healthcare.The company reported net income of $594.5 million, or $1.67 per share, up from $518.6 million, or $1.38 per share a year earlier.Aetna raised its profit expectation for the year to a range of $6.60 to $6.70 from a previous projection of $6.45 to $6.60 per share.   (Reporting by Caroline Humer Editing by W Simon)",2014-10-28,AET,"Tue Oct 28, 2014 | 6:09am EDT","Aetna third quarter profit rose, helped by Coventry",http://www.reuters.com//article/aetna-results-idUSL1N0SN0FC20141028?type=companyNews
87,"  (Adds Allergan, Kharafi National, Inditex, RCS Capital, PGE, Energy Future, Istrabenz, Aetna, National CineMedia, Danone, Cosumar, Sysco Corp, updates Altice SA, RTL Group, Yildiz Holding)Nov 3 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Monday:** Botox maker Allergan Inc, which is fending off an acquisition by Valeant Pharmaceuticals Inc, said on Monday that it had been approached by another party regarding a potential transaction.** Telecoms group Altice SA has made a bid worth 7.03 billion euros ($8.8 billion) for the Portuguese operations of Brazil's Oi SA as Oi unwinds its troubled merger with Portugal Telecom SGPS SA.** Switzerland's Holcim Ltd has received more than 60 bids for assets it must sell to win regulatory approval for a merger with Lafarge SA, the cement company said as it reported third-quarter results that missed expectations.Several private equity groupings have been formed to pursue a deal for the assets, which could be valued at anywhere between 4 billion euros ($5 billion) and 7 billion euros, according to sources familiar with the matter.** Laboratory Corp of America Holdings, a major provider of healthcare diagnostic services, said it would buy Covance Inc for about $6.1 billion in cash and stock to expand into the contract clinical trial business.** A consortium of Kuwait's Kharafi National and Turkey's Limak Holding have submitted the lowest bid for a 1.386 billion dinar ($4.78 billion) contract to build a new terminal at Kuwait's international airport, the tender committee said in a statement on Monday.** Publicis Groupe SA, the world's third-largest advertising agency, is to buy U.S.-based digital ad specialist Sapient Corp for $3.7 billion in cash as it seeks to accelerate growth after a botched merger earlier this year.** One of the daughters of Inditex SA founder Amancio Ortega has declared ownership of a 5 percent stake in the company, making her the second-largest shareholder in the world's largest retailer, owner of the Zara fashion chain. ** Turkey's largest food group Yildiz Holding has bought UK-based cookies and snacks maker United Biscuits (IPO-UNI.L), in a deal it said made it the world's third-biggest biscuit maker and would help it expand into new markets.** RCS Capital Corp, the independent retail brokerage empire amassed by real estate investment trust magnate Nicholas Schorsch, withdrew its plan on Monday to buy Cole Capital from American Realty Capital Properties Inc, another Schorsch venture.** Bankrupt power company Energy Future Holdings Corp received conditional court approval to accept bids for its majority stake in Oncor, a power transmission company in Texas worth billions of dollars.** Finland has agreed to buy utilities Fortum Oyj  and E.ON SE out of gas company Gasum for 510 million euros ($638 million) as part of a drive to cut its dependence on Russian gas and meet European Union energy rules.Also, Poland's largest utility, the state-controlled PGE , is interested in taking over SEC, a local heating unit controlled by E.ON, PGE said on Monday. ** Finland's government would consider buying Russian Gazprom OAO's 25 percent stake in the country's gas utility Gasum, if the Russian firm decided to sell, a senior official said on Monday.** Aetna Inc said on Monday it would buy Bswift, a software and technology services company that administers public and private health insurance exchanges for consumers and employees, for $400 million.** Danone SA, the world's largest yoghurt maker, said it would spend 278 million euros ($347.5 million) to further tighten control over Morocco's main dairy company, Centrale Laitiere, as it reduced dependence on slow-growth Europe.** The investment arm of Morocco's royal family, SNI, will sell its remaining 9 percent stake in the country's only sugar supplier Cosumar C.A. on the Casablanca Stock Exchange, the company said in a statement. ** Food distributor Sysco Corp said it did not expect to complete its acquisition of US Foods Inc  this year and it was still in talks with U.S. antitrust regulators to secure an approval for the deal.** Slovenia's tourism and energy firm Istrabenz  has sold its 4.05 percent stake in the country's largest fuel retailer Petrol, Istrabenz said in a statement on Monday.** The U.S. Justice Department on Monday filed a lawsuit to block National CineMedia Inc's proposed $375 million acquisition of smaller rival Screenvision LLC, a deal that would significantly concentrate a niche advertising market.** Diageo Plc has agreed to swap its Bushmills Irish whiskey label for full ownership of the high-end Don Julio tequila, as the British drinks group seeks to regain its leading position in tequila and build a bigger portfolio of ""reserve"" brands.Diageo did not give the full financial terms of the deal, but analysts at Nomura estimate its total consideration at 440 million pounds ($704 million).** UAE's Abraaj Investment Management has made a formal offer of 850 million Egyptian pounds ($118.9 million) for 100 percent of Bisco Misr, one of Egypt's main producers of cakes and biscuits, the regulator said in a statement.** European broadcaster RTL Group is buying control of online fashion channel StyleHaul, stepping up its involvement in Google's YouTube platform in the race to reach younger audiences less attracted to traditional media.** Germany's HeidelbergCement AG said it did not intend to bid for a portfolio of assets being sold by Holcim Ltd  and Lafarge SA, which have agreed to merge.** San Miguel Corp, the Philippines' most diversified conglomerate, is no longer in the running to bid for British snacks maker United Biscuits (IPO-UNI.L), San Miguel President Ramon Ang said on Monday.($1 = 0.80 euro)  ($1 = 0.63 pounds)  ($1 = 7.15 Egyptian pound)   (Compiled by Manya Venkatesh and Ankit Ajmera in Bangalore)",2014-11-03,AET,"Mon Nov 3, 2014 | 4:11pm EST",Deals of the day- Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL4N0ST33R20141103?type=companyNews
88,"  Aetna Inc (AET.N) said on Monday it would buy Bswift, a software and technology services company that administers public and private health insurance exchanges for consumers and employees, for $400 million.Aetna, the third largest U.S. health insurer, has placed big bets on the expansion of both public and private exchanges. It sells insurance in 18 states on the public exchanges created under the U.S. healthcare reform law. Aetna has also created its own private exchange and participates in those run by other companies, such as ones run by benefits administration companies Mercer International Inc MRIu.TO and Aon Hewitt, part of AON Plc (AON.N). ""Bswifts technology platform will provide Aetna with the capability to deliver a new private-exchange offering for employers of all sizes where the focus is on helping people easily choose a plan,"" Aetna Chief Executive Officer Mark Bertolini said in a statement. Bswift is based in Chicago and partly owned by private equity firm Great Hill Partners. It will become an Aetna unit.  (Reporting by Caroline Humer in New York; Editing by Jeffrey Benkoe)",2014-11-03,AET,"Mon Nov 3, 2014 | 11:20am EST",Aetna buys exchange technology company Bswift for $400 million,http://www.reuters.com//article/us-bswift-m-a-aetna-idUSKBN0IN1HL20141103?type=companyNews
89,"  Nov 3 Aetna Inc said on Monday it would buy Bswift, a software and technology services company that administers public and private health insurance exchanges for consumers and employees, for $400 million.Aetna, the third largest U.S. health insurer, has placed big bets on the expansion of both public and private exchanges. It sells insurance in 18 states on the public exchanges created under the U.S. healthcare reform law. Aetna has also created its own private exchange and participates in those run by other companies, such as ones run by benefits administration companies Mercer International Inc  and Aon Hewitt, part of AON Plc. ""Bswift's technology platform will provide Aetna with the capability to deliver a new private-exchange offering for employers of all sizes where the focus is on helping people easily choose a plan,"" Aetna Chief Executive Officer Mark Bertolini said in a statement. Bswift is based in Chicago and partly owned by private equity firm Great Hill Partners. It will become an Aetna unit.   (Reporting by Caroline Humer in New York; Editing by Jeffrey Benkoe)",2014-11-03,AET,"Mon Nov 3, 2014 | 11:15am EST",Aetna buys exchange technology company Bswift for $400 mln,http://www.reuters.com//article/bswift-ma-aetna-idUSL1N0ST14Q20141103?type=companyNews
90,"   By Anna Ringstrom and Olof Swahnberg | STOCKHOLM  STOCKHOLM Securitas (SECUb.ST), the world's second-biggest security services firm, cut its forecast on Tuesday for costs related to U.S. healthcare reform, a further boost as it posted profit-beating quarterly profit.Securitas now sees staff costs in the United States, its biggest market, rising only 4-5 percent because of an obligation from 2015 to offer health care insurance to all employees as part of the Affordable Care Act.It had previously forecast an increase of 8-10 percent but now believes fewer staff than initially expected will sign up for the insurance.The Swedish firm is renegotiating contracts across the United States as a consequence of the new law. Eighty percent of its US contracts are now compliant, up from 60 percent at the end of the second quarter, it said. Shares in Securitas, whose biggest rival is British G4S (GFS.L), rose on the news, trading up 6.4 percent at 1114 GMT (6.14 a.m. EST).However, Chief Executive Alf Goransson cautioned that the remaining 20 percent of U.S. contracts that it aims to renegotiate by the end of the year would be the toughest ones to finalise.Securitas employs around 310,000 people around the world, with a third of them in the United States, Canada and Mexico. TECHNOLOGY DRIVE Securitas still gets the bulk of revenues from supplying guards but is pushing to expand its use of less labour-intensive technology such as smart cameras that can identify potential threats. American clients have however been unexpectedly reluctant to adopt such technologies, Goransson said.He said technology-based contracts account for a mere 2 percent of turnover in the United States. That makes the firm's target for them to comprise 18 percent of group turnover by the end of next year harder to achieve.""Crucial for reaching the target is that we get a reasonable share of technology solutions in the United States, and the share is by mid-October smaller than we had counted on,"" he told Reuters.In the third quarter technology based solutions accounted for 9.5 percent of group turnover, up from 9 percent in the second quarter and 8.5 percent in the first. Operating profit before amortisation at Securitas, which operates in 52 countries, grew to 962 million crowns ($130 million) from 892 million a year ago.That beat a forecast 923 million in a Reuters poll of analysts, helped by better than expected organic sales growth of 4 percent with Argentina, Norway, Turkey and the United States performing well.As flagged in a Reuters interview in August, Securitas   said on Tuesday it would reorganise its troubled operations in crisis-hit Spain, one of its biggest markets.The overhaul will consist in moving resources to technology based solutions -- which in Spain are nearing 20 percent of turnover -- and cutting costs. Restructuring costs of up to 2 million euros ($2.50 million) would be booked in the fourth quarter. (Reporting by Anna Ringstrom; Editing by Keith Weir)",2014-11-04,AET,"Tue Nov 4, 2014 | 7:40am EST","Securitas profit tops forecast, sees lower impact from U.S. healthcare law",http://www.reuters.com//article/us-securitas-results-idUSKBN0IO0L920141104?type=companyNews
91,"  * Quarterly profit comes in ahead of estimates* Organic growth 4 pct vs forecast 2.8 pct* Cuts cost estimate for U.S. Affordable Care Act   (Recasts with comments from CEO)By Anna Ringstrom and Olof SwahnbergSTOCKHOLM, Nov 4 Securitas, the world's second-biggest security services firm, cut its forecast on Tuesday for costs related to U.S. healthcare reform, a further boost as it posted profit-beating quarterly profit.Securitas now sees staff costs in the United States, its biggest market, rising only 4-5 percent because of an obligation from 2015 to offer health care insurance to all employees as part of the Affordable Care Act.It had previously forecast an increase of 8-10 percent but now believes fewer staff than initially expected will sign up for the insurance.The Swedish firm is renegotiating contracts across the United States as a consequence of the new law. Eighty percent of its US contracts are now compliant, up from 60 percent at the end of the second quarter, it said.Shares in Securitas, whose biggest rival is British G4S , rose on the news, trading up 6.4 percent at 1114 GMT. However, Chief Executive Alf Goransson cautioned that the remaining 20 percent of US contracts that it aims to renegotiate by the end of the year would be the toughest ones to finalise.Securitas employs around 310,000 people around the world, with a third of them in the United States, Canada and Mexico.TECHNOLOGY DRIVE  Securitas still gets the bulk of revenues from supplying guards but is pushing to expand its use of less labour-intensive technology such as smart cameras that can identify potential threats.American clients have however been unexpectedly reluctant to adopt such technologies, Goransson said.He said technology-based contracts account for a mere 2 percent of turnover in the United States. That makes the firm's target for them to comprise 18 percent of group turnover by the end of next year harder to achieve.""Crucial for reaching the target is that we get a reasonable share of technology solutions in the United States, and the share is by mid-October smaller than we had counted on,"" he told Reuters. In the third quarter technology based solutions accounted for 9.5 percent of group turnover, up from 9 percent in the second quarter and 8.5 percent in the first.Operating profit before amortisation at Securitas, which operates in 52 countries, grew to 962 million crowns ($130 million) from 892 million a year ago.That beat a forecast 923 million in a Reuters poll of analysts, helped by better than expected organic sales growth of 4 percent with Argentina, Norway, Turkey and the United States performing well.As flagged in a Reuters interview in August, Securitas   said on Tuesday it would reorganise its troubled operations in crisis-hit Spain, one of its biggest markets.The overhaul will consist in moving resources to technology based solutions -- which in Spain are nearing 20 percent of turnover -- and cutting costs. Restructuring costs of up to 2 million euros ($2.50 million) would be booked in the fourth quarter.(1 US dollar = 7.4170 Swedish crown)(1 US dollar = 0.7995 euro)   (Reporting by Anna Ringstrom; Editing by Keith Weir)",2014-11-04,AET,"Tue Nov 4, 2014 | 7:29am EST","UPDATE 2-Securitas profit tops forecast, sees lower impact from U.S. healthcare law",http://www.reuters.com//article/securitas-results-idUSL6N0SU2KI20141104?type=companyNews
92,"  FRANKFURT Fresenius Medical Care (FMC), the world's largest kidney dialysis provider, said third-quarter net income eased by 1 percent as the effect of U.S. healthcare budget cuts slightly outweighed lower costs and a recent acquisition in the United States.The German group, which derives about two-thirds of its revenue from North America, said quarterly net income came to $271 million, compared with average expectations of $277 million in a Reuters poll. The company still expects sales to grow 4 percent to $15.2 billion in 2014, excluding revenue of about $500 million from acquisitions completed during the first nine months of the year.   (Reporting by Maria Sheahan; Editing by Christoph Steitz)",2014-11-04,AET,"Tue Nov 4, 2014 | 1:12am EST",FMC third-quarter profit eases on U.S. healthcare budget cuts,http://www.reuters.com//article/us-fresenius-medi-results-idUSKBN0IO0CQ20141104?type=companyNews
93,"  FRANKFURT Nov 4 Fresenius Medical Care (FMC) , the world's largest kidney dialysis provider, said third-quarter net income eased by 1 percent as the effect of U.S. healthcare budget cuts slightly outweighed lower costs and a recent acquisition in the United States.The German group, which derives about two-thirds of its revenue from North America, said quarterly net income came to $271 million, compared with average expectations of $277 million in a Reuters poll.  The company still expects sales to grow 4 percent to $15.2 billion in 2014, excluding revenue of about $500 million from acquisitions completed during the first nine months of the year.   (Reporting by Maria Sheahan; Editing by Christoph Steitz) ",2014-11-04,AET,"Tue Nov 4, 2014 | 1:11am EST",FMC Q3 profit eases on U.S. healthcare budget cuts,http://www.reuters.com//article/fresenius-medi-results-idUSFWN0SO01B20141104?type=companyNews
94,"  BRUSSELS Nov 5 The following are mergers under review by the European Commission and a brief guide to the EU merger process:APPROVALS AND WITHDRAWALS NoneNEW LISTINGS -- U.S. healthcare information company IMS Health to acquire certain businesses from French healthcare software provider Cegedim (notified Nov. 4/deadline Dec. 9)EXTENSIONS AND OTHER CHANGES NoneFIRST-STAGE REVIEWS BY DEADLINE NOV 5 -- SOCAR, Azerbaijan's state energy company, to buy stakes in Greek natural gas grid operator DESFA from Greek natural gas utility DEPA (notified Oct. 1/deadline Nov. 5)NOV 12 -- Aerospace group Airbus and French engine maker Safran to set up a joint venture (notified Oct. 8/deadline Nov. 12)NOV 13 -- Investment firm Strategic Value Partners to acquire Linpac Senior Holdings Ltd, the parent company of plastic packager Linpac Packaging Ltd (notified Oct. 9/deadline Nov. 13/simplified)-- Chemicals company Albemarle to buy specialty chemicals producer Rockwood Holdings Inc (notified Oct. 9/deadline Nov. 13)NOV 14 -- Mexican chemicals producer Mexichem to buy German plastic maker Vestolit (notified Oct. 10/deadline Nov. 14)-- U.S. medical device maker Medtronic Inc to acquire Irish peer Covidien (notified Oct. 10/deadline Nov. 14)NOV 17 -- Abu Dhabi-based Etihad Airways to acquire 49 percent stake in Italian airline Alitalia (notified Sept. 29/deadline extended to Nov. 17 from Nov. 3 after commitments submitted Oct. 27) -- Private equity firm KKR and German insurer Allianz to acquire indirect joint control of vending machine operator Selecta (notified Oct. 13/deadline Nov. 17)NOV 18 -- Property developer RREEF, a unit of Deutsche Bank , and German property consultancy ECE to jointly acquire properties (notified Oct. 14/deadline Nov. 18)NOV 20 -- Private equity firm TDR Capital to acquire British housing developer Lakeside Ltd (notified Oct. 16/deadline Nov. 20/simplified)-- French telecoms operator Orange to acquire Spanish provider Jazztel (notified Oct. 16/deadline Nov. 20)NOV 21 -- Macquarie Infrastructure and Real Assets (Europe) Ltd and Spanish transport services provider Ferrovial Aeropuertos S.A.U. which is part of Spanish builder Ferrovial, to acquire joint control of British airport operator Airport Holdings NDH1 from Heathrow Airports Holdings Ltd (notified Oct. 17/deadline Nov. 21)-- British insurer Aviva and Polish bank BZ WBK  to set up a joint venture (notified Oct. 17/deadline Nov. 21/simplified)NOV 24  -- South Korea's Lotte Chemical Corp to acquire Versalis Elastomers Co. Ltd, which is a joint venture between Italian energy group ENI subsidiary Versalis and Lotte (notified Oct. 20/deadline Nov. 24/simplified)NOV 26 -- Chinese conglomerate Fosun to purchase French holiday group Club Mediterranee (notified Oct. 22/deadline Nov. 26/simplified)-- Private equity firm Blackstone to acquire Alliance Automotive from Weinberg Capital Partners (notified Oct. 22/deadline Nov. 26)NOV 28 -- Canadian pension fund Ontario Teachers' Pension Plan to acquire minority stake in laundry solutions company CSC ServiceWorks from private equity firm Pamplona Capital Management (notified Oct. 24/deadline Nov.28/simplified)-- Spanish insurance company Mapfre to buy the Italian and German businesses of Direct Line, Britain's largest motor insurer (notified Oct. 24/deadline Nov. 28/simplified)DEC 1 -- Dutch insurer Aegon to acquire a 51 percent stake in Spanish insurers Aegon Santander Vida and Aegon Santander Nao Vida, which are now solely owned by Spanish bank Santander (notified Oct. 27/deadline Dec. 1/simplified)-- Mondelez International Inc and competitor D.E Master Blenders to merge their coffee businesses in new company called Jacobs Douwe Egberts (notified Oct. 27/deadline Dec. 1)-- Oil major BP to acquire jet fuel business Statoil Fuel and Retail Aviation (notified Oct. 27/deadline Dec. 1) DEC 2 -- U.S. car seat and electrical power systems maker Lear Corp to acquire car leather producer Eagle Ottawa LLC from priva<te investment firm Everett Smith Group Ltd (notified Oct. 28/deadline Dec. 2/simplified)DEC 4 -- French insurer CNP Assurances S.A. to acquire 51 percent of Santander Insurance Life Ltd, Santander Insurance Europe Ltd and Santander Insurance Services Ireland Ltd from Spanish bank Santander's (notified Oct. 30/deadline Dec. 4/simplified)DEC 5 -- Malaysian palm oil producer Sime Darby Bhd to acquire New Britain Palm Oil Ltd (notified Oct. 31/deadline Dec. 5/simplified-- U.S. chemicals company Eastman Chemical Co to buy U.S. peer Taminco Corp (notified Oct. 31/deadline Dec. 5/simplified)-- Private equity firm Vista Equity Partners to buy U.S. business software maker Tibco Software Inc (notified Oct. 31/deadline Dec. 5/simplified)DEC 15 -- France's Lafarge and Swiss peer Holcim  to merge (notified with commitments on Oct. 27/deadline Dec. 15)FEB 5 -- Belgian telecoms group Telenet to acquire 50 percent stake in Belgian broadcasting company De Vijver Media (notified Aug. 18/deadline extended for the second time to March 5 from Feb. 5)MARCH 11 -- U.S. orthopaedic products maker Zimmer Holdings  to acquire rival Biomet Inc (notified Aug. 29/deadline extended for the second time to March 11 from Feb. 16)GUIDE TO EU MERGER PROCESS DEADLINES: The European Commission has 25 working days after a deal is  filed for a first-stage review. It may extend that by 10 working days to 35 working days, to consider either a company's proposed remedies or an EU member state's request to handle the case.Most mergers win approval but occasionally the Commission  opens a detailed second-stage investigation for up to 90  additional working days, which it may extend to 105 working  days.SIMPLIFIED: Under the simplified procedure, the Commission announces the clearance of uncontroversial first-stage mergers without giving any reason for its decision. Cases may be reclassified as non-simplified -- that is, ordinary first-stage reviews -- until they are approved.   (Editing by Foo Yun Chee)",2014-11-05,AET,"Wed Nov 5, 2014 | 10:08am EST",EU mergers and takeovers (Nov 5),http://www.reuters.com//article/eu-mergers-takeovers-idUSL6N0SV4X820141105?type=companyNews
95,"  ZURICH Nov 6 Swiss dental implant maker Nobel Biocare, which has agreed to be bought by U.S. healthcare company Danaher, confirmed its full-year sales and profitability targets on Thursday as it posted quarterly profit that beat expectations.The Zurich-based firm said underlying sales rose 5.5 percent in the third quarter to 133.6 million euros ($167.29 million) slightly ahead of the average forecast for 132 million in a Reuters poll. Net profit came in at 12.4 million euros compared to 8.9 million a year earlier and ahead of the 7.9 million average forecast. Nobel Biocare confirmed its forecast for revenue to grow around 3 to 4 percent at constant exchange rates and for an improvement in its earnings before interest and tax (EBIT) margin of 150 to 200 basis points for this year. Danaher agreed in September to pay $2.2 billion for Nobel Biocare to get hold of Nobel's premium range of implants and boost its dental business sales to around $3 billion.     (1 US dollar = 0.7986 euro)   (Reporting by Caroline Copley)",2014-11-06,AET,"Thu Nov 6, 2014 | 12:58am EST","Nobel Biocare confirms guidance, profit beats estimates",http://www.reuters.com//article/nobel-biocare-results-idUSFWN0SV01Y20141106?type=companyNews
96,"  FRANKFURT Germany's Fresenius Medical Care (FMEG.DE) said it agreed to take over Cogent Healthcare, a U.S. provider of specialist physicians to hospitals, as part of its drive to offer additional services linked to its core business of kidney dialysis.The takeover of Cogent, with $250 million in expected 2015 sales, will be carried out by Sound Inpatient Physicians, in which FMC earlier this year took a majority stake. FMC, which did not disclose financial terms, aims to build a $5 billion care-coordination business by 2020 to offer a wider range of care for the chronically ill as part of an initiative to almost double group sales to $28 billion by then.Medical insurers in the United States are gradually moving toward a system of lump-sum payments for taking care of dialysis patients rather than reimbursing individual drugs and services, which FMC believes requires it to broaden its offering. Insurers hope that the system, called care coordination or disease management, will encourage healthcare providers to work more diligently toward preventing medical complications and increase patients' compliance with treatment regimens.For Sound Inpatient with $500 million in annual revenue, FMC paid more than 1.5 times expected sales, taking a majority stake which a person familiar with the matter at the time said was above 80 percent, for a purchase price of $600 million. That sales multiple, if applied to the Cogent purchase, would suggest a purchase price of more than $375 million.The German group expects the Cogent deal to improve group earnings within 18-24 months after closing, taking into account transaction and integration costs as well as synergies.  The transaction will be financed through available cash and is expected to be closed by year-end. (Reporting by Ludwig Burger; Editing by Maria Sheahan and Thomas Atkins)",2014-11-13,AET,"Thu Nov 13, 2014 | 4:19am EST",Fresenius Medical takes over U.S. healthcare group Cogent,http://www.reuters.com//article/us-cogent-m-a-fresenius-medi-idUSKCN0IX0UJ20141113?type=companyNews
97,"  * FMC pushes into care coordination with takeover* Aims to have $5 bln care coordination by 2020* Cogent to be folded into FMC's Sound Inpatient Physicians   (Adds background on care coordination, financial details)FRANKFURT, Nov 13 Germany's Fresenius Medical Care said it agreed to take over Cogent Healthcare, a U.S. provider of specialist physicians to hospitals, as part of its drive to offer additional services linked to its core business of kidney dialysis.The takeover of Cogent, with $250 million in expected 2015 sales, will be carried out by Sound Inpatient Physicians, in which FMC earlier this year took a majority stake. FMC, which did not disclose financial terms, aims to build a $5 billion care-coordination business by 2020 to offer a wider range of care for the chronically ill as part of an initiative to almost double group sales to $28 billion by then.Medical insurers in the United States are gradually moving toward a system of lump-sum payments for taking care of dialysis patients rather than reimbursing individual drugs and services, which FMC believes requires it to broaden its offering. Insurers hope that the system, called care coordination or disease management, will encourage healthcare providers to work more diligently towards preventing medical complications and increase patients' compliance with treatment regimens.For Sound Inpatient with $500 million in annual revenue, FMC paid more than 1.5 times expected sales, taking a majority stake which a person familiar with the matter at the time said was above 80 percent, for a purchase price of $600 million. That sales multiple, if applied to the Cogent purchase, would suggest a purchase price of more than $375 million.The German group expects the Cogent deal to improve group earnings within 18-24 months after closing, taking into account transaction and integration costs as well as synergies.The transaction will be financed through available cash and is expected to be closed by year-end.   (Reporting by Ludwig Burger; Editing by Maria Sheahan and Thomas Atkins)",2014-11-13,AET,"Thu Nov 13, 2014 | 3:48am EST",UPDATE 1-Fresenius Medical takes over U.S. healthcare group Cogent,http://www.reuters.com//article/cogent-ma-fresenius-medi-idUSL6N0T31UI20141113?type=companyNews
98,"  BRUSSELS Nov 26 The following are mergers under review by the European Commission and a brief guide to the EU merger process:APPROVALS AND WITHDRAWALS -- Aerospace group Airbus and French engine maker Safran to set up a joint venture (approved Nov. 26)-- Private equity firm Vista Equity Partners to buy U.S. business software maker Tibco Software Inc (approved Nov. 26)-- U.S. chemicals company Eastman Chemical Co to buy U.S. peer Taminco Corp (approved Nov. 25)NEW LISTINGS -- Dutch investment firm SHV to acquire Dutch animal feed and nutrition company Nutreco (notified Nov. 24/deadline Jan. 8/simplified)-- Norwegian media group Schibsted and Norwegian telecoms operator Telenor to set up a joint venture(notified Nov. 25/deadline Jan. 8/simplified)-- Investment firm Apollo Management to acquire Italian insurer Carige (notified Nov. 24/deadline Jan. 8/simplified)EXTENSIONS AND OTHER CHANGES -- SOCAR, Azerbaijan's state energy company, to buy stakes in Greek natural gas grid operator DESFA from Greek natural gas utility DEPA (notified Oct. 1/deadline extended for the second time to April 22 from March 23)FIRST-STAGE REVIEWS BY DEADLINE NOV 26 -- Private equity firm Blackstone to acquire Alliance Automotive from Weinberg Capital Partners (notified Oct. 22/deadline Nov. 26)NOV 28 -- U.S. medical device maker Medtronic Inc to acquire Irish peer Covidien (notified Oct. 10/deadline extended to Nov. 28 from Nov. 14 after Medtronic offered concessions)DEC 1 -- Mondelez International Inc and competitor D.E Master Blenders to merge their coffee businesses in new company called Jacobs Douwe Egberts (notified Oct. 27/deadline Dec. 1)-- Oil major BP to acquire jet fuel business Statoil Fuel and Retail Aviation (notified Oct. 27/deadline Dec. 1)DEC 4 -- French telecoms operator Orange to acquire Spanish provider Jazztel (notified Oct. 16/deadline extended to Dec. 4 from Nov. 20 after the Spanish competition authority asked to review the case/commitments submitted on Nov. 13)DEC 5 -- Malaysian palm oil producer Sime Darby Bhd to acquire New Britain Palm Oil Ltd (notified Oct. 31/deadline Dec. 5/simplified DEC 7 -- Brazilian juice maker Grupo Cutrale and investment firm Safra Group to jointly acquire U.S. banana producer Chiquita  (notified Nov. 21/deadline Dec. 7/simplified)DEC 9 -- U.S. healthcare information company IMS Health to acquire certain businesses from French healthcare software provider Cegedim (notified Nov. 4/deadline Dec. 9)DEC 10 -- Santander Consumer Finance, part of Spanish bank Santander, and French car maker Peugeot S.A. (PSA) to set up a series of joint finance companies (notified Nov. 5/deadline Dec. 10)DEC 11 -- Mining groups Anglo American and BHP Billiton   to acquire joint control of manganese miner Samancor which is now solely controlled by BHP Billiton (notified Nov. 6/deadline Dec. 11/simplified)-- Oil giant Saudi Aramco to buy a minority stake in South Korean refiner S-Oil Corp from Hanjin Group  (notified Nov. 6/deadline Dec. 11/simplified)DEC 12 -- U.S. investment management firm Varder Partners to acquire 51 percent of Spanish bank Popular's credit card business (notified Nov. 14/deadline Dec. 12/simplified)-- Privately-held Czech airline Travel Service to take a 34 percent stake in national carrier Czech Airlines (notified Nov. 14/deadline Dec. 12 DEC 15 -- Oil major BP to acquire jet fuel business Statoil Fuel and Retail Aviation (notified Oct. 27/deadline extended to Dec. 15 from Dec. 1 after the companies offered concessions)-- Mondelez International Inc and competitor D.E Master Blenders to merge their coffee businesses in new company called Jacobs Douwe Egberts (notified Oct. 27/deadline extended to Dec. 15 from Dec. 1 after the companies offered concessions)-- Aerospace group Airbus and Singapore Airlines  to jointly acquire Airbus Asia Training Centre (notified Nov. 10/deadline Dec. 15/simplified)-- France's Lafarge and Swiss peer Holcim  to merge (notified with commitments on Oct. 27/deadline Dec. 15)DEC 16 -- Private equity firms Blackstone and TPG to jointly acquire British mortgage lender Kensington Group plc (notified Nov. 11/deadline Dec. 16/simplified)DEC 17 -- Private equity firm 3i to acquire Diamond Holding GmbH from German jewellery retailer Group Christ Juweliere und Unrmacher Seit (notified Nov. 12/deadline Dec. 17/simplified)DEC 18 -- ReAssure to acquire HSBC's pensions manufacturing business (notified Nov. 13/deadline Dec. 18/simplified)DEC 19  -- Private equity firm CCMP Capital to acquire joint control of chemicals producer PQ Holdings Inc which is now jointly controlled by INEOS and private equity group The Carlyle Group LP (notified Nov. 14/deadline Dec. 19/simplified)-- Czech state-owned holding company Cesky Aeroholding and privately-owned low-cost Czech carrier Travel Service to jointly acquire Czech Airlines (notified Nov. 14/deadline Dec. 19)-- Private equity firm EQT to acquire German engineering groups Siemens's hearing-aids business (notified Nov. 14/deadline Dec. 19/simplified)-- CCMP Capital to acquire 47 percent stake in PQ Corp from Carlyle Group (notified Nov. 14/deadline Dec. 19/simplified)-- Yanfeng Automotive Trim Systems, a subsidiary of China's biggest automaker SAIC Motor Corp., to acquire Johnson Control's  auto interiors business (notified Nov. 14/deadline Dec. 19/simplified)DEC 23 -- U.S. company IBM to take over German airline Lufthansa's information technology infrastructure services division and staff for 1 billion euros (notified Nov. 18/deadline Dec. 23)JAN 5 -- Norwegian telecoms firm Telenor to form joint venture with media company Schibsted, South Africa's Naspers and Singapore Press Holdings  (notified Nov. 19/deadline Jan. 5/simplified)JAN 6 -- French holding company Eurazeo and Groupe Credit Agricole to jointly acquire two building complexes SCI Lafayette and SCI Stratege (notified Nov. 20/deadline Jan. 6/simplified)-- Hong Kong conglomerate Cheung Kong to form joint venture with Mitsubishi Corp's leasing arm MC Aviation Partners (notified Nov. 20/deadline Jan. 6/simplified)FEB 5 -- Belgian telecoms group Telenet to acquire 50 percent stake in Belgian broadcasting company De Vijver Media (notified Aug. 18/deadline extended for the second time to March 5 from Feb. 5)MARCH 5 -- Belgian telecoms group Telenet, which is a subsidiary of U.S. cable group Liberty Global, to acquire 50 percent stake in Belgian broadcasting company De Vijver Media (notified Aug. 18/deadline extended for the second time to March 5 from Feb. 5/companies submitted concessions on Nov. 24)MARCH 18 -- U.S. orthopaedic products maker Zimmer Holdings  to acquire rival Biomet Inc (notified Aug. 29/deadline extended for the third time to March 18 from March 11)GUIDE TO EU MERGER PROCESS DEADLINES: The European Commission has 25 working days after a deal is  filed for a first-stage review. It may extend that by 10 working days to 35 working days, to consider either a company's proposed remedies or an EU member state's request to handle the case.Most mergers win approval but occasionally the Commission  opens a detailed second-stage investigation for up to 90  additional working days, which it may extend to 105 working  days.SIMPLIFIED: Under the simplified procedure, the Commission announces the clearance of uncontroversial first-stage mergers without giving any reason for its decision. Cases may be reclassified as non-simplified -- that is, ordinary first-stage reviews -- until they are approved.   (Editing by Foo Yun Chee)",2014-11-26,AET,"Wed Nov 26, 2014 | 11:37am EST",EU mergers and takeovers (Nov 26),http://www.reuters.com//article/eu-mergers-takeovers-idUSL6N0TG43620141126?type=companyNews
99,"  NEW YORK Dec 3 U.S. healthcare spending last year increased 3.6 percent over 2012, the smallest rate of growth since 1960, government officials announced on Wednesday.The modest increase, down from the 4.1 percent increase from 2011 to 2012, continued a trend that began with the 2007-2009 recession, and is a dramatic change from the double-digit growth of a decade ago. It fed hopes that more price-conscious consumers, as well as policy initiatives like Obamacare, are reining in U.S. healthcare spending, the world's highest and a drag on both the federal budget and corporate balance sheets.Per capita growth slowed even more, from 3.4 percent in 2012 to 2.9 percent last year, found the Centers for Medicare and Medicaid Services (CMS). The analysis appears in the journal Health Affairs hereHealthcare spending in 2013 totaled $2.9 trillion, or $9,255 per person. It accounted for 17.4 percent of gross domestic product, the same percentage as it has since 2009. The analysis found that prices of doctor visits, hospital care, nursing homes and other healthcare services grew 1.3 percent, more slowly than the overall inflation rate of 1.5 percent.That modest increase likely reflects pressure that both private insurers and Medicare are putting on providers, as well as President Barack Obama's healthcare reform, which put checks on what providers charge Medicare, the government program for the elderly and disabled. Americans used hardly any more medical services in 2013 than in 2012, despite the aging and growth of the population. Use of such services rose 1 percent, after a 1.2 percent rise in 2012, largely due to lower growth in hospital care.The historically small rise in healthcare spending occurred across the board, in both private health insurance and Medicare. Premiums for private insurance rose 2.8 percent compared to 4 percent in 2012, reaching $961.7 billion. What private insurers paid out in claims ($846 billion) also rose more slowly: 2.8 percent vs. 4.4 percent in 2012, largely because of slower growth in spending for hospitals and doctors.Medicare spending rose 3.4 percent, compared to 4 percent growth in 2012, to $585.7 billion. Spending by the Medicaid program for the poor, however, rose 6.1 percent.CMS warned that healthcare spending will grow more sharply if economic growth accelerates. ""Historical evidence suggests it will,"" said statistician Micah Hartman.   (Reporting by Sharon Begley; Editing by David Gregorio)",2014-12-03,AET,"Wed Dec 3, 2014 | 4:00pm EST",U.S. healthcare spending registers smallest growth since 1960,http://www.reuters.com//article/healthcare-spending-idUSL2N0TN18W20141203?type=companyNews
100,"  Dec 4 The average monthly cost for a 2015 mid-tier health insurance plan in the 35 states that are part of Healthcare.gov rose about 2 percent to $222 for a 27-year old, the U.S. government said on Thursday.The figure represents the average premium for the second-lowest-cost silver plan, which is the benchmark plan used to set subsidy levels, the Department of Health and Human Services said. The report from its Office of the Assistant Secretary for Planning and Evaluation covered the costs of plans sold on the website run by the federal government and created under the national healthcare reform law. The report did not include states that operate their own exchanges, such as California or New York. Enrollment for individual coverage opened on Nov. 15 and closes Feb. 15. So far, more than 350,000 new customers have selected plans for 2015. Last year, HHS also analyzed data for 48 states. It said that the average monthly cost, weighted for age distribution, was $328 for benchmark 2014 plans. It did not provide a comparable figure in the 2015 report.    (Reporting by Caroline Humer; Editing by Dan Grebler)",2014-12-04,AET,"Thu Dec 4, 2014 | 3:01pm EST",U.S. Healthcare.gov average monthly premium rises 2 pct to $222 in 2015,http://www.reuters.com//article/usa-healthcare-insurance-idUSL2N0TO1VM20141204?type=companyNews
101,"  (Adds details on enrollment)Dec 11 With the deadline approaching for individuals to renew healthcare plans purchased on HealthCare.gov, Aetna has begun to see a surge in customers for 2015, the insurer's new president said on Thursday during a meeting with analysts and investors.HealthCare.gov has a Dec. 15 deadline for individuals to renew their 2014 plans or select new ones before it will automatically re-enroll them for next year. Enrollment for individual plans is open until Feb. 15, which were created under the 2010 Affordable Care Act, often called Obamacare. Karen Rohan, whose appointment was announced earlier this month, said that the company expects a surge in enrollment over the next few days and that it was ""starting to see"" that already. Aetna sells these plans in 17 states. The government has so far provided weekly enrollment data for HealthCare.gov through Dec. 5. In the period from Nov. 15 to Dec. 5, nearly 1.4 million people made plan selections for 2015, including more than 700,000 plan renewals. In 2014, more than 7 million people enrolled in the new individual plans, created as part of the national healthcare reform law. The government expects more than 9 million people to enroll in the new year.Aetna currently has about 600,000 customers who have enrolled through either HealthCare.gov, which sells plans in 36 states, or one of the other state run exchanges that make up the balance of the country. It also said it expects this business to grow in 2015.   (Reporting by Caroline Humer; editing by Franklin Paul, G Crosse)",2014-12-11,AET,"Thu Dec 11, 2014 | 1:24pm EST",UPDATE 1-Aetna says demand surging for individual Obamacare plans,http://www.reuters.com//article/aetna-exchanges-idUSL1N0TV1TF20141211?type=companyNews
102,"  (In third paragraph, corrects to show plan renewal selections, not total plan selections; corrects day of the week in same paragraph)Dec 11 With the deadline approaching for individuals to renew healthcare plans purchased on HealthCare.gov for next year, Aetna has begun to see a surge in customers, its new president Karen Rohan said on Thursday during a meeting with analysts and investors. HealthCare.gov has a Dec. 15 deadline for individuals to renew their 2014 plans or select new ones before it will automatically reenroll them for 2015. The government has been providing weekly figures on enrollment and on Wednesday released data showing that it has received plan selections from more than 700,000 individuals seeking to renew their plans in the weeks through Dec. 5. In 2014, more than 7 million people enrolled in these plans, created as part of the national healthcare reform law. Rohan, whose appointment was announced earlier this month, said that the company expects a surge over the next couple of days and that it was ""starting to see"" that surge already. Aetna sells these plans in 17 states.   (Reporting by Caroline Humer, Editing by Franklin Paul)",2014-12-11,AET,"Thu Dec 11, 2014 | 12:31pm EST",CORRECTED-Aetna says demand surging for individual Obamacare plans,http://www.reuters.com//article/aetna-exchanges-idUSL1N0TV1H520141211?type=companyNews
103,"   By Caroline Humer  With the deadline approaching for individuals to renew healthcare plans purchased on HealthCare.gov, Aetna has begun to see a surge in customers for 2015, the insurer's new president said on Thursday during a meeting with analysts and investors.HealthCare.gov has a Dec. 15 deadline for individuals to renew their 2014 plans or select new ones before it will automatically re-enroll them for next year. Enrollment for individual plans is open until Feb. 15, which were created under the 2010 Affordable Care Act, often called Obamacare. Karen Rohan, whose appointment was announced earlier this month, said that the company expects a surge in enrollment over the next few days and that it was ""starting to see"" that already. Aetna sells these plans in 17 states. The government has so far provided weekly enrollment data for HealthCare.gov through Dec. 5. In the period from Nov. 15 to Dec. 5, nearly 1.4 million people made plan selections for 2015, including more than 700,000 plan renewals. In 2014, more than 7 million people enrolled in the new individual plans, created as part of the national healthcare reform law. The government expects more than 9 million people to enroll in the new year.Aetna currently has about 600,000 customers who have enrolled through either HealthCare.gov, which sells plans in 36 states, or one of the other state run exchanges that make up the balance of the country. It also said it expects this business to grow in 2015.",2014-12-12,AET,"Fri Dec 12, 2014 | 4:28pm EST",Aetna says demand surging for individual Obamacare plans,http://www.reuters.com//article/aetna-exchanges-idUSL1N0TW25U20141212?type=companyNews
104,"  (Repeats for additional subscribers)By Caroline HumerNEW YORK Dec 15 Healthcare companies including Aetna Inc, Mercer and Towers Watson Co have invested hundreds of millions of dollars to build exchanges that allow company employees to buy their own insurance, betting that Corporate America wants to get out of managing workers' health benefits.By last year, blue chip names like Sears Holding  and Walgreen Co had signed on and industry experts predicted that more than 20 percent of the nation's employees would soon buy their health insurance in this way, compared with less than 2 percent today. But Reuters interviews with nearly a dozen industry executives has found that no major U.S. company signed up their employees for the first time to a private health insurance exchange for 2015.Many of those executives expect a similar situation in 2016, as blue chip employers wait for proof that the new exchanges will save them enough money to warrant the switch, raising doubts about this new business model.""We have a lot of wait-and-see going on with large employers,"" said Brian Marcotte, chief executive of the National Business Group on Health, a lobbying group for large corporations. ""They are not quite sure yet how they will deliver on managing costs better.""U.S. employers provide health benefits for more than 160 million people, mostly by contracting with large health insurers to administer the healthcare benefits that the company funds, with contributions from employee-paid premiums. But as healthcare costs rose steadily, and President Barack Obama's healthcare law required coverage of more medical services, many sought ways to rein in those expenses.Private exchanges such as Aon Hewitt, part of Aon PLC , aim to be the Amazon.coms of the insurance world, where employees choose and pay for their own plans and competition helps keep prices down.Employers contribute a fixed dollar amount to help their workers buy coverage, but can save money by no longer managing the benefits within their companies. They are not directly related to the state-based Obamacare insurance exchanges that offer government-subsidized health plans.Since 2012, employers covering as many as 3 million people have signed on to use the exchanges. A recent report from Mercer LLC, part of Marsh & McLennan, found that 3 percent of large employers were using private exchanges and that 28 percent of employers would make the shift within 5 years, taking a bite out of the business served by major insurers like UnitedHealth Group Inc and Anthem Inc, previously known as WellPoint. NEW SENSE OF CAUTION Industry executives are now projecting more caution about when private exchanges will take off. Aon Hewitt said in October that it would lose money on its private exchange this year, after previously expecting the business to be mildly profitable. Aon didn't say how much money it would lose. Insurer Cigna Corp  will sell health plans on the Aon exchange in 2016.""This is coming. It's just the pace at which we believe the market is going to make the transition"" that is slower than expected, said Patty Fontneau, who runs Cigna's private exchange business.Mercer and Towers Watson's Liazon unit are still seeing growth from serving more mid-sized businesses, which are signing up for exchanges at a higher rate since they have less invested in managing health coverage for employees. Other insurance experts question whether the forecasts will ever materialize.""Private exchanges were over-hyped from the beginning,"" said Dan Mendelson, chief executive of healthcare research firm Avalere Health. Large employers enjoy significant leverage in negotiating down the price of benefits for the many members of their workforce, an advantage that an exchange can't match, he said.LARGE MOVE FOR LARGE COMPANIES Darden Restaurants Inc, owner of the Olive Garden chain, was one of the first large companies to move to Aon Hewitt's private exchange. Medical costs were rising 8 to 10 percent per year and it had used the same insurer for 15 years. In 2012, it made a ""leap of faith"" that Aon Hewitt could do a better job, said Danielle Kirgan, Darden's senior vice president for human resources.It took four months to overhaul Darden's benefits systems and explain the change to employees. The pay off has been lower year-over-year increases in healthcare spending. ""We have over three years of seeing rates, and they have been dramatically and consistently less,"" Kirgan said in an interview. Starbucks Corp, however, took a close look at the private exchanges to understand them, but has never planned to move its 136,000 employees.""What we tended to learn is that what we do is just easier and better for people,"" Starbucks Chief Operating Officer Troy Alstead told Reuters.Large companies who are open to joining the exchanges are now asking to see at least two or three years, and as many as five years, of data on insurance premiums and medical claims from plans sold on the exchanges to be sure that there will not be a sudden increase in premiums to contend with, benefits consultants said.Some corporations also describe a sense of fatigue after several years of getting their coverage compliant with Obamacare and are loath to make additional changes in short order.Many have introduced health plans with high deductibles to shift costs to employees and want to see whether that will be enough to save money. They are also uncertain about what may be required of them if the Affordable Care Act is changed by a new Congress with Republican opponents of the law in charge.Aetna said last month it would spend $400 million to buy private exchange company Bswift and remain competitive against Aon and others. Kerry Sain, who runs Aetna's private exchange business, acknowledged that large companies are just ""dipping their toes"" into the new model.Aetna said it will still benefit from Bswift's technology even if the private exchange market does not end up as large as forecast.Leerink Partners analyst Ana Gupte said large companies need a catalyst to spur them to move onto the exchanges, namely the cut to U.S. corporate tax benefits that come from providing health coverage planned for 2018.""If that doesn't do it, I think we're pretty much done on this thing,"" she said.    (Additional reporting by Lisa Baertlein in Seattle; Editing by Michele Gershberg and John Pickering)",2014-12-15,AET,"Mon Dec 15, 2014 | 7:00am EST",RPT - INSIGHT-US corporate health exchanges find no new blue chip clients,http://www.reuters.com//article/usa-healthcare-exchanges-idUSL1N0TY0J020141215?type=companyNews
105,"   By Caroline Humer | NEW YORK  NEW YORK Healthcare companies including Aetna Inc, Mercer and Towers Watson Co have invested hundreds of millions of dollars to build exchanges that allow company employees to buy their own insurance, betting that Corporate America wants to get out of managing workers' health benefits. By last year, blue chip names like Sears Holding and Walgreen Co had signed on and industry experts predicted that more than 20 percent of the nation's employees would soon buy their health insurance in this way, compared with less than 2 percent today. But Reuters interviews with nearly a dozen industry executives has found that no major U.S. company signed up their employees for the first time to a private health insurance exchange for 2015. Many of those executives expect a similar situation in 2016, as blue chip employers wait for proof that the new exchanges will save them enough money to warrant the switch, raising doubts about this new business model.""We have a lot of wait-and-see going on with large employers,"" said Brian Marcotte, chief executive of the National Business Group on Health, a lobbying group for large corporations. ""They are not quite sure yet how they will deliver on managing costs better.""U.S. employers provide health benefits for more than 160 million people, mostly by contracting with large health insurers to administer the healthcare benefits that the company funds, with contributions from employee-paid premiums. But as healthcare costs rose steadily, and President Barack Obama's healthcare law required coverage of more medical services, many sought ways to rein in those expenses.Private exchanges such as Aon Hewitt, part of Aon PLC, aim to be the Amazon.coms of the insurance world, where employees choose and pay for their own plans and competition helps keep prices down. Employers contribute a fixed dollar amount to help their workers buy coverage, but can save money by no longer managing the benefits within their companies. They are not directly related to the state-based Obamacare insurance exchanges that offer government-subsidized health plans. Since 2012, employers covering as many as 3 million people have signed on to use the exchanges. A recent report from Mercer LLC, part of Marsh & McLennan, found that 3 percent of large employers were using private exchanges and that 28 percent of employers would make the shift within 5 years, taking a bite out of the business served by major insurers like UnitedHealth Group Inc and Anthem Inc, previously known as WellPoint.   NEW SENSE OF CAUTION  Industry executives are now projecting more caution about when private exchanges will take off. Aon Hewitt said in October that it would lose money on its private exchange this year, after previously expecting the business to be mildly profitable. Aon didn't say how much money it would lose. Insurer Cigna Corp will sell health plans on the Aon exchange in 2016. ""This is coming. It's just the pace at which we believe the market is going to make the transition"" that is slower than expected, said Patty Fontneau, who runs Cigna's private exchange business.   Mercer and Towers Watson's Liazon unit are still seeing growth from serving more mid-sized businesses, which are signing up for exchanges at a higher rate since they have less invested in managing health coverage for employees.Other insurance experts question whether the forecasts will ever materialize. ""Private exchanges were over-hyped from the beginning,"" said Dan Mendelson, chief executive of healthcare research firm Avalere Health. Large employers enjoy significant leverage in negotiating down the price of benefits for the many members of their workforce, an advantage that an exchange can't match, he said.   LARGE MOVE FOR LARGE COMPANIES Darden Restaurants Inc, owner of the Olive Garden chain, was one of the first large companies to move to Aon Hewitt's private exchange. Medical costs were rising 8 to 10 percent per year and it had used the same insurer for 15 years. In 2012, it made a ""leap of faith"" that Aon Hewitt could do a better job, said Danielle Kirgan, Darden's senior vice president for human resources. It took four months to overhaul Darden's benefits systems and explain the change to employees. The pay off has been lower year-over-year increases in healthcare spending. ""We have over three years of seeing rates, and they have been dramatically and consistently less,"" Kirgan said in an interview.Starbucks Corp, however, took a close look at the private exchanges to understand them, but has never planned to move its 136,000 employees.  ""What we tended to learn is that what we do is just easier and better for people,"" Starbucks Chief Operating Officer Troy Alstead told Reuters.Large companies who are open to joining the exchanges are now asking to see at least two or three years, and as many as five years, of data on insurance premiums and medical claims from plans sold on the exchanges to be sure that there will not be a sudden increase in premiums to contend with, benefits consultants said. Some corporations also describe a sense of fatigue after several years of getting their coverage compliant with Obamacare and are loath to make additional changes in short order. Many have introduced health plans with high deductibles to shift costs to employees and want to see whether that will be enough to save money. They are also uncertain about what may be required of them if the Affordable Care Act is changed by a new Congress with Republican opponents of the law in charge.Aetna said last month it would spend $400 million to buy private exchange company Bswift and remain competitive against Aon and others. Kerry Sain, who runs Aetna's private exchange business, acknowledged that large companies are just ""dipping their toes"" into the new model. Aetna said it will still benefit from Bswift's technology even if the private exchange market does not end up as large as forecast.Leerink Partners analyst Ana Gupte said large companies need a catalyst to spur them to move onto the exchanges, namely the cut to U.S. corporate tax benefits that come from providing health coverage planned for 2018.""If that doesn't do it, I think we're pretty much done on this thing,"" she said. (Additional reporting by Lisa Baertlein in Seattle; Editing by Michele Gershberg and John Pickering)",2014-12-15,AET,"Mon Dec 15, 2014 | 1:15am EST",U.S. corporate health exchanges find no new blue chip clients,http://www.reuters.com//article/us-usa-healthcare-exchanges-insight-idUSKBN0JT0GK20141215?type=companyNews
106,"   By Caroline Humer | NEW YORK  NEW YORK Dec 15 Healthcare companies including Aetna Inc, Mercer and Towers Watson Co have invested hundreds of millions of dollars to build exchanges that allow company employees to buy their own insurance, betting that Corporate America wants to get out of managing workers' health benefits.By last year, blue chip names like Sears Holding  and Walgreen Co had signed on and industry experts predicted that more than 20 percent of the nation's employees would soon buy their health insurance in this way, compared with less than 2 percent today. But Reuters interviews with nearly a dozen industry executives has found that no major U.S. company signed up their employees for the first time to a private health insurance exchange for 2015.Many of those executives expect a similar situation in 2016, as blue chip employers wait for proof that the new exchanges will save them enough money to warrant the switch, raising doubts about this new business model.""We have a lot of wait-and-see going on with large employers,"" said Brian Marcotte, chief executive of the National Business Group on Health, a lobbying group for large corporations. ""They are not quite sure yet how they will deliver on managing costs better.""U.S. employers provide health benefits for more than 160 million people, mostly by contracting with large health insurers to administer the healthcare benefits that the company funds, with contributions from employee-paid premiums. But as healthcare costs rose steadily, and President Barack Obama's healthcare law required coverage of more medical services, many sought ways to rein in those expenses.Private exchanges such as Aon Hewitt, part of Aon PLC , aim to be the Amazon.coms of the insurance world, where employees choose and pay for their own plans and competition helps keep prices down.Employers contribute a fixed dollar amount to help their workers buy coverage, but can save money by no longer managing the benefits within their companies. They are not directly related to the state-based Obamacare insurance exchanges that offer government-subsidized health plans.Since 2012, employers covering as many as 3 million people have signed on to use the exchanges. A recent report from Mercer LLC, part of Marsh & McLennan, found that 3 percent of large employers were using private exchanges and that 28 percent of employers would make the shift within 5 years, taking a bite out of the business served by major insurers like UnitedHealth Group Inc and Anthem Inc, previously known as WellPoint. NEW SENSE OF CAUTION Industry executives are now projecting more caution about when private exchanges will take off. Aon Hewitt said in October that it would lose money on its private exchange this year, after previously expecting the business to be mildly profitable. Aon didn't say how much money it would lose. Insurer Cigna Corp  will sell health plans on the Aon exchange in 2016.""This is coming. It's just the pace at which we believe the market is going to make the transition"" that is slower than expected, said Patty Fontneau, who runs Cigna's private exchange business.Mercer and Towers Watson's Liazon unit are still seeing growth from serving more mid-sized businesses, which are signing up for exchanges at a higher rate since they have less invested in managing health coverage for employees.Other insurance experts question whether the forecasts will ever materialize. ""Private exchanges were over-hyped from the beginning,"" said Dan Mendelson, chief executive of healthcare research firm Avalere Health. Large employers enjoy significant leverage in negotiating down the price of benefits for the many members of their workforce, an advantage that an exchange can't match, he said.LARGE MOVE FOR LARGE COMPANIES Darden Restaurants Inc, owner of the Olive Garden chain, was one of the first large companies to move to Aon Hewitt's private exchange. Medical costs were rising 8 to 10 percent per year and it had used the same insurer for 15 years. In 2012, it made a ""leap of faith"" that Aon Hewitt could do a better job, said Danielle Kirgan, Darden's senior vice president for human resources.It took four months to overhaul Darden's benefits systems and explain the change to employees. The pay off has been lower year-over-year increases in healthcare spending. ""We have over three years of seeing rates, and they have been dramatically and consistently less,"" Kirgan said in an interview. Starbucks Corp, however, took a close look at the private exchanges to understand them, but has never planned to move its 136,000 employees.""What we tended to learn is that what we do is just easier and better for people,"" Starbucks Chief Operating Officer Troy Alstead told Reuters.Large companies who are open to joining the exchanges are now asking to see at least two or three years, and as many as five years, of data on insurance premiums and medical claims from plans sold on the exchanges to be sure that there will not be a sudden increase in premiums to contend with, benefits consultants said.Some corporations also describe a sense of fatigue after several years of getting their coverage compliant with Obamacare and are loath to make additional changes in short order.Many have introduced health plans with high deductibles to shift costs to employees and want to see whether that will be enough to save money. They are also uncertain about what may be required of them if the Affordable Care Act is changed by a new Congress with Republican opponents of the law in charge.Aetna said last month it would spend $400 million to buy private exchange company Bswift and remain competitive against Aon and others. Kerry Sain, who runs Aetna's private exchange business, acknowledged that large companies are just ""dipping their toes"" into the new model.Aetna said it will still benefit from Bswift's technology even if the private exchange market does not end up as large as forecast.Leerink Partners analyst Ana Gupte said large companies need a catalyst to spur them to move onto the exchanges, namely the cut to U.S. corporate tax benefits that come from providing health coverage planned for 2018.""If that doesn't do it, I think we're pretty much done on this thing,"" she said.    (Additional reporting by Lisa Baertlein in Seattle; Editing by Michele Gershberg and John Pickering)",2014-12-15,AET,"Mon Dec 15, 2014 | 1:00am EST",INSIGHT-US corporate health exchanges find no new blue chip clients,http://www.reuters.com//article/usa-healthcare-exchanges-idUSL1N0TW21U20141215?type=companyNews
107,"   By Caroline Humer | NEW YORK  NEW YORK Healthcare companies including Aetna Inc, Mercer and Towers Watson & Co have invested hundreds of millions of dollars to build exchanges that allow company employees to buy their own insurance, betting that Corporate America wants to get out of managing workers' health benefits. By last year, blue chip names such as Sears Holding Corp and Walgreen Co had signed on and industry experts predicted that more than 20 percent of the nation's employees would soon buy their health insurance in this way, compared with less than 2 percent today. But Reuters interviews with nearly a dozen industry executives has found that no major U.S. company signed up their employees for the first time to a private health insurance exchange for 2015. Many of those executives expect a similar situation in 2016, as blue chip employers wait for proof that the new exchanges will save them enough money to warrant the switch, raising doubts about this new business model.""We have a lot of wait-and-see going on with large employers,"" said Brian Marcotte, chief executive officer of the National Business Group on Health, a lobbying group for large corporations. ""They are not quite sure yet how they will deliver on managing costs better.""U.S. employers provide health benefits for more than 160 million people, mostly by contracting with large health insurers to administer the healthcare benefits that the company funds, with contributions from employee-paid premiums. But as healthcare costs rose steadily, and President Barack Obama's healthcare law required coverage of more medical services, many sought ways to rein in those expenses.Private exchanges such as Aon Hewitt, part of Aon Plc, aim to be the Amazon.coms of the insurance world, where employees choose and pay for their own plans and competition helps keep prices down. Employers contribute a fixed dollar amount to help their workers buy coverage, but can save money by no longer managing the benefits within their companies. They are not directly related to the state-based Obamacare insurance exchanges that offer government-subsidized health plans. Since 2012, employers covering as many as 3 million people have signed on to use the exchanges, according to consulting firm Accenture. A recent report from Mercer LLC, part of Marsh & McLennan, found that 3 percent of large employers were using private exchanges and that 28 percent of employers would make the shift within five years, taking a bite out of the business served by major insurers like UnitedHealth Group Inc and Anthem Inc, previously known as WellPoint.   NEW SENSE OF CAUTION  Industry executives are now projecting more caution about when private exchanges will take off. Aon Hewitt said in October that it would lose money on its private exchange this year, after previously expecting the business to be mildly profitable. Aon did not say how much money it would lose. Insurer Cigna Corp will sell health plans on the Aon exchange in 2016. ""This is coming. It's just the pace at which we believe the market is going to make the transition"" that is slower than expected, said Patty Fontneau, who runs Cigna's private exchange business.   Mercer and Towers Watson's Liazon unit are still seeing growth from serving more mid-sized businesses, which are signing up for exchanges at a higher rate since they have less invested in managing health coverage for employees.Other insurance experts question whether the forecasts will ever materialize. ""Private exchanges were over-hyped from the beginning,"" said Dan Mendelson, chief executive of healthcare research firm Avalere Health. Large employers enjoy significant leverage in negotiating down the price of benefits for the many members of their workforce, an advantage that an exchange cannot match, he said.   LARGE MOVE FOR LARGE COMPANIES Darden Restaurants Inc, owner of the Olive Garden chain, was one of the first large companies to move to Aon Hewitt's private exchange. Medical costs were rising 8 to 10 percent per year and it had used the same insurer for 15 years. In 2012, it made a ""leap of faith"" that Aon Hewitt could do a better job, said Danielle Kirgan, Darden's senior vice president for human resources. It took four months to overhaul Darden's benefits systems and explain the change to employees. The pay off has been lower year-over-year increases in healthcare spending. ""We have over three years of seeing rates, and they have been dramatically and consistently less,"" Kirgan said in an interview.Starbucks Corp, however, took a close look at the private exchanges to understand them, but has never planned to move its 136,000 employees. ""What we tended to learn is that what we do is just easier and better for people,"" Starbucks Chief Operating Officer Troy Alstead told Reuters. Large companies that are open to joining the exchanges are now asking to see at least two or three years, and as many as five years, of data on insurance premiums and medical claims from plans sold on the exchanges to be sure that there will not be a sudden increase in premiums to contend with, benefits consultants said. Some corporations also describe a sense of fatigue after several years of getting their coverage compliant with Obamacare and are loath to make additional changes in short order. Many have introduced health plans with high deductibles to shift costs to employees and want to see whether that will be enough to save money. They are also uncertain about what may be required of them if the Affordable Care Act is changed by a new Congress with Republican opponents of the law in charge.Aetna said last month it would spend $400 million to buy private exchange company Bswift and remain competitive against Aon and others. Kerry Sain, who runs Aetna's private exchange business, acknowledged that large companies are just ""dipping their toes"" into the new model. Aetna said it will still benefit from Bswift's technology even if the private exchange market does not end up as large as forecast.Leerink Partners analyst Ana Gupte said large companies need a catalyst to spur them to move onto the exchanges, namely the cut to U.S. corporate tax benefits that come from providing health coverage planned for 2018.""If that doesn't do it, I think we're pretty much done on this thing,"" she said. (Additional reporting by Lisa Baertlein in Seattle; Editing by Michele Gershberg, John Pickering and Lisa Shumaker)",2014-12-16,AET,"Mon Dec 15, 2014 | 8:03pm EST",U.S. corporate health exchanges find no new blue chip clients,http://www.reuters.com//article/us-usa-healthcare-exchanges-insight-idUSKBN0JT0GK20141216?type=companyNews
108,"  (Adds Accenture as source in paragraph 8)By Caroline HumerNEW YORK Dec 15 Healthcare companies including Aetna Inc, Mercer and Towers Watson & Co have invested hundreds of millions of dollars to build exchanges that allow company employees to buy their own insurance, betting that Corporate America wants to get out of managing workers' health benefits.By last year, blue chip names such as Sears Holding Corp  and Walgreen Co had signed on and industry experts predicted that more than 20 percent of the nation's employees would soon buy their health insurance in this way, compared with less than 2 percent today. But Reuters interviews with nearly a dozen industry executives has found that no major U.S. company signed up their employees for the first time to a private health insurance exchange for 2015.Many of those executives expect a similar situation in 2016, as blue chip employers wait for proof that the new exchanges will save them enough money to warrant the switch, raising doubts about this new business model.""We have a lot of wait-and-see going on with large employers,"" said Brian Marcotte, chief executive officer of the National Business Group on Health, a lobbying group for large corporations. ""They are not quite sure yet how they will deliver on managing costs better.""U.S. employers provide health benefits for more than 160 million people, mostly by contracting with large health insurers to administer the healthcare benefits that the company funds, with contributions from employee-paid premiums. But as healthcare costs rose steadily, and President Barack Obama's healthcare law required coverage of more medical services, many sought ways to rein in those expenses.Private exchanges such as Aon Hewitt, part of Aon Plc , aim to be the Amazon.coms of the insurance world, where employees choose and pay for their own plans and competition helps keep prices down.Employers contribute a fixed dollar amount to help their workers buy coverage, but can save money by no longer managing the benefits within their companies. They are not directly related to the state-based Obamacare insurance exchanges that offer government-subsidized health plans.Since 2012, employers covering as many as 3 million people have signed on to use the exchanges, according to consulting firm Accenture. A recent report from Mercer LLC, part of Marsh & McLennan, found that 3 percent of large employers were using private exchanges and that 28 percent of employers would make the shift within five years, taking a bite out of the business served by major insurers like UnitedHealth Group Inc  and Anthem Inc, previously known as WellPoint. NEW SENSE OF CAUTION Industry executives are now projecting more caution about when private exchanges will take off. Aon Hewitt said in October that it would lose money on its private exchange this year, after previously expecting the business to be mildly profitable. Aon did not say how much money it would lose. Insurer Cigna Corp  will sell health plans on the Aon exchange in 2016.""This is coming. It's just the pace at which we believe the market is going to make the transition"" that is slower than expected, said Patty Fontneau, who runs Cigna's private exchange business.Mercer and Towers Watson's Liazon unit are still seeing growth from serving more mid-sized businesses, which are signing up for exchanges at a higher rate since they have less invested in managing health coverage for employees. Other insurance experts question whether the forecasts will ever materialize.""Private exchanges were over-hyped from the beginning,"" said Dan Mendelson, chief executive of healthcare research firm Avalere Health. Large employers enjoy significant leverage in negotiating down the price of benefits for the many members of their workforce, an advantage that an exchange cannot match, he said.LARGE MOVE FOR LARGE COMPANIES Darden Restaurants Inc, owner of the Olive Garden chain, was one of the first large companies to move to Aon Hewitt's private exchange. Medical costs were rising 8 to 10 percent per year and it had used the same insurer for 15 years. In 2012, it made a ""leap of faith"" that Aon Hewitt could do a better job, said Danielle Kirgan, Darden's senior vice president for human resources.It took four months to overhaul Darden's benefits systems and explain the change to employees. The pay off has been lower year-over-year increases in healthcare spending. ""We have over three years of seeing rates, and they have been dramatically and consistently less,"" Kirgan said in an interview. Starbucks Corp, however, took a close look at the private exchanges to understand them, but has never planned to move its 136,000 employees.""What we tended to learn is that what we do is just easier and better for people,"" Starbucks Chief Operating Officer Troy Alstead told Reuters.Large companies that are open to joining the exchanges are now asking to see at least two or three years, and as many as five years, of data on insurance premiums and medical claims from plans sold on the exchanges to be sure that there will not be a sudden increase in premiums to contend with, benefits consultants said.Some corporations also describe a sense of fatigue after several years of getting their coverage compliant with Obamacare and are loath to make additional changes in short order.Many have introduced health plans with high deductibles to shift costs to employees and want to see whether that will be enough to save money. They are also uncertain about what may be required of them if the Affordable Care Act is changed by a new Congress with Republican opponents of the law in charge.Aetna said last month it would spend $400 million to buy private exchange company Bswift and remain competitive against Aon and others. Kerry Sain, who runs Aetna's private exchange business, acknowledged that large companies are just ""dipping their toes"" into the new model.Aetna said it will still benefit from Bswift's technology even if the private exchange market does not end up as large as forecast.Leerink Partners analyst Ana Gupte said large companies need a catalyst to spur them to move onto the exchanges, namely the cut to U.S. corporate tax benefits that come from providing health coverage planned for 2018.""If that doesn't do it, I think we're pretty much done on this thing,"" she said.    (Additional reporting by Lisa Baertlein in Seattle; Editing by Michele Gershberg, John Pickering and Lisa Shumaker)",2014-12-16,AET,"Mon Dec 15, 2014 | 7:57pm EST",INSIGHT-U.S. corporate health exchanges find no new blue chip clients,http://www.reuters.com//article/usa-healthcare-exchanges-idUSL1N0U002620141216?type=companyNews
109,"  The chief executive of health insurer Aetna Inc on Tuesday said that the company had not yet decided which hepatitis C drugs to cover now that there are two breakthrough treatments on the market, but said that the company was actively working on a decision.Investors are watching closely to see how insurers decide to cover these drugs, which cost tens of thousands of dollars per treatment, after AbbVie Inc started a competitor to Gilead Sciences' breakthrough hepatitis C treatment.Express Scripts, the largest pharmacy benefit manager in the United States, dropped Gilead Sciences hepatitis C drugs from its main commercial formulary to favor the new, cheaper competitor while CVS Health said it would offer Gilead as a preferred drug.""We have not made a decision on one drug or another,"" Aetna CEO Mark Bertolini said during the J.P. Morgan Healthcare Conference. Bertolini also said that the company's public exchange business has been better than expected so far in 2015, as the Feb. 15 deadline for enrollment draws near. He said the business has been modestly profitable and that enrollment for 2014 also ended up higher than it had foreseen.In 2014, about 7 million people signed up for these new individual health insurance plans created under the national healthcare reform law. For 2015 the government hopes to increase that enrollment to more than 9 million people.  (Reporting by Susan Kelly in Chicago and Caroline Humer in San Francisco; Editing by Grant McCool)",2015-01-13,AET,"Tue Jan 13, 2015 | 6:16pm EST",Aetna CEO says no decision yet on how to cover hepatitis C drugs,http://www.reuters.com//article/us-healthcare-aetna-exchanges-idUSKBN0KM2G120150113?type=companyNews
110,"  Jan 13 The chief executive of health insurer Aetna Inc on Tuesday said that the company had not yet decided which hepatitis C drugs to cover now that there are two breakthrough treatments on the market, but said that the company was actively working on a decision.Investors are watching closely to see how insurers decide to cover these drugs, which cost tens of thousands of dollars per treatment, after AbbVie Inc started a competitor to Gilead Sciences' breakthrough hepatitis C treatment.Express Scripts, the largest pharmacy benefit manager in the United States, dropped Gilead Sciences hepatitis C drugs from its main commercial formulary to favor the new, cheaper competitor while CVS Health said it would offer Gilead as a preferred drug. ""We have not made a decision on one drug or another,"" Aetna CEO Mark Bertolini said during the J.P. Morgan Healthcare Conference. Bertolini also said that the company's public exchange business has been better than expected so far in 2015, as the Feb. 15 deadline for enrollment draws near. He said the business has been modestly profitable and that enrollment for 2014 also ended up higher than it had foreseen.In 2014, about 7 million people signed up for these new individual health insurance plans created under the national healthcare reform law. For 2015 the government hopes to increase that enrollment to more than 9 million people.   (Reporting by Susan Kelly in Chicago and Caroline Humer in San Francisco; Editing by Grant McCool)",2015-01-13,AET,"Tue Jan 13, 2015 | 6:15pm EST",Aetna CEO says no decision yet on how to cover hepatitis C drugs,http://www.reuters.com//article/healthcare-aetna-exchanges-idUSL1N0US2GU20150113?type=companyNews
111,"   By Deena Beasley and David Morgan | SAN FRANCISCO/WASHINGTON  SAN FRANCISCO/WASHINGTON U.S. healthcare executives say Obamacare is likely here to stay, despite repeated calls from Republican lawmakers for repeal of the 2010 law aimed at providing health coverage for millions of uninsured Americans.Top executives who gathered in San Francisco this week for the annual J.P. Morgan Healthcare conference, say that while President Obama's signature domestic policy achievement may well be tweaked, it is too entrenched to be removed.The Obama administration said in November that it aims to have over 9 million people enrolled in government-backed federal and state health insurance marketplaces in 2015, their second year of operation. Another 10 million have enrolled for coverage under an expansion of the Medicaid program for the poor.Opponents of the law in the newly-elected Congress, now dominated by Republicans, seek to replace Obama's Affordable Care Act with their own healthcare reforms. Some are betting that the U.S. Supreme Court strikes down the federal tax subsidies helping the uninsured buy coverage in 36 states.For private health insurers and hospitals, the addition of millions of new covered patients has helped buoy their profits. Drugmakers have benefited from the increase in the number of patients eligible for reimbursement of prescription medications.Repeal of the Affordable Care Act ""is not a possibility,"" George Scangos, chief executive officer at biotechnology company Biogen Idec Inc, said in an interview. ""They would somehow have to explain to millions of people that they will lose health insurance."" Aetna Inc, the third biggest health insurer, said it is talking to Republicans and Democrats about a possible ""grand bargain"" to salvage Obamacare if the Supreme Court up-ends the healthcare law later this year.""Blowing up the (Affordable Care Act) is like shutting down the government,"" Aetna Chief Executive Officer Mark Bertolini told a small group of investors. ""So we are having conversations on both sides of the aisle about what ... things you change in the ACA, what we could introduce, about how to make a grand bargain should the Supreme Court decide.""TRANSITION PLAN  The Supreme Court is due on March 4 to hear oral arguments in the case, with a ruling expected in June.""We're working on a proposal to lay out the transition, to make sure we can deal with this effectively and quickly,"" said Senator John Barrasso, chairman of the Senate Republican Policy Committee.""Putting aside the Supreme Court challenge, I don't see a veto-proof majority"" in Congress to overturn the law, said Merck & Co Inc Chief Executive Officer Kenneth Frazier. ""I would expect changes in the structure of the law, not a wholesale repeal."" Some key changes Republicans are expected to target include Obamacare's employer mandate, which requires businesses with at least 50 full-time workers to offer health coverage to their employees or pay a penalty, according to congressional aides and lawmakers.Republican lawmakers also want to change the law's definition of ""full time"" as any employee who works 30 hours a week or more, provisions that compensate health insurers for market losses and an excise tax on medical devices, including the machines that produce CAT scans and magnetic resonance images.The strategy around replacing Obamacare was expected to be a topic this week during a meeting of Republican leadership in Pennsylvania, congressional aides said.Sylvia Burwell, Secretary of the U.S. Department of Health and Human Services, which oversees the law's implementation, said that Republican efforts to replace Obamacare are happening ""despite increasing evidence that the law is working.""A Gallup survey showed that the percentage of Americans without health insurance fell 4.2 percentage points to just under 13 percent at the end of 2014.""I don't think it will go away,"" said Jean-Jacques Bienaim, Chief Executive Officer at BioMarin Pharmaceutical Inc. ""There will probably be some adjustments."" He said the ACA has helped companies like BioMarin that specialize in drugs for rare diseases because it prohibits lifetime caps on reimbursement, even for expensive medications.   (Additional reporting by Caroline Humer)",2015-01-15,AET,"Thu Jan 15, 2015 | 5:44pm EST",U.S. healthcare executives say Obamacare is not going anywhere,http://www.reuters.com//article/healthcare-obamacare-executives-idUSL1N0UU31520150115?type=companyNews
112,"   By Deena Beasley and David Morgan | SAN FRANCISCO/WASHINGTON  SAN FRANCISCO/WASHINGTON U.S. healthcare executives say Obamacare is likely here to stay, despite repeated calls from Republican lawmakers for repeal of the 2010 law aimed at providing health coverage for millions of uninsured Americans.Top executives who gathered in San Francisco this week for the annual J.P. Morgan Healthcare conference, say that while President Obama's signature domestic policy achievement may well be tweaked, it is too entrenched to be removed.The Obama administration said in November that it aims to have over 9 million people enrolled in government-backed federal and state health insurance marketplaces in 2015, their second year of operation. Another 10 million have enrolled for coverage under an expansion of the Medicaid program for the poor.Opponents of the law in the newly-elected Congress, now dominated by Republicans, seek to replace Obamas Affordable Care Act with their own healthcare reforms. Some are betting that the U.S. Supreme Court strikes down the federal tax subsidies helping the uninsured buy coverage in 36 states. For private health insurers and hospitals, the addition of millions of new covered patients has helped buoy their profits. Drugmakers have benefited from the increase in the number of patients eligible for reimbursement of prescription medications.Repeal of the Affordable Care Act ""is not a possibility,"" George Scangos, chief executive officer at biotechnology company Biogen Idec Inc, said in an interview. ""They would somehow have to explain to millions of people that they will lose health insurance.""Aetna Inc, the third biggest health insurer, said it is talking to Republicans and Democrats about a possible ""grand bargain"" to salvage Obamacare if the Supreme Court up-ends the healthcare law later this year. ""Blowing up the (Affordable Care Act) is like shutting down the government,"" Aetna Chief Executive Officer Mark Bertolini told a small group of investors. ""So we are having conversations on both sides of the aisle about what ... things you change in the ACA, what we could introduce, about how to make a grand bargain should the Supreme Court decide.""  TRANSITION PLAN The Supreme Court is due on March 4 to hear oral arguments in the case, with a ruling expected in June. ""We're working on a proposal to lay out the transition, to make sure we can deal with this effectively and quickly,"" said Senator John Barrasso, chairman of the Senate Republican Policy Committee.""Putting aside the Supreme Court challenge, I don't see a veto-proof majority"" in Congress to overturn the law, said Merck & Co Inc Chief Executive Officer Kenneth Frazier. ""I would expect changes in the structure of the law, not a wholesale repeal.""Some key changes Republicans are expected to target include Obamacares employer mandate, which requires businesses with at least 50 full-time workers to offer health coverage to their employees or pay a penalty, according to congressional aides and lawmakers.  Republican lawmakers also want to change the law's definition of ""full time"" as any employee who works 30 hours a week or more, provisions that compensate health insurers for market losses and an excise tax on medical devices, including the machines that produce CAT scans and magnetic resonance images.The strategy around replacing Obamacare was expected to be a topic this week during a meeting of Republican leadership in Pennsylvania, congressional aides said.Sylvia Burwell, Secretary of the U.S. Department of Health and Human Services, which oversees the laws implementation, said that Republican efforts to replace Obamacare are happening despite increasing evidence that the law is working. A Gallup survey showed that the percentage of Americans without health insurance fell 4.2 percentage points to just under 13 percent at the end of 2014.""I don't think it will go away,"" said Jean-Jacques Bienaim, Chief Executive Officer at BioMarin Pharmaceutical Inc. ""There will probably be some adjustments."" He said the ACA has helped companies like BioMarin that specialize in drugs for rare diseases because it prohibits lifetime caps on reimbursement, even for expensive medications. (Additional reporting by Caroline Humer; Editing by Michele Gershberg, Bernard Orr)",2015-01-15,AET,"Thu Jan 15, 2015 | 5:44pm EST",U.S. healthcare executives say Obamacare is not going anywhere,http://www.reuters.com//article/us-healthcare-obamacare-executives-idUSKBN0KO2PN20150115?type=companyNews
113,"   By Deena Beasley and David Morgan  SAN FRANCISCO/WASHINGTON Jan 15 U.S. healthcare executives say Obamacare is likely here to stay, despite repeated calls from Republican lawmakers for repeal of the 2010 law aimed at providing health coverage for millions of uninsured Americans.Top executives who gathered in San Francisco this week for the annual J.P. Morgan Healthcare conference, say that while President Obama's signature domestic policy achievement may well be tweaked, it is too entrenched to be removed.The Obama administration said in November that it aims to have over 9 million people enrolled in government-backed federal and state health insurance marketplaces in 2015, their second year of operation. Another 10 million have enrolled for coverage under an expansion of the Medicaid program for the poor.Opponents of the law in the newly-elected Congress, now dominated by Republicans, seek to replace Obama's Affordable Care Act with their own healthcare reforms. Some are betting that the U.S. Supreme Court strikes down the federal tax subsidies helping the uninsured buy coverage in 36 states.For private health insurers and hospitals, the addition of millions of new covered patients has helped buoy their profits. Drugmakers have benefited from the increase in the number of patients eligible for reimbursement of prescription medications.Repeal of the Affordable Care Act ""is not a possibility,"" George Scangos, chief executive officer at biotechnology company Biogen Idec Inc, said in an interview. ""They would somehow have to explain to millions of people that they will lose health insurance."" Aetna Inc, the third biggest health insurer, said it is talking to Republicans and Democrats about a possible ""grand bargain"" to salvage Obamacare if the Supreme Court up-ends the healthcare law later this year.""Blowing up the (Affordable Care Act) is like shutting down the government,"" Aetna Chief Executive Officer Mark Bertolini told a small group of investors. ""So we are having conversations on both sides of the aisle about what ... things you change in the ACA, what we could introduce, about how to make a grand bargain should the Supreme Court decide.""TRANSITION PLAN  The Supreme Court is due on March 4 to hear oral arguments in the case, with a ruling expected in June.""We're working on a proposal to lay out the transition, to make sure we can deal with this effectively and quickly,"" said Senator John Barrasso, chairman of the Senate Republican Policy Committee.""Putting aside the Supreme Court challenge, I don't see a veto-proof majority"" in Congress to overturn the law, said Merck & Co Inc Chief Executive Officer Kenneth Frazier. ""I would expect changes in the structure of the law, not a wholesale repeal."" Some key changes Republicans are expected to target include Obamacare's employer mandate, which requires businesses with at least 50 full-time workers to offer health coverage to their employees or pay a penalty, according to congressional aides and lawmakers.Republican lawmakers also want to change the law's definition of ""full time"" as any employee who works 30 hours a week or more, provisions that compensate health insurers for market losses and an excise tax on medical devices, including the machines that produce CAT scans and magnetic resonance images.The strategy around replacing Obamacare was expected to be a topic this week during a meeting of Republican leadership in Pennsylvania, congressional aides said.Sylvia Burwell, Secretary of the U.S. Department of Health and Human Services, which oversees the law's implementation, said that Republican efforts to replace Obamacare are happening ""despite increasing evidence that the law is working.""A Gallup survey showed that the percentage of Americans without health insurance fell 4.2 percentage points to just under 13 percent at the end of 2014.""I don't think it will go away,"" said Jean-Jacques Bienaim, Chief Executive Officer at BioMarin Pharmaceutical Inc. ""There will probably be some adjustments."" He said the ACA has helped companies like BioMarin that specialize in drugs for rare diseases because it prohibits lifetime caps on reimbursement, even for expensive medications.   (Additional reporting by Caroline Humer; Editing by Michele Gershberg, Bernard Orr)",2015-01-15,AET,"Thu Jan 15, 2015 | 5:38pm EST",U.S. healthcare executives say Obamacare is not going anywhere,http://www.reuters.com//article/healthcare-obamacare-executives-idUSL1N0UU2K520150115?type=companyNews
114,"   By Caroline Humer and Bill Berkrot  Aetna Inc, the third-largest U.S. health insurer, said it negotiated a discount with Gilead Sciences Inc for its hepatitis C treatment and will offer it as the preferred choice to nearly 11 million commercial customers.Aetna, which posted an updated coverage policy on its website on Friday, said it believes the price it received for Gilead's Sovaldi, and a newer combination treatment called Harvoni, is ""competitive with other recently announced agreements for this class of therapy."" It would not detail the size of the discount. Gilead shares closed up 3.4 percent at $100.71 after the Aetna deal was announced. Aetna shares closed 2.3 percent higher at $92.56.    Aetna and other insurers have pushed back against the high price of new hepatitis C treatments and other drugs, questioning their affordability after Gilead's Sovaldi was priced at $84,000 per treatment when it became the first new all-oral treatment to reach the market in late 2013. U.S. health regulators late last month approved Viekira Pak from AbbVie Inc, the first competitor to Gilead's drugs. Within a few days, Express Scripts, the largest U.S. pharmacy benefits manager, dropped coverage of Gilead's treatments in most cases in favor of the AbbVie therapy, citing a substantial discount.  Both breakthrough treatments for the first time can cure the liver-wasting disease in more than 90 percent of patients without the miserable side effects of older medicines. More than 3 million people in the United States are estimated to have hepatitis C.Since Express Scripts' move, insurers have pressed both AbbVie and Gilead for discounts on their hepatitis C treatments to keep them on reimbursement lists. CVS Health, Anthem and Humana chose Gilead drugs as their preferred treatment, while pharmacy benefits company Prime Therapeutics kept both on its list.Wall Street analysts estimate the drugmakers have provided discounts of 30 percent or more. Gilead and AbbVie would not comment on the price reductions. Some industry experts see Gilead and AbbVie gaining in terms of the number of patients treated now that they have conceded on price. Many insurers had limited use of the new hepatitis C drugs to the sickest patients to contain costs.""The floodgates (of patients) could start to open over time this year,"" said RBC Capital Markets analyst Michael Yee. He has forecast $15 billion for Gilead worldwide hepatitis C sales in 2015 and sees room for upside.  ""That number starts to go up as we start seeing some of the prescription numbers come out,"" he said.Len Yaffe, portfolio manager of the StockDoc Partners healthcare fund, expects $18 billion in Gilead hepatitis C sales this year as more patients are covered for treatment.Gilead's new two-drug treatment, Harvoni, taken as one pill once a day, is expected to replace Sovaldi use. It has a list price of $94,500 for 12 weeks. AbbVie's Viekira Pak, which involves more pills and drugs, and in most cases must be taken with the older medicine ribavirin, has a list price of $83,319 per treatment. (Reporting by Caroline Humer and Bill Berkrot; Editing by Michele Gershberg, Alan Crosby)",2015-01-16,AET,"Fri Jan 16, 2015 | 6:10pm EST","Aetna backs Gilead's hepatitis C treatment, gets discount",http://www.reuters.com//article/us-healthcare-aetna-hepatitisc-idUSKBN0KP28O20150116?type=companyNews
115,"  (Adds portfolio manager, analyst comment, updates shares)By Caroline Humer and Bill BerkrotJan 16 Aetna Inc, the third-largest U.S. health insurer, said it negotiated a discount with Gilead Sciences Inc for its hepatitis C treatment and will offer it as the preferred choice to nearly 11 million commercial customers.Aetna, which posted an updated coverage policy on its website on Friday, said it believes the price it received for Gilead's Sovaldi, and a newer combination treatment called Harvoni, is ""competitive with other recently announced agreements for this class of therapy."" It would not detail the size of the discount.Gilead shares closed up 3.4 percent at $100.71 after the Aetna deal was announced. Aetna shares closed 2.3 percent higher at $92.56.Aetna and other insurers have pushed back against the high price of new hepatitis C treatments and other drugs, questioning their affordability after Gilead's Sovaldi was priced at $84,000 per treatment when it became the first new all-oral treatment to reach the market in late 2013. U.S. health regulators late last month approved Viekira Pak from AbbVie Inc, the first competitor to Gilead's drugs. Within a few days, Express Scripts, the largest U.S. pharmacy benefits manager, dropped coverage of Gilead's treatments in most cases in favor of the AbbVie therapy, citing a substantial discount.Both breakthrough treatments for the first time can cure the liver-wasting disease in more than 90 percent of patients without the miserable side effects of older medicines. More than 3 million people in the United States are estimated to have hepatitis C. Since Express Scripts' move, insurers have pressed both AbbVie and Gilead for discounts on their hepatitis C treatments to keep them on reimbursement lists. CVS Health, Anthem  and Humana chose Gilead drugs as their preferred treatment, while pharmacy benefits company Prime Therapeutics kept both on its list.Wall Street analysts estimate the drugmakers have provided discounts of 30 percent or more. Gilead and AbbVie would not comment on the price reductions.Some industry experts see Gilead and AbbVie gaining in terms of the number of patients treated now that they have conceded on price. Many insurers had limited use of the new hepatitis C drugs to the sickest patients to contain costs. ""The floodgates (of patients) could start to open over time this year,"" said RBC Capital Markets analyst Michael Yee. He has forecast $15 billion for Gilead worldwide hepatitis C sales in 2015 and sees room for upside.""That number starts to go up as we start seeing some of the prescription numbers come out,"" he said.Len Yaffe, portfolio manager of the StockDoc Partners healthcare fund, expects $18 billion in Gilead hepatitis C sales this year as more patients are covered for treatment.Gilead's new two-drug treatment, Harvoni, taken as one pill once a day, is expected to replace Sovaldi use. It has a list price of $94,500 for 12 weeks. AbbVie's Viekira Pak, which involves more pills and drugs, and in most cases must be taken with the older medicine ribavirin, has a list price of $83,319 per treatment.   (Reporting by Caroline Humer and Bill Berkrot; Editing by Michele Gershberg, Alan Crosby)",2015-01-16,AET,"Fri Jan 16, 2015 | 6:06pm EST","UPDATE 2-Aetna backs Gilead's hepatitis C treatment, gets discount",http://www.reuters.com//article/healthcare-aetna-hepatitisc-idUSL1N0UV1VE20150116?type=companyNews
116,"  (Repeats story that originally ran on Thursday)By Deena Beasley and David MorganSAN FRANCISCO/WASHINGTON Jan 15 U.S. healthcare executives say Obamacare is likely here to stay, despite repeated calls from Republican lawmakers for repeal of the 2010 law aimed at providing health coverage for millions of uninsured Americans.Top executives who gathered in San Francisco this week for the annual J.P. Morgan Healthcare conference, say that while President Obama's signature domestic policy achievement may well be tweaked, it is too entrenched to be removed.The Obama administration said in November that it aims to have over 9 million people enrolled in government-backed federal and state health insurance marketplaces in 2015, their second year of operation. Another 10 million have enrolled for coverage under an expansion of the Medicaid program for the poor.Opponents of the law in the newly-elected Congress, now dominated by Republicans, seek to replace Obama's Affordable Care Act with their own healthcare reforms. Some are betting that the U.S. Supreme Court strikes down the federal tax subsidies helping the uninsured buy coverage in 36 states.For private health insurers and hospitals, the addition of millions of new covered patients has helped buoy their profits. Drugmakers have benefited from the increase in the number of patients eligible for reimbursement of prescription medications.Repeal of the Affordable Care Act ""is not a possibility,"" George Scangos, chief executive officer at biotechnology company Biogen Idec Inc, said in an interview. ""They would somehow have to explain to millions of people that they will lose health insurance."" Aetna Inc, the third biggest health insurer, said it is talking to Republicans and Democrats about a possible ""grand bargain"" to salvage Obamacare if the Supreme Court up-ends the healthcare law later this year.""Blowing up the (Affordable Care Act) is like shutting down the government,"" Aetna Chief Executive Officer Mark Bertolini told a small group of investors. ""So we are having conversations on both sides of the aisle about what ... things you change in the ACA, what we could introduce, about how to make a grand bargain should the Supreme Court decide."" TRANSITION PLAN The Supreme Court is due on March 4 to hear oral arguments in the case, with a ruling expected in June.""We're working on a proposal to lay out the transition, to make sure we can deal with this effectively and quickly,"" said Senator John Barrasso, chairman of the Senate Republican Policy Committee.""Putting aside the Supreme Court challenge, I don't see a veto-proof majority"" in Congress to overturn the law, said Merck & Co Inc Chief Executive Officer Kenneth Frazier. ""I would expect changes in the structure of the law, not a wholesale repeal."" Some key changes Republicans are expected to target include Obamacare's employer mandate, which requires businesses with at least 50 full-time workers to offer health coverage to their employees or pay a penalty, according to congressional aides and lawmakers.Republican lawmakers also want to change the law's definition of ""full time"" as any employee who works 30 hours a week or more, provisions that compensate health insurers for market losses and an excise tax on medical devices, including the machines that produce CAT scans and magnetic resonance images.The strategy around replacing Obamacare was expected to be a topic this week during a meeting of Republican leadership in Pennsylvania, congressional aides said.Sylvia Burwell, Secretary of the U.S. Department of Health and Human Services, which oversees the law's implementation, said that Republican efforts to replace Obamacare are happening ""despite increasing evidence that the law is working.""A Gallup survey showed that the percentage of Americans without health insurance fell 4.2 percentage points to just under 13 percent at the end of 2014.""I don't think it will go away,"" said Jean-Jacques Bienaim, Chief Executive Officer at BioMarin Pharmaceutical Inc. ""There will probably be some adjustments."" He said the ACA has helped companies like BioMarin that specialize in drugs for rare diseases because it prohibits lifetime caps on reimbursement, even for expensive medications.   (Additional reporting by Caroline Humer; Editing by Michele Gershberg, Bernard Orr)",2015-01-16,AET,"Fri Jan 16, 2015 | 7:00am EST",RPT-U.S. healthcare executives say Obamacare is not going anywhere,http://www.reuters.com//article/healthcare-obamacare-executives-idUSL1N0UU30S20150116?type=companyNews
117,"  Thermo Fisher Scientific Inc (TMO.N), the world's largest maker of scientific instruments, forecast 2015 sales and earnings below analysts' expectations, becoming the latest U.S. healthcare company to warn about a strengthening dollar.The strengthening of the dollar, particularly against the euro and the Japanese yen, would result in a 4 percent decline in Thermo Fisher's revenue in 2015, CFO Peter Wilver said on a call with analysts.Thermo Fisher expects full-year revenue of $16.80 billion to $17 billion. Analysts were expecting $17.25 billion, according to Thomson Reuters I/B/E/S.The company expects profit to be hit by 58 cents in 2015. It forecast $7.22 to $7.40, excluding special items, below analysts' average estimate of $7.62.Heavyweights such as Johnson & Johnson (JNJ.N), Bristol-Myers Squibb (BMY.N) and Pfizer Inc (PFE.N) have warned about the impact of a strengthening dollar on their 2015 earnings.After hitting a 6-1/2 month low in May, the dollar .DXY has surged nearly 20 percent against a basket of major currencies, making overseas sales denominated in other currencies less valuable in dollar terms. The stronger dollar can also make U.S.-made products more expensive for consumers in other currencies and thus cut demand.CEO Marc Casper said the company plans to move more production of reagents to its Lithuanian site to cut costs and ""get aggressive"" on its operating plan to offset the impact from a strong dollar.Thermo Fisher reported better-than-expected quarterly profit and sales on Thursday, boosted by the contribution from the Life Technologies acquisition. With the addition of Life Tech business, Thermo Fisher's life sciences business reported a surge in sales to $1.19 billion, compared with $192 million a year earlier.  The business, the company's largest division, provides reagents, instruments and consumables used in biological and medical research.     The company's other three businesses reported sales growth of 2 percent to 4 percent.The purchase of Life Tech for more than $13 billion was completed in early 2014.Thermo Fisher shares, which gained 13 percent in 2014, edged up 1 percent to $125.84 in morning trading on the New York Stock Exchange. (Reporting by Bill Berkrot, and Vidya L Nathan in Bengaluru; Editing by Don Sebastian)",2015-01-29,AET,"Thu Jan 29, 2015 | 11:24am EST","Thermo Fisher says strong dollar to hurt revenue, profit",http://www.reuters.com//article/us-thermo-fisher-results-idUSKBN0L217S20150129?type=companyNews
118,"  (Adds forecast, shares, CEO and CFO comments)Jan 29 Thermo Fisher Scientific Inc, the world's largest maker of scientific instruments, forecast 2015 sales and earnings below analysts' expectations, becoming the latest U.S. healthcare company to warn about a strengthening dollar.The strengthening of the dollar, particularly against the euro and the Japanese yen, would result in a 4 percent decline in Thermo Fisher's revenue in 2015, CFO Peter Wilver said on a call with analysts.Thermo Fisher expects full-year revenue of $16.80 billion to $17 billion. Analysts were expecting $17.25 billion, according to Thomson Reuters I/B/E/S.The company expects profit to be hit by 58 cents in 2015. It forecast $7.22 to $7.40, excluding special items, below analysts' average estimate of $7.62.Heavyweights such as Johnson & Johnson, Bristol-Myers Squibb and Pfizer Inc have warned about the impact of a strengthening dollar on their 2015 earnings. After hitting a 6-1/2 month low in May, the dollar  has surged nearly 20 percent against a basket of major currencies, making overseas sales denominated in other currencies less valuable in dollar terms.The stronger dollar can also make U.S.-made products more expensive for consumers in other currencies and thus cut demand. CEO Marc Casper said the company plans to move more production of reagents to its Lithuanian site to cut costs and ""get aggressive"" on its operating plan to offset the impact from a strong dollar.Thermo Fisher reported better-than-expected quarterly profit and sales on Thursday, boosted by the contribution from the Life Technologies acquisition.With the addition of Life Tech business, Thermo Fisher's life sciences business reported a surge in sales to $1.19 billion, compared with $192 million a year earlier. The business, the company's largest division, provides reagents, instruments and consumables used in biological and medical research.The company's other three businesses reported sales growth of 2 percent to 4 percent.The purchase of Life Tech for more than $13 billion was completed in early 2014.Thermo Fisher shares, which gained 13 percent in 2014, edged up 1 percent to $125.84 in morning trading on the New York Stock Exchange.   (Reporting by Bill Berkrot, and Vidya L Nathan in Bengaluru; Editing by Don Sebastian)",2015-01-29,AET,"Thu Jan 29, 2015 | 11:22am EST","UPDATE 1-Thermo Fisher says strong dollar to hurt revenue, profit",http://www.reuters.com//article/thermo-fisher-results-idUSL4N0V86MN20150129?type=companyNews
119,"  Aetna Inc (AET.N), the third largest U.S. health insurer, raised its 2015 profit forecast after negotiating a price cut from Gilead Sciences Inc (GILD.O) on hepatitis C treatments for this year. Aetna said the increased outlook was also due to momentum in its business early in the year after a strong finish to 2014. It boosted its full-year operating earnings forecast to at least $7.00 per share, up from $6.90. Aetna also reported quarterly profit in line with estimates.The stock rose more than 1 percent.Aetna reported an improved medical benefit ratio of 83 percent for the fourth quarter, compared with 83.9 percent a year earlier. The ratio is the amount an insurer spends on medical claims compared with its income from premiums.The company said the costs of medical care have remained moderate and that it expects its medical benefit ratio to be between 82 percent and 83 percent. Its comments on spending were in line with larger competitors UnitedHealth Group Inc (UNH.N) and Anthem Inc (ANTM.N). The company said the medical benefit ratio for commercial plans, its largest business, deteriorated to 82 percent from 81.7 percent, due to higher-than-expected medical costs in small businesses and expenses associated with the new hepatitis C treatments.Last year Aetna was among insurance companies and other payers who said that the $84,000 cost per treatment for Gilead's new hepatitis C drug, which hit the market late in 2013, was unaffordable. When AbbVie Inc (ABBV.N) launched a competing drug at the end of 2014, insurers, pharmacy benefit managers and others started negotiating for discounts from Gilead. Aetna said last month it had secured a lower cost and would back Gilead's Harvoni drug as its preferred treatment over AbbVie's.Aetna's membership rose to 23.5 million at the end of 2014 from 22.2 million a year earlier, helped by growth in new insurance created by the national healthcare reform law, often called Obamacare. Aetna said it added 560,000 members from the Obamacare exchanges at the end of 2014 and expects that to increase to 800,000 by the end of the first quarter, helped by expansion into Georgia.The company reported operating earnings of $1.22 per share for the quarter, largely in line with average analyst estimate, according to Thomson Reuters I/B/E/S. Revenue of $14.77 billion beat the average estimate of $14.60 billion.The company's shares rose $1.01 to $93.23 on the New York Stock Exchange. (Reporting by Caroline Humer in New York and Amrutha Penumudi in Bengaluru; Editing by Don Sebastian and Jeffrey Benkoe)",2015-02-03,AET,"Tue Feb 3, 2015 | 11:59am EST",Health insurer Aetna raises 2015 profit forecast,http://www.reuters.com//article/us-centene-results-idUSKBN0L710U20150203?type=companyNews
120,"  (Adds details from call on outlook)Feb 3 Aetna Inc, the third largest U.S. health insurer, raised its 2015 profit forecast after negotiating a price cut from Gilead Sciences Inc on hepatitis C treatments for this year.Aetna said the increased outlook was also due to momentum in its business early in the year after a strong finish to 2014. It boosted its full-year operating earnings forecast to at least $7.00 per share, up from $6.90. Aetna also reported quarterly profit in line with estimates.The stock rose more than 1 percent.Aetna reported an improved medical benefit ratio of 83 percent for the fourth quarter, compared with 83.9 percent a year earlier. The ratio is the amount an insurer spends on medical claims compared with its income from premiums. The company said the costs of medical care have remained moderate and that it expects its medical benefit ratio to be between 82 percent and 83 percent. Its comments on spending were in line with larger competitors UnitedHealth Group Inc  and Anthem Inc.The company said the medical benefit ratio for commercial plans, its largest business, deteriorated to 82 percent from 81.7 percent, due to higher-than-expected medical costs in small businesses and expenses associated with the new hepatitis C treatments. Last year Aetna was among insurance companies and other payers who said that the $84,000 cost per treatment for Gilead's new hepatitis C drug, which hit the market late in 2013, was unaffordable. When AbbVie Inc launched a competing drug at the end of 2014, insurers, pharmacy benefit managers and others started negotiating for discounts from Gilead. Aetna said last month it had secured a lower cost and would back Gilead's Harvoni drug as its preferred treatment over AbbVie's.Aetna's membership rose to 23.5 million at the end of 2014 from 22.2 million a year earlier, helped by growth in new insurance created by the national healthcare reform law, often called Obamacare. Aetna said it added 560,000 members from the Obamacare exchanges at the end of 2014 and expects that to increase to 800,000 by the end of the first quarter, helped by expansion into Georgia.The company reported operating earnings of $1.22 per share for the quarter, largely in line with average analyst estimate, according to Thomson Reuters I/B/E/S.Revenue of $14.77 billion beat the average estimate of $14.60 billion.The company's shares rose $1.01 to $93.23 on the New York Stock Exchange.   (Reporting by Caroline Humer in New York and Amrutha Penumudi in Bengaluru; Editing by Don Sebastian and Jeffrey Benkoe)",2015-02-03,AET,"Tue Feb 3, 2015 | 11:57am EST",UPDATE 3-Health insurer Aetna raises 2015 profit forecast,http://www.reuters.com//article/aetna-results-idUSL4N0VD4KT20150203?type=companyNews
121,"  * Staples, Office Depot in advanced merger talks - WSJ* Aetna posts Q4 results, raises 2015 outlook* Futures up: Dow 40 pts, S&P 4.25 pts, Nasdaq 5.25 pts   (Adds oil gains, updates prices)By Chuck MikolajczakNEW YORK, Feb 3 U.S. stock index futures pointed to a modestly higher open on Tuesday, with the benchmark S&P 500 index set to continue a rally fueled by hopes of a deal on Greek debt and by firmer oil prices.Stocks rallied late in the prior session on signs Greece was softening its approach to debt negotiations. A source told Reuters that Greek Finance Minister Yanis Varoufakis, in London to reassure private investors he was not seeking a showdown with Brussels over a new debt agreement, said the new left-wing government would spare privately held bonds from losses. Adding support was a further gain in oil prices, with U.S. crude up 2.4 percent to $50.76 and Brent up 2.7 percent to $56.21. The advance came after BP said it would cut  capital expenditure, raising expectations a supply glut will be lessened. Shares of offshore contract driller Transocean gained 4.2 percent to $18 in premarket trading.S&P 500 e-mini futures were up 4.25 points and fair value, a formula that evaluates pricing by taking into account interest rates, dividends and time to expiration on the contract, indicated a higher open. Dow Jones industrial average e-mini futures rose 40 points and Nasdaq 100 e-mini futures added 5.25 points. The S&P 500 is still down more than 3 percent from its Dec. 29 record high amid lackluster corporate earnings and data showing the U.S. economy growing at a slower pace than investors anticipated. January's 3.1 percent decline was the worst monthly performance for the index in a year.According to Thomson Reuters data through Monday morning, of 226 companies in the S&P 500 to report results, 73 percent beat expectations. The expected growth rate for the quarter sits at 5.4 percent, down from 11.2 percent expected on Oct. 1.Aetna, the third-largest U.S. health insurer, reported fourth-quarter earnings that matched Wall Street expectations and raised its 2015 forecast for operating earnings. Stratasys shares plunged 26.2 percent to $59.10 in premarket after the company cut its 2014 adjusted profit estimates for a second time.Office Depot shares surged 13 percent to $8.62 before the opening bell after the Wall Street Journal reported the company is in advanced talks to merge with Staples Inc . Staples shares jumped 13.1 percent to $19.38.In other merger news, Advent Software agreed to be acquired by SS&C Technologies for $2.7 billion in cash, sending shares up 5.6 percent to $43.70.Economic data expected Tuesday includes December factory orders at 10:00 a.m. (1500 GMT) and U.S. vehicle sales throughout the day.         (Editing by Bernadette Baum)",2015-02-03,AET,"Tue Feb 3, 2015 | 8:55am EST","US STOCKS-Wall St to gain at open on Greek deal hopes, oil lift",http://www.reuters.com//article/markets-stocks-usa-idUSL1N0VD0XX20150203?type=companyNews
122,"  Aetna Inc (AET.N) Chief Financial Officer Shawn Guertin said on Tuesday that it increased 2015 earnings expectations - to at least $7 per share from at least $6.90 per share - due at least in part to discounts it negotiated for pricey hepatitis C drugs. ""I do think our final negotiations on this topic are creating upside,"" Guertin said during a conference call. The company said last month it had negotiated a lower price from Gilead Sciences Inc (GILD.O) on Harvoni after a competing drug was launched by AbbVie Inc. (ABBV.N) late last year.     (Reporting by Caroline Humer)",2015-02-03,AET,"Tue Feb 3, 2015 | 8:49am EST",Aetna CFO says drug price negotiations partly boosted 2015 earnings view,http://www.reuters.com//article/us-aetna-results-cfo-idUSKBN0L71EI20150203?type=companyNews
123,"  Feb 3 Aetna Inc Chief Financial Officer Shawn Guertin said on Tuesday that it increased 2015 earnings expectations - to at least $7 per share from at least $6.90 per share - due at least in part to discounts it negotiated for pricey hepatitis C drugs. ""I do think our final negotiations on this topic are creating upside,"" Guertin said during a conference call. The company said last month it had negotiated a lower price from Gilead Sciences Inc on Harvoni after a competing drug was launched by AbbVie Inc. late last year.    (Reporting by Caroline Humer)  ",2015-02-03,AET,"Tue Feb 3, 2015 | 8:45am EST",Aetna CFO says drug price negotiations partly boosted 2015 earnings view,http://www.reuters.com//article/aetna-results-cfo-idUSL1N0VD10620150203?type=companyNews
124,"  Feb 3 Aetna Inc Chief Executive Officer Mark Bertolini said on Tuesday that he expects the U.S. health insurer to end the first quarter with 800,000 members who signed up through the individual Obamacare exchanges. Bertolini, speaking on a conference call with investors, said that the company ended 2014 with 560,000 members from these state-based online exchanges created under the Affordable Care Act, often called Obamacare.   (Reporting by Caroline Humer; Editing by Alden Bentley)  ",2015-02-03,AET,"Tue Feb 3, 2015 | 8:21am EST","Aetna CEO expects 800,000 Obamacare exchange members in Q1",http://www.reuters.com//article/aetna-results-ceo-idUSL1N0VD0WM20150203?type=companyNews
125,"  * Staples, Office Depot in advanced merger talks - WSJ* Aetna posts Q4 results, raises 2015 outlook* Futures up: Dow 46 pts, S&P 6.25 pts, Nasdaq 9.5 ptsBy Chuck MikolajczakNEW YORK, Feb 3 U.S. stock index futures climbed on Tuesday, with the benchmark S&P 500 index set to continue a rally fueled by hopes of a deal on Greek debt.* Stocks rallied late in the prior session on signs Greece was softening its approach to debt negotiations. A source told Reuters that Greek Finance Minister Yanis Varoufakis, in London to reassure private investors he was not seeking a showdown with Brussels over a new debt agreement, said the new left-wing government would spare privately held bonds from losses. * The S&P 500 is still down more than 3 percent from its Dec. 29 record high amid lackluster corporate earnings and data showing the U.S. economy growing at a slower pace than investors anticipated. January's 3.1 percent decline was the worst monthly performance for the index in a year.* According to Thomson Reuters data through Monday morning, of 226 companies in the S&P 500 that have posted earnings, 73 percent have topped expectations. The expected growth rate for the quarter sits at 5.4 percent, down from 11.2 percent expected on Oct. 1.* Aetna, the third-largest U.S. health insurer, reported fourth-quarter earnings that matched Wall Street expectations and raised its 2015 forecast for operating earnings. * Office Depot shares surged 17.8 percent to $8.99 before the opening bell after the Wall Street Journal reported the company is in advanced talks to merge with Staples Inc . Staples shares jumped 10.8 percent to $18.99.* Economic data expected Tuesday includes December factory orders at 10:00 a.m. (1500 GMT) and U.S. vehicle sales throughout the day.* European stocks rose, with the pan-European FTSEurofirst 300 index just below a seven-year high on hopes for an  agreement on the Greek debt standoff. Athens' benchmark index ATG climbed more than 9 percent. Futures snapshot at 7:32 a.m. ET (1232 GMT):* S&P 500 e-minis were up 6.25 points, or 0.31 percent, with 143,949 contracts changing hands.* Nasdaq 100 e-minis were up 9.5 points, or 0.23 percent, in volume of 25,460 contracts.* Dow e-minis were up 46 points, or 0.27 percent, with 23,031 contracts changing hands.(Editing by Bernadette Baum)",2015-02-03,AET,"Tue Feb 3, 2015 | 7:41am EST",US STOCKS-Futures climb on hopes for Greek debt deal,http://www.reuters.com//article/markets-stocks-usa-idUSL1N0VD0RT20150203?type=companyNews
126,"  Feb 3 Health insurer Aetna Inc's net income fell 37 percent in the fourth quarter as investment spending rose and expenses related to healthcare reforms increased.The third-largest U.S. health insurer's net profit fell to $232 million, or 65 cents per share, in the quarter ended Dec. 31 from $368.9 million, or $1.00 per share, a year earlier. Net income includes charges of 57 cents per share.  Revenue rose 12 percent to $14.8 billion.   (Reporting by Caroline Humer in New York and Amrutha Penumudi in Bengaluru; Editing by Don Sebastian)",2015-02-03,AET,"Tue Feb 3, 2015 | 6:32am EST",Health insurer Aetna's profit falls as expenses rise,http://www.reuters.com//article/aetna-results-idUSL4N0VD4D320150203?type=companyNews
127,"  Healthcare services provider Cardinal Health Inc said its unit was accused of fraud and violating U.S. healthcare laws by a whistleblower under the False Claims Act.The complaint was filed against Cardinal Health at Home division in November last year in the U.S. District Court in Massachusetts.The lawsuit relates to the marketing and sale of ostomy and continence care products, and charges several manufacturers and distributors of those items, the company said. Department of Justice has not yet determined if an intervention was necessary and is conducting an investigation on the matter, Cardinal said in a regulatory filing. (1.usa.gov/1HWxhoe) The company said it was providing information to the Justice Department in connection with its investigation.  (Reporting by Nayan Das in Bengaluru; Editing by Lisa Shumaker)",2015-02-04,AET,"Tue Feb 3, 2015 | 8:35pm EST",Whistleblower files U.S. fraud suit against Cardinal Health,http://www.reuters.com//article/us-cardinal-health-whistleblower-idUSKBN0L802B20150204?type=companyNews
128,"  Healthcare services provider Cardinal Health Inc said its unit was accused of fraud and violating U.S. healthcare laws by a whistleblower under the False Claims Act.The complaint was filed against Cardinal Health at Home division in November last year in the U.S. District Court in Massachusetts.The lawsuit relates to the marketing and sale of ostomy and continence care products, and charges several manufacturers and distributors of those items, the company said. Department of Justice has not yet determined if an intervention was necessary and is conducting an investigation on the matter, Cardinal said in a regulatory filing. (1.usa.gov/1HWxhoe) The company said it was providing information to the Justice Department in connection with its investigation.  (Reporting by Nayan Das in Bengaluru; Editing by Lisa Shumaker)",2015-02-04,AET,"Tue Feb 3, 2015 | 8:03pm EST",Whistleblower files U.S. fraud suit against Cardinal Health,http://www.reuters.com//article/us-cardinal-health-whistleblower-idUSKBN0L802E20150204?type=companyNews
129,"  Feb 3 Healthcare services provider Cardinal Health Inc said its unit was accused of fraud and violating U.S. healthcare laws by a whistleblower under the False Claims Act.The complaint was filed against Cardinal Health at Home division in November last year in the U.S. District Court in Massachusetts. The lawsuit relates to the marketing and sale of ostomy and continence care products, and charges several manufacturers and distributors of those items, the company said. Department of Justice has not yet determined if an intervention was necessary and is conducting an investigation on the matter, Cardinal said in a regulatory filing. (1.usa.gov/1HWxhoe) The company said it was providing information to the Justice Department in connection with its investigation.   (Reporting by Nayan Das in Bengaluru; Editing by Lisa Shumaker)",2015-02-04,AET,"Tue Feb 3, 2015 | 7:59pm EST",Whistleblower files U.S. fraud suit against Cardinal Health,http://www.reuters.com//article/cardinal-health-whistleblower-idUSL4N0VE07I20150204?type=companyNews
130,"   By Ransdell Pierson  CVS Health warned on Tuesday that the costs of a potent new class of cholesterol treatments could eclipse those of other expensive medicines and overwhelm the U.S. healthcare system ""if rigid cost control mechanisms are not put in place.""Two of the new injectable cholesterol treatments, called PCSK9 inhibitors, could gain U.S. approval this summer. CVS said they could eventually be used by as many as 15 million patients at an annual cost of up to $150 billion a year if priced at $7,000 to $12,000 a year, making it the highest-selling class of drugs in history.""The resilience and ability of our health care system to absorb such high costs will be tested if rigid cost control mechanisms are not put in place,"" William Shrank, chief scientific officer for CVS, said in a statement.CVS, the second-largest U.S. pharmacy benefit manager (PBM), negotiates drug prices for 65 million people through contracts with employers and health plans.The CVS call for cost controls follows sharp criticism from insurers, other payers and politicians over the high cost of new, highly effective treatments for hepatitis C, especially two medicines from Gilead Science Inc that have retail prices of up to $94,500 per patient for a course of treatment. Unlike those drugs, which are typically taken for about 12 weeks, the PCSK9s would be used for a lifetime.Express Scripts, the largest U.S. PBM, which has waged a campaign against Gilead's hepatitis C drugs and is now scrutinizing costly cancer medications, provided a slightly different view of the new cholesterol drug market.Express Scripts also expects annual costs of around $10,000 per year per patient. But it sees a patient population that will start small before it ever reaches a possible high of 10 million people and a potential annual cost of $100 billion. Express Scripts Chief Medical Officer Steve Miller said in an interview that limits set by regulators and the fact that the first wave of drugs are injections may slow their uptake. ""We are going to work to get these products at the best price possible, but they also deserve to get value in the marketplace,"" Miller said.Amgen Inc and a partnership of Sanofi and Regeneron Pharmaceuticals Inc are awaiting approval of rival PCSK9 inhibitors.  They are expected to be used first by patients who are genetically prone to extreme high cholesterol - a population that CVS and Express peg at 620,000 Americans. They also are likely to be used by those who cannot tolerate standard statin treatments, like Pfizer Inc's Lipitor. Amgen declined to comment on the pricing issue and Regeneron did not respond to a request for comment.Shares of Amgen closed up 0.5 percent at $154.24, while Regeneron's stock gained 0.4 percent to $404.18. Sanofi's shares slipped 0.2 percent to 85.53 euros in trading in Paris. (Additional reporing by Bill Berkrot and Caroline Humer in New York and Vidya L Nathan in Bengaluru; Editing by Simon Jennings, Paul Simao and Matthew Lewis)",2015-02-17,AET,"Tue Feb 17, 2015 | 5:57pm EST",CVS urges cost controls for new cholesterol drugs,http://www.reuters.com//article/us-cvs-health-cholesterol-idUSKBN0LL1CQ20150217?type=companyNews
131,"  (Adds comment from CVS rival Express Scripts, other background)By Ransdell PiersonFeb 17 CVS Health warned on Tuesday that the costs of a potent new class of cholesterol treatments could eclipse those of other expensive medicines and overwhelm the U.S. healthcare system ""if rigid cost control mechanisms are not put in place.""Two of the new injectable cholesterol treatments, called PCSK9 inhibitors, could gain U.S. approval this summer. CVS said they could eventually be used by as many as 15 million patients at an annual cost of up to $150 billion a year if priced at $7,000 to $12,000 a year, making it the highest-selling class of drugs in history.""The resilience and ability of our health care system to absorb such high costs will be tested if rigid cost control mechanisms are not put in place,"" William Shrank, chief scientific officer for CVS, said in a statement.CVS, the second-largest U.S. pharmacy benefit manager (PBM), negotiates drug prices for 65 million people through contracts with employers and health plans. The CVS call for cost controls follows sharp criticism from insurers, other payers and politicians over the high cost of new, highly effective treatments for hepatitis C, especially two medicines from Gilead Science Inc that have retail prices of up to $94,500 per patient for a course of treatment.Unlike those drugs, which are typically taken for about 12 weeks, the PCSK9s would be used for a lifetime.Express Scripts, the largest U.S. PBM, which has waged a campaign against Gilead's hepatitis C drugs and is now scrutinizing costly cancer medications, provided a slightly different view of the new cholesterol drug market. Express Scripts also expects annual costs of around $10,000 per year per patient. But it sees a patient population that will start small before it ever reaches a possible high of 10 million people and a potential annual cost of $100 billion.Express Scripts Chief Medical Officer Steve Miller said in an interview that limits set by regulators and the fact that the first wave of drugs are injections may slow their uptake. ""We are going to work to get these products at the best price possible, but they also deserve to get value in the marketplace,"" Miller said.Amgen Inc and a partnership of Sanofi and Regeneron Pharmaceuticals Inc are awaiting approval of rival PCSK9 inhibitors.They are expected to be used first by patients who are genetically prone to extreme high cholesterol - a population that CVS and Express peg at 620,000 Americans. They also are likely to be used by those who cannot tolerate standard statin treatments, like Pfizer Inc's Lipitor.Amgen declined to comment on the pricing issue and Regeneron did not respond to a request for comment.Shares of Amgen closed up 0.5 percent at $154.24, while Regeneron's stock gained 0.4 percent to $404.18. Sanofi's shares slipped 0.2 percent to 85.53 euros in trading in Paris.   (Additional reporing by Bill Berkrot and Caroline Humer in New York and Vidya L Nathan in Bengaluru; Editing by Simon Jennings, Paul Simao and Matthew Lewis)",2015-02-17,AET,"Tue Feb 17, 2015 | 5:55pm EST",UPDATE 2-CVS urges cost controls for new cholesterol drugs,http://www.reuters.com//article/cvs-health-cholesterol-idUSL1N0VR1OH20150217?type=companyNews
132,"  Feb 17 CVS Health Corp, the second-largest U.S. pharmacy chain operator, has warned that a new class of drugs being developed to lower ""bad"" cholesterol could cost the U.S. healthcare system as much as $150 billion per year.The new class of cholesterol drugs called PCSK9 inhibitors could be priced in the range of $7,000-$12,000 per year, CVS said. The company's statement follows resistance to ""high-priced"" treatments for hepatitis C, notably Gilead Sciences Inc's  Sovaldi and combination treatment Harvoni.  CVS Health has focused on developing its specialty pharmacy business, which sells drugs to treat complex diseases such as multiple sclerosis, rheumatoid arthritis, hepatitis C and cancer.   (Reporting by Vidya L Nathan in Bengaluru, Editing by Simon Jennings)",2015-02-17,AET,"Tue Feb 17, 2015 | 9:54am EST",CVS says new cholesterol drugs could cost U.S. $150 bln/year,http://www.reuters.com//article/cvs-health-cholesterol-idUSL4N0VR42220150217?type=companyNews
133,"   By Brendan Pierson  An Arizona hospital operator has sued three Aetna affiliates for allegedly underpaying for emergency services given to out-of-network patients. Scottsdale Healthcare Hospitals sued the Aetna affiliates in Arizona federal court on Thursday, claiming that they deliberately used a skewed system in calculating what to pay for emergency services, violating the federal Employee Retirement Income Security Act.  To read the full story on WestlawNext Practitioner Insights, click here: bit.ly/1zVTBoX",2015-03-03,AET,"Tue Mar 3, 2015 | 3:33pm EST",Arizona Aetna affiliates sued over alleged underpaying,http://www.reuters.com//article/health-arizona-idUSL1N0W52DU20150303?type=companyNews
134,"  * BOJ's ETF buying supports mood - analysts     * Drugmakers outperform on strong U.S. healthcare shares     * Rakuten falls after Goldman cuts rating      By Ayai Tomisawa     TOKYO, March 5 Japan's Nikkei share average edged up on Thursday after the central bank bought more exchange-traded funds, but gains were limited by investor caution ahead of U.S. jobs data on Friday.     The Nikkei opened lower, but rose 0.2 percent to 18,742.97 by mid-morning, not far from its 15-year high of 18,939.17.     Analysts said investors were looking to U.S. job and wage data on Friday for further clues on when the Federal Reserve may raise interest rates.     But they also said that sentiment was supported by the central bank's move on Tuesday and Wednesday to purchase 35.2 billion yen ($293.90 million) of exchange-traded funds (ETFs) each day, the first time in three weeks.     ""People expect that the BOJ will support the market by buying ETFs when the market is weak in the morning,"" said Norihiro Fujito, a senior investment strategist at Mitsubishi UFJ Morgan Stanley Securities.     Healthcare stocks, which outperformed in the U.S. market on the previous day, lifted some Japanese drugmakers.     Ono Pharmaceutical Co, which co-develops cancer treatment drug Opdivo with Bristol Myers Squibb, jumped 8 percent after U.S. health regulators approved the drug for lung cancer.     The pharmaceutical sector gained 2.3 percent and was the second biggest gainer among 33 Topix's subsectors.     Other drugmakers also got a lift from strong performances in U.S. healthcare shares while retail investors are attracted to their high dividend yields, analysts said. The drugmakers' dividend yield stood at 1.99 percent, compared with the Nikkei's 1.38 percent.     Takeda Pharmaceutical Co gained 2.2 percent. Eisai Co jumped 5.4 percent after it and Merck announced a clinical trial collaboration to explore combination regimens of Anti-PD-1 therapy.      Exporters were mixed, with Toyota Motor Corp  falling 0.4 percent and Honda Motor Co gained 0.3 percent.     Bucking the trend, Rakuten Inc dropped 1.3 percent after Goldman Sachs cut its rating to 'neutral' from 'buy,' saying that positive factors such as margin improvement in the financial business were already priced into its shares.     The broader Topix rose 0.3 percent to 1,521.98 and the JPX-Nikkei Index 400 added 0.4 percent to 13,830.90.   ($1 = 119.7700 yen)   (Editing by Kim Coghill)   ",2015-03-05,AET,"Wed Mar 4, 2015 | 9:28pm EST","Nikkei edges up, BOJ's ETF buying helps sentiment",http://www.reuters.com//article/markets-japan-stocks-idUSL4N0W71LH20150305?type=companyNews
135,"  The U.S. National Institutes of Health will admit to its hospital on Friday a U.S. healthcare worker who tested positive for the Ebola virus while working in Sierra Leone. The NIH said the patient will be transported in isolation by chartered aircraft to its high-security containment facility on its Maryland campus.Earlier on Thursday, a British military healthcare worker infected with the Ebola virus in Sierra Leone was flown to London for treatment, and health officials said four more workers were being assessed for possible infection.The unidentified American will be admitted and treated at the NIH Clinical Center's Special Clinical Studies Unit. The patient will be the second confirmed Ebola patient to be treated at the facility, which also took care of Texas nurse Nina Pham, who became infected with Ebola while treating a patient at Texas Health Presbyterian Hospital in Dallas. In addition to the two confirmed patients, NIH has also cared for two individuals who experienced high-risk exposures to Ebola while working in West Africa, but who were subsequently found not to be infected.The NIH said it is not releasing any more details about the patient at this time.  Ebola has now killed nearly 10,000 people in the three worst-affected countries, Sierra Leone, Liberia and Guinea. Rates of new infections have come down quickly in recent months, however. Liberia last week released its last known Ebola patient from hospital, but Sierra Leone still had 127 patients in Ebola treatment centers as of March 10. (Reporting by Julie Steenhuysen; Editing by Andre Grenon)",2015-03-12,AET,"Thu Mar 12, 2015 | 6:50pm EDT",NIH center to admit U.S. healthcare worker with Ebola,http://www.reuters.com//article/us-health-ebola-nih-idUSKBN0M82O820150312?type=companyNews
136,"  (Adds details on patient, Ebola)March 12 The U.S. National Institutes of Health will admit to its hospital on Friday a U.S. healthcare worker who tested positive for the Ebola virus while working in Sierra Leone.The NIH said the patient will be transported in isolation by chartered aircraft to its high-security containment facility on its Maryland campus.Earlier on Thursday, a British military healthcare worker infected with the Ebola virus in Sierra Leone was flown to London for treatment, and health officials said four more workers were being assessed for possible infection. The unidentified American will be admitted and treated at the NIH Clinical Center's Special Clinical Studies Unit. The patient will be the second confirmed Ebola patient to be treated at the facility, which also took care of Texas nurse Nina Pham, who became infected with Ebola while treating a patient at Texas Health Presbyterian Hospital in Dallas. In addition to the two confirmed patients, NIH has also cared for two individuals who experienced high-risk exposures to Ebola while working in West Africa, but who were subsequently found not to be infected.The NIH said it is not releasing any more details about the patient at this time. Ebola has now killed nearly 10,000 people in the three worst-affected countries, Sierra Leone, Liberia and Guinea.Rates of new infections have come down quickly in recent months, however. Liberia last week released its last known Ebola patient from hospital, but Sierra Leone still had 127 patients in Ebola treatment centers as of March 10.   (Reporting by Julie Steenhuysen; Editing by Andre Grenon)",2015-03-12,AET,"Thu Mar 12, 2015 | 5:47pm EDT",UPDATE 1-NIH center to admit U.S. healthcare worker with Ebola,http://www.reuters.com//article/health-ebola-nih-idUSL1N0WE2ZC20150312?type=companyNews
137,  March 12 The U.S. National Institutes of Health said it plans to admit a U.S. healthcare worker on Friday who has tested positive for Ebola while working in Sierra Leone. The NIH said the patient will be transported to its high-security containment facility in on its Maryland campus via an isolation unit in a chartered aircraft.   (Reporting by Emily Stephenson. Editing by Andre Grenon)  ,2015-03-12,AET,"Thu Mar 12, 2015 | 5:03pm EDT",NIH says to admit U.S. healthcare worker infected with Ebola,http://www.reuters.com//article/health-ebola-nih-idUSL1N0WE2W420150312?type=companyNews
138,"  (Adds CDC comments, statement from Partners in Health)By Susan HeaveyWASHINGTON, March 13 A U.S. healthcare worker who tested positive for Ebola while in Sierra Leone was in serious condition at a Maryland hospital, and a second American who may have been exposed to that patient was being flown back to the United States, U.S. health officials said on Friday.The National Institutes of Health said the U.S. Ebola patient was flown into the United States earlier on Friday and admitted to the NIH's high-security containment facility in Maryland. The patient is the 11th person with the deadly virus treated in the United States.The NIH said the patient was in serious condition. The NIH did not release any more details. The aid group Partners In Health said in a statement that the clinician was working for them in Sierra Leone, and noted their colleague ""remains in good spirits.""The U.S. Centers for Disease Control and Prevention said another American volunteering in Sierra Leone had ""potential exposure"" to that patient and was being transported to the Atlanta area to be near Emory University Hospital, which has treated other Ebola patients.The developments followed a relatively quiet period for Ebola in the United States, a reminder that while the spread of the virus has eased somewhat in West Africa, it still remains dangerous. The CDC said that as a result of the latest case it is working to trace the contacts of volunteers combating Ebola in Sierra Leone, including several other Americans, who may have been exposed to the healthcare worker now at the NIH.The CDC said none of these other people, including the one headed to Atlanta, has tested positive. However, the CDC said it was working with the State Department to develop plans to return those Americans with potential exposure to the United State, where they will isolate themselves and be under direct CDC monitoring 21 days.A British healthcare worker who tested positive for Ebola while in Sierra Leone was flown back this week to Britain, along with four others who are being monitored for possible infection.CDC spokesman Benjamin Haynes said the agency's team in Sierra Leone is still gathering information but said there is no evidence so far that the U.S. and British cases are related.While the virus has killed about 10,000 people in Sierra Leone, Liberia and Guinea, only a handful of cases have been seen in the United States, Spain and Britain.      (Additional reporting by Julie Steenhuysen, Will Dunham and Emily Stephenson; Editing by Doina Chiacu, Bernadette Baum and Jonathan Oatis)",2015-03-13,AET,"Fri Mar 13, 2015 | 3:48pm EDT","UPDATE 5-U.S. healthcare worker with Ebola in 'serious' condition, NIH says",http://www.reuters.com//article/health-ebola-nih-idUSL1N0WF0SX20150313?type=companyNews
139,"  CHICAGO Another four U.S. healthcare workers were flown back to the United States for monitoring for possible exposure to the Ebola virus, U.S. Centers for Disease Control and Prevention said on Tuesday.The return of the four U.S. healthcare workers brings to 16 the number of Americans who have returned to the United States from Sierra Leone since Friday, the CDC said.That includes a healthcare worker in critical condition who is being treated for Ebola in a Maryland biocontainment unit run by the National Institutes of Health.  Most of the healthcare workers are employed by the aid group Partners in Health.Only one of the 16 has tested positive for Ebola. The rest are being flown to Atlanta and Maryland, which have special biocontainment units. They are all undergoing monitoring for Ebola in self-imposed isolation as they wait out the remainder of the 21-day Ebola incubation period.  CDC spokesman Tom Skinner said the agency is still investigating the circumstances surrounding the exposures.  (Reporting by Julie Steenhuysen; Editing by Jonathan Oatis)",2015-03-17,AET,"Tue Mar 17, 2015 | 4:42pm EDT",Another four U.S. Ebola aid workers flown back to U.S. for monitoring,http://www.reuters.com//article/us-health-ebola-usa-idUSKBN0MD2J020150317?type=companyNews
140,"  CHICAGO, March 17 Another four U.S. healthcare workers were flown back to the United States for monitoring for possible exposure to the Ebola virus, U.S. Centers for Disease Control and Prevention said on Tuesday.The return of the four U.S. healthcare workers brings to 16 the number of Americans who have returned to the United States from Sierra Leone since Friday, the CDC said.That includes a healthcare worker in critical condition who is being treated for Ebola in a Maryland biocontainment unit run by the National Institutes of Health. Most of the healthcare workers are employed by the aid group Partners in Health. Only one of the 16 has tested positive for Ebola. The rest are being flown to Atlanta and Maryland, which have special biocontainment units. They are all undergoing monitoring for Ebola in self-imposed isolation as they wait out the remainder of the 21-day Ebola incubation period. CDC spokesman Tom Skinner said the agency is still investigating the circumstances surrounding the exposures.   (Reporting by Julie Steenhuysen; Editing by Jonathan Oatis)",2015-03-17,AET,"Tue Mar 17, 2015 | 4:39pm EDT",Another four US Ebola aid workers flown back to US for monitoring,http://www.reuters.com//article/health-ebola-usa-idUSL2N0WJ26D20150317?type=companyNews
141,"  The last two members of a group of U.S. healthcare workers whose colleague is being treated for the Ebola virus returned on Wednesday from Sierra Leone to the United States, where they are being monitored for possible exposure to the deadly virus.Their repatriation brought the total number of Americans brought back from the West African nation to 18 since last Friday, the U.S. Centers for Disease Control and Prevention said Wednesday night.""They were part of the same group that have been coming back slowly, said CDC spokeswoman Jennifer McQuiston.Neither of the two healthcare workers brought back Wednesday has tested positive for Ebola, but they are being monitored because they might have been exposed to a colleague who has contracted it. The infected healthworker is being treated at a biocontainment unit run by the National Institutes of Health in Maryland, McQuiston said. The CDC has not yet said how the initial patient was exposed to the disease.The others are being observed at several different locations in the United States, including Atlanta, Maryland and Nebraska. Most of the healthworkers were employed by the aid group Partners in Health, though CDC has not divulged their names. McQuiston did not say where the two who arrived on Wednesday entered the country, or where they were being sent for monitoring. (Reporting by Sharon Bernstein in Sacramento, California; Editing by Simon Cameron-Moore)",2015-03-19,AET,"Thu Mar 19, 2015 | 6:18am EDT",Two more U.S. healthcare workers repatriated for Ebola monitoring,http://www.reuters.com//article/us-usa-health-ebola-idUSKBN0MF0CD20150319?type=companyNews
142,"  March 18 The last two members of a group of U.S. healthcare workers whose colleague is being treated for the Ebola virus returned on Wednesday from Sierra Leone to the United States, where they are being monitored for possible exposure to the deadly virus.Their repatriation brought the total number of Americans brought back from the West African nation to 18 since last Friday, the U.S. Centers for Disease Control and Prevention said Wednesday night.""They were part of the same group that have been coming back slowly, said CDC spokeswoman Jennifer McQuiston. Neither of the two healthcare workers brought back Wednesday has tested positive for Ebola, but they are being monitored because they might have been exposed to a colleague who has contracted it.The infected healthworker is being treated at a biocontainment unit run by the National Institutes of Health in Maryland, McQuiston said. The CDC has not yet said how the initial patient was exposed to the disease. The others are being observed at several different locations in the United States, including Atlanta, Maryland and Nebraska. Most of the healthworkers were employed by the aid group Partners in Health, though CDC has not divulged their names.McQuiston did not say where the two who arrived on Wednesday entered the country, or where they were being sent for monitoring.     (Reporting by Sharon Bernstein in Sacramento, California; Editing by Simon Cameron-Moore)",2015-03-19,AET,"Thu Mar 19, 2015 | 12:21am EDT",Two more U.S. healthcare workers repatriated for Ebola monitoring,http://www.reuters.com//article/usa-health-ebola-idUSL2N0WL04I20150319?type=companyNews
143,"   By Dan Butcher  Brokerages are rolling out software to help financial advisers with a challenge that can seem like fortune-telling: projecting clients' retirement health care costs.Rising healthcare expenses can eat away at retirement savings. Future total healthcare costs for a 65-year-old couple retiring this year will average $394,000 in today's dollars, according to a report this week by HealthView services, a retirement healthcare data company in Danvers, Massachusetts. But a couple that retires in 2025 at age 65 will need $464,000 to fund those same expenses, which include various Medicare premiums, copays and dental visits. The bills only rise as couples live beyond average life expectancies, according to HealthView.Financial advisory firms are beefing up their software to tailor projections of clients' retirement healthcare costs. The figures can drive home reality, especially as the tools become more sophisticated, advisers say.The jolt is much-needed. Many Americans age 50 or more do not include healthcare costs in their retirement planning, even though the price tag is their greatest concern, according to a 2014 Merrill Lynch survey.Raymond James added a new healthcare calculator to its financial planning software last year based, in part, on concepts developed by the MIT AgeLab, a Massachusetts Institute of Technology (MIT) research program that encourages the development of new technologies to support human longevity. The calculator helps stimulate retirement planning discussions at Briggs Wealth Management in Clearwater, Florida, a Raymond James-affiliated firm. Advisers Kimberly and Dennis Briggs use it to estimate everything from future Medicare premiums to long-term care insurance premiums, she said.The tool, part of a broader financial planning analysis, relies on clients answers to questions about family histories, chronic illnesses, and other factors. Clients then review several future healthcare scenarios, which can be one based on their current strategy, and two others with and without long-term care insurance. The analysis, for example, showed one couple whose families had a history of medical problems that buying long-term care insurance could boost the probability of reaching their retirement goals from 40 percent to 76 percent. Achieving those goals can depend on curbing current expenses to save more, Kimberly Briggs said. Putting a number on future healthcare expenses can motivate clients to scale back vacations or buy a smaller house, she said.Merrill Lynch launched financial planning software last year that uses interactive graphics and charts to help clients understand future healthcare costs. Clients remember information more easily that way than after a long conversation, said Susan Acker, a Merrill Lynch adviser in Rochester New York. They interact with the program on Ackers iPad by tapping on icons to see research and charts about their future costs.Small firms are finding healthcare-focused tools in off-the-shelf programs such as MoneyGuidePro, a financial planning program by PIEtech Inc in Powhatan, Virginia. The results of the process may surprise clients. Healthy retirees, for example, typically spend more on healthcare than those with medical problems, such as diabetes, according to HealthView, the data provider. That is because good health often means living longer.(This version of the story corrects sixth paragraph to say that the Raymond James' calculator is based on concepts from MIT AgeLab, not a direct collaboration) (Reporting by Dan Butcher; Editing by Suzanne Barlyn and Cynthia Osterman)",2015-03-27,AET,"Fri Mar 27, 2015 | 7:00pm EDT",U.S. healthcare software triggers client reality check,http://www.reuters.com//article/us-yourpractice-healthcare-idUSKBN0MN1EM20150327?type=companyNews
144,"  (Corrects sixth paragraph to say that the Raymond James' calculator is based on concepts from MIT AgeLab, not a direct collaboration)By Dan ButcherMarch 27 Brokerages are rolling out software to help financial advisers with a challenge that can seem like fortune-telling: projecting clients' retirement health care costs.Rising healthcare expenses can eat away at retirement savings. Future total healthcare costs for a 65-year-old couple retiring this year will average $394,000 in today's dollars, according to a report this week by HealthView services, a retirement healthcare data company in Danvers, Massachusetts.But a couple that retires in 2025 at age 65 will need $464,000 to fund those same expenses, which include various Medicare premiums, copays and dental visits. The bills only rise as couples live beyond average life expectancies, according to HealthView.Financial advisory firms are beefing up their software to tailor projections of clients' retirement healthcare costs. The figures can drive home reality, especially as the tools become more sophisticated, advisers say. The jolt is much-needed. Many Americans age 50 or more do not include healthcare costs in their retirement planning, even though the price tag is their greatest concern, according to a 2014 Merrill Lynch survey.Raymond James added a new healthcare calculator to its financial planning software last year based, in part, on concepts developed by the MIT AgeLab, a Massachusetts Institute of Technology (MIT) research program that encourages the development of new technologies to support human longevity. The calculator helps stimulate retirement planning discussions at Briggs Wealth Management in Clearwater, Florida, a Raymond James-affiliated firm. Advisers Kimberly and Dennis Briggs use it to estimate everything from future Medicare premiums to long-term care insurance premiums, she said.The tool, part of a broader financial planning analysis, relies on clients' answers to questions about family histories, chronic illnesses, and other factors.Clients then review several future healthcare scenarios, which can be one based on their current strategy, and two others with and without long-term care insurance. The analysis, for example, showed one couple whose families had a history of medical problems that buying long-term care insurance could boost the probability of reaching their retirement goals from 40 percent to 76 percent. Achieving those goals can depend on curbing current expenses to save more, Kimberly Briggs said. Putting a number on future healthcare expenses can motivate clients to scale back vacations or buy a smaller house, she said.Merrill Lynch launched financial planning software last year that uses interactive graphics and charts to help clients understand future healthcare costs. Clients remember information more easily that way than after a long conversation, said Susan Acker, a Merrill Lynch adviser in Rochester New York. They interact with the program on Acker's iPad by tapping on icons to see research and charts about their future costs.Small firms are finding healthcare-focused tools in off-the-shelf programs such as MoneyGuidePro, a financial planning program by PIEtech Inc in Powhatan, Virginia.The results of the process may surprise clients. Healthy retirees, for example, typically spend more on healthcare than those with medical problems, such as diabetes, according to HealthView, the data provider. That is because good health often means living longer.   (Reporting by Dan Butcher; Editing by Suzanne Barlyn and Cynthia Osterman)",2015-03-27,AET,"Fri Mar 27, 2015 | 6:58pm EDT",CORRECTED-(OFFICIAL)-YOUR PRACTICE-U.S. healthcare software triggers client reality check,http://www.reuters.com//article/yourpractice-healthcare-idUSL2N0WS2BN20150327?type=companyNews
145,"   By Julie Steenhuysen | CHICAGO  CHICAGO A U.S. healthcare worker who was being treated for Ebola at a National Institutes of Health hospital in Maryland has been declared free of the virus and was released from the hospital on Thursday, according to the U.S. aid agency Partners In Health.The health worker, whose name will not be released, was admitted to the NIH facility on March 13. He contracted Ebola while working for Partners In Health in Sierra Leone.According to the group, their colleague was declared Ebola-free after two consecutive negative tests, and has been declared no longer contagious and able to return home. The NIH confirmed the release, saying the patient was no longer contagious and was discharged in good condition. The NIH said in a statement that it would provide no additional information on the healthcare worker.Sheila Davis, chief of Ebola response for Boston-based Partners In Health, said the group was ""heartened by the news that our colleague is heading home, free of Ebola, and making his way toward a full recovery."" According to the Centers for Disease Control and Prevention (CDC), 16 healthcare workers, including the infected patient, were flown from Sierra Leone to the United States for care and monitoring last month. Most were employed by Partners in Health.CDC spokeswoman Kathy Harben said all the healthcare workers who were transported to the United States from Sierra Leone have completed their period of active monitoring. Only the patient who was treated at the NIH hospital was infected with Ebola. The virus has killed more than 10,500 people in Sierra Leone, Liberia and Guinea, but only a handful of cases have been seen in the United States, Spain and Britain. (Reporting by Julie Steenhuysen; Editing by Toni Reinhold)",2015-04-09,AET,"Thu Apr 9, 2015 | 6:32pm EDT","American with Ebola released from U.S. hospital: aid group, NIH",http://www.reuters.com//article/us-health-ebola-usa-idUSKBN0N02BS20150409?type=companyNews
146,"   By Caroline Humer | NEW YORK, April 12  NEW YORK, April 12 Medical researchers call it the ""Angelina Effect,"" the surge in demand for genetic testing attributable to movie star Angelina Jolie's public crusade for more aggressive detection of hereditary breast and ovarian cancer.But there's a catch: Major insurance companies including Aetna, Anthem and Cigna are declining to pay for the latest generation of tests, known as multi-gene panel tests, Reuters has learned. The insurers say that the tests are unproven and may lead patients to seek out medical care they don't need.That's a dangerous miscalculation, a range of doctors, genetic counselors, academics and diagnostics companies said. While they acknowledge that multi-gene tests produce data that may not be useful from a diagnostic standpoint, they say that by refusing or delaying coverage, insurance companies are endangering patients who could be undergoing screenings or changing their diets if they knew about the possible risks.The tests have come a long way since Jolie, 39, went public in 2013, revealing that she underwent a double mastectomy after a genetic test found she carried mutations in the BRCA1 and BRCA2 genes, indicating a high risk of breast and ovarian cancer. She disclosed last month that she had her ovaries and fallopian tubes removed.The new panel tests, which can cost between $2,000 to $4,900, analyze 20 or more genes at once. That allows healthcare professionals to establish possible DNA links to other cancer-related conditions such as Lynch syndrome and Li-Fraumeni Syndrome earlier. Humans have about 23,000 genes.Susan Kutner, a surgeon at a Kaiser Permanente hospital in San Jose, California, who serves on a U.S. Centers for Disease Control and Prevention advisory committee on young women and breast cancer, said more women with a family history of cancer should be able get these tests.""If we have members who are not being tested in a timely manner, we know that their risk of cancer in the long run costs us and them a lot more,"" Kutner said.Kaiser, which insures its own members, covers panel tests for patients with family histories of cancer.That's not so at three of the four largest managed care companies. Aetna Inc, Anthem Inc and Cigna Corp  state in their policies that in most cases they don't cover multi-gene panel tests. The fourth, UnitedHealth Group, covers the tests if patients meet certain criteria. All insurers cover screenings for BRCA1 and BRCA2 and for certain other genes for women who have family histories of cancer. Indeed, such coverage is mandated by the Affordable Care Act, known as Obamacare.But many insurers said they simply don't know enough about the specific risk of other mutations to justify coverage of the new family of tests.They also say that the tests may find mutations with a well-established link to a disease, but which are difficult to interpret. These results could lead to patients taking misguided actions about medical care, such as preventive chemotherapy and surgery.Aetna's medical director of quality management, Robert McDonough, said Aetna pays for testing of individual genes but that ""the routine application of a panel would be considered unproven.""Cigna's David Finley, national medical officer for enterprise affordability, said multi-gene tests are more likely to find unknown mutations for which there are no care guidelines. ""This is where there is controversy and disagreement,"" Finley said. ""My problem is what do you do with that information?""Instead, he said, there need to be more clinical trials and research to establish exact risks and medical guidelines for each type of gene mutation.Healthcare professionals said that while they recognize the downside of patients getting unclear information about their genetic makeup, genetic counseling and support from doctors can mitigate risks.CATCH-22  Mary Daly, a physician who chairs the National Comprehensive Cancer Network guidelines panel for breast and ovarian cancer, oversees the process for setting guidelines that most doctors in this field follow. She points to what is, in effect, a ""Catch 22:"" Without insurance coverage of these tests, there isn't enough data to analyze how effective they are.""If we don't start looking at these genes, we'll never obtain the data we need,"" she said.Leading academics in genetic research also dispute the claim that multi-gene tests produce too much confusing information, saying they often lead to beneficial steps such as cancer screenings.""The utility of panel testing is that we know there are a lot more genes beyond BRCA1 and BRCA2 that are associated with cancer predisposition,"" said Colin Pritchard, a University of Washington geneticist.Pritchard said the understanding of the link between genetic mutations and cancer is evolving quickly. A recent study in the New England Journal of Medicine established rates of breast cancer associated with a mutation in one of the genes included in many of these panel tests, known as the PALB2 gene.Hereditary cancers are expected to account for about 5 percent of the 230,000 cases of invasive breast cancer that will be diagnosed this year in the United States. In the year Jolie went public about her testing, an AARP Public Policy Institute study found that BRCA testing had risen 40 percent. Jolie's spokesperson did not return a call requesting comment on the multi-gene testing trend.Myriad Genetics Inc, which accounts for 90 percent of the hereditary cancer-testing market, said 15 of the 25 genes that National Comprehensive Cancer Network guidelines indicate should be included in multi-gene testing are in its ""MyRisk"" panel test. The business represents a $5 billion global market opportunity for Myriad, the company said in January.Other lab companies including Ambry Genetics, Quest Diagnostics Inc  and Invitae Corp each offer a variety of panels that start at about seven genes and go up to 40 genes.""In general, the trend is moving toward more genes,"" said Carin Espenschied, a senior products manager at Ambry and a genetic counselor.  ""Research and insurance companies kind of just have to catch up.""   (Reporting by Caroline Humer, editing by Michele Gershberg, Eric Effron and John Pickering)",2015-04-12,AET,"Sun Apr 12, 2015 | 8:00am EDT","INSIGHT-Aetna, Cigna balk as Angelina effect spurs genetic cancer testing",http://www.reuters.com//article/usa-healthcare-cancer-idUSL2N0X41CY20150412?type=companyNews
147,"  (Repeats for additional subscribers)By Caroline HumerNEW YORK, April 13 Medical researchers call it the ""Angelina Effect,"" the surge in demand for genetic testing attributable to movie star Angelina Jolie's public crusade for more aggressive detection of hereditary breast and ovarian cancer.But there's a catch: Major insurance companies including Aetna, Anthem and Cigna are declining to pay for the latest generation of tests, known as multi-gene panel tests, Reuters has learned. The insurers say that the tests are unproven and may lead patients to seek out medical care they don't need.That's a dangerous miscalculation, a range of doctors, genetic counselors, academics and diagnostics companies said. While they acknowledge that multi-gene tests produce data that may not be useful from a diagnostic standpoint, they say that by refusing or delaying coverage, insurance companies are endangering patients who could be undergoing screenings or changing their diets if they knew about the possible risks.The tests have come a long way since Jolie, 39, went public in 2013, revealing that she underwent a double mastectomy after a genetic test found she carried mutations in the BRCA1 and BRCA2 genes, indicating a high risk of breast and ovarian cancer. She disclosed last month that she had her ovaries and fallopian tubes removed.The new panel tests, which can cost between $2,000 to $4,900, analyze 20 or more genes at once. That allows healthcare professionals to establish possible DNA links to other cancer-related conditions such as Lynch syndrome and Li-Fraumeni Syndrome earlier. Humans have about 23,000 genes.Susan Kutner, a surgeon at a Kaiser Permanente hospital in San Jose, California, who serves on a U.S. Centers for Disease Control and Prevention advisory committee on young women and breast cancer, said more women with a family history of cancer should be able get these tests.""If we have members who are not being tested in a timely manner, we know that their risk of cancer in the long run costs us and them a lot more,"" Kutner said.Kaiser, which insures its own members, covers panel tests for patients with family histories of cancer.That's not so at three of the four largest managed care companies. Aetna Inc, Anthem Inc and Cigna Corp  state in their policies that in most cases they don't cover multi-gene panel tests. The fourth, UnitedHealth Group, covers the tests if patients meet certain criteria. All insurers cover screenings for BRCA1 and BRCA2 and for certain other genes for women who have family histories of cancer. Indeed, such coverage is mandated by the Affordable Care Act, known as Obamacare.But many insurers said they simply don't know enough about the specific risk of other mutations to justify coverage of the new family of tests.They also say that the tests may find mutations with a well-established link to a disease, but which are difficult to interpret. These results could lead to patients taking misguided actions about medical care, such as preventive chemotherapy and surgery.Aetna's medical director of quality management, Robert McDonough, said Aetna pays for testing of individual genes but that ""the routine application of a panel would be considered unproven.""Cigna's David Finley, national medical officer for enterprise affordability, said multi-gene tests are more likely to find unknown mutations for which there are no care guidelines. ""This is where there is controversy and disagreement,"" Finley said. ""My problem is what do you do with that information?""Instead, he said, there need to be more clinical trials and research to establish exact risks and medical guidelines for each type of gene mutation.Healthcare professionals said that while they recognize the downside of patients getting unclear information about their genetic makeup, genetic counseling and support from doctors can mitigate risks.CATCH-22  Mary Daly, a physician who chairs the National Comprehensive Cancer Network guidelines panel for breast and ovarian cancer, oversees the process for setting guidelines that most doctors in this field follow. She points to what is, in effect, a ""Catch 22:"" Without insurance coverage of these tests, there isn't enough data to analyze how effective they are.""If we don't start looking at these genes, we'll never obtain the data we need,"" she said.Leading academics in genetic research also dispute the claim that multi-gene tests produce too much confusing information, saying they often lead to beneficial steps such as cancer screenings.""The utility of panel testing is that we know there are a lot more genes beyond BRCA1 and BRCA2 that are associated with cancer predisposition,"" said Colin Pritchard, a University of Washington geneticist.Pritchard said the understanding of the link between genetic mutations and cancer is evolving quickly. A recent study in the New England Journal of Medicine established rates of breast cancer associated with a mutation in one of the genes included in many of these panel tests, known as the PALB2 gene.Hereditary cancers are expected to account for about 5 percent of the 230,000 cases of invasive breast cancer that will be diagnosed this year in the United States. In the year Jolie went public about her testing, an AARP Public Policy Institute study found that BRCA testing had risen 40 percent. Jolie's spokesperson did not return a call requesting comment on the multi-gene testing trend.Myriad Genetics Inc, which accounts for 90 percent of the hereditary cancer-testing market, said 15 of the 25 genes that National Comprehensive Cancer Network guidelines indicate should be included in multi-gene testing are in its ""MyRisk"" panel test. The business represents a $5 billion global market opportunity for Myriad, the company said in January.Other lab companies including Ambry Genetics, Quest Diagnostics Inc  and Invitae Corp each offer a variety of panels that start at about seven genes and go up to 40 genes.""In general, the trend is moving toward more genes,"" said Carin Espenschied, a senior products manager at Ambry and a genetic counselor.  ""Research and insurance companies kind of just have to catch up.""   (Reporting by Caroline Humer, editing by Michele Gershberg, Eric Effron and John Pickering)",2015-04-13,AET,"Mon Apr 13, 2015 | 7:00am EDT","RPT - INSIGHT-Aetna, Cigna balk as Angelina effect spurs genetic cancer testing",http://www.reuters.com//article/usa-healthcare-cancer-idUSL2N0X727V20150413?type=companyNews
148,"   By Caroline Humer   (This version of the April 12 story corrects reference to Dr. Daly's role in publishing recommendations for genetic testing in paragraph 18)By Caroline HumerNEW YORK Medical researchers call it the ""Angelina Effect,"" the surge in demand for genetic testing attributable to movie star Angelina Jolie's public crusade for more aggressive detection of hereditary breast and ovarian cancer.But there's a catch: Major insurance companies including Aetna, Anthem and Cigna are declining to pay for the latest generation of tests, known as multi-gene panel tests, Reuters has learned. The insurers say that the tests are unproven and may lead patients to seek out medical care they don't need.That's a dangerous miscalculation, a range of doctors, genetic counselors, academics and diagnostics companies said. While they acknowledge that multi-gene tests produce data that may not be useful from a diagnostic standpoint, they say that by refusing or delaying coverage, insurance companies are endangering patients who could be undergoing screenings or changing their diets if they knew about the possible risks.The tests have come a long way since Jolie, 39, went public in 2013, revealing that she underwent a double mastectomy after a genetic test found she carried mutations in the BRCA1 and BRCA2 genes, indicating a high risk of breast and ovarian cancer. She disclosed last month that she had her ovaries and fallopian tubes removed.The new panel tests, which can cost between $2,000 to $4,900, analyze 20 or more genes at once. That allows healthcare professionals to establish possible DNA links to other cancer-related conditions such as Lynch syndrome and Li-Fraumeni Syndrome earlier. Humans have about 23,000 genes.Susan Kutner, a surgeon at a Kaiser Permanente hospital in San Jose, California, who serves on a U.S. Centers for Disease Control and Prevention advisory committee on young women and breast cancer, said more women with a family history of cancer should be able get these tests.""If we have members who are not being tested in a timely manner, we know that their risk of cancer in the long run costs us and them a lot more,"" Kutner said.Kaiser, which insures its own members, covers panel tests for patients with family histories of cancer.That's not so at three of the four largest managed care companies. Aetna Inc, Anthem Inc and Cigna Corp state in their policies that in most cases they don't cover multi-gene panel tests. The fourth, UnitedHealth Group, covers the tests if patients meet certain criteria. All insurers cover screenings for BRCA1 and BRCA2 and for certain other genes for women who have family histories of cancer. Indeed, such coverage is mandated by the Affordable Care Act, known as Obamacare.But many insurers said they simply don't know enough about the specific risk of other mutations to justify coverage of the new family of tests. They also say that the tests may find mutations with a well-established link to a disease, but which are difficult to interpret. These results could lead to patients taking misguided actions about medical care, such as preventive chemotherapy and surgery.Aetna's medical director of quality management, Robert McDonough, said Aetna pays for testing of individual genes but that ""the routine application of a panel would be considered unproven.""Cigna's David Finley, national medical officer for enterprise affordability, said multi-gene tests are more likely to find unknown mutations for which there are no care guidelines. ""This is where there is controversy and disagreement,"" Finley said. ""My problem is what do you do with that information?"" Instead, he said, there need to be more clinical trials and research to establish exact risks and medical guidelines for each type of gene mutation. Healthcare professionals said that while they recognize the downside of patients getting unclear information about their genetic makeup, genetic counseling and support from doctors can mitigate risks. CATCH-22 Mary Daly, a physician who chairs the National Comprehensive Cancer Network guidelines panel for breast and ovarian cancer, oversees the process for setting guidelines that most doctors in this field follow. She points to what is, in effect, a ""Catch 22:"" Without insurance coverage of these tests, there isn't enough data to analyze how effective they are. ""If we don't start looking at these genes, we'll never obtain the data we need,"" she said.Leading academics in genetic research also dispute the claim that multi-gene tests produce too much confusing information, saying they often lead to beneficial steps such as cancer screenings.""The utility of panel testing is that we know there are a lot more genes beyond BRCA1 and BRCA2 that are associated with cancer predisposition,"" said Colin Pritchard, a University of Washington geneticist.Pritchard said the understanding of the link between genetic mutations and cancer is evolving quickly. A recent study in the New England Journal of Medicine established rates of breast cancer associated with a mutation in one of the genes included in many of these panel tests, known as the PALB2 gene.Hereditary cancers are expected to account for about 5 percent of the 230,000 cases of invasive breast cancer that will be diagnosed this year in the United States. In the year Jolie went public about her testing, an AARP Public Policy Institute study found that BRCA testing had risen 40 percent. Jolies spokesperson did not return a call requesting comment on the multi-gene testing trend. Myriad Genetics Inc, which accounts for 90 percent of the hereditary cancer-testing market, said 15 of the 25 genes that National Comprehensive Cancer Network guidelines indicate should be included in multi-gene testing are in its ""MyRisk"" panel test. The business represents a $5 billion global market opportunity for Myriad, the company said in January.Other lab companies including Ambry Genetics, Quest Diagnostics Inc and Invitae Corp each offer a variety of panels that start at about seven genes and go up to 40 genes. ""In general, the trend is moving toward more genes, said Carin Espenschied, a senior products manager at Ambry and a genetic counselor. ""Research and insurance companies kind of just have to catch up."" (Reporting by Caroline Humer, editing by Michele Gershberg, Eric Effron and John Pickering)",2015-04-14,AET,"Tue Apr 14, 2015 | 4:29pm EDT","Aetna, Cigna balk as Angelina effect spurs genetic cancer testing",http://www.reuters.com//article/us-usa-healthcare-cancer-insight-idUSKBN0N52AJ20150414?type=companyNews
149,"  (Corrects reference to Dr. Daly's role in publishing recommendations for genetic testing in paragraph 18)By Caroline HumerNEW YORK, April 12 Medical researchers call it the ""Angelina Effect,"" the surge in demand for genetic testing attributable to movie star Angelina Jolie's public crusade for more aggressive detection of hereditary breast and ovarian cancer.But there's a catch: Major insurance companies including Aetna, Anthem and Cigna are declining to pay for the latest generation of tests, known as multi-gene panel tests, Reuters has learned. The insurers say that the tests are unproven and may lead patients to seek out medical care they don't need.That's a dangerous miscalculation, a range of doctors, genetic counselors, academics and diagnostics companies said. While they acknowledge that multi-gene tests produce data that may not be useful from a diagnostic standpoint, they say that by refusing or delaying coverage, insurance companies are endangering patients who could be undergoing screenings or changing their diets if they knew about the possible risks.The tests have come a long way since Jolie, 39, went public in 2013, revealing that she underwent a double mastectomy after a genetic test found she carried mutations in the BRCA1 and BRCA2 genes, indicating a high risk of breast and ovarian cancer. She disclosed last month that she had her ovaries and fallopian tubes removed.The new panel tests, which can cost between $2,000 to $4,900, analyze 20 or more genes at once. That allows healthcare professionals to establish possible DNA links to other cancer-related conditions such as Lynch syndrome and Li-Fraumeni Syndrome earlier. Humans have about 23,000 genes.Susan Kutner, a surgeon at a Kaiser Permanente hospital in San Jose, California, who serves on a U.S. Centers for Disease Control and Prevention advisory committee on young women and breast cancer, said more women with a family history of cancer should be able get these tests.""If we have members who are not being tested in a timely manner, we know that their risk of cancer in the long run costs us and them a lot more,"" Kutner said.Kaiser, which insures its own members, covers panel tests for patients with family histories of cancer.That's not so at three of the four largest managed care companies. Aetna Inc, Anthem Inc and Cigna Corp  state in their policies that in most cases they don't cover multi-gene panel tests. The fourth, UnitedHealth Group , covers the tests if patients meet certain criteria. All insurers cover screenings for BRCA1 and BRCA2 and for certain other genes for women who have family histories of cancer. Indeed, such coverage is mandated by the Affordable Care Act, known as Obamacare.But many insurers said they simply don't know enough about the specific risk of other mutations to justify coverage of the new family of tests.They also say that the tests may find mutations with a well-established link to a disease, but which are difficult to interpret. These results could lead to patients taking misguided actions about medical care, such as preventive chemotherapy and surgery.Aetna's medical director of quality management, Robert McDonough, said Aetna pays for testing of individual genes but that ""the routine application of a panel would be considered unproven.""Cigna's David Finley, national medical officer for enterprise affordability, said multi-gene tests are more likely to find unknown mutations for which there are no care guidelines. ""This is where there is controversy and disagreement,"" Finley said. ""My problem is what do you do with that information?""Instead, he said, there need to be more clinical trials and research to establish exact risks and medical guidelines for each type of gene mutation.Healthcare professionals said that while they recognize the downside of patients getting unclear information about their genetic makeup, genetic counseling and support from doctors can mitigate risks.CATCH-22  Dr. Mary Daly, who chairs the National Comprehensive Cancer Network Guidelines panel that publishes recommendations on the types of genetic testing doctors should use in determining a patient's risk of breast or ovarian cancer, points to what is, in effect, a ""Catch 22"" - without insurance coverage of these tests, there isn't enough data to analyze how effective they are.""If we don't start looking at these genes, we'll never obtain the data we need,"" she said.Leading academics in genetic research also dispute the claim that multi-gene tests produce too much confusing information, saying they often lead to beneficial steps such as cancer screenings.""The utility of panel testing is that we know there are a lot more genes beyond BRCA1 and BRCA2 that are associated with cancer predisposition,"" said Colin Pritchard, a University of Washington geneticist.Pritchard said the understanding of the link between genetic mutations and cancer is evolving quickly. A recent study in the New England Journal of Medicine established rates of breast cancer associated with a mutation in one of the genes included in many of these panel tests, known as the PALB2 gene.Hereditary cancers are expected to account for about 5 percent of the 230,000 cases of invasive breast cancer that will be diagnosed this year in the United States. In the year Jolie went public about her testing, an AARP Public Policy Institute study found that BRCA testing had risen 40 percent. Jolie's spokesperson did not return a call requesting comment on the multi-gene testing trend.Myriad Genetics Inc, which accounts for 90 percent of the hereditary cancer-testing market, said 15 of the 25 genes that National Comprehensive Cancer Network guidelines indicate should be included in multi-gene testing are in its ""MyRisk"" panel test. The business represents a $5 billion global market opportunity for Myriad, the company said in January.Other lab companies including Ambry Genetics, Quest Diagnostics Inc and Invitae Corp each offer a variety of panels that start at about seven genes and go up to 40 genes.""In general, the trend is moving toward more genes,"" said Carin Espenschied, a senior products manager at Ambry and a genetic counselor. ""Research and insurance companies kind of just have to catch up.""   (Reporting by Caroline Humer; editing by Michele Gershberg, Eric Effron and John Pickering)",2015-04-14,AET,"Tue Apr 14, 2015 | 4:22pm EDT","CORRECTED-INSIGHT-Aetna, Cigna balk as Angelina effect spurs genetic cancer testing",http://www.reuters.com//article/usa-healthcare-cancer-idUSL2N0XB2OK20150414?type=companyNews
150,"  (Repeats for additional subscribers)By Olivia Oran and Nadia DamouniNEW YORK, April 14 Several high-ranking bankers have left their jobs at major investment banks in the last 13 months amid a surge in U.S. healthcare deal activity to seek better compensation at boutique investment banks as well as to participate in the growth of the industry at biotech companies themselves.JPMorgan Chase & Co and Bank of America have both lost senior healthcare investment bankers to boutique investment bank Guggenheim Partners, showing that banks face challenges in being able to pay competitive rates. The biggest U.S. banks are under pressure from regulators to preserve more capital, rather than use M&A fees to pay higher bonuses.""The volume of transactions across healthcare is extreme and so the banker merry-go-round begins,"" said Paul Heller, the leader of executive recruiting firm Caldwell Partners' financial services practice.There's been $92.5 billion worth of U.S. healthcare merger activity so far this year, 73 percent more than in the same period last year, driven by 242 deals. Healthcare has been the busiest sector for deals so far this year, fueled by transactions such as Pfizer Inc's $17 billion offer for Hospira Inc and Valeant Pharmaceuticals International Ltd's $11 billion acquisition of Salix Pharmaceuticals Ltd.U.S. healthcare investment banking fees, meanwhile, have topped $1.9 billion since January, up more than 37 percent from the same period last year.Average annual pay for a healthcare investment banking managing director - the most typical role for a senior banker -- is roughly $1.5 million to $2 million, according to recruiters and bankers, and hasn't budged much in recent years despite the rise in M&A activity. Wall Street compensation rose about 4 percent on average last year, according to financial industry recruiting firm Options Group. Some large banks are hoping to stem the flow of banker departures by offering one-year pay guarantees for top performers, according to industry bankers.Guggenheim Partners said in March that Joseph Kohls, a former Bank of America Corp global healthcare co-head and Jeffrey Hoffman, JPMorgan Chase & Co's former West Coast healthcare head, would be joining the firm.Kohls helped advise medical device company Biomet Inc on its $13.4 billion acquisition by Zimmer Holdings Inc last year, and Hoffman led a team that advised AbbVie Inc on its $55 billion deal for British pharmaceutical company Shire, which it ended up abandoning. Bankers can often negotiate a 30 to 50 percent pay raise for their first-year compensation at a new bank if they jump ship, according to recruiters and bankers. Free from many of Wall Street's regulations, a boutique investment bank can also offer bankers hefty commissions on individual deals.Some boutique banks are luring rainmakers with the promise of taking home a large percentage of the fees they generate, bankers and recruiters said, a practice rarely seen at the bigger banks.Boutiques can also offer their bankers compensation in cash, while a large portion of pay at larger banks remains tied up in stock.Neither Kohls nor Hoffman responded to requests for comment. Meanwhile, Goldman Sachs Group Inc banker Lorence Kim left in March 2014 to take a job with life science company Moderna, while his Goldman colleague David Woodhouse joined NGM Biopharmaceuticals in March of this year. Morgan Stanley's  Steve Harr took an executive position at Juno Therapeutics in March 2014.Former Credit Suisse investment banker Mark Page joined biotech Macrocure Ltd in February as chief financial officer.""My whole banking career was to help set me up for an opportunity like this,"" Page said.Kim, Woodhouse and Harr all declined to respond to requests for comment.These bankers may benefit by taking executive roles at biotech companies and receiving stock as part of their compensation, in a bet that the share price will go up. The Nasdaq Biotechnology index has risen 66 percent in the last 12 months.""The potential equity upside on the corporate side is as attractive today than it ever has been compared to Wall Street compensation,"" said Burke St. John, vice chairman and head of the global financial services practice at executive search firm CTPartners. ""It might take you two or three times as long on a more traditional Wall Street career path to earn what you could make working for the right client.""    (Reporting by Olivia Oran and Nadia Damouni in New York; Editing by Greg Roumeliotis and John Pickering)",2015-04-14,AET,"Tue Apr 14, 2015 | 7:00am EDT",RPT - INSIGHT-Banks see talent flee amid healthcare M&A boom,http://www.reuters.com//article/healthcare-bankers-idUSL2N0XA27420150414?type=companyNews
151,"   By Olivia Oran and Nadia Damouni | NEW YORK  NEW YORK Several high-ranking bankers have left their jobs at major investment banks in the last 13 months amid a surge in U.S. healthcare deal activity to seek better compensation at boutique investment banks as well as to participate in the growth of the industry at biotech companies themselves. JPMorgan Chase & Co and Bank of America have both lost senior healthcare investment bankers to boutique investment bank Guggenheim Partners, showing that banks face challenges in being able to pay competitive rates. The biggest U.S. banks are under pressure from regulators to preserve more capital, rather than use M&A fees to pay higher bonuses.""The volume of transactions across healthcare is extreme and so the banker merry-go-round begins,"" said Paul Heller, the leader of executive recruiting firm Caldwell Partners' financial services practice. There's been $92.5 billion worth of U.S. healthcare merger activity so far this year, 73 percent more than in the same period last year, driven by 242 deals. Healthcare has been the busiest sector for deals so far this year, fueled by transactions such as Pfizer Inc's (PFE.N) $17 billion offer for Hospira Inc HSP.N and Valeant Pharmaceuticals International Ltd's (VRX.TO) $11 billion acquisition of Salix Pharmaceuticals Ltd.U.S. healthcare investment banking fees, meanwhile, have topped $1.9 billion since January, up more than 37 percent from the same period last year. Average annual pay for a healthcare investment banking managing director  the most typical role for a senior banker -- is roughly $1.5 million to $2 million, according to recruiters and bankers, and hasnt budged much in recent years despite the rise in M&A activity. Wall Street compensation rose about 4 percent on average last year, according to financial industry recruiting firm Options Group. Some large banks are hoping to stem the flow of banker departures by offering one-year pay guarantees for top performers, according to industry bankers.  Guggenheim Partners said in March that Joseph Kohls, a former Bank of America Corp (BAC.N) global healthcare co-head and Jeffrey Hoffman, JPMorgan Chase & Co's (JPM.N) former West Coast healthcare head, would be joining the firm. Kohls helped advise medical device company Biomet Inc on its $13.4 billion acquisition by Zimmer Holdings Inc ZMH.N last year, and Hoffman led a team that advised AbbVie Inc (ABBV.N) on its $55 billion deal for British pharmaceutical company Shire, which it ended up abandoning.  Bankers can often negotiate a 30 to 50 percent pay raise for their first-year compensation at a new bank if they jump ship, according to recruiters and bankers. Free from many of Wall Street's regulations, a boutique investment bank can also offer bankers hefty commissions on individual deals. Some boutique banks are luring rainmakers with the promise of taking home a large percentage of the fees they generate, bankers and recruiters said, a practice rarely seen at the bigger banks. Boutiques can also offer their bankers compensation in cash, while a large portion of pay at larger banks remains tied up in stock. Neither Kohls nor Hoffman responded to requests for comment. Meanwhile, Goldman Sachs Group Inc (GS.N) banker Lorence Kim left in March 2014 to take a job with life science company Moderna, while his Goldman colleague David Woodhouse joined NGM Biopharmaceuticals in March of this year. Morgan Stanley's (MS.N) Steve Harr took an executive position at Juno Therapeutics in March 2014. Former Credit Suisse investment banker Mark Page joined biotech Macrocure Ltd (MCUR.O) in February as chief financial officer.""My whole banking career was to help set me up for an opportunity like this,"" Page said.Kim, Woodhouse and Harr all declined to respond to requests for comment.These bankers may benefit by taking executive roles at biotech companies and receiving stock as part of their compensation, in a bet that the share price will go up. The Nasdaq Biotechnology index has risen 66 percent in the last 12 months.""The potential equity upside on the corporate side is as attractive today than it ever has been compared to Wall Street compensation,"" said Burke St. John, vice chairman and head of the global financial services practice at executive search firm CTPartners. ""It might take you two or three times as long on a more traditional Wall Street career path to earn what you could make working for the right client."" (Reporting by Olivia Oran and Nadia Damouni in New York; Editing by Greg Roumeliotis and John Pickering)",2015-04-14,AET,"Tue Apr 14, 2015 | 6:39am EDT",Banks see talent flee amid healthcare M&A boom,http://www.reuters.com//article/us-healthcare-bankers-insight-idUSKBN0N50AR20150414?type=companyNews
152,"   By Olivia Oran and Nadia Damouni | NEW YORK, April 14  NEW YORK, April 14 Several high-ranking bankers have left their jobs at major investment banks in the last 13 months amid a surge in U.S. healthcare deal activity to seek better compensation at boutique investment banks as well as to participate in the growth of the industry at biotech companies themselves.JPMorgan Chase & Co and Bank of America have both lost senior healthcare investment bankers to boutique investment bank Guggenheim Partners, showing that banks face challenges in being able to pay competitive rates. The biggest U.S. banks are under pressure from regulators to preserve more capital, rather than use M&A fees to pay higher bonuses.""The volume of transactions across healthcare is extreme and so the banker merry-go-round begins,"" said Paul Heller, the leader of executive recruiting firm Caldwell Partners' financial services practice.There's been $92.5 billion worth of U.S. healthcare merger activity so far this year, 73 percent more than in the same period last year, driven by 242 deals. Healthcare has been the busiest sector for deals so far this year, fueled by transactions such as Pfizer Inc's $17 billion offer for Hospira Inc and Valeant Pharmaceuticals International Ltd's $11 billion acquisition of Salix Pharmaceuticals Ltd.U.S. healthcare investment banking fees, meanwhile, have topped $1.9 billion since January, up more than 37 percent from the same period last year.Average annual pay for a healthcare investment banking managing director - the most typical role for a senior banker -- is roughly $1.5 million to $2 million, according to recruiters and bankers, and hasn't budged much in recent years despite the rise in M&A activity. Wall Street compensation rose about 4 percent on average last year, according to financial industry recruiting firm Options Group. Some large banks are hoping to stem the flow of banker departures by offering one-year pay guarantees for top performers, according to industry bankers.Guggenheim Partners said in March that Joseph Kohls, a former Bank of America Corp global healthcare co-head and Jeffrey Hoffman, JPMorgan Chase & Co's former West Coast healthcare head, would be joining the firm.Kohls helped advise medical device company Biomet Inc on its $13.4 billion acquisition by Zimmer Holdings Inc last year, and Hoffman led a team that advised AbbVie Inc on its $55 billion deal for British pharmaceutical company Shire, which it ended up abandoning.Bankers can often negotiate a 30 to 50 percent pay raise for their first-year compensation at a new bank if they jump ship, according to recruiters and bankers. Free from many of Wall Street's regulations, a boutique investment bank can also offer bankers hefty commissions on individual deals. Some boutique banks are luring rainmakers with the promise of taking home a large percentage of the fees they generate, bankers and recruiters said, a practice rarely seen at the bigger banks.Boutiques can also offer their bankers compensation in cash, while a large portion of pay at larger banks remains tied up in stock.Neither Kohls nor Hoffman responded to requests for comment. Meanwhile, Goldman Sachs Group Inc banker Lorence Kim left in March 2014 to take a job with life science company Moderna, while his Goldman colleague David Woodhouse joined NGM Biopharmaceuticals in March of this year. Morgan Stanley's  Steve Harr took an executive position at Juno Therapeutics in March 2014.Former Credit Suisse investment banker Mark Page joined biotech Macrocure Ltd in February as chief financial officer.""My whole banking career was to help set me up for an opportunity like this,"" Page said.Kim, Woodhouse and Harr all declined to respond to requests for comment.These bankers may benefit by taking executive roles at biotech companies and receiving stock as part of their compensation, in a bet that the share price will go up. The Nasdaq Biotechnology index has risen 66 percent in the last 12 months.""The potential equity upside on the corporate side is as attractive today than it ever has been compared to Wall Street compensation,"" said Burke St. John, vice chairman and head of the global financial services practice at executive search firm CTPartners. ""It might take you two or three times as long on a more traditional Wall Street career path to earn what you could make working for the right client.""    (Reporting by Olivia Oran and Nadia Damouni in New York; Editing by Greg Roumeliotis and John Pickering)",2015-04-14,AET,"Tue Apr 14, 2015 | 1:00am EDT",INSIGHT-Banks see talent flee amid healthcare M&A boom,http://www.reuters.com//article/healthcare-bankers-idUSL2N0X515S20150414?type=companyNews
153,"  NEW YORK, April 28 Aetna Inc CEO Mark Bertolini said on Tuesday that it added more new customers than expected through the individual Obamacare exchanges, and that their average age was a bit lower this year than in 2014. Bertolini told investors during a conference call that other Obamacare customer demographics - which along with age is considered an indicator of how much the company may have to spend on medical claims - looked about the same as 2014. The business was mildly profitable for Aetna in 2014, the company said previously.   (Reporting by Caroline Humer)  ",2015-04-28,AET,"Tue Apr 28, 2015 | 8:29am EDT",Aetna CEO says 2015 Obamacare members skew younger,http://www.reuters.com//article/aetna-results-ceo-idUSL1N0XP0W820150428?type=companyNews
154,"  Aetna Inc (AET.N), the third-largest U.S. health insurer, on Tuesday reported first-quarter profit that beat analyst expectations and said spending on medical claims in the first quarter remained low.Aetna's members increased 122,000 from the fourth quarter and said profits rose in its government and commercial business, the latter of which includes employer-based plans and individual healthcare created by the national healthcare reform law.The company raised its 2015 full-year operating earning forecast to a range of $7.20-$7.40 per share, up from its previous estimate of $7 per share.Wall Street analysts said that the company's earnings were likely ahead of expectations because of better-than-expected profitability in its Medicare Advantage plans for elderly and disabled people in particular.""We suspect Medicare Advantage performance improvements contributed to the better-than-forecast EPS,"" BMO Capital Markets analyst Jennifer Lynch said in a research note. Operating earnings were $2.39 per share in the quarter ended March 31, well above analysts' average estimate of $1.95, according to Thomson Reuters I/B/E/S/.Aetna's medical benefit ratio for its combined government and commercial businesses improved to 79.1 percent from 80.4 percent a year ago. The ratio compares the amount spent on medical claims with income from premiums. Low hospital and medical use has helped keep claims down and profits up in the past few years, even as the U.S. healthcare system has undergone major reforms under the Affordable Care Act.Net profit attributable to Aetna rose to $777.5 million, or $2.20 per share, from $665.5 million, or $1.82 per share. Revenue rose 8 percent to $15.09 billion, but fell short of analysts' estimate of $15.46 billion.The company's shares closed at $106.92 on Monday on the New York Stock Exchange. (Reporting by Caroline Humer in New York and Amrutha Penumudi in Bengaluru; Editing by Simon Jennings, Savio D'Souza and Chris Reese)",2015-04-28,AET,"Tue Apr 28, 2015 | 8:05am EDT","Health insurer Aetna's medical costs are low, boosting profit",http://www.reuters.com//article/us-aetna-results-idUSKBN0NJ11V20150428?type=companyNews
155,"  (Adds medical spending to first sentence, analyst reaction, changes headline)April 28 Aetna Inc, the third-largest U.S. health insurer, on Tuesday reported first-quarter profit that beat analyst expectations and said spending on medical claims in the first quarter remained low.Aetna's members increased 122,000 from the fourth quarter and said profits rose in its government and commercial business, the latter of which includes employer-based plans and individual healthcare created by the national healthcare reform law.The company raised its 2015 full-year operating earning forecast to a range of $7.20-$7.40 per share, up from its previous estimate of $7 per share.Wall Street analysts said that the company's earnings were likely ahead of expectations because of better-than-expected profitability in its Medicare Advantage plans for elderly and disabled people in particular. ""We suspect Medicare Advantage performance improvements contributed to the better-than-forecast EPS,"" BMO Capital Markets analyst Jennifer Lynch said in a research note.Operating earnings were $2.39 per share in the quarter ended March 31, well above analysts' average estimate of $1.95, according to Thomson Reuters I/B/E/S/. Aetna's medical benefit ratio for its combined government and commercial businesses improved to 79.1 percent from 80.4 percent a year ago. The ratio compares the amount spent on medical claims with income from premiums.Low hospital and medical use has helped keep claims down and profits up in the past few years, even as the U.S. healthcare system has undergone major reforms under the Affordable Care Act. Net profit attributable to Aetna rose to $777.5 million, or $2.20 per share, from $665.5 million, or $1.82 per share.Revenue rose 8 percent to $15.09 billion, but fell short of analysts' estimate of $15.46 billion.The company's shares closed at $106.92 on Monday on the New York Stock Exchange.   (Reporting by Caroline Humer in New York and Amrutha Penumudi in Bengaluru; Editing by Simon Jennings, Savio D'Souza and Chris Reese)",2015-04-28,AET,"Tue Apr 28, 2015 | 8:01am EDT","UPDATE 2-Health insurer Aetna's medical costs are low, boosting profit",http://www.reuters.com//article/aetna-results-idUSL4N0XP4ZF20150428?type=companyNews
156,"  April 28 Aetna Inc, the third-largest U.S. health insurer,  reported a 16.8 percent rise in first-quarter profit as it added 122,000 more members compared with the fourth quarter.Net profit attributable to Aetna rose to $777.5 million, or $2.20 per share, in the quarter ended March 31, from $665.5 million, or $1.82 per share, a year earlier.  Revenue rose 8 percent to $15.09 billion.   (Reporting by Amrutha Penumudi in Bengaluru; Editing by Simon Jennings) ",2015-04-28,AET,"Tue Apr 28, 2015 | 6:11am EDT",Health insurer Aetna's profit rises as it adds more members,http://www.reuters.com//article/aetna-results-idUSL4N0XP4YJ20150428?type=companyNews
157,"   By Sarah N. Lynch | WASHINGTON  WASHINGTON May 13 A newly created non-profit organization sued the U.S. Securities and Exchange Commission on Wednesday in an effort to force the agency to adopt rules requiring companies to disclose political contributions.The Campaign for Accountability said it was formed to use ""research, litigation and communications to expose misconduct and malfeasance in public life.""The SEC has been under mounting pressure from liberal groups, as well as a handful of law professors, to enact rules requiring companies to tell investors about campaign contributions.The efforts were sparked by the Supreme Court's 2010 Citizens United decision, which loosened campaign finance rules and opened the floodgates to millions of dollars in political spending by businesses and individuals.The decision inspired a new wave of politically focused non-profit groups that are not required to disclose the identity of their donors. SEC Chair Mary Jo White has said the agency is not going to write rules on corporate spending, and instead would focus on completing regulations required by Congress in 2010 and 2012.The lawsuit marks the latest effort to force the SEC into action.Last year, another group called the Corporate Reform Coalition held a news conference outside SEC headquarters to make similar demands. Earlier this year, members of the coalition also launched a public relations blitz titled ""Have you seen Mary Jo White?""The campaign features posters that depict White as a comic book style super hero rushing to rescue investors in the dark about how corporations spend money on political issues.The posters were placed in Union Station, the metro stop next door to the SEC's headquarters. The Campaign for Accountability said its lawsuit against the SEC was filed in the U.S. District Court for the District of Columbia on behalf of Steve Silberstein, who filed a rule-making petition to the SEC last year.The group says the agency ""ignored"" his request and violated federal laws that govern the rule-making process.In 2013, Silberstein sued Aetna Inc as a shareholder, saying it failed to accurately reveal its political donations.The case was later dismissed.An SEC spokesperson did not immediately respond to a request for comment on the lawsuit.   (Reporting by Sarah N. Lynch. Editing by Andre Grenon)",2015-05-13,AET,"Wed May 13, 2015 | 4:37pm EDT",Non-profit sues U.S. SEC to force political disclosures rules,http://www.reuters.com//article/sec-lawsuit-campaigns-idUSL1N0Y429X20150513?type=companyNews
158,"  Thomson Reuters May 13, 2015 - Corporate Meetings for US companies for Week ahead.         S&P 500 Earnings - MONTH AHEAD     Dividends                            Non S&P 500 - Weekly             Federal Reserve events               ConferenceCall/Webcast - Weekly  Meetings - Weekly                                Xtra users can see more details on conference calls & webcasts by hovering your mouse  over the RIC, right click, no click on Related Co Data, now click on Co Events.             ** For events after May 17 please click on                    - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - DATE       GMT      SYMBOL       EVENT TITLE  13 May     13:00        Blackbaud Inc at Jefferies Global Conf 13 May     13:00           Calpine Annual Shareholders Meeting 13 May     13:00       Comcast at MoffettNathanson Summit 13 May     13:00           DuPont Fabros Technology Inc at Jefferies Global Conf 13 May     13:00           Equifax Inc at JPMorgan Business Services Conf 13 May     13:00            Laboratory of America Annual Shareholders Meeting 13 May     13:00        Microsemi at Jefferies Global Conf 13 May     13:00           Minerals Technologies Inc Annual Shareholders Meeting 13 May     13:00        Qlik Technologies Inc Annual Shareholders Meeting 13 May     13:00           Radian Group Inc Annual Shareholders Meeting 13 May     13:00           Suburban Propane Partners LP Annual Shareholders Meeting 13 May     13:00           Watts Water Technologies Inc Annual Shareholders Meeting 13 May     13:00          WCI Communities Inc Annual Shareholders Meeting 13 May     13:30        Akamai Technologies Inc Annual Shareholders Meeting 13 May     13:30           Cabot Oil & Gas at Citi 2015 and Utilities Conf 13 May     13:30           HollyFrontier Annual Shareholders Meeting 13 May     13:30        inContact Inc at Jefferies Global Conf 13 May     13:30        Ixia at Jefferies Global Conf 13 May     13:30          Juniper Networks Inc at Jefferies Global Conf 13 May     13:30           Phillips 66 at Citi & Utilities Conf 13 May     13:35        Aegion at Oppenheimer Industrial Growth Conf 13 May     13:35           MSA Safety Inc at Oppenheimer Industrial Growth Conf 13 May     13:35          Proto Labs Inc at Oppenheimer Industrial Growth Conf 13 May     22:00        Cardtronics Inc Annual Shareholders Meeting 13 May     22:00        GenMark Diagnostics Inc at Bank of America Conf 13 May     22:00        Oclaro Inc at B. Riley & Co. Investor Conf 13 May     22:00        Phibro Animal Health at Bank of America Conf 13 May     22:00        Receptos Inc at Bank of America Conf 13 May     22:00           Universal Health Services Inc at Bank of America Conf 13 May     22:25        Qualys Inc at Credit Suisse Disruptive Technology Conf 13 May     22:30           Accuride at B. Riley & Co. Investor Conf 13 May     22:30        Farmer Bros. Co at B. Riley & Co. Investor Conf 13 May     22:30        Rockwell Medical Inc at Bank of America Conf 13 May     22:30        United Online Inc at B. Riley & Co. Investor Conf 13 May     22:40           Genesis Healthcare Inc at Bank of America Conf 13 May     22:40        Geron at Bank of America Conf 13 May     22:40        Ironwood Pharmaceuticals Inc at Bank of America Conf 13 May     22:40        Premier Inc at Bank of America Conf 13 May     22:40        Versartis Inc at Bank of America Conf 13 May                     AES at Itau BBA LatAm CEO Conf 13 May                  Ares Capital at UBS Financial Services Conf 13 May                  ARI Network Services Inc at Barrington Research Conf 13 May                  Cohu Inc at Jefferies Global Conf 13 May                     Continental Resources Inc at Morgan Stanley Conf 13 May                    Cypress Semiconductor at Barrington Research Conf 13 May                  Dealertrack Technologies Inc at Barrington Research Conf 13 May                      Delek US Inc at Citi & Utilities Conf 13 May                     Digital Realty Trust Inc at Mitsubishi Conf 13 May                     Ecolab Inc at Itau BBA LatAm CEO Conf 13 May                  Enservco at Barrington Research Conf 13 May                     Enterprise Products Partners LP at Citi & Utilities Conf 13 May                     General Mills Inc at Itau BBA LatAm CEO Conf 13 May                   GigOptix Inc at Barrington Research Conf 13 May                     Hatteras Financial at Mitsubishi Conf 13 May                     Hess at Citi & Utilities Conf 13 May                     Higher One Inc at Barrington Research Conf 13 May                  ICF International Inc at Barrington Research Conf 13 May                     Independence Contract Drilling Inc at Citi & Utilities Conf 13 May                    InvenSense Inc at Barrington Research Conf 13 May                     JAVELIN Mortgage Investment at Mitsubishi Conf 13 May                     KAR Auction Services Inc at Barrington Research Conf 13 May                 Kelly Services Inc at Bank of America Services Conf 13 May                  Lawson Products Inc at Barrington Research Conf 13 May                  Liquidity Services Inc at Barrington Research Conf 13 May                  Littelfuse Inc at Barrington Research Conf 13 May                   LKQ at Barrington Research Conf 13 May                  MRV Communications Inc at Itau BBA LatAm CEO Conf 13 May                     Navigant Consulting Inc at Barrington Research Conf 13 May                  NIC Inc at Barrington Research Conf 13 May                     Occidental Petroleum at Citi & Utilities Conf 13 May                     Oshkosh at Barrington Research Conf 13 May                  Planet Payment Inc at Barrington Research Conf 13 May                  Power Solutions International Inc at Barrington Research Conf 13 May                  PRGX Global Inc at B. Riley & Co. Investor Conf 13 May                  Profire Energy Inc at Barrington Research Conf 13 May                  Prospect Capital at UBS Financial Services Conf 13 May                     Questar at Citi & Utilities Conf 13 May                  Rentrak at Bank of America Services One-on-One Conf 13 May                     RingCentral Inc at Jefferies Global Conf 13 May                  Rovi Annual Shareholders Meeting 13 May                     Snap-On Inc at Barrington Research Conf 13 May                    SP Plus at Barrington Research Conf 13 May                  Tessera Technologies Inc at Barrington Research Conf 13 May                    Textura at Barrington Research Conf 13 May                  Ultratech Inc at Barrington Research Conf 13 May                     Xylem Inc at Oppenheimer Industrial Growth Conf 13 May                  ZAGG Inc at Barrington Research Conf one-on-one meeting 13 May     11:00        Royal Gold Inc at Bank of America Global Metals and Mining Conf 13 May     23:00        Immersion at B. Riley & Co. Investor Conf 13 May     23:00        Integrated Device Technology at B. Riley & Co. Investor Conf 13 May     23:05           Box Inc at Credit Suisse Disruptive Technology Conf 13 May     23:20        ACADIA Pharmaceuticals Inc at Bank of America Conf 13 May     23:20        Antares Pharma Inc at Bank of America Conf 13 May     23:20          Envision Healthcare Inc at Bank of America Conf 13 May     23:30        Blackbaud Inc at B. Riley & Co. Investor Conf 13 May     23:30           MaxLinear Inc at B. Riley & Co. Investor Conf 13 May     23:45             NetSuite Inc at Credit Suisse Disruptive Technology Conf 13 May     00:00        BioDelivery Sciences International Inc at Bank of America Conf 13 May     00:00        FEI Co at Bank of America Conf 13 May     00:00        Infinity Pharmaceuticals Inc at Bank of America Conf 13 May     12:00          Anthem Inc Annual Shareholders Meeting 13 May     12:00           Fleetcor Technologies Inc at Jefferies Global Conf 13 May     12:00        Harmonic Inc at Jefferies Global Conf 13 May     12:00        RigNet Inc at Jefferies Global Conf 13 May     12:00          Shutterstock Inc at Jefferies Global Conf 13 May     12:00         TriMas Annual Shareholders Meeting 13 May     12:15            General Electric Co at Oppenheimer Industrial Growth Conf 13 May     12:15        National Instruments at Oppenheimer Industrial Growth Conf 13 May     12:30         CDW Annual Shareholders Meeting 13 May     12:30            E I du Pont de Nemours and Co Annual Shareholders Meeting 13 May     12:30           Fidelity National Information Services at Jefferies Global Conf 13 May     12:30        Insulet Annual Shareholders Meeting 13 May     12:30          Micron Technology Inc at Jefferies Global Conf 13 May     12:30           Tyler Technologies Inc at Jefferies Global Conf 13 May     12:30        Veeco Instruments Inc Annual Shareholders Meeting 13 May     12:45           Alon USA Energy Inc and Partners LP at Citi & Utilities Conf 13 May     12:45           FMC Technologies Inc at Citi & Utilities Conf 13 May     12:55        Cognex at Oppenheimer Industrial Growth Conf 13 May     12:55           Honeywell International at Oppenheimer Industrial Growth Conf 13 May     12:55        LMI Aerospace Inc at Oppenheimer Industrial Growth Conf 13 May     14:00         Advanced Micro Devices Inc at Jefferies Global Conf 13 May     14:00           BankUnited Inc Annual Shareholders Meeting 13 May     14:00        Banner at DA Davidson Conf 13 May     14:00          CA Inc at Jefferies Global Conf 13 May     14:00          Calix Inc at Jefferies Global Conf 13 May     14:00           Chipotle Mexican Grill Inc Annual Shareholders Meeting 13 May     14:00        Del Frisco's Restaurant Group Inc Annual Shareholders Meeting 13 May     14:00            Everest Re Group Ltd Annual Shareholders Meeting 13 May     14:00         Frontier Communications Annual Shareholders Meeting 13 May     14:00             Genpact Ltd Annual Shareholders Meeting 13 May     14:00        Morgans Hotel Group Co Annual Shareholders Meeting 13 May     14:00        Netflix Inc at MoffettNathanson Summit 13 May     14:00          On Deck Capital Inc Annual Shareholders Meeting 13 May     14:00           Penn Virginia Annual Shareholders Meeting 13 May     14:00           Service International Annual Shareholders Meeting 13 May     14:00        Stock Yards BanInc at DA Davidson Conf 13 May     14:00        Ultra Clean Inc at Jefferies Global Conf 13 May     14:00           USG Annual Shareholders Meeting 13 May     14:00           Walter Investment Management Annual Shareholders Meeting 13 May     14:15        OSI Systems Inc at Oppenheimer Industrial Growth Conf 13 May     14:15           United Rentals Inc at Oppenheimer Industrial Growth Conf 13 May     14:30        Axcelis Technologies Inc Annual Shareholders Meeting 13 May     14:30        Blucora Inc at Jefferies Global Conf 13 May     14:30             Hyatt Hotels Annual Shareholders Meeting 13 May     14:30        ScanSource Inc at Jefferies Global Conf 13 May     14:35        Heritage Commerce at DA Davidson Conf 13 May     14:35           Red Hat Inc at Credit Suisse Disruptive Technology Conf 13 May     15:00           American International Group Inc Annual Shareholders Meeting 13 May     15:00           Capital Senior Living at Bank of America Conf 13 May     15:00           Cardinal Health Inc at Bank of America Conf 13 May     15:00        Carmike Cinemas Inc at B. Riley & Co. Investor Conf 13 May     15:00           Cloud Peak Energy Inc Annual Shareholders Meeting 13 May     15:00        CommScope Holding Company Inc at Jefferies Global Conf 13 May     15:00           ConocoPhillips at Citi & Utilities Conf 13 May     15:00       Cox Communications Inc at MoffettNathanson Summit 13 May     15:00            Dean Foods Co Annual Shareholders Meeting 13 May     15:00           Demand Media Inc at Jefferies Global Conf 13 May     15:00        Electronics for Imaging Inc Annual Shareholders Meeting 13 May     15:00           Envestnet Inc Annual Shareholders Meeting 13 May     15:00           Highwoods Properties Inc Annual Shareholders Meeting 13 May     15:00           Murphy Oil Annual Shareholders Meeting 13 May     15:00           National Oilwell Varco Inc Annual Shareholders Meeting 13 May     15:00           Northern Tier Energy LP at Citi & Utilities Conf 13 May     15:00        NTELOS at Jefferies Global Conf 13 May     15:00        Sirius XM Inc at MoffettNathanson Summit 13 May     15:00           Southwest Airlines Co Annual Shareholders Meeting 13 May     15:00           Tenneco Inc Annual Shareholders Meeting 13 May     15:00        Tokai Pharmaceuticals Inc at Bank of America Conf 13 May     15:00           Walt Disney Co at MoffettNathanson Summit 13 May     15:00           Zimmer Inc at Bank of America Conf 13 May     15:05           Zillow Group Inc at SunTrust Robinson Humphrey Conf 13 May     15:10        First Business Financial Services at DA Davidson Conf 13 May     15:10            Prosperity Bancshares Inc at DA Davidson Conf 13 May     15:25       Lithium at Credit Suisse Disruptive Technology Conf 13 May     15:25        Proofpoint Inc at Credit Suisse Disruptive Technology Conf 13 May     15:30        ADTRAN Inc Annual Shareholders Meeting 13 May     15:30        Autobytel Inc at B. Riley & Co. Investor Conf 13 May     15:30        Brooks Automation Inc at B. Riley & Co. Investor Conf 13 May     15:30           Callaway Golf Co Annual Shareholders Meeting 13 May     15:30        Cherokee Inc at B. Riley & Co. Investor Conf 13 May     15:30        Guidance Software Inc Annual Shareholders Meeting 13 May     15:30        Legacy Reserves LP Annual Shareholders Meeting 13 May     15:30         MoneyGram International Inc at Jefferies Global Conf 13 May     15:30        National Instruments at Jefferies Global Conf 13 May     15:30        NetScout Systems Inc at B. Riley & Co. Investor Conf 13 May     15:30           Westinghouse Air Brake Technologies Annual Shareholders Meeting 13 May     15:35        iRobot at Oppenheimer Industrial Growth Conf 13 May     15:40           Becton, Dickinson and Co at Bank of America Conf 13 May     15:40           CVS Health at Bank of America Conf 13 May     15:40           Hill-Rom Inc at Bank of America Conf 13 May     15:40        Juno Therapeutics Inc at Bank of America Conf 13 May     15:40           Kindred Healthcare Inc at Bank of America Conf 13 May     15:40        Wynn Resorts Ltd at Wells Fargo Conf 13 May     15:55        First Merchants at DA Davidson Conf 13 May     15:55        Pacific Continental at DA Davidson Conf 13 May     16:00        Affymetrix Inc Annual Shareholders Meeting 13 May     16:00        CalAmp at B. Riley & Co. Investor Conf 13 May     16:00           EPR Properties Annual Shareholders Meeting 13 May     16:00         Iteris Inc at B. Riley & Co. Investor Conf 13 May     16:00           Meritage Homes Annual Shareholders Meeting 13 May     16:00           Sempra Energy Annual Shareholders Meeting 13 May     16:15             AT&T Inc at Jefferies Global Conf 13 May     16:20        Arena Pharmaceuticals Inc at Bank of America Conf 13 May     16:20        Cepheid at Bank of America Conf 13 May     16:20        Isle of Capri Casinos Inc at Wells Fargo Conf 13 May     16:20           McKesson at Bank of America Conf 13 May     16:30        Angie's List Inc at B. Riley & Co. Investor Conf 13 May     16:30        FormFactor Inc at B. Riley & Co. Investor Conf 13 May     16:30        HomeStreet Inc at DA Davidson Conf 13 May     16:30        QAD Inc at B. Riley & Co. Investor Conf 13 May     16:30        Wilshire BanInc at DA Davidson Conf 13 May     17:00        Advisory Board Co at Bank of America Conf 13 May     17:00        Align Technology Inc Annual Shareholders Meeting 13 May     17:00        Biomarin Pharmaceutical Inc at Bank of America Conf 13 May     17:00        Brightcove Inc at B. Riley & Co. Investor Conf 13 May     17:00        Churchill Downs Inc at Wells Fargo Conf 13 May     17:00           Dolby Laboratories Inc at B. Riley & Co. Investor Conf 13 May     17:00           Ducommun Inc at B. Riley & Co. Investor Conf 13 May     17:00           Eli Lilly and Co at Bank of America Conf 13 May     17:00        HomeAway Inc at SunTrust Robinson Humphrey Conf 13 May     17:00        Inteliquent Inc at Bank of America Conf 13 May     17:00           Mercury General Annual Shareholders Meeting 13 May     17:00           PerkinElmer Inc at Bank of America Conf 13 May     17:00        Scientific Games at Wells Fargo Conf 13 May     17:00        Silicon Laboratories Inc at B. Riley & Co. Investor Conf 13 May     17:00           TrueBlue Inc Annual Shareholders Meeting 13 May     17:00        Viggle Inc at SunTrust Robinson Humphrey Conf 13 May     17:00           Western Inc at Citi & Utilities Conf 13 May     17:00          YuMe Inc at SunTrust Robinson Humphrey Conf 13 May     17:05        BofI Holding Inc at DA Davidson Conf 13 May     17:05        Eagle BanMontana Inc at DA Davidson Conf 13 May     17:30         FairPoint Communications Inc at Jefferies Global Conf 13 May     17:30        Intersil at B. Riley & Co. Investor Conf 13 May     17:30           Live Nation Entertainment Inc at Jefferies Global Conf 13 May     17:30           Wausau Paper Annual Shareholders Meeting 13 May     17:30         Western Digital at Jefferies Global Conf 13 May     17:40        CoStar Group Inc at SunTrust Robinson Humphrey Conf 13 May     17:40        Endologix Inc at Bank of America Conf 13 May     17:40        HMS at Bank of America Conf 13 May     17:40        Karyopharm Therapeutics Inc at Bank of America Conf 13 May     17:40          Marin Software Inc at SunTrust Robinson Humphrey Conf 13 May     17:40           Merck & Co Inc at Bank of America Conf 13 May     17:40          Puma Biotechnology Inc at Bank of America Conf 13 May     17:40           Waters at Bank of America Conf 13 May     17:40        Web.com Group Inc at SunTrust Robinson Humphrey Conf 13 May     17:45           Pioneer Natural Resources Co at Citi & Utilities Conf 13 May     18:00          Axalta Coating Systems Ltd Annual Shareholders Meeting 13 May     18:00           Cinemark Inc at MoffettNathanson Summit 13 May     18:00        Earthlink at B. Riley & Co. Investor Conf 13 May     18:00        Intevac Inc at B. Riley & Co. Investor Conf 13 May     18:00        Microchip Technology Inc at Jefferies Global Conf 13 May     18:00        Nexstar Broadcasting Group Inc at MoffettNathanson Summit 13 May     18:00        Nutrisystem Inc at B. Riley & Co. Investor Conf 13 May     18:00          Roadrunner Transportation Annual Shareholders Meeting 13 May     18:00        Selectica Inc at B. Riley & Co. Investor Conf 13 May     18:00          STR Inc Annual Shareholders Meeting 13 May     18:00        Syntel Inc at Jefferies Global Conf 13 May     18:00        United Community Banks Inc Annual Shareholders Meeting 13 May     18:00            Verizon Communications Inc at MoffettNathanson Summit 13 May     18:20        Biogen Inc at Bank of America Conf 13 May     18:20        Dyax at Bank of America Conf 13 May     18:20           Owens & Minor Inc at Bank of America Conf 13 May     18:20           Thermo Fisher Scientific Inc at Bank of America Conf 13 May     18:30        1-800-Flowers.Com Inc at B. Riley & Co. Investor Conf 13 May     18:30           Anadarko Petroleum at Citi & Utilities Conf 13 May     18:30           Cinemark Inc at B. Riley & Co. Investor Conf 13 May     18:30        EMC Insurance Group Inc Annual Shareholders Meeting 13 May     18:30           Global Payments Inc at Jefferies Global Conf 13 May     18:30        Medidata Solutions Inc at Jefferies Global Conf 13 May     18:30         TheStreet Inc at B. Riley & Co. Investor Conf 13 May     18:30        Xcerra at B. Riley & Co. Investor Conf 13 May     19:00        Charter Communications Inc at MoffettNathanson Summit 13 May     19:00           Colfax Annual Shareholders Meeting 13 May     19:00           Mallinckrodt Plc at Bank of America Conf 13 May     19:00        Mannkind at Bank of America Conf 13 May     19:00        Ophthotech at Bank of America Conf 13 May     19:00           Piper Jaffray Companies Annual Shareholders Meeting 13 May     19:00          The Rubicon Project Inc Annual Shareholders Meeting 13 May     19:00          Vantiv Inc at Jefferies Global Conf 13 May     19:30          Demandware Inc at Jefferies Global Conf 13 May     19:30        Ehealth Inc at Jefferies Global Conf 13 May     19:30        Immersion at Jefferies Global Conf 13 May     19:30        Inteliquent Inc at Jefferies Global Conf 13 May     19:30        PMC-Sierra Inc at Jefferies Global Conf 13 May     20:00          AbbVie Inc at Bank of America Conf 13 May     20:00        Aegerion Pharmaceuticals Inc at Bank of America Conf 13 May     20:00        Alexion Pharmaceuticals Inc at Bank of America Conf 13 May     20:00            Brunswick at B. Riley & Co. Investor Conf 13 May     20:00        Callidus Software Inc at B. Riley & Co. Investor Conf 13 May     20:00            Cigna at Bank of America Conf 13 May     20:00          Green Dot at Jefferies Global Conf 13 May     20:00        Marchex Inc at Jefferies Global Conf 13 May     20:00        Raptor Pharmaceutical at Bank of America Conf 13 May     20:00        Remy International Inc at B. Riley & Co. Investor Conf 13 May     20:00        Theravance Inc at Bank of America Conf 13 May     20:00           Time Warner Cable Inc at MoffettNathanson Summit 13 May     20:20        Albany Molecular Research Inc at Bank of America Conf 13 May     20:30        Blue Nile Inc at B. Riley & Co. Investor Conf 13 May     20:30        Constant Contact Inc at Jefferies Global Conf 13 May     20:30             Pandora Media Inc at B. Riley & Co. Investor Conf 13 May     20:40        Momenta Pharmaceuticals Inc at Bank of America Conf 13 May     20:40           PharMerica at Bank of America Conf 13 May     20:40        Prothena PLC at Bank of America Conf 13 May     20:40           Universal American at Bank of America Conf 13 May     20:45            Hecla Mining Co at Bank of America Conf 13 May     21:00          Charles Schwab Annual Shareholders Meeting 13 May     21:00        Insight Enterprises Inc at B. Riley & Co. Investor Conf 13 May     21:00        JDS Uniphase at B. Riley & Co. Investor Conf 13 May     21:00        Monotype Imaging Inc at B. Riley & Co. Investor Conf 13 May     21:00           Sun Communities Inc Extraordinary Shareholders Meeting 13 May     21:00        Universal Electronics Inc at B. Riley & Co. Investor Conf 13 May     21:05           Zendesk Inc at Credit Suisse Disruptive Technology Conf 13 May     21:20        DexCom Inc at Bank of America Conf 13 May     21:20        Gilead Sciences Inc at Bank of America Conf 13 May     21:20        Illumina Inc at Bank of America Conf 13 May     21:20        Vanda Pharmaceuticals Inc at Bank of America Conf 13 May     21:20           West Pharmaceutical Services Inc at Bank of America Conf 13 May     21:30        PCM Inc at B. Riley & Co. Investor Conf 14 May     13:00           Baker Hughes Inc Annual Shareholders Meeting 14 May     13:00          CACI International Inc at Jefferies Global Conf 14 May     13:00        Cogent Communications Inc at MoffettNathanson Summit 14 May     13:00           Genworth Financial Inc Annual Shareholders Meeting 14 May     13:00        Heartland Express Inc Annual Shareholders Meeting 14 May     13:00            Hyster-Yale Materials Handling Inc Annual Shareholders Meeting 14 May     13:00           Lear Annual Shareholders Meeting 14 May     13:00        Lumos Networks at Jefferies Global Conf 14 May     13:00        Manhattan Associates Inc Annual Shareholders Meeting 14 May     13:00      Mediacom Communications at MoffettNathanson Summit 14 May     13:00        New York Mortgage Trust Inc Annual Shareholders Meeting 14 May     13:00           PolyOne Annual Shareholders Meeting 14 May     13:00        Potbelly Annual Shareholders Meeting 14 May     13:00       ProPhotonix Ltd Annual Shareholders Meeting 14 May     13:00        SPS Commerce Inc Annual Shareholders Meeting 14 May     13:00        Twenty-First Century Fox Inc at MoffettNathanson Summit 14 May     13:00           Ventas Inc Annual Shareholders Meeting 14 May     13:20         American Airlines Group Inc at Bank of America Conf 14 May     13:20           Precision Castparts at RBC Capital Markets Investor Day 14 May     13:20          Swift Transportation Co at Bank of America Transportation Conf 14 May     13:30            NACCO Industries Inc Annual Shareholders Meeting 14 May     13:30           Nelnet Inc Annual Shareholders Meeting 14 May     13:30        Rentrak at Jefferies Global Conf 14 May     13:30           SolarWinds Inc Annual Shareholders Meeting 14 May     22:10        Cumulus Media Inc at Credit Suisse Disruptive Technology Conf 14 May                     Alon USA Energy Inc at Morgan Stanley Corporate Access Day 14 May                  Autobytel Inc at Barrington Research Conf 14 May                  Bottomline Technologies (DE) Inc at Barrington Research Conf 14 May                  Calumet Specialty at Morgan Stanley Corporate Access Day 14 May                     Celadon Group Inc at Bank of America Transportation Conf 14 May                  Check Point Software Technologies Ltd at Jefferies Global Conf 14 May                   Cheniere Energy at J.P. Morgan Energy Infrastructure / MLP Conf 14 May                  Cohu Inc at B. Riley & Co. Investor Conf 14 May                     Con-way Inc at Bank of America Transportation Conf 14 May                      Delek US Inc at Morgan Stanley Corporate Access Day 14 May                  Echo Global Logistics Inc at Barrington Research Conf 14 May                  Energous at Barrington Research Conf 14 May                     Envestnet Inc at Barrington Research Conf 14 May                      Franklin Covey Co at Barrington Research Conf 14 May                     General Cable Annual Shareholders Meeting 14 May                     GP Strategies at Barrington Research Conf 14 May                  Heritage-Crystal Clean Inc at Barrington Research Conf 14 May                  Huron Consulting Group Inc at Barrington Research Conf 14 May                     IDEX at Barrington Research Conf 14 May                  InnerWorkings Inc at Barrington Research Conf 14 May                     Kadant Inc at Barrington Research Conf 14 May                     Marathon Petroleum at Morgan Stanley Corporate Access Day 14 May                     MSA Safety Inc at Barrington Research Conf 14 May                     Northern Tier Energy LP at Morgan Stanley Corporate Access Day 14 May                  PRGX Global Inc at Barrington Research Conf 14 May                     Regal Beloit at Barrington Research Conf 14 May                    Rudolph Technologies Inc at Barrington Research Conf 14 May                  Sigma Designs Inc at Barrington Research Conf 14 May                     Sparton at Barrington Research Conf 14 May                  TESSCO Technologies Inc at Barrington Research Conf 14 May                   TriMas at Barrington Research Conf 14 May                    U.S. Physical Therapy Inc at Bank of America Conf 14 May                     Valero Energy at Morgan Stanley Corporate Access Day 14 May                     Western Inc at Morgan Stanley Corporate Access Day 14 May                      Workiva Inc at Barrington Research Conf 14 May     11:30           Harte Hanks Inc Annual Shareholders Meeting 14 May     00:00        Anacor Pharmaceuticals Inc at Bank of America Conf 14 May     00:00        DENTSPLY International Inc at Bank of America Conf 14 May     00:00        Keryx Biopharmaceuticals at Bank of America Conf 14 May     00:00        Surgical Care Affiliates Inc at Bank of America Conf 14 May     00:00           United Parcel Service at Bank of America Transportation Conf 14 May     00:00        Vascular Solutions Inc at Bank of America Conf 14 May     12:00            AutoNation Inc Annual Shareholders Meeting 14 May     12:00        Credit Acceptance Annual Shareholders Meeting 14 May     12:00           Delta Air Lines Inc at Bank of America Transportation Conf 14 May     12:00       Discovery Communications Inc at MoffettNathanson Summit 14 May     12:00        Esperion Therapeutics Inc Annual Shareholders Meeting 14 May     12:00        Great Lakes Dredge & Dock Annual Shareholders Meeting 14 May     12:00           Honeywell International Inc at RBC Capital Markets Investor Day 14 May     12:00        US Concrete Inc Annual Shareholders Meeting 14 May     12:30          Allison Transmission Inc Annual Shareholders Meeting 14 May     12:30        Cumulus Media Inc Annual Shareholders Meeting 14 May     12:30             Ford Motor Co Annual Shareholders Meeting 14 May     12:30           Graham Co Annual Shareholders Meeting 14 May     12:30           Norfolk Southern Annual Shareholders Meeting 14 May     12:30           Simon Property Group Inc Annual Shareholders Meeting 14 May     12:30        TESARO Inc Annual Shareholders Meeting 14 May     12:30           Washington Real Estate Investment Annual Shareholders Meeting 14 May     12:40           CSX at Bank of America Transportation Conf 14 May     12:40          Hawaiian Inc at Bank of America Transportation Conf 14 May     14:00        ARRIS Group Inc Annual Shareholders Meeting 14 May     14:00           Callon Petroleum Co Annual Shareholders Meeting 14 May     14:00        Citrix Systems Inc at Jefferies Global Conf 14 May     14:00        Computer Programs and Systems Inc Annual Shareholders Meeting 14 May     14:00           Dow Chemical Co Annual Shareholders Meeting 14 May     14:00        Heritage Financial Group Inc Annual Shareholders Meeting 14 May     14:00           Kansas City Southern at Bank of America Transportation Conf 14 May     14:00           KBR Inc Annual Shareholders Meeting 14 May     14:00           Key Energy Services Inc Annual Shareholders Meeting 14 May     14:00           Meredith at Jefferies Global Conf 14 May     14:00           Nationstar Mortgage Inc Annual Shareholders Meeting 14 May     14:00           Noranda Aluminum Holding Annual Shareholders Meeting 14 May     14:00           Nucor Annual Shareholders Meeting 14 May     14:00           Phoenix Companies Inc Annual Shareholders Meeting 14 May     14:00           Pzena Investment Management Inc Annual Shareholders Meeting 14 May     14:00           Sealed Air Annual Shareholders Meeting 14 May     14:00          SemGroup Annual Shareholders Meeting 14 May     14:00           Time Warner Inc at MoffettNathanson Summit 14 May     14:00          T-Mobile US Inc at MoffettNathanson Summit 14 May     14:00           Wabash National Annual Shareholders Meeting 14 May     14:00          Zayo Group Inc at MoffettNathanson Summit 14 May     14:30        Pegasystems Inc at Jefferies Global Conf 14 May     14:30      SIGA Technologies Inc Annual Shareholders Meeting 14 May     14:30        Zebra Technologies Annual Shareholders Meeting 14 May     14:40           Alaska Air Group Inc at Bank of America Transportation Conf 14 May     14:40          CACI International Inc at RBC Capital Markets Investor Day 14 May     15:00        Alnylam Pharmaceuticals Inc at Bank of America Conf 14 May     15:00        Ambac Financial Group Inc Annual Shareholders Meeting 14 May     15:00        AMC Networks Inc at MoffettNathanson Summit 14 May     15:00           Apache Annual Shareholders Meeting 14 May     15:00        Axcelis Technologies Inc at B. Riley & Co. Investor Conf 14 May     15:00           Build-A-Bear Workshop Inc Annual Shareholders Meeting 14 May     15:00           Cimarex Energy Co Annual Shareholders Meeting 14 May     15:00           Corrections of America Annual Shareholders Meeting 14 May     15:00         Franklin Street Properties Annual Shareholders Meeting 14 May     15:00           Host Hotels & Resorts Inc Annual Shareholders Meeting 14 May     15:00        Impax Laboratories Inc at Bank of America Conf 14 May     15:00        Incyte at Bank of America Conf 14 May     15:00        InterDigital Inc at B. Riley & Co. Investor Conf 14 May     15:00        Intuitive Surgical Inc at Bank of America Conf 14 May     15:00        IPC Healthcare Inc at Bank of America Conf 14 May     15:00        Luminex Annual Shareholders Meeting 14 May     15:00           Mosaic Co Annual Shareholders Meeting 14 May     15:00           Navigant Consulting Inc Annual Shareholders Meeting 14 May     15:00           OGE Energy Annual Shareholders Meeting 14 May     15:00           Superior Industries Inc at B. Riley & Co. Investor Conf 14 May     15:00           Two Harbors Investment Annual Shareholders Meeting 14 May     15:00        ViaSat Inc at MoffettNathanson Summit 14 May     15:00         Windstream Inc Annual Shareholders Meeting 14 May     15:20        B/E Aerospace Inc at RBC Capital Markets Investor Day 14 May     15:20        JetBlue Airways at Bank of America Transportation Conf 14 May     15:30        Dot Hill Systems at B. Riley & Co. Investor Conf 14 May     15:30           Knight Transportation Inc Annual Shareholders Meeting 14 May     15:30        Kratos Defense and Security at B. Riley & Co. Investor Conf 14 May     15:30           Lennox International Inc Annual Shareholders Meeting 14 May     15:30           Medical Properties Trust Inc Annual Shareholders Meeting 14 May     15:30           Methode Electronics Inc at B. Riley & Co. Investor Conf 14 May     15:30          WhiteWave Foods Co Annual Shareholders Meeting 14 May     15:30           Wyndham Worldwide Annual Shareholders Meeting 14 May     15:40        AngioDynamics Inc at Bank of America Conf 14 May     15:40            Laboratory of America at Bank of America Conf 14 May     15:40        Lexicon Pharmaceuticals Inc at Bank of America Conf 14 May     15:40           National Health Investors Inc at Bank of America Conf 14 May     15:40        Pacira Pharmaceuticals Inc at Bank of America Conf 14 May     16:00        C.H. Robinson Worldwide at Bank of America Transportation Conf 14 May     16:00        Endocyte Inc Annual Shareholders Meeting 14 May     16:00        Guidance Software Inc at B. Riley & Co. Investor Conf 14 May     16:00           McClatchy Co Annual Shareholders Meeting 14 May     16:00        Nanometrics Inc at B. Riley & Co. Investor Conf 14 May     16:00           Six Flags Entertainment at B. Riley & Co. Investor Conf 14 May     16:00        Solazyme Inc Annual Shareholders Meeting 14 May     16:00          Virgin America Inc Annual Shareholders Meeting 14 May     16:20        Aduro Biotech Inc at Bank of America Conf 14 May     16:20           Centene at Bank of America Conf 14 May     16:20        Integra LifeSciences at Bank of America Conf 14 May     16:30         HD Supply Inc Annual Shareholders Meeting 14 May     16:30        Lantronix at B. Riley & Co. 16th Annual Investor Conf 14 May     16:30           Republic Services Inc Annual Shareholders Meeting 14 May     16:30           Tyler Technologies Inc at B. Riley & Co. Investor Conf 14 May     16:45        Viacom Inc at MoffettNathanson Summit 14 May     17:00           Cantel Medical at Bank of America Conf 14 May     17:00        DTS Inc Annual Shareholders Meeting 14 May     17:00            Edwards Lifesciences Annual Shareholders Meeting 14 May     17:00           Genesee & Wyoming Inc at Bank of America Transportation Conf 14 May     17:00         GigOptix Inc at B. Riley & Co. Investor Conf 14 May     17:00        HeartWare International Inc at Bank of America Conf 14 May     17:00           Invesco Ltd Annual Shareholders Meeting 14 May     17:00            KapStone Paper and Packaging Annual Shareholders Meeting 14 May     17:00        Medicines Co at Bank of America Conf 14 May     17:00        Neurocrine Biosciences Inc at Bank of America Conf 14 May     17:00        PC Connection Inc at B. Riley & Co. Investor Conf 14 May     17:00           Smart & Final Stores Inc Annual Shareholders Meeting 14 May     17:00           Union Pacific Annual Shareholders Meeting 14 May     17:00         VirnetX Holding Annual Shareholders Meeting 14 May     17:00          Zulily Inc Annual Shareholders Meeting 14 May     17:30        Electro Scientific at B. Riley & Co. Investor Conf 14 May     17:40        Halozyme Therapeutics Inc at Bank of America Conf 14 May     17:40        KYTHERA Biopharmaceuticals Inc at Bank of America Conf 14 May     17:40        Seattle Genetics Inc at Bank of America Conf 14 May     17:40           Service International at Bank of America Conf 14 May     17:40        Spectranetics at Bank of America Conf 14 May     17:40        Thoratec at Bank of America Conf 14 May     18:00           American Tower at MoffettNathanson Summit 14 May     18:00        Amgen Inc Annual Shareholders Meeting 14 May     18:00        ANSYS Inc Annual Shareholders Meeting 14 May     18:00           Kohls Annual Shareholders Meeting 14 May     18:00           Parkway Properties Inc Annual Shareholders Meeting 14 May     18:00        Sonus Networks Inc at B. Riley & Co. Investor Conf 14 May     18:00           Standard Motor Products Inc Annual Shareholders Meeting 14 May     18:20        Heron Therapeutics Inc at Bank of America Conf 14 May     18:20           Mettler-Toledo International Inc at Bank of America Conf 14 May     18:20        Sangamo BioSciences Inc at Bank of America Conf 14 May     18:25           Kirby at Bank of America Transportation Conf 14 May     06:30           Stillwater Mining at Bank of America Conf 14 May     18:30           A. H. Belo Annual Shareholders Meeting 14 May     18:30        Boingo Wireless Inc at B. Riley & Co. Investor Conf 14 May     18:30        J2 Global Inc at B. Riley & Co. Investor Conf 14 May     18:30        Newport at B. Riley & Co. Investor Conf 14 May     18:30          The Rubicon Project Inc at B. Riley & Co. Investor Conf 14 May     19:00        Array Biopharma Inc at Bank of America Conf 14 May     19:00           Emergent BioSolutions Inc at Bank of America Conf 14 May     19:00          Tribune Media Co at MoffettNathanson Summit 14 May     19:40        Aratana Therapeutics Inc at Bank of America Conf 14 May     19:40        T2 Biosystems Inc at Bank of America Conf 14 May     20:00        Cadence Design Systems Inc Annual Shareholders Meeting 14 May     20:00           Demand Media Inc at B. Riley & Co. Investor Conf 14 May     20:00           Monmouth Real Estate Investment Annual Shareholders Meeting 14 May     20:00           Rayonier Inc Annual Shareholders Meeting 14 May     20:30        Independent Bank Group Inc Annual Shareholders Meeting 14 May     20:30        TTM Technologies Inc Annual Shareholders Meeting 14 May     21:00        Acacia Research Annual Shareholders Meeting 14 May     21:30        Tangoe Inc at Credit Suisse Disruptive Technology Conf 15 May     01:00        Bank of Marin BanAnnual Shareholders Meeting 15 May     13:00           Clear Channel Outdoor Inc Annual Shareholders Meeting 15 May     13:00           Forum Energy Technologies Inc Annual Shareholders Meeting 15 May     13:00           Newfield Exploration Co Annual Shareholders Meeting 15 May     13:30           Aetna Inc Annual Shareholders Meeting 15 May                     Campus Crest Communities Inc Annual Shareholders Meeting 15 May     12:00          BioAmber Inc Annual Shareholders Meeting 15 May     12:00            Western Union Co Annual Shareholders Meeting 15 May     12:00           WEX Inc Annual Shareholders Meeting 15 May     12:30           Intercontinental Exchange Inc Annual Shareholders Meeting 15 May     14:00           American Water Works Company Inc Annual Shareholders Meeting 15 May     14:00        Chefs Warehouse Inc Annual Shareholders Meeting 15 May     14:00           Macquarie Infrastructure Extraordinary Shareholders Meeting 15 May     14:00         Memorial Resource Development Annual Shareholders Meeting 15 May     14:00           Progressive Annual Shareholders Meeting 15 May     14:00           Tanger Factory Outlet Centers Inc Annual Shareholders Meeting 15 May     14:00           Terex Annual Shareholders Meeting 15 May     14:00           Westlake Chemical Annual Shareholders Meeting 15 May     14:30           John Bean Technologies Annual Shareholders Meeting 15 May     14:30           Quest Diagnostics Inc Annual Shareholders Meeting 15 May     15:00          Banc of California Inc Annual Shareholders Meeting 15 May     15:00            CF Industries Inc Annual Shareholders Meeting 15 May     15:00          Cypress Semiconductor Annual Shareholders Meeting 15 May     15:00           Dril-Quip Inc Annual Shareholders Meeting 15 May     15:00           J C Penney Company Inc Annual Shareholders Meeting 15 May     15:00             Macys Inc Annual Shareholders Meeting 15 May     15:00        QCR Inc Annual Shareholders Meeting 15 May     15:00        Rosetta Resources Inc Annual Shareholders Meeting 15 May     15:00           Transocean Ltd Annual Shareholders Meeting 15 May     15:00           Waste Connections Inc Annual Shareholders Meeting 15 May     15:00        West Annual Shareholders Meeting 15 May     15:30           CBRE Group Inc Annual Shareholders Meeting 15 May     17:00        Commercial Vehicle Group Inc Annual Shareholders Meeting 15 May     18:00        Seattle Genetics Inc Annual Shareholders Meeting 15 May     19:00          Roundy's Inc Annual Shareholders Meeting 16 May     22:00        First Interstate Bancsystem Inc Annual Shareholders Meeting 16 May     14:00           Dillard's Inc Annual Shareholders Meeting 16 May     15:00           American Works at NAIC's BetterInvesting National Convention 17 May     22:00            Laclede Group Inc at American Gas Forum 17 May                     Alliant Energy at American Gas Forum 17 May                     Atmos Energy at American Gas Forum 17 May                     Avista at American Gas Forum 17 May                     Black Hills at American Gas Forum 17 May                     Chesapeake Utilities at American Gas Forum 17 May                      Consolidated Edison Inc at American Gas Forum 17 May                  Delta Natural Gas Company Inc at American Gas Forum 17 May                      Eversource Energy at American Gas Forum 17 May                     Integrys Energy Group Inc at American Gas Forum 17 May                      Laclede Group Inc at American Gas Forum 17 May                     MDU Resources Group Inc at American Gas Forum 17 May                  MGE Energy Inc at American Gas Forum 17 May                     National Fuel Gas Co at American Gas Forum 17 May                     New Jersey Resources at American Gas Forum 17 May                      NiSource Inc at American Gas Forum 17 May                     Piedmont Natural Gas Company Inc at American Gas Forum 17 May                     Questar at American Gas Forum 17 May                     Sempra Energy at American Gas Forum 17 May                     South Jersey Industries Inc at American Gas Forum 17 May                     Southwest Gas at American Gas Forum 17 May                      Spectra Energy at American Gas Forum 17 May                      TECO Energy Inc at American Gas Forum 17 May                     UGI at American Gas Forum 17 May                     UIL at American Gas Forum 17 May                     Unitil at American Gas Forum 17 May                     Vectren at American Gas Forum 17 May                     WGL Inc at American Gas Forum 17 May                     Wisconsin Energy at American Gas Forum 17 May                     Xcel Energy Inc at American Gas Forum 17 May     21:15           Chesapeake Utilities at American Gas Forum       FOR ALL AMERICAN HOLIDAYS      FOR AN INDEX OF ALL DIARIES            If you have any questions or comments on the Corporate diary, please e-mail:     diaries@thomsonreuters.com   ",2015-05-13,AET,"Wed May 13, 2015 | 10:04am EDT",DIARY-U.S. MEETINGS/WEEK AHEAD,http://www.reuters.com//article/diary-us-meetings-week-idUSL3N0Y46IE20150513?type=companyNews
159,"  Thomson Reuters May 15, 2015 - Corporate Meetings for US companies for Week ahead.         S&P 500 Earnings - MONTH AHEAD     Dividends                            Non S&P 500 - Weekly             Federal Reserve events               ConferenceCall/Webcast - Weekly  Meetings - Weekly                                Xtra users can see more details on conference calls & webcasts by hovering your mouse  over the RIC, right click, no click on Related Co Data, now click on Co Events.             ** For events after May 19 please click on                    - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - DATE       GMT      SYMBOL       EVENT TITLE  15 May     01:00        Bank of Marin BanAnnual Shareholders Meeting 15 May     13:00           Clear Channel Outdoor Inc Annual Shareholders Meeting 15 May     13:00           Forum Energy Technologies Inc Annual Shareholders Meeting 15 May     13:00           Newfield Exploration Co Annual Shareholders Meeting 15 May     13:30           Aetna Inc Annual Shareholders Meeting 15 May                     Campus Crest Communities Inc Annual Shareholders Meeting 15 May     12:00          BioAmber Inc Annual Shareholders Meeting 15 May     12:00            Western Union Co Annual Shareholders Meeting 15 May     12:00           WEX Inc Annual Shareholders Meeting 15 May     12:30           Intercontinental Exchange Inc Annual Shareholders Meeting 15 May     14:00           American Water Works Company Inc Annual Shareholders Meeting 15 May     14:00        Chefs Warehouse Inc Annual Shareholders Meeting 15 May     14:00           Macquarie Infrastructure Extraordinary Shareholders Meeting 15 May     14:00         Memorial Resource Development Annual Shareholders Meeting 15 May     14:00           Progressive Annual Shareholders Meeting 15 May     14:00           Tanger Factory Outlet Centers Inc Annual Shareholders Meeting 15 May     14:00           Terex Annual Shareholders Meeting 15 May     14:00           Westlake Chemical Annual Shareholders Meeting 15 May     14:30           John Bean Technologies Annual Shareholders Meeting 15 May     14:30           Quest Diagnostics Inc Annual Shareholders Meeting 15 May     15:00          Banc of California Inc Annual Shareholders Meeting 15 May     15:00            CF Industries Inc Annual Shareholders Meeting 15 May     15:00          Cypress Semiconductor Annual Shareholders Meeting 15 May     15:00           Dril-Quip Inc Annual Shareholders Meeting 15 May     15:00           J C Penney Company Inc Annual Shareholders Meeting 15 May     15:00             Macys Inc Annual Shareholders Meeting 15 May     15:00        QCR Inc Annual Shareholders Meeting 15 May     15:00        Rosetta Resources Inc Annual Shareholders Meeting 15 May     15:00           Transocean Ltd Annual Shareholders Meeting 15 May     15:00           Waste Connections Inc Annual Shareholders Meeting 15 May     15:00        West Annual Shareholders Meeting 15 May     15:30           CBRE Group Inc Annual Shareholders Meeting 15 May     17:00        Commercial Vehicle Group Inc Annual Shareholders Meeting 15 May     18:00        Seattle Genetics Inc Annual Shareholders Meeting 15 May     19:00          Roundy's Inc Annual Shareholders Meeting 16 May     22:00        First Interstate Bancsystem Inc Annual Shareholders Meeting 16 May     14:00           Dillard's Inc Annual Shareholders Meeting 16 May     15:00           American Works at NAIC's BetterInvesting National Convention 17 May     22:00            Laclede Group Inc at American Gas Forum 17 May                     Alliant Energy at American Gas Forum 17 May                     Atmos Energy at American Gas Forum 17 May                     Avista at American Gas Forum 17 May                     Black Hills at American Gas Forum 17 May                     Chesapeake Utilities at American Gas Forum 17 May                      Consolidated Edison Inc at American Gas Forum 17 May                  Delta Natural Gas Company Inc at American Gas Forum 17 May                      Eversource Energy at American Gas Forum 17 May                     Integrys Energy Group Inc at American Gas Forum 17 May                      Laclede Group Inc at American Gas Forum 17 May                     MDU Resources Group Inc at American Gas Forum 17 May                  MGE Energy Inc at American Gas Forum 17 May                     National Fuel Gas Co at American Gas Forum 17 May                     New Jersey Resources at American Gas Forum 17 May                      NiSource Inc at American Gas Forum 17 May                     Piedmont Natural Gas Company Inc at American Gas Forum 17 May                     Questar at American Gas Forum 17 May                     Sempra Energy at American Gas Forum 17 May                     South Jersey Industries Inc at American Gas Forum 17 May                     Southwest Gas at American Gas Forum 17 May                      Spectra Energy at American Gas Forum 17 May                      TECO Energy Inc at American Gas Forum 17 May                     UGI at American Gas Forum 17 May                     UIL at American Gas Forum 17 May                     Unitil at American Gas Forum 17 May                     Vectren at American Gas Forum 17 May                     WGL Inc at American Gas Forum 17 May                     Wisconsin Energy at American Gas Forum 17 May                     Xcel Energy Inc at American Gas Forum 17 May     21:15           Chesapeake Utilities at American Gas Forum 18 May     13:00           3M Co at Electrical Products Group Conf 18 May     13:00        Infinity Pharmaceuticals Inc at UBS Global Healthcare Conf 18 May     13:00          Targa Resources Annual Shareholders Meeting 18 May     13:00           Tenet Healthcare at UBS Global Healthcare Conf 18 May     13:20          Care.com Inc at JPMorgan Conf 18 May     13:20        Cavium Inc at JPMorgan Conf 18 May     13:20           EMC at JPMorgan Conf 18 May     13:20            MasterCard Inc at JPMorgan Conf 18 May     13:20           Neustar Inc at JPMorgan Conf 18 May     13:20          T-Mobile US Inc at JPMorgan Conf 18 May     13:20        Virtusa at JPMorgan Conf 18 May     13:30        Akebia Therapeutics Inc at UBS Global Healthcare Conf 18 May     13:30        Bank of The Ozarks Inc Annual Shareholders Meeting 18 May     13:30           Cambrex at UBS Global Healthcare Conf 18 May     13:30        Esperion Therapeutics Inc at UBS Global Healthcare Conf 18 May     22:00        Geron Annual Shareholders Meeting 18 May     22:00        International Bancshares Annual Shareholders Meeting 18 May                  AcelRx Pharmaceuticals Inc at UBS Global Healthcare Conf 18 May                     Ameren at American Gas Forum 18 May                  Bruker at UBS Global Healthcare Conf 18 May                     CenterPoint Energy Inc at American Gas Forum 18 May                    Civitas Solutions Inc at UBS Global Healthcare Conf 18 May                     CMS Energy at American Gas Forum (One-on-One Meeting) 18 May                     DTE Energy Co at American Gas Forum (One on One Meetings) 18 May                     Empire District Electric Co at American Gas Forum 18 May                  Gas Natural Inc at American Gas Forum 18 May                      Intralinks Inc at JPMorgan Conf 18 May                     NCR at JPMorgan Conf 18 May                     NorthWestern at American Gas Forum:One-on-One Meeting 18 May                     Oasis Petroleum Inc at UBS Global Oil and Gas Conf 18 May                     ONE Gas Inc at American Gas Forum - One-on-One Meetings 18 May                     PG&E at American Gas Forum 18 May                     Public Service Enterprise Group Inc at American Gas Forum 18 May                  RTI Surgical Inc at UBS Global Healthcare Conf 18 May                    U.S. Physical Therapy Inc at UBS Global Healthcare Conf 18 May     11:30           Honeywell International Inc at Electrical Products Group Conf 18 May     12:00             AT&T Inc at JPMorgan Conf 18 May     12:00         VWR at UBS Global Healthcare Conf 18 May     12:30        Ophthotech at UBS Global Healthcare Conf 18 May     12:40        Viacom Inc at JPMorgan Conf 18 May     14:00        Cogent Communications Inc at JPMorgan Conf 18 May     14:00       Comcast at JPMorgan Conf 18 May     14:00            Consolidated Edison Inc Annual Shareholders Meeting 18 May     14:00        CoStar Group Inc at JPMorgan Conf 18 May     14:00        Cree Inc at JPMorgan Conf 18 May     14:00           Danaher at Electrical Products Group Conf 18 May     14:00      Genesis Healthcare at UBS Global Healthcare Conf 18 May     14:00           Global Payments Inc at JPMorgan Conf 18 May     14:00        NetScout Systems Inc at JPMorgan Conf 18 May     14:00        OraSure Technologies Inc at UBS Global Healthcare Conf 18 May     14:00           PerkinElmer Inc at UBS Global Healthcare Conf 18 May     14:00        Prothena PLC at UBS Global Healthcare Conf 18 May     14:00         Texas Instruments Inc at JPMorgan Conf 18 May     14:00        Ultimate Software Group Inc Annual Shareholders Meeting 18 May     14:30           Actavis PLC at UBS Global Healthcare Conf 18 May     14:30        Integra LifeSciences at UBS Global Healthcare Conf 18 May     14:30           Universal Health Services Inc at UBS Global Healthcare Conf 18 May     14:40        ANSYS Inc at JPMorgan Conf 18 May     14:40           CenturyLink Inc at JPMorgan Conf 18 May     14:40          Facebook Inc at JPMorgan Conf 18 May     14:40        Maxim Integrated Products Inc at JPMorgan Conf 18 May     14:40        Synaptics Inc at JPMorgan Conf 18 May     14:40          TriNet Group Inc at JPMorgan Conf 18 May     14:45           Stanley Black & Decker Inc at Electrical Products Group Conf 18 May     15:00           AMN Healthcare Services Inc at UBS Global Healthcare Conf 18 May     15:00        LDR Holding at UBS Global Healthcare Conf 18 May     15:00           Waters at UBS Global Healthcare Conf 18 May     15:20           Box Inc at JPMorgan Conf 18 May     15:20           Diebold Inc at JPMorgan Conf 18 May     15:20           International Business Machines at JPMorgan Conf 18 May     15:20        Orbotech Ltd at JPMorgan Conf 18 May     15:20        Qualys Inc at JPMorgan Conf 18 May     15:20        Sinclair Broadcast Group Inc at JPMorgan Conf 18 May     15:30        Achillion Pharmaceuticals Inc at UBS Global Healthcare Conf 18 May     15:30        PAREXEL International at UBS Global Healthcare Conf 18 May     15:30          Perrigo Company PLC at UBS Global Healthcare Conf 18 May     15:30           Roper Technologies Inc at Electrical Products Group Conf 18 May     16:00            Consolidated Edison Inc at American Gas Forum 18 May     16:00        Grand Canyon Education Inc Annual Shareholders Meeting 18 May     16:00           MDU Resources Group Inc at American Gas Forum 18 May     16:00           Omnicom Group Inc Annual Shareholders Meeting 18 May     16:00           Questar at American Gas Forum 18 May     16:00           South Jersey Industries Inc at American Gas Forum 18 May     16:30           WESCO International Inc at Electrical Products Group Conf 18 May     16:45           DTE Energy Co at American Gas Forum 18 May     16:45           National Fuel Gas Co at American Gas Forum 18 May     16:45           Northwest Natural Gas Co at American Gas Forum 18 May     17:00        Epizyme Inc at UBS Global Healthcare Conf 18 May     17:00           Health Care REIT Inc at UBS Global Healthcare Conf 18 May     17:00        IPC Healthcare Inc at UBS Global Healthcare Conf 18 May     17:00        Veracyte Inc Annual Shareholders Meeting 18 May     17:15           Eaton PLC at Electrical Products Group Conf 18 May     17:30        Alimera Sciences Inc at UBS Global Healthcare Conf 18 May     17:30        AngioDynamics Inc at UBS Global Healthcare Conf 18 May     17:30           CMS Energy at American Gas Forum 18 May     17:30        K2M Group Inc at UBS Global Healthcare Conf 18 May     17:30        Medivation Inc at UBS Global Healthcare Conf 18 May     17:30           ONE Gas Inc at American Gas Forum 18 May     17:30        PacWest BanAnnual Shareholders Meeting 18 May     17:30        PacWest BanCourt Meeting 18 May     17:30           Unitil at American Gas Forum 18 May     18:00        Halozyme Therapeutics Inc at UBS Global Healthcare Conf 18 May     18:00           Rockwell Automation Inc at Electrical Products Group Conf 18 May     18:10           American Tower at JPMorgan Conf 18 May     18:10            Broadridge Financial Solutions Inc at JPMorgan Conf 18 May     18:10          Everyday Health Inc at JPMorgan Conf 18 May     18:10        Medidata Solutions Inc at JPMorgan Conf 18 May     18:10        Paychex Inc at JPMorgan Conf 18 May     18:15           NorthWestern at American Gas Forum 18 May     18:15           Southwest Gas at American Gas Forum 18 May     18:15            TECO Energy Inc at American Gas Forum 18 May     18:15           WGL Inc at American Gas Forum 18 May     18:30           Aetna Inc at UBS Global Healthcare Conf 18 May     18:30        Biospecifics Technologies at UBS Global Healthcare Conf 18 May     18:45           SPX at Electrical Products Group Conf 18 May     18:50        Dealertrack Technologies Inc at JPMorgan Conf 18 May     18:50           Freescale Semiconductor Ltd at JPMorgan Conf 18 May     18:50        HomeAway Inc at JPMorgan Conf 18 May     18:50          HubSpot Inc at JPMorgan Conf 18 May     18:50           Interpublic Group of Companies Inc at JPMorgan Conf 18 May     18:50           WEX Inc at JPMorgan Conf 18 May     19:00        AMAG Pharmaceuticals Inc at UBS Global Healthcare Conf 18 May     19:30           Alliance Data Systems at JPMorgan Conf 18 May     19:30         Foundation Medicine Inc at UBS Global Healthcare Conf 18 May     19:30           Gannett Co Inc at JPMorgan Conf 18 May     19:30        LogMeIn Inc at JPMorgan Conf 18 May     19:30           RingCentral Inc at JPMorgan Conf 18 May     19:30        ShoreTel Inc at JPMorgan Conf 18 May     19:30           VeriFone Systems Technology, Media and Telecom Conf 18 May     19:30           West Pharmaceutical Services Inc at UBS Global Healthcare Conf 18 May     08:00       Nexus AG Annual Shareholders Meeting 18 May     20:00        Insmed Inc at UBS Global Healthcare Conf 18 May     20:00            Spectra Energy at American Gas Forum 18 May     20:00           UIL at American Gas Forum 18 May     20:00           Vectren at American Gas Forum 18 May     20:10        CyrusOne Inc at JPMorgan Conf 18 May     20:10        EnerNOC Inc at JPMorgan Conf 18 May     20:10          Guidewire Software Inc at JPMorgan Conf 18 May     20:10           Heartland Payment Systems Inc at JPMorgan Conf 18 May     20:10        iRobot at JPMorgan Conf 18 May     20:10          Model N Inc at JPMorgan Conf 18 May     20:10          Tribune Media Co at JPMorgan Conf 18 May     20:30        LegacyTexas Financial Group Inc Annual Shareholders Meeting 18 May     20:45           AGL Resources Inc at American Gas Forum 18 May     20:45           Black Hills at American Gas Forum 18 May     21:00           Motorola Solutions Inc Annual Shareholders Meeting 18 May     21:30           UGI at American Gas Forum 19 May     13:00        American National Bankshares Inc Annual Shareholders Meeting 19 May     13:00        Cerulean Pharma Inc at UBS Global Healthcare Conf 19 May     13:00        Chimerix Inc at UBS Global Healthcare Conf 19 May     13:00        Cross Country Healthcare Inc at UBS Global Healthcare Conf 19 May     13:00        CSG Systems International Inc Annual Shareholders Meeting 19 May     13:00        Dyax Annual Shareholders Meeting 19 May     13:00            Dynex Capital Inc Annual Shareholders Meeting 19 May     13:00           Hanover Insurance Group Inc Annual Shareholders Meeting 19 May     13:00        Inteliquent Inc Annual Shareholders Meeting 19 May     13:00        IRIDEX at UBS Global Healthcare Conf 19 May     13:00        Kratos Defense and Security Annual Shareholders Meeting 19 May     13:00        Landstar System Inc Annual Shareholders Meeting 19 May     13:00        Sirius XM Inc Annual Shareholders Meeting 19 May     13:00           Textron Inc at Electrical Products Group Conf 19 May     13:00           United States Cellular Annual Shareholders Meeting 19 May     13:00        Xenoport Inc Annual Shareholders Meeting 19 May     13:05           Newfield Exploration Co at UBS Global Oil and Gas Conf 19 May     13:15           CYS Investments Inc at Wells Fargo Conf 19 May     13:15          Ladder Capital at Wells Fargo Conf 19 May     13:20           Corning Inc at JPMorgan Conf 19 May     13:20        Fortinet Inc at JPMorgan Conf 19 May     13:20           Mosaic Co at Barclays Americas Select Conf 19 May     13:20        National CineMedia Inc at JPMorgan Conf 19 May     13:20             Pandora Media Inc at JPMorgan Conf 19 May     13:20           PulteGroup Inc at JPMorgan Conf 19 May     13:20             Sprint at JPMorgan Conf 19 May     13:20        Symantec at JPMorgan Conf 19 May     13:30          Puma Biotechnology Inc at UBS Global Healthcare Conf 19 May     13:30           Senior Housing Properties Trust Annual Shareholders Meeting 19 May     13:30           Vishay Intertechnology Inc Annual Shareholders Meeting 19 May     13:45           Eastman Chemical Co at Goldman Sachs Basic Materials Conf 19 May     10:00         Somero Enterprises Inc Annual Shareholders Meeting 19 May     22:00        Columbia Sportswear Co Annual Shareholders Meeting 19 May     10:10        Cisco Systems Inc at Barclays Americas Select Conf 19 May                     Air Products and Chemicals at Goldman Sachs Conf 19 May                     Alaska Air Group Inc at Wolfe Trahan Transport Conf 19 May                  Allegiant Travel Co at Wolfe Trahan Transport Conf 19 May                  AmTrust Financial Services Inc at SunTrust RobinsonConf 19 May                  Ares Capital at SunTrust RobinsonConf 19 May                  BOK Financial at SunTrust RobinsonConf 19 May                     BorgWarner Inc at Barclays Americas Select Conf 19 May                     California Resources at UBS Global Oil and Gas Conf 19 May                     Cash America International Inc at Wells Fargo Conf 19 May                     Celadon Group Inc at Wolfe Trahan Transport Conf 19 May                  Celladon at Wolfe Trahan Transport Conf 19 May                  Check Point Software Technologies Ltd at JPMorgan Conf 19 May                   Cheniere Energy Inc at Barclays Americas Select Conf 19 May                     Chesapeake Energy at UBS Global Oil and Gas Conf 19 May                     Chesapeake Energy at Barclays Americas Select Conf 19 May                     Chimera Investment at Wells Fargo Conf 19 May                     Con-way Inc at Wolfe Trahan Transport Conf 19 May                  Covenant Transportation at Wolfe Trahan Transport Conf 19 May                     CSX at Wolfe Trahan Transport Conf 19 May                  Echo Global Logistics Inc at Wolfe Trahan Transport Conf 19 May                  Encore Capital Group Inc at SunTrust RobinsonConf 19 May                  Expeditors International Inc at Wolfe Trahan Transport Conf 19 May                     F.N.B. at SunTrust RobinsonConf 19 May                   Fifth Street Finance at SunTrust RobinsonConf 19 May                  First NBC Bank Holding Co at SunTrust RobinsonConf 19 May                  Forward Air at Wolfe Trahan Transport Conf 19 May                     Genesee & Wyoming Inc at Wolfe Trahan Transport Conf 19 May                  Glacier BanInc at SunTrust RobinsonConf 19 May                  Golub Capital BDC Inc at SunTrust RobinsonConf 19 May                  Hancock Holding Co at SunTrust RobinsonConf 19 May                    Hawaiian Inc at Wolfe Trahan Transport Conf 19 May                  Healthcare Services Group Inc at UBS Global Healthcare Conf 19 May                  J B Hunt Transport Services Inc at Wolfe Trahan Transport Conf 19 May                  JetBlue Airways at Wolfe Trahan Transport Conf 19 May                     Knight Transportation Inc at Wolfe Trahan Transport Conf 19 May                    Main Street Capital at SunTrust RobinsonConf 19 May                      Morgan Stanley Annual Shareholders Meeting 19 May                     Occidental Petroleum at UBS Global Oil and Gas Conf 19 May                  Old Dominion Freight Line Inc at Wolfe Trahan Transport Conf 19 May                   Old National Banat SunTrust RobinsonConf 19 May                  PennantPark Investment at SunTrust RobinsonConf 19 May                    PennyMac Financial Services at Wells Fargo Conf 19 May                     PennyMac Mortgage Investment Trust at Wells Fargo Conf 19 May                  People's United Financial Inc at SunTrust RobinsonConf 19 May                  Pinnacle Financial Partners Inc at SunTrust RobinsonConf 19 May                      Prosperity Bancshares Inc at SunTrust RobinsonConf 19 May                      Regions Financial at SunTrust RobinsonConf 19 May                  Renasant at SunTrust RobinsonConf 19 May                    Roadrunner Transportation at Wolfe Trahan Transport Conf 19 May                       Ryder System Inc at Wolfe Trahan Transport Conf 19 May                  Saia Inc at Wolfe Trahan Transport Conf 19 May                  Sandy Spring BanInc at SunTrust RobinsonConf 19 May                     Schlumberger NV at UBS Global Oil and Gas Conf 19 May                  Solar Capital Ltd at SunTrust RobinsonConf 19 May                   South State at SunTrust RobinsonConf 19 May                      Southern Co at Wolfe Trahan Transport Conf 19 May                  Spirit Airlines Inc at Wolfe Trahan Transport Conf 19 May                  State Bank Financial at SunTrust RobinsonConf 19 May                    TPG Specialty Lending Inc at SunTrust RobinsonConf 19 May                     Union Pacific at Wolfe Trahan Transport Conf 19 May                  United Community Banks Inc at SunTrust RobinsonConf 19 May                     United Continental Inc at Wolfe Trahan Transport Conf 19 May                     United Parcel Service Inc at Wolfe Trahan Transport Conf 19 May                     Unum Group at SunTrust RobinsonConf 19 May                    Virgin America Inc at Wolfe Trahan Transport Conf 19 May                  Werner Enterprises Inc at Wolfe Trahan Transport Conf 19 May                     Westinghouse Air Brake at Wolfe Trahan Transport Conf 19 May                     XPO Logistics Inc at Wolfe Trahan Transport Conf 19 May     11:45        Cornerstone OnDemand Inc at JPMorgan Conf 19 May     11:45             Genpact Ltd at JPMorgan Conf 19 May     11:45           Lions Gate Entertainment at JPMorgan Conf 19 May     11:45         SciQuest Inc at JPMorgan Conf 19 May     11:45            Verizon Communications Inc at JPMorgan Conf 19 May     00:00        Cathay General BanAnnual Shareholders Meeting 19 May     12:00        Alnylam Pharmaceuticals Inc at UBS Global Healthcare Conf 19 May     12:00         American Airlines Group Inc at Wolfe Trahan Transport Conf 19 May     12:00           Community Health Systems Inc Annual Shareholders Meeting 19 May     12:00        Cosi Inc Annual Shareholders Meeting 19 May     12:00           EOG Resources Inc at Barclays Americas Select Conf 19 May     12:00            FirstEnergy Annual Shareholders Meeting 19 May     12:00        Houghton Mifflin Harcourt Co Annual Shareholders Meeting 19 May     12:00            Laboratory of America at UBS Global Healthcare Conf 19 May     12:00           Masco at JPMorgan Conf 19 May     12:00           PharMerica at UBS Global Healthcare Conf 19 May     12:00           Southwest Airlines Co at Wolfe Trahan Transport Conf 19 May     12:00        Sykes Enterprises Inc Annual Shareholders Meeting 19 May     12:00           Western Alliance BanAnnual Shareholders Meeting 19 May     12:00        Zions Banat Barclays Americas Select Conf 19 May     12:30          Anthem Inc at UBS Global Healthcare Conf 19 May     12:30        Array Biopharma Inc at UBS Global Healthcare Conf 19 May     12:30            Diamond Offshore Drilling Inc Annual Shareholders Meeting 19 May     12:30        Kite Pharma Inc at UBS Global Healthcare Conf 19 May     12:30           Nationstar Mortgage Inc at Wells Fargo Conf 19 May     12:35           Huntsman at Goldman Sachs Basic Materials Conf 19 May     12:40           Meritage Homes at JPMorgan Conf 19 May     12:40        Northern Trust at Barclays Americas Select Conf 19 May     12:40        Yahoo! Inc at JPMorgan Conf 19 May     14:00           B&G Foods Inc Annual Shareholders Meeting 19 May     14:00           Boston Properties Inc Annual Shareholders Meeting 19 May     14:00           Capstead Mortgage at Wells Fargo Conf 19 May     14:00           CARBO Ceramics Inc Annual Shareholders Meeting 19 May     14:00        Career Education Annual Shareholders Meeting 19 May     14:00        Carrizo Oil & Gas Annual Shareholders Meeting 19 May     14:00           CDI Annual Shareholders Meeting 19 May     14:00        Epizyme Inc Annual Shareholders Meeting 19 May     14:00         Fairchild Semiconductor International Inc at JPMorgan Conf 19 May     14:00        Gilead Sciences Inc at UBS Global Healthcare Conf 19 May     14:00        Gogo Inc at JPMorgan Conf 19 May     14:00        HSN Inc Annual Shareholders Meeting 19 May     14:00           JPMorgan Chase & Co Annual Shareholders Meeting 19 May     14:00          Kate Spade & Co Annual Shareholders Meeting 19 May     14:00           Laredo Petroleum Inc Annual Shareholders Meeting 19 May     14:00           Lexington Realty Trust Annual Shareholders Meeting 19 May     14:00           MDC Inc Annual Shareholders Meeting 19 May     14:00         MoneyGram International Inc at JPMorgan Conf 19 May     14:00           Outfront Media Inc at JPMorgan Conf 19 May     14:00           Principal Financial Group Inc Annual Shareholders Meeting 19 May     14:00        Qlik Technologies Inc at JPMorgan Conf 19 May     14:00           Range Resources Annual Shareholders Meeting 19 May     14:00          Starwood Waypoint Residential Trust at Wells Fargo Conf 19 May     14:00        Synchronoss Technologies Inc at JPMorgan Conf 19 May     14:00        Texas Capital Bancshares Inc Annual Shareholders Meeting 19 May     14:00        Trimble Navigation Ltd at JPMorgan Conf 19 May     14:00        TripAdvisor Inc at JPMorgan Conf 19 May     14:00          U.S. Physical Therapy Inc Annual Shareholders Meeting 19 May     14:00           XPO Logistics Inc Annual Shareholders Meeting 19 May     14:00           Xylem Inc at Electrical Products Group Conf 19 May     14:15           Western Inc at UBS Global Oil and Gas Conf 19 May     14:20            Celanese at Goldman Sachs Basic Materials Conf 19 May     14:20           Westlake Chemical at Goldman Sachs Basic Materials Conf 19 May     14:30        Alphatec Inc at UBS Global Healthcare Conf 19 May     14:30           Ellington Financial LLC Annual Shareholders Meeting 19 May     14:30        Health Insurance Innovations Inc Annual Shareholders Meeting 19 May     14:30           Merck & Co Inc at UBS Global Healthcare Conf 19 May     14:40        AMC Networks Inc at JPMorgan Conf 19 May     14:40           Crown Castle International at JPMorgan Conf 19 May     14:40        KineMed Inc at Biocentury BioEquity Europe 19 May     14:40          LinkedIn at JPMorgan Conf 19 May     14:40        Marketo Inc at JPMorgan Conf 19 May     14:40        MKS Instruments Inc at JPMorgan Conf 19 May     14:40        SanDisk at JPMorgan Conf 19 May     14:40           SolarWinds Inc at JPMorgan Conf 19 May     14:40        Stratasys Ltd at JPMorgan Conf 19 May     14:45           MFA Financial Inc at Wells Fargo Conf 19 May     14:45            Walker & Dunlop Inc at Wells Fargo Conf 19 May     14:55           D.R. Horton Inc at JPMorgan Conf 19 May     15:00         Avis Budget Group Inc Annual Shareholders Meeting 19 May     15:00            Cigna at UBS Global Healthcare Conf 19 May     15:00           Continental Resources Inc Annual Shareholders Meeting 19 May     15:00          CorEnergy Infrastructure Trust Inc Annual Shareholders Meeting 19 May     15:00           DineEquity Inc Annual Shareholders Meeting 19 May     15:00          Ellington Residential Mortgage REIT Annual Shareholders Meeting 19 May     15:00           Felcor Lodging Trust Inc Annual Shareholders Meeting 19 May     15:00           Group 1 Automotive Inc Annual Shareholders Meeting 19 May     15:00        Hologic Inc at UBS Global Healthcare Conf 19 May     15:00        Infinity Property and Casualty Annual Shareholders Meeting 19 May     15:00        Insight Enterprises Inc Annual Shareholders Meeting 19 May     15:00          Jones Energy Inc at UBS Global Oil and Gas Conf 19 May     15:00          Quad/Graphics Inc Annual Shareholders Meeting 19 May     15:00       Rush Enterprises Inc Annual Shareholders Meeting 19 May     15:00        Vertex Pharmaceuticals Inc at UBS Global Healthcare Conf 19 May     15:10           Ecolab Inc at Goldman Sachs Basic Materials Conf 19 May     15:15        YRC Worldwide Inc at Wolfe Trahan Transport Conf 19 May     15:20         Frontier Communications at JPMorgan Conf 19 May     15:20        HomeAway Inc at Barclays Americas Select Conf 19 May     15:20        Linear Technology at JPMorgan Conf 19 May     15:20           Omnicom Group Inc at JPMorgan Conf 19 May     15:20        Rovi at JPMorgan Conf 19 May     15:20        Syntel Inc at JPMorgan Conf 19 May     15:20        Web.com Group Inc at JPMorgan Conf 19 May     15:20            Western Union Co at JPMorgan Conf 19 May     15:30          Ares Commercial Real Estate at Wells Fargo Conf 19 May     15:30           Cliffs Natural Resources Inc Annual Shareholders Meeting 19 May     15:30        Concert Pharmaceuticals Inc at UBS Global Healthcare Conf 19 May     15:30           Invesco Mortgage Capital Inc at Wells Fargo Conf 19 May     15:30           MaxLinear Inc Annual Shareholders Meeting 19 May     15:30           Service International at UBS Global Healthcare Conf 19 May     15:30           United Technologies at Electrical Products Group Conf 19 May     16:00           Allstate Annual Shareholders Meeting 19 May     16:00        Boulder Brands Inc Annual Shareholders Meeting 19 May     16:00          Juniper Networks Inc Annual Shareholders Meeting 19 May     16:00        MGE Energy Inc Annual Shareholders Meeting 19 May     16:00           Mid-America Apartment Communities Annual Shareholders Meeting 19 May     16:00        Nanometrics Inc Annual Shareholders Meeting 19 May     16:00        Newport Annual Shareholder Meeting 19 May     16:00           Southwestern Energy Co Annual Shareholders Meeting 19 May     16:00           Pinnacle Entertainment Inc Annual Shareholders Meeting 19 May     16:30        Salem Media Group Inc Annual Shareholders Meeting 19 May     16:30          Starwood Property Trust Inc at Wells Fargo Conf 19 May     17:00        Biogen Inc at UBS Global Healthcare Conf 19 May     17:00        Echelon Annual Shareholders Meeting 19 May     17:00        Financial Engines Inc Annual Shareholders Meeting 19 May     17:00           Gap Inc Annual Shareholders Meeting 19 May     17:00        Henry Schein Inc at UBS Global Healthcare Conf 19 May     17:00        Isis Pharmaceuticals Inc at UBS Global Healthcare Conf 19 May     17:00        LifePoint Hospitals Inc at UBS Global Healthcare Conf 19 May     17:10           PolyOne at Goldman Sachs Basic Materials Conf 19 May     17:15           Dover at Electrical Products Group Conf 19 May     17:15           Lennar at JPMorgan Conf 19 May     17:30          Axiall Annual Shareholders Meeting 19 May     17:30        Biomarin Pharmaceutical Inc at UBS Global Healthcare Conf 19 May     17:30        Core-Mark Holding Company Inc Annual Shareholders Meeting 19 May     17:30           Devon Energy at UBS Global Oil and Gas Conf 19 May     17:30        GoPro Inc at JPMorgan Conf 19 May     17:30        NuVasive at the UBS Global Healthcare Conf 19 May     17:30           Redwood Trust Inc Annual Shareholders Meeting 19 May     17:45           Apollo Commercial Real Estate Finance Inc at Wells Fargo Conf 19 May     17:45           Hatteras Financial at Wells Fargo Conf 19 May     17:55           USG at JPMorgan Conf 19 May     06:00        Healthways Inc Annual Shareholders Meeting 19 May     18:00           3D Systems Annual Shareholders Meeting 19 May     18:00           Community Health Systems Inc at UBS Global Healthcare Conf 19 May     18:00        Flushing Financial Annual Shareholders Meeting 19 May     18:00        Immune Design at UBS Global Healthcare Conf 19 May     18:00        Impax Laboratories Inc at UBS Global Healthcare Conf 19 May     18:00            Ingersoll-Rand PLC at Electrical Products Group Conf 19 May     18:00           Ryman Hospitality Properties at Nomura Conf 19 May     18:00        Seattle Genetics Inc at UBS Global Healthcare Conf 19 May     18:00        Skyworks Solutions Inc Annual Shareholders Meeting 19 May     18:10        Akamai Technologies Inc at JPMorgan Conf 19 May     18:10           DigitalGlobe Inc at JPMorgan Conf 19 May     18:10          Paycom Software Inc at JPMorgan Conf 19 May     18:10        SBA Communications at JPMorgan Conf 19 May     18:10             Visa Inc at JPMorgan Conf 19 May     18:15        C.H. Robinson Worldwide Inc at Wolfe Trahan Transport Conf 19 May     18:20           W. R. Grace & Co at Goldman Sachs Basic Materials Conf 19 May     18:30          Hannon Armstrong Sustainable Capital Inc at Wells Fargo Conf 19 May     18:30           Stryker at UBS Global Healthcare Conf 19 May     18:30           TeamHealth Inc at UBS Global Healthcare Conf 19 May     18:30           Western Asset Mortgage Capital at Wells Fargo Conf 19 May     18:35           Hovnanian Enterprises at JPMorgan Conf 19 May     06:45        Fifth Third Banat Barclays Americas Select Conf 19 May     06:45        Hain Celestial Group Inc at JPMorgan Consumer and Retail Conf 19 May     18:50          A10 Networks Inc at JPMorgan Conf 19 May     18:50        Aspen Technology Inc at JPMorgan Conf 19 May     18:50           Cinemark Inc at JPMorgan Conf 19 May     18:50        Expedia Inc at JPMorgan Conf 19 May     18:50             Intelsat SA at JPMorgan Conf 19 May     18:50        Ultimate Software Group Inc at JPMorgan Conf 19 May     18:50        Xilinx Inc at JPMorgan Conf 19 May     18:55           Ball at Goldman Sachs Basic Materials Conf 19 May     19:00        ChemoCentryx Inc at UBS Global Healthcare Conf 19 May     19:00        Incyte at UBS Global Healthcare Conf 19 May     19:00        Interface Inc Annual Shareholders Meeting 19 May     19:15          AG Mortgage Investment Trust Inc at Wells Fargo Conf 19 May     07:30           General Mills Inc at Barclays Americas Select Conf 19 May     07:30           U.S. Banat Barclays Americas Select Conf 19 May     19:30          Chegg Inc at JPMorgan Conf 19 May     19:30        Lam Research at JPMorgan Conf 19 May     19:30        Lamar Advertising Co at JPMorgan Conf 19 May     19:30           Mettler-Toledo International Inc at UBS Global Healthcare Conf 19 May     19:30          New Relic Inc at JPMorgan Conf 19 May     19:30        Sangamo BioSciences Inc at UBS Global Healthcare Conf 19 May     19:30        Threshold Pharmaceuticals Inc at UBS Global Healthcare Conf 19 May     19:30        Verint Systems Inc at JPMorgan Conf 19 May     19:30         Windstream Inc at JPMorgan Conf 19 May     19:55           KB Home at JPMorgan Conf 19 May     20:00           Denbury Resources Inc Annual Shareholders Meeting 19 May     20:00           Essex Property Trust Inc Annual Shareholders Meeting 19 May     20:00        Exact Sciences at UBS Global Healthcare Conf 19 May     20:00        GTX Inc at UBS Global Healthcare Conf 19 May     20:00        Intercept Pharmaceuticals Inc at UBS Global Healthcare Conf 19 May     20:00        Preferred Bank Annual Shareholders Meeting 19 May     20:00          Springleaf Inc Annual Shareholders Meeting 19 May     20:00           Swift Energy Company Annual Shareholders Meeting 19 May     08:10            Colgate-Palmolive Co at Barclays Americas Select Conf 19 May     20:10           Digital Realty Trust Inc at JPMorgan Conf 19 May     20:10        Microchip Technology Inc at JPMorgan Conf 19 May     20:10        Zebra Technologies at JPMorgan Conf 19 May     20:30        Momenta Pharmaceuticals Inc at UBS Global Healthcare Conf 19 May     20:30        Sunesis Pharmaceuticals Inc at UBS Global Healthcare Conf 19 May     08:50           Wells Fargo & Co at Barclays Americas Select Conf 19 May     21:00          Diamond Resorts International Inc Annual Shareholders Meeting 19 May     21:30        Omnicell Inc Annual Shareholders Meeting 19 May     21:30            SM Energy Co Annual Shareholders Meeting           FOR ALL AMERICAN HOLIDAYS      FOR AN INDEX OF ALL DIARIES            If you have any questions or comments on the Corporate diary, please e-mail:     diaries@thomsonreuters.com   ",2015-05-15,AET,"Fri May 15, 2015 | 11:20am EDT",DIARY-U.S. MEETINGS/WEEK AHEAD,http://www.reuters.com//article/diary-us-meetings-week-idUSL3N0Y66JB20150515?type=companyNews
160,"  Thomson Reuters May 15, 2015 - Corporate Meetings for US companies for Week ahead.         S&P 500 Earnings - MONTH AHEAD     Dividends                            Non S&P 500 - Weekly             Federal Reserve events               ConferenceCall/Webcast - Weekly  Meetings - Weekly                                Xtra users can see more details on conference calls & webcasts by hovering your mouse  over the RIC, right click, no click on Related Co Data, now click on Co Events.             ** For events after May 18 please click on                    - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - DATE       GMT      SYMBOL       EVENT TITLE  15 May     01:00        Bank of Marin BanAnnual Shareholders Meeting 15 May     13:00           Clear Channel Outdoor Inc Annual Shareholders Meeting 15 May     13:00           Forum Energy Technologies Inc Annual Shareholders Meeting 15 May     13:00           Newfield Exploration Co Annual Shareholders Meeting 15 May     13:30           Aetna Inc Annual Shareholders Meeting 15 May                     Campus Crest Communities Inc Annual Shareholders Meeting 15 May     12:00          BioAmber Inc Annual Shareholders Meeting 15 May     12:00            Western Union Co Annual Shareholders Meeting 15 May     12:00           WEX Inc Annual Shareholders Meeting 15 May     12:30           Intercontinental Exchange Inc Annual Shareholders Meeting 15 May     14:00           American Water Works Company Inc Annual Shareholders Meeting 15 May     14:00        Chefs Warehouse Inc Annual Shareholders Meeting 15 May     14:00           Macquarie Infrastructure Extraordinary Shareholders Meeting 15 May     14:00         Memorial Resource Development Annual Shareholders Meeting 15 May     14:00           Progressive Annual Shareholders Meeting 15 May     14:00           Tanger Factory Outlet Centers Inc Annual Shareholders Meeting 15 May     14:00           Terex Annual Shareholders Meeting 15 May     14:00           Westlake Chemical Annual Shareholders Meeting 15 May     14:30           John Bean Technologies Annual Shareholders Meeting 15 May     14:30           Quest Diagnostics Inc Annual Shareholders Meeting 15 May     15:00          Banc of California Inc Annual Shareholders Meeting 15 May     15:00            CF Industries Inc Annual Shareholders Meeting 15 May     15:00          Cypress Semiconductor Annual Shareholders Meeting 15 May     15:00           Dril-Quip Inc Annual Shareholders Meeting 15 May     15:00           J C Penney Company Inc Annual Shareholders Meeting 15 May     15:00             Macys Inc Annual Shareholders Meeting 15 May     15:00        QCR Inc Annual Shareholders Meeting 15 May     15:00        Rosetta Resources Inc Annual Shareholders Meeting 15 May     15:00           Transocean Ltd Annual Shareholders Meeting 15 May     15:00           Waste Connections Inc Annual Shareholders Meeting 15 May     15:00        West Annual Shareholders Meeting 15 May     15:30           CBRE Group Inc Annual Shareholders Meeting 15 May     17:00        Commercial Vehicle Group Inc Annual Shareholders Meeting 15 May     18:00        Seattle Genetics Inc Annual Shareholders Meeting 15 May     19:00          Roundy's Inc Annual Shareholders Meeting 16 May     22:00        First Interstate Bancsystem Inc Annual Shareholders Meeting 16 May     14:00           Dillard's Inc Annual Shareholders Meeting 16 May     15:00           American Works at NAIC's BetterInvesting National Convention 17 May     22:00            Laclede Group Inc at American Gas Forum 17 May                     Alliant Energy at American Gas Forum 17 May                     Atmos Energy at American Gas Forum 17 May                     Avista at American Gas Forum 17 May                     Black Hills at American Gas Forum 17 May                     Chesapeake Utilities at American Gas Forum 17 May                      Consolidated Edison Inc at American Gas Forum 17 May                  Delta Natural Gas Company Inc at American Gas Forum 17 May                      Eversource Energy at American Gas Forum 17 May                     Integrys Energy Group Inc at American Gas Forum 17 May                      Laclede Group Inc at American Gas Forum 17 May                     MDU Resources Group Inc at American Gas Forum 17 May                  MGE Energy Inc at American Gas Forum 17 May                     National Fuel Gas Co at American Gas Forum 17 May                     New Jersey Resources at American Gas Forum 17 May                      NiSource Inc at American Gas Forum 17 May                     Piedmont Natural Gas Company Inc at American Gas Forum 17 May                     Questar at American Gas Forum 17 May                     Sempra Energy at American Gas Forum 17 May                     South Jersey Industries Inc at American Gas Forum 17 May                     Southwest Gas at American Gas Forum 17 May                      Spectra Energy at American Gas Forum 17 May                      TECO Energy Inc at American Gas Forum 17 May                     UGI at American Gas Forum 17 May                     UIL at American Gas Forum 17 May                     Unitil at American Gas Forum 17 May                     Vectren at American Gas Forum 17 May                     WGL Inc at American Gas Forum 17 May                     Wisconsin Energy at American Gas Forum 17 May                     Xcel Energy Inc at American Gas Forum 17 May     21:15           Chesapeake Utilities at American Gas Forum 18 May     13:00           3M Co at Electrical Products Group Conf 18 May     13:00        Infinity Pharmaceuticals Inc at UBS Global Healthcare Conf 18 May     13:00          Targa Resources Annual Shareholders Meeting 18 May     13:00           Tenet Healthcare at UBS Global Healthcare Conf 18 May     13:20          Care.com Inc at JPMorgan Conf 18 May     13:20        Cavium Inc at JPMorgan Conf 18 May     13:20           EMC at JPMorgan Conf 18 May     13:20            MasterCard Inc at JPMorgan Conf 18 May     13:20           Neustar Inc at JPMorgan Conf 18 May     13:20          T-Mobile US Inc at JPMorgan Conf 18 May     13:20        Virtusa at JPMorgan Conf 18 May     13:30        Akebia Therapeutics Inc at UBS Global Healthcare Conf 18 May     13:30        Bank of The Ozarks Inc Annual Shareholders Meeting 18 May     13:30           Cambrex at UBS Global Healthcare Conf 18 May     13:30        Esperion Therapeutics Inc at UBS Global Healthcare Conf 18 May     22:00        Geron Annual Shareholders Meeting 18 May     22:00        International Bancshares Annual Shareholders Meeting 18 May                  AcelRx Pharmaceuticals Inc at UBS Global Healthcare Conf 18 May                     Ameren at American Gas Forum 18 May                  Bruker at UBS Global Healthcare Conf 18 May                     CenterPoint Energy Inc at American Gas Forum 18 May                    Civitas Solutions Inc at UBS Global Healthcare Conf 18 May                     CMS Energy at American Gas Forum (One-on-One Meeting) 18 May                     DTE Energy Co at American Gas Forum (One on One Meetings) 18 May                     Empire District Electric Co at American Gas Forum 18 May                  Gas Natural Inc at American Gas Forum 18 May                      Intralinks Inc at JPMorgan Conf 18 May                     NCR at JPMorgan Conf 18 May                     NorthWestern at American Gas Forum:One-on-One Meeting 18 May                     Oasis Petroleum Inc at UBS Global Oil and Gas Conf 18 May                     ONE Gas Inc at American Gas Forum - One-on-One Meetings 18 May                     PG&E at American Gas Forum 18 May                     Public Service Enterprise Group Inc at American Gas Forum 18 May                  RTI Surgical Inc at UBS Global Healthcare Conf 18 May                    U.S. Physical Therapy Inc at UBS Global Healthcare Conf 18 May     11:30           Honeywell International Inc at Electrical Products Group Conf 18 May     12:00             AT&T Inc at JPMorgan Conf 18 May     12:00         VWR at UBS Global Healthcare Conf 18 May     12:30        Ophthotech at UBS Global Healthcare Conf 18 May     12:40        Viacom Inc at JPMorgan Conf 18 May     14:00        Cogent Communications Inc at JPMorgan Conf 18 May     14:00       Comcast at JPMorgan Conf 18 May     14:00            Consolidated Edison Inc Annual Shareholders Meeting 18 May     14:00        CoStar Group Inc at JPMorgan Conf 18 May     14:00        Cree Inc at JPMorgan Conf 18 May     14:00           Danaher at Electrical Products Group Conf 18 May     14:00      Genesis Healthcare at UBS Global Healthcare Conf 18 May     14:00           Global Payments Inc at JPMorgan Conf 18 May     14:00        NetScout Systems Inc at JPMorgan Conf 18 May     14:00        OraSure Technologies Inc at UBS Global Healthcare Conf 18 May     14:00           PerkinElmer Inc at UBS Global Healthcare Conf 18 May     14:00        Prothena PLC at UBS Global Healthcare Conf 18 May     14:00         Texas Instruments Inc at JPMorgan Conf 18 May     14:00        Ultimate Software Group Inc Annual Shareholders Meeting 18 May     14:30           Actavis PLC at UBS Global Healthcare Conf 18 May     14:30        Integra LifeSciences at UBS Global Healthcare Conf 18 May     14:30           Universal Health Services Inc at UBS Global Healthcare Conf 18 May     14:40        ANSYS Inc at JPMorgan Conf 18 May     14:40           CenturyLink Inc at JPMorgan Conf 18 May     14:40          Facebook Inc at JPMorgan Conf 18 May     14:40        Maxim Integrated Products Inc at JPMorgan Conf 18 May     14:40        Synaptics Inc at JPMorgan Conf 18 May     14:40          TriNet Group Inc at JPMorgan Conf 18 May     14:45           Stanley Black & Decker Inc at Electrical Products Group Conf 18 May     15:00           AMN Healthcare Services Inc at UBS Global Healthcare Conf 18 May     15:00        LDR Holding at UBS Global Healthcare Conf 18 May     15:00           Waters at UBS Global Healthcare Conf 18 May     15:20           Box Inc at JPMorgan Conf 18 May     15:20           Diebold Inc at JPMorgan Conf 18 May     15:20           International Business Machines at JPMorgan Conf 18 May     15:20        Orbotech Ltd at JPMorgan Conf 18 May     15:20        Qualys Inc at JPMorgan Conf 18 May     15:20        Sinclair Broadcast Group Inc at JPMorgan Conf 18 May     15:30        Achillion Pharmaceuticals Inc at UBS Global Healthcare Conf 18 May     15:30        PAREXEL International at UBS Global Healthcare Conf 18 May     15:30          Perrigo Company PLC at UBS Global Healthcare Conf 18 May     15:30           Roper Technologies Inc at Electrical Products Group Conf 18 May     16:00            Consolidated Edison Inc at American Gas Forum 18 May     16:00        Grand Canyon Education Inc Annual Shareholders Meeting 18 May     16:00           MDU Resources Group Inc at American Gas Forum 18 May     16:00           Omnicom Group Inc Annual Shareholders Meeting 18 May     16:00           Questar at American Gas Forum 18 May     16:00           South Jersey Industries Inc at American Gas Forum 18 May     16:30           WESCO International Inc at Electrical Products Group Conf 18 May     16:45           DTE Energy Co at American Gas Forum 18 May     16:45           National Fuel Gas Co at American Gas Forum 18 May     16:45           Northwest Natural Gas Co at American Gas Forum 18 May     17:00        Epizyme Inc at UBS Global Healthcare Conf 18 May     17:00           Health Care REIT Inc at UBS Global Healthcare Conf 18 May     17:00        IPC Healthcare Inc at UBS Global Healthcare Conf 18 May     17:00        Veracyte Inc Annual Shareholders Meeting 18 May     17:15           Eaton PLC at Electrical Products Group Conf 18 May     17:30        Alimera Sciences Inc at UBS Global Healthcare Conf 18 May     17:30        AngioDynamics Inc at UBS Global Healthcare Conf 18 May     17:30           CMS Energy at American Gas Forum 18 May     17:30        K2M Group Inc at UBS Global Healthcare Conf 18 May     17:30        Medivation Inc at UBS Global Healthcare Conf 18 May     17:30           ONE Gas Inc at American Gas Forum 18 May     17:30        PacWest BanAnnual Shareholders Meeting 18 May     17:30        PacWest BanCourt Meeting 18 May     17:30           Unitil at American Gas Forum 18 May     18:00        Halozyme Therapeutics Inc at UBS Global Healthcare Conf 18 May     18:00           Rockwell Automation Inc at Electrical Products Group Conf 18 May     18:10           American Tower at JPMorgan Conf 18 May     18:10            Broadridge Financial Solutions Inc at JPMorgan Conf 18 May     18:10          Everyday Health Inc at JPMorgan Conf 18 May     18:10        Medidata Solutions Inc at JPMorgan Conf 18 May     18:10        Paychex Inc at JPMorgan Conf 18 May     18:15           NorthWestern at American Gas Forum 18 May     18:15           Southwest Gas at American Gas Forum 18 May     18:15            TECO Energy Inc at American Gas Forum 18 May     18:15           WGL Inc at American Gas Forum 18 May     18:30           Aetna Inc at UBS Global Healthcare Conf 18 May     18:30        Biospecifics Technologies at UBS Global Healthcare Conf 18 May     18:45           SPX at Electrical Products Group Conf 18 May     18:50        Dealertrack Technologies Inc at JPMorgan Conf 18 May     18:50           Freescale Semiconductor Ltd at JPMorgan Conf 18 May     18:50        HomeAway Inc at JPMorgan Conf 18 May     18:50          HubSpot Inc at JPMorgan Conf 18 May     18:50           Interpublic Group of Companies Inc at JPMorgan Conf 18 May     18:50           WEX Inc at JPMorgan Conf 18 May     19:00        AMAG Pharmaceuticals Inc at UBS Global Healthcare Conf 18 May     19:30           Alliance Data Systems at JPMorgan Conf 18 May     19:30         Foundation Medicine Inc at UBS Global Healthcare Conf 18 May     19:30           Gannett Co Inc at JPMorgan Conf 18 May     19:30        LogMeIn Inc at JPMorgan Conf 18 May     19:30           RingCentral Inc at JPMorgan Conf 18 May     19:30        ShoreTel Inc at JPMorgan Conf 18 May     19:30           VeriFone Systems Technology, Media and Telecom Conf 18 May     19:30           West Pharmaceutical Services Inc at UBS Global Healthcare Conf 18 May     08:00       Nexus AG Annual Shareholders Meeting 18 May     20:00        Insmed Inc at UBS Global Healthcare Conf 18 May     20:00            Spectra Energy at American Gas Forum 18 May     20:00           UIL at American Gas Forum 18 May     20:00           Vectren at American Gas Forum 18 May     20:10        CyrusOne Inc at JPMorgan Conf 18 May     20:10        EnerNOC Inc at JPMorgan Conf 18 May     20:10          Guidewire Software Inc at JPMorgan Conf 18 May     20:10           Heartland Payment Systems Inc at JPMorgan Conf 18 May     20:10        iRobot at JPMorgan Conf 18 May     20:10          Model N Inc at JPMorgan Conf 18 May     20:10          Tribune Media Co at JPMorgan Conf 18 May     20:30        LegacyTexas Financial Group Inc Annual Shareholders Meeting 18 May     20:45           AGL Resources Inc at American Gas Forum 18 May     20:45           Black Hills at American Gas Forum 18 May     21:00           Motorola Solutions Inc Annual Shareholders Meeting 18 May     21:30           UGI at American Gas Forum            FOR ALL AMERICAN HOLIDAYS      FOR AN INDEX OF ALL DIARIES            If you have any questions or comments on the Corporate diary, please e-mail:     diaries@thomsonreuters.com   ",2015-05-15,AET,"Fri May 15, 2015 | 8:56am EDT",DIARY-U.S. MEETINGS/WEEK AHEAD,http://www.reuters.com//article/diary-us-meetings-week-idUSL3N0Y662Z20150515?type=companyNews
161,"   By Bill Berkrot and Caroline Humer  U.S. healthcare conglomerate Johnson & Johnson said on Wednesday it expects to submit more than 10 new medicines with annual revenue potential of at least $1 billion each to regulators by 2019, and is testing dozens of new uses for existing medicines.J&J said it would file for approval of daratumumab for the blood cancer multiple myeloma in the United States and Europe this year based on mid-stage clinical data.Wells Fargo analyst Larry Biegelsen forecast daratumumab sales reaching $1.3 billion by 2019.The company is looking to bounce back from previous failure in Alzheimer's disease with multiple programs, including an early-stage drug it believes has the potential to prevent amyloid plaque buildup in the brain and another that aims to clear it.Pharmaceuticals has been a bright spot for the company at a time when its medical devices and consumer products have seen sharp declines, hurt by competition and the strong dollar. During a pharmaceutical pipeline review for analysts and investors, J&J outlined an ambitious portfolio of drugs in development aimed at sustaining above-industry compound annual growth through 2019. The industry rate over that period is expected to be about 3 percent.The review comes as the industry prepares for the introduction of copycat versions of expensive biologic drugs, such as J&J's rheumatoid arthritis (RA) treatment Remicade, which has annual U.S. sales of more than $4 billion and a patent that expires in 2018.J&J's worldwide pharmaceuticals head Joaquin Duato said he believes Remicade's established safety would be an advantage over eventual biosimilar newcomers. ""Biosimilars are not generics and we expect the market to behave quite differently,"" Duato said.Still, the company highlighted a new antibody for RA being developed with GlaxoSmithKline, and one for psoriasis that it touted as more effective that Abbott's big-selling Humira.The company is targeting Crohn's disease with a new drug being developed along with a companion diagnostic aimed at identifying patients likely to have the best response, and is beginning Phase III trials of a promising drug for treatment resistant depression. J&J is jumping on the immuno-oncology bandwagon with programs for lung, prostate and blood cancers aimed at harnessing the immune system to attack tumors.It also aims to become a major player in the hepatitis C market now dominated by Gilead Sciences through a deal announced Tuesday with Achillion Pharmaceuticals.Investors, however, appear underwhelmed. J&J shares slipped 0.3 percent to $103.65. (Reporting by Caroline Humer; editing by Nick Zieminski)",2015-05-20,AET,"Wed May 20, 2015 | 3:49pm EDT",J&J to submit at least 10 new drugs for approval by 2019,http://www.reuters.com//article/us-johnson-johnson-pharmaceuticals-idUSKBN0O51ML20150520?type=companyNews
162,"   By Bill Berkrot and Caroline Humer  U.S. healthcare conglomerate Johnson & Johnson said on Wednesday it expects to submit more than 10 new medicines with annual revenue potential of at least $1 billion each to regulators by 2019, and is testing dozens of new uses for existing medicines.J&J said it would file for approval of daratumumab for the blood cancer multiple myeloma in the United States and Europe this year based on mid-stage clinical data.Wells Fargo analyst Larry Biegelsen forecast daratumumab sales reaching $1.3 billion by 2019.The company is looking to bounce back from previous failure in Alzheimer's disease with multiple programs, including an early-stage drug it believes has the potential to prevent amyloid plaque buildup in the brain and another that aims to clear it.Pharmaceuticals has been a bright spot for the company at a time when its medical devices and consumer products have seen sharp declines, hurt by competition and the strong dollar. During a pharmaceutical pipeline review for analysts and investors, J&J outlined an ambitious portfolio of drugs in development aimed at sustaining above-industry compound annual growth through 2019. The industry rate over that period is expected to be about 3 percent.The review comes as the industry prepares for the introduction of copycat versions of expensive biologic drugs, such as J&J's rheumatoid arthritis (RA) treatment Remicade, which has annual U.S. sales of more than $4 billion and a patent that expires in 2018.J&J's worldwide pharmaceuticals head Joaquin Duato said he believes Remicade's established safety would be an advantage over eventual biosimilar newcomers. ""Biosimilars are not generics and we expect the market to behave quite differently,"" Duato said.Still, the company highlighted a new antibody for RA being developed with GlaxoSmithKline, and one for psoriasis that it touted as more effective that Abbott's big-selling Humira.The company is targeting Crohn's disease with a new drug being developed along with a companion diagnostic aimed at identifying patients likely to have the best response, and is beginning Phase III trials of a promising drug for treatment resistant depression. J&J is jumping on the immuno-oncology bandwagon with programs for lung, prostate and blood cancers aimed at harnessing the immune system to attack tumors.It also aims to become a major player in the hepatitis C market now dominated by Gilead Sciences through a deal announced Tuesday with Achillion Pharmaceuticals.Investors, however, appear underwhelmed. J&J shares slipped 0.3 percent to $103.65. (Reporting by Caroline Humer; editing by Nick Zieminski)",2015-05-20,AET,"Wed May 20, 2015 | 3:47pm EDT",J&J to submit at least 10 new drugs for approval by 2019,http://www.reuters.com//article/us-johnson-johnson-pharmaceuticals-idUSKBN0O52J520150520?type=companyNews
163,"  (Adds further meeting details, updates shares)By Bill Berkrot and Caroline HumerMay 20 U.S. healthcare conglomerate Johnson & Johnson said on Wednesday it expects to submit more than 10 new medicines with annual revenue potential of at least $1 billion each to regulators by 2019, and is testing dozens of new uses for existing medicines.J&J said it would file for approval of daratumumab for the blood cancer multiple myeloma in the United States and Europe this year based on mid-stage clinical data.Wells Fargo analyst Larry Biegelsen forecast daratumumab sales reaching $1.3 billion by 2019.The company is looking to bounce back from previous failure in Alzheimer's disease with multiple programs, including an early-stage drug it believes has the potential to prevent amyloid plaque buildup in the brain and another that aims to clear it. Pharmaceuticals has been a bright spot for the company at a time when its medical devices and consumer products have seen sharp declines, hurt by competition and the strong dollar.During a pharmaceutical pipeline review for analysts and investors, J&J outlined an ambitious portfolio of drugs in development aimed at sustaining above-industry compound annual growth through 2019. The industry rate over that period is expected to be about 3 percent.The review comes as the industry prepares for the introduction of copycat versions of expensive biologic drugs, such as J&J's rheumatoid arthritis (RA) treatment Remicade, which has annual U.S. sales of more than $4 billion and a patent that expires in 2018. J&J's worldwide pharmaceuticals head Joaquin Duato said he believes Remicade's established safety would be an advantage over eventual biosimilar newcomers.""Biosimilars are not generics and we expect the market to behave quite differently,"" Duato said. Still, the company highlighted a new antibody for RA being developed with GlaxoSmithKline, and one for psoriasis that it touted as more effective that Abbott's  big-selling Humira.The company is targeting Crohn's disease with a new drug being developed along with a companion diagnostic aimed at identifying patients likely to have the best response, and is beginning Phase III trials of a promising drug for treatment resistant depression.J&J is jumping on the immuno-oncology bandwagon with programs for lung, prostate and blood cancers aimed at harnessing the immune system to attack tumors.It also aims to become a major player in the hepatitis C market now dominated by Gilead Sciences through a deal announced Tuesday with Achillion Pharmaceuticals.Investors, however, appear underwhelmed. J&J shares slipped 0.3 percent to $103.65.   (Reporting by Caroline Humer; editing by Nick Zieminski)",2015-05-20,AET,"Wed May 20, 2015 | 2:54pm EDT",UPDATE 2-J&J to submit at least 10 new drugs for approval by 2019,http://www.reuters.com//article/johnsonjohnson-pharmaceuticals-idUSL1N0YB0T420150520?type=companyNews
164,"  NEW YORK Medicare, the government-run health insurance program for elderly and disabled Americans, paid physicians $90 billion in 2013, up 17 percent from $77 billion in 2012, U.S. healthcare officials reported on Monday. Physician payments accounted for less than one-fifth of Medicare's 2013 net outlays of $492 billion, which rose from $466 billion in 2012. Payments to hospitals for the top 100 inpatient stays cost Medicare $62 billion in 2013, while the rest went for drugs, privately run Medicare Advantage plans and other program costs.The payments went to about 950,000 doctors, nurse practitioners and other individual healthcare providers who participate in the program. That was up from 880,000 providers in 2012.The hospital data offer a glimpse of what ails America's elderly - and the quality shortfalls in U.S. healthcare.The single-greatest hospital expense was to replace knees, hips and other joints in 446,148 operations, with $6.6 billion paid to hospitals. The second-greatest hospital payment, $5.6 billion, went for 398,004 cases of septicemia, or blood poisoning, often a sign of poor in-patient care.In a significant change from the data released last year, the Center for Medicare and Medicaid Services differentiated between what it paid physicians for their services and what it paid to cover the costs of drugs they administered. Some physicians had complained that they were portrayed as exorbitant billers because the cost of drugs was included in what Medicare paid them. Among physicians, the highest-paid specialists were radiation oncologists, who received an average of $403,512 from Medicare for their services. That was closely followed by dermatologists ($331,108), vascular surgeons ($329,874), and ophthalmologists ($326,621).In contrast, medical oncologists, who treat cancer patients with chemotherapy and generally coordinate their care, received an average of $181,747. The previous year's data portrayed them as some of the top Medicare billers, but that largely reflected reimbursements for the cost of drugs - an average $473,926 in 2013. The data showed that patients who lament how little time they get with their physicians are not imagining it. Dermatologists billed for the most office visits lasting only five or 10 minutes (nearly 30 percent of total visits), whereas oncologists had almost no visits that short.Medicare patients averaged six physician visits in 2013, but that varied significantly by state. Patients in New York, New Jersey, Florida, and Tennessee saw their doctors nearly seven times that year; those in northern New England, the Dakotas, Idaho, Montana, and New Mexico averaged fewer than four visits. (Reporting by Sharon Begley; Editing by Dan Grebler)",2015-06-01,AET,"Mon Jun 1, 2015 | 12:27pm EDT","Medicare paid doctors $90 billion in 2013, up 17 percent: officials",http://www.reuters.com//article/us-usa-medicare-payments-idUSKBN0OH2US20150601?type=companyNews
165,"  NEW YORK, June 1 Medicare, the government-run health insurance program for elderly and disabled Americans, paid physicians $90 billion in 2013, up 17 percent from $77 billion in 2012, U.S. healthcare officials reported on Monday.Physician payments accounted for less than one-fifth of Medicare's 2013 net outlays of $492 billion, which rose from $466 billion in 2012. Payments to hospitals for the top 100 inpatient stays cost Medicare $62 billion in 2013, while the rest went for drugs, privately run Medicare Advantage plans and other program costs.The payments went to about 950,000 doctors, nurse practitioners and other individual healthcare providers who participate in the program. That was up from 880,000 providers in 2012.The hospital data offer a glimpse of what ails America's elderly - and the quality shortfalls in U.S. healthcare. The single-greatest hospital expense was to replace knees, hips and other joints in 446,148 operations, with $6.6 billion paid to hospitals.The second-greatest hospital payment, $5.6 billion, went for 398,004 cases of septicemia, or blood poisoning, often a sign of poor in-patient care. In a significant change from the data released last year, the Center for Medicare and Medicaid Services differentiated between what it paid physicians for their services and what it paid to cover the costs of drugs they administered. Some physicians had complained that they were portrayed as exorbitant billers because the cost of drugs was included in what Medicare paid them.Among physicians, the highest-paid specialists were radiation oncologists, who received an average of $403,512 from Medicare for their services. That was closely followed by dermatologists ($331,108), vascular surgeons ($329,874), and ophthalmologists ($326,621). In contrast, medical oncologists, who treat cancer patients with chemotherapy and generally coordinate their care, received an average of $181,747. The previous year's data portrayed them as some of the top Medicare billers, but that largely reflected reimbursements for the cost of drugs - an average $473,926 in 2013.The data showed that patients who lament how little time they get with their physicians are not imagining it. Dermatologists billed for the most office visits lasting only five or 10 minutes (nearly 30 percent of total visits), whereas oncologists had almost no visits that short.Medicare patients averaged six physician visits in 2013, but that varied significantly by state. Patients in New York, New Jersey, Florida, and Tennessee saw their doctors nearly seven times that year; those in northern New England, the Dakotas, Idaho, Montana, and New Mexico averaged fewer than four visits.   (Reporting by Sharon Begley; Editing by Dan Grebler)",2015-06-01,AET,"Mon Jun 1, 2015 | 11:58am EDT","Medicare paid doctors $90 billion in 2013, up 17 pct -officials",http://www.reuters.com//article/usa-medicare-payments-idUSL1N0YN0WP20150601?type=companyNews
166,"  (Adds email from GE chief executive, statement from Aetna)By Edward KrudyNEW YORK, June 4 General Electric Co has assembled an ""exploratory team"" to look at moving its headquarters out of Connecticut after lawmakers passed a budget that includes $1.2 billion in tax increases despite protests from some of the state's biggest corporations.In an email sent on Thursday to GE's Connecticut employees and obtained by Reuters, Chief Executive Jeff Immelt said he had asked the team to examine the company's options to relocate the headquarters to a state with a ""more pro-business environment."" GE has 5,700 employees in Connecticut.Lawmakers passed a $40 billion biannual budget late on Wednesday. GE, Aetna Inc and Travelers Cos Inc  as well as the state's Republicans slammed the measures, which extend a 20 percent surcharge on corporate tax and introduce a tax on group-wide income even if it originates out of state.GE and Aetna, which also has a corporate headquarters in the state, said on Monday they would consider leaving Connecticut, but Immelt's email is the first sign a major corporation is taking concrete steps that could lead to it quitting the state. The loss of GE would be a huge blow to Connecticut, which bled thousands of jobs after the financial crisis and has been one of the slowest states to recover from the recession.The state's economy grew just 0.9 percent in 2013, compared with 2.2 percent for the United States as a whole, while job growth has also lagged.""If this budget would wind up driving employers out of state, it would be even harder to fund the services that this budget is intended to fund,"" said Jared Walczak at the Washington-based Tax Foundation. Walczak said the budget would increase business taxes by around $500 million over two years.Democratic Governor Dannel Malloy had trumpeted the budget as an ""historic investment"" in roads, bridges, rail and other infrastructure slated to reach $10 billion over five years.Facing the growing backlash on Thursday, a spokesman for his office said: ""We have spoken with GE in recent days and have been kept apprised of their thinking."" Separately, Aetna issued another statement on Thursday saying its annual $65 million state tax bill would jump 27 percent once all the budget measures were implemented.""Elected leaders have failed to address the state's budget obligation responsibly,"" Aetna said. ""But it's Connecticut's businesses and residents that will pay the price.""The state also increased a tax on data processing that Aetna said would ""hurt our ability to remain competitive and invest in our employees and customers.""The extension of the temporary 20 percent surcharge maintains Connecticut's effective corporate tax rate at 9 percent, compared with a base rate of 7.5 percent, the fifth-highest in the nation, according to the Tax Foundation.The budget also raises the top rate of income tax to 6.99 percent from 6.7 percent, cuts property tax credits and boosts the sales tax on luxury items to 7.75 percent from 7 percent. That includes automobiles over $50,000, jewelry over $5,000, and clothing and accessories over $1,000.   (Reporting by Edward Krudy and Lewis Krauskopf; Editing by Lisa Von Ahn and Alan Crosby)",2015-06-04,AET,"Thu Jun 4, 2015 | 6:05pm EDT",UPDATE 2-Immelt asks GE team to weigh Connecticut pullout after tax hike,http://www.reuters.com//article/usa-connecticut-budget-idUSL1N0YQ12320150604?type=companyNews
167,"  NEW YORK Aetna Inc's (AET.N) state tax burden will increase 27 percent after Connecticut's lawmakers passed a budget that extends a corporate tax surcharge, taxes business on group-wide income, and raises a tax on data processing, the company said Thursday.""Elected leaders have failed to address the state's budget obligation responsibly,"" Aetna said in a statement. ""But it's Connecticut's businesses and residents that will pay the price."" Aetna said it currently pays $65 million each year in taxes to the state.    (Reporting by Edward Krudy; Editing by Bernard Orr)",2015-06-04,AET,"Thu Jun 4, 2015 | 5:21pm EDT",Aetna says state tax burden to jump 27 percent on Connecticut budget,http://www.reuters.com//article/us-usa-connecticut-budget-aetna-idUSKBN0OK2II20150604?type=companyNews
168,"   By Edward Krudy | NEW YORK  NEW YORK Connecticut Governor Dannel Malloy on Friday proposed cutting planned business taxes by $223.7 million over two years after several large corporations threatened to leave the state.Connecticut's state legislature passed a $40 billion biannual budget last week that hiked taxes by $1.2 billion over the next two years, prompting a backlash from businesses including General Electric Co, Travelers Companies Inc and Aetna Inc.Aetna and GE, both of which have headquarters in the state, have said they would consider leaving Connecticut. GE's Chief Executive Officer Jeff Immelt said he had already assembled a team to look for alternative locations.Malloy's plan involves scrapping a proposed increase on a tax on data processing, deferring the introduction of company-wide taxation, and raising a tax credit cap.Malloy, a Democrat, said he will ask the legislature to make cuts by 1.5 percent across the board. ""Even as we have one of the lowest effective corporate tax rates in the nation, these steps are being made to protect Connecticut's long-term interests,"" Malloy said in a statement.Connecticut's lawmakers will meet this month in a special session to implement the budget plan. That would allow them to pass Malloy's amendments before the start of the fiscal year on July 1.""While the Connecticut business climate continues to be very challenging, this announcement is a step in the right direction.  We will review these changes in more detail and monitor developments through the special legislative session,"" a spokesperson for Aetna said in a statement. Last week's spending plan extended a temporary 20 percent surcharge on corporate tax, which makes Connecticut's effective corporate tax rate 9 percent, compared with a base rate of 7.5 percent, the fifth-highest in the nation, according to the Tax Foundation.""The governor and the legislature should do the right thing for small and large businesses and the citizens of Connecticut to improve the economic vitality of the state,"" GE said in a statement. The company did not comment on the substance of Malloy's proposals. Travelers said it was ""pleased that the governor has listened to the concerns expressed by the business community and has proposed changes to the budget.""""We will closely monitor the legislatures reaction to these proposed changes,"" the company said.Malloy's revised plan also calls for revenue generated through sales tax on car washes and parking to be eliminated. Taxes on Internet services would be set at 1 percent. (Additional reporting by Lewis Krauskopf; Editing by James Dalgleish and Lisa Shumaker)",2015-06-12,AET,"Fri Jun 12, 2015 | 3:48pm EDT",Connecticut governor proposes scrapping business taxes,http://www.reuters.com//article/us-usa-connecticut-budget-idUSKBN0OS21Z20150612?type=companyNews
169,"  (Adds comment from Travelers)By Edward KrudyNEW YORK, June 12 Connecticut Governor Dannel Malloy on Friday proposed cutting planned business taxes by $223.7 million over two years after several large corporations threatened to leave the state.Connecticut's state legislature passed a $40 billion biannual budget last week that hiked taxes by $1.2 billion over the next two years, prompting a backlash from businesses including General Electric Co, Travelers Companies Inc  and Aetna Inc.Aetna and GE, both of which have headquarters in the state, have said they would consider leaving Connecticut. GE's Chief Executive Officer Jeff Immelt said he had already assembled a team to look for alternative locations.Malloy's plan involves scrapping a proposed increase on a tax on data processing, deferring the introduction of company-wide taxation, and raising a tax credit cap. Malloy, a Democrat, said he will ask the legislature to make cuts by 1.5 percent across the board.""Even as we have one of the lowest effective corporate tax rates in the nation, these steps are being made to protect Connecticut's long-term interests,"" Malloy said in a statement. Connecticut's lawmakers will meet this month in a special session to implement the budget plan. That would allow them to pass Malloy's amendments before the start of the fiscal year on July 1.""While the Connecticut business climate continues to be very challenging, this announcement is a step in the right direction.  We will review these changes in more detail and monitor developments through the special legislative session,"" a spokesperson for Aetna said in a statement.Last week's spending plan extended a temporary 20 percent surcharge on corporate tax, which makes Connecticut's effective corporate tax rate 9 percent, compared with a base rate of 7.5 percent, the fifth-highest in the nation, according to the Tax Foundation. ""The governor and the legislature should do the right thing for small and large businesses and the citizens of Connecticut to improve the economic vitality of the state,"" GE said in a statement. The company did not comment on the substance of Malloy's proposals.Travelers said it was ""pleased that the governor has listened to the concerns expressed by the business community and has proposed changes to the budget.""""We will closely monitor the legislature's reaction to these proposed changes,"" the company said.Malloy's revised plan also calls for revenue generated through sales tax on car washes and parking to be eliminated. Taxes on Internet services would be set at 1 percent.   (Additional reporting by Lewis Krauskopf; Editing by James Dalgleish and Lisa Shumaker)",2015-06-12,AET,"Fri Jun 12, 2015 | 3:35pm EDT",UPDATE 4-Connecticut governor proposes scrapping business taxes,http://www.reuters.com//article/usa-connecticut-budget-idUSL1N0YY14Z20150612?type=companyNews
170,"  * Supreme Court to decide fate of U.S. healthcare* Ruling expected this month, as early as MondayBy Joan BiskupicWASHINGTON, June 14 Justice Anthony Kennedy was furious when a majority on the U.S. Supreme Court upheld President Barack Obama's healthcare law. As he read the dissenting opinion from the bench three years ago, his anger was palpable. The majority regards its opinion ""as judicial modesty,"" he declared. ""It is not. It amounts instead to a vast judicial over-reaching.""That was Kennedy on June 28, 2012.Now, as the country awaits a ruling in the second major challenge to Obama's signature Affordable Care Act, a question is whether the justice who was the voice of the opposition then could provide the critical fifth vote to uphold the law on the nine-justice court now.At stake are the tax-credit subsidies that have helped low- and moderate-income Americans obtain health insurance. The challengers say the government unlawfully extended those subsidies to states that did not create local insurance exchanges but instead relied on the federal exchange. If the court strikes down the subsidies, millions of Americans in at least 34 of the 50 states could lose coverage.Five years after its passage, the Affordable Care Act has become ingrained in American life even as it remains politically divisive. ""This is now part of the fabric of how we care for one another,"" Obama, a Democrat, declared in a speech last week. Republicans have called for repeal and among the related lawsuits simmering in lower courts is a dispute brought by Republicans in the U.S. House of Representatives over Treasury Department payments to healthcare insurers. IMPOSSIBLE TO PREDICT In the case before the court, the unique issue along with Kennedy's record and his comments in oral arguments raise the possibility he will join the four liberal justices to endorse the law. Three years ago, his fellow conservative Chief Justice John Roberts cast the swing vote with the liberals to uphold the law. It marked a rare episode when Kennedy, the usual key justice on this divided bench, did not control the outcome of a momentous case.It is impossible to predict with confidence how the court will resolve the case, King v. Burwell. A ruling is anxiously awaited by officials in Washington and the insurance and healthcare industries nationwide. What is known: Two days after the March 4 oral arguments this year, the justices, per their usual practice, took a vote in a small conference room off Chief Justice Roberts' chambers. The most senior justice on the winning side then assigned the opinion for those in the majority; the senior justice on the dissenting side tapped a writer for the main dissent. Drafts of dueling opinions began circulating among the chambers.In this conversation through memos, the justices will sharpen their arguments, sometimes compromising in reasoning and rhetoric to keep a majority together. Those in dissent similarly hone their retorts. The process is shrouded in secrecy, and the public will only know who is writing which opinion when they are issued.For King v. Burwell, the decision could come down as soon as Monday morning, when the justices next take the bench. It is more likely to be issued later this month. The toughest disputes tend to be resolved right up against the traditional end-of-June deadline for the court's nine-month session. Among the 20 awaited cases is also the question of whether the U.S. Constitution guarantees a right to same-sex marriage. A PIVOTAL POSITION On healthcare, either Kennedy or Roberts could tip the balance. Yet the 78-year-old Kennedy, appointed to the bench in 1988 by Republican President Ronald Reagan, may be in a more pivotal position based on his respect for state sovereignty and concern for the practical consequences of a decision.While the 2012 dispute posed a broad-ranging constitutional challenge to the individual insurance mandate before it even took effect, this one turns on a mere four-word clause allowing tax credits for insurance purchased through exchanges ""established by the state.""The challengers, libertarian lawyers who were among those who lodged the 2012 attack, say that means that the subsidies are not available to people who have bought insurance through federally facilitated exchanges, which vastly outnumber state-run exchanges. The Obama administration contends the law, taken as a whole, makes clear that Congress, when it passed the law, intended the subsidies to apply to all exchanges.During oral arguments Justice Kennedy suggested the challengers' view of the law could put unconstitutional federal pressure on states, because if they failed to set up exchanges, they would lose subsidies: ""The states are being told either create your own exchange or we'll send your insurance market into a death spiral,"" he said.Kennedy also does not rigidly interpret the words of a statute. He considers how a decision may play out, and he noted that if ""people pay mandated taxes"" and are denied tax credits, ""the cost of insurance will be sky-high.""Still, Kennedy may harbor skepticism about the law known as Obamacare, and he acknowledged during arguments the possibility that the challengers could ""prevail on the plain words of the statute.""   (Reporting by Joan Biskupic; Editing by Howard Goller)",2015-06-14,AET,"Sun Jun 14, 2015 | 9:00am EDT","The voice of opposition past, Justice Kennedy may save Obamacare now",http://www.reuters.com//article/usa-court-healthcare-kennedy-idUSL1N0YY0XG20150614?type=companyNews
171,"  * Anthem offered $175/share for Cigna - WSJ* UnitedHealth also eyeing Cigna and Aetna - WSJ* Cigna shares touch record high of $162.16   (Adds Breakingviews link)June 15 Health insurer Cigna Corp  rebuffed a takeover offer from larger rival Anthem Inc, as the U.S. managed care sector gears up for a round of consolidation, the Wall Street Journal reported on Monday.Cigna and Anthem have been in discussions for months, with Anthem making two takeover bids within the last 10 days, the Journal reported, citing people familiar with the matter. (on.wsj.com/1JTBQP0)Anthem's last bid was worth about $175 per Cigna share, the Journal said, valuing the company at about $45 billion according to Thomson Reuters calculations.Cigna had a market capitalization of $35.34 billion as of Friday's close. U.S. health insurers have come under pressure as the government and employers toughen their stance on spending for medical procedures and drugs. In such a scenario, growing through acquisitions makes sense and could even grant insurers leverage in negotiating prices with hospitals.Cigna's rejection of Anthem's takeover offer is the latest in a series of moves involving potential deals in the sector.UnitedHealth Group Inc, the largest U.S. health insurer, is also eyeing Cigna and Aetna, the Journal said on Monday, citing sources. Separately, Bloomberg reported that Anthem was also weighing up a bid for Humana. (bloom.bg/1FjemfT)The news comes less than a month after Humana Inc  said it was exploring a sale, with Aetna Inc and Cigna said to be among those interested.The Anthem talks for Cigna show that the next deal in the industry will not necessarily be a sale of Humana, as many industry watchers expected, the Journal said. Cigna shares jumped 18 percent to a record high of $162.16, while Anthem's stock closed up 2.3 percent at $164.46.Humana's shares closed down 2.7 percent at $206.58.Spokespersons for Anthem, Aetna, Cigna and UnitedHealth said the companies did not comment on rumors or market speculation. Humana could not immediately be reached for comment.Cigna manages insurance plans for large companies and sells health plans on government exchanges created under the U.S. Affordable Care Act, often called Obamacare. It also offers dental and other benefits.Anthem is one of the biggest players on the individual exchanges created under Obamacare and also runs a huge employer-based insurance business.(Reporting by Amrutha Penumudi in Bengaluru; Editing by Savio D'Souza and Simon Jennings)",2015-06-15,AET,"Mon Jun 15, 2015 | 4:50pm EDT",UPDATE 4-Cigna rebuffs takeover approach by Anthem - WSJ,http://www.reuters.com//article/cigna-ma-anthem-idUSL3N0Z14Z020150615?type=companyNews
172,"  (Repeating without changes for wider distribution)* Supreme Court to decide fate of U.S. healthcare* Ruling expected this month, as early as MondayBy Joan BiskupicWASHINGTON, June 14 Justice Anthony Kennedy was furious when a majority on the U.S. Supreme Court upheld President Barack Obama's healthcare law. As he read the dissenting opinion from the bench three years ago, his anger was palpable. The majority regards its opinion ""as judicial modesty,"" he declared. ""It is not. It amounts instead to a vast judicial over-reaching.""That was Kennedy on June 28, 2012.Now, as the country awaits a ruling in the second major challenge to Obama's signature Affordable Care Act, a question is whether the justice who was the voice of the opposition then could provide the critical fifth vote to uphold the law on the nine-justice court now.At stake are the tax-credit subsidies that have helped low- and moderate-income Americans obtain health insurance. The challengers say the government unlawfully extended those subsidies to states that did not create local insurance exchanges but instead relied on the federal exchange. If the court strikes down the subsidies, millions of Americans in at least 34 of the 50 states could lose coverage.Five years after its passage, the Affordable Care Act has become ingrained in American life even as it remains politically divisive. ""This is now part of the fabric of how we care for one another,"" Obama, a Democrat, declared in a speech last week. Republicans have called for repeal and among the related lawsuits simmering in lower courts is a dispute brought by Republicans in the U.S. House of Representatives over Treasury Department payments to healthcare insurers. IMPOSSIBLE TO PREDICT In the case before the court, the unique issue along with Kennedy's record and his comments in oral arguments raise the possibility he will join the four liberal justices to endorse the law. Three years ago, his fellow conservative Chief Justice John Roberts cast the swing vote with the liberals to uphold the law. It marked a rare episode when Kennedy, the usual key justice on this divided bench, did not control the outcome of a momentous case.It is impossible to predict with confidence how the court will resolve the case, King v. Burwell. A ruling is anxiously awaited by officials in Washington and the insurance and healthcare industries nationwide. What is known: Two days after the March 4 oral arguments this year, the justices, per their usual practice, took a vote in a small conference room off Chief Justice Roberts' chambers. The most senior justice on the winning side then assigned the opinion for those in the majority; the senior justice on the dissenting side tapped a writer for the main dissent. Drafts of dueling opinions began circulating among the chambers.In this conversation through memos, the justices will sharpen their arguments, sometimes compromising in reasoning and rhetoric to keep a majority together. Those in dissent similarly hone their retorts. The process is shrouded in secrecy, and the public will only know who is writing which opinion when they are issued.For King v. Burwell, the decision could come down as soon as Monday morning, when the justices next take the bench. It is more likely to be issued later this month. The toughest disputes tend to be resolved right up against the traditional end-of-June deadline for the court's nine-month session. Among the 20 awaited cases is also the question of whether the U.S. Constitution guarantees a right to same-sex marriage. A PIVOTAL POSITION On healthcare, either Kennedy or Roberts could tip the balance. Yet the 78-year-old Kennedy, appointed to the bench in 1988 by Republican President Ronald Reagan, may be in a more pivotal position based on his respect for state sovereignty and concern for the practical consequences of a decision.While the 2012 dispute posed a broad-ranging constitutional challenge to the individual insurance mandate before it even took effect, this one turns on a mere four-word clause allowing tax credits for insurance purchased through exchanges ""established by the state.""The challengers, libertarian lawyers who were among those who lodged the 2012 attack, say that means that the subsidies are not available to people who have bought insurance through federally facilitated exchanges, which vastly outnumber state-run exchanges. The Obama administration contends the law, taken as a whole, makes clear that Congress, when it passed the law, intended the subsidies to apply to all exchanges.During oral arguments Justice Kennedy suggested the challengers' view of the law could put unconstitutional federal pressure on states, because if they failed to set up exchanges, they would lose subsidies: ""The states are being told either create your own exchange or we'll send your insurance market into a death spiral,"" he said.Kennedy also does not rigidly interpret the words of a statute. He considers how a decision may play out, and he noted that if ""people pay mandated taxes"" and are denied tax credits, ""the cost of insurance will be sky-high.""Still, Kennedy may harbor skepticism about the law known as Obamacare, and he acknowledged during arguments the possibility that the challengers could ""prevail on the plain words of the statute.""   (Reporting by Joan Biskupic; Editing by Howard Goller)",2015-06-15,AET,"Mon Jun 15, 2015 | 7:00am EDT","RPT-The voice of opposition past, Justice Kennedy may save Obamacare now",http://www.reuters.com//article/usa-court-healthcare-kennedy-idUSL1N0YY29E20150615?type=companyNews
173,"  WASHINGTON Health insurer Aetna Inc (AET.N) has made a takeover proposal to rival Humana Inc (HUM.N), the Wall Street Journal reported on Saturday. It gave no details.        (Reporting by Mohammad Zargham Editing by W Simon) ",2015-06-20,AET,"Sat Jun 20, 2015 | 5:00pm EDT",Aetna Inc makes takeover proposal to Humana Inc - WSJ,http://www.reuters.com//article/us-humana-m-a-aetna-idUSKBN0P00SX20150620?type=companyNews
174,"  WASHINGTON, June 20 Health insurer Aetna Inc  has made a takeover proposal to rival Humana Inc , the Wall Street Journal reported on Saturday. It gave no details.        (Reporting by Mohammad Zargham Editing by W Simon)   ",2015-06-20,AET,"Sat Jun 20, 2015 | 4:54pm EDT",Aetna Inc makes takeover proposal to Humana Inc -WSJ,http://www.reuters.com//article/humana-ma-aetna-idUSL1N0Z60JG20150620?type=companyNews
175,"  U.S. health insurer Aetna Inc (AET.N) is close to buying rival Humana Inc (HUM.N) and a deal could be signed as early as this weekend, Bloomberg reported, citing people familiar with the matter.Humana has also received an offer from Cigna Corp (CI.N), but Humana's board prefers the offer from Aetna, Bloomberg reported. Aetna and Humana were in talks, a source familiar with the matter told Reuters on Thursday, adding that there was no certainty Aetna would prevail. Cigna is also in the running, a second source confirmed to Reuters.Aetna made a formal cash-and-stock bid this week to buy Humana, Bloomberg said.Humana, which had a market value of $27.59 billion as of Thursday's close, was not immediately available for comment.  Aetna and Cigna declined to comment.Reuters has previously reported that Humana is in takeover talks with Aetna and Cigna.Bloomberg said discussions between Humana and Aetna intensified in the past few days after it emerged over the weekend that rivals Anthem Inc (ANTM.N) and Cigna had held merger talks of their own. Anthem said on Saturday it had offered $47 billion in cash and stock for smaller rival Cigna, who rebuffed the offer the next day.The intensifying talks come as insurers seek scale to trim administrative costs and negotiate lower prices with doctors, moves they say will make plans more affordable. Aetna's shares jumped 4.3 percent to a record $133.05 after the report, while Humana's shares were up 6.5 percent at $196.21 in afternoon trading.Cigna shares rose 2.7 percent to a record high of $170.20, before giving up some gains to trade up 1 pct at $167.51. (Reporting by Rosmi Shaji in Bengaluru and Olivia Oran and Gregory Roumeliotis in New York; Editing by Maju Samuel and Savio D'Souza)",2015-06-25,AET,"Thu Jun 25, 2015 | 5:55pm EDT",Aetna close to buying Humana: Bloomberg,http://www.reuters.com//article/us-humana-m-a-aetna-idUSKBN0P52G920150625?type=companyNews
176,"  (Adds Aetna comments)June 25 U.S. health insurer Aetna Inc is close to buying rival Humana Inc and a deal could be signed as early as this weekend, Bloomberg reported, citing people familiar with the matter.Humana has also received an offer from Cigna Corp, but Humana's board prefers the offer from Aetna, Bloomberg reported. (bloom.bg/1Cwt3fL)Aetna and Humana were in talks, a source familiar with the matter told Reuters on Thursday, adding that there was no certainty Aetna would prevail. Cigna is also in the running, a second source confirmed to Reuters.Aetna made a formal cash-and-stock bid this week to buy Humana, Bloomberg said. Humana, which had a market value of $27.59 billion as of Thursday's close, was not immediately available for comment.Aetna and Cigna declined to comment. Reuters has previously reported that Humana is in takeover talks with Aetna and Cigna.Bloomberg said discussions between Humana and Aetna intensified in the past few days after it emerged over the weekend that rivals Anthem Inc and Cigna had held merger talks of their own. Anthem said on Saturday it had offered $47 billion in cash and stock for smaller rival Cigna, who rebuffed the offer the next day.The intensifying talks come as insurers seek scale to trim administrative costs and negotiate lower prices with doctors, moves they say will make plans more affordable.Aetna's shares jumped 4.3 percent to a record $133.05 after the report, while Humana's shares were up 6.5 percent at $196.21 in afternoon trading.Cigna shares rose 2.7 percent to a record high of $170.20, before giving up some gains to trade up 1 pct at $167.51.   (Reporting by Rosmi Shaji in Bengaluru and Olivia Oran and Gregory Roumeliotis in New York; Editing by Maju Samuel and Savio D'Souza)",2015-06-25,AET,"Thu Jun 25, 2015 | 5:54pm EDT",UPDATE 2-Aetna close to buying Humana - Bloomberg,http://www.reuters.com//article/humana-ma-aetna-idUSL3N0ZB58Q20150625?type=companyNews
177,"  (Adds Altice, Aetna, Cinven, Daimler, Johnson Matthey, Mylan, Penn Virginia, Societe Generale, Total, Potash Corporation of Saskatchewan, Bezeq Israel Telecom)June 25 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Thursday:** European telecoms group Altice SA defended its bid for Bouygues Telecom and confirmed it valued France's no.3 mobile operator at ""a minimum of 10 billion euros"" ($11.2 billion).** The bidding war for Integrated Silicon Solution Inc  intensified with rival chipmaker Cypress Semiconductor Corp further sweetening its offer to $22.60 per share.Cypress's latest offer values the company at about $718 million, compared with $730.5 million offered by Uphill on June 23, based on shares outstanding as of May 1.** The owner of the Miami Dolphins football team is joining forces with Qatar to buy a controlling stake in Formula One in a deal that could be worth up to $8 billion and inject new leadership into a sport facing falling TV audiences and ticket sales.**  U.S. health insurer Aetna Inc is close to buying rival Humana Inc and a deal could be signed as early as this weekend, Bloomberg reported, citing people familiar with the matter.** Buyout group Cinven has agreed to acquire German laboratory operator Synlab from BC Partners  for 1.7-1.8 billion euros ($1.9-2.0 billion) including debt, three sources familiar with the deal said on Thursday.** Daimler, the world's largest truck maker, bought a minority stake in Seattle-based telematics provider Zonar Systems Inc on Thursday, the latest step by established vehicle manufacturers to gain know-how in the area of connectivity.** Specialty chemicals firm Johnson Matthey Plc  said it would sell its research chemicals unit to Thermo Fisher Scientific Inc for 256 million pounds ($403 million) in cash.** Private equity funds CVC and KKR are studying a bid for a ""meaningful"" stake in Endesa, the Spanish subsidiary of Italy energy group Enel, sources with knowledge of the matter said.Enel declined to comment but sources close to the company said it had no interest in selling part or all of its 70 percent stake in Endesa, which is currently valued at around 13 billion euros ($14.5 billion). Endesa also declined to comment. ** European Union competition regulators will decide by July 29 whether U.S. drugmaker Mylan should be allowed to go ahead with its $34-billion hostile bid for Perrigo, the European Commission said.** Oil and natural gas producer Magnum Hunter Resources Corp  said it expected to raise $600-$700 million by selling its 45.53 percent stake in its natural gas gathering subsidiary, Eureka Hunter Holdings.** French bank Societe Generale said on Thursday it had sold a 7.04 percent stake in business consultants Sopra Steria for around 111 million euros.** British Airways-owner IAG has offered concessions in an attempt to win European Union regulatory approval for its plan to acquire a 25 percent stake in Irish rival Aer Lingus, the European Commission said on Thursday.** Penn Virginia Corp's shares rose as much as 23 percent on Thursday following a report that BP Plc had offered to buy the U.S. oil and gas producer for $8 per share. ** China's three largest airline cargo carriers, Air China Cargo, China Cargo Airlines and China Southern Cargo, will merge to form Asia's largest freight transport company, a senior official at the Civil Aviation Administration of China was quoted as saying in media reports. The reports did not provide a timeline or valuation for the deal.** South Africa's second-biggest private education firm Advtech Ltd said it had received an ""unsolicited proposal"" from a third party that its board was obliged to consider.** French oil major Total is in talks to sell its gas pipeline in the UK's North Sea to ArcLight Capital partners, a U.S.-based private equity firm focused on energy infrastructure, Bloomberg reported citing people familiar with the matter.** Potash Corporation of Saskatchewan Inc is eyeing German peer K+S for a possible takeover bid, German newspaper Handelsblatt reported on Thursday, citing financial sources.** Hillhouse Capital Group, the hedge fund headed by Chinese billionaire Zhang Lei, is in talks with existing Xiaoju Kuaizhi investors to increase its stake in the Chinese ride-sharing firm, according to a person familiar with the matter. ** DS Smith Plc agreed to buy Spanish company Grupo Lantero's corrugated products business, a move that would help the recycled packaging maker significantly expand its market share in Spain.The 190-million-euro ($213 million) purchase, including assumed debt, would deliver a return on invested capital in the second year of ownership, DS Smith said.** Snack manufacturer Orion Corp has submitted a preliminary bid for British retailer Tesco's South Korean unit Homeplus, the maker of ""Choco Pie"" said in a regulatory filing on Thursday.** Private equity firms Affinity Equity Partners, Carlyle Group and CVC Capital Partners were among seven to eight preliminary bidders for Tesco's South Korean unit, a Korean newspaper reported on Thursday.** South African iron ore producer Assore said on Thursday it had bought out African Rainbow Minerals' (ARM)  50 percent stake in the country's Dwarsrivier chrome mine for 450 million rand ($37 million) to take full ownership.** Two Samsung Group firms are looking at options to boost shareholder returns on completion of their proposed $8 billion merger, people familiar with the matter said, as the companies seek to overcome opposition from a U.S. hedge fund.** France's Vivendi does not rule out increasing its stake in Telecom Italia after becoming the group's biggest investor with 14.9 percent, CEO Arnaud de Puyfontaine told daily Corriere della Sera in an interview on Thursday.** Indonesia's Rajawali Group said on Thursday it would want to hold at least 21 percent of Felda Global Ventures Holdings Bhd if the Malaysian firm decides to seek a controlling stake in Rajawali unit PT Eagle High Plantations Tbk .** Bezeq Israel Telecom, Israel's largest telecoms group, has completed a deal to take full control of its satellite TV unit YES after the communications regulator determined it would not harm competition in the multi-channel TV market.($1 = 0.8925 euros)($1 = 12.1177 rand)($1 = 3.7735 shekels)   (Compiled by Manya Venkatesh and Yashaswini Swamynathan in Bengaluru)",2015-06-25,AET,"Thu Jun 25, 2015 | 4:01pm EDT",Deals of the day- Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL3N0ZB3DV20150625?type=companyNews
178,"  (Corrects spelling of Bloomberg in headline)June 25 Health insurer Aetna Inc is close to buying rival Humana Inc, and a deal could be signed as early as this weekend, Bloomberg reported. Aetna made a formal bid this week to buy Humana in the form of cash and stock, Bloomberg reported, citing people familiar with the matter. (bloom.bg/1Cwt3fL) Humana has also received an offer from Cigna Corp, but the Humana board prefers the offer from Aetna, Bloomberg said. Humana and Aetna were not immediately available for comment.   (Reporting by Rosmi Shaji in Bengaluru; Editing by Maju Samuel)",2015-06-25,AET,"Thu Jun 25, 2015 | 2:15pm EDT",REFILE-Aetna close to buying Humana - Bloomberg,http://www.reuters.com//article/humana-ma-aetna-idUSL3N0ZB58820150625?type=companyNews
179,"  * Healthcare stocks lead Wall St up on Supreme Court ruling* Iran talks drag crude prices lower   (Updates trading, adds U.S. markets, changes byline, dateline, previous LONDON)By Rodrigo CamposNEW YORK, June 25 A Supreme Court ruling upholding tax subsidies boosted some U.S. healthcare stocks to fresh highs on Thursday, while key global equity markets were little changed following a proposal by Greece's creditors to avoid a Greek debt default.Oil prices fell on concerns over the possible impact of Greece's debt crisis on European energy demand and the prospect of Iranian oil adding to a global glut if sanctions are lifted.Greece's international creditors presented a cash-for-reform proposal to euro zone finance ministers in a showdown with Athens, after negotiations failed to yield a plan to avert a default.""There is still a bit of optimism left that a deal can be done ... A failure to reach a deal is certainly not priced into the market just yet,"" Peregrine & Black senior analyst Markus Huber said.Market participants had assumed this week that a deal would eventually be reached after European officials said on Monday and Tuesday a proposal from Greece was a good basis for talks.The differences between Greece's proposal and that of its creditors aren't big enough to justify failing to reach an agreement, a senior Greek government official said. On Wall Street, hospital and other healthcare shares surged, with several hitting all-time peaks, after the U.S. Supreme Court upheld tax subsidies that are key to President Barack Obama's signature healthcare law.""The hospital stocks all reacted positively to the news, which isn't a surprise. While any change in policy would've been a surprise, affirming the status quo removes a lot of uncertainty from the sector,"" said Michael O'Rourke, chief market strategist at JonesTrading in Greenwich, Connecticut.The Dow Jones industrial average rose 25.12 points, or 0.14 percent, to 17,991.19, the S&P 500 gained 4.76 points, or 0.23 percent, to 2,113.34 and the Nasdaq Composite  added 13.96 points, or 0.27 percent, to 5,136.37.The pan-European FTSEurofirst 300 index was down 0.2 percent. An MSCI gauge of major global markets added less than 0.1 percent. OIL SLIDES In commodities markets, crude prices fell, with traders eyeing progress toward a June 30 deadline for an Iran nuclear accord that would be key to lifting Western sanctions on Tehran's oil exports.""Even if it does take Iran a year or more to return output and exports to pre-sanctions levels, the anticipation of this additional supply should still affect prices now,"" Capital Economics said.""The prospect of another 1 million bpd increase in supply from Iran ... could easily drag (Brent) prices below $60 again."" Brent fell 0.7 percent to $62.99 a barrel and U.S. crude was down 1 percent at $59.68 a barrel.Spot gold edged lower, down for a fifth straight session, while copper prices rose 0.3 percent.EURO HOLDS The euro was little changed against the U.S. dollar, even after data showed U.S. consumer spending recorded its largest increase in nearly six years on strong demand for automobiles and other big-ticket items.The euro was down 0.07 percent at $1.1197.""Watching Greek headlines. That's kind of holding markets back,"" said Vassili Serebriakov, currency strategist at BNP Paribas in New York.""This week we have seen appetite to start rebuilding dollar long positions,"" he said. ""Markets are feeling more confident that U.S. data is rebounding and the dollar will do well.""U.S. benchmark 10-year Treasury notes were last down 14/32 to yield 2.4197 percent, from a yield of 2.371 percent late Wednesday.   (Additional reporting by Ryan Vlastelica, Dan Bases, Sam Forgione, Barani Krishnan and European desks; Editing by Bernadette Baum)",2015-06-25,AET,"Thu Jun 25, 2015 | 12:27pm EDT",GLOBAL MARKETS-Stocks little changed with eyes on Greece; oil off,http://www.reuters.com//article/markets-global-idUSL8N0ZB3DS20150625?type=companyNews
180,"  BRUSSELS, July 2 The following are mergers under review by the European Commission and a brief guide to the EU merger process:APPROVALS AND WITHDRAWALS -- China National Chemical Corp to acquire Italian tyre maker Pirelli (approved July 1)NEW LISTINGS -- U.S. healthcare company Danaher Corp to acquire air and water filter maker Pall Corp (notified July 1/deadline Aug. 6/simplified)-- Swiss travel retailer Dufry to acquire Italian peer World Duty Free (notified July 1/deadline Aug 6)-- Private equity firm Cinven Capital Management to acquire biological testing services company Labco (notified June 29/deadline Aug. 4/simplified)EXTENSIONS AND OTHER CHANGES NoneFIRST-STAGE REVIEWS BY DEADLINE JULY 8 -- Aberdeen Infrastructure to acquire a stake in a hospital concession from Globalvia Infraestructuras (notified June 3/deadline July 8)-- Private equity firm Pamplona Capital Management to buy pet food supplier Partner in Pet Food Holdings (notified June 3/deadline July 8/simplified)-- U.S. investment company OpenGate Capital Group Europe to acquire chemicals producer Kem One Innovative Vinyls (notified June 3/deadline July 8)JULY 10 -- France's Jacquet Metal Service to acquire Swiss steel group Schmolz + Bickenbach's steel distribution business in Germany, Belgium, the Netherlands and Austria (notified June 5/deadline July 10)-- U.S. trading group Castleton Commodities International to acquire Morgan Stanley's physical oil business (notified June 5/deadline July 10/simplified)JULY 14 -- Asset management company FAM, which is owned by Sweden's Wallenberg foundations, and Luxembourg-based investment company Fanopi to acquire joint control of Swedish packaging company Nefab Packaging AB (notified June 9/deadline July 14)-- Japan's Mitsui & Co and Holding Gonvarri, which is part of the Spanish conglomerate Gestamp to acquire joint control of Gestamp Renewable Industries, which is now solely controlled by Holding Gonvarri (notified June 9/deadline July 14/simplified)-- Private equity firm Clayton, Dubilier & Rice Group to acquire British petrol station operator Scimitar Topco Ltd (notified June 9/deadline July 14/simplified) JULY 15 -- British Airways-owner IAG's to acquire Irish airline Aer Lingus (notified May 27/deadline extened to July 15 from July 1 after IAG offered concessions)JULY 17 -- Australian drugmaker CSL to acquire Swiss drugmaker Novartis' influenza vaccines business (notified June 12/deadline July 17)-- U.S. private equity firm KKR plan to buy controlling stake in Ursa Insulation Holding BV from Spanish building materials group Uralita (notified June 12/deadline July 17/simplified)-- U.S. private equity firm Platinum Equity plan to buy aviation company Worldwide Flight Services Global Holding (notified June 12/deadline July 17/simplified)JULY 20 -- U.S. drinks can maker Ball Corp to acquire British rival Rexam Plc (notified June 15/deadline July 20)-- U.S. drugmaker Pfizer to acquire U.S. peer Hospira (notified June 15/deadline July 20)JULY 22 -- French building supplies company St Gobain to acquire Swiss chemicals company Sika (notified June 16/deadline July 22)-- Private equity firms Ardian France and Goldentree Asset Management to acquire joint control of do-it-yourself retailer Maxeda DIY Group (notified June 16/deadline July 22/simplified) -- Haring Central department store to acquire 50.1 percent of KS Premium Holding (notified June 16/deadline July 22/simplified)JUNE 23 -- Meat products group Danish Crown to acquire Danish peer Tican (notified June 3/deadline extended to July 23 from July 8 after the Danish competition regulator asked to review the case)-- Private equity firm CVC Capital Partners to acquire a 65 percent stake in Dutch food and dietary supplements maker DSM  (notified June 17/deadline July 23)JULY 27 -- Swiss supermarket chain Coop Genossenschaft and Swisscom to set up an online joint venture (notified June 19/deadline July 27/simplified)-- Finnish telecoms equipment maker Nokia to acquire French peer Alcatel-Lucent (notified June 19/deadline July 27)JULY 29 -- U.S. drugmaker Mylan to acquire U.S. peer Perrigo  (notified June 23/deadline July 29)-- U.S. company Berkshire Hathaway to acquire U.S. personal care and cosmetics company Procter & Gamble's  Duracell battery unit (notified June 23/deadline July 29) JULY 30 -- Swedish insurer AMF Pensionsforsakring AB and Finnish insurer Ilmarinen Mutual Pension Insurance Company to set up a joint venture (notified June 24/deadline July 30/simplified)-- Schibsted Distribution Amedia Distribution Helthjem (notified June 24/deadline July 30/simplified)AUG 5 -- Asset manager BlackRock and private equity firm First Reserve Management to acquire joint control of a joint venture building a gas pipeline in Mexico, in which GDF Suez holds a stake (notified June 30/deadline Aug. 5/simplified)-- Spanish cars part maker Grupo Antolin to acquire auto parts maker Magna Interiors from Canadian car parts maker Magna International Inc (notified June 30/deadline Aug. 5)AUG 6 -- Commodities trader Cargill to buy rival Archer Daniels Midland Co's global chocolate business (notified Jan. 19/deadline Aug. 6/Cargill offers concessions on May 22)AUG 21 -- U.S. conglomerate General Electric to acquire most of French engineering group Alstom's power equipment business (notified Jan. 19/deadline extended for the third time to Aug. 21 from Aug. 6)SEPT 2 -- Norwegian telecoms company Telenor and Swedish peer TeliaSonera to combine their Danish mobile businesses (notified Feb. 27/deadline extended to Sept. 2 from Aug. 19 after the companies asked for more time)SUSPENDED -- SOCAR, Azerbaijan's state energy company, to buy stakes in Greek natural gas grid operator DESFA from Greek natural gas utility DEPA (notified Oct. 1/deadline suspended on Jan. 21)GUIDE TO EU MERGER PROCESS DEADLINES: The European Commission has 25 working days after a deal is  filed for a first-stage review. It may extend that by 10 working days to 35 working days, to consider either a company's proposed remedies or an EU member state's request to handle the case.Most mergers win approval but occasionally the Commission  opens a detailed second-stage investigation for up to 90  additional working days, which it may extend to 105 working  days.SIMPLIFIED: Under the simplified procedure, the Commission announces the clearance of uncontroversial first-stage mergers without giving any reason for its decision. Cases may be reclassified as non-simplified - that is, ordinary first-stage reviews - until they are approved.   (Compiled by Foo Yun Chee)",2015-07-02,AET,"Thu Jul 2, 2015 | 10:18am EDT",EU mergers and takeovers (July 2),http://www.reuters.com//article/eu-mergers-idUSL8N0ZI20H20150702?type=companyNews
181,"  (Adds no comment from Cigna, regulators involved in deal, paragraphs 2, 8)By Luciana LopezNEW YORK, July 3 Aetna Inc's $37 billion deal to buy smaller health insurer Humana Inc will face rigorous scrutiny from U.S. regulators, which antitrust experts said could also make other large-scale mergers in the sector more difficult.The Aetna-Humana tie-up would be the largest such deal among health insurers. Friday's announcement starts the clock on an examination by regulators of whether consumers will be hurt by diminished competition. Competition regulators include the Department of Justice and various state-level agencies.The deal follows weeks of intense discussions about potential combinations among the five biggest U.S. health insurers: Aetna, Humana, Cigna Corp, Anthem Inc  and UnitedHealth Group.Insurers want more leverage in a healthcare system that has seen major consolidation among hospitals and doctor practices, as well as mergers between medical device makers and other suppliers. The cost of new drugs has soared, and President Barack Obama's healthcare law has made it harder for insurers to pass on higher costs to customers.Last month, Anthem offered to buy Cigna for $47 billion. The combined company would have surpassed UnitedHealth to become the single largest U.S. health insurer.Cigna, which had also considered purchasing Humana, has so far rejected the buyout approach. Some industry watchers expect a potential buyout of Cigna to be revived after Aetna's deal.Industry sources said Cigna and Anthem may have just a few months to sign a deal if they want it to be considered by antitrust authorities along with the Aetna-Humana deal. Cigna declined to comment about the Aetna-Humana deal. Anthem said it had nothing to say about other potential mergers.Regulators ""should be exceedingly skeptical of this deal"" between Aetna and Humana, said Diana Moss, president of the American Antritrust Institute. ""Depending on who merges and the change to the market structure, that affects the concerns about the competition.""Aetna said it is ready to address regulatory concerns.""Obviously this is something that we expect will get a thorough and careful review,"" Shawn Guertin, Aetna's chief financial officer, said in an interview. ""We've spent a lot of time looking at this at a fairly detailed level, and we certainly think that's a manageable situation."" Guertin conceded that a combined company could have some overlap, but declined to name possible divestitures that regulators might seek.""We're in the same business at the highest level, and so there certainly is an overlap in that regard,"" he said.""It's really about local markets,"" Guertin said. RECENT DEALS SCUTTLED Antitrust experts said a regulatory review of Aetna and Humana could also factor in whether there is another major deal in the industry.Regulators are expected to scrutinize how competition in local markets will be affected for each line of insurance: Medicare for the elderly, Medicaid for the poor, individual insurance, commercial insurance for small and large business and the large employer business.Regulators have recently scuttled deals in other industries that would have created mega players. In April, Comcast Corp abandoned its $45 billion offer for Time Warner Cable Inc because of antitrust worries.This month, the U.S. Justice Department sued to stop Sweden's Electrolux AB from buying General Electric Co's appliance business.""Agencies are becoming increasingly skeptical about whether you can remedy anti-competitive mergers by having some kind of divestiture,"" said David Balto, formerly the policy director of the Bureau of Competition of the Federal Trade Commission.Mergers might give insurers more punch to negotiate lower prices with pharmaceutical companies, Balto said. But he called that a ""Faustian bargain.""""Maybe they have more buying power, but then they're going to have more selling power.""   (Additional reporting by Caroline Humer and Gregory Roumeliotis; Editing by David Gregorio)",2015-07-03,AET,"Fri Jul 3, 2015 | 4:46pm EDT",UPDATE 1-Aetna's Humana deal to bring scrutiny on other insurer tie-ups -experts,http://www.reuters.com//article/healthcare-ma-regulator-idUSL1N0ZJ10J20150703?type=companyNews
182,"   By Luciana Lopez | NEW YORK  NEW YORK Aetna Inc's (AET.N) $37 billion deal to buy smaller health insurer Humana Inc (HUM.N) will face rigorous scrutiny from U.S. regulators, which antitrust experts said could also make other large-scale mergers in the sector more difficult. The Aetna-Humana tie-up would be the largest such deal among health insurers. Friday's announcement starts the clock on an examination by regulators of whether consumers will be hurt by diminished competition.The deal follows weeks of intense discussions about potential combinations among the five biggest U.S. health insurers: Aetna, Humana, Cigna Corp (CI.N), Anthem Inc (ANTM.N) and UnitedHealth Group (UNH.N).  Insurers want more leverage in a healthcare system that has seen major consolidation among hospitals and doctor practices, as well as mergers between medical device makers and other suppliers. The cost of new drugs has soared, and President Barack Obama's healthcare law has made it harder for insurers to pass on higher costs to customers. Last month, Anthem offered to buy Cigna for $47 billion. The combined company would have surpassed UnitedHealth to become the single largest U.S. health insurer.Cigna, which had also considered purchasing Humana, has so far rejected the buyout approach. Some industry watchers expect a potential buyout of Cigna to be revived after Aetna's deal. Industry sources said Cigna and Anthem may have just a few months to sign a deal if they want it to be considered by antitrust authorities along with the Aetna-Humana deal.Cigna did not respond to a request for comment about the Aetna-Humana deal. Anthem said it had nothing to say about other potential mergers.  Regulators ""should be exceedingly skeptical of this deal"" between Aetna and Humana, said Diana Moss, president of the American Antritrust Institute. ""Depending on who merges and the change to the market structure, that affects the concerns about the competition."" Aetna said it is ready to address regulatory concerns.""Obviously this is something that we expect will get a thorough and careful review,"" Shawn Guertin, Aetna's chief financial officer, said in an interview. ""We've spent a lot of time looking at this at a fairly detailed level, and we certainly think that's a manageable situation. Guertin conceded that a combined company could have some overlap, but declined to name possible divestitures that regulators might seek.""We're in the same business at the highest level, and so there certainly is an overlap in that regard,"" he said. ""It's really about local markets,"" Guertin said.RECENT DEALS SCUTTLED  Antitrust experts said a regulatory review of Aetna and Humana could also factor in whether there is another major deal in the industry.  Regulators are expected to scrutinize how competition in local markets will be affected for each line of insurance: Medicare for the elderly, Medicaid for the poor, individual insurance, commercial insurance for small and large business and the large employer business.Regulators have recently scuttled deals in other industries that would have created mega players. In April, Comcast Corp abandoned its $45 billion offer for Time Warner Cable Inc because of antitrust worries. This month, the U.S. Justice Department sued to stop Sweden's Electrolux AB from buying General Electric Co's appliance business. ""Agencies are becoming increasingly skeptical about whether you can remedy anti-competitive mergers by having some kind of divestiture,"" said David Balto, formerly the policy director of the Bureau of Competition of the Federal Trade Commission. Mergers might give insurers more punch to negotiate lower prices with pharmaceutical companies, Balto said. But he called that a ""Faustian bargain."" ""Maybe they have more buying power, but then they're going to have more selling power."" (Additional reporting by Caroline Humer and Gregory Roumeliotis; Editing by David Gregorio)",2015-07-03,AET,"Fri Jul 3, 2015 | 4:28pm EDT",Aetnas Humana deal to bring scrutiny on other insurer tie-ups,http://www.reuters.com//article/us-healthcare-m-a-regulator-idUSKCN0PD28X20150703?type=companyNews
183,"   By Luciana Lopez | NEW YORK, July 3  NEW YORK, July 3 Aetna Inc's $37 billion deal to buy smaller health insurer Humana Inc will face rigorous scrutiny from U.S. regulators, which antitrust experts said could also make other large-scale mergers in the sector more difficult.The Aetna-Humana tie-up would be the largest such deal among health insurers. Friday's announcement starts the clock on an examination by regulators of whether consumers will be hurt by diminished competition.The deal follows weeks of intense discussions about potential combinations among the five biggest U.S. health insurers: Aetna, Humana, Cigna Corp, Anthem Inc  and UnitedHealth Group.Insurers want more leverage in a healthcare system that has seen major consolidation among hospitals and doctor practices, as well as mergers between medical device makers and other suppliers. The cost of new drugs has soared, and President Barack Obama's healthcare law has made it harder for insurers to pass on higher costs to customers.Last month, Anthem offered to buy Cigna for $47 billion. The combined company would have surpassed UnitedHealth to become the single largest U.S. health insurer.Cigna, which had also considered purchasing Humana, has so far rejected the buyout approach. Some industry watchers expect a potential buyout of Cigna to be revived after Aetna's deal.Industry sources said Cigna and Anthem may have just a few months to sign a deal if they want it to be considered by antitrust authorities along with the Aetna-Humana deal.Cigna did not respond to a request for comment about the Aetna-Humana deal. Anthem said it had nothing to say about other potential mergers. Regulators ""should be exceedingly skeptical of this deal"" between Aetna and Humana, said Diana Moss, president of the American Antritrust Institute. ""Depending on who merges and the change to the market structure, that affects the concerns about the competition.""Aetna said it is ready to address regulatory concerns.""Obviously this is something that we expect will get a thorough and careful review,"" Shawn Guertin, Aetna's chief financial officer, said in an interview. ""We've spent a lot of time looking at this at a fairly detailed level, and we certainly think that's a manageable situation.""Guertin conceded that a combined company could have some overlap, but declined to name possible divestitures that regulators might seek. ""We're in the same business at the highest level, and so there certainly is an overlap in that regard,"" he said.""It's really about local markets,"" Guertin said.RECENT DEALS SCUTTLED  Antitrust experts said a regulatory review of Aetna and Humana could also factor in whether there is another major deal in the industry.Regulators are expected to scrutinize how competition in local markets will be affected for each line of insurance: Medicare for the elderly, Medicaid for the poor, individual insurance, commercial insurance for small and large business and the large employer business.Regulators have recently scuttled deals in other industries that would have created mega players. In April, Comcast Corp abandoned its $45 billion offer for Time Warner Cable Inc because of antitrust worries.This month, the U.S. Justice Department sued to stop Sweden's Electrolux AB from buying General Electric Co's appliance business.""Agencies are becoming increasingly skeptical about whether you can remedy anti-competitive mergers by having some kind of divestiture,"" said David Balto, formerly the policy director of the Bureau of Competition of the Federal Trade Commission.Mergers might give insurers more punch to negotiate lower prices with pharmaceutical companies, Balto said. But he called that a ""Faustian bargain.""""Maybe they have more buying power, but then they're going to have more selling power.""   (Additional reporting by Caroline Humer and Gregory Roumeliotis; Editing by David Gregorio)",2015-07-03,AET,"Fri Jul 3, 2015 | 4:13pm EDT",Aetna's Humana deal to bring scrutiny on other insurer tie-ups -experts,http://www.reuters.com//article/healthcare-ma-regulator-idUSL1N0ZJ0U520150703?type=companyNews
184,"   By Greg Roumeliotis  Health insurer Aetna Inc (AET.N) on Friday said it would buy smaller rival Humana Inc (HUM.N) for about $37 billion in cash and stock, in the largest ever deal in the insurance industry.The combination will push Aetna close to Anthem Inc's (ANTM.N) No.2 insurer spot by membership, and would nearly triple Aetna's Medicare Advantage business.The deal will face antitrust scrutiny but if it goes through it would dwarf the previous largest insurance deal announced just this week, where Swiss property and casualty giant ACE Ltd (ACE.N) announced it was buying Chubb Corp (CB.N) for $28 billion. It would also dwarf Anthem Inc's purchase of WellPoint in 2004 for $16.6 billion.Analysts have said that M&A activity in the healthcare sector had been waiting for last week's Supreme Court ruling on Obamacare, which upheld key subsidies that underpin the reform and thus gave more certainty to healthcare insurers.The bigger the insurer, the more power it has negotiating prices and improving its doctor networks.Anthem has offered to buy Cigna Corp (CI.N) to create the largest insurer in the country, toppling UnitedHealth Group Inc (UNH.N).Media reports have also said UnitedHealth could be eyeing Cigna and Aetna. On Thursday, Centene Corp (CNC.N) said it would buy smaller rival Health Net Inc HNT.N for $6.3 billion.ANTITRUST ISSUES Antitrust authorities, who were aggressive in their review of the failed deal between Comcast (CMCSA.O) and Time Warner Cable TWC.N, are expected to scrutinize how the combination of insurers will affect competition for each line of insurance: Medicare, Medicaid for the poor, individual insurance, commercial insurance for small and large businesses and the large employer business. Aetna and Humana are in nine of the same states in Medicare Advantage. Combined, they would have market share of 88 percent in Kansas, 80 percent in West Virginia, 58 percent in Iowa and 51 percent in Missouri.    Wall Street analysts and some antitrust experts have said  they expect the combination will be approved, although regulators may ask for some divestitures. Others have said it is unclear that this group of regulators will stick to the usual review playbook for such a large deal and may add other restrictions. The Justice Department, which reviews insurance mergers, will scrutinize deals city-by-city to see if the combination would have a monopoly in any metropolitan area, said Andre Barlow, a veteran of the department who is now at Washington law firm Doyle, Barlow and Mazard PLLC.Aetna said the combined company is projected to have over 33 million medical members, based on memberships as of March 31. Operating revenue is expected to be about $115 billion this year, with approximately 56 percent from government-sponsored programs including Medicare and Medicaid.Last week, the U.S. Supreme Court upheld subsidies for individuals under President Barack Obama's signature healthcare law, keeping a large chunk of patients intact under the Medicare and Medicaid programs.Insurers have said subsidies are key to bringing in new customers and the ruling has removed uncertainty for insurers looking for acquisitions. It could also spur more deal making in the health insurance sector, which has already seen a blitz of merger activity this year. U.S. Senate Majority Leader Mitch McConnell, of Kentucky, praised Humana's presence in his home state but also noted the role of the healthcare law in the merger.""This morning's announcement, as I predicted during the debate five years ago, is the inevitable result of Obamacares push toward consolidation as doctors, hospitals, and insurers merge in response to an ever-growing government,"" the Republican said in a statement.The deal includes a $1 billion break-up fee payable by Aetna to Humana, should the deal fail because of antitrust concerns, an Aetna spokeswoman confirmed. The fee was first reported by the Wall Street Journal. CASH AND SHARES Hartford, Conn.-based Aetna said it would pay Humana shareholders $125 in cash and 0.8375 Aetna shares for each share held. The offer of about $230 per share is a 23 percent premium to Humana's closing price on Thursday.Following the deal, Aetna shareholders would own about 74 percent of the combined company with Humana shareholders owning the rest. Aetna Chief Executive Mark Bertolini will serve as chairman and CEO of the combined company. The deal is expected to close in the second half of 2016 and add to operating earnings per share from 2017.Humana's sale has been anticipated since May when it was first reported that Cigna Corp (CI.N) and Aetna were interested, and multiple sources confirmed to Reuters that the company was entertaining offers. Humana, based in Louisville, Kentucky, has been under pressure for more than a year from investors, which include activist fund Glenview Capital Management, to produce higher returns.   Last year Humana hired a CFO from investment bank Goldman Sachs and went through a strategic review that included asset sales. But it missed several quarters of earnings targets and struggled with profits in its individual business, disappointing Wall Street.Aetna said it has received commitments from Citi and UBS Investment Bank to finance the deal.Citi and Lazard are financial advisers for Aetna and Davis Polk & Wardwell LLP is its legal adviser. Goldman Sachs is the financial adviser to Humana, while Fried, Frank, Harris, Shriver & Jacobson LLP is its legal adviser. (Additional reporting by Rama Venkat Raman in Bengaluru and Caroline Humer in New York; Editing by Ken Wills and Andrea Ricci)",2015-07-03,AET,"Fri Jul 3, 2015 | 12:32pm EDT",Aetna to buy Humana for $37 billion in largest insurance deal,http://www.reuters.com//article/us-humana-m-a-aetna-idUSKCN0PD04720150703?type=companyNews
185,"  (Adds break-up fee)By Greg RoumeliotisJuly 3 Health insurer Aetna Inc on Friday said it would buy smaller rival Humana Inc for about $37 billion in cash and stock, in the largest ever deal in the insurance industry.The combination will push Aetna close to Anthem Inc's  No.2 insurer spot by membership, and would nearly triple Aetna's Medicare Advantage business.The deal will face antitrust scrutiny but if it goes through it would dwarf the previous largest insurance deal announced just this week, where Swiss property and casualty giant ACE Ltd  announced it was buying Chubb Corp for $28 billion. It would also dwarf Anthem Inc's purchase of WellPoint in 2004 for $16.6 billion.Analysts have said that M&A activity in the healthcare sector had been waiting for last week's Supreme Court ruling on Obamacare, which upheld key subsidies that underpin the reform and thus gave more certainty to healthcare insurers.The bigger the insurer, the more power it has negotiating prices and improving its doctor networks.Anthem has offered to buy Cigna Corp to create the largest insurer in the country, toppling UnitedHealth Group Inc .Media reports have also said UnitedHealth could be eyeing Cigna and Aetna. On Thursday, Centene Corp said it would buy smaller rival Health Net Inc for $6.3 billion.ANTITRUST ISSUES  Antitrust authorities, who were aggressive in their review of the failed deal between Comcast and Time Warner Cable, are expected to scrutinize how the combination of insurers will affect competition for each line of insurance: Medicare, Medicaid for the poor, individual insurance, commercial insurance for small and large businesses and the large employer business.Aetna and Humana are in nine of the same states in Medicare Advantage. Combined, they would have market share of 88 percent in Kansas, 80 percent in West Virginia, 58 percent in Iowa and 51 percent in Missouri.Wall Street analysts and some antitrust experts have said  they expect the combination will be approved, although regulators may ask for some divestitures.Others have said it is unclear that this group of regulators will stick to the usual review playbook for such a large deal and may add other restrictions.The Justice Department, which reviews insurance mergers, will scrutinize deals city-by-city to see if the combination would have a monopoly in any metropolitan area, said Andre Barlow, a veteran of the department who is now at Washington law firm Doyle, Barlow and Mazard PLLC.Aetna said the combined company is projected to have over 33 million medical members, based on memberships as of March 31. Operating revenue is expected to be about $115 billion this year, with approximately 56 percent from government-sponsored programs including Medicare and Medicaid. Last week, the U.S. Supreme Court upheld subsidies for individuals under President Barack Obama's signature healthcare law, keeping a large chunk of patients intact under the Medicare and Medicaid programs.Insurers have said subsidies are key to bringing in new customers and the ruling has removed uncertainty for insurers looking for acquisitions. It could also spur more deal making in the health insurance sector, which has already seen a blitz of merger activity this year.U.S. Senate Majority Leader Mitch McConnell, of Kentucky, praised Humana's presence in his home state but also noted the role of the healthcare law in the merger.""This morning's announcement, as I predicted during the debate five years ago, is the inevitable result of Obamacare's push toward consolidation as doctors, hospitals, and insurers merge in response to an ever-growing government,"" the Republican said in a statement.The deal includes a $1 billion break-up fee payable by Aetna to Humana, should the deal fail because of antitrust concerns, an Aetna spokeswoman confirmed. The fee was first reported by the Wall Street Journal. CASH AND SHARES Hartford, Conn.-based Aetna said it would pay Humana shareholders $125 in cash and 0.8375 Aetna shares for each share held. The offer of about $230 per share is a 23 percent premium to Humana's closing price on Thursday.Following the deal, Aetna shareholders would own about 74 percent of the combined company with Humana shareholders owning the rest. Aetna Chief Executive Mark Bertolini will serve as chairman and CEO of the combined company.The deal is expected to close in the second half of 2016 and add to operating earnings per share from 2017.Humana's sale has been anticipated since May when it was first reported that Cigna Corp and Aetna were interested, and multiple sources confirmed to Reuters that the company was entertaining offers.Humana, based in Louisville, Kentucky, has been under pressure for more than a year from investors, which include activist fund Glenview Capital Management, to produce higher returns.Last year Humana hired a CFO from investment bank Goldman Sachs and went through a strategic review that included asset sales. But it missed several quarters of earnings targets and struggled with profits in its individual business, disappointing Wall Street.Aetna said it has received commitments from Citi and UBS Investment Bank to finance the deal.Citi and Lazard are financial advisers for Aetna and Davis Polk & Wardwell LLP is its legal adviser. Goldman Sachs is the financial adviser to Humana, while Fried, Frank, Harris, Shriver & Jacobson LLP is its legal adviser.   (Additional reporting by Rama Venkat Raman in Bengaluru and Caroline Humer in New York; Editing by Ken Wills and Andrea Ricci)",2015-07-03,AET,"Fri Jul 3, 2015 | 12:28pm EDT",UPDATE 7-Aetna to buy Humana for $37 bln in largest insurance deal,http://www.reuters.com//article/humana-ma-aetna-idUSL1N0ZJ07920150703?type=companyNews
186,"  July 3 Health insurer Aetna Inc said it will buy Humana Inc for about $37 billion, or about $230 per share, in a cash-and-stock deal.Humana shareholders will receive $125 in cash and 0.8375 Aetna shares for each share held, an about 23 percent premium to the stock's closing price on Thursday.  Following the deal, Aetna's shareholders would own about 74 percent of the combined company.   (Reporting by Rama Venkat Raman in Bangalore; Editing by Gopakumar Warrier) ",2015-07-03,AET,"Fri Jul 3, 2015 | 2:33am EDT",Aetna to buy Humana for $37 bln in cash and stock,http://www.reuters.com//article/humana-ma-aetna-idUSL3N0ZJ2D320150703?type=companyNews
187,"  (Fixes Humana's location to Louisville, not Lexington, in 7th paragraph)By Greg RoumeliotisJuly 2 U.S health insurer Aetna Inc is nearing an agreement to buy rival Humana Inc for about $34 billion in a cash and stock deal, people familiar with the matter told Reuters on Thursday.One person said Aetna's offer would value Humana at about $230 per share and that a deal could be announced as early as Friday.The offer, if it goes through, would make it the largest deal in the insurance industry, dwarfing Anthem Inc's  acquisition of WellPoint in 2004 for $16.6 billion.A $230 per share offer would be at a premium of nearly 23 percent to Humana's close on the New York Stock Exchange on Thursday.Representatives from Humana and Aetna declined to comment. Humana's sale has been anticipated since May when it was first reported that Cigna Corp and Aetna were interested, and multiple sources confirmed to Reuters that the company was entertaining offers.Humana, based in Louisville, Kentucky, has been under pressure for more than a year from investors, who include activist fund Glenview Capital Management, to produce higher returns.Last year Humana hired a CFO from investment bank Goldman Sachs and went through a strategic review that included asset sales. But it missed several quarters of earnings targets and struggled with profits in its individual business, disappointing Wall Street. A deal would push Hartford, Conn.-based Aetna close to Anthem's No. 2 insurer spot by membership, and would nearly triple Aetna's Medicare Advantage business.The company's Medicare Advantage business offers government paid insurance for older people and the disabled to about 4.6 million customers. ANTITRUST ISSUES Antitrust authorities, who were aggressive in their review of the failed deal between Comcast and Time Warner Cable, are expected to scrutinize how the combination of insurers will affect competition for each line of insurance: Medicare, Medicaid for the poor, individual insurance, commercial insurance for small and large businesses and the large employer business.Aetna and Humana are in nine of the same states in Medicare Advantage. Combined, they would have market share of 88 percent in Kansas, 80 percent in West Virginia, 58 percent in Iowa and 51 percent in Missouri.Wall Street analysts and some antitrust experts have said  they expect the combination will be approved, although regulators may ask for some divestitures. Others have said it is unclear that this group of regulators will stick to the usual review playbook for such a large deal and may add other restrictions.The Justice Department, which reviews insurance mergers, will scrutinize any possible deal city-by-city to see if the combination would have a monopoly in any metropolitan area, said Andre Barlow, a veteran of the Justice Department who is now at Washington law firm Doyle, Barlow and Mazard PLLC.   (Reporting by Rosmi Shaji and Aurindom Mukherjee and Rama Venkat Raman in Bengaluru; Editing by Ken Wills)",2015-07-03,AET,"Fri Jul 3, 2015 | 1:30am EDT",CORRECTED-UPDATE 4-Aetna nears deal to buy Humana for about $34 bln -sources,http://www.reuters.com//article/humana-ma-aetna-idUSL1N0ZJ01T20150703?type=companyNews
188,"  July 2 U.S health insurer Aetna Inc is nearing an agreement to buy rival Humana Inc in a cash and stock deal, two people familiar with the matter told Reuters on Thursday.One source said Aetna's offer would value Humana at about $230 per share and could be announced as early as Friday. Earlier, Bloomberg reported the expected deal was valued at about $34 billion, citing unnamed sources. (bloom.bg/1GShqBy)  The $230 per share offer is at a premium of nearly 23 percent to Humana's close on the New York Stock Exchange on Thursday.   (Reporting by Rosmi Shaji in Bengaluru; Editing by Ken Wills) ",2015-07-03,AET,"Thu Jul 2, 2015 | 9:30pm EDT",Aetna nears deal to buy Humana at $230 a share -sources,http://www.reuters.com//article/humana-ma-aetna-idUSL3N0ZJ0GA20150703?type=companyNews
189,"   By Caroline Humer | NEW YORK  NEW YORK Aetna Inc's chief executive said Monday he was confident any antitrust review of the health insurer's proposed purchase of smaller rival Humana Inc  would allow the deal to close in the second half of 2016.Mark Bertolini said Aetna had already prepared for possible divestitures to address overlaps with Humana's business in the largest-ever U.S. health insurance deal. The two sides announced the $37 billion transaction on Friday. Hospital and state officials said they would take a hard look at whether the deal would diminish competition for consumers.""We took a conservative view of what we would need to divest,"" Bertolini said during an investor conference call.Aetna has not discussed the deal directly with the U.S. Department of Justice, but has consulted with regulatory experts, Bertolini told cable channel CNBC.""We believe that given the legal advice we have...that this is a very manageable transaction,"" he said.The bigger the insurer, the more power it has negotiating prices with hospitals and other providers, as well as improving its doctor networks. Aetna and Humana are in nine of the same states in one of their key businesses - Medicare Advantage plans for the elderly. Combined, they would have market share of 88 percent in Kansas, 80 percent in West Virginia, 58 percent in Iowa and 51 percent in Missouri.Regulators would also look for the impact on competition in each local market for the companies' Medicaid plans for the poor, individual insurance, commercial insurance for small and large businesses and the large employer business.Attorneys general in several U.S. states said on Monday they would be ready to review the proposed deal. ""Our office is aware of these mergers, and we will be looking to determine whether or not there's any significant impact on Massachusetts,"" said Chloe Gotsis, a spokeswoman for the state AG's office.Healthcare providers are concerned that further consolidation will decrease competition in the insurance industry, said Alicia Mitchell, spokeswoman for the American Hospital Association.""Any potential deal of this magnitude needs rigorous scrutiny. That's why the AHA will call upon the DOJ and Congress to exercise a significant level of scrutiny,"" Mitchell said in an emailed statement. Health insurers have been in a race to consolidate, saying that being larger would help them negotiate better prices with doctors and hospitals as well as cut administrative costs.No. 2 health insurer Anthem Inc has offered to buy No. 5 Cigna Corp. The two companies have revived discussions in light of the Humana-Aetna deal, though it is not clear whether they can agree on terms including price and governance issues, sources familiar with the matter have told Reuters.If an Anthem-Cigna deal is announced within the next two to three months, regulators could look at the impact of both mergers at the same time, Bertolini said.""It really depends on whether or not any other deals are announced,"" he told investors. ""Currently we anticipate that our transaction will be viewed alone at this point in time, but they could be bundled together at some point.""Aetna shares fell 6.4 percent to $117.43 on Monday as investors took stock of the regulatory and financial risks of the deal. Humana also lowered its 2015 financial forecasts, citing higher than expected expenses in its Medicare business.Humana shares closed up 0.8 percent at $188.96, well below the value of Aetna's proposed cash and stock offer of $223, based on the most recent share prices.    (Additional reporting by Greg Roumeliotis, Susan Kelly and Karen Freifeld)",2015-07-06,AET,"Mon Jul 6, 2015 | 6:40pm EDT",Aetna CEO addresses antitrust concerns over Humana deal,http://www.reuters.com//article/humana-ma-aetna-idUSL1N0ZM18G20150706?type=companyNews
190,"   By Caroline Humer | NEW YORK  NEW YORK Aetna Inc's (AET.N) chief executive said Monday he was confident any antitrust review of the health insurer's proposed purchase of smaller rival Humana Inc (HUM.N) would allow the deal to close in the second half of 2016.Mark Bertolini said Aetna had already prepared for possible divestitures to address overlaps with Humana's business in the largest-ever U.S. health insurance deal. The two sides announced the $37 billion transaction on Friday. Hospital and state officials said they would take a hard look at whether the deal would diminish competition for consumers.""We took a conservative view of what we would need to divest,"" Bertolini said during an investor conference call.Aetna has not discussed the deal directly with the U.S. Department of Justice, but has consulted with regulatory experts, Bertolini told cable channel CNBC.""We believe that given the legal advice we have...that this is a very manageable transaction,"" he said.The bigger the insurer, the more power it has negotiating prices with hospitals and other providers, as well as improving its doctor networks. Aetna and Humana are in nine of the same states in one of their key businesses - Medicare Advantage plans for the elderly. Combined, they would have market share of 88 percent in Kansas, 80 percent in West Virginia, 58 percent in Iowa and 51 percent in Missouri.  Regulators would also look for the impact on competition in each local market for the companies' Medicaid plans for the poor, individual insurance, commercial insurance for small and large businesses and the large employer business.Attorneys general in several U.S. states said on Monday they would be ready to review the proposed deal. ""Our office is aware of these mergers, and we will be looking to determine whether or not there's any significant impact on Massachusetts,"" said Chloe Gotsis, a spokeswoman for the state AG's office.  Healthcare providers are concerned that further consolidation will decrease competition in the insurance industry, said Alicia Mitchell, spokeswoman for the American Hospital Association.""Any potential deal of this magnitude needs rigorous scrutiny. That's why the AHA will call upon the DOJ and Congress to exercise a significant level of scrutiny, Mitchell said in an emailed statement.Health insurers have been in a race to consolidate, saying that being larger would help them negotiate better prices with doctors and hospitals as well as cut administrative costs. No. 2 health insurer Anthem Inc (ANTM.N) has offered to buy No. 5 Cigna Corp (CI.N). The two companies have revived discussions in light of the Humana-Aetna deal, though it is not clear whether they can agree on terms including price and governance issues, sources familiar with the matter have told Reuters. If an Anthem-Cigna deal is announced within the next two to three months, regulators could look at the impact of both mergers at the same time, Bertolini said.""It really depends on whether or not any other deals are announced,"" he told investors. ""Currently we anticipate that our transaction will be viewed alone at this point in time, but they could be bundled together at some point.""    Aetna shares fell 6.4 percent to $117.43 on Monday as investors took stock of the regulatory and financial risks of the deal. Humana also lowered its 2015 financial forecasts, citing higher than expected expenses in its Medicare business.Humana shares closed up 0.8 percent at $188.96, well below the value of Aetna's proposed cash and stock offer of $223, based on the most recent share prices.  (Reporting by Caroline Humer in New York; Additional reporting by Greg Roumeliotis, Susan Kelly and Karen Freifeld; Editing by Bernadette Baum and Christian Plumb)",2015-07-06,AET,"Mon Jul 6, 2015 | 6:32pm EDT",Aetna CEO addresses antitrust concerns over Humana deal,http://www.reuters.com//article/us-humana-m-a-aetna-idUSKCN0PG1EO20150706?type=companyNews
191,"  (Adds comments from Massachusetts attorney general, American Hospital Association)By Caroline HumerNEW YORK, July 6 Aetna Inc's chief executive said Monday he was confident any antitrust review of the health insurer's proposed purchase of smaller rival Humana Inc would allow the deal to close in the second half of 2016.Mark Bertolini said Aetna had already prepared for possible divestitures to address overlaps with Humana's business in the largest-ever U.S. health insurance deal. The two sides announced the $37 billion transaction on Friday. Hospital and state officials said they would take a hard look at whether the deal would diminish competition for consumers.""We took a conservative view of what we would need to divest,"" Bertolini said during an investor conference call.Aetna has not discussed the deal directly with the U.S. Department of Justice, but has consulted with regulatory experts, Bertolini told cable channel CNBC.""We believe that given the legal advice we have...that this is a very manageable transaction,"" he said. The bigger the insurer, the more power it has negotiating prices with hospitals and other providers, as well as improving its doctor networks.Aetna and Humana are in nine of the same states in one of their key businesses - Medicare Advantage plans for the elderly. Combined, they would have market share of 88 percent in Kansas, 80 percent in West Virginia, 58 percent in Iowa and 51 percent in Missouri.Regulators would also look for the impact on competition in each local market for the companies' Medicaid plans for the poor, individual insurance, commercial insurance for small and large businesses and the large employer business.Attorneys general in several U.S. states said on Monday they would be ready to review the proposed deal. ""Our office is aware of these mergers, and we will be looking to determine whether or not there's any significant impact on Massachusetts,"" said Chloe Gotsis, a spokeswoman for the state AG's office.Healthcare providers are concerned that further consolidation will decrease competition in the insurance industry, said Alicia Mitchell, spokeswoman for the American Hospital Association.""Any potential deal of this magnitude needs rigorous scrutiny. That's why the AHA will call upon the DOJ and Congress to exercise a significant level of scrutiny,"" Mitchell said in an emailed statement. Health insurers have been in a race to consolidate, saying that being larger would help them negotiate better prices with doctors and hospitals as well as cut administrative costs.No. 2 health insurer Anthem Inc has offered to buy No. 5 Cigna Corp. The two companies have revived discussions in light of the Humana-Aetna deal, though it is not clear whether they can agree on terms including price and governance issues, sources familiar with the matter have told Reuters.If an Anthem-Cigna deal is announced within the next two to three months, regulators could look at the impact of both mergers at the same time, Bertolini said.""It really depends on whether or not any other deals are announced,"" he told investors. ""Currently we anticipate that our transaction will be viewed alone at this point in time, but they could be bundled together at some point.""Aetna shares fell 6.4 percent to $117.43 on Monday as investors took stock of the regulatory and financial risks of the deal. Humana also lowered its 2015 financial forecasts, citing higher than expected expenses in its Medicare business.Humana shares closed up 0.8 percent at $188.96, well below the value of Aetna's proposed cash and stock offer of $223, based on the most recent share prices.    (Reporting by Caroline Humer in New York; Additional reporting by Greg Roumeliotis, Susan Kelly and Karen Freifeld; Editing by Bernadette Baum and Christian Plumb)",2015-07-06,AET,"Mon Jul 6, 2015 | 6:31pm EDT",UPDATE 3-Aetna CEO addresses antitrust concerns over Humana deal,http://www.reuters.com//article/humana-ma-aetna-idUSL1N0ZM1GU20150706?type=companyNews
192,"   By Caroline Humer | NEW YORK  NEW YORK Humana Inc, fresh from announcing an agreement to be purchased by larger rival Aetna Inc, prompted new investor concerns about the $33 billion deal on Monday by lowering its 2015 financial forecasts.The transaction announced on Friday is already expected to face a tough review by U.S. antitrust regulators, particularly if another major deal among health insurers emerges.Humana, which has posted disappointing results for several quarters in a row, said on Monday that members of its Medicare Advantage plans for the elderly were using hospital services at a higher rate than the company expected.That increase could cut into already tight profit margins, if Humana ends up paying more for medical claims than they anticipated when setting monthly insurance rates. Humana CEO Bruce Broussard said on a conference call with investors that inpatient hospital admissions have not performed in line with what the company had forecast. That contributed to its decision to slash expected 2015 operating profits by more than 8 percent. The company said it had taken the higher Medicare Advantage hospital use into account when it priced premiums for 2016.""If you take the 8 percent downgrade of their earnings and roll that through, that makes what Aetna paid pretty expensive,"" said Joel Emery, a portfolio manager at Tareo Capital Management in New York. The degree to which Humana will boost Aetna's earnings in 2017 and 2018 is less than what some investors had hoped for, he said.Aetna's offer of $125 in cash and 0.8375 Aetna shares for each Humana share valued Humana at $230 per share. On Monday, Aetna fell 6 percent to $117, bringing down the offer price to $223 per share. Reflecting growing doubts about the deal, Humana shares traded well below the proposed offer price, closing at $188.96.""Aetna shareholders have to approve the deal, and with such a large premium, there is some outside chance that shareholders will not approve it,"" said Standard & Poor's equity analyst Jeffrey Loo. Humana's negative comments provided a silver lining to hospital operators, who stand to benefit if patient admissions rise and they are reimbursed for more of their services, said Les Funtledyer, portfolio manager at ESquared asset management. He owns shares of HCA Holdings and Universal Health Services.Consolidation among health insurers is also spurring investors to seek out cheaper stocks in the healthcare sector, such as hospitals, said Jessica Bemer, portfolio manager for Snow Capital Management in Sewickley, Pennsylvania.""If there are fewer insurers for healthcare investors to own, that means they have to get their healthcare exposure elsewhere,"" Bemer said.Shares of Community Health Systems, Tenet Healthcare  and HCA bucked the overall market's decline and gained 0.7 percent, 0.5 percent and 1.8 percent on Monday. Bemer holds Community Health shares.   (Additional reporting by Susan Kelly in Chicago)",2015-07-06,AET,"Mon Jul 6, 2015 | 6:27pm EDT","Humana cuts outlook, raising new concerns about Aetna deal",http://www.reuters.com//article/humana-ma-aetna-investors-idUSL1N0ZM2HT20150706?type=companyNews
193,"   By Caroline Humer | NEW YORK  NEW YORK Humana Inc, fresh from announcing an agreement to be purchased by larger rival Aetna Inc, prompted new investor concerns about the $33 billion deal on Monday by lowering its 2015 financial forecasts. The transaction announced on Friday is already expected to face a tough review by U.S. antitrust regulators, particularly if another major deal among health insurers emerges. Humana, which has posted disappointing results for several quarters in a row, said on Monday that members of its Medicare Advantage plans for the elderly were using hospital services at a higher rate than the company expected. That increase could cut into already tight profit margins, if Humana ends up paying more for medical claims than they anticipated when setting monthly insurance rates.Humana CEO Bruce Broussard said on a conference call with investors that inpatient hospital admissions have not performed in line with what the company had forecast. That contributed to its decision to slash expected 2015 operating profits by more than 8 percent. The company said it had taken the higher Medicare Advantage hospital use into account when it priced premiums for 2016. ""If you take the 8 percent downgrade of their earnings and roll that through, that makes what Aetna paid pretty expensive,"" said Joel Emery, a portfolio manager at Tareo Capital Management in New York. The degree to which Humana will boost Aetna's earnings in 2017 and 2018 is less than what some investors had hoped for, he said.Aetna's offer of $125 in cash and 0.8375 Aetna shares for each Humana share valued Humana at $230 per share. On Monday, Aetna fell 6 percent to $117, bringing down the offer price to $223 per share.Reflecting growing doubts about the deal, Humana shares traded well below the proposed offer price, closing at $188.96. ""Aetna shareholders have to approve the deal, and with such a large premium, there is some outside chance that shareholders will not approve it,"" said Standard & Poor's equity analyst Jeffrey Loo.Humana's negative comments provided a silver lining to hospital operators, who stand to benefit if patient admissions rise and they are reimbursed for more of their services, said Les Funtledyer, portfolio manager at ESquared asset management. He owns shares of HCA Holdings and Universal Health Services.  Consolidation among health insurers is also spurring investors to seek out cheaper stocks in the healthcare sector, such as hospitals, said Jessica Bemer, portfolio manager for Snow Capital Management in Sewickley, Pennsylvania. ""If there are fewer insurers for healthcare investors to own, that means they have to get their healthcare exposure elsewhere,"" Bemer said.Shares of Community Health Systems, Tenet Healthcare and HCA bucked the overall market's decline and gained 0.7 percent, 0.5 percent and 1.8 percent on Monday. Bemer holds Community Health shares. (Additional reporting by Susan Kelly in Chicago; Editing by Christian Plumb)",2015-07-06,AET,"Mon Jul 6, 2015 | 6:26pm EDT","Humana cuts outlook, raising new concerns about Aetna deal",http://www.reuters.com//article/us-humana-m-a-aetna-investors-idUSKCN0PG2HI20150706?type=companyNews
194,"   By Caroline Humer | NEW YORK, July 6  NEW YORK, July 6 Humana Inc, fresh from announcing an agreement to be purchased by larger rival Aetna Inc, prompted new investor concerns about the $33 billion deal on Monday by lowering its 2015 financial forecasts.The transaction announced on Friday is already expected to face a tough review by U.S. antitrust regulators, particularly if another major deal among health insurers emerges.Humana, which has posted disappointing results for several quarters in a row, said on Monday that members of its Medicare Advantage plans for the elderly were using hospital services at a higher rate than the company expected.That increase could cut into already tight profit margins, if Humana ends up paying more for medical claims than they anticipated when setting monthly insurance rates. Humana CEO Bruce Broussard said on a conference call with investors that inpatient hospital admissions have not performed in line with what the company had forecast. That contributed to its decision to slash expected 2015 operating profits by more than 8 percent. The company said it had taken the higher Medicare Advantage hospital use into account when it priced premiums for 2016.""If you take the 8 percent downgrade of their earnings and roll that through, that makes what Aetna paid pretty expensive,"" said Joel Emery, a portfolio manager at Tareo Capital Management in New York. The degree to which Humana will boost Aetna's earnings in 2017 and 2018 is less than what some investors had hoped for, he said.Aetna's offer of $125 in cash and 0.8375 Aetna shares for each Humana share valued Humana at $230 per share. On Monday, Aetna fell 6 percent to $117, bringing down the offer price to $223 per share. Reflecting growing doubts about the deal, Humana shares traded well below the proposed offer price, closing at $188.96.""Aetna shareholders have to approve the deal, and with such a large premium, there is some outside chance that shareholders will not approve it,"" said Standard & Poor's equity analyst Jeffrey Loo. Humana's negative comments provided a silver lining to hospital operators, who stand to benefit if patient admissions rise and they are reimbursed for more of their services, said Les Funtledyer, portfolio manager at ESquared asset management. He owns shares of HCA Holdings and Universal Health Services.Consolidation among health insurers is also spurring investors to seek out cheaper stocks in the healthcare sector, such as hospitals, said Jessica Bemer, portfolio manager for Snow Capital Management in Sewickley, Pennsylvania.""If there are fewer insurers for healthcare investors to own, that means they have to get their healthcare exposure elsewhere,"" Bemer said.Shares of Community Health Systems, Tenet Healthcare  and HCA bucked the overall market's decline and gained 0.7 percent, 0.5 percent and 1.8 percent on Monday. Bemer holds Community Health shares.   (Additional reporting by Susan Kelly in Chicago; Editing by Christian Plumb)",2015-07-06,AET,"Mon Jul 6, 2015 | 6:20pm EDT","Humana cuts outlook, raising new concerns about Aetna deal",http://www.reuters.com//article/humana-ma-aetna-investors-idUSL1N0ZM1P120150706?type=companyNews
195,"  * Tsipras to present aid proposal at euro zone meet Tuesday* Aetna falls after Humana deal* U.S. crude futures settle down near 8 pct for the session* Indexes down: Dow 0.3 pct, S&P 0.4 pct, Nasdaq 0.3 pct   (Updates prices, changes comment, byline)By Rodrigo CamposJuly 6 U.S. stocks fell in a volatile Monday session as Greeks resoundingly backed their government in rejecting the austerity terms of a bailout and China implemented emergency measures to stop a selloff in Shanghai's market.Greek Prime Minister Alexis Tsipras promised German Chancellor Angela Merkel that Greece would bring a proposal for a cash-for-reforms deal to an emergency summit of euro zone leaders on Tuesday, a Greek official said. It was unclear how much it would differ from other proposals rejected in the past.Equity futures tumbled at the open late on Sunday after Greeks voted 'No' to the terms imposed by its creditors. However the S&P 500 didn't fall more than 1 percent throughout the Monday session and even turned positive in morning trading.Though Greece is causing a lot of uncertainty, a deal should get done to keep them in the Euro Zone, according to Karyn Cavanaugh, market strategist at Voya Investment Management in New York. ""Greece can't pay their bills, there's no middle ground there and other countries are going to have to foot the bill and they are angry,"" she said.But more than billions in debt are in play as ""Greece is the southern gateway to Europe. The strategic value is not being quantified.""The Dow Jones industrial average fell 46.53 points, or 0.26 percent, to 17,683.58, the S&P 500 lost 8.02 points, or 0.39 percent, to 2,068.76 and the Nasdaq Composite  dropped 17.27 points, or 0.34 percent, to 4,991.94.Weighing further on investor sentiment, Chinese brokerages and fund managers vowed to buy massive amounts of stocks as Beijing unleashed an unprecedented series of support measures to stem a decline of nearly 30 percent in the main Shanghai index over the past three weeks. ""People see 'emergency measures' and they think 'that can't be good',"" said Voya's Cavanaugh.The Shanghai index rose 2.4 percent overnight but a measure of Chinese stocks traded in the United States  fell the most in 19 months, pointing to caution from investors outside of China about the effectiveness of the government's measures.Energy stocks led the decline on Wall Street after U.S. crude futures prices settled almost 8 percent lower on concern over growth in China and the Greek uncertainty.The S&P 500 energy index fell 1.3 percent, marking its fourth decline of more than 1 percent in the past seven sessions. Health insurer Aetna fell 6.4 percent to $117.43 after it said it would buy smaller rival Humana for about $37 billion. Humana closed up 0.8 percent to $188.96.The deal is seen facing antitrust scrutiny, which could make other large-scale mergers in the sector more difficult. Anthem , Cigna, Centene and Health Net, which are all in takeover talks, ended lower.Declining issues outnumbered advancing ones on the NYSE by 1,946 to 1,132, for a 1.72-to-1 ratio on the downside; on the Nasdaq, 1,600 issues fell and 1,181 advanced for a 1.35-to-1 ratio favoring decliners.The benchmark S&P 500 index posted 5 new 52-week highs and 32 new lows; the Nasdaq Composite recorded 44 new highs and 130 new lows.About 6.6 billion shares traded on all U.S. platforms, according to BATS exchange data, below the average of 7.6 billion in the past five sessions.(Reporting by Rodrigo Campos; Editing by Andrew Hay)",2015-07-06,AET,"Mon Jul 6, 2015 | 4:27pm EDT","US STOCKS-Energy leads Wall St lower with eyes on Greece, China",http://www.reuters.com//article/markets-stocks-usa-idUSL1N0ZM24620150706?type=companyNews
196,"  (Adds Teva, Unicredit, Rosneft, Black Swan Energy, Saint-Gobain, Siemens, PKP, Aston Martin; updates Aetna, Royal Bank of Scotland, Stemcor)July 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:** Health insurer Aetna Inc said on Friday it would buy smaller rival Humana Inc for about $37 billion in cash and stock, in the largest ever deal in the insurance industry.Aetna's chief executive said on Monday that he was confident an antitrust review of the health insurer's proposed purchase of smaller rival Humana would allow the deal to close in the second half of 2016, seeking to allay investor concerns.** Teva Pharmaceutical Industries Ltd is preparing to raise its bid for rival drugmaker Mylan NV by as much as $2 billion to $43 billion, Bloomberg reported on Monday, citing people familiar with the matter.** The Chinese central bank has bought a 2 percent stake in lenders UniCredit and Monte dei Paschi di Siena , adding to a string of investments in large Italian companies, a regulatory filing showed on Monday.** Russia's top oil producer Rosneft said on Monday that Brazilian regulator had cleared a purchase of 55 percent stake in oil and gas project in the Solimoes Basin from PetroRio, allowing the Kremlin-controlled company to gain full control over it.** Britain is planning to sell half its stake in Royal Bank of Scotland, worth 16 billion pounds ($25 billion), within two years of a possible first sale in September, sources with knowledge of government thinking told Reuters.** Black Swan Energy Ltd, a privately held exploration and production company, said on Monday it completed its planned C$200 million ($158 million) acquisition of Carmel Bay Exploration, boosting its land position in the highly sought after Montney region in British Columbia.** A 2.2 billion euro ($2.43 billion) loan and bond financing backing the buyout of Saint-Gobain's glass bottle unit Verallia remains on hold after Greece rejected a compromise with international creditors, bankers said on Monday.** Siemens could still be interested in buying power generation assets from French rival Alstom on the same terms it offered a year ago if General Electric's  deal to buy them falls through, a senior management source said.** State-controlled oil producer Petroleo Brasileiro SA  could sell a stake in Brazil's Braskem SA and build provisions against tax debts nearing 40 billion reais ($12.7 billion) to reduce costs and make finances sustainable, Valor Economico newspaper said.** Canada's Potash Corp of Saskatchewan said it was confident of addressing concerns raised by K+S over its 7.9 billion euro ($8.7 billion) takeover proposal for the German potash miner, giving K+S's stock a boost.** Polish state-run railway group PKP said on Monday it invited global private equity fund CVC to exclusive talks on the takeover of its utility arm PKP Energetyka.** Russian broadcaster CTC Media said it had received a $200 million offer for 75 percent of its operating assets in Russia and Kazakhstan from UTH Russia, part-owned by billionaire Alisher Usmanov. ** Family-owned German car parts maker Eberspaecher is exploring a partnership with an overseas peer or a partial sale as it seeks to expand internationally, several sources familiar with the matter said.** Abu Dhabi Islamic Bank, which recently failed in its bid for Citigroup's Egypt retail business, is targeting acquisitions in 2016 in Asia, the Middle East, and North Africa, its chief executive said.** Kuwait's Al Ahli Bank received approval from the Gulf state's central bank to buy Piraeus Bank's  Egyptian unit, it said on Monday.** German asset manager Union Investment has bought most of the remaining assets of Austria's Volksbanken as the part-nationalized group winds down after failing European bank stress tests.** U.S. cigarette giant Philip Morris International Inc  plans to sell a stake worth at least $1 billion in Indonesian unit PT HM Sampoerna Tbk to comply with free-float rules, two people familiar with the matter said on Monday.** China Molybdenum Luoyang Co is poised to make an offer for an overseas mining project costing up to $2.15 billion, the latest push by a Chinese enterprise to acquire resource assets beyond its borders. ** U.S. media group Scripps Networks Interactive has offered to pay a total of 3.2 billion zlotys ($843.64 million) to buy the shares in Polish broadcaster TVN it does not already own to take full control over the company and delist it.** Elliott Associates has bought shares in Samsung Fire & Marine Insurance Co Ltd, a spokeswoman for the South Korean firm said, potentially strengthening the U.S. hedge fund's hand in its bid to block an $8 billion proposed merger of another two Samsung Group companies.** Australian childcare operator Affinity Education  on Monday urged shareholders not to accept a $121 million takeover offer from larger rival G8 Education Ltd, saying it would refer the all-share bid to regulators after what it called ""opportunistic"" off-market purchases of Affinity stock by G8.** Berlin is wooing private investors including Macquarie  and JP Morgan to take a stake in its much-delayed new international airport, German newspaper Bild wrote on Sunday.** Mercedes F1 non-executive chairman Niki Lauda has dismissed a report suggesting Formula One rival Red Bull could switch from Renault to Mercedes engines with Aston Martin branding.** Aston Martin has had plenty of approaches from Formula One teams wanting to bring the brand back to the sport but the chances of a deal are improbable at best, Chief Executive Andy Palmer told Reuters on Monday.** Formula One's commercial rights holders CVC Capital Partners are under no pressure to sell their controlling stake in the sport and want to keep it, co-chairman Donald Mackenzie told Reuters. ** German utility RWE is considering a restructuring that could see units such as RWE Generation and RWE Innogy being merged or swallowed up by the parent group as it battles an industry-wide crisis, a German newspaper reported on Saturday.** Consolidation continues to be necessary in the auto industry but there is nothing new to report on Fiat Chrysler's   desire for a tie-up with General Motors , FCA CEO Sergio Marchionne said on Friday.** South African gaming and hotel group Tsogo Sun Holdings  has scrapped plans to buy a minority stake in two casinos owned by Sun International, the companies said.** Copenhagen-based private equity firm Polaris said it had made a binding offer to acquire all outstanding shares in Danish ferry company Mols-Linien and planned to delist the company from the stock exchange.** Creditors of insolvent German wind park operator Prokon have voted to try to revive the company themselves, rejecting a takeover bid from utility EnBW, the administrator said on Thursday.** The entertainment arm of Chinese property conglomerate Dalian Wanda Group said on Friday it would lead an almost 6 billion yuan ($967 million) investment into one of China's biggest travel websites, its first foray into online tourism.** Dutch lender ING Group is set to win the auction to buy HSBC Holdings Plc's Turkish business, people familiar with the matter said on Thursday.** Dollar Tree Inc was given the go-ahead to buy Family Dollar Stores Inc by the U.S. Federal Trade Commission on condition that they sell 330 Family Dollar stores, putting to rest a year-long merger saga.** Sycamore Partners is preparing an offer for Belk Inc that could value the U.S. department store chain at between $3 billion and $3.5 billion, including debt, and become the buyout firm's largest deal, people familiar with the matter said on Thursday.** Debt-laden steel trader Stemcor, one of Britain's largest private companies, has agreed a deal with U.S. distressed investment fund Apollo and with its other creditors which ""secures its future,"" it said on Monday.** India's Reliance Industries Ltd plans to sell a 3.1 percent stake, worth $32 million at the current market price, in unit Network18 Media & Investments Ltd to comply with rules mandating public ownership in listed firms.** The European Bank for Reconstruction and Development said it was considering taking a significant minority stake in the loss-making Ukrainian unit of Raiffeisen Bank International (RBI).($1 = 3.79 zlotys)  ($1 = 0.90 euros)  ($1 = 6.20 Chinese yuan renminbi)  ($1 = 0.64 pounds)  ($1 = 3.15 Brazilian reais)   (Compiled by Anya George Tharakan, Natalie Grover and Lehar Maan in Bengaluru)",2015-07-06,AET,"Mon Jul 6, 2015 | 4:00pm EDT",Deals of the day-Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL3N0ZM4EZ20150706?type=companyNews
197,"  * IMF says will help Greece if asked, ECB holds call* Tsipras to present aid proposal at euro zone meet Tuesday* Aetna falls after Humana deal, other insurers lower* Energy index leads losses as oil prices fall* Indexes down: Dow 0.2 pct, S&P 0.29 pct, Nasdaq 0.3 pct   (Updates to early afternoon)By Tanya AgrawalJuly 6 U.S. stocks were lower in early afternoon trading, but were well off their lows earlier on Monday as investors remained optimistic that a deal could be reached to prevent Greece's exit from the euro zone.Greeks rejected the conditions of a rescue package from creditors on Sunday and the country's finance minister resigned on Monday, removing a major obstacle to any deal. Prime Minister Alexis Tsipras agreed to present an aid proposal at an emergency euro zone meeting on Tuesday. Stock markets globally fell, but analysts said the declines were less than expected due to expectations that the European Central Bank would act to limit any damage.U.S. stocks opened more than half a percent lower, but pared some of those losses, even turning positive briefly, after the International Monetary Fund said it is ready to assist Greece if asked.""The referendum doesn't really change anything with the negotiations,"" said Mark Luschini, chief investment strategist at Janney Montgomery Scott in Philadelphia.""I think after the initial knee jerk reaction, the majority opinion is that there is still a possibility of some sort of a deal that keeps Greece in the euro zone."" Greece's immediate fate is in the hands of the ECB, which began a conference call late afternoon to decide how long to go on keeping Greek banks afloat. Several people familiar with ECB policy said it would probably reject a Greek request to raise a cap on emergency liquidity assistance.U.S. economic growth prospects got a boost after data from the Institute for Supply Management showed the pace of growth in the U.S. services ticked higher in June after dropping in May. The Federal Reserve has said it will raise rates only when it sees a sustained economic recovery.At 13:03 p.m. ET the Dow Jones industrial average was down 35.47 points, or 0.2 percent, at 17,694.64. The S&P 500  was lower by 6.01 points, or 0.29 percent, at 2,070.77. The Nasdaq Composite was down 14.89 points, or 0.3 percent, at 4,994.32. All the 10 major S&P 500 sectors were lower. The energy index led the declines with a 0.73 percent fall as oil prices slumped more than 6 percent after the Greek referendum and on a strengthening dollar.Chevron's shares dropped as much as 1.5 percent to $94.48, its lowest since November 2011.Health insurer Aetna fell 7.3 percent to $116.40 after it said it would buy smaller rival Humana for about $37 billion. Humana rose 2 percent to $191.38.The deal is sure to face rigorous antitrust scrutiny, which could also make other large-scale mergers in the sector more difficult. Anthem, Cigna, Centene and Health Net, which are all in takeover talks, were lower.Weight Watchers soared 17.6 percent to $4.81 after the New York Post reported an activist hedge fund was in talks with potential partners to buy the company. The hedge fund and a partner ""would like to offer perhaps double"" Thursday's closing price, the report said.Declining issues outnumbered advancing ones on the NYSE by 1,932 to 1,057. On the Nasdaq, 1,664 issues fell and 1,041 advanced.The S&P 500 index showed four new 52-week highs and 27 new lows, while the Nasdaq recorded 32 new highs and 113 new lows.   (Editing by Savio D'Souza)",2015-07-06,AET,"Mon Jul 6, 2015 | 1:40pm EDT",US STOCKS-Wall St off session lows as Greece aid deal optimism grows,http://www.reuters.com//article/markets-stocks-usa-idUSL3N0ZM4ZL20150706?type=companyNews
198,"  (Corrects to add dropped word ""is"" in first paragraph)* IMF says will help Greece if asked to* ECB's governing council to hold call this afternoon* Aetna falls after Humana deal, other insurers lower* Energy index leads losses as oil prices fall* Indexes down: Dow 0.22 pct, S&P 0.21 pct, Nasdaq 0.14 pctBy Tanya AgrawalJuly 6 U.S. stocks erased most of their earlier losses, even turning positive briefly, on Monday after the International Monetary Fund said it is ready to assist Greece if asked.Greeks rejected the conditions of a rescue package from creditors on Sunday, but investors remained optimistic that a deal could be reached to prevent the country's exit from the euro zone. Stock markets globally fell, but analysts said the declines were less than expected due to expectations that the European Central Bank would act to limit any damage.""The referendum doesn't really change anything with the negotiations,"" said Mark Luschini, chief investment strategist at Janney Montgomery Scott in Philadelphia.""I think after the initial knee jerk reaction, the majority opinion is that there is still a possibility of some sort of a deal that keeps Greece in the euro zone.""The ECB's governing council is due to hold a conference call on Monday afternoon to discuss the provisions of emergency funding to Greece's banks. A new deal is needed for Greece to meet a July 20 deadline to repay $3.9 billion of bonds to the ECB. Greece's finance minister quit after the vote and Prime Minister Alexis Tsipras said his government was ready to return immediately to negotiations with creditors.U.S. stocks opened more than half a percent lower, but by 11:39 a.m. ET they had pared most of their losses and even briefly turned positive after the IMF offered a helping hand.The Dow Jones industrial average was down 46.73 points, or 0.26 percent, at 17,683.38. The S&P 500 was lower 5.71 points, or 0.27 percent, at 2,071.07. The Nasdaq Composite was down 15.25 points, or 0.3 percent, at 4,993.97.Nine of the 10 major S&P 500 sectors were lower. The energy index led the declines with a 0.85 percent fall as oil prices fell more than 3 percent after the Greek referendum and on a strengthening dollar. Chevron fell as much as 1.5 percent to $94.68, its lowest since November 2011. U.S. economic growth prospects got a boost after Institute for Supply Management data showed the pace of growth in the U.S. services ticked higher in June after dropping in May.The Federal Reserve has said it will raise rates only when it sees a sustained economic recovery.Health insurer Humana's shares rose 3.6 percent to $194.50 after bigger rival Aetna said on Friday it would buy the company for about $37 billion. Aetna fell 4.9 percent at $119.20.The deal follows weeks of intense discussions about potential combinations among health insurers, but rigorous scrutiny from U.S. regulators could also make mergers more difficult. Anthem and Cigna, which are in takeover talks, declined more than 1 percent.Weight Watchers soared 16.4 percent to $4.76 after the New York Post reported an activist hedge fund was in talks with potential partners to buy the company. The hedge fund and a partner ""would like to offer perhaps double"" Thursday's closing price, the report said.Declining issues outnumbered advancers on the NYSE by 1,912 to 1,038. On the Nasdaq, 1,680 issues fell and 976 advanced.The S&P 500 index showed five new 52-week highs and 28 new lows, while the Nasdaq recorded 23 new highs and 106 new lows.   (Editing by Savio D'Souza)",2015-07-06,AET,"Mon Jul 6, 2015 | 11:54am EDT",REFILE-US STOCKS-Wall St pares losses after IMF says ready to help Greece,http://www.reuters.com//article/markets-stocks-usa-idUSL3N0ZM4SC20150706?type=companyNews
199,"  Health insurer Humana Inc and buyer Aetna Inc set fees to be paid in the event of a failure of the largest deal in the health insurance industry. Aetna, which said last week it would buy Humana for about $37 billion in cash and stock, has to pay a termination fee of $1.69 billion, Humana said in a regulatory filing on Tuesday (1.usa.gov/1JSxWVr)Humana would pay the larger rival $1.31 billion if the deal is terminated. The deal faces antitrust issues as the authorities scrutinize how the combination will affect competition for each line of insurance: Medicare, Medicaid for the poor, individual insurance, commercial insurance for small and large businesses and the large employer business. (reut.rs/1LLQn1n) Wall Street analysts and some antitrust experts have said that they expect the combination to be approved, although regulators may insist on some divestitures. Aetna's chief executive said on Monday that he was confident about an antitrust approval for the deal to close by June 30, 2016. The company had already prepared for possible divestitures to address overlaps with Humana's business, he added.  Aetna is also required to pay Humana $1 billion if the deal is not closed by June 30, 2016, according to Tuesday's filing.  (Reporting by Rosmi Shaji in Bengaluru)",2015-07-07,AET,"Tue Jul 7, 2015 | 6:43pm EDT","Humana, Aetna set termination fees for deal",http://www.reuters.com//article/us-humana-m-a-aetna-idUSKCN0PH2JG20150707?type=companyNews
200,"  July 7 Health insurer Humana Inc and buyer Aetna Inc set fees to be paid in the event of a failure of the largest deal in the health insurance industry.Aetna, which said last week it would buy Humana for about $37 billion in cash and stock, has to pay a termination fee of $1.69 billion, Humana said in a regulatory filing on Tuesday (1.usa.gov/1JSxWVr)Humana would pay the larger rival $1.31 billion if the deal is terminated. The deal faces antitrust issues as the authorities scrutinize how the combination will affect competition for each line of insurance: Medicare, Medicaid for the poor, individual insurance, commercial insurance for small and large businesses and the large employer business. (reut.rs/1LLQn1n) Wall Street analysts and some antitrust experts have said that they expect the combination to be approved, although regulators may insist on some divestitures. Aetna's chief executive said on Monday that he was confident about an antitrust approval for the deal to close by June 30, 2016. The company had already prepared for possible divestitures to address overlaps with Humana's business, he added.Aetna is also required to pay Humana $1 billion if the deal is not closed by June 30, 2016, according to Tuesday's filing.   (Reporting by Rosmi Shaji in Bengaluru)",2015-07-07,AET,"Tue Jul 7, 2015 | 6:36pm EDT","Humana, Aetna set termination fees for deal",http://www.reuters.com//article/humana-ma-aetna-idUSL3N0ZN5NL20150707?type=companyNews
201,"  (The following statement was released by the rating agency) NEW YORK, July 07 (Fitch) The for-profit hospital industry is well positioned  with respect to the anticipated wave of mergers and acquisitions (M&A) amongst  the largest for-profit health insurers, but consolidation could have some  important longer term ramifications, according to Fitch Ratings. M&A amongst health insurers is not likely to immediately result in outright  price pressure for hospitals. In many markets, health insurers are already  fairly consolidated and recent actions by hospitals to build market presence  will shore up negotiating power. However, over the longer term it could have a  negative effect on competition by smaller insurers in some markets. In addition,  it could accelerate the nascent shift towards value based payments for hospitals  and other healthcare providers if larger insurers find it financially beneficial  to advance the use of these payment models.  The planned tie-up of Aetna and Humana could create the second largest national  for-profit health insurer by revenue if approved by anti-trust regulators. The  announcement of the merger comes on the back of some favorable developments for  the hospital industry. Most importantly, the U.S. Supreme Court recently ruled  that more than 6 million enrollees in the public health insurance exchange plans  created by the Affordable Care Act (ACA) can keep the financial subsidies that  make these plans more affordable. In part because of the ACA-related expansion  of health insurance coverage, hospitals have recently experienced a marked  improvement in organic operating trends, particularly in growth of volumes of  patients.  Actions by hospital management teams to respond to certain challenges in the  operating environment are also contributing to the industry's improved  performance. These same activities are now encouraging consolidation by health  insurers. Horizontal M&A activity amongst acute care hospitals to build bigger  systems with more negotiating clout with payors has been a durable trend since  the passage of the ACA in early 2010. More recently, hospitals have been  expanding their presence in key geographies through acquisitions and financial  partnerships in adjacent care delivery verticals as well as taking actions to  improve financial alignment with physicians.  Hospital companies will begin reporting 2Q15 results later this month. Many of  the trends supporting the industry's recently improved performance remain  intact, so Fitch expects another quarter of decent results. However, volume  growth in particular is likely to back-off the very strong results posted in the  past couple quarters. The full report, ""Hospitals' Credit Diagnosis: ACA Ruling  Positive but Facing Insurer Consolidation Wave"" is available at  www.fitchratings.com. The report provides a summary of the quarterly operating  performance and credit metrics of companies in the for-profit hospital sector,  including detailed debt and organizational structure charts.  Contact: Megan Neuburger, CFA  Managing Director +1 212 908-0501 Fitch, Inc. 33 Whitehall Street New York, NY 10004  Kellie Geressy-Nilsen  Senior Director  Fitch Wire  +1 212 908-9123  Media Relations: Alyssa Castelli, New York, Tel: +1 (212) 908 0540, Email:  alyssa.castelli@fitchratings.com. Additional information is available on www.fitchratings.com The above article originally appeared as a post on the Fitch Wire credit market  commentary page. The original article, which may include hyperlinks to companies  and current ratings, can be accessed at www.fitchratings.com. All opinions  expressed are those of Fitch Ratings. Hospitals' Credit Diagnosis (Favorable Subsidy Ruling Means the ACA Is Here to  Stay) here Applicable Criteria  Corporate Rating Methodology: Including Short-Term Ratings and Parent and  Subsidiary Linkage  (pub. 05 Aug 2013) here Related Research  2014 Outlook: U.S. Healthcare  Secular Challenges Require a Compelling Value  Propositihere High-Yield Healthcare Checkup: Comprehensive Analysis of High-Yield U.S.  Healthcare Companies  here High-Yield Healthcare Checkup: Comprehensive Analysis of High-Yield U.S.  Healthcare Companies  here Margin Preservation Strategies  Different Angles (Credit Implications for U.S.  Hospitals and Health Insurers)  here The Affordable Care Act and Healthcare Providers (Assessing the Potential  Impact)  here U.S. Leveraged Finance Spotlight Series - HCA Holdings, Inc.  here ALL FITCH CREDIT RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND DISCLAIMERS.  PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING THIS LINK:  here. IN ADDITION, RATING  DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE AVAILABLE ON THE AGENCY'S  PUBLIC WEBSITE 'WWW.FITCHRATINGS.COM'. PUBLISHED RATINGS, CRITERIA AND  METHODOLOGIES ARE AVAILABLE FROM THIS SITE AT ALL TIMES. FITCH'S CODE OF  CONDUCT, CONFIDENTIALITY, CONFLICTS OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE  AND OTHER RELEVANT POLICIES AND PROCEDURES ARE ALSO AVAILABLE FROM THE 'CODE OF  CONDUCT' SECTION OF THIS SITE. FITCH MAY HAVE PROVIDED ANOTHER PERMISSIBLE  SERVICE TO THE RATED ENTITY OR ITS RELATED THIRD PARTIES. DETAILS OF THIS  SERVICE FOR RATINGS FOR WHICH THE LEAD ANALYST IS BASED IN AN EU-REGISTERED  ENTITY CAN BE FOUND ON THE ENTITY SUMMARY PAGE FOR THIS ISSUER ON THE FITCH  WEBSITE.   ",2015-07-07,AET,"Tue Jul 7, 2015 | 4:01pm EDT",Fitch: US Hospitals Well Positioned for Insurer Consolidation,http://www.reuters.com//article/idUSFit92726920150707?type=companyNews
202,"  (The following statement was released by the rating agency) CHICAGO, July 07 (Fitch) Fitch Ratings has placed the ratings of Aetna Inc.  (Aetna) on Rating Watch Negative. The rating action follows Aetna's recent  announcement that it has reached an agreement to acquire Humana Inc. (Humana) in  a cash and stock transaction valued at approximately $37 billion. A full list of  rating actions follows at the end of this release. KEY RATING DRIVERS The rating action reflects Fitch's concern about Aetna's expected financial  leverage metrics following the close of the transaction, as well as potential  operational and/or earnings disruptions that could arise as these two very large  and complex organizations are integrated.  Assuming the acquisition and its financing are completed as currently  envisioned, upon close of the acquisition Fitch expects to downgrade Aetna's  ratings by one notch. Fitch notes that Aetna's financial leverage has not fully  returned to the level at which the company operated prior to its acquisition of  Coventry Health Care, Inc. in 2013, although the company has been progressing in  line with expectations. At close of the acquisition, Fitch expects Aetna's financial leverage to be  approximately 46%, and debt to EBITDA to be in excess of 3.0x due to the debt  being issued to fund the cash portion of the purchase price. Fitch does not  anticipate that Aetna's financial leverage metrics will return to a level  appropriate for its current rating category within a 12 to 24 month time horizon  normally associated with a Rating Outlook. Given Aetna's size and business  profile, these metrics at its current rating would be a run-rate debt to EBITDA  ratio approximating 1.8x and financial leverage of 30-35%. The ratings of Humana have also historically reflected Fitch's view that  Medicare Advantage (MA) enrollment generally supports lower ratings relative to  employer group and individual enrollment due to the U.S. government's large role  in the MA market and the suppressive effect this role has in terms of margins  and capital formation. As a large portion of Humana's revenue is associated with  MA business, Aetna's exposure to this business will increase significantly at  close of the transaction. Fitch views the combination of Aetna and Humana as strategically beneficial to  both organizations in terms of the application of Aetna's strong performance in  commercial risk business to Humana's commercial block, geographic and business  diversification, particularly with regard to Humana, as well as stronger  provider networks and pharmacy claims costs. RATING SENSITIVITIES At the close of the transaction, Fitch expects to downgrade the ratings of Aetna  by one notch, at which time Fitch will establish new rating triggers associated  with the combined company's new ratings. FULL LIST OF RATING ACTIONS Fitch has placed the following ratings on Watch Negative: Aetna Inc. --$750 million of 3.50% senior unsecured notes due Nov. 15, 2024 'A-'; --$250 million of 1.75% senior unsecured notes due May 15, 2017 'A-'; --$500 million of 1.5% senior unsecured notes due Nov. 15, 2017 'A-'; --$383 million of 5.95% senior unsecured notes due March 15, 2017 'A-'; --$375 million of 2.2% senior unsecured notes due March 15, 2019 'A-'; --$750 million of 3.95% senior unsecured notes due Sept. 1, 2020 'A-'; --$500 million of 4.125% senior unsecured notes due June 1, 2021 'A-'; --$600 million of 5.450% senior unsecured notes due June 15, 2021 'A-';  --$1 billion of 2.75% senior unsecured notes due Nov. 15, 2022 'A-'; --$771 million of 6.625% senior unsecured notes due June 15, 2036 'A-'; --$534 million of 6.75% senior unsecured notes due Dec. 15, 2037 'A-'; --$500 million of 4.5% senior unsecured notes due May 15, 2042 'A-'; --$500 million of 4.125% senior unsecured notes due Nov. 15, 2042 'A-'; --$375 million of 4.75% senior unsecured notes due March 15, 2044 'A-'; --Short-term IDR 'F1'; --$2 billion commercial paper program 'F1'. Aetna Inc.  --Long-term IDR 'A'. Aetna Life Insurance Company  Aetna Health Inc. (a Pennsylvania Corporation)  Aetna Health Inc. (a Florida Corporation)  Aetna Health Inc. (a New Jersey Corporation)  Aetna Health Inc. (a Texas Corporation)  Aetna Health Inc. (a New York Corporation) Aetna Health of California Inc. --IFS 'AA-'. Contact:  Primary Analyst Bradley S. Ellis, CFA Director +1-312-368-2089 Fitch Ratings, Inc. 70 W. Madison St. Chicago, IL 60602 Secondary Analyst Mark E. Rouck, CPA, CFA Senior Director +1-312-368-2085 Committee Chairperson James B. Auden, CFA Managing Director +1-312-368-3146 Media Relations: Alyssa Castelli, New York, Tel: +1 (212) 908 0540, Email:  alyssa.castelli@fitchratings.com. Additional information is available on www.fitchratings.com Applicable Criteria  Exposure Draft: Insurance Notching Criteria (Proposed Methodology Changes) (pub.  12 May 2015) here Insurance Rating Methodology (pub. 04 Sep 2014) here Additional Disclosures  Solicitation Status  here <a  href=""https://www.fitchratings.com/jsp/creditdesk/PolicyRegulation.faces?context   =2&detail=31"">Endorsement Policy    ALL FITCH CREDIT RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND DISCLAIMERS.  PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING THIS LINK:  here. IN ADDITION, RATING  DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE AVAILABLE ON THE AGENCY'S  PUBLIC WEBSITE 'WWW.FITCHRATINGS.COM'. PUBLISHED RATINGS, CRITERIA AND  METHODOLOGIES ARE AVAILABLE FROM THIS SITE AT ALL TIMES. FITCH'S CODE OF  CONDUCT, CONFIDENTIALITY, CONFLICTS OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE  AND OTHER RELEVANT POLICIES AND PROCEDURES ARE ALSO AVAILABLE FROM THE 'CODE OF  CONDUCT' SECTION OF THIS SITE. FITCH MAY HAVE PROVIDED ANOTHER PERMISSIBLE  SERVICE TO THE RATED ENTITY OR ITS RELATED THIRD PARTIES. DETAILS OF THIS  SERVICE FOR RATINGS FOR WHICH THE LEAD ANALYST IS BASED IN AN EU-REGISTERED  ENTITY CAN BE FOUND ON THE ENTITY SUMMARY PAGE FOR THIS ISSUER ON THE FITCH  WEBSITE.   ",2015-07-07,AET,"Tue Jul 7, 2015 | 9:13am EDT",Fitch Places Aetna on Rating Watch Negative,http://www.reuters.com//article/idUSFit92805320150707?type=companyNews
203,"   By Leela Parker Deo and Karen Schwartz | NEW YORK  NEW YORK U.S. health insurer Aetna Inc (AET.N) is lining up a $16.2 billion bridge loan to fund its acquisition of smaller rival Humana Inc (HUM.N), which is the first multibillion M&A loan of the second half of 2015 and the second-largest acquisition bridge loan so far this year, according to Thomson Reuters LPC data.Aetna said on July 3 that it would buy Humana for $37 billion in cash and stock in the insurance industrys largest-ever acquisition.The deal will boost third quarter investment grade loan issuance and support expectations that a surplus of corporate cash is contributing to a growing pipeline of M&A transactions.Investment grade M&A-related lending totaled $63 billion in the first half of the year. 2015 totals could reach $200 billion based on the pipeline of financings building in the second half of the year, according to a lender survey by Thomson Reuters LPC.The merger is the latest transaction amid ongoing consolidation in the health insurance sector and was announced just before global markets were roiled by the decisive July 5 referendum in Greece which rejected additional harsh austerity measures and Chinas attempts to stabilize its ailing stock market.These macroeconomic developments and slumping oil and iron ore prices have the potential to disrupt the syndicated loan market, but dislocation is more likely to be felt by non-investment grade companies rather than high-grade issuers, one analyst said.Highly rated companies are in a relatively strong position to attract financing because of their credit profiles, he noted, and tend to benefit from any flight to quality in a risk-off environment. I wont say its not going to be somewhat choppy. The marketplace always tends to be somewhat choppier when you have these big geopolitical issues popping up. Its just one of several things theyre going to need to navigate over the next six months, the analyst said.HEALTHY BRIDGE Citigroup and UBS are providing the 364-day senior unsecured bridge facility, according to regulatory filings. The bridge loan is expected to be taken out with permanent financing that could include a mix of term debt, bonds and commercial paper, sources said. Citigroup and UBS are currently syndicating a $3.2 billion, three-year term loan, the sources added. If the merger clears antitrust scrutiny, it will dwarf the previous largest ever insurance deal announced in early July, when Swiss property and casualty giant ACE Ltd (ACE.N) said it was buying Chubb Corp (CB.N) for $28 billion, Reuters reported.In the past two weeks, Anthem also has offered to buy Cigna Corp to create the largest insurer in the country, toppling UnitedHealth Group Inc, according to Reuters, as U.S. insurers grapple with the issue of providing universal coverage, which is a key policy of Barak Obamas presidency.Were through this tunnel of managing through at least the initial implementation phase of the ACA [Affordable Care Act], said the analyst. Companies are now thinking more strongly about how they want to position in the next 3-5 years, and I think M&A will increasingly be a part of that thought process. The acquisition gives Aetna a strong leg up in government-sponsored managed Medicare, a growth market in the health insurance sector, the analyst added. This will vault them into a leadership position, assuming the deal goes through.The bridge loan pricing is tied to a ratings grid, ranging from 75bp-125bp over Libor.Pricing opens at 100bp over Libor based on Aetnas senior unsecured debt ratings of Baa1/A/A- and the loan pays a 10bp commitment fee. Pricing includes 25bp margin step-ups at 90, 180 and 270 days, respectively, after closing. The loan also pays duration fees, a periodic fee on the outstanding balance of the bridge loan, of 50bp, 75bp and 100bp, according to the same schedule.The deal, which is expected to close in the second half of 2016, is also being financed through $3.4 billion of available cash, and $16 billion of new shares. Humanas existing debt of $3.8 billion will be assumed.Aetna expects to maintain a solid investment grade rating and access to short-term debt markets. The company also expects to deleverage rapidly thanks to strong cash flow. (Editing By Tessa Walsh and Jon Methven)",2015-07-09,AET,"Thu Jul 9, 2015 | 3:33pm EDT",Aetna's $16.2 billion bridge loan is second-biggest this year,http://www.reuters.com//article/us-aetna-bridge-idUSKCN0PJ2KI20150709?type=companyNews
204,"   By Leela Parker Deo and Karen Schwartz | NEW YORK, July 9  NEW YORK, July 9 U.S. health insurer Aetna Inc  is lining up a $16.2 billion bridge loan to fund its acquisition of smaller rival Humana Inc, which is the first multibillion M&A loan of the second half of 2015 and the second-largest acquisition bridge loan so far this year, according to Thomson Reuters LPC data.Aetna said on July 3 that it would buy Humana for $37 billion in cash and stock in the insurance industry's largest-ever acquisition.The deal will boost third quarter investment grade loan issuance and support expectations that a surplus of corporate cash is contributing to a growing pipeline of M&A transactions.Investment grade M&A-related lending totaled $63 billion in the first half of the year. 2015 totals could reach $200 billion based on the pipeline of financings building in the second half of the year, according to a lender survey by Thomson Reuters LPC.The merger is the latest transaction amid ongoing consolidation in the health insurance sector and was announced just before global markets were roiled by the decisive July 5 referendum in Greece which rejected additional harsh austerity measures and China's attempts to stabilize its ailing stock market.These macroeconomic developments and slumping oil and iron ore prices have the potential to disrupt the syndicated loan market, but dislocation is more likely to be felt by non-investment grade companies rather than high-grade issuers, one analyst said. Highly rated companies are in a relatively strong position to attract financing because of their credit profiles, he noted, and tend to benefit from any flight to quality in a risk-off environment.""I won't say it's not going to be somewhat choppy. The marketplace always tends to be somewhat choppier when you have these big geopolitical issues popping up. It's just one of several things they're going to need to navigate over the next six months,"" the analyst said.HEALTHY BRIDGE  Citigroup and UBS are providing the 364-day senior unsecured bridge facility, according to regulatory filings. The bridge loan is expected to be taken out with permanent financing that could include a mix of term debt, bonds and commercial paper, sources said. Citigroup and UBS are currently syndicating a $3.2 billion, three-year term loan, the sources added.If the merger clears antitrust scrutiny, it will dwarf the previous largest ever insurance deal announced in early July, when Swiss property and casualty giant ACE Ltd said it was buying Chubb Corp for $28 billion, Reuters reported.In the past two weeks, Anthem also has offered to buy Cigna Corp to create the largest insurer in the country, toppling UnitedHealth Group Inc, according to Reuters, as U.S. insurers grapple with the issue of providing universal coverage, which is a key policy of Barak Obama's presidency. ""We're through this tunnel of managing through at least the initial implementation phase of the ACA [Affordable Care Act],"" said the analyst. ""Companies are now thinking more strongly about how they want to position in the next 3-5 years, and I think M&A will increasingly be a part of that thought process.""The acquisition gives Aetna a strong leg up in government-sponsored managed Medicare, a growth market in the health insurance sector, the analyst added. ""This will vault them into a leadership position, assuming the deal goes through.""The bridge loan pricing is tied to a ratings grid, ranging from 75bp-125bp over Libor.Pricing opens at 100bp over Libor based on Aetna's senior unsecured debt ratings of Baa1/A/A- and the loan pays a 10bp commitment fee. Pricing includes 25bp margin step-ups at 90, 180 and 270 days, respectively, after closing. The loan also pays duration fees, a periodic fee on the outstanding balance of the bridge loan, of 50bp, 75bp and 100bp, according to the same schedule.The deal, which is expected to close in the second half of 2016, is also being financed through $3.4 billion of available cash, and $16 billion of new shares. Humana's existing debt of $3.8 billion will be assumed.Aetna expects to maintain a solid investment grade rating and access to short-term debt markets. The company also expects to deleverage rapidly thanks to strong cash flow.   (Editing By Tessa Walsh and Jon Methven)",2015-07-09,AET,"Thu Jul 9, 2015 | 3:25pm EDT",TRLPC: Aetna's $16.2B bridge loan is second-biggest this year,http://www.reuters.com//article/aetna-bridge-idUSL1N0ZP1TV20150709?type=companyNews
205,"   By Caroline Humer, Karen Freifeld and Diane Bartz | NEW YORK/WASHINGTON  NEW YORK/WASHINGTON U.S. insurance regulators and state attorneys general are lining up to scrutinize Aetna Inc's proposed $33 billion takeover of rival Humana Inc for potential harm to consumers, complicating what is already expected to be a tough and lengthy review by federal antitrust authorities.Insurance commissioners in 18 states including Texas, Kentucky and Florida will study merger documents provided by Humana to determine whether the deal will harm competition and lead to higher insurance premiums or diminished access to healthcare providers, according to Reuters interviews with regulators and insurance experts.At least three state attorneys general - in Florida, Mississippi and Massachusetts - said they will look at the proposed acquisition. Local politicians and medical industry groups such as the American Medical Association have also voiced concerns about the biggest deal ever in the U.S. health insurance industry.The Department of Justice is taking the lead on the transaction and may ask for asset sales or challenge a deal in court. But the concerns of state insurance commissioners are likely to have added weight since health insurance is heavily regulated at the local level, antitrust experts said. State regulators are also expected to provide the DOJ with their own data on how the deal will affect insurance markets.""The antitrust division makes the final decision on the competitive analysis but will take into account the information provided by the states,"" said Andre Barlow, an antitrust lawyer at Doyle, Barlow and Mazard PLLC, who's not involved in the inquiry.The proposed acquisition comes after years of health insurance change driven by the politically divisive Affordable Care Act, often called Obamacare. Republicans say the new law has driven insurance costs higher and hurt consumers, while Democrats say it is insuring more people. Aetna and Humana have said that because the health insurance market is now more focused on consumers, being bigger will let them offer more competitive products.When the nation's largest insurer, UnitedHealth Group , bought Nevada's Sierra Health Services in 2008, the Nevada Attorney General and the DOJ both filed antitrust complaints and signed off on a settlement requiring UnitedHealth to divest administration and sales of Medicare Advantage plans for seniors and the disabled in two counties.In 2004, California's state regulator first rejected the acquisition of WellPoint Health Networks by Anthem. The companies challenged the move in court and eventually agreed to concessions, including putting $265 million towards California health projects that would benefit consumers. The Humana purchase would create a company with more than 33 million customers in two-thirds of the United States. In individual states, their footprint is much bigger.In a combined Medicare Advantage business, Aetna and Humana would have an 88 percent market share in Kansas, 80 percent in West Virginia, 58 percent in Iowa and 51 percent in Missouri, according to data from the Kaiser Family Foundation. In commercial insured plans, the new company would have more than a third of individual customers in Florida, Illinois and Kansas and 68 percent of Georgia, according to SG Cowen and SNL Financial.Healthcare investors already have concerns over the Humana deal passing muster at the federal level, particularly after antitrust objections scuttled several other major transactions this year, including Sysco Corp's proposed purchase of US Foods and Comcast Corp's planned acquisition of Time Warner Cable Inc. They are also weighing the risk of another major health insurance merger being forged, possibly between Anthem Inc  and Cigna Corp. In that case, antitrust authorities would have to account for the market effect of both deals when raising any objections. The value of Aetna's cash and stock offer has dropped 10 percent since it was announced on July 3, as its share price fell over antitrust risk and other concerns. Aetna and Humana have said they view the regulatory process as ""manageable,"" targeting a deal closing in the second half of 2016 to account for a lengthy review. Aetna and Humana both declined to comment on antitrust issues for this story.STATE BY STATE California Insurance Commissioner Dave Jones plans to talk to antitrust authorities and other states through the National Association of Insurance Commissioners about the Humana deal's impact on California, where he sees even their combined 5 percent share as an issue. ""I will be raising whatever concerns I have on behalf of California consumers,"" Jones said in an interview. ""I am generally concerned that historically health insurance company mergers have resulted in higher, not lower, premiums for consumers.""For example, insurance premiums rose 13.7 percent in Nevada in the year after UnitedHealth Group's acquisition of Sierra Health Services compared to health plans in a similar market that was not affected, according to a 2013 study published in the journal Health Management, Policy and Innovation.In Kentucky, where Humana is based, Insurance Commissioner Sharon Clark said her department would work with federal regulators as they evaluate the transaction as well as conduct its own review, which could take six months to a year to complete.Georgia state commissioner Charles Hudgens said in a statement he will perform an in-depth analysis of the proposed transaction's effect on competition in the state. Texas, Illinois and Florida said they are also awaiting filings from Humana.State attorneys general may also look at the deal, but often don't disclose if they have opened an investigation.In Connecticut, where Aetna is based, a spokesman for Connecticut Attorney General George Jepsen declined to comment on whether the office plans to probe the deal. ""In Connecticut, the AG has the independent authority to look into mergers and to challenge them if it will lessen competition under the state's antitrust laws,"" Robert Blanchard said.In Kentucky, where Humana is based, a spokesman for Attorney General Jack Conway said his office will look at the terms of the potential merger when they are released and determine if any action is necessary. In Florida, where Humana has 1.63 million customers, a spokeswoman for Florida Attorney General Pam Bondi said the state would look into the proposed merger for its effect on competition.",2015-07-10,AET,"Fri Jul 10, 2015 | 5:59pm EDT",States line up to scrutinize Aetna's $33 bln Humana deal,http://www.reuters.com//article/humana-ma-aetna-antitrust-idUSL1N0ZQ2BQ20150710?type=companyNews
206,"   By Caroline Humer, Karen Freifeld and Diane Bartz | NEW YORK/WASHINGTON  NEW YORK/WASHINGTON U.S. insurance regulators and state attorneys general are lining up to scrutinize Aetna Inc's proposed $33 billion takeover of rival Humana Inc for potential harm to consumers, complicating what is already expected to be a tough and lengthy review by federal antitrust authorities.Insurance commissioners in 18 states including Texas, Kentucky and Florida will study merger documents provided by Humana to determine whether the deal will harm competition and lead to higher insurance premiums or diminished access to healthcare providers, according to Reuters interviews with regulators and insurance experts. At least three state attorneys general  in Florida, Mississippi and Massachusetts  said they will look at the proposed acquisition. Local politicians and medical industry groups such as the American Medical Association have also voiced concerns about the biggest deal ever in the U.S. health insurance industry.The Department of Justice is taking the lead on the transaction and may ask for asset sales or challenge a deal in court. But the concerns of state insurance commissioners are likely to have added weight since health insurance is heavily regulated at the local level, antitrust experts said. State regulators are also expected to provide the DOJ with their own data on how the deal will affect insurance markets.""The antitrust division makes the final decision on the competitive analysis but will take into account the information provided by the states,"" said Andre Barlow, an antitrust lawyer at Doyle, Barlow and Mazard PLLC, who's not involved in the inquiry.The proposed acquisition comes after years of health insurance change driven by the politically divisive Affordable Care Act, often called Obamacare. Republicans say the new law has driven insurance costs higher and hurt consumers, while Democrats say it is insuring more people. Aetna and Humana have said that because the health insurance market is now more focused on consumers, being bigger will let them offer more competitive products.When the nation's largest insurer, UnitedHealth Group (UNH.N), bought Nevada's Sierra Health Services in 2008, the Nevada Attorney General and the DOJ both filed antitrust complaints and signed off on a settlement requiring UnitedHealth to divest administration and sales of Medicare Advantage plans for seniors and the disabled in two counties. In 2004, California's state regulator first rejected the acquisition of WellPoint Health Networks by Anthem. The companies challenged the move in court and eventually agreed to concessions, including putting $265 million towards California health projects that would benefit consumers. The Humana purchase would create a company with more than 33 million customers in two-thirds of the United States. In individual states, their footprint is much bigger. In a combined Medicare Advantage business, Aetna and Humana would have an 88 percent market share in Kansas, 80 percent in West Virginia, 58 percent in Iowa and 51 percent in Missouri, according to data from the Kaiser Family Foundation. In commercial insured plans, the new company would have more than a third of individual customers in Florida, Illinois and Kansas and 68 percent of Georgia, according to SG Cowen and SNL Financial. Healthcare investors already have concerns over the Humana deal passing muster at the federal level, particularly after antitrust objections scuttled several other major transactions this year, including Sysco Corp's proposed purchase of US Foods and Comcast Corp's planned acquisition of Time Warner Cable Inc. They are also weighing the risk of another major health insurance merger being forged, possibly between Anthem Inc (ANTM.N) and Cigna Corp (CI.N). In that case, antitrust authorities would have to account for the market effect of both deals when raising any objections.The value of Aetna's cash and stock offer has dropped 10 percent since it was announced on July 3, as its share price fell over antitrust risk and other concerns. Aetna and Humana have said they view the regulatory process as ""manageable,"" targeting a deal closing in the second half of 2016 to account for a lengthy review. Aetna and Humana both declined to comment on antitrust issues for this story.   STATE BY STATE California Insurance Commissioner Dave Jones plans to talk to antitrust authorities and other states through the National Association of Insurance Commissioners about the Humana deals impact on California, where he sees even their combined 5 percent share as an issue. ""I will be raising whatever concerns I have on behalf of California consumers,"" Jones said in an interview. ""I am generally concerned that historically health insurance company mergers have resulted in higher, not lower, premiums for consumers.""For example, insurance premiums rose 13.7 percent in Nevada in the year after UnitedHealth Group's acquisition of Sierra Health Services compared to health plans in a similar market that was not affected, according to a 2013 study published in the journal Health Management, Policy and Innovation. In Kentucky, where Humana is based, Insurance Commissioner Sharon Clark said her department would work with federal regulators as they evaluate the transaction as well as conduct its own review, which could take six months to a year to complete.Georgia state commissioner Charles Hudgens said in a statement he will perform an in-depth analysis of the proposed transaction's effect on competition in the state. Texas, Illinois and Florida said they are also awaiting filings from Humana.State attorneys general may also look at the deal, but often don't disclose if they have opened an investigation. In Connecticut, where Aetna is based, a spokesman for Connecticut Attorney General George Jepsen declined to comment on whether the office plans to probe the deal. ""In Connecticut, the AG has the independent authority to look into mergers and to challenge them if it will lessen competition under the state's antitrust laws,"" Robert Blanchard said. In Kentucky, where Humana is based, a spokesman for Attorney General Jack Conway said his office will look at the terms of the potential merger when they are released and determine if any action is necessary. In Florida, where Humana has 1.63 million customers, a spokeswoman for Florida Attorney General Pam Bondi said the state would look into the proposed merger for its effect on competition. (Reporting by Caroline Humer and Karen Freifeld in New York, Susan Kelly in Chicago and Diane Bartz in Washington D.C. Editing by Michele Gershberg and John Pickering.)",2015-07-10,AET,"Fri Jul 10, 2015 | 5:44pm EDT",States line up to scrutinize Aetna's $33 billion Humana deal,http://www.reuters.com//article/us-humana-m-a-aetna-antitrust-idUSKCN0PK2II20150710?type=companyNews
207,"   By Robin Respaut | SAN FRANCISCO  SAN FRANCISCO A year and a half after the Affordable Care Act brought widespread reforms to the U.S. healthcare system, Chicago's Cook County Health & Hospitals System has made its first profit in 180 years.Seven hundred miles south, the fortunes of Atlanta's primary public hospital, Grady Health System, haven't improved, and it remains as dependent as ever on philanthropy and county funding to stay afloat.The disparity between the two ""safety net"" hospitals, both of which serve a disproportionate share of their communities' poorest patients, illustrates a growing divide nationwide.In states like Illinois that have opted to accept federal money to expand Medicaid, some large, public hospitals are finding themselves on solid financial footing for the first time in decades, and formerly uninsured patients are now getting regular care.But in states that did not expand the government medical program for the poor, primarily ones with conservative electorates opposed to Obamacare, including Georgia, the impact of the Affordable Care Act on public hospitals has been negligible.While the public exchanges established by the federal government and 14 states have brought coverage to many previously uninsured people in all parts of the country, the effect on the poorest Americans varies drastically from state to state.Nearly four million low-income, uninsured Americans living in states that didn't expand Medicaid would have qualified for coverage had their states chosen to expand it, according to the Kaiser Family Foundation. And public hospitals in those states, many of which rely on bond markets for funding, are likely to feel the pinch even more acutely over time, experts said.""Providers in these states are going to be at a disadvantage,"" said Jim LeBuhn, senior director at Fitch Ratings. ""It's going to make it that much more challenging for these providers to maintain their financial profiles.""Since the Affordable Care Act's first open enrollment in 2013, the number of Americans covered under Medicaid has risen by 21 percent, to 71.1 million. Nonprofit hospitals in the 30 states that expanded Medicaid reported on average 13 percent less bad debt from unpaid bills last year, according to Moody's Investors Service. In contrast, according to Moody's, such ""hospitals in non-expansion states saw bad debt increase through much of the year.""Hospitals in Medicaid expansion states, according to Kaiser, reported an average 32 percent decrease in uninsured patients and a 40 percent cut in unreimbursed costs of care for patients without the ability to pay, known in the industry as charity care costs. In non-expansion states, the number of uninsured patients declined by 4.4 percent and charity care costs dropped by 6.2 percent.New recipients of Medicaid benefited, too. After one year, adults who gained the coverage were 55 percent more likely to have their own doctor than those who did not, Kaiser found. Medicaid also increased the likelihood of receiving preventive care, such as mammograms and cholesterol checks.A TALE OF TWO HOSPITALS  Both Cook County and Grady are safety-net hospitals based in urban counties where the poverty level is slightly higher than the national average, and both have handled high numbers of uninsured clients in recent years: about half of the patients at Cook and nearly a third at Grady.Since Obamacare took effect, the numbers at the Georgia hospital have remained about the same. But things have changed dramatically at the Illinois hospital, in large part due to the area's enrollment of about 170,000 of an estimated 330,000 eligible for the expanded Medicaid.""This has been a sea change for us,"" said Dr. John Jay Shannon, Cook County Health's chief executive.Within two years, the percent of uninsured patients at the hospital had dropped from more than a half to about a third, almost entirely driven by increased Medicaid coverage, hospital data show. And for the first time in the hospital's history, a majority of the patients it treated had coverage. A third of the new Medicaid enrollees treated at Cook County were patients new to the system. And, hospital administrators say, those with chronic diseases such as diabetes, who used to be frequent emergency room visitors, now have personal physicians to help them manage their conditions.In the fiscal year ending in November 2014, uncompensated charity care dropped to $342 million from $500 million the year before. Funding from Medicaid nearly doubled the health system's operating revenues, a major reason that, after ending 2013 with a net loss of $67.6 million, Cook County Health finished its most recent fiscal year in the black.Now, the provider, like other safety-net hospitals, has a new challenge: holding onto old clients.""For the first time in our history, we need to compete for our patients,"" said Shannon. ""A world of improved access is also a world of choice.""At Grady Health System in Atlanta, meanwhile, the number of patients covered by insurance increased by less than 2 percent last year. Bad debt from unpaid bills has continued to climb, to $396 million from $269 million in 2013. And the percentage of patients covered by Medicaid didn't change.""We've seen no difference from the Affordable Care Act,"" said John Haupert, Grady's chief executive. Many patients ""are still coming to us as a safety-net provider and falling under our charity care.""Georgia is one of 20 states, disproportionately clustered in the South, that didn't expand Medicaid. About 89 percent of those left out of the new Medicaid coverage, because their states chose not to expand the program, live in the South, Kaiser Family Foundation found.Grady has a better financial outlook than many hospitals in states that didn't expand Medicaid, thanks to a philanthropic campaign that has raised $350 million since 2008 to fund new infrastructure and expand clinical services. But, unlike Cook County, which has reduced some dependence on local government support with the help of Medicaid expansion dollars, Grady remains reliant on $57 million in tax support from two local counties. Without the local funding, Grady would be running a deficit.""From a global perspective, it seems like the ACA is working,"" said Kevin Holloran, senior director at Standard & Poor's. But in non-expansion states, like Georgia, ""it's really a neutral. It's just the status quo.""",2015-07-23,AET,"Thu Jul 23, 2015 | 7:52am EDT","Some public hospitals win, others lose with Obamacare",http://www.reuters.com//article/usa-hospital-medicaid-idUSL1N1030WX20150723?type=companyNews
208,"   By Robin Respaut | SAN FRANCISCO  SAN FRANCISCO A year and a half after the Affordable Care Act brought widespread reforms to the U.S. healthcare system, Chicago's Cook County Health & Hospitals System has made its first profit in 180 years.Seven hundred miles south, the fortunes of Atlanta's primary public hospital, Grady Health System, haven't improved, and it remains as dependent as ever on philanthropy and county funding to stay afloat.The disparity between the two ""safety net"" hospitals, both of which serve a disproportionate share of their communities' poorest patients, illustrates a growing divide nationwide.     In states like Illinois that have opted to accept federal money to expand Medicaid, some large, public hospitals are finding themselves on solid financial footing for the first time in decades, and formerly uninsured patients are now getting regular care. But in states that did not expand the government medical program for the poor, primarily ones with conservative electorates opposed to Obamacare, including Georgia, the impact of the Affordable Care Act on public hospitals has been negligible. While the public exchanges established by the federal government and 14 states have brought coverage to many previously uninsured people in all parts of the country, the effect on the poorest Americans varies drastically from state to state.Nearly four million low-income, uninsured Americans living in states that didn't expand Medicaid would have qualified for coverage had their states chosen to expand it, according to the Kaiser Family Foundation. And public hospitals in those states, many of which rely on bond markets for funding, are likely to feel the pinch even more acutely over time, experts said. ""Providers in these states are going to be at a disadvantage,"" said Jim LeBuhn, senior director at Fitch Ratings. ""Its going to make it that much more challenging for these providers to maintain their financial profiles.""Since the Affordable Care Act's first open enrollment in 2013, the number of Americans covered under Medicaid has risen by 21 percent, to 71.1 million. Nonprofit hospitals in the 30 states that expanded Medicaid reported on average 13 percent less bad debt from unpaid bills last year, according to Moodys Investors Service. In contrast, according to Moody's, such ""hospitals in non-expansion states saw bad debt increase through much of the year.""  Hospitals in Medicaid expansion states, according to Kaiser, reported an average 32 percent decrease in uninsured patients and a 40 percent cut in unreimbursed costs of care for patients without the ability to pay, known in the industry as charity care costs. In non-expansion states, the number of uninsured patients declined by 4.4 percent and charity care costs dropped by 6.2 percent.New recipients of Medicaid benefited, too. After one year, adults who gained the coverage were 55 percent more likely to have their own doctor than those who did not, Kaiser found. Medicaid also increased the likelihood of receiving preventive care, such as mammograms and cholesterol checks.A TALE OF TWO HOSPITALS Both Cook County and Grady are safety-net hospitals based in urban counties where the poverty level is slightly higher than the national average, and both have handled high numbers of uninsured clients in recent years: about half of the patients at Cook and nearly a third at Grady.   Since Obamacare took effect, the numbers at the Georgia hospital have remained about the same. But things have changed dramatically at the Illinois hospital, in large part due to the area's enrollment of about 170,000 of an estimated 330,000 eligible for the expanded Medicaid.""This has been a sea change for us, said Dr. John Jay Shannon, Cook County Health's chief executive. Within two years, the percent of uninsured patients at the hospital had dropped from more than a half to about a third, almost entirely driven by increased Medicaid coverage, hospital data show. And for the first time in the hospitals history, a majority of the patients it treated had coverage. A third of the new Medicaid enrollees treated at Cook County were patients new to the system. And, hospital administrators say, those with chronic diseases such as diabetes, who used to be frequent emergency room visitors, now have personal physicians to help them manage their conditions. In the fiscal year ending in November 2014, uncompensated charity care dropped to $342 million from $500 million the year before. Funding from Medicaid nearly doubled the health system's operating revenues, a major reason that, after ending 2013 with a net loss of $67.6 million, Cook County Health finished its most recent fiscal year in the black.  Now, the provider, like other safety-net hospitals, has a new challenge: holding onto old clients.For the first time in our history, we need to compete for our patients, said Shannon. ""A world of improved access is also a world of choice.""At Grady Health System in Atlanta, meanwhile, the number of patients covered by insurance increased by less than 2 percent last year. Bad debt from unpaid bills has continued to climb, to $396 million from $269 million in 2013. And the percentage of patients covered by Medicaid didnt change.Weve seen no difference from the Affordable Care Act, said John Haupert, Grady's chief executive. Many patients ""are still coming to us as a safety-net provider and falling under our charity care. Georgia is one of 20 states, disproportionately clustered in the South, that didnt expand Medicaid. About 89 percent of those left out of the new Medicaid coverage, because their states chose not to expand the program, live in the South, Kaiser Family Foundation found. Grady has a better financial outlook than many hospitals in states that didn't expand Medicaid, thanks to a philanthropic campaign that has raised $350 million since 2008 to fund new infrastructure and expand clinical services. But, unlike Cook County, which has reduced some dependence on local government support with the help of Medicaid expansion dollars, Grady remains reliant on $57 million in tax support from two local counties. Without the local funding, Grady would be running a deficit. From a global perspective, it seems like the ACA is working, said Kevin Holloran, senior director at Standard & Poors. But in non-expansion states, like Georgia, its really a neutral. Its just the status quo. (Reporting By Robin Respaut; Editing by Peter Henderson and Sue Horton)",2015-07-23,AET,"Thu Jul 23, 2015 | 2:49am EDT","Some public hospitals win, others lose with Obamacare",http://www.reuters.com//article/us-usa-hospital-medicaid-insight-idUSKCN0PX0CY20150723?type=companyNews
209,"  * Combined company would be No. 1 insurer, cover 53 mln members* Antitrust review would include proposed Aetna buy of Humana* U.S. lawmakers, medical group express concern for consumers   (Adds details on antitrust review, concerns from lawmakers, Breakingviews link)By Ankur Banerjee and Ransdell PiersonJuly 24 Anthem Inc said on Friday it would buy Cigna Corp for about $54.2 billion, creating the largest U.S. health insurer by membership and accelerating the industry's consolidation from five national players to three.The proposed acquisition, the health insurance industry's largest, comes three weeks after Aetna Inc agreed to buy Humana Inc for $37 billion.Health insurers are finding it tougher to raise prices following the roll-out of President Barack Obama's healthcare law, while grappling with soaring expenses of medications including cancer drugs that can cost each patient more than $100,000 a year. Anthem said buying Cigna would help it reduce costs and negotiate lower prices with doctors and hospitals.State insurance regulators and federal antitrust authorities are expected to scrutinize how the Anthem-Cigna and Aetna-Humana deals would affect competition for Medicare and individual and commercial insurance.Within a few hours of the announcement, several U.S. lawmakers and a leading physicians group said they feared the pending acquisitions would hurt consumers by raising prices or limiting access to healthcare providers.""The lack of a competitive health insurance market allows the few remaining companies to exploit their market power, dictate premium increases and pursue corporate policies that are contrary to patient interests,"" the American Medical Association (AMA) said in a statement.Under the deal, which the companies expect to close in the second half of 2016, Anthem Chief Executive Joseph Swedish would serve as CEO and chairman. Cigna CEO David Cordani would be president and chief operating officer.In a joint conference call, Swedish told analysts Anthem had no prior discussions ""at all"" with regulators about the deal, but was confident about approval.Shares of Cigna on Friday fell 5.6 percent to $145.72, far below the $188 offered in the buyout, suggesting major Wall Street concern over the antitrust risk. ""Strategically and financially it's very attractive, but they will face regulatory scrutiny,"" said Ana Gupte, analyst with Leerink Partners. ""They also both possibly face divestitures and may have to make concessions to consumers to make the merger go through.""The AMA said its own analysis shows 41 percent of U.S. metropolitan areas already have a single health insurer with a commercial market share of 50 percent or more. It believes the Anthem-Cigna merger would be presumed anticompetitive in at least nine of the states where Anthem operates.""It is imperative that we closely examine changes in the healthcare market, and what has caused these changes, to ensure that consumers are not harmed,"" said Senator Mike Lee, a Republican from Utah who is chairman of the Senate's antitrust panel.Apparent worries about regulatory scrutiny have also hit Humana shares, which closed at $181.76 on Friday, well below the value of Aetna's cash-and-stock offer of $230 per share when it was announced on July 3. BIGGER THAN UNITEDHEALTH Cigna has 15 million members, and about 80 percent of its business is with self-insured companies which pay it a management fee, according to Leerink. It also serves large and small employers, Medicare Advantage customers and individuals.About 61 percent of Anthem's 39 million members are served through self-insured companies, while 15 percent have Medicaid coverage. Large and small group policies make up about 12 percent of its business, while Medicare Advantage accounts for 1 percent.The combined company would have about 53 million members, surpassing UnitedHealth Group's 45.86 million as of June 30.Anthem said it will pay $103.40 in cash and 0.5152 of its shares for each Cigna share. The deal is valued at $181.12 per share based on Anthem's Friday close of $150.86. Anthem said on Friday the offer was valued at $188 per share based on its stock price on May 28 before media reports surfaced that the two companies were in talks.The offer's equity portion is valued at $49.11 billion, according to Reuters calculations based on 261.2 million Cigna shares outstanding as of March 31.Another question is whether Anthem would violate rules of  the Blue Cross and Blue Shield Association, a federation of 36 independent insurers of which it is the biggest member.The association collectively insures 106 million Americans. Anthem provides coverage to the most people and operates in 14 states. No other Blue Cross member operates in more than five states.Blue Cross operators are not supposed to compete with one another, but Cigna does compete against Blue Cross members in a handful of states, which could cause controversy in the association.""There will no doubt be debate among the board of directors,"" said a person knowledgeable about Blue Cross who requested anonymity to protect business relationships.""We will remain Blue,"" Swedish said on the conference call, adding that Anthem feels confident that even after acquiring Cigna, the combined company will satisfy ""the Blue rules.""Swedish said he would serve as CEO for only two years, and remain as chairman afterward. Cordani could be a contender for the CEO role at that point, but no guarantees were provided, said a source familiar with the matter who requested anonymity because the person was unauthorized to publicly discuss details of the transaction.Both Anthem and Cigna would be liable to pay the other a fee equivalent to 3.8 percent of the deal's value if either walks away from the planned merger.Anthem's lead financial adviser is UBS Investment Bank. Credit Suisse also served as financial adviser, and White & Case LLP as legal adviser.Morgan Stanley is Cigna's financial adviser and Cravath, Swaine & Moore LLP its legal adviser.   (Additional reporting by Caroline Humer and Kylie Gumpert in New York and Diane Bartz in Washington; Editing by Alan Crosby and Richard Chang)",2015-07-24,AET,"Fri Jul 24, 2015 | 4:49pm EDT","UPDATE 5-Anthem to buy Cigna, creating biggest U.S. health insurer",http://www.reuters.com//article/cigna-ma-anthem-idUSL1N1041DO20150724?type=companyNews
210,"   By Diane Bartz  The U.S. House of Representatives Judiciary Committee is planning two hearings for September to discuss concerns about reduced competition in the healthcare industry, lawmakers from both parties said. In July, insurer Aetna said it would buy rival Humana for $33 billion, while Anthem said it would buy Cigna for $54.2 billion. The dual deals would effectively lower the number of major U.S. health insurers from five to three.  To read the full story on WestlawNext Practitioner Insights, click here: bit.ly/1Ipsome",2015-07-27,AET,"Mon Jul 27, 2015 | 7:15am EDT",U.S. House panel to hold hearings on competition in healthcare,http://www.reuters.com//article/congress-healthcare-antitrust-idUSL1N1070E420150727?type=companyNews
211,"  BRUSSELS, July 28 The following are mergers under review by the European Commission and a brief guide to the EU merger process:APPROVALS AND WITHDRAWALS -- Private equity firm Cinven Capital Management to acquire biological testing services company Labco (approved July 28-- U.S. healthcare company Danaher Corp to acquire air and water filter maker Pall Corp (approved July 27)-- Talanx Asset Management GmbH and Norddeutsche Landesbank Girozentrale (Nord LB) to acquire joint control of alternative asset investment management company Caplantic GmbH (approved July 24)NEW LISTINGS -- U.S. real estate services provider DTZ to acquire U.S. peer Cushman & Wakefield (notified July 24/deadline Aug. 28)-- Volkswagen Financial Services, which is part of German carmaker Volkswagen, and Spanish lender Banco Bilbao Vizcaya Argentaria to set up a joint venture called Volkswagen Credit Compania Financiera (notified July 17/deadliine Aug. 24/simplified)EXTENSIONS AND OTHER CHANGES NoneFIRST-STAGE REVIEWS BY DEADLINE JULY 29 -- U.S. drugmaker Mylan to acquire U.S. peer Perrigo  (notified June 23/deadline July 29)AUG 4 -- U.S. drugmaker Pfizer to acquire U.S. peer Hospira (notified June 15/deadline extended to Aug. 4 from July 20 after Pfizer offered concessions)AUG 5 -- Asset manager BlackRock and private equity firm First Reserve Management to acquire joint control of a joint venture building a gas pipeline in Mexico, in which GDF Suez holds a stake (notified June 30/deadline Aug. 5/simplified)-- Spanish cars part maker Grupo Antolin to acquire auto parts maker Magna Interiors from Canadian car parts maker Magna International Inc (notified June 30/deadline Aug. 5)AUG 6 -- Swiss travel retailer Dufry to acquire Italian peer World Duty Free (notified July 1/deadline Aug 6)AUG 7 -- Private equity firm CVC Capital Partners to acquire beauty products retailer Douglas Group (notified July 2/deadline Aug. 7/simplified)-- German insurer Axa Konzern and Compugroup Medical Mobile DTL to set up a joint venture (notified July 2/deadline Aug. 7/simplified) AUG 10 -- Private equity firm Lone Star Fund IX to acquire textile floor coverings producer Balta (notified July 3/deadline Aug. 10/simplified)AUG 11 -- Investment fund Apollo Management L.P. to acquire Saint-Gobain Emballage, Saint Gobain Vicasa S.A., Saint Gobain Vidros and Obale, with the group known as Verallia (notified July 6/deadline Aug. 11/simplified)AUG 13 -- Swiss bakery products maker Aryzta to acquire 49 percent of frozen food retailer Picard Groupe (notified July 8/deadline Aug. 13)AUG 14 -- NH Hotel Group SA and HNA Hospitality Group Co Ltd to set up a joint venture which will operate mainly in China (notified July 9/deadline Aug. 14/simplified)AUG 17 -- Investment fund Canada Pension Plan Investment Board (CPPIB) and real estate investment trust Intu Holding S.a.r.l. to indirectly acquire a joint controlling stake in Spanish shopping mall Puerto Venecia Investments SOCIMI S.A. (notified July 10/deadline Aug. 17/simplified) -- Private equity firm CVC to acquire theatre producer Stage Entertainment (notified July 10/deadline Aug. 17/simplified)-- Spanish energy company Repsol and Mexican industrial group Grupo Kuo to expand their joint venture Dynasol (notified July 10/deadline Aug. 17/simplified)-- Investment bank Goldman Sachs and Altor to jointly acquire soy-based protein solutions maker Hamlet Protein (notified July 10/deadline Aug. 17)AUG 18 -- U.S. staffing company ManpowerGroup Inc to acquire German peer 7S Group (notified July 13/deadline Aug. 18/simplified)AUG 19 -- French companies Groupe In Vivo and Groupe Scael to set up a joint venture (notified July 14/deadline Aug. 19/simplified)-- Fuel supplier World Fuel Services Corp to acquire businesses divested by BP Plc (notified July 14/deadline Aug. 19/simplified)AUG 20 -- Dutch building materials distributor PontMeyer, which is part of Deli Building Supplies B.V., to acquire Dutch holding company DBS (notified July 15/deadline Aug. 20)AUG 24 -- Funds advised by Apax Partners LLP to acquire online retailer RFS (notified July 17/deadline Aug. 24/simplified) -- Real estate services firm CBRE Group Inc to buy Johnson Controls Inc's workplace solutions business (notified July 17/deadline Aug. 24/simplified)-- Magyar Telekom, 59 percent owned by Deutsche Telekom, to form a joint venture with Swiss-based energy sales and trading group MET Holding AG (notified July 17/deadline Aug. 24)AUG 26 -- Italian confectionery maker Ferrero to purchase British chocolate retailer Thornstons  (notified July 22/deadline Aug. 26/simplified)-- U.S. drugmaker Perrigo to buy portfolio of over-the-counter brands form British peer GlaxoSmithKline  (notified July 22/deadline Aug. 26)-- Varo Energy, a joint venture between the world's top oil trader Vitol and private equity firm Carlyle Group , is expanding its reach in Europe through a merger with Dutch-based storage and trading company Argos (notified July 22/ deadline Aug. 26)AUG 27 -- Oilfield services provider Halliburton to buy rival Baker Hughes in a stock and cash transaction (notified July 23/deadline Aug. 27)SEPT 2 -- Norwegian telecoms company Telenor and Swedish peer TeliaSonera to combine their Danish mobile businesses (notified Feb. 27/deadline extended to Sept. 2 from Aug. 19 after the companies asked for more time)SEPT 11 -- U.S. conglomerate General Electric to acquire most of French engineering group Alstom's power equipment business (notified Jan. 19/deadline extended for third time to Sept. 11 from Aug. 21)NOV 25 -- U.S. drinks can maker Ball Corp to acquire British rival Rexam Plc (notified June 15/deadline extended to Nov. 25 from July 20 after Commission opened in-depth investigation)SUSPENDED -- SOCAR, Azerbaijan's state energy company, to buy stakes in Greek natural gas grid operator DESFA from Greek natural gas utility DEPA (notified Oct. 1/deadline suspended on Jan. 21)GUIDE TO EU MERGER PROCESS DEADLINES: The European Commission has 25 working days after a deal is  filed for a first-stage review. It may extend that by 10 working days to 35 working days, to consider either a company's proposed remedies or an EU member state's request to handle the case.Most mergers win approval but occasionally the Commission  opens a detailed second-stage investigation for up to 90  additional working days, which it may extend to 105 working  days.SIMPLIFIED: Under the simplified procedure, the Commission announces the clearance of uncontroversial first-stage mergers without giving any reason for its decision. Cases may be reclassified as non-simplified - that is, ordinary first-stage reviews - until they are approved.   (Compiled by Foo Yun Chee)",2015-07-28,AET,"Tue Jul 28, 2015 | 10:47am EDT",EU mergers and takeovers (July 28),http://www.reuters.com//article/eu-mergers-idUSL5N10841V20150728?type=companyNews
212,"  Health insurer Humana Inc (HUM.N), which earlier this month agreed to be bought by Aetna Inc (AET.N) for $37 billion, on Wednesday reported a rise in a key medical cost metric that missed analyst expectations.Humana's consolidated benefit ratio, or the ratio of its spending on medical claims versus premium revenue it takes in, was 85.2 percent compared with 83.1 percent a year ago.   Leerink Partners analyst Ana Gupte said in a research note that the ratio was 50 basis points worse than Wall Street consensus.Investors closely watch this ratio as a sign of whether insurers, who have benefited from years of low medical use and claims, will be caught out by sudden shifts in demand. Humana first said in early July that costs related to the rate of hospital admissions among Medicare customers were higher than it had anticipated. It cut its 2015 outlook by 8 percent and shares fell at that time. On Wednesday, Humana said medical costs have not worsened since it issued that outlook earlier this month. It reiterated that it believes it has priced its 2016 premium rates to cover these costs, indicating that this key metric should improve. Humana had missed analyst expectations several quarters in a row because of cost issues, contributing to investor skepticism about the Aetna deal. The deal is also expected to face antitrust scrutiny as regulators weigh the impact of the combination on competition. Authorities are also expected to closely look at Anthem Inc's (ANTM.N) $54 billion purchase of Cigna Corp (CI.N) and require some asset sales.    The managed care sector is consolidating as insurers seek to cut costs and negotiate with doctors and hospitals over pricing. Humana shares were off 0.5 percent at $183.59 in Wednesday morning trade. Aetna was off 2 cents at $112.29.Excluding tax benefits from the sale of Concerta Inc, Humana earned $1.67 per share, compared with the average analyst estimate of $1.63 per share, according to Thomson Reuters I/B/E/S. On that basis, it had reported earnings of $2.19 per share in the year-ago quarter. In early July, the company told analysts to expect earnings of $1.60 to $1.65 per share on an adjusted basis.Net income rose to $431 million, or $2.85 per share, in the second quarter, from $344 million, or $2.19 per share, a year earlier.The company reported revenue of $13.73 billion, which missed the average analyst estimate of $13.81 billion. (Reporting by Caroline Humer in New York and Vidya L Nathan in Bengaluru; Editing by Anil D'Silva and Meredith Mazzilli)",2015-07-29,AET,"Wed Jul 29, 2015 | 11:45am EDT",Humana says medical costs cut into second-quarter profit,http://www.reuters.com//article/us-humana-results-idUSKCN0Q31GK20150729?type=companyNews
213,"  (New throughout)July 29 Health insurer Humana Inc, which earlier this month agreed to be bought by Aetna Inc for $37 billion, on Wednesday reported a rise in a key medical cost metric that missed analyst expectations.Humana's consolidated benefit ratio, or the ratio of its spending on medical claims versus premium revenue it takes in, was 85.2 percent compared with 83.1 percent a year ago.Leerink Partners analyst Ana Gupte said in a research note that the ratio was 50 basis points worse than Wall Street consensus.Investors closely watch this ratio as a sign of whether insurers, who have benefited from years of low medical use and claims, will be caught out by sudden shifts in demand.Humana first said in early July that costs related to the rate of hospital admissions among Medicare customers were higher than it had anticipated. It cut its 2015 outlook by 8 percent and shares fell at that time. On Wednesday, Humana said medical costs have not worsened since it issued that outlook earlier this month. It reiterated that it believes it has priced its 2016 premium rates to cover these costs, indicating that this key metric should improve.Humana had missed analyst expectations several quarters in a row because of cost issues, contributing to investor skepticism about the Aetna deal. The deal is also expected to face antitrust scrutiny as regulators weigh the impact of the combination on competition. Authorities are also expected to closely look at Anthem Inc's  $54 billion purchase of Cigna Corp and require some asset sales.The managed care sector is consolidating as insurers seek to cut costs and negotiate with doctors and hospitals over pricing.Humana shares were off 0.5 percent at $183.59 in Wednesday morning trade. Aetna was off 2 cents at $112.29. Excluding tax benefits from the sale of Concerta Inc, Humana earned $1.67 per share, compared with the average analyst estimate of $1.63 per share, according to Thomson Reuters I/B/E/S. On that basis, it had reported earnings of $2.19 per share in the year-ago quarter.In early July, the company told analysts to expect earnings of $1.60 to $1.65 per share on an adjusted basis.Net income rose to $431 million, or $2.85 per share, in the second quarter, from $344 million, or $2.19 per share, a year earlier.The company reported revenue of $13.73 billion, which missed the average analyst estimate of $13.81 billion.       (Reporting by Caroline Humer in New York and Vidya L Nathan in Bengaluru; Editing by Anil D'Silva and Meredith Mazzilli)",2015-07-29,AET,"Wed Jul 29, 2015 | 11:38am EDT",UPDATE 2-Humana says medical costs cut into second-quarter profit,http://www.reuters.com//article/humana-results-idUSL3N10949A20150729?type=companyNews
214,"   By Caroline Humer  Aetna Inc (AET.N) on Tuesday reported a better-than-expected adjusted net profit for the second quarter and said ""moderate"" medical costs boosted the profitability of its government Medicare and Medicaid plans.The third-largest U.S. health insurer, which is in the process of buying rival Humana Inc (HUM.N), also raised its full-year forecast for adjusted net profit to at least $7.40 per share from $7.20-$7.40.The $37 billion Aetna-Humana combination is part of a consolidation that insurers say will help them offer more competitive products amid changes due to the national healthcare reform law, often called Obamacare. Anthem Inc (ANTM.N) and Cigna Corp (CI.N) also plan to merge in a $47 billion deal. The merger trend is also related to medical costs that have risen with the improved economy and as millions more people who have become insured through Obamacare visit doctors and hospitals.Investors are closely watching how these costs impact insurers. Aetna said on Tuesday that its medical cost trends were moderate during the quarter, which helped improve its medical benefit ratio to 81.1 percent from 83.1 percent. The ratio represents the percentage of premium income that an insurer spends on medical claims. Aetna said its second-quarter medical benefit ratio in its government business, which includes Medicare for elderly people and Medicaid for the poor, fell to 80.3 percent from 86.5 percent as it raised premiums and costs remained low. The ratio for its commercial business rose to 81.8 percent from 80.6 percent, reflecting payments it put aside for the risk adjustment program that redistributes the costs of providing individual Obamacare insurance among insurers selling these plans. ""Second quarter results were well above consensus estimates as the companys government business continued to report better-than-expected performance, while commercial underwriting margins were steady despite the company absorbing a significant hit from a $252 million risk adjustment payable,"" Susquehanna Financial Group analyst Chris Rigg said in a note.Aetna shares closed on Monday at $113.79, up 28 percent this year.Aetna's net profit rose to $731.8 million, or $2.08 per share, in the second quarter ended June 30, from $548.8 million, or $1.52 per share, a year earlier. Excluding items, the company earned $2.05 per share, beating average analyst estimates of $1.82 per share, according to Thomson Reuters I/B/E/S.Revenue rose 5 percent to $15.24 billion, still short of analyst expectations of $15.43 billion. (Additional reporting by Amrutha Penumudi in Bengaluru)",2015-08-04,AET,"Tue Aug 4, 2015 | 12:35pm EDT",Aetna profit beats as moderate medical costs help government plans,http://www.reuters.com//article/us-aetna-results-idUSKCN0Q910S20150804?type=companyNews
215,"   By Caroline Humer | NEW YORK  NEW YORK Aetna Inc (AET.N) Chief Executive Mark Bertolini said on Tuesday the company is talking to federal and state officials on its $37 billion acquisition of Humana Inc (HUM.N) and that there is enough insurance competition for it to receive approval.""The process is underway. We've engaged in conversations with insurance commissioners, with governors, with Washington,"" Bertolini told investors during a conference call to announce the company's earnings. ""We're doing deep analysis, even deeper than we did before the deal on the number of competitors by market,"" he said. If Aetna or Humana need to divest in a market because of the competitive dynamics, ""there will be plenty of competitors in each market,"" he added.    Investors expect regulators and states to push back on the combination of the company's Medicare Advantage offerings. It will become the largest provider of these plans and in some states, will have dominant market share.Aetna shares were unchanged in late morning trading after it announced second-quarter profit rose beyond Wall Street expectations, suggesting that investor worries about the antitrust prospect are still at the front of their minds. ""I think people are looking for more than just assurances from management,"" said Ana Gupte, analyst at Leerink Partners. ""They want to see some actual progress on the regulatory process"" which could take until next year, she said. Aetna has filed its initial antitrust documents with federal regulators and has begun to make the needed filings with state insurance regulators in about 20 states, Bertolini said.  Aetna has spoken with many governors and generally those conversations have been positive, Chief Financial Officer Shawn Guertin said in an interview.Governors of states have a variety of concerns, from jobs to insurance offerings to price stability, he said. The regulatory process is expected to take at least a year. Aetna's acquisition will be reviewed by the Department of Justice as well as state insurance regulators who oversee the commercial insurance industry. Aetna expects to close the deal in the second half of 2016. Bertolini said Aetna will likely need to divest assets in some markets - as Wall Street analysts have suggested - but that in all, the company will have about 8 percent market share of the overall Medicare market, which includes both Medicare Advantage and Medicare fee for service. Antitrust regulators will also be looking at Blue Cross Blue Shield insurer Anthem Inc's (ANTM.N) acquisition of Cigna Corp's (CI.N) at the same time as Aetna's Humana purchase.  (Reporting by Caroline Humer; Editing by Meredith Mazzilli and Alan Crosby)",2015-08-04,AET,"Tue Aug 4, 2015 | 12:35pm EDT",Aetna CEO says antitrust process underway in Humana deal,http://www.reuters.com//article/us-aetna-results-cfo-idUSKCN0Q91D720150804?type=companyNews
216,"   By Caroline Humer  Aetna Inc Chief Executive Mark Bertolini said on Tuesday the company is talking to federal and state officials on its $37 billion acquisition of Humana Inc  and that there is enough insurance competition for it to receive approval.""The process is underway. We've engaged in conversations with insurance commissioners, with governors, with Washington,"" Bertolini told investors during a conference call to announce the company's earnings.""We're doing deep analysis, even deeper than we did before the deal on the number of competitors by market,"" he said. If Aetna or Humana need to divest in a market because of the competitive dynamics, ""there will be plenty of competitors in each market,"" he added.Investors expect regulators and states to push back on the combination of the company's Medicare Advantage offerings. It will become the largest provider of these plans and in some states, will have dominant market share. Aetna shares were unchanged in late morning trading after it announced second-quarter profit rose beyond Wall Street expectations, suggesting that investor worries about the antitrust prospect are still at the front of their minds.""I think people are looking for more than just assurances from management,"" said Ana Gupte, analyst at Leerink Partners. ""They want to see some actual progress on the regulatory process"" which could take until next year, she said. Aetna has filed its initial antitrust documents with federal regulators and has begun to make the needed filings with state insurance regulators in about 20 states, Bertolini said.Aetna has spoken with many governors and generally those conversations have been positive, Chief Financial Officer Shawn Guertin said in an interview. Governors of states have a variety of concerns, from jobs to insurance offerings to price stability, he said.The regulatory process is expected to take at least a year. Aetna's acquisition will be reviewed by the Department of Justice as well as state insurance regulators who oversee the commercial insurance industry. Aetna expects to close the deal in the second half of 2016.Bertolini said Aetna will likely need to divest assets in some markets - as Wall Street analysts have suggested - but that in all, the company will have about 8 percent market share of the overall Medicare market, which includes both Medicare Advantage and Medicare fee for service.Antitrust regulators will also be looking at Blue Cross Blue Shield insurer Anthem Inc's acquisition of Cigna Corp's  at the same time as Aetna's Humana purchase.",2015-08-04,AET,"Tue Aug 4, 2015 | 12:35pm EDT",Aetna CEO says antitrust process underway in Humana deal,http://www.reuters.com//article/aetna-results-ceo-idUSL1N10F1Y420150804?type=companyNews
217,"  (Adds CEO quotes, CFO comment, analyst)By Caroline HumerNEW YORK Aug 4 Aetna Inc Chief Executive Mark Bertolini said on Tuesday the company is talking to federal and state officials on its $37 billion acquisition of Humana Inc and that there is enough insurance competition for it to receive approval.""The process is underway. We've engaged in conversations with insurance commissioners, with governors, with Washington,"" Bertolini told investors during a conference call to announce the company's earnings.""We're doing deep analysis, even deeper than we did before the deal on the number of competitors by market,"" he said. If Aetna or Humana need to divest in a market because of the competitive dynamics, ""there will be plenty of competitors in each market,"" he added. Investors expect regulators and states to push back on the combination of the company's Medicare Advantage offerings. It will become the largest provider of these plans and in some states, will have dominant market share.Aetna shares were unchanged in late morning trading after it announced second-quarter profit rose beyond Wall Street expectations, suggesting that investor worries about the antitrust prospect are still at the front of their minds.""I think people are looking for more than just assurances from management,"" said Ana Gupte, analyst at Leerink Partners. ""They want to see some actual progress on the regulatory process"" which could take until next year, she said. Aetna has filed its initial antitrust documents with federal regulators and has begun to make the needed filings with state insurance regulators in about 20 states, Bertolini said.Aetna has spoken with many governors and generally those conversations have been positive, Chief Financial Officer Shawn Guertin said in an interview. Governors of states have a variety of concerns, from jobs to insurance offerings to price stability, he said.The regulatory process is expected to take at least a year. Aetna's acquisition will be reviewed by the Department of Justice as well as state insurance regulators who oversee the commercial insurance industry. Aetna expects to close the deal in the second half of 2016.Bertolini said Aetna will likely need to divest assets in some markets - as Wall Street analysts have suggested - but that in all, the company will have about 8 percent market share of the overall Medicare market, which includes both Medicare Advantage and Medicare fee for service.Antitrust regulators will also be looking at Blue Cross Blue Shield insurer Anthem Inc's acquisition of Cigna Corp's  at the same time as Aetna's Humana purchase.    (Reporting by Caroline Humer; Editing by Meredith Mazzilli and Alan Crosby)",2015-08-04,AET,"Tue Aug 4, 2015 | 12:13pm EDT",UPDATE 1-Aetna CEO says antitrust process underway in Humana deal,http://www.reuters.com//article/aetna-results-ceo-idUSL1N10F1LQ20150804?type=companyNews
218,"  NEW YORK Aug 4 Aetna Inc chief executive Mark Bertolini said on Tuesday that the company had begun making regulatory filings with both federal and state authorities related to its acquisition of Humana Inc. Bertolini said the company had also begun talking to state insurance commissioners and officials in Washington D.C. about the $37 billion deal, which he said will leave ""plenty of competitors"" in the Medicare markets where the combined company will operate.   (Reporting by Caroline Humer; Editing by Meredith Mazzilli)  ",2015-08-04,AET,"Tue Aug 4, 2015 | 9:10am EDT",Aetna CEO says has begun antitrust work on Humana deal,http://www.reuters.com//article/aetna-results-ceo-idUSL1N10F16820150804?type=companyNews
219,  NEW YORK Aug 4 Aetna Inc Chief Financial Officer Shawn Guertin said on Tuesday that the health insurer expects 2015 medical cost trend to increase at the low end of a range of 6 percent to 7 percent.The trend reflects spending on medical services like doctor visits and hospitals.  Guertin also reaffirmed that the company expects to close its $37 billion Humana Inc acquisition in the second half of 2016. Investors have reacted skeptically to the deal as they worry that the combination of the two Medicare Advantage providers will run into resistance from regulators.   (Reporting by Caroline Humer; Editing by Chizu Nomiyama) ,2015-08-04,AET,"Tue Aug 4, 2015 | 9:00am EDT",Aetna CFO says expects 2015 medical cost trend at low end,http://www.reuters.com//article/aetna-results-cfo-idUSL1N10F14R20150804?type=companyNews
220,"  (Adds details on cost trend)Aug 4 Aetna Inc on Tuesday reported a better-than-expected adjusted net profit for the second quarter and said ""moderate"" medical costs boosted the profitability of its government Medicare and Medicaid plans.The third-largest U.S. health insurer, which is in the process of buying rival Humana Inc, also raised its full-year forecast for adjusted net profit to at least $7.40 per share from $7.20-$7.40.The $37 billion Aetna-Humana combination is part of a consolidation that insurers say will help them offer more competitive products amid changes due to the national healthcare reform law, often called Obamacare. Anthem Inc and Cigna Corp also plan to merge in a $47 billion deal.The merger trend is also related to medical costs that have risen with the improved economy and as millions more people who have become insured through Obamacare visit doctors and hospitals. Investors are closely watching how these costs impact insurers. Aetna said on Tuesday that its medical cost trends were moderate during the quarter, which helped improve its medical benefit ratio to 81.1 percent from 83.1 percent. The ratio represents the percentage of premium income that an insurer spends on medical claims.Aetna said its second-quarter medical benefit ratio in its government business, which includes Medicare for elderly people and Medicaid for the poor, fell to 80.3 percent from 86.5 percent as it raised premiums and costs remained low. The ratio for its commercial business rose to 81.8 percent from 80.6 percent, reflecting payments it put aside for the risk adjustment program that redistributes the costs of providing individual Obamacare insurance among insurers selling these plans.""Second quarter results were well above consensus estimates as the company's government business continued to report better-than-expected performance, while commercial underwriting margins were steady despite the company absorbing a significant hit from a $252 million risk adjustment payable,"" Susquehanna Financial Group analyst Chris Rigg said in a note. Aetna shares closed on Monday at $113.79, up 28 percent this year.Aetna's net profit rose to $731.8 million, or $2.08 per share, in the second quarter ended June 30, from $548.8 million, or $1.52 per share, a year earlier.Excluding items, the company earned $2.05 per share, beating average analyst estimates of $1.82 per share, according to Thomson Reuters I/B/E/S.Revenue rose 5 percent to $15.24 billion, still short of analyst expectations of $15.43 billion.   (Reporting by Caroline Humer in New York; Additional reporting by Amrutha Penumudi in Bengaluru; Editing by Don Sebastian and Chizu Nomiyama)",2015-08-04,AET,"Tue Aug 4, 2015 | 8:19am EDT",UPDATE 2-Aetna profit beats as moderate medical costs help government plans,http://www.reuters.com//article/aetna-results-idUSL3N10F3QJ20150804?type=companyNews
221,"  Aug 4 Health insurer Aetna Inc, which is in the process of buying rival Humana Inc for $37 billion, reported a 33 percent rise in quarterly profit as it added more members to its government plans.Aetna's net profit rose to $731.8 million, or $2.08 per share, in the second quarter ended June 30, from $548.8 million, or $1.52 per share, a year earlier.  Revenue rose 5 percent to $15.24 billion.    (Reporting by Amrutha Penumudi in Bengaluru; Editing by Don Sebastian) ",2015-08-04,AET,"Tue Aug 4, 2015 | 6:16am EDT",Health insurer Aetna's profit rises 33 pct,http://www.reuters.com//article/aetna-results-idUSL4N0XP6SL20150804?type=companyNews
222,"  * 2nd-qtr profit $1.34/share vs est. $0.96* Medicaid memberships rise 10.8 pct* Shares rise as much as 9.6 pct   (Adds details from conference call; updates shares)By Amrutha PenumudiAug 5 WellCare Health Plans Inc raised its full-year adjusted profit forecast and said it was interested in buying healthcare insurance plans that might be put on the block as the industry consolidates.Companies in the U.S. managed care industry are looking to gain scale to cut costs and negotiate better prices with healthcare providers as Obamacare brings more people under insurance coverage.Shares of WellCare, which also reported better-than-expected quarterly profit and revenue, rose as much as 9.6 percent on Wednesday. The company said it would focus on building scale in its existing markets in the United States, but was open to entering new markets. WellCare currently has greater presence in Florida, Georgia and Kentucky.Last month, Anthem Inc said it would buy Cigna Corp  and Aetna Inc announced the acquisition of Humana Inc.The deals could present acquisition opportunities for WellCare and rival Centene Corp as Anthem and Aetna might have to sell some Medicare Advantage plans to satisfy antitrust regulators. Centene, which has said it was looking to buy Medicare Advantage plans, is also acquiring Health Net Inc for $6.3 billion to scale up its government plans business.WellCare raised its adjusted earnings forecast for 2015 to $3.30-$3.45 per share from $3.15-$3.40.Memberships in the company's Medicaid plans, which offer government-sponsored insurance to low-income families, rose 10.8 percent to 2.4 million in the second quarter. Adjusted medical benefits ratio, the share of premium WellCare spends on claims, improved to 88.8 percent from 93.5 percent in the business. WellCare reported net income of $51.7 million, or $1.17 per share, for the quarter ended June 30 compared with a loss of $7.5 million, or 17 cents per share, a year earlier.Excluding items, the company earned $1.34 per share.Revenue rose 10.5 percent to $3.48 billion.Analysts on average had expected a profit of 96 cents per share and revenue of $3.45 billion, according to Thomson Reuters I/B/E/S.WellCare's shares were up 8.6 percent at $86.99 in late morning trading on the New York Stock Exchange. Up to Tuesday's close, the stock had risen 33 percent in the past 12 months.   (Editing by Don Sebastian and Kirti Pandey)",2015-08-05,AET,"Wed Aug 5, 2015 | 11:33am EDT","UPDATE 2-Health insurer WellCare raises forecast, looks to buy assets",http://www.reuters.com//article/wellcare-health-results-idUSL3N10G3S420150805?type=companyNews
223,"   By Mike Stone and Greg Roumeliotis  Credit card lender Capital One Financial Corp (COF.N) is in exclusive talks to acquire General Electric Co's (GE.N) U.S. healthcare finance unit, in a deal likely to top $10 billion, according to people familiar with the matter.The potential deal could bulk up Capital One's existing healthcare lending operations and bring GE one step closer to achieving its target of shedding about $200 billion worth of finance assets to focus on industrial manufacturing.Capital One has outbid other potential buyers in an auction for the unit, the people said on Thursday, cautioning that the negotiations are ongoing and that a deal has not yet been finalized.The sources asked not to be identified because the negotiations are confidential. Capital One and GE did not immediately respond to requests for comment. The healthcare finance unit offers direct loans to healthcare product and services companies as well as real estate loans to operators of assisted living facilities, nursing homes and medical practices.The size of GE's finance arm and the potential risk stemming from its lending portfolio has made it subject to government oversight. GE plans to apply next year to escape its designation as a systemically important financial institution following the finance asset sales. To date, GE has announced several deals as it advances with its initiative to refocus on its industrial roots. In April, the Stamford, Connecticut-based company agreed to sell about $26 billion of real estate assets to Wells Fargo & Co (WFC.N) and Blackstone (BX.N). Subsequently, GE Capital agreed to sell its private equity lending portfolio to Canada Pension Plan Investment Board for $12 billion. GE has also sold its vehicle fleet management arm in the United States, Mexico, Australia and New Zealand to Canada's Element Financial (EFN.TO) for $6.9 billion. Based in McClean, Virginia, Capital One offers banking and credit card services to both individuals and businesses as well as investment services and healthcare finance. Capital One has a market capitalization of $44 billion. (Reporting by Mike Stone and Greg Roumeliotis in New York; Editing by Bernard Orr)",2015-08-06,AET,"Thu Aug 6, 2015 | 7:11pm EDT",Exclusive: Capital One nears deal to acquire GE health finance unit - sources,http://www.reuters.com//article/us-gehealthcare-m-a-capitalone-idUSKCN0QB2JJ20150806?type=companyNews
224,"   By Mike Stone and Greg Roumeliotis  Credit card lender Capital One Financial Corp (COF.N) is in exclusive talks to acquire General Electric Co's (GE.N) U.S. healthcare finance unit, in a deal likely to top $10 billion, according to people familiar with the matter.The potential deal could bulk up Capital One's existing healthcare lending operations and bring GE one step closer to achieving its target of shedding about $200 billion worth of finance assets to focus on industrial manufacturing.Capital One has outbid other potential buyers in an auction for the unit, the people said on Thursday, cautioning that the negotiations are ongoing and that a deal has not yet been finalized.The sources asked not to be identified because the negotiations are confidential. GE did not respond to requests for comment. ""As a matter of practice, we do not comment on market rumors or speculation. As disclosed in our SEC filings, the company has every intention to fully deliver on our approved capital distribution plan,"" Capital One said in a statement.The healthcare finance unit offers direct loans to healthcare product and services companies as well as real estate loans to operators of assisted living facilities, nursing homes and medical practices.The size of GE's finance arm and the potential risk stemming from its lending portfolio has made it subject to government oversight. GE plans to apply next year to escape its designation as a systemically important financial institution following the finance asset sales. To date, GE has announced several deals as it advances with its initiative to refocus on its industrial roots. In April, the Stamford, Connecticut-based company agreed to sell about $26 billion of real estate assets to Wells Fargo & Co (WFC.N) and Blackstone (BX.N). Subsequently, GE Capital agreed to sell its private equity lending portfolio to Canada Pension Plan Investment Board for $12 billion. GE has also sold its vehicle fleet management arm in the United States, Mexico, Australia and New Zealand to Canada's Element Financial (EFN.TO) for $6.9 billion. Based in McClean, Virginia, Capital One offers banking and credit card services to both individuals and businesses as well as investment services and healthcare finance. Capital One has a market capitalization of $44 billion. (Reporting by Mike Stone and Greg Roumeliotis in New York; Editing by Bernard Orr and Ken Wills)",2015-08-07,AET,"Thu Aug 6, 2015 | 9:33pm EDT",Exclusive: Capital One nears deal to acquire GE health finance unit - sources,http://www.reuters.com//article/us-gehealthcare-m-a-capitalone-idUSKCN0QB2JJ20150807?type=companyNews
225,"   By Neha Dimri and Anil D'Silva  General Electric Co (GE.N) said it would sell its U.S. healthcare finance unit to credit card lender Capital One Financial Corp (COF.N) for about $9 billion as it winds down its finance arm and returns to its industrial roots.The deal, which includes the sale of healthcare-related loans worth $8.5 billion, brings GE one step closer to achieving its target of shedding about $100 billion worth of finance assets by the end of this year.The latest sale, expected to close in the fourth quarter, will take GE's announced divestitures of finance assets to about $78 billion.Reuters reported last week that Capital One was in exclusive talks to acquire GE's healthcare finance unit and that it had outbid other potential buyers in an auction for the unit.The size of GE's finance arm  GE Capital  and the potential risk stemming from its lending portfolio has made it subject to government oversight. GE plans to apply next year to escape its designation as a systemically important financial institution following the sale of finance assets. For Capital One, the deal will bolster its healthcare lending operations.""This addition will catapult us to a leading market position in providing financial services to the healthcare sector,"" said Michael Slocum, president of Capital One's Commercial Bank.GE's healthcare finance unit offers direct loans to healthcare product and services companies as well as real estate loans to operators of assisted living facilities, nursing homes and medical practices. GE also said on Tuesday it agreed to sell about $600 million of the unit's real estate equity investments to another buyer, which it did not name.In April, GE agreed to sell about $26 billion of real estate assets to Wells Fargo & Co (WFC.N) and Blackstone Group LP (BX.N). Subsequently, GE agreed to sell its private equity lending portfolio to Canada Pension Plan Investment Board for $12 billion. Citigroup Global Markets and J.P. Morgan Securities LLC advised GE and Hogan Lovells US LLP was the legal adviser.Credit Suisse and Wells Fargo Securities were financial advisers to Capital One and Wachtell, Lipton, Rosen & Katz was the legal adviser.Capital One's shares were up marginally at $81.43 in extended trading on Tuesday. GE's stock also rose slightly to $25.80. (Editing by Saumyadeb Chakrabarty)",2015-08-11,AET,"Tue Aug 11, 2015 | 6:08pm EDT",GE to sell healthcare finance business to Capital One for $9 billion,http://www.reuters.com//article/us-gehealthcare-m-a-capitalone-idUSKCN0QG25520150811?type=companyNews
226,"  * Deal includes healthcare-related loans worth $8.5 bln* Transaction expected to close in Q4* GE has now announced finance asset sales of $78 bln   (Adds details, background, shares)By Neha Dimri and Anil D'SilvaAug 11 General Electric Co said it would sell its U.S. healthcare finance unit to credit card lender Capital One Financial Corp for about $9 billion as it winds down its finance arm and returns to its industrial roots.The deal, which includes the sale of healthcare-related loans worth $8.5 billion, brings GE one step closer to achieving its target of shedding about $100 billion worth of finance assets by the end of this year. The latest sale, expected to close in the fourth quarter, will take GE's announced divestitures of finance assets to about $78 billion.Reuters reported last week that Capital One was in exclusive talks to acquire GE's healthcare finance unit and that it had outbid other potential buyers in an auction for the unit.The size of GE's finance arm - GE Capital - and the potential risk stemming from its lending portfolio has made it subject to government oversight. GE plans to apply next year to escape its designation as a systemically important financial institution following the sale of finance assets. For Capital One, the deal will bolster its healthcare lending operations.""This addition will catapult us to a leading market position in providing financial services to the healthcare sector,"" said Michael Slocum, president of Capital One's Commercial Bank.GE's healthcare finance unit offers direct loans to healthcare product and services companies as well as real estate loans to operators of assisted living facilities, nursing homes and medical practices. GE also said on Tuesday it agreed to sell about $600 million of the unit's real estate equity investments to another buyer, which it did not name.In April, GE agreed to sell about $26 billion of real estate assets to Wells Fargo & Co and Blackstone Group LP . Subsequently, GE agreed to sell its private equity lending portfolio to Canada Pension Plan Investment Board for $12 billion.Citigroup Global Markets and J.P. Morgan Securities LLC advised GE and Hogan Lovells US LLP was the legal adviser.Credit Suisse and Wells Fargo Securities were financial advisers to Capital One and Wachtell, Lipton, Rosen & Katz was the legal adviser.Capital One's shares were up marginally at $81.43 in extended trading on Tuesday. GE's stock also rose slightly to $25.80.   (Editing by Saumyadeb Chakrabarty)",2015-08-11,AET,"Tue Aug 11, 2015 | 5:28pm EDT",UPDATE 2-GE to sell healthcare finance business to Capital One for $9 bln,http://www.reuters.com//article/gehealthcare-ma-capitalone-idUSL3N10M5RB20150811?type=companyNews
227,"   By Jilian Mincer | NEW YORK  NEW YORK Angered by videos in which Planned Parenthood officials discussed compensation for providing fetal tissue from abortions, Republicans in Congress are again demanding an end to government funding for the nearly 100-year-old provider of women's health services.Away from the headlines, however, the group is facing other major challenges, including one from a far different source: the Affordable Care Act, which it avidly supports.Many formerly uninsured women who once depended on Planned Parenthood for low-cost access to birth control, abortions and other reproductive healthcare have gotten coverage under President Barack Obama's healthcare law, making them less reliant on the organization's 700 clinics.In many states, Planned Parenthood is losing clients as newly insured patients turn to medical providers included in their health plan's networks, according to data provided to Reuters and interviews with more than two dozen of its affiliates.""Some people relied on us because they were uninsured prior to the Affordable Care Act. Now they can go anywhere for care, and some of them have been,"" said Lori Carpentier, president and CEO of Planned Parenthood of Mid and South Michigan, which expects to treat 58,000 patients in 2015, down about 15 percent from the 68,000 it treated in fiscal 2012, before major parts of the law went into effect.The ACA has also brought some benefits to the organization, its leaders say. In interviews, affiliates all reported a significantly larger percentage of insured visitors among their remaining patients. Some locations - including Ohio, New York City, Chicago and the Northwest - are even adding clients as they expand services to better compete for women with medical coverage.Still, Planned Parenthood client numbers nationwide are on the decline. Part of the drop in patient numbers can be traced to decisions by legislatures in Republican-leaning states like Texas to cut funding to affiliates beginning in 2011.The declines then accelerated after Obamacare took full effect in 2014, when Planned Parenthood served 2.68 million patients, down about six percent from 2.84 million a year earlier, according to numbers last updated in July.The decline was apparent even in areas like upstate New York, New England and parts of the Midwest, which have not seen decreases in state funding. Some declines are considered positive. The U.S. abortion rate is down, for example, and Obamacare has increased contraceptive coverage, making it easier for women to afford long-lasting birth control methods such as IUDs, which require fewer office visits.""Data about health centers and patients will fluctuate,"" said Kim Custer, executive vice president of health care, Planned Parenthood Federation of America. ""But at the end of the day, Planned Parenthood has a unique relationship with our patients, some of whom would not be able to get healthcare anywhere else.""The National Right to Life Educational Trust Fund, an arm of one of the nation's biggest anti-abortion groups, said the numbers could suggest that women are acting on their beliefs once they have a choice of provider.Insurance coverage allows them to ""go someplace where they can get a broader range of services and can avoid a place that also does abortions,"" said Randall K. O'Bannon, director of education and research at the group. A DIFFERENT MODEL Planned Parenthood's latest public battle has come from the anti-abortion group Center for Medical Progress, which began posting secretly recorded videos online in July. The center says the tapes show Planned Parenthood engaged in illegal sales of fetal tissue. Planned Parenthood denies the charges, saying that a few affiliates donate tissue for research and are paid a small fee to cover costs.In recent weeks, citing the videos as a reason, several Republican-leaning states including Louisiana and Alabama have moved to defund Planned Parenthood by ending agreements under the Medicaid program for the poor. Democrats are calling the controversy a ""War on Women,"" saying it could delay final action on the federal spending bill.But even before the most recent dispute, Planned Parenthood had begun reconsidering its model of serving primarily the poor. It has spent hundreds of millions of dollars in recent years to expand services, upgrade buildings and improve customer service, hoping to better compete for more affluent insured patients and tap a more stable source of revenue than public funding. Many states now provide services that promote broader wellness and preventive healthcare, including prenatal care, screenings for men, sex education for teenagers and smoking cessation counseling.""The Affordable Care Act hit at the same time we were defunded by the state,"" said Kelly Hart, director of government relations at Planned Parenthood of Greater Texas. ""We realized we needed to diversify our patient base if we wanted to be viable in the 21st century.""The law is reshaping U.S. healthcare, encouraging consolidation of hospitals and medical practices and increasing competition from walk-in clinics. About 17 million more people have insurance now than in 2013 through private insurance plans, many of which are subsidized by the government, or the expansion of Medicaid, according to the Rand Corp.""Twenty-five years ago, this was about rights, justice and access,"" said Clare Coleman, president and CEO of the National Family Planning & Reproductive Health Association and a former Planned Parenthood affiliate CEO. Now there are additional concerns. ""Can you make it financially? Do you have the right revenue mix? Are you running in debt or running a reserve?""A major focus is to attract Millennials, now in their 20s and early 30s, with online scheduling and short wait times. Some affiliates are trying programs that use smartphone apps to help determine if patients need tests, access birth control and provide advice without an office visit.Many are offering more services to men, older women and the gay and transgender communities. They also are expanding partnerships with other medical providers. One affiliate in the Midwest, for example, works with pediatricians who refer sexually-active teenagers interested in obtaining an IUD.Last month, painters added finishing touches on a new $9 million, 14,000-square foot Planned Parenthood health center in Long Island City, Queens. Just beyond the guarded entrance is a round sign that says ""Welcome"" in 11 languages.The atmosphere is bright and airy with walls painted in shades of yellow, blue and green, with no obvious references to reproductive health other than the name.""You have to have a great customer experience,"" said Joan Malin, president and CEO of Planned Parenthood of New York City, which oversees the Queens facility. ""Word of mouth brings people in.""",2015-09-08,AET,"Tue Sep 8, 2015 | 7:43am EDT",Planned Parenthood faces unexpected challenge from Obamacare,http://www.reuters.com//article/usa-plannedparenthood-insight-pix-video-idUSL1N11E0JQ20150908?type=companyNews
228,"  (Repeating for additional clients without changes to text)By Jilian MincerNEW YORK, Sept 8 Angered by videos in which Planned Parenthood officials discussed compensation for providing fetal tissue from abortions, Republicans in Congress are again demanding an end to government funding for the nearly 100-year-old provider of women's health services.Away from the headlines, however, the group is facing other major challenges, including one from a far different source: the Affordable Care Act, which it avidly supports.Many formerly uninsured women who once depended on Planned Parenthood for low-cost access to birth control, abortions and other reproductive healthcare have gotten coverage under President Barack Obama's healthcare law, making them less reliant on the organization's 700 clinics.In many states, Planned Parenthood is losing clients as newly insured patients turn to medical providers included in their health plan's networks, according to data provided to Reuters and interviews with more than two dozen of its affiliates.""Some people relied on us because they were uninsured prior to the Affordable Care Act. Now they can go anywhere for care, and some of them have been,"" said Lori Carpentier, president and CEO of Planned Parenthood of Mid and South Michigan, which expects to treat 58,000 patients in 2015, down about 15 percent from the 68,000 it treated in fiscal 2012, before major parts of the law went into effect.The ACA has also brought some benefits to the organization, its leaders say. In interviews, affiliates all reported a significantly larger percentage of insured visitors among their remaining patients. Some locations - including Ohio, New York City, Chicago and the Northwest - are even adding clients as they expand services to better compete for women with medical coverage.Still, Planned Parenthood client numbers nationwide are on the decline. Part of the drop in patient numbers can be traced to decisions by legislatures in Republican-leaning states like Texas to cut funding to affiliates beginning in 2011.The declines then accelerated after Obamacare took full effect in 2014, when Planned Parenthood served 2.68 million patients, down about six percent from 2.84 million a year earlier, according to numbers last updated in July. The decline was apparent even in areas like upstate New York, New England and parts of the Midwest, which have not seen decreases in state funding.Some declines are considered positive. The U.S. abortion rate is down, for example, and Obamacare has increased contraceptive coverage, making it easier for women to afford long-lasting birth control methods such as IUDs, which require fewer office visits.""Data about health centers and patients will fluctuate,"" said Kim Custer, executive vice president of health care, Planned Parenthood Federation of America. ""But at the end of the day, Planned Parenthood has a unique relationship with our patients, some of whom would not be able to get healthcare anywhere else.""The National Right to Life Educational Trust Fund, an arm of one of the nation's biggest anti-abortion groups, said the numbers could suggest that women are acting on their beliefs once they have a choice of provider.Insurance coverage allows them to ""go someplace where they can get a broader range of services and can avoid a place that also does abortions,"" said Randall K. O'Bannon, director of education and research at the group. A DIFFERENT MODEL Planned Parenthood's latest public battle has come from the anti-abortion group Center for Medical Progress, which began posting secretly recorded videos online in July. The center says the tapes show Planned Parenthood engaged in illegal sales of fetal tissue. Planned Parenthood denies the charges, saying that a few affiliates donate tissue for research and are paid a small fee to cover costs.In recent weeks, citing the videos as a reason, several Republican-leaning states including Louisiana and Alabama have moved to defund Planned Parenthood by ending agreements under the Medicaid program for the poor. Democrats are calling the controversy a ""War on Women,"" saying it could delay final action on the federal spending bill.But even before the most recent dispute, Planned Parenthood had begun reconsidering its model of serving primarily the poor. It has spent hundreds of millions of dollars in recent years to expand services, upgrade buildings and improve customer service, hoping to better compete for more affluent insured patients and tap a more stable source of revenue than public funding. Many states now provide services that promote broader wellness and preventive healthcare, including prenatal care, screenings for men, sex education for teenagers and smoking cessation counseling.""The Affordable Care Act hit at the same time we were defunded by the state,"" said Kelly Hart, director of government relations at Planned Parenthood of Greater Texas. ""We realized we needed to diversify our patient base if we wanted to be viable in the 21st century.""The law is reshaping U.S. healthcare, encouraging consolidation of hospitals and medical practices and increasing competition from walk-in clinics. About 17 million more people have insurance now than in 2013 through private insurance plans, many of which are subsidized by the government, or the expansion of Medicaid, according to the Rand Corp.""Twenty-five years ago, this was about rights, justice and access,"" said Clare Coleman, president and CEO of the National Family Planning & Reproductive Health Association and a former Planned Parenthood affiliate CEO. Now there are additional concerns. ""Can you make it financially? Do you have the right revenue mix? Are you running in debt or running a reserve?""A major focus is to attract Millennials, now in their 20s and early 30s, with online scheduling and short wait times. Some affiliates are trying programs that use smartphone apps to help determine if patients need tests, access birth control and provide advice without an office visit.Many are offering more services to men, older women and the gay and transgender communities. They also are expanding partnerships with other medical providers. One affiliate in the Midwest, for example, works with pediatricians who refer sexually-active teenagers interested in obtaining an IUD.Last month, painters added finishing touches on a new $9 million, 14,000-square foot Planned Parenthood health center in Long Island City, Queens. Just beyond the guarded entrance is a round sign that says ""Welcome"" in 11 languages.The atmosphere is bright and airy with walls painted in shades of yellow, blue and green, with no obvious references to reproductive health other than the name.""You have to have a great customer experience,"" said Joan Malin, president and CEO of Planned Parenthood of New York City, which oversees the Queens facility. ""Word of mouth brings people in.""   (Reporting by Jilian Mincer; Editing by Michele Gershberg and Sue Horton)",2015-09-08,AET,"Tue Sep 8, 2015 | 7:00am EDT",RPT-INSIGHT-Planned Parenthood faces unexpected challenge from Obamacare,http://www.reuters.com//article/usa-plannedparenthood-insight-pix-video-idUSL1N11A21Q20150908?type=companyNews
229,"   By Jilian Mincer | NEW YORK  NEW YORK Angered by videos in which Planned Parenthood officials discussed compensation for providingfetal tissue from abortions,Republicans in Congress are again demanding an end to government funding for the nearly 100-year-old provider of womens health services. Away from the headlines, however, the group is facing other major challenges, including one from a far different source: the Affordable Care Act, which it avidly supports. Many formerly uninsured women who once depended on Planned Parenthood for low-cost access to birth control, abortions and other reproductive healthcare have gotten coverage under President Barack Obamas healthcare law, making them less reliant on the organizations 700 clinics. In many states, Planned Parenthood is losing clients as newly insured patients turn to medical providers included in their health plan's networks, according to data provided to Reuters and interviews with more than two dozen of its affiliates.Some people relied on us because they were uninsured prior to the Affordable Care Act. Now they can go anywhere for care, and some of them have been, said Lori Carpentier, president and CEO of Planned Parenthood of Mid and South Michigan, which expects to treat 58,000 patients in 2015, down about 15 percent from the 68,000 it treated in fiscal 2012, before major parts of the law went into effect.The ACA has also brought some benefits to the organization, its leaders say. In interviews, affiliates all reported a significantly larger percentage of insured visitors among their remaining patients. Some locations  including Ohio, New York City, Chicagoand the Northwest  are even adding clients as they expand services to better compete for women with medical coverage. Still,Planned Parenthood client numbers nationwide are on the decline. Part of the drop in patient numbers can be traced to decisions by legislatures in Republican-leaning states like Texas to cut funding to affiliates beginning in 2011. The declines then accelerated after Obamacare took full effect in 2014, when Planned Parenthood served 2.68 million patients, down about six percent from 2.84 million a year earlier, according to numbers last updated in July. The decline was apparent even in areas like upstate New York, New England and parts of the Midwest, which have not seen decreases in state funding. Some declines are considered positive. The U.S. abortion rate is down, for example, and Obamacare has increased contraceptive coverage, making it easier for women to afford long-lasting birth control methods such as IUDs, which require fewer office visits. Data about health centers and patients will fluctuate, said Kim Custer, executive vice president of health care, Planned Parenthood Federation of America. But at the end of the day, Planned Parenthood has a unique relationship with our patients, some of whom would not be able to get healthcare anywhere else. The National Right to Life Educational Trust Fund, an arm of one of the nations biggest anti-abortion groups, said the numbers could suggest that women are acting on their beliefs once they have a choice of provider. Insurance coverage allows them to go someplace where they can get a broader range of services and can avoid a place that also does abortions, said Randall K. OBannon, director of education and research at the group.  A DIFFERENT MODEL  Planned Parenthoods latest public battle has come from the anti-abortion group Center for Medical Progress, which began posting secretly recorded videos online in July. The center says the tapes show Planned Parenthood engaged in illegal sales of fetal tissue. Planned Parenthood denies the charges, saying that a few affiliates donate tissue for research and are paid a small fee to cover costs.In recent weeks, citing the videos as a reason, several Republican-leaning states including Louisiana and Alabama have moved to defund Planned Parenthood by ending agreements under the Medicaid program for the poor. Democrats are calling the controversy a War on Women, saying it could delay final action on the federal spending bill. But even before the most recent dispute, Planned Parenthood had begun reconsidering its model of serving primarily the poor. It has spent hundreds of millions of dollars in recent years to expand services, upgrade buildings and improve customer service, hoping to better compete for more affluent insured patients and tap a more stable source of revenue than public funding. Many states now provide services that promote broader wellness and preventive healthcare, including prenatal care, screenings for men, sex education for teenagers and smoking cessation counseling. The Affordable Care Act hit at the same time we were defunded by the state,"" said Kelly Hart, director of government relations at Planned Parenthood of Greater Texas. ""We realized we needed to diversify our patient base if we wanted to be viable in the 21st century. The law is reshaping U.S. healthcare, encouraging consolidation of hospitals and medical practices and increasing competition from walk-in clinics. About 17 million more people have insurance now than in 2013 through private insurance plans, many of which are subsidized by the government, or the expansion of Medicaid, according to the Rand Corp. Twenty-five years ago, this was about rights, justice and access, said Clare Coleman, president and CEO of the National Family Planning & Reproductive Health Association and a former Planned Parenthood affiliate CEO. Now there are additional concerns. Can you make it financially? Do you have the right revenue mix? Are you running in debt or running a reserve?A major focus is to attract Millennials, now in their 20s and early 30s, with online scheduling and short wait times. Some affiliates are trying programs that use smartphone apps to help determine if patients need tests, access birth control and provide advice without an office visit. Many are offering more services to men, older women and the gay and transgender communities. They also are expanding partnerships with other medical providers. One affiliate in the Midwest, for example, works with pediatricians who refer sexually-active teenagers interested in obtaining an IUD. Last month, painters added finishing touches on a new $9 million, 14,000-square foot Planned Parenthood health center in Long Island City, Queens. Just beyond the guarded entrance is a round sign that says Welcome in 11 languages. The atmosphere is bright and airy with walls painted in shades of yellow, blue and green, with no obvious references to reproductive health other than the name.You have to have a great customer experience, said Joan Malin, president and CEO of Planned Parenthood of New York City, which oversees the Queens facility. Word of mouth brings people in. (Reporting by Jilian Mincer; Editing by Michele Gershberg and Sue Horton)",2015-09-08,AET,"Tue Sep 8, 2015 | 1:30am EDT",Planned Parenthood faces unexpected challenge from Obamacare,http://www.reuters.com//article/us-usa-plannedparenthood-insight-idUSKCN0R80B420150908?type=companyNews
230,"   By Jilian Mincer | NEW YORK, Sept 8  NEW YORK, Sept 8 Angered by videos in which Planned Parenthood officials discussed compensation for providing fetal tissue from abortions, Republicans in Congress are again demanding an end to government funding for the nearly 100-year-old provider of women's health services.Away from the headlines, however, the group is facing other major challenges, including one from a far different source: the Affordable Care Act, which it avidly supports.Many formerly uninsured women who once depended on Planned Parenthood for low-cost access to birth control, abortions and other reproductive healthcare have gotten coverage under President Barack Obama's healthcare law, making them less reliant on the organization's 700 clinics.In many states, Planned Parenthood is losing clients as newly insured patients turn to medical providers included in their health plan's networks, according to data provided to Reuters and interviews with more than two dozen of its affiliates.""Some people relied on us because they were uninsured prior to the Affordable Care Act. Now they can go anywhere for care, and some of them have been,"" said Lori Carpentier, president and CEO of Planned Parenthood of Mid and South Michigan, which expects to treat 58,000 patients in 2015, down about 15 percent from the 68,000 it treated in fiscal 2012, before major parts of the law went into effect.The ACA has also brought some benefits to the organization, its leaders say. In interviews, affiliates all reported a significantly larger percentage of insured visitors among their remaining patients. Some locations - including Ohio, New York City, Chicago and the Northwest - are even adding clients as they expand services to better compete for women with medical coverage.Still, Planned Parenthood client numbers nationwide are on the decline. Part of the drop in patient numbers can be traced to decisions by legislatures in Republican-leaning states like Texas to cut funding to affiliates beginning in 2011.The declines then accelerated after Obamacare took full effect in 2014, when Planned Parenthood served 2.68 million patients, down about six percent from 2.84 million a year earlier, according to numbers last updated in July.The decline was apparent even in areas like upstate New York, New England and parts of the Midwest, which have not seen decreases in state funding. Some declines are considered positive. The U.S. abortion rate is down, for example, and Obamacare has increased contraceptive coverage, making it easier for women to afford long-lasting birth control methods such as IUDs, which require fewer office visits.""Data about health centers and patients will fluctuate,"" said Kim Custer, executive vice president of health care, Planned Parenthood Federation of America. ""But at the end of the day, Planned Parenthood has a unique relationship with our patients, some of whom would not be able to get healthcare anywhere else.""The National Right to Life Educational Trust Fund, an arm of one of the nation's biggest anti-abortion groups, said the numbers could suggest that women are acting on their beliefs once they have a choice of provider.Insurance coverage allows them to ""go someplace where they can get a broader range of services and can avoid a place that also does abortions,"" said Randall K. O'Bannon, director of education and research at the group. A DIFFERENT MODEL Planned Parenthood's latest public battle has come from the anti-abortion group Center for Medical Progress, which began posting secretly recorded videos online in July. The center says the tapes show Planned Parenthood engaged in illegal sales of fetal tissue. Planned Parenthood denies the charges, saying that a few affiliates donate tissue for research and are paid a small fee to cover costs.In recent weeks, citing the videos as a reason, several Republican-leaning states including Louisiana and Alabama have moved to defund Planned Parenthood by ending agreements under the Medicaid program for the poor. Democrats are calling the controversy a ""War on Women,"" saying it could delay final action on the federal spending bill.But even before the most recent dispute, Planned Parenthood had begun reconsidering its model of serving primarily the poor. It has spent hundreds of millions of dollars in recent years to expand services, upgrade buildings and improve customer service, hoping to better compete for more affluent insured patients and tap a more stable source of revenue than public funding. Many states now provide services that promote broader wellness and preventive healthcare, including prenatal care, screenings for men, sex education for teenagers and smoking cessation counseling.""The Affordable Care Act hit at the same time we were defunded by the state,"" said Kelly Hart, director of government relations at Planned Parenthood of Greater Texas. ""We realized we needed to diversify our patient base if we wanted to be viable in the 21st century.""The law is reshaping U.S. healthcare, encouraging consolidation of hospitals and medical practices and increasing competition from walk-in clinics. About 17 million more people have insurance now than in 2013 through private insurance plans, many of which are subsidized by the government, or the expansion of Medicaid, according to the Rand Corp.""Twenty-five years ago, this was about rights, justice and access,"" said Clare Coleman, president and CEO of the National Family Planning & Reproductive Health Association and a former Planned Parenthood affiliate CEO. Now there are additional concerns. ""Can you make it financially? Do you have the right revenue mix? Are you running in debt or running a reserve?""A major focus is to attract Millennials, now in their 20s and early 30s, with online scheduling and short wait times. Some affiliates are trying programs that use smartphone apps to help determine if patients need tests, access birth control and provide advice without an office visit.Many are offering more services to men, older women and the gay and transgender communities. They also are expanding partnerships with other medical providers. One affiliate in the Midwest, for example, works with pediatricians who refer sexually-active teenagers interested in obtaining an IUD.Last month, painters added finishing touches on a new $9 million, 14,000-square foot Planned Parenthood health center in Long Island City, Queens. Just beyond the guarded entrance is a round sign that says ""Welcome"" in 11 languages.The atmosphere is bright and airy with walls painted in shades of yellow, blue and green, with no obvious references to reproductive health other than the name.""You have to have a great customer experience,"" said Joan Malin, president and CEO of Planned Parenthood of New York City, which oversees the Queens facility. ""Word of mouth brings people in.""   (Reporting by Jilian Mincer; Editing by Michele Gershberg and Sue Horton)",2015-09-08,AET,"Tue Sep 8, 2015 | 1:00am EDT",INSIGHT-Planned Parenthood faces unexpected challenge from Obamacare,http://www.reuters.com//article/usa-plannedparenthood-idUSL1N11A1JD20150908?type=companyNews
231,"  Health insurer Aetna's (AET.N) proposed $37 billion acquisition of smaller rival Humana Inc (HUM.N) was approved by the shareholders of both companies.The companies continue to expect the deal to close in the second half of 2016, they said in separate statements on Monday.Aetna in July said it would buy Humana to become the largest provider of Medicare plans for the elderly.Three weeks later, rival Anthem Inc (ANTM.N) proposed to acquire Cigna Corp (CI.N) for about $47 billion in a deal that would make it the largest U.S. health insurer by membership. The proposed mergers follow the implementation of President Barack Obama's healthcare overhaul, the Affordable Care Act, which extended health insurance to millions of people. Insurers say joining forces will help them better compete as the government tries to rein in healthcare spending.However, federal antitrust authorities are expected to closely scrutinize these proposed deals for potential harm to consumers.  (Reporting by Natalie Grover in Bengaluru; Editing by Savio D'Souza)",2015-10-19,AET,"Mon Oct 19, 2015 | 5:21pm EDT","Aetna, Humana shareholders approve proposed merger",http://www.reuters.com//article/us-humana-m-a-aetna-idUSKCN0SD2FD20151019?type=companyNews
232,"  (Adds context)Oct 19 Health insurer Aetna's proposed $37 billion acquisition of smaller rival Humana Inc was approved by the shareholders of both companies.The companies continue to expect the deal to close in the second half of 2016, they said in separate statements on Monday. Aetna in July said it would buy Humana to become the largest provider of Medicare plans for the elderly.Three weeks later, rival Anthem Inc proposed to acquire Cigna Corp for about $47 billion in a deal that would make it the largest U.S. health insurer by membership. The proposed mergers follow the implementation of President Barack Obama's healthcare overhaul, the Affordable Care Act, which extended health insurance to millions of people. Insurers say joining forces will help them better compete as the government tries to rein in healthcare spending.However, federal antitrust authorities are expected to closely scrutinize these proposed deals for potential harm to consumers.   (Reporting by Natalie Grover in Bengaluru; Editing by Savio D'Souza)",2015-10-19,AET,"Mon Oct 19, 2015 | 5:18pm EDT","UPDATE 1-Aetna, Humana shareholders approve proposed merger",http://www.reuters.com//article/humana-ma-aetna-idUSL3N12J5JN20151019?type=companyNews
233,"  Oct 19 Health insurer Aetna's proposed acquisition of smaller rival Humana Inc was approved by the shareholders of both companies.Aetna continues to expect the deal to close in the second half of 2016, it said on Monday.  Aetna in July said it would buy Humana for about $37 billion.   (Reporting by Natalie Grover in Bengaluru; Editing by Savio D'Souza) ",2015-10-19,AET,"Mon Oct 19, 2015 | 4:54pm EDT","Aetna, Humana shareholders approve proposed merger",http://www.reuters.com//article/humana-ma-aetna-idUSL3N12J5J120151019?type=companyNews
234,"   By Amanda Becker | WASHINGTON  WASHINGTON Democratic presidential candidate Hillary Clinton has ""serious concerns"" about health insurer Aetna's plan to acquire Humana and Anthem's proposal to buy Cigna, saying the multi-billion-dollar deals should be closely reviewed by U.S. regulators.Stocks of the health insurers fell at least over 5 percent after Clinton said she was ""very skeptical"" the mergers would be good for consumers.A $37 billion plan for Aetna Inc to acquire smaller rival Humana Inc approved by the shareholders of both companies this week would make Aetna the largest provider of Medicare Advantage plans for the elderly.Anthem Inc agreed over the summer to acquire Cigna Corp in a $47 billion deal that would make it the largest U.S. health insurer by membership.Clinton said she was ""very skeptical"" the mergers would be good for consumers. Both deals, which would reduce the number of nationwide for-profit health insurers from five to three, are being closely reviewed by the U.S. Department of Justice and state insurance regulators, and have been the subject of hearings in the U.S. Congress.""As we see more consolidation in health care, among both providers and insurers, I'm worried that the balance of power is moving too far away from consumers,"" Clinton said in a statement. ""These mergers should be scrutinized very closely with an eye to preventing the undue concentration that they appear to create,"" Clinton added.Clinton, the frontrunner for the Democratic nomination, has over the past month detailed how she would reduce healthcare costs for consumers if she wins the White House in November 2016.Cigna stock fell more than 8 percent, and Humana shares tumbled over 7 percent. Aetna's stock dropped over 6 percent and Anthem shares fell by over 5 percent. Clinton has taken aim at the pharmaceutical industry for what she calls ""price gouging"" and said she would cap out-of-pocket prescription costs at $250 per month.Insurers say mergers will help them compete in the market as the government tries to rein in healthcare spending following the implementation of President Barack Obama's signature healthcare law, the Affordable Care Act.Anthem is ""engaged in a constructive and transparent dialog"" with regulators about how the Cigna transaction would lead affordable care and robust competition, spokeswoman Jill Becher said.""Aetna is focused on evolving the health care industry to a new model,"" Aetna spokeswoman Cynthia Michener wrote in a statement, saying the Humana deal would create ""positive change"" in the marketplace.   (additional reporting by Caroline Humer in New York)",2015-10-21,AET,"Wed Oct 21, 2015 | 4:00pm EDT","Clinton has ""serious concerns"" about Aetna-Humana, Anthem-Cigna mergers",http://www.reuters.com//article/usa-election-clinton-idUSL1N12L2H420151021?type=companyNews
235,"   By Amanda Becker | WASHINGTON  WASHINGTON Democratic presidential candidate Hillary Clinton has ""serious concerns"" about health insurer Aetna's plan to acquire Humana and Anthem's proposal to buy Cigna, saying the multi-billion-dollar deals should be closely reviewed by U.S. regulators.Stocks of the health insurers fell at least over 5 percent after Clinton said she was ""very skeptical"" the mergers would be good for consumers. A $37 billion plan for Aetna Inc (AET.N) to acquire smaller rival Humana Inc (HUM.N) approved by the shareholders of both companies this week would make Aetna the largest provider of Medicare Advantage plans for the elderly.Anthem Inc (ANTM.N) agreed over the summer to acquire Cigna Corp (CI.N) in a $47 billion deal that would make it the largest U.S. health insurer by membership. Clinton said she was ""very skeptical"" the mergers would be good for consumers. Both deals, which would reduce the number of nationwide for-profit health insurers from five to three, are being closely reviewed by the U.S. Department of Justice and state insurance regulators, and have been the subject of hearings in the U.S. Congress.""As we see more consolidation in health care, among both providers and insurers, I'm worried that the balance of power is moving too far away from consumers,"" Clinton said in a statement. ""These mergers should be scrutinized very closely with an eye to preventing the undue concentration that they appear to create,"" Clinton added. Clinton, the frontrunner for the Democratic nomination, has over the past month detailed how she would reduce healthcare costs for consumers if she wins the White House in November 2016.Cigna stock fell more than 8 percent, and Humana shares tumbled over 7 percent. Aetna's stock dropped over 6 percent and Anthem shares fell by over 5 percent. Clinton has taken aim at the pharmaceutical industry for what she calls ""price gouging"" and said she would cap out-of-pocket prescription costs at $250 per month. Insurers say mergers will help them compete in the market as the government tries to rein in healthcare spending following the implementation of President Barack Obama's signature healthcare law, the Affordable Care Act.Anthem is ""engaged in a constructive and transparent dialog"" with regulators about how the Cigna transaction would lead affordable care and robust competition, spokeswoman Jill Becher said.""Aetna is focused on evolving the health care industry to a new model,"" Aetna spokeswoman Cynthia Michener wrote in a statement, saying the Humana deal would create ""positive change"" in the marketplace. (Reporting By Amanda Becker in Washington; additional reporting by Caroline Humer in New York Editing by W Simon)",2015-10-21,AET,"Wed Oct 21, 2015 | 1:57pm EDT","Clinton has 'serious concerns' about Aetna-Humana, Anthem-Cigna mergers",http://www.reuters.com//article/us-usa-election-clinton-idUSKCN0SF21R20151021?type=companyNews
236,"  (Adds company responses, market reaction)By Amanda BeckerWASHINGTON Oct 21 Democratic presidential candidate Hillary Clinton has ""serious concerns"" about health insurer Aetna's plan to acquire Humana and Anthem's proposal to buy Cigna, saying the multi-billion-dollar deals should be closely reviewed by U.S. regulators.Stocks of the health insurers fell at least over 5 percent after Clinton said she was ""very skeptical"" the mergers would be good for consumers.A $37 billion plan for Aetna Inc to acquire smaller rival Humana Inc approved by the shareholders of both companies this week would make Aetna the largest provider of Medicare Advantage plans for the elderly.Anthem Inc agreed over the summer to acquire Cigna Corp in a $47 billion deal that would make it the largest U.S. health insurer by membership. Clinton said she was ""very skeptical"" the mergers would be good for consumers.Both deals, which would reduce the number of nationwide for-profit health insurers from five to three, are being closely reviewed by the U.S. Department of Justice and state insurance regulators, and have been the subject of hearings in the U.S. Congress.""As we see more consolidation in health care, among both providers and insurers, I'm worried that the balance of power is moving too far away from consumers,"" Clinton said in a statement. ""These mergers should be scrutinized very closely with an eye to preventing the undue concentration that they appear to create,"" Clinton added.Clinton, the frontrunner for the Democratic nomination, has over the past month detailed how she would reduce healthcare costs for consumers if she wins the White House in November 2016. Cigna stock fell more than 8 percent, and Humana shares tumbled over 7 percent. Aetna's stock dropped over 6 percent and Anthem shares fell by over 5 percent.Clinton has taken aim at the pharmaceutical industry for what she calls ""price gouging"" and said she would cap out-of-pocket prescription costs at $250 per month.Insurers say mergers will help them compete in the market as the government tries to rein in healthcare spending following the implementation of President Barack Obama's signature healthcare law, the Affordable Care Act.Anthem is ""engaged in a constructive and transparent dialog"" with regulators about how the Cigna transaction would lead affordable care and robust competition, spokeswoman Jill Becher said.""Aetna is focused on evolving the health care industry to a new model,"" Aetna spokeswoman Cynthia Michener wrote in a statement, saying the Humana deal would create ""positive change"" in the marketplace.   (Reporting By Amanda Becker in Washington; additional reporting by Caroline Humer in New York Editing by W Simon)",2015-10-21,AET,"Wed Oct 21, 2015 | 1:30pm EDT","UPDATE 1-Clinton has ""serious concerns"" about Aetna-Humana, Anthem-Cigna mergers",http://www.reuters.com//article/usa-election-clinton-idUSL1N12L1PM20151021?type=companyNews
237,"  (Repeats to broaden distribution)By Amanda BeckerWASHINGTON Oct 21 Democratic presidential candidate Hillary Clinton has ""serious concerns"" about health insurer Aetna's plan to acquire Humana and Anthem's proposal to buy Cigna, saying the multi-billion-dollar deals should be closely reviewed by U.S. regulators.A $37 billion plan for Aetna Inc to acquire smaller rival Humana Inc approved by the shareholders of both companies this week would make Aetna the largest provider of Medicare Advantage plans for the elderly.Anthem Inc agreed over the summer to acquire Cigna Corp in a $47 billion deal that would make it the largest U.S. health insurer by membership. Clinton said she was ""very skeptical"" the mergers would be good for consumers.Both deals, which would reduce the number of nationwide for-profit health insurers from five to three, are being closely reviewed by the U.S. Department of Justice and state insurance regulators, and have been the subject of hearings in the U.S. Congress.""As we see more consolidation in health care, among both providers and insurers, I'm worried that the balance of power is moving too far away from consumers,"" Clinton said in a statement. ""These mergers should be scrutinized very closely with an eye to preventing the undue concentration that they appear to create,"" Clinton added.Clinton, the frontrunner for the Democratic nomination, has over the past month detailed how she would reduce healthcare costs for consumers if she wins the White House in November 2016. Clinton has taken aim at the pharmaceutical industry for what she calls ""price gouging"" and said she would cap out-of-pocket prescription costs at $250 per month.Clinton said Wednesday another way to contain costs for consumers was by appointing ""aggressive regulators"" at the Department of Justice and Federal Trade Commission to take on ""troubling concentration"" within the healthcare industry.Insurers say mergers will help them compete in the market as the government tries to rein in healthcare spending following the implementation of President Barack Obama's signature healthcare law, the Affordable Care Act.But Clinton said companies proposing mergers should bear a ""heavy burden"" in showing the deal would lead to care coordination, innovation and savings for consumers.   (Reporting By Amanda Becker in Washington; additional reporting by Caroline Humer in New York Editing by W Simon)",2015-10-21,AET,"Wed Oct 21, 2015 | 10:41am EDT","RPT-Clinton has ""serious concerns"" about Aetna-Humana, Anthem-Cigna mergers",http://www.reuters.com//article/usa-election-clinton-idUSL1N12L0XG20151021?type=companyNews
238,"  (Adds index futures, more company news items)MILAN Oct 26 European shares were seen opening little changed on Monday, with a rate-cut effect seen as fading slightly in Europe after markets rallied to two-month highs on Friday on signs of more central bank support.Futures for the euro zone's blue-chip Euro STOXX 50 index, France's CAC and Britain's FTSE were all down by between 0.1-0.3 percent, while Germany's DAX futures edged up 0.1 percent.Earnings season was in full swing, with carmaker Peugeot posting a 3.2 percent increase in quarterly revenue helped by recovering European demand.Technology group Philips reported better-than-expected quarterly profits on cost cutting and strong orders for its U.S. healthcare business, but said the sale of its Lumileds division, worth $3.3 billion, is in doubt..Eyes will also be on Germany's Ifo business climate sentiment for October, with any further deterioration seen adding reasons for the ECB to act.On Friday, European equities rose to two-month highs as China announced a surprise rate cut just a day after the European Central Bank signalled the possibility of stronger stimulus measures.The pan-European FTSEurofirst 300 index rose 1.95 percent and the euro zone's blue-chip Euro STOXX 50 index advanced 2.17 percent.COMPANY NEWS: PHILIPS Philips said on Monday the sale of its $3.3-billion Lumileds business to Go Scale Capital was uncertain, due to U.S. government concerns. In the third quarter the company swung to a net profit of 324 million euros.PSA PEUGEOT CITROEN PSA Peugeot Citroen PEUP.PA posted a 3.2 percent increase in third-quarter revenue on Monday as recovering European demand shielded the carmaker from the worst of a sales slowdown in China.TALKTALK : British broadband provider TalkTalk said on Sunday it had hired defence company BAE Systems to investigate a cyber attack that may have led to the theft of personal data from its more than 4 million customers.ABERDEEN ASSET MANAGEMENT : Aberdeen Asset Management has begun to sound out potential buyers as Europe's second-largest fund house struggles to put an end to a slump in its profits and share price, the Financial Times reported. STANDARD CHARTERED Standard Chartered  said on Monday it plans to exit from its equity derivatives and convertible bonds businesses, following a step earlier this year to close the bulk of its global equities operations.VOLKSWAGEN Volkswagen's new head, Matthias Mueller, will update German Chancellor Angela Merkel on the carmaker's internal investigation into an emissions-rigging scandal during a trip to China, a person close to the matter told Reuters.Also, news agency DPA reported Volkswagen may offer VW owners in Germany discounts on new cars if they turn in certain old models affected by the emissions scandal.DEUTSCHE BANK U.S. regulators are expanding their probe into Deutsche Bank as a money laundering investigation of a Moscow unit has widened into possible sanctions violations, the Financial Times reported, citing sources. CREDIT SUISSE Credit Suisse Group has priced its private placement of 58 million new registered shares with a group of investors at 22.75 Swiss francs each, which is expected to raise gross proceeds of 1.32 billion Swiss francs ($1.35 billion), it said on Monday.SYNGENTA The group's new chief executive does not necessarily need to come from outside the company and big strategy changes would be ""inopportune"", the chairman of the Swiss agrochemicals group told a newspaper.DAIMLER, DEUTSCHE TELEKOM Germany has set a Nov. 10 deadline for Toll Collect, a joint venture of Daimler and Deutsche Telekom, to bid for a contract to extend a truck toll to all federal roads, the transport ministry said on Saturday. RWE Utilities RWE, Vattenfall and Mibrag will start shifting coal-fired power plant capacity to Germany's power reserve at the start of the European winter next year as part of a plan to reduce carbon emissions, the government said.AIRBUS Airbus CEO Tom Enders said Germany should deregulate its labour market and create more lower-paid jobs to help refugees find work and integrate better into society.Saudi Arabian budget carrier flynas, which made its first profit this year, is in talks with plane manufacturers Airbus and Boeing as it seeks to purchase four new aircraft over the next four years, its chief executive told reporters.Afghan carrier Safi Airways plans to aggressively expand in the coming three years and will approach Airbus and Boeing about aircraft purchases, its chief commercial officer said.FNAC The French books and music retailer said its proposed acquisition of London-listed electrical goods retailer Darty could generate at least 85 million euros ($94 million) per year of synergies before tax.French newspaper Le Journal du Dimanche said the talks had been met with hostility from Darty's current managing director, while its British board members wanted a higher offer.VIVENDI, TELECOM ITALIA The media group said it now holds 20.03 percent of Telecom Italia, and reiterated its plan to be a long-term shareholder and to develop Vivendi's business in southern Europe.ACS Spain's ACS won a contract worth 84.5 million euros to build and operate a 48 MW photovoltaic plant in Japan, the company said on Sunday.------------------------------------------------------------------------------ > Asian stocks advance on China rate cut, US tech earnings    > Techs lead Wall St higher; S&P 500 erases 2015 loss    > Nikkei ends at 2-month high as China cuts rates, Hitachi and Panasonic soar     > China rate cut boosts U.S. yields at end of flat week    > Dollar dips after rally, but improved risk appetite curbs losses    > Gold struggles on firmer dollar, Fed rate hike fears     > London copper edges higher after China rate cut    > Oil prices weak as demand seen sagging towards year-end    (Reporting by Sudip Kar-Gupta)",2015-10-26,AET,"Mon Oct 26, 2015 | 3:50am EDT",European Factors to Watch-Shares seen flat as rate-cut effect fades,http://www.reuters.com//article/europe-stocks-factors-idUSL8N12Q0GY20151026?type=companyNews
239,"  (Repeats to additional subscribers, no change to text)AMSTERDAM Oct 26 Philips on Monday reported better-than-expected quarterly profits on cost cutting and strong orders for its  U.S. healthcare business, but said the sale of its Lumileds division, worth $3.3 billion, is in doubt.The Dutch company said the sale of Lumileds, which makes automotive lights and LED components, to a consortium of mostly Chinese investors had run into unexpected opposition from the U.S. government.Third-quarter net income swung to a profit of 324 million euros from a loss of 103 million euros in the same period a year earlier while sales were up 2 percent to 5.80 billion euros from the same period a year earlier. In the third quarter of 2014 Philips booked losses related to the temporary closure of a factory in Cleveland, Ohio.Analysts polled by Thomson Reuters had expected net profit of 191 million euros and sales of 5.80 billion euros. Philips repeated its full year guidance for ""modest"" sales growth and an improved operating profit in 2015.Philips announced in March it would sell 80.1 percent of the Lumileds business to Go Scale Capital, an investment fund run by GSR Ventures and Oak Investment Partners. But the Dutch company said on Monday the Committee on Foreign Investment in the United States (CFIUS) had expressed ""certain unforeseen concerns"" about the deal. It did immediately say what those concerns were.""Philips and Go Scale Capital will continue to engage with CFIUS and will take all reasonable steps to address its concerns, but given these, the closing of the transaction is uncertain,"" Philips said. Most of Lumileds' sales and profits come from its automotive components business, but it also includes LED production and a large portfolio of LED patents. Investors in Go Scale include GSR Capital, Nanchang Industrial Group, and Asia Pacific Resource Development, all based in China.Philips said the rest of its lighting business -- which is the world's largest maker of lights - is still on track for an initial public offering or sale in 2016.($1 = 0.9064 euros)   (Reporting by Toby Sterling; Editing by Edwina Gibbs)",2015-10-26,AET,"Mon Oct 26, 2015 | 3:20am EDT","RPT-Philips beats on Q3 profit, but sale of Lumileds in doubt",http://www.reuters.com//article/philips-results-idUSL8N12Q0RC20151026?type=companyNews
240,"  AMSTERDAM Oct 26 Philips on Monday reported better-than-expected quarterly profits on cost cutting and strong orders for its  U.S. healthcare business, but said the sale of its Lumileds division, worth $3.3 billion, is in doubt.The Dutch company said the sale of Lumileds, which makes automotive lights and LED components, to a consortium of mostly Chinese investors had run into unexpected opposition from the U.S. government.Third-quarter net income swung to a profit of 324 million euros from a loss of 103 million euros in the same period a year earlier while sales were up 2 percent to 5.80 billion euros from the same period a year earlier. In the third quarter of 2014 Philips booked losses related to the temporary closure of a factory in Cleveland, Ohio.Analysts polled by Thomson Reuters had expected net profit of 191 million euros and sales of 5.80 billion euros. Philips repeated its full year guidance for ""modest"" sales growth and an improved operating profit in 2015.Philips announced in March it would sell 80.1 percent of the Lumileds business to Go Scale Capital, an investment fund run by GSR Ventures and Oak Investment Partners. But the Dutch company said on Monday the Committee on Foreign Investment in the United States (CFIUS) had expressed ""certain unforeseen concerns"" about the deal. It did immediately say what those concerns were.""Philips and Go Scale Capital will continue to engage with CFIUS and will take all reasonable steps to address its concerns, but given these, the closing of the transaction is uncertain,"" Philips said. Most of Lumileds' sales and profits come from its automotive components business, but it also includes LED production and a large portfolio of LED patents. Investors in Go Scale include GSR Capital, Nanchang Industrial Group, and Asia Pacific Resource Development, all based in China.Philips said the rest of its lighting business -- which is the world's largest maker of lights - is still on track for an initial public offering or sale in 2016.($1 = 0.9064 euros)   (Reporting by Toby Sterling; Editing by Edwina Gibbs)",2015-10-26,AET,"Mon Oct 26, 2015 | 3:16am EDT","Philips beats on Q3 profit, but sale of Lumileds in doubt",http://www.reuters.com//article/philips-results-idUSL8N12P0X820151026?type=companyNews
241,"  (Recasts to focus on individual exchange business, adds CFO and analyst comments, share prices)By Caroline HumerOct 28 Health insurer Anthem Inc said on Wednesday that its Obamacare insurance business is being hampered by lower-than-anticipated enrollment due to fewer applicants than expected and cheaper premium rates at competitors.Anthem has been one of the biggest and most profitable insurers in the new individual market, which was overhauled in 2014 with new government subsidized plans sold on exchanges created under Obamacare. Now Anthem says that business will drag on profit growth in 2016 and could even affect its long-term 2018 financial target.The comments from the second-largest U.S. health insurer came in its third-quarter financial report, which showed that other government-based businesses had outperformed expectations.Shares of Anthem were down 5.1 percent at $137.35 in morning trading. Cigna Corp, which Anthem has announced plans to buy, was down 3.2 percent while shares of Aetna Inc, which reports on Thursday, were down 2.8 percent.""We're trending the wrong direction on enrollment,"" Anthem Chief Financial Officer Wayne DeVeydt told investors on a conference call. The company lost 69,000 exchange customers during the quarter, ending with 824,000 customers. It has 1.75 million total individual customers. Anthem, which operates Blue Cross Blue Shield plans in more than a dozen states, said it expects continued enrollment declines in the fourth quarter and that 2016 will be weak as competitors undercut prices. After that, it is counting on improvements in 2017 and 2018 when it expects to be able to compete better on prices.Many of its individual customers buy their insurance on the exchanges created under President Barack Obama's national healthcare reform law and receive subsidies from the government aimed at making it more affordable. The government expects about 9.1 million people to have this insurance at the end of 2015, a lower target than the 15 million it once aimed for, and for next year expects 10 million people to enroll.Earlier this week, the U.S. government said that in the 37 states where it runs exchanges, the monthly premium rate of the benchmark health insurance plan will increase 7.5 percent on average. DeVeydt said the company was not seeing what hospitals attested to this week: patients dropping coverage because of premium prices.Two weeks ago, UnitedHealth Group Inc disappointed investors when it told them the individual business was cutting into profit this year. Unlike Anthem, it said it expected 2016 to improve.Leerink Partners analyst Ana Gupte described Anthem's commentary on the call as being ""very cautious"" and noted the pressure from market share losses to other plans that had priced below them in 2016. Anthem said its other businesses did well as more people enrolled for its government plans in Medicare for the elderly and disabled and Medicaid for lower-income families. Medicaid enrollment rose by 786,000 members in the third quarter.Anthem said earnings rose to $654.8 million, or $2.43 per share, from $630.9 million, or $2.22 per share, a year earlier.The company said spending on medical claims as a percentage of premiums rose to 83.6 percent from 82.5 percent a year ago, due to expenses in its individual business. The metric is keenly watched for signs of rising costs.On an adjusted basis, Anthem earned $2.73 per share, well above analysts' average estimate of $2.33 according to Thomson Reuters I/B/E/S.Revenue rose to $19.77 billion from $18.37 billion. Analysts were expecting revenue of $19.64 billion.The company also forecast full-year profit of $10.10-$10.20 per share, below analysts' expectations of $10.22.   (Reporting by Caroline Humer in New York and Amrutha Penumudi in Bengaluru; Editing by Savio D'Souza and Matthew Lewis)",2015-10-28,AET,"Wed Oct 28, 2015 | 11:04am EDT",UPDATE 2-Anthem shares falls as Obamacare business hampers profit,http://www.reuters.com//article/anthem-results-idUSL3N12S3HI20151028?type=companyNews
242,"  Health insurer Aetna Inc (AET.N) raised its full-year operating earnings forecast for the fourth time this year on strong performance in its government business and said underlying operating earnings would increase in 2016.Aetna, whose shares rose 4 percent in early trading, said it expects 2016 operating earnings per share to rise at low double-digit rates from a baseline of $7 on membership growth in its Medicare and Medicaid plans.The baseline does not presume any prior year's reserve development, the company said.Insurers have been benefiting from the expansion of Medicaid, a federal health insurance program for lower-income people that is administered by the states.J.P. Morgan analyst Gary P Taylor noted that Aetna struck a more bullish tone than rival Anthem Inc (ANTM.N), which reported results on Wednesday.Aetna said on Thursday it was not making money this year from its individual business that sells government-subsidized plans on exchanges created under the Affordable Care Act (ACA), but said profitability could improve in the business next year.""We think it's way too early to call it quits on the ACA and on the exchanges ... we view it still as a big opportunity,"" Aetna Chief Executive Mark Bertolini said on a conference call with analysts. Aetna said it added 815,000 members through the Obamacare exchanges and 280,000 off it in the third quarter ended Sept. 30.UnitedHealth Group Inc (UNH.N) and Anthem had said their Obamacare insurance businesses was being hampered by lower-than-anticipated enrollment. Aetna, which is in the process of buying rival Humana Inc (HUM.N), raised its 2015 operating earnings to $7.45-$7.55 per share from its previous estimate of at least $7.40.  Leerink Partners analyst Ana Gupte said the 2016 forecast looked achievable and that she expected margins in the Obamacare business to improve next year.Net earnings fell 5 percent to $560.1 million, or $1.59 per share, in the third quarter. On an adjusted basis, the company earned $1.90 per share, above the average analyst estimate of $1.77 per share, according to Thomson Reuters I/B/E/S. Spending on medical claims as a percentage of premiums improved to 81.1 percent from 82.3 percent a year earlier. Total revenue rose to $14.95 billion from $14.73 billion, helped by higher premium yields.The company's shares rose 4.4 percent to $116.07 on the New York Stock Exchange. (Reporting by Amrutha Penumudi in Bengaluru; Editing by Don Sebastian)",2015-10-29,AET,"Thu Oct 29, 2015 | 1:12pm EDT",Aetna raises forecast as government plans expand,http://www.reuters.com//article/us-aetna-results-idUSKCN0SN14X20151029?type=companyNews
243,"  (Adds Hillary Clinton comment, updates shares)By Bill Berkrot and Ransdell PiersonOct 29 Pfizer Inc, the No. 1 U.S. drugmaker, and Botox maker Allergan Plc said they were in friendly talks to create a pharmaceutical colossus but the prospect that the company would seek to avoid U.S. taxes sounded political alarm bells.Both New York-based Pfizer and Dublin-based Allergan said no agreement has been reached and declined to discuss any terms of the deal, which would potentially set up Pfizer to take advantage of Ireland's lower tax rates.Allergan shares rose 6 percent to $304.38 in U.S. trading, while Pfizer closed off 1.9 percent at $34.77.Pfizer is already facing political pushback at home that is only likely to intensify with the U.S. presidential campaign underway, as candidates take aim at high prescription drug prices and companies looking to avoid paying U.S. taxes.A spokesman for Democratic front-runner Hillary Clinton said the candidate had not seen details of the proposed merger, but is against tax inversion maneuvers, in which U.S. companies relocate overseas to take advantage of lower tax rates.""Clinton is committed to cracking down on so-called 'inversions,' where a company chooses to leave the U.S. on paper to game the tax system, and believes we should reform our tax code to encourage investment in the U.S., rather than shipping earnings and jobs overseas,"" Clinton spokesman Ian Sams said.Democratic U.S. Senator Charles Schumer of New York said in a statement: ""The continued pursuit of inversions, mergers and foreign acquisitions of major U.S. companies for purely tax purposes shows there is a lot more work to be done to stop them.""From the right, developer and Republican presidential candidate Donald Trump said the deal was a reminder that the U.S. tax code needed an overhaul.SMOOTHER PATH ""These corporate inversions take capital and, more importantly, jobs offshore,"" he said in a statement. ""We need leadership in Washington to get the tax code changed so companies will be coming to America, not looking for ways to leave."" Billionaire investor Carl Icahn, who has endorsed Trump and launched a $150 million political action committee advocating tax reform to eliminate inversions, said a Pfizer-Allergan deal would result in the loss of the country's 10th largest company to Ireland.Analysts speculated a deal could be all or primarily done with stock because under new U.S. rules aimed at curtailing tax inversions, shareholders of the overseas company must own at least 40 percent of the combined entity.Credit Suisse analyst Vamil Divan suggested a price of $390 per Allergan share, funded by equity and debt. Allergan's U.S.-traded shares soared as high as $316.80 on Thursday.Earlier Thursday before the companies confirmed the talks, Pfizer Chief Executive Officer Ian Read reiterated his criticism of U.S. corporate taxes.""Our tax rate highly disadvantages American multinational high-tech businesses,"" Read said at a Wall Street Journal event. ""I am fighting with one hand tied behind my back.""Pfizer's effective tax rate is 25 percent, while Allergan's is 15 percent. Given that both sides characterized the talks as ""friendly,"" Pfizer is likely to have a much smoother path outside of the United States after running into intense political opposition in Britain and from AstraZeneca Plc's  board in its failed, unsolicited bid last year.""It's definitely a far easier target for Pfizer than AstraZeneca,"" said Christophe Eggmann, investment director at GAM, who holds shares in both companies. ""The hurdle will really be the price.""Moody's Investor Service said the deal would have ""credit positive implications for both companies.""A tax inversion is being discussed in the current talks, a person familiar with the matter told Reuters. In its pursuit of AstraZeneca, Pfizer had hoped to employ such a strategy.Read said Thursday he was open to any moves that produce the best long-term value for the company and shareholders. He said he was looking at various growth strategies, including a deal.Pfizer is expected to decide by late next year whether to sell or spin off its older, off-patent products unit to pare the business and focus on innovative, patent-protected medicines. Allergan, the product of a recent merger with generic drugmaker Actavis, is selling a large portfolio of generic medicines to Teva Pharmaceutical Industries Ltd   for $40.5 billion.CASH FROM BOTOX A purchase of Allergan, with a market value of more than $113 billion, would be the biggest in Pfizer's long history of huge deals, eclipsing the $90 billion Warner-Lambert acquisition through which it gained control of Lipitor, once the world's top-selling medicine.It would also restore the Viagra maker as the world's largest pharmaceutical company, worth about $330 billion, a position it relinquished after Lipitor went off-patent.Allergan expects revenue of more than $8 billion in the second half of 2015, not including generic drugs it is selling to Teva.Pfizer has annual sales of about $48 billion, with about $27 billion from patent-protected drugs, consumer products and vaccines, and about $21 billion from the business it is considering selling.Since the Warner-Lambert purchase, Pfizer has acquired Pharmacia and Wyeth, each deal under a different CEO.The deals have led to many thousands of job cuts. It is not known how many cuts would result from a tie-up with Allergan.Apart from the tax considerations, the deal would give Pfizer access to Allergan's wrinkle treatment Botox, with $2.4 billion in annual sales, and its $1.3 billion Restasis dry eye treatment.By Sept. 10, deal-making in all sectors of healthcare this year had reached a record $447.5 billion, according to Thomson Reuters data.Other large pending tie-ups include pharmacy chain Walgreens Boots Alliance Inc's planned purchase of smaller rival Rite Aid Corp announced this week, and pending mergers of health insurers Aetna Inc with Humana Inc, and Anthem Inc with Cigna Corp.(Additional reporting by Gregory Roumeliotis and Caroline Humer in New York, Vidya L Nathan in Bengaluru, Ben Hirschler in London and Amanda Becker in Littleton, N.H.; Editing by Jeffrey Benkoe and Christian Plumb)",2015-10-29,AET,"Thu Oct 29, 2015 | 6:02pm EDT","UPDATE 5-Pfizer, Allergan drug merger talks raise tax hackles in U.S.",http://www.reuters.com//article/allergan-ma-pfizer-idUSL3N12T51K20151029?type=companyNews
244,"  * Raises 2015 operating profit to $7.45-$7.55/share* Q3 adj profit $1.90/share, above est of $1.77/share* Shares rise as much as 4.4 percent to $116.07   (Adds comments from CEO, analysts; updates shares)Oct 29 Health insurer Aetna Inc raised its full-year operating earnings forecast for the fourth time this year on strong performance in its government business and said underlying operating earnings would increase in 2016.Aetna, whose shares rose 4 percent in early trading, said it expects 2016 operating earnings per share to rise at low double-digit rates from a baseline of $7 on membership growth in its Medicare and Medicaid plans.The baseline does not presume any prior year's reserve development, the company said.Insurers have been benefiting from the expansion of Medicaid, a federal health insurance program for lower-income people that is administered by the states. J.P. Morgan analyst Gary P Taylor noted that Aetna struck a more bullish tone than rival Anthem Inc, which reported results on Wednesday.Aetna said on Thursday it was not making money this year from its individual business that sells government-subsidized plans on exchanges created under the Affordable Care Act (ACA), but said profitability could improve in the business next year.""We think it's way too early to call it quits on the ACA and on the exchanges ... we view it still as a big opportunity,"" Aetna Chief Executive Mark Bertolini said on a conference call with analysts. Aetna said it added 815,000 members through the Obamacare exchanges and 280,000 off it in the third quarter ended Sept. 30.UnitedHealth Group Inc and Anthem had said their Obamacare insurance businesses was being hampered by lower-than-anticipated enrollment.Aetna, which is in the process of buying rival Humana Inc , raised its 2015 operating earnings to $7.45-$7.55 per share from its previous estimate of at least $7.40. Leerink Partners analyst Ana Gupte said the 2016 forecast looked achievable and that she expected margins in the Obamacare business to improve next year.Net earnings fell 5 percent to $560.1 million, or $1.59 per share, in the third quarter.On an adjusted basis, the company earned $1.90 per share, above the average analyst estimate of $1.77 per share, according to Thomson Reuters I/B/E/S.Spending on medical claims as a percentage of premiums improved to 81.1 percent from 82.3 percent a year earlier.Total revenue rose to $14.95 billion from $14.73 billion, helped by higher premium yields.The company's shares rose 4.4 percent to $116.07 on the New York Stock Exchange.   (Reporting by Amrutha Penumudi in Bengaluru; Editing by Don Sebastian)",2015-10-29,AET,"Thu Oct 29, 2015 | 1:10pm EDT",UPDATE 3-Aetna raises forecast as government plans expand,http://www.reuters.com//article/aetna-results-idUSL3N12T3ZF20151029?type=companyNews
245,"  Oct 29 Health insurer Aetna Inc reported a 1.5 percent increase in quarterly revenue, helped by membership growth in its government business.The company's earnings fell to $560.1 million, or $1.59 per share, for the third quarter ended Sept. 30, from $594.5 million, or $1.67 per share, a year earlier. Revenue rose to $14.95 billion from $14.73 billion.  (Reporting by Amrutha Penumudi in Bengaluru)",2015-10-29,AET,"Thu Oct 29, 2015 | 6:12am EDT",Health insurer Aetna revenue rises,http://www.reuters.com//article/aetna-results-idUSL3N12T3UY20151029?type=companyNews
246,"  * UnitedHealth to decide next year about leaving exchanges* CEO says Obamacare exchanges are not sustainable business* Shares fall 5.5 percent, weigh on other insurers, hospitals   (New throughout, adds outside comment)By Caroline HumerNov 19 UnitedHealth Group Inc said it may exit the individual insurance exchanges created under U.S. President Barack Obama's healthcare law, raising new questions about the long-term sustainability of a key Obamacare program.The largest U.S. health insurer said weak enrollment and high medical costs for exchange members were taking too big a toll on its performance. It will evaluate during the first half of next year whether it will offer Obamacare plans in 2017.Rivals Aetna Inc and Anthem Inc said last month that they were seeing too few people enroll, but have not said they were considering exiting the business.""We cannot sustain these losses,"" UnitedHealth Chief Executive Stephen Hemsley said during a conference call with investors. ""We can't really subsidize a marketplace that doesn't appear at the moment to be sustaining itself.""A deterioration in the exchanges in the midst of the 2016 election campaign could give ammunition to Republican candidates opposed to the health care law. Democrats could also face pressure if UnitedHealth and other players depart the exchanges because less competition could mean higher insurance premiums.The U.S. government said the exchanges were growing and giving millions of Americans access to affordable insurance. Enrollment for 2016 opened earlier this month.""We continue to see more people signing up for health insurance and more issuers entering the marketplaces,"" U.S. Department of Health and Human Services spokesman Ben Wakana said in email. ""Today's statement by one issuer is not indicative of the marketplace's strength and viability."" UnitedHealth shares fell 5.5 percent on Thursday, while Aetna lost 7.2 percent and Anthem dropped 6.4 percent. Shares of hospital operators, which had benefited in recent years from an increase in insured patients, also fell, with HCA Holdings Inc  down 5.9 percent and Community Health Systems  down 8.5 percent.More than 9 million people are enrolled through the exchanges, which operate in each of the 50 states and the District of Columbia. Most policyholders receive government subsidies to help pay for the plans, based on household income.UnitedHealth has reversed course on its expectations. Last month, it predicted substantial improvement in 2016 for the Obamacare business. Since then, Hemsley said, the enrollment picture has worsened, making it clearer the medical costs of new customers are unsustainable.The Obama administration recently estimated that 10 million people would enroll in 2016, far below the forecast of 20 million sign-ups issued by the Congressional Budget Office in June.UnitedHealth has about 500,000 members with Obamacare plans, making it the fourth-largest insurer on the exchanges. On Thursday, the company said it expected these plans to hurt current-quarter profit by $425 million, or 26 cents per share. As a result, the company cut its full-year earnings forecast to $6 per share from a previous range of $6.25 to $6.35.UnitedHealth also said it was pulling back on 2016 marketing for these plans and that they had raised premiums, which should slow growth in the individual business.For next year, it forecast earnings of $7.10 to $7.30 per share. Analysts on average are expecting $7.28, according to Thomson Reuters I/B/E/S.NEW COST CONCERNS  UnitedHealth had entered a small number of markets in 2014, the first year the exchanges opened. It began selling plans in about two dozen states in 2015. It is still a smaller player on these markets than Anthem, Aetna and Humana Inc.""United's experience is unique. They got in late and they entered into some very competitive markets,"" said Dan Mendelson, president of consultancy Avalere Health. ""That said, I think that every insurer is having a harder time in 2016 than they had in 2015, and that they are all going to evaluate this carefully.""UnitedHealth was in many markets where competitors could be helped by its departure, he said.Spokeswomen for Anthem and Aetna did not provide any new comment on their plans regarding the exchanges.If large insurers do exit, the exchanges could be dominated by smaller providers who specialize in Medicaid health plans for the poor, said Kaiser Family Foundation senior vice president Larry Levitt.Insurers had criticized the exchanges before they opened, due to technology problems with the federal government-run HealthCare.gov website and concerns about the cost of covering customers who might be sicker than the general population.The Obama administration mitigated some of that risk in the first year with payments to insurers, but that funding has declined. About a dozen nonprofit cooperative health plans that sold plans on the exchanges have collapsed.Consumers have criticized plans for high out-of-pocket deductibles that must be paid before coverage kicks in, as well as steep increases in monthly premiums from year to year.While the administration could try to boost funding to help mitigate insurer losses, such a plan would not be likely to find support from either political party.""I don't think any Democrats would want to spend political capital on that right now,"" said Yevgeniy Feyman, deputy director of health policy at the Manhattan Institute. ""Republicans get political capital out of the exchanges failing.""   (Reporting by Caroline Humer in New York and Amrutha Penumudi and Ankur Banerjee in Bengaluru; Editing by Savio D'Souza, Michele Gershberg, Lisa Von Ahn and David Gregorio)",2015-11-19,AET,"Thu Nov 19, 2015 | 4:18pm EST",UPDATE 5-UnitedHealth may exit Obamacare individual exchanges,http://www.reuters.com//article/unitedhealth-grp-outlook-idUSL3N13E3BY20151119?type=companyNews
247,"   By Caroline Humer, Amrutha Penumudi and Ankur Banerjee  UnitedHealth Group Inc, the largest U.S. health insurer, warned on Thursday that it might stop selling individual health plans on the Obamacare exchanges in 2017, citing weak enrollment and high medical costs for people who did sign up.UnitedHealth's comments raise new questions about the viability of individual insurance exchanges set up under President Barack Obama's healthcare law. Rival insurers Aetna Inc and Anthem Inc also said last month they were seeing too few people sign up, but have not signaled they would exit the business.""We cannot sustain these losses,"" UnitedHealth Chief Executive Stephen Hemsley said during a conference call with investors. ""We can't really subsidize a marketplace that doesn't appear at the moment to be sustaining itself.""A deterioration in the exchanges in the midst of the 2016 election campaign could provide additional fuel to Republican efforts to overturn the healthcare law. Several of Obama's fellow Democrats are also considering changes to the Affordable Care Act, including whether to alter the ""Cadillac tax,"" a levy on high-cost health plans sponsored by employers.UnitedHealth shares fell 4.5 percent on Thursday, while Aetna lost 5.7 percent, and Anthem dropped 6.2 percent. Hospital operators, which had benefited in recent years from a rise in insured patients, also fell, with HCA Holdings Inc  shares down 5.7 percent and Community Health Systems  down 8.3 percent.UnitedHealth has about 500,000 members with Obamacare plans, making it the fourth-largest insurer on the exchanges. On Thursday, the company said it expected these plans to hurt current-quarter profit by $425 million, or 26 cents per share. As a result, the company said it cut its full-year earnings forecast to $6 per share from a previous range of $6.25 to $6.35.UnitedHealth also said it was pulling back on 2016 advertising. For next year, it forecast earnings of $7.10 to $7.30 per share. Analysts on average are expecting $7.28, according to Thomson Reuters I/B/E/S.The company plans to evaluate during the first half of next year whether it would continue to offer Obamacare plans in 2017.More than 9 million people are enrolled through the exchanges, which operate in each of the 50 states and the District of Columbia. The majority of the policyholders receive some level of government subsidy to help pay for the plans, based on household income. The government recently estimated that 10 million people would enroll in 2016. NEW COST CONCERNS Just a month ago, UnitedHealth said that it was expecting substantial improvement for the Obamacare business in 2016. Hemsley said that since then, the enrollment picture has become worse, and it has become clearer that the medical costs of new customers were unsustainable. UnitedHealth had entered a small number of markets in 2014, the first year that the exchanges opened, but began selling plans in about two dozen states in 2015. It is still a smaller player on these markets than Anthem, Aetna and Humana Inc .Insurers had criticized the exchanges before they opened, due to technology problems tied to the federal government-run HealthCare.gov website and concerns about the cost of covering customers who might be sicker than the general population.The Obama administration mitigated some of that risk in the first year with payments to insurers, but that funding has since declined. About a dozen nonprofit cooperative health plans that sold plans on the exchanges have collapsed.Consumers have also criticized plans for requiring them to meet high deductibles out of pocket before their coverage kicks in, as well as steep increases in monthly premiums from year to year.The company said the rest of its business continued to perform in line with its expectations.""If exchange pricing/risk does not stabilize near-term,"" Susquehanna analyst Chris Rigg wrote in a note, ""we'd expect a quick rebound in profits as (UnitedHealth) exits this business line.""",2015-11-19,AET,"Thu Nov 19, 2015 | 12:32pm EST",UnitedHealth may exit Obamacare individual exchanges,http://www.reuters.com//article/unitedhealth-grp-outlook-idUSL1N13E1SN20151119?type=companyNews
248,"  (Repeats to show availability of photos)* UnitedHealth to decide next year whether to leave exchanges* CEO says Obamacare exchanges may not be sustaining themselves* Shares fall 4.5 percent, weigh on other insurers, hospitalsBy Caroline HumerNov 19 UnitedHealth Group Inc, the largest U.S. health insurer, warned on Thursday that it might stop selling individual health plans on the Obamacare exchanges in 2017, citing weak enrollment and high medical costs for people who did sign up.UnitedHealth's comments raise new questions about the viability of individual insurance exchanges set up under President Barack Obama's healthcare law. Rival insurers Aetna Inc and Anthem Inc also said last month they were seeing too few people sign up, but have not signaled they would exit the business.""We cannot sustain these losses,"" UnitedHealth Chief Executive Stephen Hemsley said during a conference call with investors. ""We can't really subsidize a marketplace that doesn't appear at the moment to be sustaining itself.""A deterioration in the exchanges in the midst of the 2016 election campaign could provide additional fuel to Republican efforts to overturn the healthcare law. Several of Obama's fellow Democrats are also considering changes to the Affordable Care Act, including whether to alter the ""Cadillac tax,"" a levy on high-cost health plans sponsored by employers. UnitedHealth shares fell 4.5 percent on Thursday, while Aetna lost 5.7 percent, and Anthem dropped 6.2 percent. Hospital operators, which had benefited in recent years from a rise in insured patients, also fell, with HCA Holdings Inc  shares down 5.7 percent and Community Health Systems  down 8.3 percent.UnitedHealth has about 500,000 members with Obamacare plans, making it the fourth-largest insurer on the exchanges. On Thursday, the company said it expected these plans to hurt current-quarter profit by $425 million, or 26 cents per share.As a result, the company said it cut its full-year earnings forecast to $6 per share from a previous range of $6.25 to $6.35.UnitedHealth also said it was pulling back on 2016 advertising. For next year, it forecast earnings of $7.10 to $7.30 per share. Analysts on average are expecting $7.28, according to Thomson Reuters I/B/E/S. The company plans to evaluate during the first half of next year whether it would continue to offer Obamacare plans in 2017.More than 9 million people are enrolled through the exchanges, which operate in each of the 50 states and the District of Columbia. The majority of the policyholders receive some level of government subsidy to help pay for the plans, based on household income. The government recently estimated that 10 million people would enroll in 2016.NEW COST CONCERNS  Just a month ago, UnitedHealth said that it was expecting substantial improvement for the Obamacare business in 2016. Hemsley said that since then, the enrollment picture has become worse, and it has become clearer that the medical costs of new customers were unsustainable.UnitedHealth had entered a small number of markets in 2014, the first year that the exchanges opened, but began selling plans in about two dozen states in 2015. It is still a smaller player on these markets than Anthem, Aetna and Humana Inc .Insurers had criticized the exchanges before they opened, due to technology problems tied to the federal government-run HealthCare.gov website and concerns about the cost of covering customers who might be sicker than the general population.The Obama administration mitigated some of that risk in the first year with payments to insurers, but that funding has since declined. About a dozen nonprofit cooperative health plans that sold plans on the exchanges have collapsed.Consumers have also criticized plans for requiring them to meet high deductibles out of pocket before their coverage kicks in, as well as steep increases in monthly premiums from year to year.The company said the rest of its business continued to perform in line with its expectations.""If exchange pricing/risk does not stabilize near-term,"" Susquehanna analyst Chris Rigg wrote in a note, ""we'd expect a quick rebound in profits as (UnitedHealth) exits this business line.""    (Reporting by Caroline Humer in New York and Amrutha Penumudi and Ankur Banerjee in Bengaluru; Editing by Savio D'Souza, Michele Gershberg and Lisa Von Ahn)",2015-11-19,AET,"Thu Nov 19, 2015 | 12:04pm EST",RPT-UPDATE 3-UnitedHealth may exit Obamacare individual exchanges,http://www.reuters.com//article/unitedhealth-grp-outlook-idUSL1N13E1PB20151119?type=companyNews
249,"   By Caroline Humer  U.S. health insurers Aetna Inc (AET.N) and Anthem Inc (ANTM.N) on Friday sought to reassure investors that their Obamacare businesses had not worsened after UnitedHealth Group Inc (UNH.N) warned of mounting losses in that sector.Aetna and Anthem said their individual insurance businesses, which include the plans created by President Barack Obama's national healthcare reform law, had performed in line with projections through October. Both backed their earnings forecasts for 2015. The announcements came the day after UnitedHealth cut its earnings forecast and said it might exit the Obamacare exchanges in 2017. It said it was losing money on that business because of low enrollment and high costs. Anthem remains committed to the exchanges and to ""continuing our dialogue with policymakers and regulators regarding how we can improve the stability of the individual market,"" Chief Executive Officer Joseph Swedish said in a statement.Enrollment for 2016 exchange plans opened earlier this month. In October, the U.S. Department of Health and Human Services forecast about 10 million people would have plans next year, significantly below industry expectations of 20 million. Enrollment in 2015 also fell short of initial goals, and insurers say that trend has made it difficult to price their plans.  About a dozen start-up cooperative insurers have collapsed this year, driven out of the business by paying more medical claims than expected. Also, government payments to mitigate the costs of insuring sicker-than-expected members are declining and will be mostly phased out after next year. Aetna shares, which had fallen 7 percent on Thursday, rose 4.1 percent to $103.97 on Friday. Anthem, the second-largest player on the exchanges, was up 2.5 percent at $131.10 after dropping 9 percent the previous day, and UnitedHealth gained 2.1 percent to $113.00 after a 6 percent decline. Aetna said it still expected 2015 operating earnings of $7.45 to $7.55 per share, and Anthem reiterated its outlook of $9.53 to $9.63 per share. Leerink Partners analyst Ana Gupte said Aetna's statement showed the company had already factored in the individual business' challenges to its forecasts. Aetna and Anthem had referred back to earlier comments when asked on Thursday about UnitedHealth's commentary.In October, Aetna had said it was not making money from the business, which sells government-subsidized plans on exchanges created under the U.S. Affordable Care Act but that profitability could improve next year. It has about 815,000 members in plans on the exchanges.Anthem said last month that 2016 would be a challenging year on the exchanges, where it has about 824,000 customers, and that the business would drag on profit. The earnings affirmations echo that of Centene Corp (CNC.N) and Molina Healthcare Inc (MOH.N). The small health insurers, which focus on Medicaid, also said its exchange business was performing in line with its expectations.Molina CEO J. Mario Molina said that Molina was targeting low-income people, similar to its Medicaid patients, and that it was not having the same problems as UnitedHealth.Kaiser Permanente, a hospital and insurer system, also said that it was ""strongly committed"" to the exchanges.     (Reporting by Caroline Humer in New York and Amrutha Penumudi in Bengaluru; Editing by Savio D'Souza, Lisa Von Ahn and Diane Craft)",2015-11-20,AET,"Fri Nov 20, 2015 | 4:16pm EST","Aetna, Anthem reassure investors on Obamacare business",http://www.reuters.com//article/us-aetna-outlook-idUSKCN0T91HG20151120?type=companyNews
250,"   By Caroline Humer and Amrutha Penumudi  U.S. health insurers Aetna Inc and Anthem Inc on Friday sought to reassure investors that their Obamacare businesses had not worsened after UnitedHealth Group Inc warned of mounting losses in that sector.Aetna and Anthem said in regulatory filings that their individual insurance businesses, which include the plans created by President Barack Obama's national healthcare reform law, had performed in line with projections through October. Both backed their earnings forecasts for 2015.The announcements came the day after UnitedHealth cut its earnings forecast and said it might exit the Obamacare business in 2017. It said it was losing money on the Obamacare business because of low enrollment and high costs.Aetna shares, which had fallen 7 percent on Thursday, rose 3.6 percent to $103.55 on Friday. Anthem, the second-largest player on the exchanges, was up 1.8 percent at $130.15 after falling 9 percent the previous day, and UnitedHealth gained 2.4 percent to $113.23 after a 6 percent decline. Aetna said it still expected 2015 operating earnings of $7.45 to $7.55 per share, and Anthem reiterated its outlook of $9.53 to $9.63 per share.Leerink Partners analyst Ana Gupte said Aetna's statement showed the company had already factored in challenges in the individual business to its 2015 outlook and commentary about 2016. Aetna and Anthem had referred back to earlier comments when asked on Thursday about UnitedHealth's commentary. In October, Aetna had said it was not making money from the business, which sells government-subsidized plans on exchanges created under the U.S. Affordable Care Act but that profitability could improve next year. It had about 815,000 members in plans on the exchanges and 275,000 in plans sold off the exchanges.Anthem, which has about 824,000 exchange customers, said last month that 2016 would be a challenging year on the exchanges and that the business would drag on profit. Enrollment for 2016 exchange plans opened earlier this month. In October, the U.S. Department of Health and Human Services forecast about 10 million people would have plans in 2016, significantly below industry expectations of 20 million.The earnings affirmations echo that of Centene Corp. The small health insurer, which focuses on Medicaid, also said its exchange business was performing in line with its expectations.Kaiser Permanente, a hospital and insurer system that sells Obamacare plans in eight states and the District of Columbia, said in an emailed statement on Thursday that it was ""strongly committed"" to participating in the exchanges.",2015-11-20,AET,"Fri Nov 20, 2015 | 12:17pm EST","Aetna, Anthem say individual Obamacare business performing as expected",http://www.reuters.com//article/aetna-outlook-idUSL1N13F19320151120?type=companyNews
251,"  Nov 20 Health insurer Aetna reaffirmed its full-year 2015 operating earnings forecast on Friday, a day after UnitedHealth Group Inc cut its guidance, blaming deteriorating performance in its individual Obamacare business.Aetna said its individual commercial business continued to perform in line with its expectations. UnitedHealth said on Thursday it may exit Obamacare individual business as weak enrollment and high medical costs for exchange members were taking too big a toll on its performance.  Aetna on Friday said it continues to expect operating earnings of $7.45 to $7.55 per share in 2015.   (Reporting by Amrutha Penumudi in Bengaluru; Editing by Savio D'Souza)",2015-11-20,AET,"Fri Nov 20, 2015 | 7:13am EST",Health insurer Aetna reaffirms 2015 profit forecast,http://www.reuters.com//article/aetna-outlook-idUSL3N13F3HW20151120?type=companyNews
252,"   By Simon Johnson and Diane Bartz | STOCKHOLM/WASHINGTON  STOCKHOLM/WASHINGTON General Electric on Monday walked away from a $3.3 billion agreement to sell its appliances business to Sweden's Electrolux, terminating the deal after months of opposition from U.S. antitrust regulators.  GE (GE.N) said it would pursue other suitors for its century-old appliance unit but declined to say who they might be. ""The appliances business is performing well and GE will continue to run the business while it pursues a sale,"" the company said in a statement. Shares of Electrolux, which sought to double its U.S. sales with the purchase, tumbled on the news, and the company said it will now focus on developing existing brands such as Frigidaire, Kenmore and Tappan and could look at other acquisitions. The U.S. Justice Department had filed a lawsuit in July asking a judge to stop the deal, arguing that it would push appliance prices up by 5 percent. Electrolux, GE and larger competitor Whirlpool (WHR.N) make up more than 90 percent of major kitchen appliances sold to homebuilders, according to the lawsuit.""This deal was bad for the millions of consumers who buy cooking appliances every year. Electrolux and General Electric could not overcome that reality at trial,"" said Deputy Assistant Attorney General David Gelfand of the departments Antitrust Division.This has been a year of megadeals but also a year of aggressive deals killed by equally aggressive U.S. antitrust authorities.Dead deals include Comcast's (CMCSA.O) bid to buy Time Warner Cable TWC.N, Sysco's (SYY.N) plan to buy US Foods, Thai Union's plan to buy Bumble Bee tuna and Applied Materials' (AMAT.O) scrapped plan to merge with Tokyo Electron (8035.T). More mergers are under review including two insurance deals, Aetna's (AET.N) deal for Humana (HUM.N) and Anthem's (ANTM.N) planned merger with Cigna (CI.N), along with a deal between Baker Hughes (BHI.N) and Halliburton (HAL.N) and Staples' (SPLS.O) merger with Office Depot (ODP.O).Electrolux shares fell 13.4 percent to 207 Swedish crowns, the biggest fall by a European blue-chip stock on Monday. They earlier touched a 14-month low of 203.2 crowns. GE closed 0.4 percent lower at $30.37.FUTURE OF ELECTROLUX The acquisition of GE's appliance business would have seen Electrolux leapfrog Whirlpool as the world's biggest appliances maker, strengthening its position in North and South America. ""We're disappointed but we're certainly not defeated,"" Chief Executive Keith McLoughlin told a conference call. He said the firm would ""continue to have a strong, robust M&A (mergers and acquisitions) process"", without elaborating.Some analysts suggested McLaughlin might decide to leave in the face of the deal collapse. ""I'm not sure how much he will enjoy staying on now that what might have been his last deal won't go through,"" Handelsbanken Capital Markets' Karri Rinta said. With his family having returned to the United States several years ago, speculation has been rife McLoughlin, who has been CEO for almost five years and imported manufacturing practices from the auto industry to boost profitability, could soon leave.   McLoughlin said in a statement he remained committed to Electrolux and would continue as CEO.In 2014, Electrolux made around 33 percent of its 112 billion crowns ($13.2 billion) of sales in North America against around 35 percent in Europe.Before the GE deal was announced, Electrolux had been looking to buy into growth in emerging markets, a strategy it may now revisit.The Swedish firm said GE had asked it pay out a termination fee of $175 million that was part of the transaction agreement.It said fourth-quarter results would include about 175 million crowns of transaction and integration costs and would be hit by about 225 million crowns of costs arising from a bridge facility intended to finance the deal. (Additional reporting by Helena Soderpalm, Olof Swahnberg, Violette Goarant Johan Sennero,; Editing by Soyoung Kim and Meredith Mazzilli)",2015-12-07,AET,"Mon Dec 7, 2015 | 4:45pm EST",GE calls off Electrolux appliance deal amid U.S. antitrust fight,http://www.reuters.com//article/us-ge-equity-electrolux-idUSKBN0TQ0MP20151207?type=companyNews
253,"  * GE terminates agreement after regulatory objections* Deal was opposed by DOJ on competition grounds* Analysts say failed deal may mean exit for Electrolux CEO* Electrolux shares fall as much as 15 percent   (Adds Breakingviews link, updates share prices)By Simon Johnson and Diane BartzSTOCKHOLM/WASHINGTON, Dec 7 General Electric on Monday walked away from a $3.3 billion agreement to sell its appliances business to Sweden's Electrolux, terminating the deal after months of opposition from U.S. antitrust regulators.GE said it would pursue other suitors for its century-old appliance unit but declined to say who they might be.""The appliances business is performing well and GE will continue to run the business while it pursues a sale,"" the company said in a statement.Shares of Electrolux, which sought to double its U.S. sales with the purchase, tumbled on the news, and the company said it will now focus on developing existing brands such as Frigidaire, Kenmore and Tappan and could look at other acquisitions.The U.S. Justice Department had filed a lawsuit in July asking a judge to stop the deal, arguing that it would push appliance prices up by 5 percent. Electrolux, GE and larger competitor Whirlpool make up more than 90 percent of major kitchen appliances sold to homebuilders, according to the lawsuit.""This deal was bad for the millions of consumers who buy cooking appliances every year. Electrolux and General Electric could not overcome that reality at trial,"" said Deputy Assistant Attorney General David Gelfand of the department's Antitrust Division. This has been a year of megadeals but also a year of aggressive deals killed by equally aggressive U.S. antitrust authorities.Dead deals include Comcast's bid to buy Time Warner Cable, Sysco's plan to buy US Foods, Thai Union's plan to buy Bumble Bee tuna and Applied Materials'  scrapped plan to merge with Tokyo Electron.More mergers are under review including two insurance deals, Aetna's deal for Humana and Anthem's  planned merger with Cigna, along with a deal between Baker Hughes and Halliburton and Staples'  merger with Office Depot.Electrolux shares fell 13.4 percent to 207 Swedish crowns, the biggest fall by a European blue-chip stock on Monday. They earlier touched a 14-month low of 203.2 crowns. GE closed 0.4 percent lower at $30.37. FUTURE OF ELECTROLUX The acquisition of GE's appliance business would have seen Electrolux leapfrog Whirlpool as the world's biggest appliances maker, strengthening its position in North and South America.""We're disappointed but we're certainly not defeated,"" Chief Executive Keith McLoughlin told a conference call.He said the firm would ""continue to have a strong, robust M&A (mergers and acquisitions) process"", without elaborating.Some analysts suggested McLaughlin might decide to leave in the face of the deal collapse. ""I'm not sure how much he will enjoy staying on now that what might have been his last deal won't go through,"" Handelsbanken Capital Markets' Karri Rinta said.With his family having returned to the United States several years ago, speculation has been rife McLoughlin, who has been CEO for almost five years and imported manufacturing practices from the auto industry to boost profitability, could soon leave.McLoughlin said in a statement he remained committed to Electrolux and would continue as CEO.In 2014, Electrolux made around 33 percent of its 112 billion crowns ($13.2 billion) of sales in North America against around 35 percent in Europe.Before the GE deal was announced, Electrolux had been looking to buy into growth in emerging markets, a strategy it may now revisit.The Swedish firm said GE had asked it pay out a termination fee of $175 million that was part of the transaction agreement.It said fourth-quarter results would include about 175 million crowns of transaction and integration costs and would be hit by about 225 million crowns of costs arising from a bridge facility intended to finance the deal.($1 = 8.5125 Swedish crowns)(Additional reporting by Helena Soderpalm, Olof Swahnberg, Violette Goarant Johan Sennero,; Editing by Soyoung Kim and Meredith Mazzilli)",2015-12-07,AET,"Mon Dec 7, 2015 | 4:42pm EST",UPDATE 5-GE calls off Electrolux appliance deal amid U.S. antitrust fight,http://www.reuters.com//article/ge-ma-electrolux-idUSL8N13W0SX20151207?type=companyNews
254,"   By Diane Bartz  Dec 7 - The U.S. Federal Trade Commission said it has filed a complaint aimed at stopping Staples Inc, the nation's largest office supply store, from buying its top rival, Office Depot Inc.Canada's Competition Bureau also said on Monday it would challenge the proposed transaction, which has received the green light from competition authorities in China, Australia and New Zealand.Office Depot's shares fell as much as 17.6 percent to a year low of $5.46, while Staples' stock dropped 13.6 percent to a year low of $10.68.""The commission has reason to believe that the proposed merger between Staples and Office Depot is likely to eliminate beneficial competition that large companies rely on to reduce the costs of office supplies,"" FTC Chairwoman Edith Ramirez said in a statement. (1.usa.gov/1NeaaD9)The FTC said Staples and Office Depot were often the top two bidders for large business customers and the deal would hurt customers who wanted nationwide contracts for office supplies. The companies said in a statement on Monday that they would fight the FTC in court, arguing that they face stiff competition from manufacturers who sell their own products, e-commerce companies, big box stores and others.The deal is also being investigated by EU regulators, who in September raised concerns about possible price hikes.The FTC stopped a merger attempt between the same two companies in 1997 on similar concerns. But in the past 19 years, Amazon and other online sellers, which deliver to almost anywhere in the United States, have exploded onto the scene, while megastores such as Costco  and Wal-Mart Stores Inc have further crowded the market.Staples was emboldened to make a $6.3 billion offer for Office Depot in February after that chain succeeded in buying No. 3 OfficeMax in November 2013 with no divestitures. This time around, Staples has offered divestitures totaling ""more than $500 million in commercial business"" in order to allay the FTC's concerns.This has been a year of aggressive deals killed by equally aggressive U.S. antitrust authorities.Other deals contested by regulators include General Electric Co's $3.3 billion agreement to sell its appliances business to Sweden's Electrolux, Comcast's bid to buy Time Warner Cable, and Sysco's plan to buy US Foods.Other mergers under review include two insurance deals: Aetna's deal for Humana and Anthem's  planned merger with Cigna.Halliburton's offer to buy its rival oilfield services provider Baker Hughes is also under review.",2015-12-07,AET,"Mon Dec 7, 2015 | 3:22pm EST",U.S. files complaint to stop Staples from buying Office Depot,http://www.reuters.com//article/officedepot-staples-antitrust-idUSL1N13W1PY20151207?type=companyNews
255,"   By Diane Bartz  The U.S. Federal Trade Commission said it has filed a complaint aimed at stopping Staples Inc, the nation's largest office supply store, from buying its top rival, Office Depot Inc.Canada's Competition Bureau also said on Monday it would challenge the proposed transaction, which has received the green light from competition authorities in China, Australia and New Zealand.Office Depot's shares fell as much as 17.6 percent to a year low of $5.46, while Staples' stock dropped 13.6 percent to a year low of $10.68.""The commission has reason to believe that the proposed merger between Staples and Office Depot is likely to eliminate beneficial competition that large companies rely on to reduce the costs of office supplies,"" FTC Chairwoman Edith Ramirez said in a statement. (1.usa.gov/1NeaaD9)The FTC said Staples and Office Depot were often the top two bidders for large business customers and the deal would hurt customers who wanted nationwide contracts for office supplies. The companies said in a statement on Monday that they would fight the FTC in court, arguing that they face stiff competition from manufacturers who sell their own products, e-commerce companies, big box stores and others.The deal is also being investigated by EU regulators, who in September raised concerns about possible price hikes.The FTC stopped a merger attempt between the same two companies in 1997 on similar concerns. But in the past 19 years, Amazon and other online sellers, which deliver to almost anywhere in the United States, have exploded onto the scene, while megastores such as Costco  and Wal-Mart Stores Inc have further crowded the market.Staples was emboldened to make a $6.3 billion offer for Office Depot in February after that chain succeeded in buying No. 3 OfficeMax in November 2013 with no divestitures. This time around, Staples has offered divestitures totaling ""more than $500 million in commercial business"" in order to allay the FTC's concerns.This has been a year of aggressive deals killed by equally aggressive U.S. antitrust authorities.Other deals contested by regulators include General Electric Co's $3.3 billion agreement to sell its appliances business to Sweden's Electrolux, Comcast's bid to buy Time Warner Cable, and Sysco's plan to buy US Foods.Other mergers under review include two insurance deals: Aetna's deal for Humana and Anthem's  planned merger with Cigna.Halliburton's offer to buy its rival oilfield services provider Baker Hughes is also under review.",2015-12-07,AET,"Mon Dec 7, 2015 | 3:12pm EST",U.S. files complaint to stop Staples from buying Office Depot,http://www.reuters.com//article/officedepot-staples-antitrust-idUSL1N13W1IL20151207?type=companyNews
256,"  The U.S. Federal Trade Commission said it has filed a complaint aimed at stopping Staples Inc (SPLS.O), the nation's largest office supply store, from buying its top rival, Office Depot Inc (ODP.O).Canada's Competition Bureau also said on Monday it would challenge the proposed transaction, which has received the green light from competition authorities in China, Australia and New Zealand.Office Depot's shares fell as much as 17.6 percent to a year low of $5.46, while Staples' stock dropped 13.6 percent to a year low of $10.68.""The commission has reason to believe that the proposed merger between Staples and Office Depot is likely to eliminate beneficial competition that large companies rely on to reduce the costs of office supplies,"" FTC Chairwoman Edith Ramirez said in a statement. (1.usa.gov/1NeaaD9)The FTC said Staples and Office Depot were often the top two bidders for large business customers and the deal would hurt customers who wanted nationwide contracts for office supplies.The companies said in a statement on Monday that they would fight the FTC in court, arguing that they face stiff competition from manufacturers who sell their own products, e-commerce companies, big box stores and others. The deal is also being investigated by EU regulators, who in September raised concerns about possible price hikes.The FTC stopped a merger attempt between the same two companies in 1997 on similar concerns.But in the past 19 years, Amazon (AMZN.O) and other online sellers, which deliver to almost anywhere in the United States, have exploded onto the scene, while megastores such as Costco (COST.O) and Wal-Mart Stores Inc (WMT.N) have further crowded the market. Staples was emboldened to make a $6.3 billion offer for Office Depot in February after that chain succeeded in buying No. 3 OfficeMax in November 2013 with no divestitures.This time around, Staples has offered divestitures totaling ""more than $500 million in commercial business"" in order to allay the FTC's concerns.This has been a year of aggressive deals killed by equally aggressive U.S. antitrust authorities. Other deals contested by regulators include General Electric Co's (GE.N) $3.3 billion agreement to sell its appliances business to Sweden's Electrolux, Comcast's (CMCSA.O) bid to buy Time Warner Cable TWC.N, and Sysco's (SYY.N) plan to buy US Foods.Other mergers under review include two insurance deals: Aetna's (AET.N) deal for Humana (HUM.N) and Anthem's (ANTM.N) planned merger with Cigna (CI.N).Halliburton's (HAL.N) offer to buy its rival oilfield services provider Baker Hughes (BHI.N) is also under review. (Reporting by Diane Bartz in Washington and Ramkumar Iyer in Bengaluru; Editing by Alan Crosby and Savio D'Souza)",2015-12-07,AET,"Mon Dec 7, 2015 | 3:05pm EST",U.S. files complaint to stop Staples from buying Office Depot,http://www.reuters.com//article/us-officedepot-staples-antitrust-idUSKBN0TQ28A20151207?type=companyNews
257,"   By Jonathan Stempel  A federal judge on Monday dismissed a lawsuit seeking to force the U.S. Securities and Exchange Commission to adopt a rule requiring publicly traded companies to disclose political contributions.U.S. District Judge Rosemary Collyer in Washington, D.C. found no showing by the plaintiff Stephen Silberstein that the SEC had a ""clear legal duty"" to begin a rulemaking proceeding, and that its failure was arbitrary and capricious.She also said she lacked jurisdiction to consider whether the SEC engaged in ""unreasonable delay"" by ignoring Silberstein's rulemaking petition. Collyer said such a claim might be raised before a federal appeals court.The lawsuit was filed last May by the nonprofit Campaign for Accountability on behalf of Silberstein, an Aetna Inc shareholder who had unsuccessfully sued the insurer in New York to force it to reveal its political donations.Silberstein said improved disclosure is necessary in light of the U.S. Supreme Court's Citizens United decision in 2010, which allowed unlimited independent spending by corporations and labor unions in federal elections. He said shareholders deserve the right to assess whether corporate contributions are in companies' best interests.Daniel Stevens, a spokesman for the Campaign for Accountability, said the group is disappointed in Tuesday's decision and may file a complaint with the appeals court. SEC spokesman Kevin Callahan had no immediate comment.The regulator had argued that it had discretion, but no obligation, to begin a rulemaking proceeding.The Citizens United decision inspired a wave of new campaign spending, including from politically-focused nonprofits that need not disclose the identities of their donors. The Campaign for Accountability has estimated that the 2016 U.S. presidential campaign may cost at least $5 billion, roughly double the $2.6 billion that the nonprofit Center for Responsive Politics has estimated was spent on the 2012 campaign.The case is Silberstein v SEC, U.S. District Court, District of Columbia, No. 15-00722.     (Reporting by Jonathan Stempel in New York; Editing by Paul Simao)",2016-01-04,AET,"Mon Jan 4, 2016 | 3:31pm EST",SEC not required to make firms disclose political contributions: judge,http://www.reuters.com//article/us-sec-politics-idUSKBN0UI1XU20160104?type=companyNews
258,"   By Jonathan Stempel  Jan 4 A federal judge on Monday dismissed a lawsuit seeking to force the U.S. Securities and Exchange Commission to adopt a rule requiring publicly traded companies to disclose political contributions.U.S. District Judge Rosemary Collyer in Washington, D.C. found no showing by the plaintiff Stephen Silberstein that the SEC had a ""clear legal duty"" to begin a rulemaking proceeding, and that its failure was arbitrary and capricious.She also said she lacked jurisdiction to consider whether the SEC engaged in ""unreasonable delay"" by ignoring Silberstein's rulemaking petition. Collyer said such a claim might be raised before a federal appeals court.The lawsuit was filed last May by the nonprofit Campaign for Accountability on behalf of Silberstein, an Aetna Inc  shareholder who had unsuccessfully sued the insurer in New York to force it to reveal its political donations. Silberstein said improved disclosure is necessary in light of the U.S. Supreme Court's Citizens United decision in 2010, which allowed unlimited independent spending by corporations and labor unions in federal elections.He said shareholders deserve the right to assess whether corporate contributions are in companies' best interests. Daniel Stevens, a spokesman for the Campaign for Accountability, said the group is disappointed in Tuesday's decision and may file a complaint with the appeals court.SEC spokesman Kevin Callahan had no immediate comment. The regulator had argued that it had discretion, but no obligation, to begin a rulemaking proceeding.The Citizens United decision inspired a wave of new campaign spending, including from politically-focused nonprofits that need not disclose the identities of their donors.The Campaign for Accountability has estimated that the 2016 U.S. presidential campaign may cost at least $5 billion, roughly double the $2.6 billion that the nonprofit Center for Responsive Politics has estimated was spent on the 2012 campaign.The case is Silberstein v SEC, U.S. District Court, District of Columbia, No. 15-00722.       (Reporting by Jonathan Stempel in New York; Editing by Paul Simao)",2016-01-04,AET,"Mon Jan 4, 2016 | 3:28pm EST",SEC not required to make firms disclose political contributions -judge,http://www.reuters.com//article/sec-politics-idUSL1N14O1F520160104?type=companyNews
259,"   By Caroline Humer | SAN FRANCISCO  SAN FRANCISCO Aetna Inc (AET.N) Chief Executive Mark Bertolini said on Tuesday that he still expects the company's $37 billion acquisition of rival Humana Inc (HUM.N) to close this year.The deal is being reviewed by the U.S. Department of Justice, which has been seeking documents about Aetna's and Humana's business as it assesses how the deal, and a pending $47 billion combination of Anthem Inc (ANTM.N) and Cigna Corp (CI.N), could affect consumers. ""So far, we have nothing to believe it will be any slower than that, or any faster,"" Bertolini said in an interview at the JP Morgan Healthcare conference.The two proposed mergers would be an unprecedented consolidation of the U.S. health insurance industry, and critics have warned it could lead to higher prices for consumers. Insurers say the combinations will give them greater leverage to control rising healthcare costs. Aetna said it expects the regulators to wrap up their document requests in the next month, and then the company will move onto discussions with them and consider any divestitures that might be needed.Aetna and Humana sell health plans for individuals as well as Medicare Advantage plans for seniors. Humana's operations  does not overlap with Aetnas large corporate business. U.S. antitrust regulators have recently blocked large mergers in a variety of industries, raising questions among investors about whether Aetna's and Anthem's acquisitions will close. Reuters reported on Monday that about 15 state attorneys general have joined the Justice Department's probe into the insurance mergers, potentially complicating what is already expected to be a tough and lengthy review.The government's joint review of both deals has probably increased the breadth and volume of information that Aetna has supplied, Bertolini said. ""If we were to look at 2016 we have two things to do. Deliver our results, and close our deal,"" he said.  (Reporting by Caroline Humer; Editing by Michele Gershberg and Steve Orlofsky)",2016-01-12,AET,"Tue Jan 12, 2016 | 3:52pm EST",Aetna CEO sees Humana deal on track to close this year,http://www.reuters.com//article/us-humana-m-a-aetna-idUSKCN0UQ2FV20160112?type=companyNews
260,"   By Susan Kelly  The chief executive of Aetna Inc on Tuesday said the health insurer is not about to withdraw from the public health exchange market, even after losing money on the business last year.""We believe it is incredibly important, in the business we're in, that we insure all Americans,"" Chief Executive Mark Bertolini said. ""We believe we have an obligation to stick it out and work with it until we know that it won't work. And I believe it is too early to give up on this process.""Bertolini's comments contrast with a warning in November from UnitedHealth Group Inc, the largest U.S. health insurer, that it was considering exiting the exchanges in 2017 due to weak enrollment and high costs. Aetna's exchange business represents 5 percent of its total membership and 6 percent of its total operating revenue, Bertolini said in remarks at the J.P. Morgan Healthcare Conference in San Francisco. Aetna has invested more money in developing accountable care organizations than it has lost on exchange products, he said.""From a tactical standpoint, this is not breaking the bank, one way or the other,"" Bertolini said. It is important to make a retail market in healthcare work, because that is where the industry is headed, he said.Aetna's loss on its exchange business will be in the mid-single digits in 2015, and the company has priced its products to get mid-single-digit growth in 2016, Bertolini said.  The company is taking steps to improve the performance of its exchange business that include withdrawing from the Kansas market, he said. (Reporting by Susan Kelly; Editing by Leslie Adler)",2016-01-13,AET,"Tue Jan 12, 2016 | 9:27pm EST",Aetna CEO says he is not giving up on public insurance exchanges,http://www.reuters.com//article/us-usa-healthcare-aetna-idUSKCN0UR07020160113?type=companyNews
261,"   By Susan Kelly  Jan 12 The chief executive of Aetna Inc  on Tuesday said the health insurer is not about to withdraw from the public health exchange market, even after losing money on the business last year.""We believe it is incredibly important, in the business we're in, that we insure all Americans,"" Chief Executive Mark Bertolini said. ""We believe we have an obligation to stick it out and work with it until we know that it won't work. And I believe it is too early to give up on this process.""Bertolini's comments contrast with a warning in November from UnitedHealth Group Inc, the largest U.S. health insurer, that it was considering exiting the exchanges in 2017 due to weak enrollment and high costs. Aetna's exchange business represents 5 percent of its total membership and 6 percent of its total operating revenue, Bertolini said in remarks at the J.P. Morgan Healthcare Conference in San Francisco. Aetna has invested more money in developing accountable care organizations than it has lost on exchange products, he said. ""From a tactical standpoint, this is not breaking the bank, one way or the other,"" Bertolini said.It is important to make a retail market in healthcare work, because that is where the industry is headed, he said. Aetna's loss on its exchange business will be in the mid-single digits in 2015, and the company has priced its products to get mid-single-digit growth in 2016, Bertolini said.The company is taking steps to improve the performance of its exchange business that include withdrawing from the Kansas market, he said.   (Reporting by Susan Kelly; Editing by Leslie Adler)",2016-01-13,AET,"Tue Jan 12, 2016 | 9:22pm EST",Aetna CEO says he is not giving up on public insurance exchanges,http://www.reuters.com//article/usa-healthcare-aetna-idUSL2N14X03F20160113?type=companyNews
262,  Jan 12 AETNA CEO MARK BERTOLINI SAYS IT'S NOT TIME TO GIVE UP ON PUBLIC HEALTH INSURANCE EXCHANGES AETNA CEO SAYS IMPORTANT TO INSURE ALL AMERICANS AETNA CEO SAYS IT'S IMPORTANT TO MAKE RETAIL MARKET WORK IN HEALTHCARE   (Reporting by Susan Kelly in Chicago)   ,2016-01-13,AET,"Tue Jan 12, 2016 | 7:03pm EST",Aetna CEO says not time to give up on health insurance exchanges,http://www.reuters.com//article/idUSL2N14W2SG20160113?type=companyNews
263,"   By Diane Bartz  Aetna Inc's plan to buy smaller insurer Humana Inc for $31 billion will mean seniors will pay higher Medicare Advantage premiums, according to a new report by the think tank Center for American Progress (CAP).Aetna's proposed deal for Humana would combine Aetna's 7 percent of the Medicare Advantage market with Humana's 19 percent, and make it the largest provider, according to CAP, which was founded by John Podesta who worked in the White House under Presidents Bill Clinton and Barack Obama.Medicare Advantage is an insurance plan for seniors that is largely paid for by the government but administered by private insurers. The deal is one of two giant insurance mergers announced in July. The other was Anthem's $45 billion bid for Cigna Corp. Deal values were calculated based on Wednesday's closing stock prices.CAP said in one analysis it found that in counties where Aetna competed with Humana, Aetna's average annual premiums were $302 lower. Using a more conservative approach, it determined that Aetna's average annual premiums were $155 less if it competed against Humana, while Humana's premiums were $43 less if it competed against Aetna, CAP said. Aetna said that seniors who are hit with price increases with Medicare Advantage could always switch to traditional Medicare, and that two-thirds of seniors are on traditional Medicare. ""This keeps downward pressure on prices and upward pressure on quality,"" said Aetna spokeswoman Kristine Grow in an email.She also said that Aetna and Humana combined have 4.4 million Medicare Advantage enrollees, about 8 percent of the 54 million people enrolled in Medicare. ""There will continue to be significant competition in Medicare Advantage, with many health plans and other new industry entrants,"" she said in the email.Despite the predicted price increase, CAP stopped short of asking the U.S. Justice Department outright to sue to stop the proposed deal.""All of the available evidence suggests that the bar should be very high for approving these mergers and that they should be stopped absent clear and compelling evidence that they will benefit consumers,"" the think tank said in its report.   (Additional reporting by Caroline Humer)",2016-01-21,AET,"Thu Jan 21, 2016 | 12:04pm EST",Aetna's deal for Humana will push up costs for seniors - think tank,http://www.reuters.com//article/humana-aetna-cap-idUSL2N1551RQ?type=companyNews
264,"   By Diane Bartz | WASHINGTON  WASHINGTON Aetna Inc's (AET.N) plan to buy smaller insurer Humana Inc (HUM.N) for $31 billion will mean seniors will pay higher Medicare Advantage premiums, according to a new report by the think tank Center for American Progress (CAP).Aetna's proposed deal for Humana would combine Aetna's 7 percent of the Medicare Advantage market with Humana's 19 percent, and make it the largest provider, according to CAP, which was founded by John Podesta who worked in the White House under Presidents Bill Clinton and Barack Obama.Medicare Advantage is an insurance plan for seniors that is largely paid for by the government but administered by private insurers.The deal is one of two giant insurance mergers announced in July. The other was Anthem's (ANTM.N) $45 billion bid for Cigna Corp (CI.N). Deal values were calculated based on Wednesday's closing stock prices. CAP said in one analysis it found that in counties where Aetna competed with Humana, Aetna's average annual premiums were $302 lower. Using a more conservative approach, it determined that Aetna's average annual premiums were $155 less if it competed against Humana, while Humana's premiums were $43 less if it competed against Aetna, CAP said.Aetna said that seniors who are hit with price increases with Medicare Advantage could always switch to traditional Medicare, and that two-thirds of seniors are on traditional Medicare. ""This keeps downward pressure on prices and upward pressure on quality,"" said Aetna spokeswoman Kristine Grow in an email. She also said that Aetna and Humana combined have 4.4 million Medicare Advantage enrollees, about 8 percent of the 54 million people enrolled in Medicare.""There will continue to be significant competition in Medicare Advantage, with many health plans and other new industry entrants,"" she said in the email. Despite the predicted price increase, CAP stopped short of asking the U.S. Justice Department outright to sue to stop the proposed deal.""All of the available evidence suggests that the bar should be very high for approving these mergers and that they should be stopped absent clear and compelling evidence that they will benefit consumers,"" the think tank said in its report. (Additional reporting by Caroline Humer; Editing by Jeffrey Benkoe)",2016-01-21,AET,"Thu Jan 21, 2016 | 12:03pm EST",Aetna's deal for Humana will push up costs for seniors: think tank,http://www.reuters.com//article/us-humana-aetna-cap-idUSKCN0UZ2CV?type=companyNews
265,"   By Diane Bartz | WASHINGTON  WASHINGTON Aetna Inc's (AET.N) plan to buy smaller insurer Humana Inc (HUM.N) for $31 billion will mean seniors will pay higher Medicare Advantage premiums, according to a new report by the think tank Center for American Progress (CAP).Aetna's proposed deal for Humana would combine Aetna's 7 percent of the Medicare Advantage market with Humana's 19 percent, and make it the largest provider, according to CAP, which was founded by John Podesta who worked in the White House under Presidents Bill Clinton and Barack Obama.Medicare Advantage is an insurance plan for seniors that is largely paid for by the government but administered by private insurers.The deal is one of two giant insurance mergers announced in July. The other was Anthem's (ANTM.N) $45 billion bid for Cigna Corp (CI.N). Deal values were calculated based on Wednesday's closing stock prices. CAP said in one analysis it found that in counties where Aetna competed with Humana, Aetna's average annual premiums were $302 lower. Using a more conservative approach, it determined that Aetna's average annual premiums were $155 less if it competed against Humana, while Humana's premiums were $43 less if it competed against Aetna, CAP said.Aetna said that seniors who are hit with price increases with Medicare Advantage could always switch to traditional Medicare, and that two-thirds of seniors are on traditional Medicare. ""This keeps downward pressure on prices and upward pressure on quality,"" said Aetna spokeswoman Kristine Grow in an email. She also said that Aetna and Humana combined have 4.4 million Medicare Advantage enrollees, about 8 percent of the 54 million people enrolled in Medicare.""There will continue to be significant competition in Medicare Advantage, with many health plans and other new industry entrants,"" she said in the email. Despite the predicted price increase, CAP stopped short of asking the U.S. Justice Department outright to sue to stop the proposed deal.""All of the available evidence suggests that the bar should be very high for approving these mergers and that they should be stopped absent clear and compelling evidence that they will benefit consumers,"" the think tank said in its report. (Additional reporting by Caroline Humer; Editing by Jeffrey Benkoe)",2016-01-21,AET,"Thu Jan 21, 2016 | 12:03pm EST",Aetna's deal for Humana will push up costs for seniors - think tank,http://www.reuters.com//article/humana-aetna-cap-idUSL2N1542CY?type=companyNews
266,"   By Caroline Humer  Aetna Inc Chief Executive Officer Mark Bertolini said on Monday that he is concerned that the individual healthcare exchanges created under the Affordable Care Act are not sustainable and that recent government proposals for changes are not enough.The U.S. Department of Health and Human Services recently proposed restricting the special enrollment period that insurers say has been abused by customers who are taking on insurance only when they know about upcoming medical bills. The government ""has made some recent changes but more needs to be done,"" Bertolini said during a conference call with investors. Chief Financial Officer Shawn Guertin said that Aetna's individual commercial business - which includes plans sold on the exchange and directly by Aetna - had an operating loss of 3 percent to 4 percent in 2015. ",2016-02-01,AET,"Mon Feb 1, 2016 | 12:13pm EST",Aetna CEO says Obamacare exchanges need change to be sustainable,http://www.reuters.com//article/aetna-results-ceo-idUSL2N15G1FC?type=companyNews
267,"   By Caroline Humer  Health insurer Aetna Inc, which is in the process of buying smaller rival Humana Inc, said on Monday its Obamacare insurance business improved at the end of last year, providing a stronger starting point for 2016.Aetna said its individual insurance sold on the exchanges created by the Affordable Care Act, also called Obamacare, had  operating losses of about 3 to 4 percent in 2015 as fourth-quarter operations improved from mid-single digit losses earlier in the year.The late-year improvements in that segment for Aetna contrasted with recent reports from UnitedHealth Group Inc and Anthem Inc, whose profits missed expectations because of fourth-quarter losses in the individual business.""We are positioning that to try to get back to breakeven,"" Chief Financial Officer Shawn Guertin said during a call with analysts.That difference helped shares, said Vishnu Lekraj, an analyst at Morningstar Research. ""A lot of their peers have reported some issues as far as the exchanges go,"" he said.  Aetna shares surged about 1.7 percent to $103.50 in late morning trading, while Anthem and UnitedHealth both dipped slightly.Aetna reported a better-than-expected profit in the quarter ended Dec. 31, amid a robust performance by Aetna's Medicare business for the elderly and disabled.NEW RULES   Chief Executive Mark Bertolini said that new government rules were needed to stabilize the pool of customers enrolled in these subsidized insurance plans, an issue that has pushed up insurer costs. Recent changes proposed by the U.S. government do not go far enough, he said.""We continue to have serious concerns about the sustainability of the public exchanges,"" Bertolini said.Bertolini said he still expects to close the company's $31 billion acquisition of Humana in the second half of 2016, based on Monday's share price.  The Aetna-Humana deal and Anthem Inc's proposed acquisition of Cigna Corp are under intense regulatory and political scrutiny.The company's medical benefit ratio, which compares the amount spent on medical claims with income from premiums, improved to 81.9 percent from 83 percent a year ago. Aetna said it expects full-year operating earnings of at least $7.75 a share, compared with $7.71 in 2015. Net income rose to $320.8 million, or 91 cents per share, in the quarter, from $232 million, or 65 cents per share, a year earlier. Aetna's operating earnings of $1.37 per share also beat the average analyst estimate of $1.21 per share. (Reporting by Caroline Humer in New York and Amrutha Penumudi in Bengaluru; Editing by Anil D'Silva and Bernadette Baum)",2016-02-01,AET,"Mon Feb 1, 2016 | 11:43am EST",Aetna says individual exchange business improved; shares gain,http://www.reuters.com//article/us-aetna-results-idUSKCN0VA283?type=companyNews
268,"   By Caroline Humer  Health insurer Aetna Inc, which is in the process of buying smaller rival Humana Inc, said on Monday its Obamacare insurance business improved at the end of last year, providing a stronger starting point for 2016.Aetna said its individual insurance sold on the exchanges created by the Affordable Care Act, also called Obamacare, had  operating losses of about 3 to 4 percent in 2015 as fourth-quarter operations improved from mid-single digit losses earlier in the year.The late-year improvements in that segment for Aetna contrasted with recent reports from UnitedHealth Group Inc and Anthem Inc, whose profits missed expectations because of fourth-quarter losses in the individual business.""We are positioning that to try to get back to breakeven,"" Chief Financial Officer Shawn Guertin said during a call with analysts.That difference helped shares, said Vishnu Lekraj, an analyst at Morningstar Research. ""A lot of their peers have reported some issues as far as the exchanges go,"" he said.  Aetna shares surged about 1.7 percent to $103.50 in late morning trading, while Anthem and UnitedHealth both dipped slightly.Aetna reported a better-than-expected profit in the quarter ended Dec. 31, amid a robust performance by Aetna's Medicare business for the elderly and disabled.NEW RULES   Chief Executive Mark Bertolini said that new government rules were needed to stabilize the pool of customers enrolled in these subsidized insurance plans, an issue that has pushed up insurer costs. Recent changes proposed by the U.S. government do not go far enough, he said.""We continue to have serious concerns about the sustainability of the public exchanges,"" Bertolini said.Bertolini said he still expects to close the company's $31 billion acquisition of Humana in the second half of 2016, based on Monday's share price.  The Aetna-Humana deal and Anthem Inc's proposed acquisition of Cigna Corp are under intense regulatory and political scrutiny.The company's medical benefit ratio, which compares the amount spent on medical claims with income from premiums, improved to 81.9 percent from 83 percent a year ago. Aetna said it expects full-year operating earnings of at least $7.75 a share, compared with $7.71 in 2015. Net income rose to $320.8 million, or 91 cents per share, in the quarter, from $232 million, or 65 cents per share, a year earlier. Aetna's operating earnings of $1.37 per share also beat the average analyst estimate of $1.21 per share. (Reporting by Caroline Humer in New York and Amrutha Penumudi in Bengaluru; Editing by Anil D'Silva and Bernadette Baum)",2016-02-01,AET,"Mon Feb 1, 2016 | 11:43am EST",UPDATE 4-Aetna says individual exchange business improved; shares gain,http://www.reuters.com//article/aetna-results-idUSL3N15G3RO?type=companyNews
269,"  NEW YORK Aetna Inc Chief Executive Officer Mark Bertolini said on Monday that he is concerned that the individual healthcare exchanges created under the Affordable Care Act are not sustainable and that recent government proposals for changes are not enough.The U.S. Department of Health and Human Services recently proposed restricting the special enrollment period that insurers say has been abused by customers who are taking on insurance only when they know about upcoming medical bills.The government ""has made some recent changes but more needs to be done,"" Bertolini said during a conference call with investors. Chief Financial Officer Shawn Guertin said that Aetna's individual commercial business - which includes plans sold on the exchange and directly by Aetna - had an operating loss of 3 percent to 4 percent in 2015.   (Reporting by Caroline Humer)",2016-02-01,AET,"Mon Feb 1, 2016 | 8:59am EST",Aetna CEO says Obamacare exchanges need change to be sustainable,http://www.reuters.com//article/us-aetna-results-ceo-idUSKCN0VA2M8?type=companyNews
270,"  NEW YORK Aetna Inc Chief Executive Officer Mark Bertolini said on Monday that he is concerned that the individual healthcare exchanges created under the Affordable Care Act are not sustainable and that recent government proposals for changes are not enough.The U.S. Department of Health and Human Services recently proposed restricting the special enrollment period that insurers say has been abused by customers who are taking on insurance only when they know about upcoming medical bills.The government ""has made some recent changes but more needs to be done,"" Bertolini said during a conference call with investors. Chief Financial Officer Shawn Guertin said that Aetna's individual commercial business - which includes plans sold on the exchange and directly by Aetna - had an operating loss of 3 percent to 4 percent in 2015.   (Reporting by Caroline Humer)",2016-02-01,AET,"Mon Feb 1, 2016 | 8:59am EST",Aetna CEO says Obamacare exchanges need change to be sustainable,http://www.reuters.com//article/aetna-results-ceo-idUSL2N15G0QM?type=companyNews
271,"  Feb 1 Health insurer Aetna reported a 38 percent rise in quarterly profit, helped by strong performance in its government business that sells Medicare and Medicaid plans.Net income attributable to Aetna rose to $320.8 million, or 91 cents per share, for the fourth quarter ended Dec. 31, from $232 million, or 65 cents per share, a year earlier. Total revenue rose to $15.05 billion from $14.77 billion.  (Reporting by Amrutha Penumudi in Bengaluru; Editing by Anil D'Silva)",2016-02-01,AET,"Mon Feb 1, 2016 | 6:09am EST",Health insurer Aetna profit rises,http://www.reuters.com//article/aetna-results-idUSL3N15G3NB?type=companyNews
272,"   By Caroline Humer | NEW YORK  NEW YORK U.S.-based health insurers Cigna Corp and Aetna Inc have struck deals with Novartis AG for a performance-based price for the Swiss drugmaker's new heart drug, Entresto, the companies said on Monday.The agreements are among the few performance-based deals that have been made public by drugmakers and U.S. managed-care companies, which say they have been having more discussions about linking price to health outcomes in order to cut unneeded drug spending.Drug prices jumped about 13 percent in the United States last year, spurring a public outcry and moving the issue onto the campaign platform of Hillary Clinton and other U.S. presidential candidates for the November 2016 election.  Under the agreement, Cigna said its payments to Novartis will be linked to how well the drug improves the relative health of Cigna customers. Entresto is approved for the treatment of chronic heart failure.Specifically, Cigna said payments will be based on a reduction in the proportion of customers who are admitted to hospital for heart failure. The agreement applies to Cigna's commercial business and does not apply to its Medicaid or Medicare plans.Entresto, which costs about $12.50 a day, or $4,560 per year, was approved by the U.S. Food and Drug Administration in July. It is cheaper than some other new drugs, but costs more than analysts expected. The Boston-based Institute for Clinical and Economic Review, an independent group that analyzes drug prices, has said the price should be 9 percent lower. Aetna, in an emailed statement, said it signed a value-based agreement with Novartis that is based on the drug replicating results that it achieved during clinical trials. In trials, Entresto cut hospitalizations and the rate of cardiovascular death related to heart failure.Aetna did not provide further information about the terms of the agreement.Novartis Chief Executive Joe Jimenez has publicly discussed  signing more outcome-based pricing deals. A Novartis spokesman on Monday confirmed that the company's head of pharmaceuticals, David Epstein, was referring to Cigna and Aetna when he said during an investor conference call late last month that Novartis had signed deals with two health insurers.Epstein, on the Jan. 27 call, said that under the deals, Novartis had agreed to a base price and a modest rebate, which would fluctuate based on hospitalizations and savings to the plan. (Corrects discount Institute for Clinical and Economic Review recommended to 9 percent from 17 percent in paragraph 9) (Reporting by Caroline Humer; Additional reporting by John Miller in Zurich; Editing by Bernadette Baum and Leslie Adler)",2016-02-09,AET,"Tue Feb 9, 2016 | 2:08pm EST",Novartis sets heart-drug price with two insurers based on health outcome,http://www.reuters.com//article/us-cigna-novartis-drugpricing-idUSKCN0VH25K?type=companyNews
273,"   By Caroline Humer | NEW YORK  NEW YORK U.S.-based health insurers Cigna Corp and Aetna Inc have struck deals with Novartis AG for a performance-based price for the Swiss drugmaker's new heart drug, Entresto, the companies said on Monday.The agreements are among the few performance-based deals that have been made public by drugmakers and U.S. managed-care companies, which say they have been having more discussions about linking price to health outcomes in order to cut unneeded drug spending.Drug prices jumped about 13 percent in the United States last year, spurring a public outcry and moving the issue onto the campaign platform of Hillary Clinton and other U.S. presidential candidates for the November 2016 election.  Under the agreement, Cigna said its payments to Novartis will be linked to how well the drug improves the relative health of Cigna customers. Entresto is approved for the treatment of chronic heart failure.Specifically, Cigna said payments will be based on a reduction in the proportion of customers who are admitted to hospital for heart failure. The agreement applies to Cigna's commercial business and does not apply to its Medicaid or Medicare plans.Entresto, which costs about $12.50 a day, or $4,560 per year, was approved by the U.S. Food and Drug Administration in July. It is cheaper than some other new drugs, but costs more than analysts expected. The Boston-based Institute for Clinical and Economic Review, an independent group that analyzes drug prices, has said the price should be 9 percent lower. Aetna, in an emailed statement, said it signed a value-based agreement with Novartis that is based on the drug replicating results that it achieved during clinical trials. In trials, Entresto cut hospitalizations and the rate of cardiovascular death related to heart failure.Aetna did not provide further information about the terms of the agreement.Novartis Chief Executive Joe Jimenez has publicly discussed  signing more outcome-based pricing deals. A Novartis spokesman on Monday confirmed that the company's head of pharmaceuticals, David Epstein, was referring to Cigna and Aetna when he said during an investor conference call late last month that Novartis had signed deals with two health insurers.Epstein, on the Jan. 27 call, said that under the deals, Novartis had agreed to a base price and a modest rebate, which would fluctuate based on hospitalizations and savings to the plan. (Corrects discount Institute for Clinical and Economic Review recommended to 9 percent from 17 percent in paragraph 9) (Reporting by Caroline Humer; Additional reporting by John Miller in Zurich; Editing by Bernadette Baum and Leslie Adler)",2016-02-09,AET,"Tue Feb 9, 2016 | 2:08pm EST",CORRECTED-UPDATE 1-Novartis sets heart-drug price with two insurers based on health outcome,http://www.reuters.com//article/cigna-novartis-drugpricing-idUSL2N15O1VK?type=companyNews
274,"  (Corrects discount Institute for Clinical and Economic Review recommended to 9 percent from 17 percent in paragraph 9)By Caroline HumerNEW YORK Feb 8 U.S.-based health insurers Cigna Corp and Aetna Inc have struck deals with Novartis AG for a performance-based price for the Swiss drugmaker's new heart drug, Entresto, the companies said on Monday.The agreements are among the few performance-based deals that have been made public by drugmakers and U.S. managed-care companies, which say they have been having more discussions about linking price to health outcomes in order to cut unneeded drug spending.Drug prices jumped about 13 percent in the United States last year, spurring a public outcry and moving the issue onto the campaign platform of Hillary Clinton and other U.S. presidential candidates for the November 2016 election.Under the agreement, Cigna said its payments to Novartis will be linked to how well the drug improves the relative health of Cigna customers. Entresto is approved for the treatment of chronic heart failure.Specifically, Cigna said payments will be based on a reduction in the proportion of customers who are admitted to hospital for heart failure.The agreement applies to Cigna's commercial business and does not apply to its Medicaid or Medicare plans. Entresto, which costs about $12.50 a day, or $4,560 per year, was approved by the U.S. Food and Drug Administration in July. It is cheaper than some other new drugs, but costs more than analysts expected.The Boston-based Institute for Clinical and Economic Review, an independent group that analyzes drug prices, has said the price should be 9 percent lower. Aetna, in an emailed statement, said it signed a value-based agreement with Novartis that is based on the drug replicating results that it achieved during clinical trials. In trials, Entresto cut hospitalizations and the rate of cardiovascular death related to heart failure.Aetna did not provide further information about the terms of the agreement.Novartis Chief Executive Joe Jimenez has publicly discussed  signing more outcome-based pricing deals.A Novartis spokesman on Monday confirmed that the company's head of pharmaceuticals, David Epstein, was referring to Cigna and Aetna when he said during an investor conference call late last month that Novartis had signed deals with two health insurers.Epstein, on the Jan. 27 call, said that under the deals, Novartis had agreed to a base price and a modest rebate, which would fluctuate based on hospitalizations and savings to the plan.    (Reporting by Caroline Humer; Additional reporting by John Miller in Zurich; Editing by Bernadette Baum and Leslie Adler)",2016-02-09,AET,"Tue Feb 9, 2016 | 1:58pm EST",CORRECTED-UPDATE 1-Novartis sets heart-drug price with two insurers based on health outcome,http://www.reuters.com//article/cigna-novartis-drugpricing-idUSL2N15N1ZB?type=companyNews
275,"  Health insurer Humana Inc (HUM.N), which is being bought by rival Aetna Inc (AET.N), on Wednesday said that it had set aside 74 cents per share in the fourth quarter to cover anticipated shortfalls in its 2016 individual health plan business. Humana had said last month that it would book anticipated losses on the money-losing business but had not given details on the amount. Wall Street analysts had estimated last month that the set aside would be about 70 cents per share.It made the disclosure as part of its quarterly earnings report.Humana also said that it continues to evaluate its participation in the individual commercial business for 2017.Other insurers including UnitedHealth Group (UNH.N) are considering the extent of their individual business in 2017 and have also taken losses, saying that some members are costing more than they expected.Humana said that many of its high cost members from 2015 had renewed their 2016 plans through Obamacare, a new type of individual insurance created under President Barack Obama's national healthcare reform law. The company said it had 899,100 individual customers at the end of 2015 and expects that number to decline 200,000 to 300,000 people in 2016.In addition to Obamacare plans, Humana also has individual customers in plans that do not comply with the Affordable Care Act but that were grandfathered through this year.Humana said that it had set aside a total reserve of $176 million in the fourth quarter, saying it set premium prices too low for the medical services use. Humana, whose business is primarily managing Medicare Advantage health plans for the elderly and disabled and also runs individual plans under Obamacare, said it expects growth in both earnings per share and revenue in 2017.Humana said it continues to expect its deal to be bought by Aetna to close by the end of the year.The company said it expects adjusted earnings of at least $8.85 in 2016, well above the average analysts' estimate of $8.73 per share, according to Thomson Reuters I/B/E/S. The company's net income fell to $101 million, or 67 cents per share, for the fourth quarter ended Dec. 31, from $145 million, or 94 cents per share, a year earlier. On an adjusted basis, Humana earned $1.45 per share, beating the average analysts' estimate of $1.44 per share.Total revenue rose 8.4 percent to $13.36 billion, missing average analysts' estimate of $13.51 billion. (Reporting by Amrutha Penumudi in Bengaluru and Caroline Humer in New York; Editing by Shounak Dasgupta)",2016-02-10,AET,"Wed Feb 10, 2016 | 9:05am EST",Health insurer Humana takes fourth-quarter charge for 2016 individual losses,http://www.reuters.com//article/us-humana-results-idUSKCN0VJ1BM?type=companyNews
276,"  Health insurer Humana Inc (HUM.N), which is being bought by rival Aetna Inc (AET.N), on Wednesday said that it had set aside 74 cents per share in the fourth quarter to cover anticipated shortfalls in its 2016 individual health plan business. Humana had said last month that it would book anticipated losses on the money-losing business but had not given details on the amount. Wall Street analysts had estimated last month that the set aside would be about 70 cents per share.It made the disclosure as part of its quarterly earnings report.Humana also said that it continues to evaluate its participation in the individual commercial business for 2017.Other insurers including UnitedHealth Group (UNH.N) are considering the extent of their individual business in 2017 and have also taken losses, saying that some members are costing more than they expected.Humana said that many of its high cost members from 2015 had renewed their 2016 plans through Obamacare, a new type of individual insurance created under President Barack Obama's national healthcare reform law. The company said it had 899,100 individual customers at the end of 2015 and expects that number to decline 200,000 to 300,000 people in 2016.In addition to Obamacare plans, Humana also has individual customers in plans that do not comply with the Affordable Care Act but that were grandfathered through this year.Humana said that it had set aside a total reserve of $176 million in the fourth quarter, saying it set premium prices too low for the medical services use. Humana, whose business is primarily managing Medicare Advantage health plans for the elderly and disabled and also runs individual plans under Obamacare, said it expects growth in both earnings per share and revenue in 2017.Humana said it continues to expect its deal to be bought by Aetna to close by the end of the year.The company said it expects adjusted earnings of at least $8.85 in 2016, well above the average analysts' estimate of $8.73 per share, according to Thomson Reuters I/B/E/S. The company's net income fell to $101 million, or 67 cents per share, for the fourth quarter ended Dec. 31, from $145 million, or 94 cents per share, a year earlier. On an adjusted basis, Humana earned $1.45 per share, beating the average analysts' estimate of $1.44 per share.Total revenue rose 8.4 percent to $13.36 billion, missing average analysts' estimate of $13.51 billion. (Reporting by Amrutha Penumudi in Bengaluru and Caroline Humer in New York; Editing by Shounak Dasgupta)",2016-02-10,AET,"Wed Feb 10, 2016 | 9:05am EST",UPDATE 2-Health insurer Humana takes 4Q charge for 2016 individual losses,http://www.reuters.com//article/humana-results-idUSL3N15P269?type=companyNews
277,"  Feb 10 Health insurer Humana Inc, which is being bought by rival Aetna Inc, reported an 8.4 percent rise in quarterly total revenue, helped by strength in its Medicare Advantage business.The company's net income fell to $101 million, or 67 cents per share, for the fourth quarter ended Dec. 31, from $145 million, or 94 cents per share, a year earlier. (bit.ly/1T70NLr)  Humana, which manages large Medicare Advantage health plans for the elderly and disabled and also runs individual plans under Obamacare, said total revenue rose to $13.36 billion from $12.33 billion a year ago.   (Reporting by Amrutha Penumudi in Bengaluru; Editing by Shounak Dasgupta) ",2016-02-10,AET,"Wed Feb 10, 2016 | 7:42am EST",Health insurer Humana's quarterly revenue rises,http://www.reuters.com//article/humana-results-idUSL3N15P263?type=companyNews
278,"  Health insurer Aetna Inc (AET.N) said on Monday Florida's insurance regulator approved its acquisition of Humana Inc (HUM.N). The company said that with the approval from Florida's Office of Insurance Regulation, it has secured 10 of the 20 state approvals required.Aetna said in July it would buy smaller rival Humana for about $37 billion in cash and stock, the largest deal ever in the insurance industry. The announced mergers of Aetna and Humana, as well as Anthem Inc's (ANTM.N) bid for Cigna Corp (CI.N), have come under increased scrutiny as the deals would reduce the number of nationwide health insurers to three from five.About 15 state attorneys general have joined the U.S. Justice Department's probe of the two mergers, Reuters reported last month, citing people familiar with the matter.  Aetna said it continued to cooperate with the Department of Justice in its probe and said it was possible DoJ would require divestitures in some regions.      (Reporting by Kshitiz Goliya in Bengaluru; Editing by Dan Grebler)",2016-02-16,AET,"Mon Feb 15, 2016 | 10:38pm EST",Aetna gets Florida insurance regulator's approval for Humana deal,http://www.reuters.com//article/us-humana-m-a-aetna-idUSKCN0VP09X?type=companyNews
279,"  Health insurer Aetna Inc (AET.N) said on Monday Florida's insurance regulator approved its acquisition of Humana Inc (HUM.N). The company said that with the approval from Florida's Office of Insurance Regulation, it has secured 10 of the 20 state approvals required.Aetna said in July it would buy smaller rival Humana for about $37 billion in cash and stock, the largest deal ever in the insurance industry. The announced mergers of Aetna and Humana, as well as Anthem Inc's (ANTM.N) bid for Cigna Corp (CI.N), have come under increased scrutiny as the deals would reduce the number of nationwide health insurers to three from five.About 15 state attorneys general have joined the U.S. Justice Department's probe of the two mergers, Reuters reported last month, citing people familiar with the matter.  Aetna said it continued to cooperate with the Department of Justice in its probe and said it was possible DoJ would require divestitures in some regions.      (Reporting by Kshitiz Goliya in Bengaluru; Editing by Dan Grebler)",2016-02-16,AET,"Mon Feb 15, 2016 | 10:38pm EST",Aetna gets Florida insurance regulator's approval for Humana deal,http://www.reuters.com//article/humana-ma-aetna-idUSL3N15V05D?type=companyNews
280,"  WASHINGTON U.S. Republican presidential front-runner candidate Donald Trump on Wednesday unveiled proposals for reforming U.S. healthcare that included repealing Obamacare, allowing prescription drugs to be imported, and turning the Medicaid program for the poor into block grants to states.The plan also calls for the sale of health insurance plans across state lines, full deduction of health insurance premiums from income tax and adds: ""We must also make sure that no one slips through the cracks simply because they cannot afford insurance.""  (here)Trump, who is the front-runner in the race to become the Republican nominee in November's presidential election, is also proposing allowing individuals to use Health Savings Accounts (HAS) to pay for out-of-pocket expenses. Contributions to HSAs would be tax-free and could be passed on to heirs without any tax penalty.The proposals include requiring ""...price transparency from all healthcare providers, especially doctors and healthcare organizations like clinics and hospitals. Individuals should be able to shop to find the best prices for procedures, exams or any other medical-related procedure.""         On drug prices, Trump departs from standard Republican policy by calling for lowering barriers to cheaper imported pharmaceuticals.""Allowing consumers access to imported, safe and dependable drugs from overseas will bring more options to consumers,"" the statement says, adding that ""Congress will need the courage to step away from the special interests and do what is right for America.""The proposals also call for reforming mental health programs and institutions, but provides few details about how to do this. Trump also called for tighter enforcement of immigration laws, a key plank in his campaign platform, as a way to bring down healthcare costs.""Providing healthcare to illegal immigrants costs us some $11 billion annually. If we were to simply enforce the current immigration laws and restrict the unbridled granting of visas to this country, we could relieve healthcare cost pressures on state and local governments,"" the proposal statement says.    Democrats were quick to criticize the plan. ""As Democrats have said all along, Donald Trump is not an outsider engaging in a hostile takeover of the GOP  in fact, he embodies the Republican Party.""The fact that his healthcare 'plan' is clearly cribbed from worn-out and false GOP talking points proves that Trump is just another Republican politician who wants to take healthcare away from millions of Americans without offering any substantive alternative,"" Democratic National Committee Communications Director Luis Miranda said in a statement. (Reporting by Eric Walsh; Editing by Sandra Maler)",2016-03-03,AET,"Thu Mar 3, 2016 | 2:47am EST",Republican Trump releases healthcare proposals,http://www.reuters.com//article/us-usa-election-trump-healthcare-idUSKCN0W5066?type=companyNews
281,"  WASHINGTON U.S. Republican presidential front-runner candidate Donald Trump on Wednesday unveiled proposals for reforming U.S. healthcare that included repealing Obamacare, allowing prescription drugs to be imported, and turning the Medicaid program for the poor into block grants to states.The plan also calls for the sale of health insurance plans across state lines, full deduction of health insurance premiums from income tax and adds: ""We must also make sure that no one slips through the cracks simply because they cannot afford insurance.""  (here)Trump, who is the front-runner in the race to become the Republican nominee in November's presidential election, is also proposing allowing individuals to use Health Savings Accounts (HAS) to pay for out-of-pocket expenses. Contributions to HSAs would be tax-free and could be passed on to heirs without any tax penalty.The proposals include requiring ""...price transparency from all healthcare providers, especially doctors and healthcare organizations like clinics and hospitals. Individuals should be able to shop to find the best prices for procedures, exams or any other medical-related procedure.""         On drug prices, Trump departs from standard Republican policy by calling for lowering barriers to cheaper imported pharmaceuticals.""Allowing consumers access to imported, safe and dependable drugs from overseas will bring more options to consumers,"" the statement says, adding that ""Congress will need the courage to step away from the special interests and do what is right for America.""The proposals also call for reforming mental health programs and institutions, but provides few details about how to do this. Trump also called for tighter enforcement of immigration laws, a key plank in his campaign platform, as a way to bring down healthcare costs.""Providing healthcare to illegal immigrants costs us some $11 billion annually. If we were to simply enforce the current immigration laws and restrict the unbridled granting of visas to this country, we could relieve healthcare cost pressures on state and local governments,"" the proposal statement says.    Democrats were quick to criticize the plan. ""As Democrats have said all along, Donald Trump is not an outsider engaging in a hostile takeover of the GOP  in fact, he embodies the Republican Party.""The fact that his healthcare 'plan' is clearly cribbed from worn-out and false GOP talking points proves that Trump is just another Republican politician who wants to take healthcare away from millions of Americans without offering any substantive alternative,"" Democratic National Committee Communications Director Luis Miranda said in a statement. (Reporting by Eric Walsh; Editing by Sandra Maler)",2016-03-03,AET,"Thu Mar 3, 2016 | 2:47am EST",Republican Trump releases healthcare proposals,http://www.reuters.com//article/us-usa-election-trump-healthcare-idUSMTZSAPEC33FXA283?type=companyNews
282,"  WASHINGTON U.S. Republican presidential front-runner candidate Donald Trump on Wednesday unveiled proposals for reforming U.S. healthcare that included repealing Obamacare, allowing prescription drugs to be imported, and turning the Medicaid program for the poor into block grants to states.The plan also calls for the sale of health insurance plans across state lines, full deduction of health insurance premiums from income tax and adds: ""We must also make sure that no one slips through the cracks simply because they cannot afford insurance.""  (here)Trump, who is the front-runner in the race to become the Republican nominee in November's presidential election, is also proposing allowing individuals to use Health Savings Accounts (HAS) to pay for out-of-pocket expenses. Contributions to HSAs would be tax-free and could be passed on to heirs without any tax penalty.The proposals include requiring ""...price transparency from all healthcare providers, especially doctors and healthcare organizations like clinics and hospitals. Individuals should be able to shop to find the best prices for procedures, exams or any other medical-related procedure.""         On drug prices, Trump departs from standard Republican policy by calling for lowering barriers to cheaper imported pharmaceuticals.""Allowing consumers access to imported, safe and dependable drugs from overseas will bring more options to consumers,"" the statement says, adding that ""Congress will need the courage to step away from the special interests and do what is right for America.""The proposals also call for reforming mental health programs and institutions, but provides few details about how to do this. Trump also called for tighter enforcement of immigration laws, a key plank in his campaign platform, as a way to bring down healthcare costs.""Providing healthcare to illegal immigrants costs us some $11 billion annually. If we were to simply enforce the current immigration laws and restrict the unbridled granting of visas to this country, we could relieve healthcare cost pressures on state and local governments,"" the proposal statement says.    Democrats were quick to criticize the plan. ""As Democrats have said all along, Donald Trump is not an outsider engaging in a hostile takeover of the GOP  in fact, he embodies the Republican Party.""The fact that his healthcare 'plan' is clearly cribbed from worn-out and false GOP talking points proves that Trump is just another Republican politician who wants to take healthcare away from millions of Americans without offering any substantive alternative,"" Democratic National Committee Communications Director Luis Miranda said in a statement. (Reporting by Eric Walsh; Editing by Sandra Maler)",2016-03-03,AET,"Thu Mar 3, 2016 | 2:47am EST",UPDATE 2-U.S. Republican Trump releases healthcare proposals,http://www.reuters.com//article/usa-election-trump-healthcare-idUSL2N16B03D?type=companyNews
283,"  WASHINGTON, March 2 U.S. Republican presidential front-runner candidate Donald Trump on Wednesday unveiled proposals for reforming U.S. healthcare that included repealing Obamacare, allowing prescription drugs to be imported, and turning the Medicaid program for the poor into block grants to states. The plan also calls for the sale of health insurance plans across state lines, full deduction of health insurance premiums from income tax and adds: ""We must also make sure that no one slips through the cracks simply because they cannot afford insurance.""  here   (Reporting by Eric Walsh; Editing by Sandra Maler)  ",2016-03-03,AET,"Wed Mar 2, 2016 | 8:47pm EST",U.S. Republican Trump releases healthcare proposals,http://www.reuters.com//article/usa-election-trump-healthcare-idUSL2N16B02E?type=companyNews
284,"   By Brendan Pierson  A federal judge has dismissed a proposed class action accusing Aetna Inc of violating a New Jersey regulation by trying to recoup money from its insureds' personal injury recoveries as preempted by the federal law, but suggested a way the litigation could move forward. The lawsuit, filed in 2013 by two individuals insured by Aetna, alleged that Aetna violated Section 42.10 of the New Jersey Administrative Code by claiming liens on the plaintiffs' personal injury recoveries.  To read the full story on WestlawNext Practitioner Insights, click here: bit.ly/1LCTt9v",2016-03-04,AET,"Thu Mar 3, 2016 | 8:04pm EST",New Jersey anti-subrogation rule may allow relief under ERISA - judge,http://www.reuters.com//article/health-liens-idUSL2N16C028?type=companyNews
285,  March 10 Linde* Manager Bruch says sees possibility of new projects in Iran in 2016 * Manager Blades says U.S. state reimbursements for healthcare services to drop about 40 percent by year-end  * CEO says sees no need to negotiate about any job cuts in plant engineering at the moment  Further company coverage:    (Reporting By Georgina Prodhan),2016-03-10,AET,"Thu Mar 10, 2016 | 6:28am EST",BRIEF-Linde sees U.S. healthcare reimbursements dropping 40 pct,http://www.reuters.com//article/idUSF9N16400W?type=companyNews
286,  March 15 Aetna Inc :* Rreaffirm full-year 2016 operating earnings per share projection of at least $7.75  * Continue to expect to complete proposed acquisition of Humana Inc. in second half of 2016.  Source text: 1.usa.gov/1VagFOA Further company coverage: ,2016-03-15,AET,"Tue Mar 15, 2016 | 4:48pm EDT",BRIEF-Aetna reaffirm 2016 oper earnings outlook of at least $7.75/share,http://www.reuters.com//article/idUSFWN16N0EE?type=companyNews
287,  April 8 Aetna Inc* CEO Mark T. Bertolini 2015 total compensation of $17.3 million versus $15.1 million in 2014 - SEC FILING * President Karen S. Lynch 's 2015 total compensation was $7.8 million versus $4.2 million in 2014 - SEC FILING  * CFO Shawn M. Guertin 2015 total compensation of $6.4 million versus $4.5 million in 2014  Source text - 1.usa.gov/1XlJSoK Further company coverage:    (Bengaluru Newsroom: +1 646 223 8780),2016-04-08,AET,"Fri Apr 8, 2016 | 3:25pm EDT",BRIEF-Aetna CEO Mark Bertolini's  2015 total compensation of $17.3 mln vs. $15.1 mln in 2014 - SEC Filing,http://www.reuters.com//article/idUSFWN17B0O3?type=companyNews
288,"  Augmedix Inc, a startup that uses Alphabet Inc's Google Glass to provide documentation services to doctors and other healthcare workers, said on Monday it had closed a $17 million funding round led by investment firm Redmile Group.Augmedix's employees transcribe doctors' notes and update patients' electronic medical record through Google Glass.The San Francisco company, which has raised $40 million so far, also said it had received investments from five U.S. healthcare networks, including Sutter Health and Dignity Health, which together have more than 100,000 healthcare workers. Augmedix, with 400 employees, said it serves doctors in nearly all 50 U.S. states.Funds raised will be used to build up the service to serve more health systems and private clinics, the company said. Augmedix is one of 10 partners authorized by Alphabet to deliver enterprise services through Google Glass.  (Reporting by Kshitiz Goliya in Bengaluru; Editing by Ted Kerr)",2016-04-25,AET,"Mon Apr 25, 2016 | 1:33pm EDT",Google Glass-based startup raises $17 mln in funding,http://www.reuters.com//article/augmedix-funding-idUSL3N17S41S?type=companyNews
289,"   By Amrutha Penumudi  Aetna Inc (AET.N) said more customers opted for its Obamacare plans in the first quarter than it had expected, but added that the program needed to be more flexible to become sustainable.The health insurer hopes that the next government would allow companies to tailor Obamacare individual plans every year, just like it does with Medicare and Medicaid, Chief Executive Mark Bertolini said.Many insurers have lost money on the healthcare exchanges, which were set up under the Affordable Care Act, because total enrollment has fallen sharply, while some patient costs have been higher than expected.""We have not been able to touch this product because of the politics, but if we can get to that point, we believe, we are in a very good place to make this a sustainable program,"" he said on a call with analysts. Aetna said it had ended the quarter with 1.2 million individual members, which exceeded their previous membership estimates. Anthem Inc (ANTM.N), another big player in the industry, said on Wednesday it planned to stick to the business and was planning to grow in that market.However, UnitedHealth Group Inc (UNH.N), the biggest U.S. health insurer, confirmed last week that it was exiting the business in 2017.Aetna, which is in the process of buying smaller rival Humana Inc (HUM.N), reported first-quarter operating earnings that topped analysts' estimates.  The company said it was on track to close the Humana acquisition by the second half of the year and that it had obtained about two-thirds of the necessary state approvals required to close the deal.Aetna's medical benefit ratio, which compares the amount spent on medical claims with income from premiums, deteriorated to 80.5 percent from 79.1 percent a year ago.  The company's operating earnings of $2.30 per share was above the average analyst estimate of $2.23, according to Thomson Reuters I/B/E/S.Total revenue rose 4 percent to $15.69 billion, beating estimates of $15.45 billion.Aetna shares were up 1.5 percent at $115.52 in morning trading on the New York Stock Exchange. (Reporting by Amrutha Penumudi in Bengaluru; Editing by Maju Samuel and Anil D'Silva)",2016-04-28,AET,"Thu Apr 28, 2016 | 11:10am EDT",Aetna adds more individual Obamacare customers than projected,http://www.reuters.com//article/us-aetna-results-idUSKCN0XP1BJ?type=companyNews
290,"   By Amrutha Penumudi  Aetna Inc (AET.N) said more customers opted for its Obamacare plans in the first quarter than it had expected, but added that the program needed to be more flexible to become sustainable.The health insurer hopes that the next government would allow companies to tailor Obamacare individual plans every year, just like it does with Medicare and Medicaid, Chief Executive Mark Bertolini said.Many insurers have lost money on the healthcare exchanges, which were set up under the Affordable Care Act, because total enrollment has fallen sharply, while some patient costs have been higher than expected.""We have not been able to touch this product because of the politics, but if we can get to that point, we believe, we are in a very good place to make this a sustainable program,"" he said on a call with analysts. Aetna said it had ended the quarter with 1.2 million individual members, which exceeded their previous membership estimates. Anthem Inc (ANTM.N), another big player in the industry, said on Wednesday it planned to stick to the business and was planning to grow in that market.However, UnitedHealth Group Inc (UNH.N), the biggest U.S. health insurer, confirmed last week that it was exiting the business in 2017.Aetna, which is in the process of buying smaller rival Humana Inc (HUM.N), reported first-quarter operating earnings that topped analysts' estimates.  The company said it was on track to close the Humana acquisition by the second half of the year and that it had obtained about two-thirds of the necessary state approvals required to close the deal.Aetna's medical benefit ratio, which compares the amount spent on medical claims with income from premiums, deteriorated to 80.5 percent from 79.1 percent a year ago.  The company's operating earnings of $2.30 per share was above the average analyst estimate of $2.23, according to Thomson Reuters I/B/E/S.Total revenue rose 4 percent to $15.69 billion, beating estimates of $15.45 billion.Aetna shares were up 1.5 percent at $115.52 in morning trading on the New York Stock Exchange. (Reporting by Amrutha Penumudi in Bengaluru; Editing by Maju Samuel and Anil D'Silva)",2016-04-28,AET,"Thu Apr 28, 2016 | 11:10am EDT",UPDATE 2-Aetna adds more individual Obamacare customers than projected,http://www.reuters.com//article/aetna-results-idUSL3N17V42C?type=companyNews
291,"  April 28 Aetna Inc, which is in the process of buying rival Humana Inc, reported a near 4 percent fall in quarterly operating earnings as the health insurer lost members in its commercial business.Aetna's operating earnings fell to $810.8 million, or $2.30 per share, in the first quarter ended March 31, from $844.3 million, or $2.39 per share, a year earlier.  Revenue rose to $15.69 billion from $15.09 billion.   (Reporting by Amrutha Penumudi in Bengaluru; Editing by Maju Samuel) ",2016-04-28,AET,"Thu Apr 28, 2016 | 6:16am EDT",Health insurer Aetna's operating earnings fall nearly 4 pct,http://www.reuters.com//article/aetna-results-idUSL3N17V41G?type=companyNews
292,"   By Megan Cassella | WASHINGTON  WASHINGTON Planned Parenthood filed a lawsuit against Ohio officials on Wednesday over a plan by the state to restrict the U.S. healthcare agency's access to state and federal funds, saying it was being singled out for providing abortion services.The lawsuit, filed in federal court on behalf of Planned Parenthood branches of greater Ohio and of the southwest region, said attempts to defund the healthcare agency and several affiliated programs were an ""extreme punishment"" exacted solely because abortion services are part of its range of care, court filings showed.Agency officials also said such actions violated the equal protection clause of the U.S. Constitution for singling out Planned Parenthood and treating it differently from other healthcare providers.Ohio Right to Life director Katie Franklin called the lawsuit ""frivolous.""The Ohio bill was signed by Governor John Kasich in February and bars the state from contracts with organizations that perform or promote abortions. It is set to take effect on May 23. Kasich's press secretary, Joe Andrews, said in an email he would not discuss pending litigation, but added the governor, a former Republican presidential candidate, was pleased to sign legislation ""that continued our progress in moving funding to other eligible providers.""The lawsuit is the 15th filed by Planned Parenthood over access to care at its centers since mid-2015, when anti-abortion activists began releasing videos purporting to show group officials negotiating prices for aborted fetal tissue. Planned Parenthood denied wrongdoing and said the videos were distorted and politically motivated. Officials in 12 states have since blocked efforts to cut funding from the clinics, and the federal director of Medicaid, a government healthcare program for the poor, warned states in April against cutting off funds to Planned Parenthood simply because its services include abortions.Planned Parenthood officials said they were asking the court to hand down an order before the law takes effect. If allowed to continue, the action would ""constitute an undue, constitutionally intolerable burden on the abortion rights of Ohio women,"" the filing said.Also on Wednesday, Kansas Governor Sam Brownback signed into law a bill that directs the state's spending of federal funds for family planning services to health centers and hospitals that provide a full range of healthcare.  The governors office said in a statement the bill would eliminate funding for Planned Parenthood clinics out of federal grants for family planning programs.  (Additional reporting by Kim Palmer in Cleveland and Fiona Ortiz in Chicago)",2016-05-11,AET,"Wed May 11, 2016 | 6:59pm EDT",Planned Parenthood sues Ohio over plan to restrict funds,http://www.reuters.com//article/us-ohio-plannedparenthood-idUSKCN0Y22CQ?type=companyNews
293,"   By Megan Cassella | WASHINGTON  WASHINGTON Planned Parenthood filed a lawsuit against Ohio officials on Wednesday over a plan by the state to restrict the U.S. healthcare agency's access to state and federal funds, saying it was being singled out for providing abortion services.The lawsuit, filed in federal court on behalf of Planned Parenthood branches of greater Ohio and of the southwest region, said attempts to defund the healthcare agency and several affiliated programs were an ""extreme punishment"" exacted solely because abortion services are part of its range of care, court filings showed.Agency officials also said such actions violated the equal protection clause of the U.S. Constitution for singling out Planned Parenthood and treating it differently from other healthcare providers.Ohio Right to Life director Katie Franklin called the lawsuit ""frivolous.""The Ohio bill was signed by Governor John Kasich in February and bars the state from contracts with organizations that perform or promote abortions. It is set to take effect on May 23. Kasich's press secretary, Joe Andrews, said in an email he would not discuss pending litigation, but added the governor, a former Republican presidential candidate, was pleased to sign legislation ""that continued our progress in moving funding to other eligible providers.""The lawsuit is the 15th filed by Planned Parenthood over access to care at its centers since mid-2015, when anti-abortion activists began releasing videos purporting to show group officials negotiating prices for aborted fetal tissue. Planned Parenthood denied wrongdoing and said the videos were distorted and politically motivated. Officials in 12 states have since blocked efforts to cut funding from the clinics, and the federal director of Medicaid, a government healthcare program for the poor, warned states in April against cutting off funds to Planned Parenthood simply because its services include abortions.Planned Parenthood officials said they were asking the court to hand down an order before the law takes effect. If allowed to continue, the action would ""constitute an undue, constitutionally intolerable burden on the abortion rights of Ohio women,"" the filing said.Also on Wednesday, Kansas Governor Sam Brownback signed into law a bill that directs the state's spending of federal funds for family planning services to health centers and hospitals that provide a full range of healthcare.  The governors office said in a statement the bill would eliminate funding for Planned Parenthood clinics out of federal grants for family planning programs.  (Additional reporting by Kim Palmer in Cleveland and Fiona Ortiz in Chicago)",2016-05-11,AET,"Wed May 11, 2016 | 6:59pm EDT",Planned Parenthood sues Ohio over plan to restrict funds,http://www.reuters.com//article/ohio-plannedparenthood-idUSL2N1881MF?type=companyNews
294,"  (Adds comment by Ohio governor's office, action in Kansas)By Megan CassellaWASHINGTON May 11 Planned Parenthood filed a lawsuit against Ohio officials on Wednesday over a plan by the state to restrict the U.S. healthcare agency's access to state and federal funds, saying it was being singled out for providing abortion services.The lawsuit, filed in federal court on behalf of Planned Parenthood branches of greater Ohio and of the southwest region, said attempts to defund the healthcare agency and several affiliated programs were an ""extreme punishment"" exacted solely because abortion services are part of its range of care, court filings showed.Agency officials also said such actions violated the equal protection clause of the U.S. Constitution for singling out Planned Parenthood and treating it differently from other healthcare providers. Ohio Right to Life director Katie Franklin called the lawsuit ""frivolous.""The Ohio bill was signed by Governor John Kasich in February and bars the state from contracts with organizations that perform or promote abortions. It is set to take effect on May 23.Kasich's press secretary, Joe Andrews, said in an email he would not discuss pending litigation, but added the governor, a former Republican presidential candidate, was pleased to sign legislation ""that continued our progress in moving funding to other eligible providers."" The lawsuit is the 15th filed by Planned Parenthood over access to care at its centers since mid-2015, when anti-abortion activists began releasing videos purporting to show group officials negotiating prices for aborted fetal tissue.Planned Parenthood denied wrongdoing and said the videos were distorted and politically motivated. Officials in 12 states have since blocked efforts to cut funding from the clinics, and the federal director of Medicaid, a government healthcare program for the poor, warned states in April against cutting off funds to Planned Parenthood simply because its services include abortions. Planned Parenthood officials said they were asking the court to hand down an order before the law takes effect. If allowed to continue, the action would ""constitute an undue, constitutionally intolerable burden on the abortion rights of Ohio women,"" the filing said.Also on Wednesday, Kansas Governor Sam Brownback signed into law a bill that directs the state's spending of federal funds for family planning services to health centers and hospitals that provide a full range of healthcare.The governor's office said in a statement the bill would eliminate funding for Planned Parenthood clinics out of federal grants for family planning programs.(Reporting by Megan Cassella in Washington; Additional reporting by Kim Palmer in Cleveland and Fiona Ortiz in Chicago; Editing by James Dalgleish and Peter Cooney)",2016-05-11,AET,"Wed May 11, 2016 | 6:47pm EDT",UPDATE 2-Planned Parenthood sues Ohio over plan to restrict funds,http://www.reuters.com//article/ohio-plannedparenthood-idUSL2N1881PP?type=companyNews
295,  June 10 Fitch:* Fitch: large deals persist for US outpatient providers  * Consolidation in US healthcare provider industry is likely to continue as CMS accelerates value-based care initiatives under Medicare program  Source text for Eikon: ,2016-06-10,AET,"Fri Jun 10, 2016 | 10:54am EDT",BRIEF-Fitch says U.S. healthcare provider industry consolidation likely to continue,http://www.reuters.com//article/idUSFWN1920GG?type=companyNews
296,"   By Jason Lange | WASHINGTON  WASHINGTON Rising wages for U.S. healthcare workers had helped to drive a modest acceleration of inflation over the past year, but these gains in earnings have slowed, which could make it harder for the Federal Reserve to achieve its inflation target.Rising prices for healthcare has been one bright spot in an economy where wage and price gains have been tepid. The Fed views an inflation rate of 2 percent as healthy, but has undershot this target the last four years.But data on Friday appeared to confirm a trend of slowing wage gains in the sector, dimming the outlook for the faster price gains that would make the Fed more comfortable raising interest rates from very low levels.""We'd like to see a little more inflation,"" New York Fed President William Dudley said on Tuesday.Wage gains for hospital workers tend to affect prices paid months down the road, and in recent years the connection between compensation and prices has appeared tighter in the sector than in the rest of the economy, possibly because hospitals spend a relatively large share of revenues on wages. Healthcare wages began rising sharply in 2014 as President Barack Obama's healthcare reform law fueled a surge of hiring at hospitals to treat an influx of newly insured patients.Wages for healthcare workers were up 2.1 percent in the year through May, according to the most recent figures available for the sector released by the Labor Department on Friday. That's about twice the rate of increase logged in mid-2014, just before wages in the sector began to pick up. The wage acceleration that began that year was followed by a rise in healthcare service inflation, from 0.7 percent in the year through September 2015 to a 12-month gain of 1.3 percent in May of this year. The increase in healthcare costs had pushed overall inflation higher.But job growth in the sector has cooled, as has the acceleration in wage gains, which peaked at a 2.7 percent rate in December, well above the rate in May. Slower growth in the sector ""may mean less pressure on wages, and ultimately on healthcare prices,"" said Larry Levitt, a healthcare economist at the Kaiser Family Foundation in Menlo Park, California. And that could work against the Fed meeting its goal.  (Reporting by Jason Lange; Editing by Tim Ahmann and Andrea Ricci)",2016-07-08,AET,"Fri Jul 8, 2016 | 1:06pm EDT",Cooling wages for U.S. healthcare workers dim inflation outlook,http://www.reuters.com//article/us-usa-economy-healthcare-idUSKCN0ZO20S?type=companyNews
297,"   By Jason Lange | WASHINGTON  WASHINGTON Rising wages for U.S. healthcare workers had helped to drive a modest acceleration of inflation over the past year, but these gains in earnings have slowed, which could make it harder for the Federal Reserve to achieve its inflation target.Rising prices for healthcare has been one bright spot in an economy where wage and price gains have been tepid. The Fed views an inflation rate of 2 percent as healthy, but has undershot this target the last four years.But data on Friday appeared to confirm a trend of slowing wage gains in the sector, dimming the outlook for the faster price gains that would make the Fed more comfortable raising interest rates from very low levels.""We'd like to see a little more inflation,"" New York Fed President William Dudley said on Tuesday.Wage gains for hospital workers tend to affect prices paid months down the road, and in recent years the connection between compensation and prices has appeared tighter in the sector than in the rest of the economy, possibly because hospitals spend a relatively large share of revenues on wages. Healthcare wages began rising sharply in 2014 as President Barack Obama's healthcare reform law fueled a surge of hiring at hospitals to treat an influx of newly insured patients.Wages for healthcare workers were up 2.1 percent in the year through May, according to the most recent figures available for the sector released by the Labor Department on Friday. That's about twice the rate of increase logged in mid-2014, just before wages in the sector began to pick up. The wage acceleration that began that year was followed by a rise in healthcare service inflation, from 0.7 percent in the year through September 2015 to a 12-month gain of 1.3 percent in May of this year. The increase in healthcare costs had pushed overall inflation higher.But job growth in the sector has cooled, as has the acceleration in wage gains, which peaked at a 2.7 percent rate in December, well above the rate in May. Slower growth in the sector ""may mean less pressure on wages, and ultimately on healthcare prices,"" said Larry Levitt, a healthcare economist at the Kaiser Family Foundation in Menlo Park, California. And that could work against the Fed meeting its goal.  (Reporting by Jason Lange; Editing by Tim Ahmann and Andrea Ricci)",2016-07-08,AET,"Fri Jul 8, 2016 | 1:06pm EDT",Cooling wages for U.S. healthcare workers dim inflation outlook,http://www.reuters.com//article/usa-economy-healthcare-idUSL1N19F16Q?type=companyNews
298,"  Aug 5 Molina Healthcare* In case of termination of asset purchase deal on or prior to dec 31, , aetna,or humana to pay to co termination fee of $50 million  * If deal is terminated on or after jan 1, 2017 but prior to july 1, 2017,aetna and or humana to pay to co termination fee of $100 million  Source text for Eikon:  Further company coverage: ",2016-08-05,AET,"Fri Aug 5, 2016 | 6:00pm EDT","BRIEF-Molina says Aetna or Humana may pay to co fee of $50 mln, if deal is terminated on or prior to Dec 31",http://www.reuters.com//article/idUSFWN1AM1FG?type=companyNews
299,"   By Diane Bartz  The federal judge hearing the U.S. Justice Department's case to block Aetna Inc's $34 billion purchase of Humana Inc has set a trial date for Dec. 5, later than the companies had requested.Aetna and Humana are fighting the U.S. Department of Justice's lawsuit asserting that combining the two companies will harm consumers and raise prices.Aetna had asked for a trial date in the fall, perhaps October, because of a Dec. 31 deadline for the deal's completion. The Justice Department has said that that deadline can be pushed back. Judge John Bates, who will decide if the merger may go forward, said during a hearing on Wednesday that the companies had failed to define any harm in a later trial. Bates said that the trial would likely end on Dec. 21 and that the case would most likely be decided in mid- to late January.The Justice Department filed lawsuits on July 21 asking a federal court to stop Aetna's planned acquisition of Humana as well as Anthem's planned $45 billion purchase of Cigna. Aetna has argued that a single question will dominate the trial: Does Medicare Advantage, which is managed by insurance companies, compete with Medicare, which is managed by the government? The government says that the two products do not compete while insurers argue that they do.If Medicare Advantage competes against traditional Medicare, then Aetna's MA products compete against the government's Medicare and the deal is much likely to be deemed legal under antitrust law.",2016-08-10,AET,"Wed Aug 10, 2016 | 1:40pm EDT",Judge sets Aetna-Humana antitrust trial date for Dec. 5,http://www.reuters.com//article/humana-aetna-court-idUSL1N1AR1GI?type=companyNews
300,"  (Add quotes, background on dispute)Washington DC Aug 10 The federal judge hearing the U.S. Justice Department's case to block Aetna Inc's  $34 billion purchase of Humana Inc has set a trial date for Dec. 5, later than the companies had requested.Aetna and Humana are fighting the U.S. Department of Justice's lawsuit asserting that combining the two companies will harm consumers and raise prices.Aetna had asked for a trial date in the fall, perhaps October, because of a Dec. 31 deadline for the deal's completion. The Justice Department has said that that deadline can be pushed back. Judge John Bates, who will decide if the merger may go forward, said during a hearing on Wednesday that the companies had failed to define any harm in a later trial. Bates said that the trial would likely end on Dec. 21 and that the case would most likely be decided in mid- to late January.The Justice Department filed lawsuits on July 21 asking a federal court to stop Aetna's planned acquisition of Humana as well as Anthem's planned $45 billion purchase of Cigna. Aetna has argued that a single question will dominate the trial: Does Medicare Advantage, which is managed by insurance companies, compete with Medicare, which is managed by the government? The government says that the two products do not compete while insurers argue that they do.If Medicare Advantage competes against traditional Medicare, then Aetna's MA products compete against the government's Medicare and the deal is much likely to be deemed legal under antitrust law.   (Reporting by Diane Bartz in Washington D.C.; Editing by Chizu Nomiyama and Alan Crosby)",2016-08-10,AET,"Wed Aug 10, 2016 | 12:54pm EDT",UPDATE 1-Judge sets Aetna-Humana antitrust trial date for Dec. 5,http://www.reuters.com//article/humana-aetna-court-idUSL1N1AR15X?type=companyNews
301,"  Washington DC The U.S. District Court judge hearing the U.S. Justice Department's case to block Aetna Inc.'s (AET.N) $34 billion purchase of Humana Inc. (HUM.N) has set a trial date for Dec. 5, 2016, later than the companies had requested.Aetna and Humana are fighting the U.S. Department of Justice's lawsuit asserting that combining the two companies will harm consumers and raise prices. The companies were seeking an earlier date for the trial to increase the possibility of closing the deal within their target timeframe. Judge John Bates of the U.S. District Court for the District of Columbia said during a hearing on Wednesday that the companies had failed to define any harm that would be caused by setting the date in December.   (Reporting by Diane Bartz in Washington D.C.; Editing by Chizu Nomiyama)",2016-08-10,AET,"Wed Aug 10, 2016 | 12:38pm EDT",Judge sets Aetna-Humana antitrust trial date for December 5,http://www.reuters.com//article/us-humana-aetna-court-idUSKCN10L1VH?type=companyNews
302,"  NEW YORK Aetna Inc, the No. 3 U.S. health insurer, on Monday said that due to persistent financial losses on Obamacare plans, it will sell individual insurance on the government-run online marketplaces in only four states next year, down from the current 15 states.Aetna's decision follows similar moves from UnitedHealth Group Inc. and Humana Inc., which have cited similar concerns about financial losses on these exchanges created under President Barack Obama's national healthcare reform law.Aetna is also trying to buy Humana and is currently fighting a U.S. government lawsuit aimed at blocking the $34 billion deal.Aetna, which earlier this year said it was too soon to give up on the exchanges despite its challenges, this month signaled it was reconsidering. On Aug. 2, the company said it would not expand in 2017 and would review all its individual business.Many insurers last year had said they expected to profit on the exchanges, but now say more exchange rules must be changed for it to be sustainable. Only about 11 million people have signed up through the exchanges, about half as many as expected.Larry Levitt, healthcare economist at the Kaiser Family Foundation, said that if enrollment stagnates, small technical fixes likely will not be enough to bring big insurers back. ""More healthy people need to be encouraged to sign up,"" Levitt said by email.  Aetna said that the current risk adjustment system, in which the government balances out the costs of sicker than typical populations through payments to insurers, is not adequate. Aetna said that it had a second-quarter pretax loss of $200 million on the individual business and has lost $430 million since the plans first went on sale in 2014. Kevin Counihan, Chief Executive of the U.S. government-run individual marketplace, said that the risks of the customer pool is improving. ""Its no surprise that companies are adapting at different rates to a market where they compete for business on cost and quality rather than by denying coverage to people with preexisting conditions,"" Counihan said in a statement.Aetna on Monday said it would continue to sell plans on the exchanges in Delaware, Iowa, Nebraska and Virginia in 2017. The plans, which are eligible for income-based government subsidies, will be sold in 242 counties, down from 778 counties this year. States it is exiting include Florida and Ohio. It will continue to sell individual plans that meet the law's requirements - such as not denying coverage to people with pre-existing conditions - outside of the exchanges where it does now, the company said. (Reporting by Caroline Humer; Editing by Diane Craft)",2016-08-16,AET,"Mon Aug 15, 2016 | 9:58pm EDT",Aetna pulls back on Obamacare health insurance plans in 2017,http://www.reuters.com//article/us-aetna-exchanges-idUSKCN10R01N?type=companyNews
303,"  NEW YORK Aetna Inc, the No. 3 U.S. health insurer, on Monday said that due to persistent financial losses on Obamacare plans, it will sell individual insurance on the government-run online marketplaces in only four states next year, down from the current 15 states.Aetna's decision follows similar moves from UnitedHealth Group Inc. and Humana Inc., which have cited similar concerns about financial losses on these exchanges created under President Barack Obama's national healthcare reform law.Aetna is also trying to buy Humana and is currently fighting a U.S. government lawsuit aimed at blocking the $34 billion deal.Aetna, which earlier this year said it was too soon to give up on the exchanges despite its challenges, this month signaled it was reconsidering. On Aug. 2, the company said it would not expand in 2017 and would review all its individual business.Many insurers last year had said they expected to profit on the exchanges, but now say more exchange rules must be changed for it to be sustainable. Only about 11 million people have signed up through the exchanges, about half as many as expected.Larry Levitt, healthcare economist at the Kaiser Family Foundation, said that if enrollment stagnates, small technical fixes likely will not be enough to bring big insurers back. ""More healthy people need to be encouraged to sign up,"" Levitt said by email.  Aetna said that the current risk adjustment system, in which the government balances out the costs of sicker than typical populations through payments to insurers, is not adequate. Aetna said that it had a second-quarter pretax loss of $200 million on the individual business and has lost $430 million since the plans first went on sale in 2014. Kevin Counihan, Chief Executive of the U.S. government-run individual marketplace, said that the risks of the customer pool is improving. ""Its no surprise that companies are adapting at different rates to a market where they compete for business on cost and quality rather than by denying coverage to people with preexisting conditions,"" Counihan said in a statement.Aetna on Monday said it would continue to sell plans on the exchanges in Delaware, Iowa, Nebraska and Virginia in 2017. The plans, which are eligible for income-based government subsidies, will be sold in 242 counties, down from 778 counties this year. States it is exiting include Florida and Ohio. It will continue to sell individual plans that meet the law's requirements - such as not denying coverage to people with pre-existing conditions - outside of the exchanges where it does now, the company said. (Reporting by Caroline Humer; Editing by Diane Craft)",2016-08-16,AET,"Mon Aug 15, 2016 | 9:58pm EDT",UPDATE 1-Aetna pulls back on Obamacare health insurance plans in 2017,http://www.reuters.com//article/aetna-exchanges-idUSL1N1AX00O?type=companyNews
304,"   By Caroline Humer | NEW YORK  NEW YORK Aetna Inc warned in July that it would exit much of the individual Obamacare health insurance market if the government challenged its deal to buy rival Humana Inc, according to a letter it sent to the U.S. Department of Justice.The public release of the letter came after Aetna said on Monday that it would pull out of selling individual insurance on the government-run websites in 11 states, citing financial losses on the business.The company's withdrawal followed similar moves by UnitedHealth Group Inc and Humana, representing a blow to the marketplace for the government-subsidized insurance plans created under President Barack Obama's signature healthcare reform law.In the July 5 letter, Aetna Chief Executive Officer Mark Bertolini said it would have to cut back because it would be some time before the company recouped the investment it had made in this market over the past 2-1/2 years.""Our ability to withstand these losses is dependent on our achieving anticipated synergies in the Humana acquisition,"" Bertolini wrote. A copy of the letter was posted on the Huffington Post website, which obtained the document though the Freedom of Information Act. ""Unfortunately, a challenge by the DOJ to that acquisition and/or the DOJ successfully blocking the transaction would have a negative financial impact on Aetna and would impair Aetna's ability to continue its support,"" he wrote.Many insurers have said they are losing money because the Obamacare population is sicker than foreseen and the risk-adjustment payments from the government are insufficient. The government has made changes aimed at helping the insurers, which say it has not gone far enough to make the business sustainable.The Justice Department moved on July 21 to block Aetna's acquisition of Humana and Anthem Inc's purchase of Cigna Corp after an antitrust review, saying the two deals would lead to higher prices. Aetna spokesman TJ Crawford said the letter was a response to the department's written request for information. The company's ultimate decision was based on financial information obtained after the letter was sent, he said.""That deterioration, and not the DOJ challenge to our Humana transaction, is ultimately what drove us to announce the narrowing of our public exchange presence for the 2017 plan year,"" Crawford said. The release of the documents is unusual in a Justice Department antitrust investigation. So was the review, which was conducted in tandem with the Anthem-Cigna investigation and involved a business in which the Obama administration was deeply invested.In June, ongoing dialogue between Aetna and the department about the exchanges turned to discussions about the potential impact of a failed deal on those markets, according to a person familiar with the situation.Assistant Attorney General William Baer, who was leading the review, sent a June 30 request to Aetna for information on the consequences of not completing the deal.A copy of the government document sent to Aetna shows the Justice Department asked for data on costs such as the breakup fee; the impact on Aetna's business strategy, including participation on the Obamacare exchanges; and documents related to a June board meeting, the Humana deal or the exchanges.Aetna shares rose 1 percent to $120.09. Humana fell 0.5 percent to $178.69.",2016-08-17,AET,"Wed Aug 17, 2016 | 4:28pm EDT",Aetna warned it would cut Obamacare if Humana deal was blocked,http://www.reuters.com//article/humana-aetna-obamacare-idUSL1N1AY0L8?type=companyNews
305,"   By Caroline Humer | NEW YORK  NEW YORK Aetna Inc (AET.N) warned in July that it would exit much of the individual Obamacare health insurance market if the government challenged its deal to buy rival Humana Inc (HUM.N), according to a letter it sent to the U.S. Department of Justice.The public release of the letter came after Aetna said on Monday that it would pull out of selling individual insurance on the government-run websites in 11 states, citing financial losses on the business.The company's withdrawal followed similar moves by UnitedHealth Group Inc (UNH.N) and Humana, representing a blow to the marketplace for the government-subsidized insurance plans created under President Barack Obama's signature healthcare reform law.In the July 5 letter, Aetna Chief Executive Officer Mark Bertolini said it would have to cut back because it would be some time before the company recouped the investment it had made in this market over the past 2-1/2 years.""Our ability to withstand these losses is dependent on our achieving anticipated synergies in the Humana acquisition,"" Bertolini wrote. A copy of the letter was posted on the Huffington Post website, which obtained the document though the Freedom of Information Act. ""Unfortunately, a challenge by the DOJ to that acquisition and/or the DOJ successfully blocking the transaction would have a negative financial impact on Aetna and would impair Aetna's ability to continue its support,"" he wrote. Many insurers have said they are losing money because the Obamacare population is sicker than foreseen and the risk-adjustment payments from the government are insufficient. The government has made changes aimed at helping the insurers, which say it has not gone far enough to make the business sustainable.The Justice Department moved on July 21 to block Aetna's acquisition of Humana and Anthem Inc's (ANTM.N) purchase of Cigna Corp (CI.N) after an antitrust review, saying the two deals would lead to higher prices. Aetna spokesman TJ Crawford said the letter was a response to the department's written request for information. The company's ultimate decision was based on financial information obtained after the letter was sent, he said. ""That deterioration, and not the DOJ challenge to our Humana transaction, is ultimately what drove us to announce the narrowing of our public exchange presence for the 2017 plan year,"" Crawford said.The release of the documents is unusual in a Justice Department antitrust investigation. So was the review, which was conducted in tandem with the Anthem-Cigna investigation and involved a business in which the Obama administration was deeply invested.In June, ongoing dialogue between Aetna and the department about the exchanges turned to discussions about the potential impact of a failed deal on those markets, according to a person familiar with the situation.  Assistant Attorney General William Baer, who was leading the review, sent a June 30 request to Aetna for information on the consequences of not completing the deal. A copy of the government document sent to Aetna shows the Justice Department asked for data on costs such as the breakup fee; the impact on Aetna's business strategy, including participation on the Obamacare exchanges; and documents related to a June board meeting, the Humana deal or the exchanges.Aetna shares rose 1 percent to $120.09. Humana fell 0.5 percent to $178.69.     (Reporting by Caroline Humer; Editing by Lisa Von Ahn)",2016-08-17,AET,"Wed Aug 17, 2016 | 3:13pm EDT",Aetna warned it would cut Obamacare if Humana deal was blocked,http://www.reuters.com//article/us-humana-aetna-obamacare-idUSKCN10S1D4?type=companyNews
306,"   By Caroline Humer | NEW YORK  NEW YORK Aetna Inc (AET.N) warned in July that it would exit much of the individual Obamacare health insurance market if the government challenged its deal to buy rival Humana Inc (HUM.N), according to a letter it sent to the U.S. Department of Justice.The public release of the letter came after Aetna said on Monday that it would pull out of selling individual insurance on the government-run websites in 11 states, citing financial losses on the business.The company's withdrawal followed similar moves by UnitedHealth Group Inc (UNH.N) and Humana, representing a blow to the marketplace for the government-subsidized insurance plans created under President Barack Obama's signature healthcare reform law.In the July 5 letter, Aetna Chief Executive Officer Mark Bertolini said it would have to cut back because it would be some time before the company recouped the investment it had made in this market over the past 2-1/2 years.""Our ability to withstand these losses is dependent on our achieving anticipated synergies in the Humana acquisition,"" Bertolini wrote. A copy of the letter was posted on the Huffington Post website, which obtained the document though the Freedom of Information Act. ""Unfortunately, a challenge by the DOJ to that acquisition and/or the DOJ successfully blocking the transaction would have a negative financial impact on Aetna and would impair Aetna's ability to continue its support,"" he wrote. Many insurers have said they are losing money because the Obamacare population is sicker than foreseen and the risk-adjustment payments from the government are insufficient. The government has made changes aimed at helping the insurers, which say it has not gone far enough to make the business sustainable.The Justice Department moved on July 21 to block Aetna's acquisition of Humana and Anthem Inc's (ANTM.N) purchase of Cigna Corp (CI.N) after an antitrust review, saying the two deals would lead to higher prices. Aetna spokesman TJ Crawford said the letter was a response to the department's written request for information. The company's ultimate decision was based on financial information obtained after the letter was sent, he said. ""That deterioration, and not the DOJ challenge to our Humana transaction, is ultimately what drove us to announce the narrowing of our public exchange presence for the 2017 plan year,"" Crawford said.The release of the documents is unusual in a Justice Department antitrust investigation. So was the review, which was conducted in tandem with the Anthem-Cigna investigation and involved a business in which the Obama administration was deeply invested.In June, ongoing dialogue between Aetna and the department about the exchanges turned to discussions about the potential impact of a failed deal on those markets, according to a person familiar with the situation.  Assistant Attorney General William Baer, who was leading the review, sent a June 30 request to Aetna for information on the consequences of not completing the deal. A copy of the government document sent to Aetna shows the Justice Department asked for data on costs such as the breakup fee; the impact on Aetna's business strategy, including participation on the Obamacare exchanges; and documents related to a June board meeting, the Humana deal or the exchanges.Aetna shares rose 1 percent to $120.09. Humana fell 0.5 percent to $178.69.     (Reporting by Caroline Humer; Editing by Lisa Von Ahn)",2016-08-17,AET,"Wed Aug 17, 2016 | 3:13pm EDT",UPDATE 2-Aetna warned it would cut Obamacare if Humana deal was blocked,http://www.reuters.com//article/humana-aetna-obamacare-idUSL1N1AY0ML?type=companyNews
307,"  NEW YORK Aug 17 Aetna Inc's CEO said in a letter to the U.S. Department of Justice during the review of its deal to buy rival Humana Inc that the insurer would exit much of the individual Obamacare insurance market if the agency challenged the merger.In the July 5 letter, Chief Executive Officer Mark Bertolini said it would be some time before the company recouped the investment it had made over the past 2 1/2 years in the government-subsidized insurance plans created under President Barack Obama's national healthcare reform law.""Our ability to withstand these losses is dependent on our achieving anticipated synergies in the Humana acquisition,"" Bertolini wrote, according to a copy of the letter posted on the Huffington Post website, which obtained the document though the Freedom of Information Act.""Unfortunately, a challenge by the DOJ to that acquisition and/or the DOJ successfully blocking the transaction would have a negative financial impact on Aetna and would impair Aetna's ability to continue its support,"" he wrote. UnitedHealth Group Inc and Humana Inc have cited similar concerns about financial losses on the Obamacare exchanges and have also cut back most of their plans for 2017.The Justice Department moved on July 21 to block Aetna's acquisition of Humana and Anthem Inc's purchase of Cigna Corp, saying the two deals would lead to higher prices. Aetna on Monday announced it would pull out of selling individual insurance on the government-run websites in 11 states, saying its losses on the business were too high. Aetna spokesman TJ Crawford said in an e-mailed statement that since the company submitted the letter to the Justice Department, it had a better view of the business line's second-quarter performance.""That deterioration, and not the DOJ challenge to our Humana transaction, is ultimately what drove us to announce the narrowing of our public exchange presence for the 2017 plan year,"" Crawford said.Aetna shares were unchanged in premarket trading.   (Reporting by Caroline Humer; Editing by Lisa Von Ahn)",2016-08-17,AET,"Wed Aug 17, 2016 | 9:16am EDT",Aetna CEO warned it would cut Obamacare if Humana deal was blocked,http://www.reuters.com//article/humana-aetna-obamacare-idUSL1N1AY0J3?type=companyNews
308,  Sept 6 Aetna Inc :* Aetna and Piedmont Healthcare announce new contract  * Agreement will give Aetna members continued in-network access to all piedmont facilities  Source text for Eikon:  Further company coverage: ,2016-09-06,AET,"Tue Sep 6, 2016 | 9:29am EDT","BRIEF-Aetna, Piedmont Healthcare announce new contract",http://www.reuters.com//article/idUSFWN1BI0BD?type=companyNews
309,"  Sept 8 Hana Must Second Special Purpose Acquisition Co :* Says it will change company name to SELVAS Healthcare, Inc., effective from Sept. 13  Source text in Korean: goo.gl/3zXHX2 Further company Coverage:    (Beijing Headline News)",2016-09-08,AET,"Thu Sep 8, 2016 | 4:09am EDT",BRIEF-Hana Must Second Special Purpose Acquisition to change co name,http://www.reuters.com//article/idUSL3N1BK2VJ?type=companyNews
310,"  Sept 12 Aetna Inc :* Expect to reaffirm our full-year 2016 net income per share projection of $6.28 to $6.48* Expect to reaffirm full-year 2016 operating earnings per share projection of $7.90 to $8.10 * Fy2016 earnings per share view $8.05 -- Thomson Reuters I/B/E/S * Will experience net realized capital gains or net realized capital losses during portion of 2016 following June 30, 2016 * Cannot project amount of such future gains or losses during portion of 2016 following June 30, 2016* Aetna has assumed no net realized capital gains or losses after June 30, 2016 for purposes of projecting net income and net income per share  Source text (bit.ly/2cg9k2Y) Further company coverage:",2016-09-12,AET,"Mon Sep 12, 2016 | 4:52pm EDT",BRIEF-Aetna expects to reaffirm FY 2016 net income per share projection of $6.28 to $6.48,http://www.reuters.com//article/idUSFWN1BO0I4?type=companyNews
311,"  (The following statement was released by the rating agency) NEW YORK, September 12 (Fitch) The U.S. healthcare industry's shift to value has  created a secular upheaval that permeates nearly every sub-sector, says Fitch  Ratings in a report published today.  ""As the industry grapples with a range of issues, it's increasingly clear that  no corner of the healthcare industry will remain totally untouched,"" says Megan  Neuburger, Managing Director, U.S. Corporates. ""All types of healthcare  companies have some imperative to reshape their business models around the shift  to value, and that in itself is creating a host of challenges and opportunities  for them."" During the month of August, Fitch's U.S. healthcare team answered investors'  questions about the trends cited below, which embody the secular challenges  arising from the shift to value.  Lower Acuity Admissions Some acute care hospital operators with operations in rural and small suburban  markets saw weak 2Q16 results. Since it can be difficult to predict the bottom  on inpatient hospital admissions in those types of markets, more of the same may  be in store.  ""Patients and insurers both have price incentives to shift care away from  hospitals with their high fixed costs to higher-value settings,"" says Neuburger.  ""For hospital companies, this highlights the importance of having a strategy to  preserve market share in the long term."" Investments in outpatient facilities like Tenet Healthcare Corp's acquisition of  United Surgical Partners, or divestitures in non-competitive markets like  Community Health Systems' divestiture of Quorum Health Corp, are both long-term  strategies that may be employed by other hospitals, even if they raise execution  risk in the short term.  Health Insurance Consolidation While it is fairly obvious to assume that health insurer consolidation will  erode providers' pricing power, Fitch believes that erosion is overstated  because price negotiations take place market-by-market.  ""Pricing battles will continue to be won and lost at the local market level, so  national breadth - both for insurance companies and providers - does not  necessarily trump in-market depth,"" says Neuburger.  The impact of insurer consolidation on the ACA health insurance marketplaces is  a complex issue. Acute care hospitals in particular are exposed to this issue,  as competitive public insurance markets support lower levels of uninsured  patients and uncompensated care, which will bolster cash flows in the longer  term.  Medicare Reimbursement Reforms Vertical consolidation and rationalization of capacity in some segments has been  necessary for post-acute care (PAC) providers to adjust to Medicare  reimbursement reform. Medicare bundling initiatives will bear fruit for PACs  longer-term through better provider relationships and referral sources. ""Initiatives like the Comprehensive Care for Joint Replacement (CJR) model will  differentiate PAC providers by how well they reduce financial risk for acute  care hospitals under bundled payments,"" says Neuburger. ""The wheat will separate  from the chaff along the lines of which PACs have the best physician and  referral relationships in place."" The importance of acute care referral relationships will be compounded by the  long-term acute care (LTAC) specific reforms such as site neutral payments and  the 25% rule.  Generic Drug Pricing Amid the headlines on significant drug price increases, there is a juxtaposition  of a small number of very expensive specialty drug launches that either improve  efficacy or are significantly complex to manufacture, and generic drugs with  relatively little clinical differentiation.  ""At the heart of the recent momentum on drug pricing are the effects of  competitive market forces,"" says Neuburger. ""Outside the few drugs making  headlines, the U.S. market for generic pharmaceuticals remains highly  competitive."" Generic pharma will likely remain highly competitive given the number of new  suppliers that entered the market in recent years to accommodate abbreviated new  drug applications (ANDAs). This may squeeze the margins of pharmaceutical  wholesalers and distributors who profit from the purchase and sale of generics.  Opioid Addiction Epidemic Efforts to address increasing levels of narcotics abuse has spurred a shift  among the way opioid drugs are developed, marketed and prescribed.  ""For physicians and policy makers, these efforts constitute rethink of pain  management practices from policy to prescription,"" says Neuburger.  For generic drug manufacturers offering ndirect substitutes or alternatives to  opioids, pricing has been an effective tool in grabbing market share. Specialty  pharmaceutical companies will feel competitive and regulatory pressures, making  strategic deals and drug development important components of their strategy.  The full report, ""What Investors Want to Know: U.S. Healthcare: Takeaways from  Recent Investor Meetings,"" is available at www.fitchratings.com or by clicking  on the link. Contact: Megan Neuburger, CFA Managing Director +1-212-908-0501 Fitch Ratings, Inc. 33 Whitehall Street New York, NY 10004 Robert Kirby, CFA Director +1-312-368-3169 Media Relations: Alyssa Castelli, New York, Tel: +1 (212) 908 0540, Email:  alyssa.castelli@fitchratings.com. Additional information is available at www.fitchratings.com Related Research  What Investors Want to Know: U.S. Healthcare (Takeaways from Recent Investor  Meetings) here ALL FITCH CREDIT RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND DISCLAIMERS.  PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING THIS LINK:  here. IN ADDITION, RATING  DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE AVAILABLE ON THE AGENCY'S  PUBLIC WEBSITE 'WWW.FITCHRATINGS.COM'. PUBLISHED RATINGS, CRITERIA AND  METHODOLOGIES ARE AVAILABLE FROM THIS SITE AT ALL TIMES. FITCH'S CODE OF  CONDUCT, CONFIDENTIALITY, CONFLICTS OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE  AND OTHER RELEVANT POLICIES AND PROCEDURES ARE ALSO AVAILABLE FROM THE 'CODE OF  CONDUCT' SECTION OF THIS SITE. FITCH MAY HAVE PROVIDED ANOTHER PERMISSIBLE  SERVICE TO THE RATED ENTITY OR ITS RELATED THIRD PARTIES. DETAILS OF THIS  SERVICE FOR RATINGS FOR WHICH THE LEAD ANALYST IS BASED IN AN EU-REGISTERED  ENTITY CAN BE FOUND ON THE ENTITY SUMMARY PAGE FOR THIS ISSUER ON THE FITCH  WEBSITE.   ",2016-09-12,AET,"Mon Sep 12, 2016 | 9:58am EDT",Fitch: U.S. Healthcare's Shift to Value Leaves No Sub-Sector Untouched,http://www.reuters.com//article/idUSFit972225?type=companyNews
312,"  U.S. health insurer Aetna Inc said it would offer some customers discounts on Apple Inc's smartwatch, marking the first deal made by the tech giant with an insurer for its devices.Aetna, which has about 23 million members in the United States, will also give away the Apple Watch for free to its nearly 50,000 employees, Aetna said in a statement on Tuesday.The deal could help Apple boost the appeal of its Watch to potential customers as the company looks to target health and fitness conscious users with its new device.Aetna will discount a significant portion of the cost, and will offer users monthly payment options to pay off the remaining amount.The discounts on the devices will vary for customers, according to Aetna spokesman Ethan Slavin. However, reaction to the second edition of the Apple Watch has been muted since its launch earlier this month with the device likely to remain a niche offering, according to some analysts.Apple shipped 1.6 million units of the original Apple Watch, in the second quarter, down by 56.7 percent from last year, according to research firm IDC. In comparison, Fitbit Inc shipped 5.7 million units in that period.Aetna is also developing health applications for Apple's devices that will remind users to take their medications, order refills for prescriptions and message or call their doctor. The applications, which will use Apple Wallet to allow customers to pay their bills, will be available early next year. (Reporting by Narottam Medhora and Siddharth Cavale in Bengaluru; Editing by Shounak Dasgupta)",2016-09-27,AET,"Tue Sep 27, 2016 | 4:01pm EDT",Aetna to offer Apple Watch at a discount to certain customers,http://www.reuters.com//article/us-aetna-watch-apple-idUSKCN11X2BX?type=companyNews
313,"  U.S. health insurer Aetna Inc said it would offer some customers discounts on Apple Inc's smartwatch, marking the first deal made by the tech giant with an insurer for its devices.Aetna, which has about 23 million members in the United States, will also give away the Apple Watch for free to its nearly 50,000 employees, Aetna said in a statement on Tuesday.The deal could help Apple boost the appeal of its Watch to potential customers as the company looks to target health and fitness conscious users with its new device.Aetna will discount a significant portion of the cost, and will offer users monthly payment options to pay off the remaining amount.The discounts on the devices will vary for customers, according to Aetna spokesman Ethan Slavin. However, reaction to the second edition of the Apple Watch has been muted since its launch earlier this month with the device likely to remain a niche offering, according to some analysts.Apple shipped 1.6 million units of the original Apple Watch, in the second quarter, down by 56.7 percent from last year, according to research firm IDC. In comparison, Fitbit Inc shipped 5.7 million units in that period.Aetna is also developing health applications for Apple's devices that will remind users to take their medications, order refills for prescriptions and message or call their doctor. The applications, which will use Apple Wallet to allow customers to pay their bills, will be available early next year. (Reporting by Narottam Medhora and Siddharth Cavale in Bengaluru; Editing by Shounak Dasgupta)",2016-09-27,AET,"Tue Sep 27, 2016 | 4:01pm EDT",Aetna to offer Apple Watch at a discount to certain customers,http://www.reuters.com//article/aetna-watch-apple-idUSL3N1C34DG?type=companyNews
314,  Sept 30 Aetna Inc * Sets quarterly cash dividend of $0.25/shr  Source text for Eikon:  Further company coverage:  ,2016-09-30,AET,"Fri Sep 30, 2016 | 2:34pm EDT",BRIEF-Aetna sets quarterly cash dividend of $0.25 per share,http://www.reuters.com//article/idUSFWN1C60QW?type=companyNews
315,"  Oct 11 Aetna Inc* Aetna and Merck sign a unique value-based contract for Januvia and Janumet * Says Merck also agrees to collaborate on Aetnacare * Says Aetnacare program will initially target patients with diabetes and hypertension in mid-Atlantic markets * Says Merck's rebates on Januvia, Janumet to be based in part on products' contributions to helping commercial members with type 2 diabetes achieve treatment objectives  Source text for Eikon:  Further company coverage:",2016-10-11,AET,"Tue Oct 11, 2016 | 9:50am EDT",BRIEF-Aetna and Merck sign a contract for Januvia and Janumet,http://www.reuters.com//article/idUSFWN1CH0RR?type=companyNews
316,"   By Sijia Jiang | HONG KONG  HONG KONG Alibaba Group Holdings' finance arm on Wednesday demonstrated a payment service that will allow virtual reality shoppers to pay for things in future just by nodding their heads.VR Pay, the new payment system, is part of Alibaba's efforts to capitalize on the latest technology in online shopping. In 2015, for example, it introduced a facial recognition technology for Alipay mobile payments service advertised as ""pay with a selfie"". The VR payment technology means people using virtual reality goggles to browse virtual reality shopping malls will be able pay for purchases without taking off the goggles. They can just nod or look instead. Lin Feng, who is in charge of Ant Financial's incubator F Lab that has been developing the payment service over the past few months, told Reuters: ""It is very boring to have to take off your goggles for payment. With this, you will never need to take out your phone."" User identity can be verified on VR Pay via account logins on connected devices or via voice print technology that recognizes each person's unique voice. Lin said this was the most convenient method in a VR setting compared with other biometric recognition technologies.    But passwords will still be needed for authentication, which the user can also enter with head movements, touch, or by staring at a point on virtual display for longer than 1.5 seconds, he said. VR Pay is expected to be ready for commercial launch by the end of this year.  Ant Financial said its new VR-based payment infrastructure can make VR ""a tool rather than just a toy"" by connecting various VR goggle makers and app developers to the Alipay payments platform. Ant Financial Services Group, which was demonstrating VR Pay in Shenzhen on Wednesday, operates China's largest online payments service Alipay with more than 450 million daily users. In September, it bought U.S.company EyeVerify, a maker of optical verification technology used by U.S. banks including Wells Fargo. (Reporting by Sijia Jiang. Editing by Jane Merriman)",2016-10-12,AET,"Wed Oct 12, 2016 | 9:35am EDT",Alibaba's new payment system lets virtual reality shoppers pay by nodding,http://www.reuters.com//article/alibaba-ant-financial-vr-idUSL4N1CI39W?type=companyNews
317,"   By Carl O'Donnell  EQT on Friday closed its acquisition of Press Ganey Holdings Inc, a provider of patient satisfaction surveys, giving the Swedish buyout firm its first foothold in the U.S. healthcare market, the company said. The acquisition, which values Press Ganey at around $2.35 billion, gives EQT a platform in the healthcare technology space at a time when hospitals, governments and insurers are increasingly relying on data and analytics to improve the quality of care.Press Ganey conducts patient satisfaction surveys that are relied on by government healthcare payers to help determine reimbursements for hospitals.It provides data to the U.S. government's Medicare program, which in recent years has increasingly used performance data to determine reimbursement rates. Analysts and investors expect data providers like Press Ganey to continue to benefit as private insurers also ramp up their use of performance measurements. South Bend, Indiana-based Press Ganey was founded in 1985 and went public in May 2015. At the time of its sale to EQT, its previous private equity owner, Vestar Capital, still held a nearly 60 percent stake.  Based in Stockholm, EQT was founded in 1994 in connection with the Wallenberg family, a Swedish business family that owns stakes in about half the country's publicly traded companies by market capitalization. EQT focuses heavily on operations, putting industry practitioners on the boards of its portfolio companies, many of which work in other companies partly owned by the Wallenbergs.  ""EQT will leverage its deep platform and global capabilities to provide valuable resources in support of Press Ganeys continued growth,said Eric Liu, a partner at EQT.  (Reporting by Carl O'Donnell; Editing by Sandra Maler)",2016-10-21,AET,"Fri Oct 21, 2016 | 4:58pm EDT",EQT completes acquisition of Press Ganey,http://www.reuters.com//article/us-press-ganey-hldg-m-a-eqt-idUSKCN12L2PK?type=companyNews
318,"   By Carl O'Donnell  EQT on Friday closed its acquisition of Press Ganey Holdings Inc, a provider of patient satisfaction surveys, giving the Swedish buyout firm its first foothold in the U.S. healthcare market, the company said. The acquisition, which values Press Ganey at around $2.35 billion, gives EQT a platform in the healthcare technology space at a time when hospitals, governments and insurers are increasingly relying on data and analytics to improve the quality of care.Press Ganey conducts patient satisfaction surveys that are relied on by government healthcare payers to help determine reimbursements for hospitals.It provides data to the U.S. government's Medicare program, which in recent years has increasingly used performance data to determine reimbursement rates. Analysts and investors expect data providers like Press Ganey to continue to benefit as private insurers also ramp up their use of performance measurements. South Bend, Indiana-based Press Ganey was founded in 1985 and went public in May 2015. At the time of its sale to EQT, its previous private equity owner, Vestar Capital, still held a nearly 60 percent stake.  Based in Stockholm, EQT was founded in 1994 in connection with the Wallenberg family, a Swedish business family that owns stakes in about half the country's publicly traded companies by market capitalization. EQT focuses heavily on operations, putting industry practitioners on the boards of its portfolio companies, many of which work in other companies partly owned by the Wallenbergs.  ""EQT will leverage its deep platform and global capabilities to provide valuable resources in support of Press Ganeys continued growth,said Eric Liu, a partner at EQT.  (Reporting by Carl O'Donnell; Editing by Sandra Maler)",2016-10-21,AET,"Fri Oct 21, 2016 | 4:58pm EDT",EQT completes acquisition of Press Ganey,http://www.reuters.com//article/press-ganey-hldg-ma-eqt-idUSL1N1CR1PT?type=companyNews
319,"  Oct 27 Aetna Inc * Aetna adds Sarepta's DMD drug Exondys 51 to its precertification list, effective nov 15  Source text for Eikon: aet.na/2eR7liT Further company coverage:  ",2016-10-27,AET,"Thu Oct 27, 2016 | 7:36pm EDT",BRIEF-Aetna adds Sarepta's DMD drug Exondys 51 to its precertification list,http://www.reuters.com//article/idUSFWN1CX1HQ?type=companyNews
320,"   By Caroline Humer and Ankur Banerjee  U.S. health insurer Aetna Inc warned on Thursday that losses from its Obamacare individual insurance plans will likely continue despite pulling out of the exchanges in most states, creating uncertainty for next year's earnings.Chief Executive Officer Mark Bertolini said the earliest the health insurer might return to the exchanges is 2019, more likely 2020, and then only if operations improve. Shares fell 1 percent to $109.81.The CEO's comments came during a conference call to discuss third-quarter earnings and revenue, both of which beat analysts' expectations.Aetna said in August it will reduce participation in  individual insurance on government-run online marketplaces to four states from the current 15 states due to financial losses. It will continue to sell plans on the exchanges. Bertolini's comments came two days after the U.S. government said premium rates for Obamacare plans would increase by 25 percent, on average, in 2017, reflecting higher medical costs of insuring members.Bertolini said two problems are the risk adjustment calculation that smooths out the costs of sick patients and the number of people enrolled in the program. ""Until that mechanism changes, or until the pool substantively changes, we're going to find ourselves in a premium spiral that's going to continue to drive rates up,"" Bertolini said.The government estimates 2017 enrollment to rise 1 million about 11.4 million people. Aetna said it expects operating losses of $350 million on the individual insurance business in 2016. In 2017, it may book losses both in the states where it remains in exchanges and in the states where it sells plan outside the exchanges.Bertolini said Aetna, which is fighting a U.S. government lawsuit to block its $34 billion acquisition of Humana, is committed to the deal and expects to close in 2017.The exchanges and the lawsuit are two uncertainties for 2017, Aetna said. Other potential bumps include high costs in its fully insured plans for small companies and the possible loss of some Medicaid contracts.",2016-10-27,AET,"Thu Oct 27, 2016 | 12:10pm EDT",Aetna says losses not over for Obamacare plans,http://www.reuters.com//article/aetna-results-idUSL1N1CX1BT?type=companyNews
321,"   By Caroline Humer and Ankur Banerjee  U.S. health insurer Aetna Inc (AET.N) warned on Thursday that losses from its Obamacare individual insurance plans will likely continue despite pulling out of the exchanges in most states, creating uncertainty for next year's earnings.Chief Executive Officer Mark Bertolini said the earliest the health insurer might return to the exchanges is 2019, more likely 2020, and then only if operations improve. Shares fell 1 percent to $109.81.The CEO's comments came during a conference call to discuss third-quarter earnings and revenue, both of which beat analysts' expectations.Aetna said in August it will reduce participation in  individual insurance on government-run online marketplaces to four states from the current 15 states due to financial losses. It will continue to sell plans on the exchanges.Bertolini's comments came two days after the U.S. government said premium rates for Obamacare plans would increase by 25 percent, on average, in 2017, reflecting higher medical costs of insuring members. Bertolini said two problems are the risk adjustment calculation that smooths out the costs of sick patients and the number of people enrolled in the program.  ""Until that mechanism changes, or until the pool substantively changes, we're going to find ourselves in a premium spiral that's going to continue to drive rates up,"" Bertolini said.The government estimates 2017 enrollment to rise 1 million about 11.4 million people. Aetna said it expects operating losses of $350 million on the individual insurance business in 2016. In 2017, it may book losses both in the states where it remains in exchanges and in the states where it sells plan outside the exchanges.   Bertolini said Aetna, which is fighting a U.S. government lawsuit to block its $34 billion acquisition of Humana, is committed to the deal and expects to close in 2017.The exchanges and the lawsuit are two uncertainties for 2017, Aetna said. Other potential bumps include high costs in its fully insured plans for small companies and the possible loss of some Medicaid contracts. Chief Financial Officer Shawn Guertin said the combination of factors made it difficult to give a 2017 outlook, and that the company does not normally give a financial forecast with its third-quarter report.Leerink analyst Ana Gupte said Aetna did not alleviate Wall Street concerns about the outlook for 2017 earnings. Analysts expect earnings of $8.88 per share, according to Thomson Reuters I/B/E/S. ""They were not willing to guide at all, or even give any directional color on whether consensus was too high or too low,"" Gupte said. (Reporting by Caroline Humer in New York and Ankur Banerjee in Bengaluru; Editing by Martina D'Couto and Jeffrey Benkoe)",2016-10-27,AET,"Thu Oct 27, 2016 | 11:10am EDT",Aetna says losses not over for Obamacare plans,http://www.reuters.com//article/us-aetna-results-idUSKCN12R17G?type=companyNews
322,"   By Caroline Humer and Ankur Banerjee  U.S. health insurer Aetna Inc (AET.N) warned on Thursday that losses from its Obamacare individual insurance plans will likely continue despite pulling out of the exchanges in most states, creating uncertainty for next year's earnings.Chief Executive Officer Mark Bertolini said the earliest the health insurer might return to the exchanges is 2019, more likely 2020, and then only if operations improve. Shares fell 1 percent to $109.81.The CEO's comments came during a conference call to discuss third-quarter earnings and revenue, both of which beat analysts' expectations.Aetna said in August it will reduce participation in  individual insurance on government-run online marketplaces to four states from the current 15 states due to financial losses. It will continue to sell plans on the exchanges.Bertolini's comments came two days after the U.S. government said premium rates for Obamacare plans would increase by 25 percent, on average, in 2017, reflecting higher medical costs of insuring members. Bertolini said two problems are the risk adjustment calculation that smooths out the costs of sick patients and the number of people enrolled in the program.  ""Until that mechanism changes, or until the pool substantively changes, we're going to find ourselves in a premium spiral that's going to continue to drive rates up,"" Bertolini said.The government estimates 2017 enrollment to rise 1 million about 11.4 million people. Aetna said it expects operating losses of $350 million on the individual insurance business in 2016. In 2017, it may book losses both in the states where it remains in exchanges and in the states where it sells plan outside the exchanges.   Bertolini said Aetna, which is fighting a U.S. government lawsuit to block its $34 billion acquisition of Humana, is committed to the deal and expects to close in 2017.The exchanges and the lawsuit are two uncertainties for 2017, Aetna said. Other potential bumps include high costs in its fully insured plans for small companies and the possible loss of some Medicaid contracts. Chief Financial Officer Shawn Guertin said the combination of factors made it difficult to give a 2017 outlook, and that the company does not normally give a financial forecast with its third-quarter report.Leerink analyst Ana Gupte said Aetna did not alleviate Wall Street concerns about the outlook for 2017 earnings. Analysts expect earnings of $8.88 per share, according to Thomson Reuters I/B/E/S. ""They were not willing to guide at all, or even give any directional color on whether consensus was too high or too low,"" Gupte said. (Reporting by Caroline Humer in New York and Ankur Banerjee in Bengaluru; Editing by Martina D'Couto and Jeffrey Benkoe)",2016-10-27,AET,"Thu Oct 27, 2016 | 11:10am EDT",UPDATE 3-Aetna says losses not over for Obamacare plans,http://www.reuters.com//article/aetna-results-idUSL4N1CX3WD?type=companyNews
323,  Oct 27 Aetna Inc* Aetna CEO says earliest it would reenter Obamacare exchanges if risks there improve is 2019 or more likely 2020  * Aetna CEO says it reduced marketing and number of plans in off exchange individual offerings for 2017    (Reporting By Caroline Humer) ,2016-10-27,AET,"Thu Oct 27, 2016 | 9:44am EDT",BRIEF-Aetna reduced off exchange individual offerings for 2017,http://www.reuters.com//article/idUSL1N1CX0RH?type=companyNews
324,"  NEW YORK Aetna Inc. (AET.N) is committed to defending its proposed acquisition of Humana Inc. (HUM.N) in court, where the U.S. Department of Justice is seeking to block the acquisition, Chief Executive Officer Mark Bertolini said on a conference call on Thursday.Aetna Chief Financial Officer, also speaking on the call, said that based on continued issues during the third quarter in the Affordable Care Act-compliant individual health insurance plans, the company expects a loss of $350 million on that business in 2016.    (Reporting by Caroline Humer)",2016-10-27,AET,"Thu Oct 27, 2016 | 8:55am EDT",Aetna CEO is committed to defending Humana acquisition,http://www.reuters.com//article/us-aetna-results-ceo-idUSKCN12R1PE?type=companyNews
325,"  NEW YORK Oct 27 Aetna Inc. is committed to defending its proposed acquisition of Humana Inc. in court, where the U.S. Department of Justice is seeking to block the acquisition, Chief Executive Officer Mark Bertolini said on a conference call on Thursday. Aetna Chief Financial Officer, also speaking on the call, said that based on continued issues during the third quarter in the Affordable Care Act-compliant individual health insurance plans, the company expects a loss of $350 million on that business in 2016.   (Reporting by Caroline Humer)  ",2016-10-27,AET,"Thu Oct 27, 2016 | 8:54am EDT",Aetna CEO is committed to defending Humana acquisition,http://www.reuters.com//article/aetna-results-ceo-idUSL1N1CX0OU?type=companyNews
326,"  Oct 27 Aetna Inc* Aetna reports third-quarter 2016 results* Q3 earnings per share $1.70* Q3 revenue $15.8 billion versus I/B/E/S view $15.71 billion * Q3 operating earnings per share $2.07* Q3 earnings per share view $2.03 -- Thomson Reuters I/B/E/S * Q3 healthcare medical benefit ratio 82 percent versus 81.1 percent* Aetna Inc - Medical membership totaled 23.1 million at September 30, 2016 * Sees FY 2016 operating earnings per share $7.95 to $8.05* Sees FY 2016 earnings per share $6.89 to $6.99* FY 2016 earnings per share view $8.05 -- Thomson Reuters I/B/E/S  Source text for Eikon:  Further company coverage:",2016-10-27,AET,"Thu Oct 27, 2016 | 6:17am EDT",BRIEF-Aetna Q3 earnings per share $1.70,http://www.reuters.com//article/idUSASC09DJV?type=companyNews
327,"  Oct 27 Aetna Inc, No. 3 U.S. health insurer, reported an 8 percent rise in quarterly profit as memberships grew in its government business, which sells Medicaid and Medicare plans.The company, which is currently fighting a U.S. government lawsuit aimed at blocking its $34 billion deal for smaller rival Humana Inc, said its net income rose to $603.9 million, or $1.70 per share, in the third quarter ended Sept. 30, from $560.1 million, or $1.59 per share, a year earlier.  Revenue rose to $15.78 billion from $14.95 billion.   (Reporting by Ankur Banerjee in Bengaluru; Editing by Martina D'Couto) ",2016-10-27,AET,"Thu Oct 27, 2016 | 6:09am EDT",Health insurer Aetna's quarterly profit rises 8 pct,http://www.reuters.com//article/aetna-results-idUSL4N1CX3VH?type=companyNews
328,"  Oct 31 Aetna Inc :* Aetna and Banner Health launch a new joint venture health plan in Arizona * new commercial products for fully insured and self-insured customers in Maricopa, Pinal counties will be available beginning January 1, 2017  * Aetna members who are currently part of Aetna Whole Health Network ACO plans can  transition into plans offered through new partnership  Source text for Eikon:  Further company coverage:",2016-10-31,AET,"Mon Oct 31, 2016 | 2:03pm EDT",BRIEF-Aetna and Banner Health announces a new JV health plan in Arizona,http://www.reuters.com//article/idUSASC09EG7?type=companyNews
329,"  NEW YORK Aetna Inc Chief Executive Officer Mark Bertolini said he expected some benefits of President Barack Obama's national healthcare reform law will stick under President-elect Donald Trump, like allowing young adults to stay on their family's health insurance.Bertolini, speaking at the New York Times Dealbook conference, said he expects the expansion of Medicaid to more people will continue but with new mechanisms for federal financing. He also sees some sort of subsidies for individual insurance remaining. Trump has promised to repeal the Affordable Care Act, known as Obamacare, which passed in 2010 and was Obama's signature domestic policy.    (Reporting by Caroline Humer; Editing by Chizu Nomiyama)",2016-11-10,AET,"Thu Nov 10, 2016 | 11:45am EST",Aetna CEO expects some ACA benefits to stay: Dealbook conference,http://www.reuters.com//article/us-aetna-ceo-idUSKBN13523N?type=companyNews
330,"  NEW YORK Aetna Inc Chief Executive Officer Mark Bertolini said he expected some benefits of President Barack Obama's national healthcare reform law will stick under President-elect Donald Trump, like allowing young adults to stay on their family's health insurance.Bertolini, speaking at the New York Times Dealbook conference, said he expects the expansion of Medicaid to more people will continue but with new mechanisms for federal financing. He also sees some sort of subsidies for individual insurance remaining. Trump has promised to repeal the Affordable Care Act, known as Obamacare, which passed in 2010 and was Obama's signature domestic policy.    (Reporting by Caroline Humer; Editing by Chizu Nomiyama)",2016-11-10,AET,"Thu Nov 10, 2016 | 11:45am EST",Aetna CEO expects some ACA benefits to stay-Dealbook conference,http://www.reuters.com//article/aetna-ceo-idUSL1N1DB1GF?type=companyNews
331,"  Nov 22 Aetna Inc -* On November 21, company entered into a first amendment to term loan credit agreement dated as of July 30, 2015- SEC filing  * First amendment extends latest date on which lenders' commitments under term credit agreement may expire to December 31, 2016  Source text: (bit.ly/2gdHwIT) Further company coverage: ",2016-11-22,AET,"Tue Nov 22, 2016 | 4:49pm EST",BRIEF-Aetna entered into a first amendment to term loan credit agreement,http://www.reuters.com//article/idUSFWN1DN0TY?type=companyNews
332,"   By Diane Bartz | WASHINGTON  WASHINGTON Anthem Inc (ANTM.N) and the U.S. Justice Department dug in their heels on Monday in court over whether the lower prices the health insurer expects to negotiate after buying smaller rival Cigna Corp (CI.N) are an efficiency that benefits customers or an antitrust violation.In the first phase of what could be a two-stage trial, a lawyer for Anthem argued that the $45-billion deal, which was announced more than a year ago, would create a new, bigger insurer with the power to push down prices that it would pass onto customers.But the Justice Department argued that any cost cuts would come from Anthem using its clout in the market to force hospitals and doctors to work for less.""Efficiencies don't count if the only way you get them is more market power,"" the Justice Department's attorney Jon Jacobs said in opening statements.Judge Amy Berman Jackson of the U.S. District Court for the District of Columbia may opt to block the proposed deal if she decides it will mean higher prices for consumers or that it hurts suppliers. The Justice Department asked her to declare the deal illegal under antitrust law. The Justice Department's Jacobs argued that the deal would also lead to fewer companies selling health insurance to big, nationwide employers that need a broad network of services.  Fewer companies usually means higher prices for these big companies, and Anthem's lawyer Christopher Curran took issue with that idea. ""The notion that these Fortune 500 companies are going to be victimized here ... is not realistic,"" Curran said in court.Curran also argued that the Justice Department had failed to consider the new online private exchanges where corporations allow employees to choose from multiple insurers.Judge Jackson noted that the major insurance companies were the ones in the exchanges and asked: ""How's that the answer to the problem?"" The Justice Department's Jacobs noted the tough competition between the companies, referring to an Anthem document. ""It offered its sales force a bounty if they took business away from Aetna or Cigna,"" said Jacobs.The trial is expected to end by the end of the year.The Justice Department filed lawsuits on July 21 asking a federal court to stop the $45-billion purchase of Cigna and Aetna Inc's (AET.N) $33-billion planned acquisition of Humana (HUM.N), arguing that such consolidation among the largest health insurers would be anti-competitive. Anthem attempted to make the case that it was not truly a national insurance company because it is only in 14 states.Joseph Swedish, chief executive of Anthem, the largest member of the Blue Cross Blue Shield Association, testified that  he would be inclined to assist another so-called blue plan land a national contract in a way it would not help one of the other major companies.""If a blue plan reaches out to me to give help, I'll give help,"" Swedish said. Anthem shares closed up 1.5 percent at $137.36, while Cigna shares fell 1.2 percent to close at $137.08. (Reporting by Diane Bartz, writing by Caroline Humer and Diane Bartz; Editing by Nick Zieminski, Bernard Orr)",2016-11-22,AET,"Tue Nov 22, 2016 | 6:19am EST",Anthem argues Fortune 500 will not suffer from Cigna deal,http://www.reuters.com//article/us-cigna-m-a-anthem-idUSKBN13G1VM?type=companyNews
333,"   By Diane Bartz | WASHINGTON  WASHINGTON Anthem Inc and the U.S. Justice Department dug in their heels on Monday in court over whether the lower prices the health insurer expects to negotiate after buying smaller rival Cigna Corp are an efficiency that benefits customers or an antitrust violation.In the first phase of what could be a two-stage trial, a lawyer for Anthem argued that the $45-billion deal, which was announced more than a year ago, would create a new, bigger insurer with the power to push down prices that it would pass onto customers.But the Justice Department argued that any cost cuts would come from Anthem using its clout in the market to force hospitals and doctors to work for less.""Efficiencies don't count if the only way you get them is more market power,"" the Justice Department's attorney Jon Jacobs said in opening statements.Judge Amy Berman Jackson of the U.S. District Court for the District of Columbia may opt to block the proposed deal if she decides it will mean higher prices for consumers or that it hurts suppliers. The Justice Department asked her to declare the deal illegal under antitrust law.The Justice Department's Jacobs argued that the deal would also lead to fewer companies selling health insurance to big, nationwide employers that need a broad network of services. Fewer companies usually means higher prices for these big companies, and Anthem's lawyer Christopher Curran took issue with that idea. ""The notion that these Fortune 500 companies are going to be victimized here ... is not realistic,"" Curran said in court.Curran also argued that the Justice Department had failed to consider the new online private exchanges where corporations allow employees to choose from multiple insurers.Judge Jackson noted that the major insurance companies were the ones in the exchanges and asked: ""How's that the answer to the problem?"" The Justice Department's Jacobs noted the tough competition between the companies, referring to an Anthem document. ""It offered its sales force a bounty if they took business away from Aetna or Cigna,"" said Jacobs.The trial is expected to end by the end of the year.The Justice Department filed lawsuits on July 21 asking a federal court to stop the $45-billion purchase of Cigna and Aetna Inc's $33-billion planned acquisition of Humana , arguing that such consolidation among the largest health insurers would be anti-competitive. Anthem attempted to make the case that it was not truly a national insurance company because it is only in 14 states.Joseph Swedish, chief executive of Anthem, the largest member of the Blue Cross Blue Shield Association, testified that  he would be inclined to assist another so-called blue plan land a national contract in a way it would not help one of the other major companies.""If a blue plan reaches out to me to give help, I'll give help,"" Swedish said.Anthem shares closed up 1.5 percent at $137.36, while Cigna shares fell 1.2 percent to close at $137.08.",2016-11-22,AET,"Mon Nov 21, 2016 | 7:03pm EST",Anthem argues Fortune 500 will not suffer from Cigna deal,http://www.reuters.com//article/cigna-ma-anthem-idUSL1N1DN008?type=companyNews
334,"  Nov 24 U.S. healthcare company Johnson & Johnson  has approached Swiss biotechnology firm Actelion Ltd  about a potential takeover, Bloomberg reported on Thursday, citing people it said were familiar with the matter.The report said that deliberations are still at an early stage following Johnson & Johnson's initial offer, and Actelion is working with an adviser to explore options. (bloom.bg/2g8UTe3) Actelion shares have risen more than 13 percent this year, valuing it at about $17 billion.  Johnson & Johnson and Actelion were not immediately available for comment.    (Reporting by Ankit Ajmera in Bengaluru; Editing by Bill Rigby)",2016-11-24,AET,"Thu Nov 24, 2016 | 2:07pm EST",J&J makes takeover approach for Swiss drugmaker Actelion -Bloomberg,http://www.reuters.com//article/actelion-ma-johnsonjohnson-idUSL1N1DP12C?type=companyNews
335,"  ZURICH Shares in Swiss biotech company Actelion (ATLN.S) plunged on Tuesday after a report the company was not actively considering selling itself, but instead weighing a ""complicated deal"" to link with U.S. healthcare giant Johnson & Johnson (JNJ.N).Actelion shares fell more than 8 percent in early trading, after having risen sharply over the last four days to value the company at about $20 billion amid takeover speculation.Johnson & Johnson approached Actelion Chief Executive Jean-Paul Clozel expecting him to reject a takeover, so it instead has focused on another proposal to take a major stake in the Swiss company while leaving it independent, the Financial Times reported late on Monday. Actelion declined to comment on the FT report. A Johnson & Johnson spokesman also declined comment.    (Reporting by John Miller, editing by Michael Shields)",2016-11-29,AET,"Tue Nov 29, 2016 | 3:20am EST",Actelion shares plunge on report it eyes 'complicated' J&J deal,http://www.reuters.com//article/us-actelion-m-a-johnson-johnson-stocks-idUSKBN13O0MM?type=companyNews
336,"  ZURICH Shares in Swiss biotech company Actelion (ATLN.S) plunged on Tuesday after a report the company was not actively considering selling itself, but instead weighing a ""complicated deal"" to link with U.S. healthcare giant Johnson & Johnson (JNJ.N).Actelion shares fell more than 8 percent in early trading, after having risen sharply over the last four days to value the company at about $20 billion amid takeover speculation.Johnson & Johnson approached Actelion Chief Executive Jean-Paul Clozel expecting him to reject a takeover, so it instead has focused on another proposal to take a major stake in the Swiss company while leaving it independent, the Financial Times reported late on Monday. Actelion declined to comment on the FT report. A Johnson & Johnson spokesman also declined comment.    (Reporting by John Miller, editing by Michael Shields)",2016-11-29,AET,"Tue Nov 29, 2016 | 3:20am EST","Actelion shares plunge on report it eyes ""complicated"" J&J deal",http://www.reuters.com//article/actelion-ma-johnsonjohnson-stocks-idUSFWN1DU01Z?type=companyNews
337,"  VIENNA Novartis Chief Executive Joe Jimenez has played down suggestions the Swiss drugmaker could bid for Swiss biotech group Actelion, which is in talks with U.S. healthcare group Johnson & Johnson about a transaction. Asked by Swiss Sunday newspaper SonntagsBlick whether Novartis could emerge as a white knight, he said: ""We have always said that we will concentrate on complementary acquisitions in the range of $2 billion to $5 billion."" He did not elaborate.Actelion is worth nearly $20 billion at Friday's closing price.Jimenez said Novartis was still gauging what impact  President-elect Donald Trump could have on the U.S. healthcare system and was watching what his priorities would be. ""Less has been invested in the United States in recent years, probably because of high corporate taxes. If these are now cut, as is being signaled, that is certainly positive,"" he said. He said Novartis should have intervened earlier and more decisively at its Alcon eyecare business, which Novartis bought in 2010 and had flourished until 2014, when innovation waned. ""We are disappointed that the turnaround is taking so long but I am convinced that the new management will get the job done. As far as the future of the business is concerned we are keeping all options open,"" he was quoted as saying.   (Reporting by Michael Shields; editing by Francois Murphy)",2016-12-04,AET,"Sun Dec 4, 2016 | 7:52am EST",Novartis CEO plays down prospects for Actelion bid: Blick,http://www.reuters.com//article/us-actelion-m-a-johnson-johnson-novartis-idUSKBN13T0IO?type=companyNews
338,"   By Diane Bartz | WASHINGTON  WASHINGTON A U.S. Justice Department attorney told a federal judge on Monday that health insurer Aetna Inc's planned acquisition of Humana Inc would break antitrust law by reducing competition in Medicare Advantage and Obamacare exchange businesses, kicking off a trial expected to last weeks.The Justice Department filed a lawsuit in July asking the court to stop Aetna's $34 billion deal for Humana, arguing it would lead to higher prices for seniors and the disabled on Medicare and for people who use the individual insurance program created under the Affordable Care Act, popularly known as Obamacare. Aetna defended the deal on Monday, arguing that Medicare Advantage competes with the government's traditional Medicare program for elderly or disabled patients. It also said that it plans to stay out of the Obamacare exchanges in the near future.Both programs, as well as antitrust enforcement, could face changes under Republican President-elect Donald Trump.Justice Department lawyer Craig Conrath told Judge John Bates of the U.S. District Court for the District of Columbia that traditional government-managed Medicare does not compete with Medicare Advantage, which is run by insurers. A witness called by the government, Aetna executive Nancy Cocozza, president of Aetna's Medicare Business, was shown internal documents that appeared to show that Aetna considered Humana a major competitor but not original Medicare. The documents were not visible in the court.Shown one assessment of top competitors that did not have Medicare, Cocozza protested, ""These are MA (Medicare Advantage) competitors but there are others.""Conrath also said that Aetna's plan to largely exit the Obamacare exchanges in 2017 should be disregarded because the company could re-enter the market as soon as 2018 if it chooses. Conrath said written communications showed that Aetna left Obamacare because of the antitrust lawsuit. Aetna has said it would not return to the exchanges until 2019 at the earliest.Share prices of both companies dropped Monday. Humana closed down 2.2 percent at $208.83 while Aetna was down 3 percent at $129.45.Aetna attorney John Majoras argued that traditional Medicare and Medicare Advantage did compete, citing a U.S. government website. There could soon be more competition, he said, noting ""entry has been common and it has been widespread."" Majoras also argued that the Obamacare exchanges were unprofitable and said that was the real reason the company planned to drop out of 11 of the 15 states where they are on the exchanges. ""The result to Aetna has been mounting losses,"" Majoras said. ""Humana's losses were actually even a bit worse.""The Justice Department filed another lawsuit in July to stop Anthem Inc's planned $45 billion purchase of Cigna Corp. That trial is underway in the same courthouse. The trials will be over before Trump's inauguration on Jan. 20. He has pledged to repeal and replace Obamacare and has said Medicare should be modernized.   Humana is the second largest Medicare Advantage insurer while Aetna is the fourth, and the two compete in more than 600 counties, the government said in its complaint. (Reporting by Diane Bartz and Caroline Humer; Editing by Jonathan Oatis and Leslie Adler)",2016-12-05,AET,"Mon Dec 5, 2016 | 6:23pm EST",U.S. attorneys argue Aetna-Humana deal violates antitrust law,http://www.reuters.com//article/us-humana-m-a-aetna-idUSKBN13U23N?type=companyNews
